<SEC-DOCUMENT>0001999480-26-000012.txt : 20260513
<SEC-HEADER>0001999480-26-000012.hdr.sgml : 20260513
<ACCEPTANCE-DATETIME>20260513073044
ACCESSION NUMBER:		0001999480-26-000012
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260513
DATE AS OF CHANGE:		20260513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alto Neuroscience, Inc.
		CENTRAL INDEX KEY:			0001999480
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				834210124
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41944
		FILM NUMBER:		26970939

	BUSINESS ADDRESS:	
		STREET 1:		650 CASTRO STREET, SUITE 450
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94041
		BUSINESS PHONE:		773-255-5012

	MAIL ADDRESS:	
		STREET 1:		650 CASTRO STREET, SUITE 450
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94041
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>alto-20260331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cfc6e-a845-7559-941c-e87ca4915109,g:515d2a5a-b4b4-4d42-8d26-d42921144f4b,d:f33b9e8d46eb467b84758fa9b250d8f7-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:alto="http://www.altoneuroscience.com/20260331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>alto-20260331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0001999480</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-30">False</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" id="f-612">1</ix:nonFraction><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-613" escape="true">Subsequent Events<div><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">PLACEHOLDER</span></div></ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="alto-20260331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="subsidiary"><xbrli:measure>alto:subsidiary</xbrli:measure></xbrli:unit><xbrli:unit id="clinical-stageasset"><xbrli:measure>alto:clinical-stageAsset</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>alto:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>alto:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-21</xbrli:startDate><xbrli:endDate>2025-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:K2HealthventuresLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:K2HealthventuresLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-17</xbrli:startDate><xbrli:endDate>2025-11-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-17</xbrli:startDate><xbrli:endDate>2026-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:K2HealthventuresLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:K2HealthventuresLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-18</xbrli:startDate><xbrli:endDate>2026-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alto:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alto:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alto:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alto:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alto:K2WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alto:NewK2WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:A2025InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:A2025InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alto:TwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">alto:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alto:K2CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alto:K2CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alto:K2WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alto:K2WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alto:AdditionalK2WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:K2WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:K2WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alto:EmployeeStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alto:EmployeeStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alto:EmployeeStockOptionsAvailableForFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alto:EmployeeStockOptionsAvailableForFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto100Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto100Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto300Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto300Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto101Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto101Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto203Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto203Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto207Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto207Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">alto:AmitEtkinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">alto:AmitEtkinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">alto:NicholasSmithMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001999480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">alto:NicholasSmithMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:12pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"/><td style="width:2.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2026</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"/><td style="width:2.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from            to         .</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-41944</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Alto Neuroscience, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.944%"><tr><td style="width:1.0%"/><td style="width:42.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.179%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">83-4210124</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">650 Castro Street, Suite 450</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Mountain View</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94041</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">200-0412</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code</span></div><div style="margin-top:12pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.388%"><tr><td style="width:1.0%"/><td style="width:36.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.942%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">ANRO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.861%"><tr><td style="width:1.0%"/><td style="width:30.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.856%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.030%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.858%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-21">x</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-22">x</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-23">o</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">No</ix:nonNumeric> </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:12pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of registrant&#8217;s Common Stock outstanding as of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;8, 2026 </span><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">was </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">35,093,940</ix:nonFraction></span><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span><br/></span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_13">Part I - Financial Information</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_16">Item 1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_88">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_88">20</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_115">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_115">35</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_118">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_118">35</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_121">Part II - Other Information</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_124">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_124">37</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_127">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_127">37</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_130">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_130">37</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_133">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_133">37</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_136">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_136">37</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_139">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_139">38</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_142">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_142">39</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_145">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if33b9e8d46eb467b84758fa9b250d8f7_145">40</a></span></div></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unless context otherwise requires, the terms the &#8220;Company,&#8221; &#8220;Alto,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar references in this Quarterly Report on Form 10-Q refer to Alto Neuroscience, Inc. and its consolidated subsidiary.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span><br/></span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this Quarterly Report, including statements regarding our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans, or intentions relating to product candidates and markets and business trends are forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections. In some cases, you can identify forward-looking statements because they contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;shall,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these words or other similar terms or expressions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">These statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">the initiation, timing, progress, and results of our research and development programs, preclinical studies, any clinical trials, and investigational new drug, or IND, and other regulatory submissions;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">the ability of our approach to reproducibly predict treatment outcomes for product candidates amongst identified patient populations and achieve clinical success;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">our ability to continue to identify appropriate biomarkers for use in further clinical development;</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">the timing of and costs involved in obtaining and maintaining regulatory approval of our current product candidates and any future product candidates that we may identify or develop;</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">the beneficial characteristics, including potential safety, efficacy, and therapeutic effects, of our product candidates;</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">our ability to efficiently and cost-effectively conduct our current and future clinical trials;</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates, if approved;</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">our ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements, including our ability to comply with our financial obligations pursuant to the terms of such agreements;</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">the timing and likelihood of the achievement of milestones pursuant to our existing collaboration and licensing agreements;</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">our ability to identify and develop product candidates for treatment of additional indications;</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">the performance of our third-party service providers, including our suppliers and manufacturers;</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">the rate and degree of market acceptance and clinical utility for our current product candidates and any other product candidates we may develop;</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">the effects of competition with respect to our current product candidates or any of our future product candidates, as well as innovations by current and future competitors in our industry;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">our estimates regarding the potential market opportunities and the number of patients for our product candidates and any future product candidates, if approved for commercial use;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">the implementation of our strategic plans for our business, any product candidates we may develop;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">our intellectual property position, including the scope of protection we are able to establish, maintain, defend and enforce for intellectual property rights covering our product candidates and our Precision Psychiatry Platform;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">our ability to attract and retain key scientific or management personnel;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">regulatory and legal developments in the United States and foreign countries;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">our ability to attract and retain employees and collaborators with development, regulatory, and commercialization expertise;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">our ability to comply with the terms of our loan agreements and our expectations regarding our ability to access additional tranches thereunder;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">the accuracy of our estimates regarding future expenses, future revenue, capital requirements, and need for additional financing;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the anticipated impact of global economic uncertainty, financial market conditions and geopolitical events, including the conflict between Ukraine and Russia, the conflict in the Middle East, geopolitical tensions, high levels of inflation, fluctuating interest rates, and tariffs on our business, results of operations, and financial condition;</span></div><div style="padding-left:18pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; and</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Quarterly Report and are subject to risks and uncertainties. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">You are urged to carefully review the disclosures we make </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">concerning risks and other factors that may affect our business and operating results under &#8220;Item 1A. Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2025, or Annual Report, under &#8220;Item 1A. Risk Factors&#8221; in this Quarterly Report, and in our other reports filed with the Securities and Exchange Commission, or SEC. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in such statements.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Any public statements or disclosures by us following this Quarterly Report that modify or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">impact any of the forward-looking statements contained in this </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Quarterly</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> Report will be deemed to modify or supersede such statements in this </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Quarterly</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> Report. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events, or otherwise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Availability of Information on Our Website</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We routinely use our investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, we encourage investors and others interested in Alto to review the information it makes public on its investor relations website.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span><br/></span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL INFORMATION</span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements (Unaudited).</span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_19"></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (Unaudited)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">263,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">176,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">269,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">177,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-37">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-38">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-39">2,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-40">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-41">4,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-42">4,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="f-43">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="f-44">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-45">276,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-46">184,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">3,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">1,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">7,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">8,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Term loan, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-52">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">13,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">11,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Term loan,&#160;non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">13,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">16,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Convertible Grant Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="f-57">2,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="f-58">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability, long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">3,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">3,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-61">32,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-62">33,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-63"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-64"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Common stock (par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-65"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-66">0.0001</ix:nonFraction></ix:nonFraction>), <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-67"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-68">500,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-69"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-70">35,053</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-71"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-72">31,924</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="f-73">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="f-74">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additional&#160;paid-in&#160;capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-75">471,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-76">352,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-77">227,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-78">201,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-79">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-80">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-81">243,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-82">151,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-83">276,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-84">184,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.991%"><tr><td style="width:1.0%"/><td style="width:70.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.447%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-85">20,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-86">9,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-87">6,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-88">5,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-89">27,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-90">15,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-91">27,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-92">15,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-93">1,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-94">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-95">545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-96">598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="f-98">681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-99">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-100">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-101">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-102">507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-103">26,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-104">15,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value attributable to instrument specific credit risk</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent" scale="3" id="f-105">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent" scale="3" id="f-106">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-107">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-108">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-109">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-110">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-111">26,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-112">15,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-113"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-114">0.80</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-115"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-116">0.56</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-117"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-118">32,893</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-119"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-120">27,049</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.574%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>&#160;Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">(Par Value of Shares $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-121">0.0001</ix:nonFraction>)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Shares&#160;<br/>(#)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Amount&#160;<br/>($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-122">26,987</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-123">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-124">289,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-125">138,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-126">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-127">151,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of common stock options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-128">85</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-129">198</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-130">198</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of K2 warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="alto:APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock" scale="3" id="f-131">524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alto:APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock" scale="3" id="f-132">524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-133">1,968</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-134">1,968</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-135">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-136">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-137">15,169</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">15,169</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-139">27,072</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-140">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-141">292,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-142">153,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-143">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-144">139,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>&#160;Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">(Par Value of Shares $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-145">0.0001</ix:nonFraction>)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Shares&#160;<br/>(#)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">Amount&#160;<br/>($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-146">31,924</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-147">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-148">352,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-149">201,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-150">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-151">151,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-152">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-153">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-154">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-155">18</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="f-156">190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="f-157">190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock and pre-funded warrants in 2026 private placement, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-3" name="alto:IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-158">2,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="alto:StockAndPreFundedWarrantsIssuedDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-159">114,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alto:StockAndPreFundedWarrantsIssuedDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-160">114,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock for conversion of the K2 term loan, net of issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-3" name="alto:StockIssuedDuringPeriodShareConversionOfTermLoan" scale="3" id="f-161">207</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="alto:StockIssuedDuringPeriodValueConversionOfTermLoan" scale="3" id="f-162">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alto:StockIssuedDuringPeriodValueConversionOfTermLoan" scale="3" id="f-163">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-164">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-165">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-166">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-167">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-168">26,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-169">26,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-170">35,053</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-171">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-172">471,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">227,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-174">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-175">243,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Cash Flows (Unaudited)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-176">26,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-177">15,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-178">2,824</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-179">1,968</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-180">184</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-181">171</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash&#160;interest expense related to term loan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alto:InterestExpenseNoncash" scale="3" id="f-182">206</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alto:InterestExpenseNoncash" scale="3" id="f-183">180</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash&#160;lease expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-184">200</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-185">190</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-186">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-187">41</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alto:GainLossInOtherOperatingActivitiesNet" scale="3" id="f-188">116</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alto:GainLossInOtherOperatingActivitiesNet" scale="3" id="f-189">41</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-190">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="f-191">681</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-192">4,130</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-193">1,692</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-194">1,490</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-195">266</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-196">1,753</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-197">2,701</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-198">27,091</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-199">16,556</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-200">556</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-201">24</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-202">556</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-203">24</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from sale of common stock and pre-funded warrants in 2026 private placement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alto:ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-204">120,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alto:ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" format="ixt:fixed-zero" scale="3" id="f-205">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments from sale of common stock and pre-funded warrants in 2026 private placement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-206">4,875</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" format="ixt:fixed-zero" scale="3" id="f-207">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payment of withholding taxes for stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-208">190</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" id="f-209"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments on issuance cost from registration statement </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alto:PaymentsOnIssuanceCostFromRegistrationStatement" format="ixt:fixed-zero" scale="3" id="f-210">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alto:PaymentsOnIssuanceCostFromRegistrationStatement" scale="3" id="f-211">419</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of term loan, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-212">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-213">19,688</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of former term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-214">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-215">10,213</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payment of loan financing cost</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-216">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-217">127</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-218">6</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-219">198</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-220">114,941</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-221">9,127</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-222">16</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-223">22</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-224">87,278</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-225">7,475</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at the beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-226">176,984</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-227">168,729</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at the end of the period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-228">264,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-229">161,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of&#160;Non-cash&#160;Activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Conversion of K2 term loan into shares of common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-230">941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs from sale of common stock and pre-funded warrants in 2026 private placement not yet paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid" scale="3" id="f-232">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred offering and share issue costs not yet paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alto:DeferredOfferingAndShareIssueCostsNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alto:DeferredOfferingAndShareIssueCostsNotYetPaid" scale="3" id="f-235">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of warrants in connection with term loan agreement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:fixed-zero" scale="3" id="f-236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-237">524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Disclosure of&#160;Cash Flow Information </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-238">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-239">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_37"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-240" continuedAt="f-240-1" escape="true">Description of the Business</ix:nonNumeric></span></div><ix:continuation id="f-240-1"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Alto Neuroscience, Inc. (the &#8220;Company&#8221; or &#8220;Alto&#8221;) was incorporated in Delaware on March&#160;25, 2019. The Company maintains its headquarters in Mountain View, California. The Company has <ix:nonFraction unitRef="subsidiary" contextRef="c-3" decimals="INF" name="alto:NumberOfWhollyOwnedSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="f-241">one</ix:nonFraction> wholly-owned subsidiary in Australia that was formed during 2020 to conduct clinical trials.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Alto is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Through insights derived from the Company&#8217;s scalable and proprietary Precision Psychiatry Platform, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. The Company&#8217;s current pipeline consists of <ix:nonFraction unitRef="clinical-stageasset" contextRef="c-3" decimals="INF" name="alto:NumberOfClinicalStageAssets" format="ixt-sec:numwordsen" scale="0" id="f-242">seven</ix:nonFraction> clinical-stage assets addressing high-need therapeutic areas, including major depressive disorder (&#8220;MDD&#8221;), bipolar depression (&#8220;BPD&#8221;), treatment resistant depression (&#8220;TRD&#8221;), schizophrenia, and Parkinson&#8217;s disease.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred significant operating losses since inception and has relied primarily upon equity financings to fund its operations. At March&#160;31, 2026, the Company had an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-243">227.9</ix:nonFraction> million. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the generation of sufficient revenues to support its cost structure. No assurance can be provided that the Company will ever be profitable, and unless or until it becomes profitable, the Company will need to continue to raise additional capital.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company completed its initial public offering (&#8220;IPO&#8221;) of its common stock. The Company issued and sold <ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-244">9,246,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-33" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-245">16.00</ix:nonFraction> per share, which included <ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-246">1,206,000</ix:nonFraction> shares sold pursuant to the exercise of the underwriters&#8217; option to purchase additional shares, and received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-247">133.0</ix:nonFraction> million after deducting underwriting discounts and commissions and other offering costs. Upon completion of the IPO, all outstanding shares of the Company&#8217;s outstanding preferred stock converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="alto:TemporaryEquitySharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-248">13,664,261</ix:nonFraction> shares of common stock. In addition, the IPO resulted in the net exercise and conversion of all outstanding Series A Preferred Stock Warrants for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-249">72,631</ix:nonFraction> shares of common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2025, the Company completed a private placement transaction in which it issued and sold (i) <ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-250">3,832,263</ix:nonFraction> shares of common stock and (ii) pre-funded warrants (in lieu of common stock) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-251">4,622,251</ix:nonFraction> shares of common stock. The Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-252">49.7</ix:nonFraction>&#160;million (see Note 10 for additional information). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2025, K2 HealthVentures LLC elected to convert $<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="alto:SaleOfStockConversionOfOutstandingLoan" scale="6" id="f-253">4.0</ix:nonFraction>&#160;million of its outstanding loan balance into the Company&#8217;s common stock. Pursuant to the terms of the Amended Loan Agreement, the conversion price was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-38" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-254">4.83</ix:nonFraction> per share, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="0" id="f-255">828,860</ix:nonFraction> shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2026, the Company completed a private placement transaction in which it issued and sold (i) <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-256">2,900,000</ix:nonFraction> shares of common stock and (ii) pre-funded warrants (in lieu of common stock) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-257">3,100,000</ix:nonFraction> shares of common stock. The Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-258">114.9</ix:nonFraction>&#160;million (See Note 10 for additional information).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2026, K2 HealthVentures LLC elected to convert $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="alto:SaleOfStockConversionOfOutstandingLoan" scale="6" id="f-259">1.0</ix:nonFraction>&#160;million of its outstanding loan balance into the Company&#8217;s common stock. Pursuant to the terms of the Amended Loan Agreement, the conversion price was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-260">4.83</ix:nonFraction> per share, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="0" id="f-261">207,215</ix:nonFraction> shares.</span></div></ix:continuation><div><span><br/></span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_43"></div><div style="margin-top:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-262" continuedAt="f-262-1" escape="true">Summary of Significant Accounting Policies and Basis of Presentation</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-263" continuedAt="f-263-1" escape="true"><ix:continuation id="f-262-1" continuedAt="f-262-2"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), as determined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;), and include the accounts of Alto and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><ix:continuation id="f-262-2" continuedAt="f-262-3"><ix:continuation id="f-263-1"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated financial statements are unaudited and have been prepared on the same basis as the audited annual financial st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">atements and, in management&#8217;s opinion, include all adjustments consisting of only normal recurring adjustments necessary for the fair statement of the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Company&#8217;s financial position as of March&#160;31, 2026 and its results of operations and statements of equity for the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March&#160;31, 2026 and 2025 and cash flows for the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March&#160;31, 2026 and 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">f operations for the three months ended March&#160;31, 2026 are not necessarily indicative of the results to be expected for the full fiscal year or any other period.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and the related notes thereto for the year ended December&#160;31, 2025 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 16, 2026 (the &#8220;Annual Report&#8221;).</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-264" escape="true"><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ materially from those estimates. The most significant estimates and assumptions in the Company&#8217;s condensed consolidated financial statements relate to the determination of the volatility of its common stock (as an input for calculating stock-based compensation and warrants), estimating accrued or prepaid research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies used in the preparation of these condensed consolidated financial statements for the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March&#160;31, 2026 are consistent with those discussed in Note 3 to the consolidated financial statements in the Annual Report. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-265" continuedAt="f-265-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-04, Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, which affects entities that settle convertible debt instruments for which the conversion privileges were changed to induce conversion. The standard is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company adopted the provisions of ASU 2024-04 prospectively beginning January 1, 2026. The adoption did not have an impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03, Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which expands disclosures about specific expense categories presented on the face of the income statement. The standard is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. This standard clarifies current interim reporting requirements on Topic 270 and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. This standard will be effective for fiscal years beginning after December 15, 2027, with the option to apply it retrospectively. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><ix:continuation id="f-265-1"><ix:continuation id="f-262-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Early adoption is allowed. Currently, the Company is evaluating the impact the adoption of this standard will have on its consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="if33b9e8d46eb467b84758fa9b250d8f7_46"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-266" continuedAt="f-266-1" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="f-266-1"><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="f-267" escape="true"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"><tr><td style="width:1.0%"/><td style="width:63.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.371%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:120%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="f-268">1,894</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-269">191</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other prepaid expenses</span></div></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-270">3,470</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-271">1,043</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-272">5,364</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-273">1,234</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-274" escape="true"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"><tr><td style="width:1.0%"/><td style="width:63.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.371%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-275">2,667</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-276">2,125</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-277">453</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-278">453</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer software and equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-279">574</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-280">574</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-281">246</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-282">246</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Less</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">: accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-283">1,706</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-284">1,526</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-285">2,234</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-286">1,872</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-287"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-288">0.2</ix:nonFraction></ix:nonFraction> million for both the three months ended March&#160;31, 2026, and 2025.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-289" escape="true"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"><tr><td style="width:1.0%"/><td style="width:63.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.371%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll, vacation and employee-related expenses</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-290">2,001</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-291">4,870</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="alto:AccruedResearchExpense" format="ixt:num-dot-decimal" scale="3" id="f-292">3,142</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="alto:AccruedResearchExpense" format="ixt:num-dot-decimal" scale="3" id="f-293">2,124</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest, short term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-294">115</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-295">118</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other accruals and current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-296">1,048</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-297">599</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability, short term </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-298">1,304</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-299">1,151</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-300">7,610</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-301">8,862</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="if33b9e8d46eb467b84758fa9b250d8f7_52"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-302" continuedAt="f-302-1" escape="true">Debt</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-302-1" continuedAt="f-302-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">K2 HealthVentures LLC Loan Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On December&#160;16, 2022, the Company entered into a Loan and Security Agreement (the &#8220;Original Loan Agreement&#8221;) with K2 HealthVentures LLC as a lender, the other lenders party thereto (collectively, the &#8220;Lender&#8221;), K2 HealthVentures LLC, as administrative agent for Lender (the &#8220;Administrative Agent&#8221;), and Ankura Trust Company, LLC, as collateral agent for the Lender. Pursuant to the terms of the Original Loan Agreement, the Lender agreed to make available to the Company term loans (each, collectively, the &#8220;Term Loan&#8221;) in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-303">35.0</ix:nonFraction> million. As of December </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><ix:continuation id="f-302-2" continuedAt="f-302-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">31, 2024, the Company had drawn a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-304">10.0</ix:nonFraction> million. The Lender&#8217;s commitment to make available additional Term Loans under the Original Loan Agreement expired without being drawn on January 1, 2025. The Original Loan Agreement had a Term Loan maturity date of December&#160;1, 2026 (the &#8220;Original Term Loan Maturity Date&#8221;).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On January 13, 2025, the Company entered into an amendment to the Original Loan Agreement (the &#8220;Amendment&#8221; and the Original Loan Agreement as amended thereby, the &#8220;Amended Loan Agreement&#8221;) to, among other things, extend the Original Term Loan Maturity Date and increase the maximum available amount of term loans. The Amended Loan Agreement provides for term loans in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-305">75.0</ix:nonFraction>&#160;million, consisting of:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a first tranche term loan of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-306">20.0</ix:nonFraction>&#160;million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">second tranche term loans of up to $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-307">30.0</ix:nonFraction>&#160;million in the aggregate available at the Company&#8217;s request until December 15, 2025, subject to certain time-based, clinical milestones; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">third tranche term loans of up to $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-308">25.0</ix:nonFraction>&#160;million in the aggregate available at the Company&#8217;s request subject to the Lender&#8217;s approval. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company drew $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="6" id="f-309">20.0</ix:nonFraction>&#160;million upon entry into the Amendment (approximately $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" id="f-310">10.0</ix:nonFraction>&#160;million of which was used to refinance obligations under the Original Loan Agreement and pay fees and expenses incurred in connection with the Amendment). The second tranche term loan was available until December 15, 2025 based on certain milestones and expired without being drawn.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Loan Agreement has a Term Loan maturity date of January 1, 2029 (the &#8220;Amended Term Loan Maturity Date&#8221;). The Amended Loan Agreement provides for an interest only period until January 1, 2027, following which the Term Loan shall be repaid in equal monthly payments through the Amended Term Loan Maturity Date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan bears interest at (i) a variable per annum cash pay rate equal to the Prime Rate plus <ix:nonFraction unitRef="number" contextRef="c-60" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-311">1.45</ix:nonFraction>% (subject to a floor of <ix:nonFraction unitRef="number" contextRef="c-60" decimals="4" name="alto:DebtInstrumentInterestRateFloor" scale="-2" id="f-312">8.45</ix:nonFraction>% per annum) and (ii) a fixed per annum paid-in-kind rate equal to <ix:nonFraction unitRef="number" contextRef="c-60" decimals="3" name="alto:DebtInstrumentFixedRatePaidInKind" scale="-2" id="f-313">1.0</ix:nonFraction>%. Interest is due and payable monthly in arrears. Upon final payment or prepayment of the Term Loan, the Company is required to pay a final payment equal to <ix:nonFraction unitRef="number" contextRef="c-60" decimals="4" name="alto:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed" scale="-2" id="f-314">5.95</ix:nonFraction>% of the amount borrowed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Loan Agreement was accounted for as a debt extinguishment, as the new loan was considered substantially different from the original loan. The Company recognized debt issuance costs and discount upon issuance of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="f-315">2.0</ix:nonFraction>&#160;million within Term Loan, non-current on its condensed consolidated balance sheet and recorded a loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-316">0.7</ix:nonFraction>&#160;million, which was recorded within loss on debt extinguishment in its condensed consolidated statement of operations and comprehensive loss for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the three mont</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">hs ended March&#160;31, 2025. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Original Loan Agreement, the Company was obligated to pay a final fee equal to <ix:nonFraction unitRef="number" contextRef="c-52" decimals="4" name="alto:DebtInstrumentExitFeePercentOfLoansFunded" scale="-2" id="f-317">6.25</ix:nonFraction>% of the aggregate amount of the term loans funded thereunder (the &#8220;Original Exit Fee&#8221;) upon the earliest of (i)&#160;the Original Term Loan Maturity Date, (ii)&#160;the acceleration of the Term Loan, and (iii)&#160;the prepayment of the Term Loan. The Company was also obligated to pay the Lender a one-time facility fee of $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" scale="6" id="f-318">0.2</ix:nonFraction>&#160;million (&#8220;Original Facility Fee&#8221;) on the initial closing date. The Original Exit Fee of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="alto:DebtInstrumentExitFee" scale="6" id="f-319">0.6</ix:nonFraction> million and Original Facility Fee of $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" scale="6" id="f-320">0.2</ix:nonFraction>&#160;million were recorded as debt discount, and were being accreted using the effective interest method within interest expense in the condensed consolidated statements of operations and comprehensive loss. The Company&#8217;s obligation to pay the Original Exit Fee remains outstanding, and the timing for payment thereof was unaffected by, and reaffirmed in connection with, the Amendment, and is recorded in the condensed consolidated balance sheet within Term loan, current as of March&#160;31, 2026 and December&#160;31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company was obligated to pay the Lender a one-</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">time facility fee of $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" scale="6" id="f-321">0.3</ix:nonFraction>&#160;million upon entry into the Amendment. The Company is also obligated to pay a funding fee on each third tranche term loan in an amount equal to the sum of <ix:nonFraction unitRef="number" contextRef="c-57" decimals="3" name="alto:DebtInstrumentFundingFeeMultiplier" scale="-2" id="f-322">0.5</ix:nonFraction>% multiplied by the amount of such third tranche term loan, if and when funded. Under the terms of the Amended Loan Agreement, the Company is obligated to pay a final fee equal to <ix:nonFraction unitRef="number" contextRef="c-60" decimals="4" name="alto:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed" scale="-2" id="f-323">5.95</ix:nonFraction>% of the aggregate amount of the Term Loan funded thereunder (the &#8220;Amended Exit Fee&#8221;) upon the earliest of (i)&#160;the Amended Term Loan Maturity Date, (ii) the acceleration of the Term Loan, and (iii) the prepayment of the Term Loan. As of March&#160;31, 2026, the amount owed under the Amended Exit Fee is equal to $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="alto:DebtInstrumentExitFee" scale="6" id="f-324">1.2</ix:nonFraction>&#160;million. The Original Exit Fe</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e and the Amended Exit Fee have been fully accrued and recorded as debt discount as of the closing date of the Amendment and are being accreted using the effective interest method within interest expense in the consolidated statement of operations and comprehensive loss.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><div><span><br/></span></div><ix:continuation id="f-302-3" continuedAt="f-302-4"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the option to prepay all, but not less than all, of the Term Loan prior to the Amended Term Loan Maturity Date, which would require that the Company pay the Lender a prepayment penalty fee based on a percentage of the outstanding principal balance and the funding date of the individual tranches thereunder. As to each such tranche under the Term Loan, such fee shall be equal to <ix:nonFraction unitRef="number" contextRef="c-65" decimals="2" name="alto:DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" scale="-2" id="f-325">3</ix:nonFraction>% if the payment occurs on or before 24 months after the funding date of such tranche, <ix:nonFraction unitRef="number" contextRef="c-65" decimals="2" name="alto:DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" scale="-2" id="f-326">2</ix:nonFraction>% if the prepayment occurs more than 24 months after, but on or before 36 months after the funding date of such tranche, or <ix:nonFraction unitRef="number" contextRef="c-65" decimals="2" name="alto:DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" scale="-2" id="f-327">1</ix:nonFraction>% if the prepayment occurs more than 36 months after the funding date of such tranche. No prepayment penalty fee is required if the applicable tranche is prepaid within six months prior to the Amended Term Loan Maturity Date or refinanced with the Lender. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Terms</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company must maintain, at all times, a cash runway of at least <ix:nonNumeric contextRef="c-60" name="alto:DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum" format="ixt-sec:durmonth" id="f-328">5</ix:nonNumeric> months, provided that this covenant will be waived during any period in which the Company&#8217;s market capitalization exceeds $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="alto:DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount" scale="6" id="f-329">700.0</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Amended Loan Agreement are secured by a first priority security interest in substantially all of its assets (with an exclusion for intellectual property). The Amended Loan Agreement contains customary represent</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ations and warranties, and also includes customary events of default, including payment default, breach of covenants, change of control, and material adverse effects. The Amended Loa</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">n Agreement restricts certain activities, such as disposing of the Company&#8217;s business or certain assets, incurring additional debt or liens or making payments on other debt, making certain investments and declaring dividends, acquiring or merging with another entity, engaging in transactions with affiliates or encumbering intellectual property, among others. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of an event of default, a default interest rate of an additional <ix:nonFraction unitRef="number" contextRef="c-52" decimals="2" name="alto:DebtInstrumentInterestRateIncreaseInEventOfDefault" scale="-2" id="f-330">5</ix:nonFraction>% per annum may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and exercise all of its rights and remedies as set forth in the Amended Loan Agreement and u</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">nder applicable law. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Original Loan Agreement, the Company issued to the Lender a warrant (the &#8220;Original Warrant&#8221;), which Original Warrant is exercisable for <ix:nonFraction unitRef="shares" contextRef="c-66" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-331">35,773</ix:nonFraction> shares of the Company&#8217;s common stock and expires on December 15, 2032. In connection with the Amendment, the Original Warrant was amended and restated (the &#8220;Amended and Restated Warrant&#8221;) to reduce the exercise price from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-67" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-332">10.49</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-333">3.71</ix:nonFraction> per share (the &#8220;Exercise Price&#8221;). The incremental value associated with this modification was immaterial, and was included as part of the determination of the loss on debt extinguishment, with a corresponding increase in additional paid-in capital during</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> the three months ended </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Amendment, the Company issued an additional warrant (the &#8220;New Warrant&#8221;, together with the Amended and Restated Warrant, the &#8220;Warrants&#8221;) to purchase a number of shares of the Company&#8217;s common stock calculated as follows: (a) (i) <ix:nonFraction unitRef="number" contextRef="c-54" decimals="INF" name="alto:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier" scale="0" id="f-334">0.025</ix:nonFraction>, multiplied by (ii) the aggregate principal amount of the term loans actually funded under the Amended Loan Agreement, divided by (b) the Exercise Price. The New Warrant expires on January 13, 2035 and allows for the purchase of <ix:nonFraction unitRef="shares" contextRef="c-68" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-335">134,691</ix:nonFraction> shares of the Company&#8217;s common stock. If the Company draws down on additional tranches of the Term Loan, the number of shares available for purchase by the Lender under the New Warrant would increase. The Company determined the estimated fair value of the New Warrant at the date of issuance to be $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="f-336">0.5</ix:nonFraction>&#160;million, which was included as part of the determination of the loss on debt extinguishment, with a corresponding increase in additional paid-in capital. As of the date of the issuance, significant assumptions include an expected life of <ix:nonNumeric contextRef="c-69" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-337">10</ix:nonNumeric> years, a risk-free rate of <ix:nonFraction unitRef="number" contextRef="c-70" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-338">4.79</ix:nonFraction>% and an expected volatility of <ix:nonFraction unitRef="number" contextRef="c-71" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-339">89.47</ix:nonFraction>%. See Note 10 for additional information regarding the New Warrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loan Conversion Feature</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Amended Loan Agreement, the Lender may, at its option, elect to convert up to $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="alto:DebtInstrumentPortionConvertibleToEquityAtElectionOfLender" scale="6" id="f-340">9.0</ix:nonFraction>&#160;million of the then outstanding Term Loan (the &#8220;Conversion Amount&#8221;) ($<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="alto:DebtInstrumentPortionConvertibleToEquityAtElectionOfLender" scale="6" id="f-341">4.0</ix:nonFraction>&#160;million of which was reflected in the Original Loan Agreement and $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="alto:DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender" scale="6" id="f-342">5.0</ix:nonFraction>&#160;million of which is reflected in the Amended Loan Agreement) into shares of the Company&#8217;s common stock (the &#8220;Conversion Shares&#8221;). The number of shares to be issued upon conversion is determined by dividing (a) the portion of the term loan amount converted, by (b) the Applicable Conversion Price. Applicable Conversion Price means (i) with respect to any conversion of up to $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="alto:DebtInstrumentPortionConvertibleToEquityAtElectionOfLender" scale="6" id="f-343">4.0</ix:nonFraction>&#160;million of the Conversion Amount, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-67" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-344">10.49</ix:nonFraction>, and (ii) with respect to any conversion of the remaining $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="alto:DebtInstrumentPortionConvertibleToEquityAtElectionOfLender" scale="6" id="f-345">5.0</ix:nonFraction>&#160;million of the Conversion Amount, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-65" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-346">4.83</ix:nonFraction>, in each case subject to certain adjustments set </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><ix:continuation id="f-302-4" continuedAt="f-302-5"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">forth in the Amended Loan Agreement. The Company determined that the embedded conversion option is not required to be separated from the Term Loan. The embedded conversion option meets the derivative accounting scope exception since the embedded conversion option is indexed to the Company&#8217;s own common stock and qualifies for classification within stockholders&#8217; equity. On November 17, 2025 and March 18, 2026, the Lender elected to convert $<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="alto:SaleOfStockConversionOfOutstandingLoan" scale="6" id="f-347">4.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="alto:SaleOfStockConversionOfOutstandingLoan" scale="6" id="f-348">1.0</ix:nonFraction>&#160;million, respectively, of its outstanding loan balance into the Company&#8217;s common stock. Pursuant to the terms of the Amended Loan Agreement, the conversion price was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-75" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-349"><ix:nonFraction unitRef="usdPerShare" contextRef="c-76" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-350">4.83</ix:nonFraction></ix:nonFraction> per share, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="0" id="f-351">828,860</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="0" id="f-352">207,215</ix:nonFraction> shares, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense and future repayments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The C</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ompany recorded interest expense at a weighted average rate of <ix:nonFraction unitRef="number" contextRef="c-77" decimals="4" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="f-353">12.35</ix:nonFraction>% and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="4" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="f-354">12.94</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> related to the Loan Agreement for the three months ended March&#160;31, 2026, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> respectively. During the three months ended March&#160;31, 2026, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-355">0.5</ix:nonFraction> million and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-356">0.6</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-357" continuedAt="f-357-1" escape="true"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future principal debt payments and Exit Fee of the term loan funded as of March&#160;31, 2026 are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"><tr><td style="width:1.0%"/><td style="width:79.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026 (remainder of year)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="3" id="f-358">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-359">6,858</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-360">7,467</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="f-361">675</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-362">15,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exit Fee</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="alto:DebtInstrumentExitFee" format="ixt:num-dot-decimal" scale="3" id="f-363">1,815</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred interest</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="alto:DebtInstrumentDeferredInterest" scale="3" id="f-364">235</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments and Exit Fee</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="alto:LongTermDebtPrincipalPaymentsAndExitFee" format="ixt:num-dot-decimal" scale="3" id="f-365">17,050</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: unamortized debt discount</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="alto:DebtInstrumentUnamortizedExitFee" format="ixt:num-dot-decimal" scale="3" id="f-366">1,029</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Term loan, current portion</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-367">2,136</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Term loan,&#160;non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-368">13,885</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Wellcome Trust Limited Convertible Grant Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, the Company entered into a convertible loan agreement (the &#8220;Convertible Grant Agreement&#8221;) with The Wellcome Trust Limited (&#8220;Wellcome&#8221;). The Convertible Grant Agreement provides for an unsecured convertible loan (the &#8220;Convertible Loan&#8221;) from Wellcome of up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-369">11.7</ix:nonFraction>&#160;million, payable to Alto in <ix:nonFraction unitRef="tranche" contextRef="c-81" decimals="INF" name="alto:DebtInstrumentNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-370">six</ix:nonFraction> tranches, of which up to $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-371">2.0</ix:nonFraction>&#160;million could be funded upon the execution of the Convertible Grant Agreement and the remainder of which will be funded upon the completion of certain milestones as set forth in the Convertible Grant Agreement. As of March&#160;31, 2026, the Company has drawn down the entirety of the $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-372">2.0</ix:nonFraction>&#160;million execution tranche and will continue to access the loan as needed as the ALTO-100 study in bipolar depression progresses. Interest accrues at an annual rate equal to the Sterling Overnight Index Rate plus <ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-373">2</ix:nonFraction>%, subject to potential adjustment if such annual interest rate equals or exceeds <ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="alto:DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment" scale="-2" id="f-374">9</ix:nonFraction>% at any time. Proceeds from the Convertible Loan may be used by the Company solely to advance development of ALTO-100 in bipolar depression. The Convertible Grant Agreement also includes customary covenants, representations and warranties, including with respect to the conduct of the Company&#8217;s Phase 2b clinical trial evaluating ALTO-100 in patients with bipolar depression and certain information and audit rights of Wellcome in connection therewith, as well as with respect to the Company&#8217;s efforts to develop and exploit ALTO-100. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At any time after the second anniversary of the effective date of the Convertible Grant Agreement or in connection with an event of default, Wellcome has the right, at its election, to convert some or all of the Convertible Loan into shares of the Company&#8217;s common stock at a price per share equal to a <ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="alto:DebtInstrumentConvertibleDiscountOnSharesConverted" scale="-2" id="f-375">20</ix:nonFraction>% discount to the <ix:nonNumeric contextRef="c-85" name="alto:DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement" format="ixt-sec:durwordsen" id="f-376">thirty-day</ix:nonNumeric> volume-weighted average price of Common Stock on the New York Stock Exchange at the date of such conversion. The Convertible Grant Agreement provides that in no event shall the aggregate number of shares of Common Stock issued pursuant to conversion of the Convertible Loan exceed <ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="alto:DebtInstrumentConvertibleMaximumSharesIssuable" format="ixt:num-dot-decimal" scale="0" id="f-377">5,363,326</ix:nonFraction>, which is equal to <ix:nonFraction unitRef="number" contextRef="c-85" decimals="3" name="alto:DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum" scale="-2" id="f-378">19.9</ix:nonFraction>% of the number of shares of Common Stock outstanding as of the date of the Convertible Grant Agreement. At any time after the fifth anniversary of the effective date of the Convertible Grant Agreement or in connection with an event of default, Wellcome may require repayment of the Convertible Loan in full, together with accrued interest, to the extent not converted as described above.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><ix:continuation id="f-302-5"><ix:continuation id="f-357-1"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future principal debt payments of the Convertible Grant Agreement funded as of March&#160;31, 2026 are as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"><tr><td style="width:1.0%"/><td style="width:79.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026 (remainder of year)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-382">2,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Term loan,&#160;non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-383">2,000</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the terms and features of the Convertible Grant Agreement and determined that the Company was eligible to elect the fair value option under ASC 825, Financial Instruments. The Convertible Grant Agreement contains various embedded features and the election of the fair value option allowed the Company to bypass analysis of potential embedded derivatives and further analysis of bifurcation of any recognized financial liabilities. Under the fair value option, the financial liability is initially measured at its fair value on the issue date and subsequently remeasured at estimated fair value on a recurring basis at each reporting date. Changes in the fair value of the Convertible Grant Agreement, which include accrued interest, if any, are recorded as a component </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of other, net or within other comprehensive income (loss) in the</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> condensed consolidated statements of operations and comprehensive loss. The Company has not elected to present interest expense separately from changes in fair value and therefore will not present interest expense associated with the Convertible Grant Agreement. Any changes in fair value caused by instrument-specific credit risk are presented separately in other comprehensive income or loss. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial fair value of the Convertible Grant Agreement using a probability-weighted income approach. Draw downs under the Convertible Grant Agreement were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="f-384">0.8</ix:nonFraction> million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="f-385">1.3</ix:nonFraction> million </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">during the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">years</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> ended December&#160;31, 2025, and 2024, respectively. The Company remeasured the fair value of the Convertible Grant Agreement as of March&#160;31, 2026 to b</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-386">2.3</ix:nonFraction> million using</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> a probability-weighted income approach. The Company calculated discounted cash flows of the Convertible Grant Agreement using a discount rate of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="4" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="f-387">20.69</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and adjusted for the probability of various repayment scenarios. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="f-388" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in fair value of the Convertible Grant Agreement during the three months ended March&#160;31, 2026 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value balance as of December 31, 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-389">2,227</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of new tranches</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:fixed-zero" scale="3" id="f-390">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="f-391">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value reported in statements of operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-392">115</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value reported in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="3" id="f-393">7</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value balance as of March 31, 2026</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-394">2,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><div style="margin-top:18pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-395" continuedAt="f-395-1" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="f-395-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments that are measured at fair value on a recurring basis consist of money market funds and the Convertible Grant Agreement. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-396" continuedAt="f-396-1" escape="true">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands):</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-396-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-397">263,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-398">263,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-401">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-402">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-405">263,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-406">263,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Convertible Grant Agreement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="f-409">2,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="3" id="f-410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="3" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="f-412">2,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-413">2,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-416">2,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-417">176,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-418">176,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-421">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-422">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-425">176,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-426">176,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-427">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Convertible Grant Agreement</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="f-429">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="3" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="f-432">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-433">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-436">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its money market funds, which are valued based on quoted market prices in an active market with no valuation adjustment, as Level 1 assets within the fair value hierarchy. The Company&#8217;s Convertible Grant Agreement is classified as a Level 3 instrument under the fair value hierarchy as the fair values were determined based on significant inputs not observable in the market. See Note 4 for additional information on the Convertible Grant Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6. </span><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-437" continuedAt="f-437-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Asset Purchase and License Agreements</span></ix:nonNumeric></div><div><span><br/></span></div><ix:continuation id="f-437-1"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into asset purchase and license agreements with third parties. For a detailed description of the significant agreements with certain financial commitments to which the Company is a party, see Note 10 to the consolidated financial statements included in the Company&#8217;s Annual Report. No payments were made during the three months ended </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> pursuant to any of these significant agreements.</span></div></ix:continuation><div id="if33b9e8d46eb467b84758fa9b250d8f7_61"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-438" continuedAt="f-438-1" escape="true">Stock-Based Plans</ix:nonNumeric></span></div><ix:continuation id="f-438-1" continuedAt="f-438-2"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Equity Incentive Plan</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the Board adopted, and the Company&#8217;s stockholders approved, the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), which became effective on the execution of the underwriting agreement related to the IPO. Under the 2024 Plan, the Company may grant incentive stock options</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to employees, including employees of any parent or subsidiary, and nonstatutory stock options, stock appreciation rights, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), performance awards and other forms of stock awards to employees, directors, and consultants, including employees and consultants of the Company&#8217;s affiliates. The 2024 Plan is a successor to the 2019 Equity Incentive Plan, which was adopted by the Board of Directors in March 2019 (as amended, the &#8220;2019 Plan&#8221;). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following effectiveness of the 2024 Plan, no further issuance may be made under the 2019 Plan. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> total of <ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-439">2,000,000</ix:nonFraction> shares of common stock were approved to be initially reserved for issuance under the 2024 Plan. In addition, the number of shares of the Company&#8217;s common stock reserved for issuance under the 2024 Plan automatically increases on January 1 of each calendar year, starting on January 1, 2025 and continuing through and including January 1, 2034, in an amount equal to <ix:nonFraction unitRef="number" contextRef="c-109" decimals="2" name="alto:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock" scale="-2" id="f-440">5</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Board.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the total number of shares authorized to be issued under the 2024 Plan was </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-441">4,945,504</ix:nonFraction> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-442">3,349,328</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. As of March&#160;31, 2026 and December&#160;31, 2025, there wer</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-443">527,407</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-444">625,142</ix:nonFraction> shares of common stock, respectively, reserved and available for issuance under the 2024 Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2025 Inducement Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2025, the Board adopted the 2025 Inducement Plan (the &#8220;Inducement Plan&#8221;), pursuant to which it reserved&#160;<ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-445">500,000</ix:nonFraction> shares of common stock for issuance to individuals who were not previously employees of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company, in accordance with New York Stock Exchange Listed Company Manual Rule 303A.08. Under the&#160;Inducement&#160;Plan, the Company has the ability to issue non-statutory stock options, stock appreciation rights, RSAs, RSUs, and performance awards. As of March&#160;31, 2026, stock options to purchase <ix:nonFraction unitRef="shares" contextRef="c-113" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-446">150,000</ix:nonFraction> shares of common stock had been granted under the Inducement Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2026, the Company had not opened the 2024 Employee Stock Purchase Plan for enrollment, and therefore there were no purchases or share issuances during this period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Repricing </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In July 2025, the Board approved a stock option repricing, which was effective at the close of market on July 3, 2025 (&#8220;Repricing Effective Date&#8221;). The repricing generally applied to the outstanding stock options held by then current employees and consultants that had an exercise price greater than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-114" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-447">2.35</ix:nonFraction> per share. As of the Repricing Effective Date, the eligible stock options were immediately repriced such that the exercise price per share for such stock options was reduced to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-114" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-448">2.35</ix:nonFraction> (the closing price of the Company&#8217;s common stock on the New York Stock Exchange on the Repricing Effective Date), subject to certain retention requirements. The retention period is <ix:nonNumeric contextRef="c-115" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durmonth" id="f-449">12</ix:nonNumeric> months following the Repricing Effective Date and can be accelerated under certain conditions. If an eligible stock option is exercised prior to the end of the relevant retention period, the participant will be required to pay a premium exercise price equal to the original exercise price per share of such stock option. There were no changes to the number of shares underlying the eligible stock options or to the vesting schedules or expiration dates of the eligible stock options. There were <ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-450">4,225,763</ix:nonFraction> shares underlying the repriced stock options, which had then-current exercise prices ranging from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-451">2.44</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-452">16.00</ix:nonFraction> per share. An incremental $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-453">1.4</ix:nonFraction> million </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><ix:continuation id="f-438-2" continuedAt="f-438-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">of stock-based compensation expense will be recognized over the greater of the <ix:nonNumeric contextRef="c-117" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-454">12-month</ix:nonNumeric> retention period or the remaining vesting period of the outstanding stock options. Stock options held by non-employee members of the Board were not eligible for the repricing. For the three months ended March&#160;31, 2026, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-455">0.2</ix:nonFraction> million of incremental stock-based compensation expense in connection with the stock option repricing. In addition, the Company has $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-456">0.8</ix:nonFraction> million of unrecognized stock based compensation related to the stock option repricing which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-119" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-457">1.0</ix:nonNumeric> year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The options have a&#160;<ix:nonNumeric contextRef="c-120" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-458">10</ix:nonNumeric>-year&#160;contractual life and generally vest over a period of <ix:nonNumeric contextRef="c-120" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-459">four years</ix:nonNumeric>, with the first <ix:nonFraction unitRef="number" contextRef="c-121" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-460">25</ix:nonFraction>% of the award vesting after <ix:nonNumeric contextRef="c-121" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-461">one year</ix:nonNumeric> and then monthly thereafter, subject to continuous service. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the three months ended March&#160;31, 2026 and 2025 for awards subject only to service-based vesting conditions wer</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e $<ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-462">12.90</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-122" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-463">3.09</ix:nonFraction> per</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> share, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-464" continuedAt="f-464-1" escape="true">Weighted-average grant date fair value assumptions were based on the following: </ix:nonNumeric></span></div><ix:continuation id="f-464-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.090%"><tr><td style="width:1.0%"/><td style="width:56.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-465">16.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-466">4.08</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of common stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="alto:ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" scale="0" id="f-467">16.72</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="alto:ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" scale="0" id="f-468">4.08</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 10.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-118" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-469">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 10.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-122" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-470">6.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-118" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-471">92.0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-472">88.7</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-118" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-473">3.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-474">4.2</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-118" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-475">0.0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-476">0.0</ix:nonFraction>%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-477" escape="true"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> below summarizes activity related to stock options subject only to service-based vesting conditions (in thousands, except per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>average<br/>exercise<br/>price per share</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted &#8211;<br/>average<br/>remaining<br/>contractual<br/>term (in<br/>years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>value </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-478">4,950</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-479">7.28</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-126" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-480">7.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-481">52,078</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-482">1,727</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-483">16.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="f-484">4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-485">1.64</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="f-486">85</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and cancelled</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="f-487">30</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-488">9.62</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-489">6,643</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-490">9.73</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-118" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-491">8.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-492">84,702</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-493">2,733</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-494">6.91</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-118" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-495">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-496">42,552</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="24" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Since the reporting period covered by the table above is before the expiration of the aforementioned retention period and any employees who exercised their repriced stock options during the reporting period, with certain exceptions, would have to pay the original exercise price, the weighted average exercise price and intrinsic value in the table above does not reflect the effect of repricing.</span></div></td></tr><tr style="height:15pt"><td colspan="24" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, there was approximate</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ly $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-497">34.0</ix:nonFraction> million of unrecognized stock-based compensation expense related to these service-based unvested stock options, excluding the impact of the option repricing, which is expected to be recognized ov</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">er a weighted-average period of <ix:nonNumeric contextRef="c-118" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-498">2.9</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-499" continuedAt="f-499-1" escape="true"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below summ</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">arizes activity related to RSUs subject only to service-based vesting conditions (in thousands, except per share amounts):</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><ix:continuation id="f-438-3"><ix:continuation id="f-499-1"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.787%"><tr><td style="width:1.0%"/><td style="width:60.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-average<br/>grant date fair value per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-500">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-501">14.88</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="f-502">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-503">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-128" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-504">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-505">14.88</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and cancelled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="3" id="f-506">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-507">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, March 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="3" id="f-508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-509">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-510">53,864</ix:nonFraction> RSUs under the 2024 Plan; <ix:nonFraction unitRef="number" contextRef="c-131" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-511"><ix:nonFraction unitRef="number" contextRef="c-132" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-512">50</ix:nonFraction></ix:nonFraction>% of the shares of common stock underlying the RSUs vest after <ix:nonNumeric contextRef="c-131" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-513">18</ix:nonNumeric> months and the remainder vest after <ix:nonNumeric contextRef="c-132" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-514">24</ix:nonNumeric> months from the grant date. The RSUs are subject only to a service-based vesting condition. Such shares are not accounted for as outstanding until they vest.&#160;As of March&#160;31, 2026, there is <ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:fixed-zero" scale="0" id="f-515">no</ix:nonFraction> unrecognized stock-based compensation expense related to the RSUs. The fair value of the RSUs vested during the three months ended March&#160;31, 2026 was $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-516">0.5</ix:nonFraction> million.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Option Awards</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Board granted options to purchase common stock to certain employees and consultants that vest upon the achievement of certain performance conditions (&#8220;Performance Awards&#8221;) such as the completion of a future financing event or upon the achievement of defined clinical milestones or outcomes. The Company did <ix:nonFraction unitRef="shares" contextRef="c-133" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-517"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-518">not</ix:nonFraction></ix:nonFraction> issue Performance Awards during the three months ended March&#160;31, 2026 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2026, there are <ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-519">435,381</ix:nonFraction> Performance Awards vested and outstanding, and <ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:fixed-zero" scale="0" id="f-520">no</ix:nonFraction> Performance awards remain unvested</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Performance Awards have a contractual term of <ix:nonNumeric contextRef="c-133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-521">10</ix:nonNumeric> years. There is <ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt-sec:numwordsen" scale="0" id="f-522">no</ix:nonFraction> unrecognized stock-based compensation expense related to Performance Awards.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-523" escape="true"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash&#160;stock-based compensation expense recognized in the accompanying condensed consolidated statements of operations and comprehensive loss for the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March&#160;31, 2026 and 2025 was as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.030%"><tr><td style="width:1.0%"/><td style="width:61.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.952%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-524">1,524</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-525">982</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-526">1,300</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-527">986</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-528">2,824</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-529">1,968</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="if33b9e8d46eb467b84758fa9b250d8f7_64"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-530" continuedAt="f-530-1" escape="true">Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="f-530-1" continuedAt="f-530-2"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The Company&#8217;s unvested restricted common stock is not included in the determination of loss per share until the award vests. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025 and March 2026, the Company issued equity-classified Pre-Funded Warrants with a nominal exercise price of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-531">0.0001</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> per share (see Note </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). In accordance with ASC 260, Earnings Per Share (ASC 260), shares issuable for little to no cash consideration should be included in the number of outstanding shares used to calculate basic loss per share as long as all conditions necessary for exercise are met. The Pre-Funded Warrants are therefore included as outstanding shares as of their issuance date to calculate the weighted average number of shares outstanding to calculate basic loss per share.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-532" escape="true"><ix:continuation id="f-530-2"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.363%"><tr><td style="width:1.0%"/><td style="width:58.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.649%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">K2 Common Stock Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-141" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-533">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-142" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-534">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-143" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="f-535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-144" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-536">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-145" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-537">7,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-146" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-538">5,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-539">7,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-540">5,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="if33b9e8d46eb467b84758fa9b250d8f7_67"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-541" continuedAt="f-541-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-541-1"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, including its net operating losses. Based on its history of operating losses, the Company believes that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for its net deferred tax assets as of March&#160;31, 2026 and December&#160;31, 2025.</span></div></ix:continuation><div id="if33b9e8d46eb467b84758fa9b250d8f7_70"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-542" continuedAt="f-542-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-542-1" continuedAt="f-542-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">K2 Warrant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, in connection with the closing of the Original Loan Agreement, the Company issued a warrant to the Lender to purchase a number of shares of the Company&#8217;s Series B convertible preferred stock, or at Lender&#8217;s election, next round stock (&#8220;K2 Warrant&#8221;). The number of shares of convertible preferred stock issuable upon exercise of the warrant was equal to (a) (i) <ix:nonFraction unitRef="number" contextRef="c-147" decimals="4" name="alto:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier" scale="0" id="f-543">0.0375</ix:nonFraction>, multiplied by (ii)&#160;the aggregate principal amount of term loans actually funded under the Original Loan Agreement, divided by (b)&#160;the warrant price then in effect. Following the conversion of all outstanding convertible preferred stock to common stock upon the completion of the IPO in February 2024, the K2 Warrant became a warrant to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-66" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-544">35,773</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-66" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-545">10.49</ix:nonFraction> per share (referred to in Note 4 as the Original Warrant).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2025, in connection with the Amended Loan Agreement (see Note 4 for additional information), the K2 Warrant was amended and restated (referred to in Note 4 as the Amended and Restated Warrant) to reduce the exercise price from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-66" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-546">10.49</ix:nonFraction> per share to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-148" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-547">3.71</ix:nonFraction> per share (referred to in Note 4 as the Exercise Price). Further, in connection with the Amendment, the Company issued an additional warrant (referred to in Note 4 as the New Warrant and, together with the Amended and Restated Warrant, the Warrants) to purchase a number of shares of the Company&#8217;s common stock calculated as follows: (a) (i) <ix:nonFraction unitRef="number" contextRef="c-54" decimals="INF" name="alto:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier" scale="0" id="f-548">0.025</ix:nonFraction>, multiplied by (ii) the aggregate principal amount of the term loans actually funded under the Amended Loan Agreement, divided by (b) the Exercise Price. The New Warrant expires on January 13, 2035. The New Warrant is classified as equity as it meets all the conditions under GAAP for equity classification, and is therefore not subject to ongoing remeasurement. The Company reassesses whether equity classification for the warrant is appropriate upon any changes to the warrants or capital structure, at each balance sheet date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">f March&#160;31, 2026 the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">New Warrant allowed for the purchase of <ix:nonFraction unitRef="shares" contextRef="c-68" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-549">134,691</ix:nonFraction> shares of the Company&#8217;s common stock. If the Company draws down on additional tranches of the Term Loan, the number of shares available for purchase by the Lender under the New Warrant would increase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is conditionally obligated to issue a fixed number of additional shares in connection with the New Warrant (&#8220;Additional Warrants&#8221;) in the potential amount of <ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-550">168,363</ix:nonFraction> shares upon the funding of additional amounts under the Term Loan with the same exercise price and contractual term. The contingent obligation to issue the Additional Warrants did not meet the derivative scope exception or equity classification criteria and were accounted for as a derivative liability. The </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><ix:continuation id="f-542-2" continuedAt="f-542-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">con</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">tingently issuable Additional Warrants derivative liability had a de minimis value at the time of issuance and as of March&#160;31, 2026. The Additional Warrants derivative liability will be remeasured each reporting period until settled or extinguished</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> with subsequent changes in fair value recorded through other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. The initial fair value of the Additional Warrants derivative liability was determined using a Black-Scholes option pricing model based on the same input assumptions above, with an additional assessment required for the probability that additional amounts under the Term Loan will be funded which would trigger the issuance of the Additional Warrants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-Funded Warrants Issued in October 2025 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025, the Company entered into a Securities Purchase Agreement (the &#8220;2025 PIPE Purchase Agreement&#8221;) with certain institutional and other accredited investors (the &#8220;2025 PIPE Purchasers&#8221;), pursuant to which the Company sold and issued to the 2025 PIPE Purchasers in a private placement transaction (the &#8220;2025 Private Placement&#8221;) (i) <ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-551">3,832,263</ix:nonFraction>&#160;shares of the Company&#8217;s common stock (the &#8220;2025 PIPE Shares&#8221;), and (ii) with respect to certain 2025 PIPE Purchasers, pre-funded warrants to purchase&#160;<ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-552">4,622,251</ix:nonFraction>&#160;shares of the Company&#8217;s common stock (the &#8220;2025 Pre-Funded Warrants&#8221;) in lieu of shares of the Company&#8217;s common stock. The purchase price per share of common stock was$<ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="3" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-553">5.9140</ix:nonFraction>&#160;per share (the &#8220;2025 PIPE Purchase Price&#8221;), and the purchase price for the 2025 Pre-Funded Warrants was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="4" name="alto:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" scale="0" id="f-554">5.9139</ix:nonFraction>&#160;per 2025 Pre-Funded Warrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Pre-Funded Warrants have a per share exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-555">0.0001</ix:nonFraction>, subject to proportional adjustments in the event of stock splits or combinations or similar events. The 2025 Pre-Funded Warrants will not expire until exercised in full. The 2025 Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation; provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving&#160;<ix:nonNumeric contextRef="c-153" name="alto:ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation" format="ixt-sec:durday" id="f-556">61</ix:nonNumeric> days&#8217; notice to the Company, but not to any percentage in excess of&#160;<ix:nonFraction unitRef="number" contextRef="c-153" decimals="3" name="alto:ClassOfWarrantsOrRightsWarrantExcessPercentage" scale="-2" id="f-557">19.9</ix:nonFraction>%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the 2025 Pre-Funded Warrants meet the criteria for equity classification at issuance and were recorded as a component of stockholders&#8217; equity within additional paid-in capital. The 2025 Pre-Funded Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such 2025 Pre-Funded Warrants do not provide any guarantee of value or return.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-Funded Warrants Issued in March 2026 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2026, the Company entered into a Securities Purchase Agreement (the &#8220;2026 PIPE Purchase Agreement&#8221;) with certain institutional investors (the &#8220;2026 PIPE Purchasers&#8221;), pursuant to which the Company sold and issued to the 2026 PIPE Purchasers in a private placement transaction (the &#8220;2026 Private Placement&#8221;) (i) <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-558">2,900,000</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;2026 PIPE Shares&#8221;), and (ii) with respect to certain 2026 PIPE Purchasers, pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-155" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-559">3,100,000</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;2026 Pre-Funded Warrants&#8221;) in lieu of shares of the Company&#8217;s common stock. The purchase price per share of common stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-156" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-560">20.00</ix:nonFraction> per share (the &#8220;2026 PIPE Purchase Price&#8221;), and the purchase price for the 2026 Pre-Funded Warrants was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-155" decimals="4" name="alto:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" scale="0" id="f-561">19.9999</ix:nonFraction> per 2026 Pre-Funded Warrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2026 Pre-Funded Warrants have a per share exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-155" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-562">0.0001</ix:nonFraction>, subject to proportional adjustments in the event of stock splits or combinations or similar events. The 2026 Pre-Funded Warrants will not expire until exercised in full. The 2026 Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation; provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving&#160;<ix:nonNumeric contextRef="c-153" name="alto:ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation" format="ixt-sec:durday" id="f-563">61</ix:nonNumeric> days&#8217; notice to the Company, but not to any percentage in excess of&#160;<ix:nonFraction unitRef="number" contextRef="c-153" decimals="3" name="alto:ClassOfWarrantsOrRightsWarrantExcessPercentage" scale="-2" id="f-564">19.9</ix:nonFraction>%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the 2026 Pre-Funded Warrants meet the criteria for equity classification at issuance and were recorded as a component of stockholders&#8217; equity within additional paid-in capital. The 2026 Pre-Funded Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><ix:continuation id="f-542-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such 2026 Pre-Funded Warrants do not provide any guarantee of value or return.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock and Authorized Shares</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of both March&#160;31, 2026 and December&#160;31, 2025, the Company h</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ad <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-565"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-566">500,000,000</ix:nonFraction></ix:nonFraction> authorized shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-567"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-568">0.0001</ix:nonFraction></ix:nonFraction> per share, of which <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-569"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-570">35,052,731</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-571"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-572">31,923,521</ix:nonFraction></ix:nonFraction> shares, respectively, were issued and outstanding. On February 6, 2024, the Company amended its certificate of incorporation such that the total number of shares of common stock authorized to be issued was increased to <ix:nonFraction unitRef="shares" contextRef="c-157" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-573">500,000,000</ix:nonFraction>, and the total number of shares of new preferred stock authorized to be issued was <ix:nonFraction unitRef="shares" contextRef="c-157" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-574">10,000,000</ix:nonFraction> with a par value per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-157" decimals="4" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-575">0.0001</ix:nonFraction>. As of March&#160;31, 2026, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-576"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-577">no</ix:nonFraction></ix:nonFraction> shares of preferred stock were issued or outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="alto:ScheduleOfStockReservedForIssuanceTableTextBlock" id="f-578" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, the Company had reserved common stock, on an&#160;as-if&#160;converted basis, for issuance as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.393%"><tr><td style="width:1.0%"/><td style="width:60.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.897%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">K2 Warrants</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-579">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-580">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-Funded Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-155" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-581">7,722</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 4.37pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-160" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-582">4,622</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options issued and outstanding from 2024, 2019 Equity Incentive Plan and Inducement Plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-583">7,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-584">5,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future grant from 2024 Equity Incentive Plan and Inducement Plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-585">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-586">975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-587">15,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-588">11,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reserved common stock in the table above does not include (i) the number of shares of the Company&#8217;s common stock issuable upon conversion of the remaining amount of the Conversion Amount specified within the Amended Loan Agreement (see Note 4), (ii) the variable number of shares issuable pursuant to conversion of amounts funded under the Convertible Grant Agreement (see Note 4), and (iii) the variable number of shares issuable pursuant to terms of the asset purchase agreement, dated May 31, 2025, between the Company and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chase Therapeutics Corporation.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if33b9e8d46eb467b84758fa9b250d8f7_76"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-589" continuedAt="f-589-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-589-1" continuedAt="f-589-2"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to occasional lawsuits, investigations and claims arising out of the ordinary course of business.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Other than as set forth below, the Company had no significant pending or threatened litigation as of March&#160;31, 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On July 21, 2025, a purported stockholder of the Company filed a lawsuit against the Company, certain executive officers, and certain current and former directors in the United States District Court for the Northern District of California (Case No. 3:25-cv-06105). The plaintiff filed an amended complaint on January 23, 2026 and a second amended complaint on April 6, 2026. The complaint is a putative class action alleging violations of the Securities Act of 1933, as amended, related to the Company&#8217;s IPO in February 2024, and violations of the Exchange Act thereafter. The proposed classes consist of purchasers or acquirers of the Company&#8217;s common stock pursuant or traceable to the Company&#8217;s IPO as well as purchasers or acquirers of the Company&#8217;s common stock between March 18, 2024 and October 22, 2024, both dates inclusive. The plaintiff seeks unspecified damages, as well as interest, fees, and costs. The complaint claims, among other things, that the Company&#8217;s offering documents and subsequent public disclosures contained materially false and misleading statements and omitted material facts about the prospects of ALTO-100. The Company believes these allegations lack merit, and the Company filed a motion to dismiss on May 5, 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a consolidated stockholder derivative action, captioned In re Alto Neuroscience, Inc. Derivative Litigation, Lead Case No. 5:25-cv-07144-NW was filed on behalf of the Company against certain executive officers and certain current and former directors for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the federal securities laws. The claims arise out of the same factual allegations as the putative class action described above. The plaintiffs seek unspecified damages, as well as interest, fees, and costs. The </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alto Neuroscience, Inc. and Subsidiary</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><ix:continuation id="f-589-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">consolidated stockholder derivative action was stayed on January 14, 2026 pending resolution of the motion to dismiss in the securities class action. The Company believes that these claims lack merit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not recorded a liability related to these lawsuits because, at this time, the Company does not believe that an unfavorable outcome is either probable or estimable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is unknown at March&#160;31, 2026. The Company does not anticipate recognizing any significant losses relating to these arrangements.</span></div></ix:continuation><div id="if33b9e8d46eb467b84758fa9b250d8f7_82"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-590" continuedAt="f-590-1" escape="true">Segments</ix:nonNumeric></span></div><ix:continuation id="f-590-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a single reportable segment entity, the Company&#8217;s segment performance measure is consolidated net loss. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Asset information is not used by the Company&#8217;s President and Chief Executive Officer, its chief operating decision maker (&#8220;CODM&#8221;) to allocate resources.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Certain significant segment expenses below loss from operations are presented in the Company&#8217;s consolidated statements of operations and are therefore not presented below. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-591" continuedAt="f-591-1" escape="true">Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company&#8217;s condensed consolidated statements of operations, are presented below (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-591-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"><tr><td style="width:1.0%"/><td style="width:71.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expenses excluding stock-based compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-592">6,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-593">5,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-594">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-595">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct external program expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-100</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-596">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-597">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-300</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-598">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-599">922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-101</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-600">5,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-601">969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-203</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-602">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-603">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-207</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-604">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="f-605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other research and development </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-606">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-607">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-608">4,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-609">3,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-610">27,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-611">15,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(a) Other research and development expenses primarily consists of license fees, facility charges, third party consultant costs, early research costs related to other product candidates, and other unallocated costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(b) General and administrative costs include professional fees, insurance, consultant fees and facility charges.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated fina</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ncial statements and the related notes included elsewhere in this Quarterly Report and the audited financial statements and notes thereto as of and for the year ended December 31, 2025 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report filed with the SEC on March 16, 2026.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As discussed in the section titled &#8220;Special Note Regarding Forward Looking Statements,&#8221; the following discussion and analysis includes forward-looking statements that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those discussed below. Factors that could cau</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">se or contribute to such differences include, but are not limited to those identified below and those set forth under &#8220;Item 1A. Risk Factors&#8221; in our Annual Report, under &#8220;Item 1A. Risk Factors&#8221; in this Quarterly Report, and in our other reports filed with the SEC.</span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Through insights derived from our scalable and proprietary Precision Psychiatry Platform, or our Platform, we aim to develop novel medicines that are more targeted based on a deep understanding of patient biology and the activity of our product candidates on brain processes. Our current pipeline consists of seven clinical-stage assets addressing high-need therapeutic areas, focusing on major depressive disorder, or MDD, bipolar depression, or BPD, treatment resistant depression, or TRD, schizophrenia, and Parkinson&#8217;s disease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical-stage product candidates are being advanced based on extensive preclinical and clinical data that suggest the potential to bring significant improvements to patient populations not adequately treated with current standard-of-care&#8239;medications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline of clinical-stage product candidates is depicted below:</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="alto-20260331_g1.jpg" alt="2026.05_1Q Pipeline.jpg" style="height:462px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" id="i-1"/></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement Transactions</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">October 2025 Private Placement</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In October 2025, we entered into a Securities Purchase Agreement, or the 2025 PIPE Purchase Agreement, with certain institutional and other accredited investors, or the 2025 PIPE Purchasers, pursuant to which we sold and issued to the 2025 PIPE Purchasers in a private placement transaction, or the 2025 Private Placement: (i) 3,832,263 shares of our common stock, or the 2025 PIPE Shares and (ii) with respect to certain 2025 PIPE Purchasers, pre-funded warrants to purchase 4,622,251 shares of our common stock, or the 2025 Pre-Funded Warrants, in lieu of shares of common stock. The purchase price per share of common stock was $5.9140 per share, or the 2025 PIPE Purchase Price, and the purchase price for the 2025 Pre-Funded Warrants was $5.9139 per 2025 Pre-Funded Warrant. The closing occurred on October 21, 2025. The total gross proceeds to us were approximately $50.0 million, and, after deducting offering expenses payable by us, net proceeds were approximately $49.7 million.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">March 2026 Private Placement</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In March 2026, we entered into a Securities Purchase Agreement, or the 2026 PIPE Purchase Agreement, with certain institutional investors, or the 2026 PIPE Purchasers, pursuant to which we sold and issued to the 2026 PIPE Purchasers in a private placement transaction, or 2026 Private Placement: (i) 2,900,000 shares of our common stock, or the 2026 PIPE Shares and (ii) with respect to certain 2026 PIPE Purchasers, pre-funded warrants to purchase 3,100,000 shares of our common stock, or the 2026 Pre-Funded Warrants, in lieu of shares of common stock. The purchase price per share of common stock was $20.00 per share, or the 2026 PIPE Purchase Price, and the purchase price for the 2026 Pre-Funded Warrants was $19.9999 per 2026 Pre-Funded Warrant. The closing occurred on March 17, 2026. The total gross proceeds to us were approximately $120.0 million, and, after deducting offering expenses payable by us, net proceeds were approximately $114.9 million.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Product Candidates</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ALTO-207 </span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist, approved for the treatment of Parkinson&#8217;s disease with demonstrated antidepressant effect through multiple robust randomized, placebo-controlled clinical trials, and ondansetron, an antiemetic, selective 5-HT3 receptor antagonist. As a fixed-dose combination, ALTO-207 is designed to enable rapid titration and higher dosing by mitigating the dose-limiting adverse events typically experienced with pramipexole. ALTO-207 is being developed to address the significant unmet need for patients with TRD. The Phase 2b trial of ALTO-207, which has the potential to serve as a pivotal trial subject to U.S. Food and Drug Administration, or FDA, feedback and review of data, was initiated in April 2026. The Phase 2b trial is a randomized, double-blind, placebo-controlled study evaluating ALTO-207 as an adjunctive treatment in approximately 178 adults with TRD. Eligible participants will have experienced two to five prior treatment failures and have moderate to severe depression symptoms, and will remain on their baseline antidepressant medication. Participants will be randomized 1:1 to receive ALTO-207 or placebo during an eight-week double-blind treatment period, which includes a 12-day dose titration period to reach a target total daily dose of 3.2mg pramipexole/15mg ondansetron. The study will be conducted across clinical sites in the U.S. and U.K. The primary endpoint is change from baseline in MADRS. The Company expects to report topline data from the trial in the second half of 2027. Following an FDA meeting in October 2025, we also expect to initiate a Phase 3 trial by early 2027 following Phase 3 readiness work and alignment with the FDA on the planned trial design.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025, we acquired ALTO-207 (formerly known as CTC-501) from Chase Therapeutics Corporation, or Chase. Prior to the acquisition, Chase completed a randomized, placebo-controlled Phase 2a clinical trial evaluating CTC-501 in 32 patients with depression. CTC-501 met the primary and secondary endpoints in this trial, demonstrating statistically significant and clinically meaningful improvements on the Montgomery &#197;sberg Depression Rating Scale, or MADRS, compared to placebo. Patients randomized to receive CTC-501 reached a mean dose of 4.1mg per day. Real-world data demonstrate that it is challenging to achieve doses above 1mg per day of pramipexole. CTC-501 was generally well tolerated in the maintenance period of the study with an adverse event rate similar to placebo.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our acquisition of ALTO-207 was motivated by the results from the PAX-D study conducted by the University of Oxford. Results, which were published in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet Psychiatry</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, showed pramipexole augmentation of antidepressant treatment, at a target dose of 2.5mg, demonstrated a large (Cohen&#8217;s&#8239;d=0.87) reduction in symptoms relative to placebo at 12 weeks (and continuing through 48 weeks), but was associated with a high rate of adverse effects.&#8239;We believe the profile of ALTO-207 will enable higher dosing of pramipexole while mitigating the significant rates of nausea and vomiting that have limited its use for depression. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ALTO-300</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-300, also known as agomelatine, is an investigational oral, small molecule melatonergic (MT1 and MT2) agonist and serotonergic (5-HT2C)&#8239;antagonist with antidepressant properties, and is being developed at 25mg as an adjunctive treatment in the United States for patients with MDD, characterized by an electroencephalography, or EEG, biomarker. Agomelatine has been approved as an antidepressant in Europe and Australia at both 25mg and 50mg, but has not been approved in the United States. In comparison to the 50mg dose of agomelatine, the 25mg dose has been shown to have equivalent antidepressant efficacy and has not been associated with reversible, low liver enzyme elevations observed with the 50mg dose. A published meta analysis including more than 58,000 patients demonstrated that agomelatine is not associated with elevated aspartate transferase, or AST, or alanine transaminase, or ALT, unlike certain other commonly used antidepressants. In our development program, including our completed Phase 2a and ongoing Phase 2b study, we have observed low rates of liver function test, or LFT, elevations (greater than 3 times the upper limit of normal, or ULN) with the 25mg dose which supports our strategy of developing only the 25mg dosage strength.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are currently evaluating ALTO-300 in a double-blind, placebo-controlled, randomized Phase 2b clinical trial in patients with MDD characterized by an EEG biomarker signature. We expect to enroll approximately 200 biomarker positive patients in the final analysis sample, which is therefore expected to result in approximately 320 patients enrolled in the study in total (inclusive of biomarker negative patients and patients not included in the final analysis sample as a result of the completed blinded site and patient case review). Patients are randomized to receive either 25mg of ALTO-300 once daily before bedtime, or QHS, or placebo in addition to a background antidepressant, to which they have had inadequate response, over a six-week treatment period. Patients are then enrolled into an eight-week open-label extension in which they receive 25mg QHS of ALTO-300. We selected the 25mg dose of ALTO-300 with the aim to optimize clinical efficacy while balancing safety and tolerability. The primary endpoint in the trial is the change in MADRS score from baseline to week six in the EEG biomarker positive group. We expect to report topline data from this trial in the first half of 2027. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025, we announced a favorable outcome from the planned interim analysis for the Phase 2b trial of ALTO-300 as an adjunctive treatment for patients with MDD. The interim analysis resulted in a recommendation to continue the study and increase the biomarker positive sample, which we believe will improve the overall probability of success of this trial. Prior to the interim analysis, a blinded committee conducted an in-depth site and patient eligibility review that resulted in the prospective exclusion of sites and patients from the analysis population. Following the eligibility review, the biomarker positive population in the interim analysis consisted of 87 patients. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025, we presented additional analyses at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) Annual Meeting supporting the unique biomarker opportunity for patient stratification and reinforcing the well-established safety and tolerability profile for ALTO-300 in MDD. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ALTO-100</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are currently evaluating ALTO-100 in a Phase 2b trial in patients with BPD in which patients are assigned to take ALTO-100 as adjunctive treatment to a stable dose of a background mood stabilizing treatment over a six-week treatment period. BPD is associated with memory, cognitive, and neuroplasticity abnormalities at similar or greater rates than seen in MDD. Much like MDD, poor memory and cognition patients typically experience greater treatment resistance and disability, with overall worse outcomes. Moreover, the only currently approved therapies are antipsychotics. We believe the pro-neuroplasticity mechanism of ALTO-100 has the potential to address the high unmet need in this important patient population. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A blinded pharmacokinetic, or PK, analysis from the first cohort of patients in this trial demonstrated that 96% of samples for ALTO-100 qualified as PK positive. A sample was considered PK positive if observed drug levels </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">were above a pre-specified minimum threshold. We believe these results underscore the effectiveness of the operational adjustments made to trial design and execution following the completion of the ALTO-100 MDD Phase 2b trial. Enrollment in this trial is ongoing, with a target of approximately 200 patients, and we expect to report topline data from the study in mid-2027.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2024, we completed the Phase 2b trial evaluating ALTO-100 as a treatment for MDD. The clinically meaningful signal in the adjunctive subgroup and the evidence of biomarker enrichment in the compliant subset of patients support the ongoing Phase 2b trial of ALTO-100 as an adjunctive treatment in BPD. </span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ALTO-101</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2026, we announced that our Phase 2 proof-of-concept, or POC, clinical trial evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia, or CIAS, did not achieve statistical significance on primary EEG or cognitive endpoints versus placebo; however, the study demonstrated directional improvements across certain EEG measures, including a near-significant effect on theta-ITC (n=83, d=0.34, p=0.052) &#8211; a measure correlated with cognitive performance across datasets. In a pre-specified analysis in a more cognitively impaired subgroup (n=59), ALTO-101 exhibited nominally significant effects on theta-ITC compared to placebo (d=0.44, p=0.03). Further, certain EEG measures, including theta-ITC, showed improvements from day 5 to day 10 in the trial, suggesting a longer treatment period may elucidate greater effects. ALTO-101 demonstrated a favorable tolerability profile, with rates of nausea and vomiting &#8212; hallmark side effects associated with the PDE4 inhibitor class &#8212; in line with placebo rates. This finding suggests the pharmacokinetic profile of ALTO-101 may overcome a key tolerability barrier that has historically limited PDE4 inhibitor adoption. High rates of application site skin reactions were observed across both active and placebo arms.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a modified-release oral formulation of ALTO-101 that has demonstrated an improved pharmacokinetic and tolerability profile relative to the immediate-release formulation. We believe this formulation may offer potential benefits across multiple therapeutic areas and intend to explore partnering opportunities. The formulation is covered by a pending patent application.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following the topline data readout of the Phase 2 proof-of-concept study, further analyses have been completed and the findings reflect a potential product profile suitable for a range of cognitive disorders. Specifically, further analyses identified large and statistically significant effects of ALTO-101 across the overall study population on multiple EEG markers relevant to cognition. ALTO-101 produced an increase in individual alpha peak frequency (d=0.59, p=0.001), a heritable index of neurophysiological efficiency that tracks a range of cognitive functions, as well as a shift toward greater cortical excitability, evidenced by increases in high frequency power (beta: d=0.70, p&lt;0.001; gamma: d=0.61, p=0.001) and a decrease in low frequency power (theta: d=0.50, p=0.007). These changes resulted in a decrease in the theta/beta ratio (d=0.57, p=0.003), an FDA-cleared measure of attention-deficit/hyperactivity disorder. Significant improvement was also observed in sustained attention, as measured by the Continuous Performance Task (d=0.41, p=0.02), while no significant effects were observed in processing speed or memory.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Taken together with the topline data, the deeper analysis of the ALTO-101 proof-of-concept data reveal compelling signals that we believe merit further evaluation of this product candidate.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ALTO-203 </span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-203 is an investigational novel, oral, small molecule histamine H3 inverse agonist. We are currently advancing&#8239;ALTO-203&#8239;for the treatment of patients with MDD associated with increased levels of anhedonia.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2025, we announced the completion of our exploratory Phase 2 POC trial of ALTO-203 in MDD with elevated levels of anhedonia and the resulting identification of a patient selection biomarker and positive pharmacodynamic results. The exploratory Phase 2 POC trial, which enrolled 69 patients, was conducted in two sequential, double-blind, placebo-controlled periods. The trial was designed to characterize the pharmacodynamic, pharmacokinetic, safety, and tolerability profile of ALTO-203 across two dose levels compared to placebo in a crossover design and was not powered to detect statistical significance on traditional depression outcome scales (e.g., MADRS).</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The profile exhibited by ALTO-203 in the exploratory POC trial demonstrated clear effects on objective measures of attention and wakefulness, with observed improvements linked to changes in the EEG theta/beta ratio&#8212;a biomarker indexing cortical arousal and attentional control. This biomarker is FDA-cleared for use alongside clinical evaluation in the diagnosis of attention-deficit/hyperactivity disorder or ADHD, reinforcing its clinical relevance. These findings replicate results from the Phase 1 study in healthy volunteers, where ALTO-203 treatment led to improvements in sustained attention and reductions in the EEG theta/beta ratio. Baseline EEG theta/beta ratio predicted attentional benefits of ALTO-203 in both the Phase 1 study and Phase 2 POC trial. A higher-than-expected placebo response was observed on Bond &amp; Lader measurements, therefore no significant separation of subjective effects between ALTO-203 and placebo were observed. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We presented data in early 2026 demonstrating the potential benefits of ALTO-203 in indications with excessive daytime sleepiness/hypersomnolence and/or impairments in sustained attention. We continue to evaluate the best indication to pursue with ALTO-203, and expect to provide further details on planned development in the future.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ALTO-202</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the N-methyl-D-aspartate, or NMDA receptor, for the treatment of patients with MDD. We are currently in the process of planning the next phase of clinical development for ALTO-202.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ALTO-208 </span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-208 is a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist. We plan to develop ALTO-208 for patients with Parkinson&#8217;s disease (PD). In May 2025, we acquired ALTO-208 (formerly known as CTC-413) from Chase. </span></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2019, we have devoted substantially all of our resources to the research and development of our product candidates by conducting clinical trials and preclinical studies, building our Platform, and recruiting management and technical staff to support these operations. To date, we have funded our operations primarily through the aggregate net proceeds from equity financings (including from our initial public offering, or IPO, private placement transactions, and pre-IPO sales of our convertible preferred stock) and borrowings under our loan and security agreem</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ent.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have not gen</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">erated any revenue from product sales and we have incurred recurring losses since our inception. Our net losses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> were $26.2&#160;million and $15.2&#160;million for the three months ended March&#160;31, 2026 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, respectively.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> As of March&#160;31, 2026, we had an accumulated deficit of $227.9&#160;million. We expect to continue to generate operating losses and negative operating cash flows for the foreseeable future. We anticipa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">te that our operating expenses and capital expenditures will increase substantially with our ongoing activities, particularly as we:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">continue to progress the clinical development of our product candidates, including ALTO-207 in our  Phase 2b clinical trial and planned Phase 3 clinical trial, and ALTO-100 and ALTO-300 in ongoing Phase 2b clinical trials, as well as ALTO-203, and ALTO-208;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">advance additional product candidates through clinical development;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">require the manufacture of larger quantities of our product candidates to support future clinical trials or potential commercialization;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">seek marketing authorizations for any of our product candidates that successfully complete clinical development, if any;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">acquire or license other product candidates or technologies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">make milestone, royalty, or other payments under any current or future license agreements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">obtain, maintain, protect, and enforce our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">seek to attract and retain new and existing skilled personnel; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">add operational, legal, financial and management information systems and personnel to support our product development and clinical execution, as well as to support our transition to a public company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We will not generate any revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing, and distribution.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our operating activities as we advance our product candidates through clinical development, seek regulatory approval, and prepare for and, if any of our product candidates are approved, proceed to commercialization. Until such time, if ever, as we can generate substantial revenue from product sales to support our cost structure, we expect to finance our operating activities through a combination of public or private sales of equity, government or private party grants, debt financings, or other capital sources, including potential collaborations with other companies or other strategic transactions. Adequate funding may not be available to us on acceptable terms, or at all.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding, we will be forced to delay, reduce, or eliminate some or all of our research and development programs, product portfolio expansion, or commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations. Although we continue to pursue these plans, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, we had cash, cash equivalents and restricted cash of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$264.3&#160;million.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that our existing cash and cash equivalents, together with the anticipated proceeds under our Convertible Grant Agreement with Wellcome, will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 12 months. See &#8220;&#8212;Liquidity and Capital Resources.&#8221;</span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_97"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for the development of our product candidates and our platform and technology building efforts, which include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">personnel expenses, including salaries, benefits, and stock-based compensation expense for our employees engaged in research and development functions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">expenses incurred in connection with the clinical development of our product candidates, including under agreements with clinical sites and contract research organizations, or CROs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">fees incurred in connection with license agreements and asset acquisitions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">costs of manufacturing drug product and drug supply related to our current or future product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">cost of outside consultants engaged in research and development functions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">expenses related to regulatory affairs; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">fees for maintaining licenses and other amounts due under our third-party licensing agreements.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs in the periods in which they are incurred. Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks, using information provided to us by our vendors and analyzing the progress of our clinical trials or other services performed. Significant judgment and estimates are made in determining the accrued expense balances at the end of any reporting period.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Research and development activities are central to our business model. We expect our research and development expenses to increase substantially for the foreseeable future as we advance our product candidates into and through later stage clinical trials, pursue regulatory approval of our product candidates, build our operational and commercial capabilities for supplying and marketing our products, if approved, and expand our pipeline of product candidates. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. Furthermore, product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. The actual probability of success for our product candidates may be affected by a variety of factors, including the safety and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">efficacy of our product candidates, conduct of clinical trials, investment in our clinical programs, competition, manufacturing capability, and commercial viability. We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion of costs of our research and development projects or if, when, and to what extent we will generate revenue from the commercialization and sale of our product candidates, if approved by the FDA and other applicable regulatory authorities.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future research and development costs may vary significantly based on factors such as:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the timing and progress of our clinical development activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the number and scope of preclinical and clinical programs we decide to pursue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the amount and timing of any milestone payment due under an existing, or any future, license or collaboration agreement or asset acquisition;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the number of patients that participate in our clinical trials, and per participant clinical trial costs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the number and duration of clinical trials required for approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the number of sites included in our clinical trials, and the locations of those sites;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays or difficulties in adding trial sites and enrolling participants in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">patient drop-out or discontinuation rates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">potential additional safety monitoring requested by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the phase of development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the efficacy and safety profile of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the timing, receipt, and terms of any approvals from applicable regulatory authorities including the FDA and non-U.S. regulators;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">changes in the competitive outlook;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the extent to which we establish additional strategic collaborations or other arrangements; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the impact of any business interruptions to our operations or to those of the third parties with whom we work.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also expect to incur significant manufacturing costs as our contract manufacturing organizations, or CMOs, develop scaled commercial manufacturing processes. However, we do not believe that it is possible at this time to accurately project expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans. </span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, corporate and business development, and administrative functions. General and administrative expenses also include professional fees for legal, patent, accounting, information technology, auditing, tax and consultin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">g services, travel expenses, and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future as we expand our headcount to support our continued research and development of our product candidates. We also expect to incur increased expenses associated with operating as a public company, including costs related to accounting, audit, legal (including legal costs related to the stockholder litigation described in &#8220;Part II, Item I. Legal Proceedings,&#8221; below), regulatory, and tax-related services, costs </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">related to compliance with the rules and regulations of the SEC and listing standards applicable to companies listed on a national securities exchange, director and officer insurance costs, and investor relations costs. In addition, if we obtain regulatory approval for any of our product candidates and do no</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">t enter into a third-party commercialization collaboration, we expect to incur significant expenses related to building a sales and marketing team to support product sales, marketing, and distribution activities.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of interest income on our cash and cash equivalents, interest expense on borrowings under our loan and security agreement, loss on debt extinguishment, and&#160;non-cash&#160;changes in the fair value of our Convertible Grant Agreement with Wellcome (See &#8220;&#8212; Liquidity and Capital Resources&#8221;).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March 31, 2026 and 2025</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March&#160;31, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.000%"><tr><td style="width:1.0%"/><td style="width:62.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.477%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27,138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27,138)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(15,676)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(598)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(681)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(26,237)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(15,169)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses by program for the periods presented </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.000%"><tr><td style="width:1.0%"/><td style="width:62.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.477%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct external program expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-100</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-300</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-101</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-203</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-207</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other clinical development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Internal and unallocated expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other unallocated expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,294&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,974&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $20.3 million for the three months ended March 31, 2026, compared to $10.0 million for the three months ended March 31, 2025. Increases in research and development expenses were due primarily to: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of approximately $4.4 million in expenses related to the development of our ALTO-101 program, including our Phase 2 POC trial of ALTO-101 for which we announced top line data on April 1, 2026.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of approximately $4.1 million in expenses related to development of our ALTO-207 program, which we acquired in May 2025. The costs primarily related to clinical and manufacturing activities required to launch the Phase 2b clinical trial, which we announced the initiation of in April 2026.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $1.2 million in salary and personnel related costs, which includes $0.5 million of non-cash stock-based compensation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $6.8&#160;million for the three months ended March 31, 2026, compared to $5.7&#160;million for the three months ended March 31, 2025. The increase of $1.1&#160;million was primarily due to increases in professional fees.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net increased $0.4&#160;million during the three months ended March 31, 2026, compared to the three months ended March 31, 2025. The increase was primarily due to debt extinguishment costs of $0.7 million that were incurred during the three months ended March 31, 2025. This increase was partially offset by a decrease in interest income of $0.3 million during the three months ended March 31, 2026 compared to the three months ended March 31, 2025.</span></div><div><span><br/></span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_106"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. We have not yet commercialized any of our product candidates, which are in various phases of development, and we do not expect to generate revenue from sales of any of our product candidates for several years, if at all. As we progress through the phases of development, we anticipate that we will incur increasing losses in future quarters and years compared to historical periods. To date, we have funded our operations primarily through the aggregate net proceeds from equity financings (including from our IPO, our October 2025 and March 2026 private placement transactions, and pre-IPO sales of our convertible preferred stock) and borrowings under our loan and security agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of March&#160;31, 2026 and December&#160;31, 2025, we had cash, cash equivalents and restricted cash of $264.3&#160;million and $177.0 million, respectively. </span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Private Placement Transactions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025, we entered into the 2025 PIPE Purchase Agreement with the 2025 PIPE Purchasers pursuant to which we sold and issued to the 2025 PIPE Purchasers: (i) 3,832,263 shares of our common stock and (ii) with respect to certain 2025 PIPE Purchasers, 2025 Pre-Funded Warrants to purchase 4,622,251 shares of common stock in lieu of shares of common stock. The purchase price per share of common stock was $5.9140 per share and the purchase price for the 2025 Pre-Funded Warrants was $5.9139 per 2025 Pre-Funded Warrant. The closing occurred on October 21, 2025. The total gross proceeds to us were approximately $50.0 million, and, after deducting offering expenses payable by us, net proceeds were approximately $49.7&#160;million.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2026, we entered into the 2026 PIPE Purchase Agreement with the 2026 PIPE Purchasers pursuant to which we sold and issued to the 2026 PIPE Purchasers: (i) 2,900,000 shares of our common stock and (ii) with respect to certain 2026 PIPE Purchasers, 2026 Pre-Funded Warrants to purchase 3,100,000 shares of common stock in lieu of shares of common stock. The purchase price per share of common stock was $20.00 per share and the purchase price for the 2026 Pre-Funded Warrants was $19.9999 per 2026 Pre-Funded Warrant. The closing occurred on March 17, 2026. The total gross proceeds to us were approximately $120.0 million, and, after deducting offering expenses payable by us, net proceeds were approximately $114.9&#160;million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended Loan and Security Agreement</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In December </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">, we </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">entered into a Loan and Security Agreement, or the Original Loan Agreement, with K2 HealthVentures LLC as a lender, the other lenders party thereto (collectively, the Lenders), K2 HealthVentures LLC, or the Administrative Agent, and Ankura Trust Company, LLC, as collateral agent for the Lender. In January 2025, we entered into an amendment to the Original Loan Agreement (the Amendment, and the Original Loan Agreement as amended thereby, the Amended Loan Agreement) to, among other things, extend the maturity date of the facility and increase the maximum available amount of term loans. The Amended Loan Agreement provides for term loans, which we refer to collectively as the Term Loan, in an aggregate principal amount of up to $75.0 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">consisting of:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">a first tranche term loan of $20.0 million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">second tranche term loans of up to $30.0 million in the aggregate available at our request until December 15, 2025, subject to certain time-based, clinical milestones; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">third tranche term loans of up to $25.0 million in the aggregate available at our request subject to the Lender&#8217;s approval. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We drew $20.0 million upon entry into the Amendment </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(approximately $10.0 million of which was used to refinance obligations under the Original Loan Agreement and pay fees and expenses incurred in connection with the Amendment). The second tranche term loans, which were tied to the timing of clinical milestones, expired without being drawn.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of March&#160;31, 2026 and December&#160;31, 2025, we had an outstanding principal balance of $15.0&#160;million and $16.0 million under the Amended Loan Agreement, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Amended Loan Agreement has a Term Loan maturity date of January 1, 2029, or the Amended Term Loan Maturity Date.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Amended Loan Agreement provides for an interest only period until January 1, 2027, following which the Term Loan shall be repaid in equal monthly payments through the Amended Term Loan Maturity Date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Term Loan bears interest at (i) a variable per annum cash pay rate equal to the Prime Rate plus 1.45% (subject to a floor of 8.45% per annum) and (ii) a fixed per annum paid-in-kind rate equal to 1.0%. Interest is due and payable monthly in arrears. Upon final payment or prepayment of the Term Loan, the Company is required to pay a final payment equal to 5.95% of the amount borrowed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We were obligated to pay the Lender a one-time facility fee of $0.3 million upon entry into the Amendment. We are also obligated to pay a funding fee on each third tranche term loan in an amount equal to the sum of 0.5% multiplied by the amount of such third tranche term loan, if and when funded. Our obligation under the Original Loan Agreement to pay the Lender a one-time fee of $0.6 million, or the Original Exit Fee, remains outstanding. We are also obligated to pay a final fee equal to 5.95% of the aggregate amount of the Term Loan funded thereunder, or the Amended Exit Fee, upon the earliest of (i) the Amended Term Loan Maturity Date, (ii) the acceleration of the Term Loan, and (iii) the prepayment of the Term Loan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have the option to prepay all, but not less than all, of the Term Loan prior to the Amended Term Loan Maturity Date, which would require that we pay the Lender a prepayment penalty fee based on a percentage of the outstanding principal balance and the funding date of the individual tranches thereunder.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As to each such tranche under the Term Loan, such fee shall be equal to 3% if the payment occurs on or before 24 months after the funding date of such tranche, 2% if the prepayment occurs more than 24 months after, but on or before 36 months after the funding date of such tranche, or 1% if the prepayment occurs more than 36 months after the funding date of such tranche. No prepayment penalty fee is required if the applicable tranche is prepaid within six months prior to the Amended Term Loan Maturity Date or refinanced with the Lender. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Beginning January 1, 2026, we must maintain, at all times, a cash runway of at least five months based upon a trailing three month cash consumption calculation, provided that this covenant will be waived during any period in which our market capitalization exceeds $700.0 million. The Term Loan is secured by substantially all of our assets, excluding intellectual property.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, under the terms of the Amended Loan Agreement, the Lender may, at its option, elect to convert up to $9.0 million of the then outstanding Term Loan ($4.0 million of which was reflected in the Original Loan Agreement and $5.0 million of which is reflected in the Amendment) into shares of our common stock. On November 17, 2025 and March 19, 2026, the Lender elected to convert $4.0 million and $1.0 million, respectively, of its outstanding loan balance into the Company&#8217;s common stock. Pursuant to the terms of the Amended Loan Agreement, the conversion price was $4.83 per </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">share, resulting in the issuance of 828,860 and 207,215 shares, respectively. The Lender has the option to convert a remaining $4.0 million into shares of common stock; the conversion price per share for the remaining option is $10.49.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Convertible Grant Agreement</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In July </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">2024, we entered into a convertible loan agreement, or the Convertible Grant Agreement, with Wellcome. The Convertible Grant Agreement provides for an unsecured convertible loan, or the Convertible Loan, from Wellcome of up to approximately $11.7 million, payable in six tranches. As of March&#160;31, 2026, we had drawn down $2.0 million under the Convertible Grant Agreement, and the remainder will be funded upon draw down of payments following the completion of certain milestones as set forth in the Convertible Grant Agreement, subject to certain conditions described therein, which may or may not be achieved. In addition to the funds that we have drawn down as of March&#160;31, 2026, we have achieved clinical milestones that allow us to draw down an incremental $3.0 million under the Convertible Grant Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We may use proceeds from the Convertible Loan solely to advance development of ALTO-100 in bipolar depression. In addition, if we do not exploit or develop ALTO-100 (other than for safety or efficacy concerns) within a specified period following the completion of our Phase 2b clinical trial evaluating ALTO-100 in patients with bipolar depression, the Convertible Grant Agreement provides Wellcome with a limited right to exploit ALTO-100, solely in bipolar depression, subject to a revenue share between Wellcome and us of any proceeds arising from Wellcome&#8217;s exploitation. Outstanding amounts under the Convertible Loan accrue interest at an annual rate equal to the Sterling Overnight Index Rate plus 2%, subject to potential adjustment if such interest rate equals or exceeds 9% at any time. At any time after the second anniversary of the effective date of the Convertible Grant Agreement or in connection with an event of default, Wellcome has the right, at its election, to convert some or all of the Convertible Loan into shares of our common stock at a price per share equal to a 20% discount to the thirty-day volume-weighted average price of Common Stock on the New York Stock Exchange at the date of such conversion. The Convertible Grant Agreement provides that in no event shall the aggregate number of shares of our common stock issued pursuant to conversion of the Convertible Loan exceed 5,363,326, which is equal to 19.9% of the number of shares of our common stock outstanding as of the date of the Convertible Grant Agreement. At any time after the fifth anniversary of the date of the Convertible Grant Agreement or in connection with an event of default, Wellcome may require repayment of the Convertible Loan in full, together with accrued interest, to the extent not converted as described above. </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Shelf Registration Statement</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On February 3, 2025, we filed a shelf registration statement on Form S-3 with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and units or any combination thereof up to a total aggregate offering price of $300.0 million.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On February 3, 2025, we also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Leerink Partners LLC, or the Sales Agent, pursuant to which we could issue and sell, from time to time at our discretion, shares of our common stock having an aggregate offering price of up to $75.0 million through or to the Sales Agent. We terminated the Sales Agreement effective as of October 30, 2025. We had not sold any shares of common stock under the Sales Agreement prior to termination.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the net cash flow activity for each of the periods indicated (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.545%"><tr><td style="width:1.0%"/><td style="width:71.150%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.438%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">114,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">87,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,475)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$27.1&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> f</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or the three months ended March 31, 2026, as compared to $16.6&#160;million for the three months ended March 31, 2025. The increase in cash used was the result of an increase in net </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">losses of $11.1 million which was partially offset by increased non-cash stock-based compensation expenses of $0.9 million.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities consisted of purchases of property and equipment that are being used for research and development purposes.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The net cash used in investing activities for the three months ended </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> was negligible.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provide</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d by financing activities was $114.9&#160;million for the three months ended March 31, 2026, primarily related to the proceeds from our 2026 PIPE Purchase Agreement.  </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$9.1&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, primarily related to borrowings under our Amended Loan Agreement, offset by the repayment of our original loan and related financing obligations and lender fees.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash and cash equivalents of $263.8&#160;million as of March&#160;31, 2026, together with the anticipated proceeds under our Convertible Grant Agreement with Wellcome, will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 12 months. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we currently expect.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We will need substantial additional capital to develop our product candidates and fund operations for the foreseeable future. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the scope, timing, rate of progress, and costs of our clinical trials for our current and any future product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the number and scope of clinical programs we decide to pursue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the cost, timing, and outcome of preparing for and undergoing regulatory review of our current and any future product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the cost and timing of manufacturing our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the terms and timing of establishing and maintaining collaborations, licenses, and other similar arrangements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the timing of any milestone and royalty payments to our existing or future suppliers, collaborators, or licensors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our efforts to enhance operational systems and our ability to attract, hire, and retain qualified personnel, including personnel to support the development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the costs associated with being a public company;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the extent to which we acquire or in-license other product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the extent to which we enter into licensing or collaboration arrangements for any of our programs; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and distribution of our product candidates, if they receive marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenue from product sales to support our cost structure, we expect to finance our cash needs through the public or private sale of equity, government or private party grants, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">stockholders may be diluted, and the terms of these securities may include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, which could adversely impact our ability to conduct our business, and may require the issuance of warrants, which could potentially dilute the ownership interests of our stockholders. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings on acceptable terms when needed, we may be required to delay, limit, reduce, or terminate our drug development or future commercialization efforts or grant rights to develop and market our current or any future product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to ongoing needs to fund our operations, our material cash requirements as of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> consist primarily of obligations under both our Amended Loan Agreement (see Note </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report) and our lease commitment for our headquarters office space located in Mountain View, California with an initial lease term of 65 months that terminates in March 2030 for which we currently have a $5.9 million commitment remaining. If the Company elects to terminate the lease after the third lease year, including payments already made, the Company will make payments of approximately $4.0 million over the term of the lease. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturers and with vendors for preclinical studies and clinical trials, research supplies, and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, we believe that our&#160;non-cancelable&#160;obligations under these agreements are not material.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we enter into agreements in the normal course of business with clinical trial sites, CROs, CMOs, and other vendors for research and development services. Such agreements genera</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">lly provide for termination upon limited written notice. These payments are therefore not included in our contractual obligations discussion above. For additional information regarding our contractual obligations and commitments, see Note 11 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are also party to certain collaboration and license agreements, which contain a number of contractual obligations. Those contractual obligations may entitle us to receive, or may obligate us to make, certain payments. The amount and timing of those payments are unknown or uncertain as we are unable to estimate the timing or likelihood of the events that will obligate those payments. We have milestones, royalties, and/or other payments due to third parties under our existing license agreements. For additional information concerning these agreements, which are described below, including a detailed description of the financial terms, please see Note 6 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report, Note 10 to our audited consolidated financial statements included in our Annual Report, and the section titled &#8220;Business&#8212; License and Other Agreements&#8221; in our Annual Report.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Stanford University</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In December 2019, we entered into an exclusive license agreement with equity, or the Stanford Agreement, with the Board of Trustees of the Leland Stanford Junior University, or Stanford, which was subsequently amended in May 2020 and December 2023. Under the terms of the Stanford Agreement, we obtained a worldwide, royalty-bearing license, with the right to sublicense during the exclusive term only, under certain patent rights in five patent families relating to brain stimulation, electroencephalogram and functional MRI that we could use to guide treatment of psychiatry patients, or the Stanford Licensed Patents, and under certain technology relating to the inventions covered by the Stanford Licensed Patents, or the Stanford Licensed Technology, to make, have made, use, import, offer for sale and sell licensed products for use in any indication. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Sanofi</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In May 2021, we entered into a license agreement, or the Sanofi Agreement, with Sanofi, pursuant to which we obtained an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under certain patent rights and know-how of Sanofi relating to a PDE4 inhibitor compound, now known as ALTO-101, to use, have used, develop, have developed, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">manufacture, have manufactured, commercialize, have commercialized or otherwise exploit ALTO-101 and products incorporating ALTO-101, or the Sanofi Licensed Products, for all human therapeutic, prophylactic and diagnostic uses. We also obtained a non-exclusive, worldwide license to use certain other specified know-how licensed to Sanofi by a specified third party to exploit Sanofi Licensed Products solely with respect to Parkinson&#8217;s disease. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Cerecor</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In May 2021, we entered into a patent and know-how license agreement, or the Cerecor Agreement, with Cerecor Inc.<br/>(n/k/a Avalo Therapeutics, Inc.), or Cerecor, pursuant to which we obtained an exclusive worldwide, royalty-bearing license, with the right to sublicense, under certain patent rights and know-how owned or controlled by Cerecor relating to an NR2B inhibitor compound now known as ALTO-202, including certain rights licensed to Cerecor by Essex Chemie AG, or Merck, to research, develop, make, have made, use, import, offer for sale and sell ALTO-202 and products incorporating ALTO-202, or Cerecor Licensed Products, for the prevention, diagnosis and/or treatment of all diseases in humans. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teva Asset Purchase Agreement</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, we entered into an asset purchase agreement, or the Teva Agreement, with Teva Pharmaceutical Industries, Ltd. and its affiliate Cephalon, Inc., or together Teva, pursuant to which we acquired patents, know-how and other rights to ALTO-203 and a specified related compound, or Teva Acquired Compounds, and we assumed all post-acquisition liabilities related thereto.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Palisade Asset Purchase Agreement</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we entered into an asset transfer agreement, or the Palisade Agreement, with Palisade Bio, Inc., or Palisade, pursuant to which we acquired all patent, know-how and other rights to ALTO-100. Palisade also transferred and assigned to us all right, title, and interest in, to, and under that certain exclusive license agreement, or the Dow Agreement, between Dow Agrosciences LLC, or Dow, and Palisade (f/k/a Neuralstem, Inc.), dated as of December 1, 2016, pursuant to which we licensed patent rights covering an intermediate compound in the manufacturing process for ALTO-100.  </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with MedRx</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we entered into a joint development and license agreement, or the MedRx Agreement, with MedRx Co., Ltd., or MedRx, pursuant to which we obtained an exclusive, sublicensable, worldwide license, with the right to sublicense, under certain patent rights and know-how of MedRx relating to transdermal drug delivery to develop (excluding any pre-clinical development), manufacture, and commercialize transdermally delivered pharmaceutical products comprising MedRx&#8217;s transdermal patch technology and our ALTO-101, or MedRx Licensed Product, for all therapeutic, prophylactic, and diagnostic uses. We granted MedRx an exclusive, sublicensable, worldwide license under certain patent rights and know-how relating to ALTO-101 owned or controlled by us, including certain patents and know how licensed to us pursuant to the Sanofi Agreement, solely to conduct pre-clinical development and manufacturing of the MedRx Licensed Products for us in accordance with t</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">he MedRx Agreement and a separate manufacturing and supply agreement to be entered into between us and MedRx. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chase Asset Purchase Agreement</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2025, we entered into an asset purchase agreement, or Chase Agreement, with Chase Therapeutics Corporation, or Chase, to acquire all patent, know-how and other rights to ALTO-207, ALTO-208, and certain related assets. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We could not estimate when milestones, royalties, and/or other payments due to third parties under our existing license agreements will be due, and none of these events were probable to occur as of March&#160;31, 2026.</span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes to our critical accounting policies that are disclosed in our audited consolidated financial statements for the year ended December&#160;31, 2025 filed with the SEC on March 16, 2026.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act, and we may remain an emerging growth company for up to five years following the completion of our IPO. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. In particular, in our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Annual Report, we provided only two years of audited financial statements and did not include all of the executive compensation-related information that would be required if we were not an emerging growth company. Accordingly, the in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">formation contained herein may be different than the information you receive from other public companies in which you hold stock.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period, and therefore, we are not subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies; however, we may adopt certain new or revised accounting standards early. We would cease to be an &#8220;emerging growth company&#8221; upon the earliest to occur of: (i)&#160;the last day of the fiscal year in which we have $1.235&#160;billion or more in annual revenue; (ii)&#160;the date on which we first qualify as a large accelerated filer under the rules of the SEC; (iii)&#160;the date on which we have, in any three-year period issued more than $1.0&#160;billion in&#160;non-convertible&#160;debt securities; and (iv)&#160;the last day of the fiscal year ending after the fifth anniversary of our IPO (December 31, 2029).</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and&#160;non-voting&#160;common stock held by&#160;non-affiliates&#160;is less than $250.0&#160;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and our voting and&#160;non-voting&#160;common stock held by&#160;non-affiliates&#160;is less than $700.0&#160;million measured on the last business day of our second fiscal quarter.</span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule&#160;12b-2 of the Exchange Act and are not required to provide the information required under this item.</span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> and reported, within the time periods specified in the SEC&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this report, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">There was no change in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2026 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II<br/>OTHER INFORMATION</span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_124"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Information pertaining to legal proceedings can be found in Part I of this Quarterly Report under &#8220;Item 1. Financial Statements - Note 11. Commitments and Contingencies&#8221; and is incorporated by reference herein.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In addition, from time to time, we may be involved in legal proceedings arising in the ordinary course of business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm.</span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_127"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the risks described in our Annual Report, you should carefully consider the other information set forth in this Quarterly Report and the information in our other filings with the SEC, as they could materially affect our business, financial condition or future results of operations. There have been no material changes to the risk factors previously disclosed in &#8220;Item 1A. Risk Factors&#8221; in our Annual Report.</span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Except for those unregistered securities previously disclosed in a current report on Form 8-K filed with the SEC during the period covered by this report, we have not sold any securities under the Securities Act of 1933, as amended, or the Securities Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds from Public Offering of Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, our Registration Statement on Form S-1, as amended (File No. 333-276495) relating to our IPO was declared effective. On February 6, 2024, we closed the IPO and 9,246,000 shares of our common stock were issued and sold at a public offering price of $16.00 per share, inclusive of the exercise in full by the underwriters of their option to purchase up to an additional 1,206,000 shares of common stock.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The aggregate net proceeds from the IPO, after underwriting discounts and commissions, and other offering expenses of $4.6 million, were $133.0 million. There has been no material change in the planned use of proceeds from our IPO as described in our prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on February 5, 2024.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Issuer Purchases of Equity Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_136"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-614"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-615">Trading Arrangements</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the Company&#8217;s last fiscal quarter, certain of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-616">terminated</ix:nonNumeric> contracts, instructions or written plans for the purchase or sale of the Company&#8217;s securities as set forth below.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-177" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-617" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-177" name="ecd:TrdArrTerminationDate" id="f-618">March 13, 2026</ix:nonNumeric>, <ix:nonNumeric contextRef="c-177" name="ecd:TrdArrIndName" id="f-619">Amit Etkin, M.D., Ph.D.</ix:nonNumeric>, our <ix:nonNumeric contextRef="c-177" name="ecd:TrdArrIndTitle" id="f-620">President, Chief Executive Officer, and Chair of the Board</ix:nonNumeric>, <ix:nonNumeric contextRef="c-177" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true" id="f-621">terminated</ix:nonNumeric> a Rule 10b5-1 trading plan effective March 17, 2026. No sales of common stock occurred under the plan prior to its termination. Prior to its termination, the plan had provided for the potential sale of up to <ix:nonFraction unitRef="shares" contextRef="c-178" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-622">100,000</ix:nonFraction> shares of our common stock at each of two specified price points (60,000 shares to be sold at $35.00 and 40,000 shares to be sold at $80.00). Transactions under Dr. Etkin&#8217;s plan were based upon pre-established dates and stock price thresholds and would only occur upon the expiration of the applicable mandatory cooling-off period. Dr. Etkin&#8217;s plan had a termination date of December&#160;31, 2026, or the date all shares subject to the plan had been sold.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-179" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-623" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-179" name="ecd:TrdArrTerminationDate" id="f-624">March 11, 2026</ix:nonNumeric>, <ix:nonNumeric contextRef="c-179" name="ecd:TrdArrIndName" id="f-625">Nicholas Smith</ix:nonNumeric>, our <ix:nonNumeric contextRef="c-179" name="ecd:TrdArrIndTitle" id="f-626">Chief Financial Officer and Chief Business Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-179" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true" id="f-627">terminated</ix:nonNumeric> a Rule 10b5-1 trading plan effective March 13, 2026. No sales of common stock occurred under the plan prior to its termination. Prior to its termination, the plan had provided for the potential sale of up to <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-628">14,376</ix:nonFraction> shares of our common stock at a price per share of $45.00. Transactions under Mr. Smith&#8217;s plan were based upon pre-established dates and stock price thresholds and would only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Smith&#8217;s plan had a termination date of December&#160;31, 2026, or the date all shares subject to the plan had been sold.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Both Dr. Etkin&#8217;s plan and Mr. Smith&#8217;s plan were intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">File No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Filed Herewith</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:7pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#3051f2;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1999480/000119312524025266/d736911dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">001-41944</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2/6/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#3051f2;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1999480/000119312524025266/d736911dex32.htm">Amended and Restated Bylaws of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">001-41944</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2/6/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1999480/000110465925100801/tm2529007d1_ex4-1.htm">Form of Pre-Funded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">001-41944</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10/20/2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1999480/000110465926027953/tm268876d1_ex4-1.htm">Form of Pre-Funded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">001-41944</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3/16/2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit311-302certceo1q2026.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit312-302certcfo1q2026.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit321-906certceo1q2026.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit322-906certcfo1q2026.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Taxonomy Extension Schema With Embedded Linkbase Documents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101).</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification is deemed not filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="if33b9e8d46eb467b84758fa9b250d8f7_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if33b9e8d46eb467b84758fa9b250d8f7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ALTO NEUROSCIENCE, INC.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">May 13, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Amit Etkin</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amit Etkin, M.D., Ph.D.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">May 13, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Nicholas Smith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nicholas Smith</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Business Officer</span></div></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311-302certceo1q2026.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="id6b37a5ca2b340fa98722363c3f00278_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Certification of the Chief Executive Officer</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">I, Amit Etkin, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of Alto Neuroscience, Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:25.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.183%"><tr><td style="width:1.0%"></td><td style="width:5.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="15" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2026</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Amit Etkin</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amit Etkin, M.D., Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312-302certcfo1q2026.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="id455d99bdc0f4917bb4cc79c55b645f4_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Certification of the Chief Financial Officer</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">I, Nicholas Smith, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of Alto Neuroscience, Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:1.18pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"></td><td style="width:5.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.310%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="15" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2026</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Nicholas Smith</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nicholas Smith</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Business Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321-906certceo1q2026.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ib30a6d29b990484ea971f1fc8ebd9c9d_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></div></div><div><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Amit Etkin, Chief Executive Officer of Alto Neuroscience, Inc. (the &#8220;Company&#8221;), hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March&#160;31, 2026 (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="padding-left:25.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.787%"><tr><td style="width:1.0%"></td><td style="width:6.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.269%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="15" style="padding:0 1pt"><div style="text-indent:36pt"><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2026</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Amit Etkin</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amit Etkin, M.D., Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322-906certcfo1q2026.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="if867f6b14f584916a676e9177b30685b_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.2</font></div></div><div><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Nicholas Smith, Chief Financial Officer of Alto Neuroscience, Inc. (the &#8220;Company&#8221;), hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March&#160;31, 2026 (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="padding-left:6.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.580%"><tr><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.099%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="15" style="padding:0 1pt"><div style="text-indent:36pt"><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2026</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Nicholas Smith</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nicholas Smith</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Business Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>alto-20260331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cfc6e-a845-7559-941c-e87ca4915109,g:515d2a5a-b4b4-4d42-8d26-d42921144f4b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:alto="http://www.altoneuroscience.com/20260331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.altoneuroscience.com/20260331">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alto-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alto-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alto-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alto-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.altoneuroscience.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>9952152 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityUnaudited" roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
        <link:definition>9952154 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>9952156 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://www.altoneuroscience.com/role/DescriptionoftheBusiness">
        <link:definition>9952157 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandBasisofPresentation" roleURI="http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentation">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponents">
        <link:definition>9952159 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.altoneuroscience.com/role/Debt">
        <link:definition>9952160 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://www.altoneuroscience.com/role/FairValue">
        <link:definition>9952161 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetPurchaseandLicenseAgreements" roleURI="http://www.altoneuroscience.com/role/AssetPurchaseandLicenseAgreements">
        <link:definition>9952162 - Disclosure - Asset Purchase and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedPlans" roleURI="http://www.altoneuroscience.com/role/StockBasedPlans">
        <link:definition>9952163 - Disclosure - Stock-Based Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShare" roleURI="http://www.altoneuroscience.com/role/LossPerShare">
        <link:definition>9952164 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.altoneuroscience.com/role/IncomeTaxes">
        <link:definition>9952165 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.altoneuroscience.com/role/StockholdersEquity">
        <link:definition>9952166 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.altoneuroscience.com/role/CommitmentsandContingencies">
        <link:definition>9952167 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.altoneuroscience.com/role/Segments">
        <link:definition>9952168 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.altoneuroscience.com/role/SubsequentEvents">
        <link:definition>9952169 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandBasisofPresentationPolicies" roleURI="http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentationPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsTables">
        <link:definition>9955512 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.altoneuroscience.com/role/DebtTables">
        <link:definition>9955513 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://www.altoneuroscience.com/role/FairValueTables">
        <link:definition>9955514 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedPlansTables" roleURI="http://www.altoneuroscience.com/role/StockBasedPlansTables">
        <link:definition>9955515 - Disclosure - Stock-Based Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareTables" roleURI="http://www.altoneuroscience.com/role/LossPerShareTables">
        <link:definition>9955516 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.altoneuroscience.com/role/StockholdersEquityTables">
        <link:definition>9955517 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.altoneuroscience.com/role/SegmentsTables">
        <link:definition>9955518 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessDetails" roleURI="http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails">
        <link:definition>9955519 - Disclosure - Description of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails" roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails">
        <link:definition>9955520 - Disclosure - Balance Sheet Components - Schedule of prepaid expenses and other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails">
        <link:definition>9955521 - Disclosure - Balance Sheet Components - Schedule of property and equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsNarrativeDetails" roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsNarrativeDetails">
        <link:definition>9955522 - Disclosure - Balance Sheet Components - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails" roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails">
        <link:definition>9955523 - Disclosure - Balance Sheet Components - Schedule of accrued expenses and other current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.altoneuroscience.com/role/DebtNarrativeDetails">
        <link:definition>9955524 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails" roleURI="http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails">
        <link:definition>9955525 - Disclosure - Debt - Schedule of future principal debt payments and exit fee (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConvertiblegrantnarrativeDetails" roleURI="http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails">
        <link:definition>9955526 - Disclosure - Debt - Convertible grant narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConvertiblegrantmaturityDetails" roleURI="http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails">
        <link:definition>9955527 - Disclosure - Debt - Convertible grant maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtChangeinfairvalueofconvertiblegrantagreementDetails" roleURI="http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails">
        <link:definition>9955528 - Disclosure - Debt - Change in fair value of convertible grant agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueDetails" roleURI="http://www.altoneuroscience.com/role/FairValueDetails">
        <link:definition>9955529 - Disclosure - Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedPlansNarrativeDetails" roleURI="http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails">
        <link:definition>9955530 - Disclosure - Stock-Based Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedPlansStockoptionweightedaverageassumptionsDetails" roleURI="http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails">
        <link:definition>9955531 - Disclosure - Stock-Based Plans - Stock option weighted average assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedPlansScheduleofstockoptionactivityDetails" roleURI="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails">
        <link:definition>9955532 - Disclosure - Stock-Based Plans - Schedule of stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedPlansScheduleofactivityrelatedtoRSUsDetails" roleURI="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails">
        <link:definition>9955533 - Disclosure - Stock-Based Plans - Schedule of activity related to RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedPlansScheduleofstockbasedcompensationexpenseDetails" roleURI="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails">
        <link:definition>9955534 - Disclosure - Stock-Based Plans - Schedule of stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareNarrativeDetails" roleURI="http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails">
        <link:definition>9955535 - Disclosure - Loss Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>9955536 - Disclosure - Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9955537 - Disclosure - Stockholders&#8217; Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofstockreservedforissuanceDetails" roleURI="http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails">
        <link:definition>9955538 - Disclosure - Stockholders&#8217; Equity - Schedule of stock reserved for issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsNarrativeDetails" roleURI="http://www.altoneuroscience.com/role/SegmentsNarrativeDetails">
        <link:definition>9955539 - Disclosure - Segments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>9955540 - Disclosure - Segments - Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock" abstract="false" name="APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock" abstract="false" name="IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue" abstract="false" name="StockAndPreFundedWarrantsIssuedDuringPeriodValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_StockIssuedDuringPeriodShareConversionOfTermLoan" abstract="false" name="StockIssuedDuringPeriodShareConversionOfTermLoan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alto_StockIssuedDuringPeriodValueConversionOfTermLoan" abstract="false" name="StockIssuedDuringPeriodValueConversionOfTermLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_InterestExpenseNoncash" abstract="false" name="InterestExpenseNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_GainLossInOtherOperatingActivitiesNet" abstract="false" name="GainLossInOtherOperatingActivitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" abstract="false" name="ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" abstract="false" name="CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_PaymentsOnIssuanceCostFromRegistrationStatement" abstract="false" name="PaymentsOnIssuanceCostFromRegistrationStatement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid" abstract="false" name="CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_DeferredOfferingAndShareIssueCostsNotYetPaid" abstract="false" name="DeferredOfferingAndShareIssueCostsNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_ScheduleOfStockReservedForIssuanceTableTextBlock" abstract="false" name="ScheduleOfStockReservedForIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="alto_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_K2HealthventuresLLCMember" abstract="true" name="K2HealthventuresLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_NumberOfWhollyOwnedSubsidiaries" abstract="false" name="NumberOfWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alto_NumberOfClinicalStageAssets" abstract="false" name="NumberOfClinicalStageAssets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alto_TemporaryEquitySharesConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquitySharesConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alto_SaleOfStockConversionOfOutstandingLoan" abstract="false" name="SaleOfStockConversionOfOutstandingLoan" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_ComputerSoftwareAndEquipmentMember" abstract="true" name="ComputerSoftwareAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_AccruedResearchExpense" abstract="false" name="AccruedResearchExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_LoanAndSecurityAgreementMember" abstract="true" name="LoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_AmendedLoanAgreementMember" abstract="true" name="AmendedLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_DebtInstrumentTrancheAxis" abstract="true" name="DebtInstrumentTrancheAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alto_DebtInstrumentTrancheDomain" abstract="true" name="DebtInstrumentTrancheDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_DebtInstrumentTrancheFourMember" abstract="true" name="DebtInstrumentTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_DebtInstrumentTrancheOneMember" abstract="true" name="DebtInstrumentTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_DebtInstrumentTrancheTwoMember" abstract="true" name="DebtInstrumentTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_DebtInstrumentTrancheThreeMember" abstract="true" name="DebtInstrumentTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_K2WarrantMember" abstract="true" name="K2WarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_NewK2WarrantMember" abstract="true" name="NewK2WarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_DebtInstrumentInterestRateFloor" abstract="false" name="DebtInstrumentInterestRateFloor" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_DebtInstrumentFixedRatePaidInKind" abstract="false" name="DebtInstrumentFixedRatePaidInKind" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed" abstract="false" name="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_DebtInstrumentExitFeePercentOfLoansFunded" abstract="false" name="DebtInstrumentExitFeePercentOfLoansFunded" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_DebtInstrumentExitFee" abstract="false" name="DebtInstrumentExitFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_DebtInstrumentFundingFeeMultiplier" abstract="false" name="DebtInstrumentFundingFeeMultiplier" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" abstract="false" name="DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" abstract="false" name="DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" abstract="false" name="DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum" abstract="false" name="DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount" abstract="false" name="DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_DebtInstrumentInterestRateIncreaseInEventOfDefault" abstract="false" name="DebtInstrumentInterestRateIncreaseInEventOfDefault" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender" abstract="false" name="DebtInstrumentPortionConvertibleToEquityAtElectionOfLender" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender" abstract="false" name="DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_DebtInstrumentDeferredInterest" abstract="false" name="DebtInstrumentDeferredInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_LongTermDebtPrincipalPaymentsAndExitFee" abstract="false" name="LongTermDebtPrincipalPaymentsAndExitFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_DebtInstrumentUnamortizedExitFee" abstract="false" name="DebtInstrumentUnamortizedExitFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alto_GrantAgreementMember" abstract="true" name="GrantAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_DebtInstrumentNumberOfTranches" abstract="false" name="DebtInstrumentNumberOfTranches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment" abstract="false" name="DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_DebtInstrumentConvertibleDiscountOnSharesConverted" abstract="false" name="DebtInstrumentConvertibleDiscountOnSharesConverted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement" abstract="false" name="DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alto_DebtInstrumentConvertibleMaximumSharesIssuable" abstract="false" name="DebtInstrumentConvertibleMaximumSharesIssuable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum" abstract="false" name="DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_The2024EquityIncentivePlanMember" abstract="true" name="The2024EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_A2025InducementPlanMember" abstract="true" name="A2025InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" abstract="false" name="ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alto_TwoThousandTwentyFivePreFundedWarrantsMember" abstract="true" name="TwoThousandTwentyFivePreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_SecuritiesPurchaseAgreementMember" abstract="true" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_K2CommonStockWarrantsMember" abstract="true" name="K2CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_AdditionalK2WarrantsMember" abstract="true" name="AdditionalK2WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation" abstract="false" name="ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alto_ClassOfWarrantsOrRightsWarrantExcessPercentage" abstract="false" name="ClassOfWarrantsOrRightsWarrantExcessPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alto_EmployeeStockOptionsIssuedAndOutstandingMember" abstract="true" name="EmployeeStockOptionsIssuedAndOutstandingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_EmployeeStockOptionsAvailableForFutureGrantMember" abstract="true" name="EmployeeStockOptionsAvailableForFutureGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_Alto100Member" abstract="true" name="Alto100Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_Alto300Member" abstract="true" name="Alto300Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_Alto101Member" abstract="true" name="Alto101Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_Alto203Member" abstract="true" name="Alto203Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_Alto207Member" abstract="true" name="Alto207Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_AmitEtkinMember" abstract="true" name="AmitEtkinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alto_NicholasSmithMember" abstract="true" name="NicholasSmithMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>alto-20260331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cfc6e-a845-7559-941c-e87ca4915109,g:515d2a5a-b4b4-4d42-8d26-d42921144f4b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="alto-20260331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7d27-9dd4-b5bd59e6603f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_019cfc6e-a903-7026-bb80-515b55c5ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7d27-9dd4-b5bd59e6603f" xlink:to="loc_us-gaap_CommonStockValueOutstanding_019cfc6e-a903-7026-bb80-515b55c5ceca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cfc6e-a903-7603-bed9-2a04e736c737" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7d27-9dd4-b5bd59e6603f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cfc6e-a903-7603-bed9-2a04e736c737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019cfc6e-a903-7933-9fe2-17383a25af5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7d27-9dd4-b5bd59e6603f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019cfc6e-a903-7933-9fe2-17383a25af5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cfc6e-a903-72eb-bb54-c21cd0087519" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7d27-9dd4-b5bd59e6603f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cfc6e-a903-72eb-bb54-c21cd0087519" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019cfc6e-a903-7638-9c52-80e13b5bef1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cfc6e-a903-7d76-8944-68c6ae5e49ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019cfc6e-a903-7638-9c52-80e13b5bef1b" xlink:to="loc_us-gaap_LiabilitiesCurrent_019cfc6e-a903-7d76-8944-68c6ae5e49ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_019cfc6e-a903-7ba9-98d2-481bcc658e25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019cfc6e-a903-7638-9c52-80e13b5bef1b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_019cfc6e-a903-7ba9-98d2-481bcc658e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_019cfc6e-a903-7b7a-8cd2-58a2502cc6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019cfc6e-a903-7638-9c52-80e13b5bef1b" xlink:to="loc_us-gaap_ConvertibleDebt_019cfc6e-a903-7b7a-8cd2-58a2502cc6ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019cfc6e-a903-77a6-b0cf-11f99ef305ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019cfc6e-a903-7638-9c52-80e13b5bef1b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019cfc6e-a903-77a6-b0cf-11f99ef305ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019cfc6e-a903-774b-acb9-58f23c0ceb06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a903-7a7e-9313-49f17e65aa19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cfc6e-a903-774b-acb9-58f23c0ceb06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a903-7a7e-9313-49f17e65aa19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_019cfc6e-a903-70ce-b931-ef95cfabbd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cfc6e-a903-774b-acb9-58f23c0ceb06" xlink:to="loc_us-gaap_OtherAssets_019cfc6e-a903-70ce-b931-ef95cfabbd4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_019cfc6e-a903-7c1b-aea3-48c9d9756629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cfc6e-a903-774b-acb9-58f23c0ceb06" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_019cfc6e-a903-7c1b-aea3-48c9d9756629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019cfc6e-a903-7d19-9eda-2fb2e78e64b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cfc6e-a903-774b-acb9-58f23c0ceb06" xlink:to="loc_us-gaap_AssetsCurrent_019cfc6e-a903-7d19-9eda-2fb2e78e64b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019cfc6e-a903-766d-96bc-46a84f0f346f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cfc6e-a903-774b-acb9-58f23c0ceb06" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019cfc6e-a903-766d-96bc-46a84f0f346f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cfc6e-a903-70fe-898b-c2319a9981c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019cfc6e-a903-77c6-90ca-be89060d9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cfc6e-a903-70fe-898b-c2319a9981c5" xlink:to="loc_us-gaap_Liabilities_019cfc6e-a903-77c6-90ca-be89060d9f8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7aa3-8f92-3c5be1abb501" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cfc6e-a903-70fe-898b-c2319a9981c5" xlink:to="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7aa3-8f92-3c5be1abb501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019cfc6e-a903-7db1-bb09-061c630717c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cfc6e-a903-70fe-898b-c2319a9981c5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019cfc6e-a903-7db1-bb09-061c630717c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019cfc6e-a903-7f52-9067-32cdc03aaac4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cfc6e-a903-72ac-9c08-ee568a0f3b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cfc6e-a903-7f52-9067-32cdc03aaac4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cfc6e-a903-72ac-9c08-ee568a0f3b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cfc6e-a903-71dc-a248-597f699d4794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cfc6e-a903-7f52-9067-32cdc03aaac4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cfc6e-a903-71dc-a248-597f699d4794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cfc6e-a903-7585-a4e2-85908af78419" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019cfc6e-a903-792d-912a-9d4da12c7e10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cfc6e-a903-7585-a4e2-85908af78419" xlink:to="loc_us-gaap_AccountsPayableCurrent_019cfc6e-a903-792d-912a-9d4da12c7e10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-a903-76d3-982e-9b1494f875dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cfc6e-a903-7585-a4e2-85908af78419" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-a903-76d3-982e-9b1494f875dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_019db813-589d-78f8-ae77-923267083218" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cfc6e-a903-7585-a4e2-85908af78419" xlink:to="loc_us-gaap_LongTermDebtCurrent_019db813-589d-78f8-ae77-923267083218" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="alto-20260331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cfc6e-a903-7c46-a220-08ba702ce92d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cfc6e-a903-735c-b7ae-34465ca39c69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019cfc6e-a903-7c46-a220-08ba702ce92d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cfc6e-a903-735c-b7ae-34465ca39c69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cfc6e-a903-74f8-99e2-187e10aaff25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019cfc6e-a903-7c46-a220-08ba702ce92d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cfc6e-a903-74f8-99e2-187e10aaff25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cfc6e-a903-7282-b767-b4d1dcbac7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent_019cfc6e-a903-7d6c-9358-8b86e5f6ab76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cfc6e-a903-7282-b767-b4d1dcbac7b2" xlink:to="loc_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent_019cfc6e-a903-7d6c-9358-8b86e5f6ab76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019cfc6e-a903-744f-a212-9da8e2ebb526" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cfc6e-a903-7282-b767-b4d1dcbac7b2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019cfc6e-a903-744f-a212-9da8e2ebb526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cfc6e-a903-733f-898c-3633da188fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a903-72c4-9487-a817ef1db4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019cfc6e-a903-733f-898c-3633da188fc6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a903-72c4-9487-a817ef1db4f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019cfc6e-a903-7eac-b572-b2a731955f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019cfc6e-a903-733f-898c-3633da188fc6" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019cfc6e-a903-7eac-b572-b2a731955f6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_019cfc6e-a903-7c19-be7f-fa4049176509" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019cfc6e-a903-733f-898c-3633da188fc6" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_019cfc6e-a903-7c19-be7f-fa4049176509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019cfc6e-a903-7c67-a89c-4288cdf0efc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019cfc6e-a903-733f-898c-3633da188fc6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019cfc6e-a903-7c67-a89c-4288cdf0efc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-73b5-ae87-b8a4c7ccd49a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cfc6e-a903-7ce4-9400-e4b4adfc0045" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-73b5-ae87-b8a4c7ccd49a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019cfc6e-a903-7ce4-9400-e4b4adfc0045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cfc6e-a903-71f1-8ee9-2ebf366a8106" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-73b5-ae87-b8a4c7ccd49a" xlink:to="loc_us-gaap_OperatingIncomeLoss_019cfc6e-a903-71f1-8ee9-2ebf366a8106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cfc6e-a903-7925-9928-6df5ff79bebd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cfc6e-a903-75bb-9093-f5909bc5e0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019cfc6e-a903-7925-9928-6df5ff79bebd" xlink:to="loc_us-gaap_OperatingExpenses_019cfc6e-a903-75bb-9093-f5909bc5e0ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="alto-20260331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cfc6e-a903-7d37-b79c-3be6d5ab5614" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cfc6e-a903-7f33-9321-795aa404d7df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cfc6e-a903-7d37-b79c-3be6d5ab5614" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cfc6e-a903-7f33-9321-795aa404d7df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-77a8-b702-578a43a1e6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_InterestExpenseNoncash_019cfc6e-a903-72d7-ad3a-ffee13893e10" xlink:href="alto-20260331.xsd#alto_InterestExpenseNoncash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-77a8-b702-578a43a1e6d4" xlink:to="loc_alto_InterestExpenseNoncash_019cfc6e-a903-72d7-ad3a-ffee13893e10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a903-7060-9426-3b556761a8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-77a8-b702-578a43a1e6d4" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a903-7060-9426-3b556761a8a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019cfc6e-a903-7a9c-9a2e-33118b9c007d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-77a8-b702-578a43a1e6d4" xlink:to="loc_us-gaap_ShareBasedCompensation_019cfc6e-a903-7a9c-9a2e-33118b9c007d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_GainLossInOtherOperatingActivitiesNet_019cfc6e-a903-7009-a167-0d1ee57d9135" xlink:href="alto-20260331.xsd#alto_GainLossInOtherOperatingActivitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-77a8-b702-578a43a1e6d4" xlink:to="loc_alto_GainLossInOtherOperatingActivitiesNet_019cfc6e-a903-7009-a167-0d1ee57d9135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cfc6e-a903-7d42-95c9-7b13fa0da1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-77a8-b702-578a43a1e6d4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cfc6e-a903-7d42-95c9-7b13fa0da1e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019cfc6e-a903-7c7f-b5a1-c9cf602d69a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-77a8-b702-578a43a1e6d4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019cfc6e-a903-7c7f-b5a1-c9cf602d69a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019cfc6e-a903-7c82-a74d-8bdbcdf1b4af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-77a8-b702-578a43a1e6d4" xlink:to="loc_us-gaap_Depreciation_019cfc6e-a903-7c82-a74d-8bdbcdf1b4af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cfc6e-a903-7359-a6d1-7f601bf51705" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-77a8-b702-578a43a1e6d4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cfc6e-a903-7359-a6d1-7f601bf51705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019cfc6e-a903-7b24-94a6-8672492baeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-77a8-b702-578a43a1e6d4" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019cfc6e-a903-7b24-94a6-8672492baeaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-7b44-9d17-5dfed1bd9ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-77a8-b702-578a43a1e6d4" xlink:to="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-7b44-9d17-5dfed1bd9ed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cfc6e-a903-78b0-8210-550c43ae91ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-77a8-b702-578a43a1e6d4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cfc6e-a903-78b0-8210-550c43ae91ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-790d-b810-cbc73e04a5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_PaymentsOnIssuanceCostFromRegistrationStatement_019cfc6e-a903-74e3-af9b-b27f67bf6d6e" xlink:href="alto-20260331.xsd#alto_PaymentsOnIssuanceCostFromRegistrationStatement"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-790d-b810-cbc73e04a5b9" xlink:to="loc_alto_PaymentsOnIssuanceCostFromRegistrationStatement_019cfc6e-a903-74e3-af9b-b27f67bf6d6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_019cfc6e-a903-71ac-a3b8-3e4a6d5ab573" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-790d-b810-cbc73e04a5b9" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_019cfc6e-a903-71ac-a3b8-3e4a6d5ab573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019cfc6e-a903-79af-a19d-70d5fe86b216" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-790d-b810-cbc73e04a5b9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019cfc6e-a903-79af-a19d-70d5fe86b216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_019cfc6e-a903-7c42-9544-945966600df7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-790d-b810-cbc73e04a5b9" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_019cfc6e-a903-7c42-9544-945966600df7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_019db856-0fb5-7288-9b29-9b60adcb257d" xlink:href="alto-20260331.xsd#alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-790d-b810-cbc73e04a5b9" xlink:to="loc_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_019db856-0fb5-7288-9b29-9b60adcb257d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_019cfc6e-a903-7823-ac39-f7b5e7b9e477" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-790d-b810-cbc73e04a5b9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_019cfc6e-a903-7823-ac39-f7b5e7b9e477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_019db856-3f9f-7f35-8941-f42b150f7f08" xlink:href="alto-20260331.xsd#alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-790d-b810-cbc73e04a5b9" xlink:to="loc_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_019db856-3f9f-7f35-8941-f42b150f7f08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019dd756-28e3-7b06-a402-8c3d1650f7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-790d-b810-cbc73e04a5b9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019dd756-28e3-7b06-a402-8c3d1650f7c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cfc6e-a903-7e4c-b8f9-15d6273f187a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-7062-8f0f-150ffb340a00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cfc6e-a903-7e4c-b8f9-15d6273f187a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-7062-8f0f-150ffb340a00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cfc6e-a903-76ad-a7ec-7cb4acaecaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cfc6e-a903-7e4c-b8f9-15d6273f187a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cfc6e-a903-76ad-a7ec-7cb4acaecaf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cfc6e-a903-75a9-aafc-656a5081e5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cfc6e-a903-7e4c-b8f9-15d6273f187a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cfc6e-a903-75a9-aafc-656a5081e5dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-7a28-8272-ceaf730e17f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cfc6e-a903-7e4c-b8f9-15d6273f187a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-7a28-8272-ceaf730e17f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails"/>
  <link:calculationLink xlink:role="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cfc6e-a903-7a92-9d6a-8e38d3cbe729" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_019cfc6e-a903-7945-8762-11798219dde6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cfc6e-a903-7a92-9d6a-8e38d3cbe729" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_019cfc6e-a903-7945-8762-11798219dde6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_019cfc6e-a903-7d52-a458-89a217167b63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cfc6e-a903-7a92-9d6a-8e38d3cbe729" xlink:to="loc_us-gaap_PrepaidInsurance_019cfc6e-a903-7d52-a458-89a217167b63" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"/>
  <link:calculationLink xlink:role="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a903-7638-9adf-c6aeecc40fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019cfc6e-a903-782f-ac27-04d3484ad3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a903-7638-9adf-c6aeecc40fb5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019cfc6e-a903-782f-ac27-04d3484ad3f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019cfc6e-a903-7a56-9f9c-4847b4db10f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a903-7638-9adf-c6aeecc40fb5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019cfc6e-a903-7a56-9f9c-4847b4db10f1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-a903-7ffe-ba9e-591c634b8556" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cfc6e-a903-7fac-92f9-3a7c1246e134" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-a903-7ffe-ba9e-591c634b8556" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cfc6e-a903-7fac-92f9-3a7c1246e134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AccruedResearchExpense_019cfc6e-a903-70ae-b22a-7975a5cb7d12" xlink:href="alto-20260331.xsd#alto_AccruedResearchExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-a903-7ffe-ba9e-591c634b8556" xlink:to="loc_alto_AccruedResearchExpense_019cfc6e-a903-70ae-b22a-7975a5cb7d12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_019cfc6e-a903-7d0c-bec7-ae436c78a00b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-a903-7ffe-ba9e-591c634b8556" xlink:to="loc_us-gaap_InterestPayableCurrent_019cfc6e-a903-7d0c-bec7-ae436c78a00b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019cfc6e-a903-7a18-a39c-b142df3e5782" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-a903-7ffe-ba9e-591c634b8556" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019cfc6e-a903-7a18-a39c-b142df3e5782" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cfc6e-a903-7efc-b666-21c814e38b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-a903-7ffe-ba9e-591c634b8556" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cfc6e-a903-7efc-b666-21c814e38b5b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"/>
  <link:calculationLink xlink:role="http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019cfc6e-a903-7647-bf43-05b325738e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a903-7ce6-90d6-854db9af9789" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_019cfc6e-a903-7647-bf43-05b325738e2e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a903-7ce6-90d6-854db9af9789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a903-78d1-85d4-349d4ddd7235" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_019cfc6e-a903-7647-bf43-05b325738e2e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a903-78d1-85d4-349d4ddd7235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-a903-7fef-af16-1290bef7695b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_019cfc6e-a903-7647-bf43-05b325738e2e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-a903-7fef-af16-1290bef7695b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a903-7ce7-bbaa-48f17df54b70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_019cfc6e-a903-7647-bf43-05b325738e2e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a903-7ce7-bbaa-48f17df54b70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_LongTermDebtPrincipalPaymentsAndExitFee_019cfc6e-a903-7f28-8faa-6501dd21bf11" xlink:href="alto-20260331.xsd#alto_LongTermDebtPrincipalPaymentsAndExitFee"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019cfc6e-a903-7da1-aa71-04bcee9499f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_alto_LongTermDebtPrincipalPaymentsAndExitFee_019cfc6e-a903-7f28-8faa-6501dd21bf11" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019cfc6e-a903-7da1-aa71-04bcee9499f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentExitFee_019cfc6e-a903-734c-9faa-5859b8a65ac2" xlink:href="alto-20260331.xsd#alto_DebtInstrumentExitFee"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_alto_LongTermDebtPrincipalPaymentsAndExitFee_019cfc6e-a903-7f28-8faa-6501dd21bf11" xlink:to="loc_alto_DebtInstrumentExitFee_019cfc6e-a903-734c-9faa-5859b8a65ac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentDeferredInterest_019cfc6e-a903-7326-be28-b43c27b92e2b" xlink:href="alto-20260331.xsd#alto_DebtInstrumentDeferredInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_alto_LongTermDebtPrincipalPaymentsAndExitFee_019cfc6e-a903-7f28-8faa-6501dd21bf11" xlink:to="loc_alto_DebtInstrumentDeferredInterest_019cfc6e-a903-7326-be28-b43c27b92e2b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtConvertiblegrantmaturityDetails"/>
  <link:calculationLink xlink:role="http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019cfc6e-a9b8-704f-a08a-a36143cf11ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-a9b8-71c4-be8e-f0e6a298a3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_019cfc6e-a9b8-704f-a08a-a36143cf11ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-a9b8-71c4-be8e-f0e6a298a3d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a9b8-74d6-a3d9-dcaeb70d20d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_019cfc6e-a9b8-704f-a08a-a36143cf11ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a9b8-74d6-a3d9-dcaeb70d20d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a9b8-70c2-a49c-d4153e3c9423" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_019cfc6e-a9b8-704f-a08a-a36143cf11ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a9b8-70c2-a49c-d4153e3c9423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a9b8-70d1-b000-88daae622fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_019cfc6e-a9b8-704f-a08a-a36143cf11ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a9b8-70d1-b000-88daae622fa4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/FairValueDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#FairValueDetails"/>
  <link:calculationLink xlink:role="http://www.altoneuroscience.com/role/FairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019cfc6e-a9b8-7b3b-8e6b-fa8d0452c8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_019cfc6e-a9b8-7b59-bd96-551cf6380d53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019cfc6e-a9b8-7b3b-8e6b-fa8d0452c8ba" xlink:to="loc_us-gaap_RestrictedCash_019cfc6e-a9b8-7b59-bd96-551cf6380d53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cfc6e-a9b8-7542-914e-c3b1f442607d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019cfc6e-a9b8-7b3b-8e6b-fa8d0452c8ba" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cfc6e-a9b8-7542-914e-c3b1f442607d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_019cfc6e-a9b8-7fb5-89d7-1f543063bb92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019cfc6e-a9b8-79a0-8f2f-053b285e78d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_019cfc6e-a9b8-7fb5-89d7-1f543063bb92" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019cfc6e-a9b8-79a0-8f2f-053b285e78d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#SegmentsScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:calculationLink xlink:role="http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cfc6e-a9b8-7cff-9d36-c60de1e58a73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cfc6e-a9b8-75b2-b378-f676d6b5f487" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cfc6e-a9b8-7cff-9d36-c60de1e58a73" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cfc6e-a9b8-75b2-b378-f676d6b5f487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_019cfc6e-a9b8-70ba-8448-e883884db9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cfc6e-a9b8-7cff-9d36-c60de1e58a73" xlink:to="loc_us-gaap_LaborAndRelatedExpense_019cfc6e-a9b8-70ba-8448-e883884db9b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_019cfc6e-a9b8-75ea-b7ea-58a1fe6b76b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cfc6e-a9b8-7cff-9d36-c60de1e58a73" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_019cfc6e-a9b8-75ea-b7ea-58a1fe6b76b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-7769-87f3-49a3f9be4fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cfc6e-a9b8-7cff-9d36-c60de1e58a73" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-7769-87f3-49a3f9be4fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_019cfc6e-a9b8-7090-9892-e54edeb2e309" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cfc6e-a9b8-7cff-9d36-c60de1e58a73" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_019cfc6e-a9b8-7090-9892-e54edeb2e309" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>alto-20260331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cfc6e-a845-7559-941c-e87ca4915109,g:515d2a5a-b4b4-4d42-8d26-d42921144f4b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="alto-20260331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cfc6e-a903-7b5a-9063-d0a72d0cc9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cfc6e-a903-7eae-9d10-79cc5d4d0c98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019cfc6e-a903-7b5a-9063-d0a72d0cc9c3" xlink:to="loc_us-gaap_StatementTable_019cfc6e-a903-7eae-9d10-79cc5d4d0c98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019cfc6e-a903-7c30-b8a0-a0b6dc8bc367" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019cfc6e-a903-7eae-9d10-79cc5d4d0c98" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019cfc6e-a903-7c30-b8a0-a0b6dc8bc367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7c30-b8a0-a0b6dc8bc367_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019cfc6e-a903-7c30-b8a0-a0b6dc8bc367" xlink:to="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7c30-b8a0-a0b6dc8bc367_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7eee-82ca-5e5dd352e51f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019cfc6e-a903-7c30-b8a0-a0b6dc8bc367" xlink:to="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7eee-82ca-5e5dd352e51f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019cfc6e-a903-7b6d-b8f3-e2336a897c45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7eee-82ca-5e5dd352e51f" xlink:to="loc_us-gaap_CommonStockMember_019cfc6e-a903-7b6d-b8f3-e2336a897c45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019cfc6e-a903-7fd1-94f0-1898e1ceddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7eee-82ca-5e5dd352e51f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019cfc6e-a903-7fd1-94f0-1898e1ceddf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019cfc6e-a903-7f22-87e5-2b2f219c3ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7eee-82ca-5e5dd352e51f" xlink:to="loc_us-gaap_RetainedEarningsMember_019cfc6e-a903-7f22-87e5-2b2f219c3ffd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cfc6e-a903-753f-a7b6-641bcc9cc1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7eee-82ca-5e5dd352e51f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cfc6e-a903-753f-a7b6-641bcc9cc1c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cfc6e-a903-7b5a-9063-d0a72d0cc9c3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a903-7754-a078-e0d5753cae39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a903-7754-a078-e0d5753cae39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7e04-870a-5abda82ac354" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7e04-870a-5abda82ac354" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cfc6e-a903-739f-8b6f-30d1e5472f69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cfc6e-a903-739f-8b6f-30d1e5472f69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019cfc6e-a903-7b76-9f41-3e70c0517aec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019cfc6e-a903-7b76-9f41-3e70c0517aec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock_019cfc6e-a903-771c-9bf9-9cae168a7f1a" xlink:href="alto-20260331.xsd#alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock_019cfc6e-a903-771c-9bf9-9cae168a7f1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_019dd74d-b0a9-7ded-91b8-3890cfa06837" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_019dd74d-b0a9-7ded-91b8-3890cfa06837" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_019dd74e-693c-7222-b463-6d4e53963e92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_019dd74e-693c-7222-b463-6d4e53963e92" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock_019dd74c-96b4-74f7-867d-89d86313655a" xlink:href="alto-20260331.xsd#alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock_019dd74c-96b4-74f7-867d-89d86313655a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue_019db84c-e2b7-7197-a3a6-46b6fbe08f82" xlink:href="alto-20260331.xsd#alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue_019db84c-e2b7-7197-a3a6-46b6fbe08f82" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_StockIssuedDuringPeriodShareConversionOfTermLoan_019dd74a-a2f1-769f-b806-042eb514305e" xlink:href="alto-20260331.xsd#alto_StockIssuedDuringPeriodShareConversionOfTermLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_alto_StockIssuedDuringPeriodShareConversionOfTermLoan_019dd74a-a2f1-769f-b806-042eb514305e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_StockIssuedDuringPeriodValueConversionOfTermLoan_019dd74b-2c11-72a4-9cd4-4737e868cd73" xlink:href="alto-20260331.xsd#alto_StockIssuedDuringPeriodValueConversionOfTermLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_alto_StockIssuedDuringPeriodValueConversionOfTermLoan_019dd74b-2c11-72a4-9cd4-4737e868cd73" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cfc6e-a903-7826-893b-08537ce70e60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cfc6e-a903-7826-893b-08537ce70e60" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cfc6e-a903-78ac-8e62-2c1c79817af2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cfc6e-a903-78ac-8e62-2c1c79817af2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-79a8-a510-129fcaff3b96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-79a8-a510-129fcaff3b96" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a903-7f25-af8c-83e0531dcbde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cfc6e-a903-787e-8a04-7dd3b47b1a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DescriptionoftheBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_019cfc6e-a903-76cf-96e4-f4403c0b4b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_019cfc6e-a903-76cf-96e4-f4403c0b4b5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019cfc6e-a903-7905-9b2a-21940194f96f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_019cfc6e-a903-76cf-96e4-f4403c0b4b5e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019cfc6e-a903-7905-9b2a-21940194f96f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7905-9b2a-21940194f96f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019cfc6e-a903-7905-9b2a-21940194f96f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7905-9b2a-21940194f96f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019cfc6e-a903-7905-9b2a-21940194f96f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_019cfc6e-a903-755a-818a-466a92629ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:to="loc_us-gaap_IPOMember_019cfc6e-a903-755a-818a-466a92629ff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_019cfc6e-a903-73da-abd9-58604fab86b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:to="loc_us-gaap_OverAllotmentOptionMember_019cfc6e-a903-73da-abd9-58604fab86b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_019cfc6e-a903-7fdf-8925-90dc5d2886cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:to="loc_us-gaap_PrivatePlacementMember_019cfc6e-a903-7fdf-8925-90dc5d2886cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_PreFundedWarrantsMember_019cfc6e-a903-71f0-800f-773fcab37f9f" xlink:href="alto-20260331.xsd#alto_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:to="loc_alto_PreFundedWarrantsMember_019cfc6e-a903-71f0-800f-773fcab37f9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2HealthventuresLLCMember_019db87a-f783-7a0b-a215-49e6c294a345" xlink:href="alto-20260331.xsd#alto_K2HealthventuresLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:to="loc_alto_K2HealthventuresLLCMember_019db87a-f783-7a0b-a215-49e6c294a345" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NumberOfWhollyOwnedSubsidiaries_019cfc6e-a903-7b0e-9d3a-46235df0c0b0" xlink:href="alto-20260331.xsd#alto_NumberOfWhollyOwnedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_alto_NumberOfWhollyOwnedSubsidiaries_019cfc6e-a903-7b0e-9d3a-46235df0c0b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NumberOfClinicalStageAssets_019cfc6e-a903-7726-bfae-60a6e77e7f1f" xlink:href="alto-20260331.xsd#alto_NumberOfClinicalStageAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_alto_NumberOfClinicalStageAssets_019cfc6e-a903-7726-bfae-60a6e77e7f1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cfc6e-a903-7b94-a5fc-b20ccf5a0712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cfc6e-a903-7b94-a5fc-b20ccf5a0712" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cfc6e-a903-7d8e-971c-5d1569cda2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cfc6e-a903-7d8e-971c-5d1569cda2f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019cfc6e-a903-72c3-9225-8770004bcbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019cfc6e-a903-72c3-9225-8770004bcbb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cfc6e-a903-7310-891f-eac85c6ab68b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cfc6e-a903-7310-891f-eac85c6ab68b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_TemporaryEquitySharesConversionOfConvertibleSecurities_019cfc6e-a903-7ede-941d-25ef58514af3" xlink:href="alto-20260331.xsd#alto_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_alto_TemporaryEquitySharesConversionOfConvertibleSecurities_019cfc6e-a903-7ede-941d-25ef58514af3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a903-7a8e-94b4-f83794aafc57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a903-7a8e-94b4-f83794aafc57" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_SaleOfStockConversionOfOutstandingLoan_019db87a-f783-7b98-8733-1a8047daded4" xlink:href="alto-20260331.xsd#alto_SaleOfStockConversionOfOutstandingLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_alto_SaleOfStockConversionOfOutstandingLoan_019db87a-f783-7b98-8733-1a8047daded4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_019db87a-f783-77a5-b07c-03a51fbf9e49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_019db87a-f783-77a5-b07c-03a51fbf9e49" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019cfc6e-a903-7111-94d2-76b7509259bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019cfc6e-a903-7edc-8260-c65a1c11d372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019cfc6e-a903-7111-94d2-76b7509259bf" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019cfc6e-a903-7edc-8260-c65a1c11d372" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019cfc6e-a903-7587-a16d-c9262e8d646d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019cfc6e-a903-7edc-8260-c65a1c11d372" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019cfc6e-a903-7587-a16d-c9262e8d646d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-7587-a16d-c9262e8d646d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019cfc6e-a903-7587-a16d-c9262e8d646d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-7587-a16d-c9262e8d646d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-75e2-93a1-585864097d89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019cfc6e-a903-7587-a16d-c9262e8d646d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-75e2-93a1-585864097d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_LaboratoryEquipmentMember_019cfc6e-a903-7fa5-8d86-c3c280dd708d" xlink:href="alto-20260331.xsd#alto_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-75e2-93a1-585864097d89" xlink:to="loc_alto_LaboratoryEquipmentMember_019cfc6e-a903-7fa5-8d86-c3c280dd708d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_019cfc6e-a903-7930-9ff8-a2c7906482e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-75e2-93a1-585864097d89" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_019cfc6e-a903-7930-9ff8-a2c7906482e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ComputerSoftwareAndEquipmentMember_019cfc6e-a903-7e0c-86ff-9233863ae1a5" xlink:href="alto-20260331.xsd#alto_ComputerSoftwareAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-75e2-93a1-585864097d89" xlink:to="loc_alto_ComputerSoftwareAndEquipmentMember_019cfc6e-a903-7e0c-86ff-9233863ae1a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_019cfc6e-a903-764b-af50-fabf418355ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-75e2-93a1-585864097d89" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_019cfc6e-a903-764b-af50-fabf418355ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019cfc6e-a903-700b-a2e9-ad8fc1d8fe8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019cfc6e-a903-7111-94d2-76b7509259bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019cfc6e-a903-700b-a2e9-ad8fc1d8fe8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019cfc6e-a903-7b91-b40b-0b6ef48db6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019cfc6e-a903-7111-94d2-76b7509259bf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019cfc6e-a903-7b91-b40b-0b6ef48db6fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a903-7c00-8f7d-ad924dbf1783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019cfc6e-a903-7111-94d2-76b7509259bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a903-7c00-8f7d-ad924dbf1783" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-716e-a98c-6cd9ed2ce612" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-716e-a98c-6cd9ed2ce612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-716e-a98c-6cd9ed2ce612_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-716e-a98c-6cd9ed2ce612" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-716e-a98c-6cd9ed2ce612_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7609-a2e8-bf5c9f55ca04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-716e-a98c-6cd9ed2ce612" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7609-a2e8-bf5c9f55ca04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_LoanAndSecurityAgreementMember_019cfc6e-a903-7fdf-a068-25f46f9bb9c1" xlink:href="alto-20260331.xsd#alto_LoanAndSecurityAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7609-a2e8-bf5c9f55ca04" xlink:to="loc_alto_LoanAndSecurityAgreementMember_019cfc6e-a903-7fdf-a068-25f46f9bb9c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AmendedLoanAgreementMember_019cfc6e-a903-74da-ba43-a2f2dac99eee" xlink:href="alto-20260331.xsd#alto_AmendedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7609-a2e8-bf5c9f55ca04" xlink:to="loc_alto_AmendedLoanAgreementMember_019cfc6e-a903-74da-ba43-a2f2dac99eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-791b-8926-c1426189d2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-791b-8926-c1426189d2e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-791b-8926-c1426189d2e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-791b-8926-c1426189d2e4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-791b-8926-c1426189d2e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7f18-b4e0-0c9212108372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-791b-8926-c1426189d2e4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7f18-b4e0-0c9212108372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019cfc6e-a903-7ac4-b1ee-c4f92303c396" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7f18-b4e0-0c9212108372" xlink:to="loc_us-gaap_SecuredDebtMember_019cfc6e-a903-7ac4-b1ee-c4f92303c396" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-7d03-9246-ab8a8a1f4b65" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-7d03-9246-ab8a8a1f4b65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7d03-9246-ab8a8a1f4b65_default" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-7d03-9246-ab8a8a1f4b65" xlink:to="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7d03-9246-ab8a8a1f4b65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7306-b717-11a9b79d2390" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-7d03-9246-ab8a8a1f4b65" xlink:to="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7306-b717-11a9b79d2390" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheFourMember_019cfc6e-a903-76ae-878c-9c54e6b5e85b" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7306-b717-11a9b79d2390" xlink:to="loc_alto_DebtInstrumentTrancheFourMember_019cfc6e-a903-76ae-878c-9c54e6b5e85b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheOneMember_019cfc6e-a903-7853-a04e-96af0e461d2f" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7306-b717-11a9b79d2390" xlink:to="loc_alto_DebtInstrumentTrancheOneMember_019cfc6e-a903-7853-a04e-96af0e461d2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheTwoMember_019cfc6e-a903-7d0f-a112-4ea7c3368a9d" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7306-b717-11a9b79d2390" xlink:to="loc_alto_DebtInstrumentTrancheTwoMember_019cfc6e-a903-7d0f-a112-4ea7c3368a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheThreeMember_019cfc6e-a903-7d72-aad3-99618bb48363" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7306-b717-11a9b79d2390" xlink:to="loc_alto_DebtInstrumentTrancheThreeMember_019cfc6e-a903-7d72-aad3-99618bb48363" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a903-7d92-8a0d-5e2ab9e59689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a903-7d92-8a0d-5e2ab9e59689" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a903-7d92-8a0d-5e2ab9e59689_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a903-7d92-8a0d-5e2ab9e59689" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a903-7d92-8a0d-5e2ab9e59689_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a903-72ff-a2da-84983cc8fad6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a903-7d92-8a0d-5e2ab9e59689" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a903-72ff-a2da-84983cc8fad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2WarrantMember_019cfc6e-a903-7ffb-a6a6-ac5745219a4a" xlink:href="alto-20260331.xsd#alto_K2WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a903-72ff-a2da-84983cc8fad6" xlink:to="loc_alto_K2WarrantMember_019cfc6e-a903-7ffb-a6a6-ac5745219a4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NewK2WarrantMember_019cfc6e-a903-75f8-8ac7-a7790fad65d4" xlink:href="alto-20260331.xsd#alto_NewK2WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a903-72ff-a2da-84983cc8fad6" xlink:to="loc_alto_NewK2WarrantMember_019cfc6e-a903-75f8-8ac7-a7790fad65d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a903-76e3-8977-467b9741e04e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a903-76e3-8977-467b9741e04e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019cfc6e-a903-76e3-8977-467b9741e04e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a903-76e3-8977-467b9741e04e" xlink:to="loc_us-gaap_ClassOfStockDomain_019cfc6e-a903-76e3-8977-467b9741e04e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019cfc6e-a903-7222-98c2-41d69591f1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a903-76e3-8977-467b9741e04e" xlink:to="loc_us-gaap_ClassOfStockDomain_019cfc6e-a903-7222-98c2-41d69591f1ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019cfc6e-a903-7efe-b229-e8b0fe385b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019cfc6e-a903-7222-98c2-41d69591f1ee" xlink:to="loc_us-gaap_CommonStockMember_019cfc6e-a903-7efe-b229-e8b0fe385b06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-76d7-9969-3b878e22c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-76d7-9969-3b878e22c37b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-76d7-9969-3b878e22c37b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-76d7-9969-3b878e22c37b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-76d7-9969-3b878e22c37b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7eec-a95c-ab61b1056585" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-76d7-9969-3b878e22c37b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7eec-a95c-ab61b1056585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_019cfc6e-a903-7841-8300-0e193a014b85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7eec-a95c-ab61b1056585" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_019cfc6e-a903-7841-8300-0e193a014b85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_019cfc6e-a903-7b4e-8f30-d5523a6ed8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7eec-a95c-ab61b1056585" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_019cfc6e-a903-7b4e-8f30-d5523a6ed8ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_019cfc6e-a903-7488-b078-2d22e676c89e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7eec-a95c-ab61b1056585" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_019cfc6e-a903-7488-b078-2d22e676c89e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019cfc6e-a903-72a6-9a9c-77580065481e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_srt_RangeAxis_019cfc6e-a903-72a6-9a9c-77580065481e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cfc6e-a903-72a6-9a9c-77580065481e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019cfc6e-a903-72a6-9a9c-77580065481e" xlink:to="loc_srt_RangeMember_019cfc6e-a903-72a6-9a9c-77580065481e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cfc6e-a903-7acc-b8f2-a2b694bdce2f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019cfc6e-a903-72a6-9a9c-77580065481e" xlink:to="loc_srt_RangeMember_019cfc6e-a903-7acc-b8f2-a2b694bdce2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019cfc6e-a903-73f9-90f1-be772dbdeb65" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019cfc6e-a903-7acc-b8f2-a2b694bdce2f" xlink:to="loc_srt_MaximumMember_019cfc6e-a903-73f9-90f1-be772dbdeb65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019db923-fb4a-75e5-af2b-cdd4b0c3f96d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019db923-fb4a-75e5-af2b-cdd4b0c3f96d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db923-fb4a-75e5-af2b-cdd4b0c3f96d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019db923-fb4a-75e5-af2b-cdd4b0c3f96d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db923-fb4a-75e5-af2b-cdd4b0c3f96d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db923-fb4a-76f7-ba6d-e2e58589b8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019db923-fb4a-75e5-af2b-cdd4b0c3f96d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db923-fb4a-76f7-ba6d-e2e58589b8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2HealthventuresLLCMember_019db923-fb4a-75c2-8b14-bc44ccdd85f0" xlink:href="alto-20260331.xsd#alto_K2HealthventuresLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db923-fb4a-76f7-ba6d-e2e58589b8e4" xlink:to="loc_alto_K2HealthventuresLLCMember_019db923-fb4a-75c2-8b14-bc44ccdd85f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019cfc6e-a903-79c7-b0b0-dbec7b12baa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019cfc6e-a903-79c7-b0b0-dbec7b12baa6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_019cfc6e-a903-7a62-a74d-c236d80feb91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_019cfc6e-a903-7a62-a74d-c236d80feb91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019cfc6e-a903-7350-8df5-e4609c3900a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019cfc6e-a903-7350-8df5-e4609c3900a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_019cfc6e-a903-71f8-9842-02968eef2411" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_019cfc6e-a903-71f8-9842-02968eef2411" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019cfc6e-a903-7207-9632-c73fc4e963ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019cfc6e-a903-7207-9632-c73fc4e963ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentInterestRateFloor_019cfc6e-a903-72b9-8ec6-a4faa372d4b3" xlink:href="alto-20260331.xsd#alto_DebtInstrumentInterestRateFloor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentInterestRateFloor_019cfc6e-a903-72b9-8ec6-a4faa372d4b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentFixedRatePaidInKind_019cfc6e-a903-7051-a428-9f82f3fa2f2e" xlink:href="alto-20260331.xsd#alto_DebtInstrumentFixedRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentFixedRatePaidInKind_019cfc6e-a903-7051-a428-9f82f3fa2f2e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed_019cfc6e-a903-7b78-95fe-63da2940ed34" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed_019cfc6e-a903-7b78-95fe-63da2940ed34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019cfc6e-a903-772a-8d48-19d58ca9cac5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019cfc6e-a903-772a-8d48-19d58ca9cac5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a903-73ce-b0ed-0b27228d813e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a903-73ce-b0ed-0b27228d813e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentExitFeePercentOfLoansFunded_019cfc6e-a903-746b-a1a7-8f944d245625" xlink:href="alto-20260331.xsd#alto_DebtInstrumentExitFeePercentOfLoansFunded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentExitFeePercentOfLoansFunded_019cfc6e-a903-746b-a1a7-8f944d245625" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_019cfc6e-a903-7fb2-a58c-3a24270e80e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_019cfc6e-a903-7fb2-a58c-3a24270e80e4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentExitFee_019cfc6e-a903-7854-bbbe-c563128510fb" xlink:href="alto-20260331.xsd#alto_DebtInstrumentExitFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentExitFee_019cfc6e-a903-7854-bbbe-c563128510fb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentFundingFeeMultiplier_019cfc6e-a903-701a-9845-6eb96f263adc" xlink:href="alto-20260331.xsd#alto_DebtInstrumentFundingFeeMultiplier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentFundingFeeMultiplier_019cfc6e-a903-701a-9845-6eb96f263adc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a903-71d4-b87b-b19afbbc1198" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a903-71d4-b87b-b19afbbc1198" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a903-7bd4-a736-77a305461ed6" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a903-7bd4-a736-77a305461ed6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a903-7a63-9924-64d15ea4fb28" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a903-7a63-9924-64d15ea4fb28" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum_019cfc6e-a903-7ab0-9d76-b3263055e663" xlink:href="alto-20260331.xsd#alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum_019cfc6e-a903-7ab0-9d76-b3263055e663" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount_019cfc6e-a903-7f18-9962-5619c6eb9cf3" xlink:href="alto-20260331.xsd#alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount_019cfc6e-a903-7f18-9962-5619c6eb9cf3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault_019cfc6e-a903-78c2-aa08-d8881fd8238a" xlink:href="alto-20260331.xsd#alto_DebtInstrumentInterestRateIncreaseInEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault_019cfc6e-a903-78c2-aa08-d8881fd8238a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019cfc6e-a903-7fb2-8e6c-16ec10f5188b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019cfc6e-a903-7fb2-8e6c-16ec10f5188b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_019cfc6e-a903-71a5-b3d4-cb0570d46bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_019cfc6e-a903-71a5-b3d4-cb0570d46bb7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier_019cfc6e-a903-7ade-87d1-6512a97e03a4" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier_019cfc6e-a903-7ade-87d1-6512a97e03a4" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a903-7921-a367-2624ef9019b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a903-7921-a367-2624ef9019b7" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_019cfc6e-a903-7d17-9091-02b774eb3a05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_019cfc6e-a903-7d17-9091-02b774eb3a05" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_019cfc6e-a903-72a1-9cd5-be845b12f419" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_019cfc6e-a903-72a1-9cd5-be845b12f419" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_019cfc6e-a903-7b30-8315-334c16033642" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_019cfc6e-a903-7b30-8315-334c16033642" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender_019cfc6e-a903-72d4-a197-bc1b9b814260" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender_019cfc6e-a903-72d4-a197-bc1b9b814260" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender_019cfc6e-a903-72ba-8090-9cc019c8cb13" xlink:href="alto-20260331.xsd#alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender_019cfc6e-a903-72ba-8090-9cc019c8cb13" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_SaleOfStockConversionOfOutstandingLoan_019db923-fb4a-74ec-835f-deaefdac2fac" xlink:href="alto-20260331.xsd#alto_SaleOfStockConversionOfOutstandingLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_SaleOfStockConversionOfOutstandingLoan_019db923-fb4a-74ec-835f-deaefdac2fac" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019db923-fb4a-75de-9878-6c29ce6ff4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019db923-fb4a-75de-9878-6c29ce6ff4c8" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_019db923-fb4a-7330-8f63-a7c9afdde5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_019db923-fb4a-7330-8f63-a7c9afdde5f6" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_019cfc6e-a903-74bd-be8a-96320e327063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_019cfc6e-a903-74bd-be8a-96320e327063" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_019cfc6e-a903-7469-97f8-67f3d0d36180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_InterestExpenseDebt_019cfc6e-a903-7469-97f8-67f3d0d36180" xlink:type="arc" order="33"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-75dd-9d5c-3bbdade05684" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-75dd-9d5c-3bbdade05684" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7a65-a485-b322ea05ac37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-75dd-9d5c-3bbdade05684" xlink:to="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7a65-a485-b322ea05ac37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7a65-a485-b322ea05ac37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7a65-a485-b322ea05ac37" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7a65-a485-b322ea05ac37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-79b3-8d70-988c0d127984" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7a65-a485-b322ea05ac37" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-79b3-8d70-988c0d127984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AmendedLoanAgreementMember_019cfc6e-a903-7545-9614-51cd3f0ee8cf" xlink:href="alto-20260331.xsd#alto_AmendedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-79b3-8d70-988c0d127984" xlink:to="loc_alto_AmendedLoanAgreementMember_019cfc6e-a903-7545-9614-51cd3f0ee8cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-a903-726a-b7c6-43410ede2de7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-a903-726a-b7c6-43410ede2de7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a903-7b86-9160-328a60ea1ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a903-7b86-9160-328a60ea1ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a903-7276-848a-703bbae06727" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a903-7276-848a-703bbae06727" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a903-7271-9560-cc2248b9c96d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a903-7271-9560-cc2248b9c96d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019cfc6e-a903-75a9-9689-f5a1902c8c16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019cfc6e-a903-75a9-9689-f5a1902c8c16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentExitFee_019cfc6e-a903-7f3e-8476-a0bd2306c23d" xlink:href="alto-20260331.xsd#alto_DebtInstrumentExitFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_alto_DebtInstrumentExitFee_019cfc6e-a903-7f3e-8476-a0bd2306c23d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentDeferredInterest_019cfc6e-a903-789b-b69f-242b6e6a932b" xlink:href="alto-20260331.xsd#alto_DebtInstrumentDeferredInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_alto_DebtInstrumentDeferredInterest_019cfc6e-a903-789b-b69f-242b6e6a932b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_LongTermDebtPrincipalPaymentsAndExitFee_019cfc6e-a903-7546-97dc-8579106e226b" xlink:href="alto-20260331.xsd#alto_LongTermDebtPrincipalPaymentsAndExitFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_alto_LongTermDebtPrincipalPaymentsAndExitFee_019cfc6e-a903-7546-97dc-8579106e226b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentUnamortizedExitFee_019cfc6e-a903-7fcb-b9e3-f9213c6c5246" xlink:href="alto-20260331.xsd#alto_DebtInstrumentUnamortizedExitFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_alto_DebtInstrumentUnamortizedExitFee_019cfc6e-a903-7fcb-b9e3-f9213c6c5246" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_019dd75c-e2c9-72d8-82ab-666a8bdafb45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_LongTermDebtCurrent_019dd75c-e2c9-72d8-82ab-666a8bdafb45" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_019cfc6e-a903-7423-bf42-18d7c2dec38b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_019cfc6e-a903-7423-bf42-18d7c2dec38b" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtConvertiblegrantnarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019cfc6e-a903-75f5-98ca-1341a8fe9ea7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_srt_RangeAxis_019cfc6e-a903-75f5-98ca-1341a8fe9ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cfc6e-a903-75f5-98ca-1341a8fe9ea7_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019cfc6e-a903-75f5-98ca-1341a8fe9ea7" xlink:to="loc_srt_RangeMember_019cfc6e-a903-75f5-98ca-1341a8fe9ea7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cfc6e-a903-75ab-a675-d3eeb53fe16c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019cfc6e-a903-75f5-98ca-1341a8fe9ea7" xlink:to="loc_srt_RangeMember_019cfc6e-a903-75ab-a675-d3eeb53fe16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019cfc6e-a903-75e1-a8e6-ef0203f960d9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019cfc6e-a903-75ab-a675-d3eeb53fe16c" xlink:to="loc_srt_MaximumMember_019cfc6e-a903-75e1-a8e6-ef0203f960d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7956-9195-e90ee39c3720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7956-9195-e90ee39c3720" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7956-9195-e90ee39c3720_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7956-9195-e90ee39c3720" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7956-9195-e90ee39c3720_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7728-848f-88cb55583b88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7956-9195-e90ee39c3720" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7728-848f-88cb55583b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_GrantAgreementMember_019cfc6e-a903-75d3-9499-2a2fc4ba2ec4" xlink:href="alto-20260331.xsd#alto_GrantAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7728-848f-88cb55583b88" xlink:to="loc_alto_GrantAgreementMember_019cfc6e-a903-75d3-9499-2a2fc4ba2ec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-7423-b969-fa581c84e07c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-7423-b969-fa581c84e07c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7423-b969-fa581c84e07c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-7423-b969-fa581c84e07c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7423-b969-fa581c84e07c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7df6-8d18-9577f2505683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-7423-b969-fa581c84e07c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7df6-8d18-9577f2505683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a903-7af6-8928-3d62874c16e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7df6-8d18-9577f2505683" xlink:to="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a903-7af6-8928-3d62874c16e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-78c9-8092-951ddbb0eefc" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-78c9-8092-951ddbb0eefc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-78c9-8092-951ddbb0eefc_default" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-78c9-8092-951ddbb0eefc" xlink:to="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-78c9-8092-951ddbb0eefc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-76b4-b941-60def6750290" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-78c9-8092-951ddbb0eefc" xlink:to="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-76b4-b941-60def6750290" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheOneMember_019cfc6e-a903-7416-8781-331070d04a40" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-76b4-b941-60def6750290" xlink:to="loc_alto_DebtInstrumentTrancheOneMember_019cfc6e-a903-7416-8781-331070d04a40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a903-7ef4-9239-91a2f78002fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a903-7ef4-9239-91a2f78002fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a903-7ef4-9239-91a2f78002fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a903-7ef4-9239-91a2f78002fb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a903-7ef4-9239-91a2f78002fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a903-780a-9a26-9923ce894ded" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a903-7ef4-9239-91a2f78002fb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a903-780a-9a26-9923ce894ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a903-7e4b-86a2-588b1fb01782" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a903-780a-9a26-9923ce894ded" xlink:to="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a903-7e4b-86a2-588b1fb01782" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-7e76-9285-71665dcc2ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-7e76-9285-71665dcc2ce5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7e76-9285-71665dcc2ce5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-7e76-9285-71665dcc2ce5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7e76-9285-71665dcc2ce5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7fbf-a7c2-72fab0d8f675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-7e76-9285-71665dcc2ce5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7fbf-a7c2-72fab0d8f675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_019cfc6e-a903-7cbc-907b-63163097a039" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7fbf-a7c2-72fab0d8f675" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_019cfc6e-a903-7cbc-907b-63163097a039" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_019cfc6e-a903-7e5d-9252-d0728899b662" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_019cfc6e-a903-7e5d-9252-d0728899b662" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentNumberOfTranches_019cfc6e-a903-7f08-a6b4-95e793516ae5" xlink:href="alto-20260331.xsd#alto_DebtInstrumentNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_alto_DebtInstrumentNumberOfTranches_019cfc6e-a903-7f08-a6b4-95e793516ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019cfc6e-a903-7f4b-afbf-96f0a4789b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019cfc6e-a903-7f4b-afbf-96f0a4789b06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019cfc6e-a903-70f9-bb31-64da5be027e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019cfc6e-a903-70f9-bb31-64da5be027e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment_019cfc6e-a9b8-71c3-83a6-b9d582e0aee3" xlink:href="alto-20260331.xsd#alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment_019cfc6e-a9b8-71c3-83a6-b9d582e0aee3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentConvertibleDiscountOnSharesConverted_019cfc6e-a9b8-7abf-ac76-4d3a115f2744" xlink:href="alto-20260331.xsd#alto_DebtInstrumentConvertibleDiscountOnSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_alto_DebtInstrumentConvertibleDiscountOnSharesConverted_019cfc6e-a9b8-7abf-ac76-4d3a115f2744" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement_019cfc6e-a9b8-74d9-a099-465850d2be18" xlink:href="alto-20260331.xsd#alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement_019cfc6e-a9b8-74d9-a099-465850d2be18" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentConvertibleMaximumSharesIssuable_019cfc6e-a9b8-7b72-945b-0290938a3b84" xlink:href="alto-20260331.xsd#alto_DebtInstrumentConvertibleMaximumSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_alto_DebtInstrumentConvertibleMaximumSharesIssuable_019cfc6e-a9b8-7b72-945b-0290938a3b84" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum_019cfc6e-a9b8-70e1-89cf-b5a3df66f2ed" xlink:href="alto-20260331.xsd#alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum_019cfc6e-a9b8-70e1-89cf-b5a3df66f2ed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019cfc6e-a9b8-7233-a9fc-cd5934cac39c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019cfc6e-a9b8-7233-a9fc-cd5934cac39c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-734c-95ee-742d38375d26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-734c-95ee-742d38375d26" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_019cfc6e-a9b8-7845-9d0e-aa1f04366ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_019cfc6e-a9b8-7845-9d0e-aa1f04366ca8" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtConvertiblegrantmaturityDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019cfc6e-a9b8-71b0-b7e1-66cc4d650e97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:to="loc_us-gaap_DebtInstrumentTable_019cfc6e-a9b8-71b0-b7e1-66cc4d650e97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-70ce-a0ca-3b6451c4b8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a9b8-71b0-b7e1-66cc4d650e97" xlink:to="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-70ce-a0ca-3b6451c4b8a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-70ce-a0ca-3b6451c4b8a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-70ce-a0ca-3b6451c4b8a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-70ce-a0ca-3b6451c4b8a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7889-89a3-85c8e7a3597c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-70ce-a0ca-3b6451c4b8a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7889-89a3-85c8e7a3597c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a9b8-77a8-8635-ac7cdd9d9068" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7889-89a3-85c8e7a3597c" xlink:to="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a9b8-77a8-8635-ac7cdd9d9068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-a9b8-79c9-b356-8866febdb22c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-a9b8-79c9-b356-8866febdb22c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a9b8-75c6-9e72-0c661666162d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a9b8-75c6-9e72-0c661666162d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a9b8-7d20-b27b-92ab23cf5091" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a9b8-7d20-b27b-92ab23cf5091" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a9b8-71d9-b49a-ddcab3f8cfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a9b8-71d9-b49a-ddcab3f8cfa0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019cfc6e-a9b8-7c80-8447-11a937407649" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:to="loc_us-gaap_LongTermDebt_019cfc6e-a9b8-7c80-8447-11a937407649" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtChangeinfairvalueofconvertiblegrantagreementDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019cfc6e-a9b8-7571-a1ca-4656f03f4336" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019cfc6e-a9b8-70c7-a6dc-726ef9be936d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019cfc6e-a9b8-7571-a1ca-4656f03f4336" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019cfc6e-a9b8-70c7-a6dc-726ef9be936d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a9b8-7b85-8eb1-5b676bf34ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019cfc6e-a9b8-70c7-a6dc-726ef9be936d" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a9b8-7b85-8eb1-5b676bf34ce9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a9b8-7b85-8eb1-5b676bf34ce9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a9b8-7b85-8eb1-5b676bf34ce9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a9b8-7b85-8eb1-5b676bf34ce9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a9b8-7d24-9f13-8ff41e7e54d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a9b8-7b85-8eb1-5b676bf34ce9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a9b8-7d24-9f13-8ff41e7e54d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a9b8-7f8c-99f0-6420047ad59d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a9b8-7d24-9f13-8ff41e7e54d0" xlink:to="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a9b8-7f8c-99f0-6420047ad59d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019cfc6e-a9b8-7571-a1ca-4656f03f4336" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-7674-82ee-9c056c7e49cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-7674-82ee-9c056c7e49cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_019cfc6e-a9b8-70ac-89d8-0ba0dbaaa8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_019cfc6e-a9b8-70ac-89d8-0ba0dbaaa8b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019db8ea-bcdc-7d5b-9c2f-9b9af67351a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019db8ea-bcdc-7d5b-9c2f-9b9af67351a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019cfc6e-a9b8-7d29-bb29-4b79b66e7a81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019cfc6e-a9b8-7d29-bb29-4b79b66e7a81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_019cfc6e-a9b8-7e2b-8b70-34d087e4fafb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_019cfc6e-a9b8-7e2b-8b70-34d087e4fafb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-7311-87f2-5e67772aa2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/FairValueDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#FairValueDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/FairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cfc6e-a9b8-73ad-a987-cc72827508a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cfc6e-a9b8-709b-bfa2-c42abe3d025f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cfc6e-a9b8-73ad-a987-cc72827508a2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cfc6e-a9b8-709b-bfa2-c42abe3d025f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cfc6e-a9b8-7088-9d87-325485569844" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cfc6e-a9b8-709b-bfa2-c42abe3d025f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cfc6e-a9b8-7088-9d87-325485569844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-a9b8-7088-9d87-325485569844_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cfc6e-a9b8-7088-9d87-325485569844" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-a9b8-7088-9d87-325485569844_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-a9b8-7712-9cce-c56ea3cf3e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cfc6e-a9b8-7088-9d87-325485569844" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-a9b8-7712-9cce-c56ea3cf3e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019cfc6e-a9b8-7195-85ce-28ac249d2835" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-a9b8-7712-9cce-c56ea3cf3e9c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019cfc6e-a9b8-7195-85ce-28ac249d2835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019cfc6e-a9b8-7bd5-b770-d7e89ebd996a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-a9b8-7712-9cce-c56ea3cf3e9c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019cfc6e-a9b8-7bd5-b770-d7e89ebd996a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019cfc6e-a9b8-76a8-8098-3b1aadc24d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-a9b8-7712-9cce-c56ea3cf3e9c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019cfc6e-a9b8-76a8-8098-3b1aadc24d3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019cfc6e-a9b8-7834-9669-ad7f9a427fae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cfc6e-a9b8-709b-bfa2-c42abe3d025f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019cfc6e-a9b8-7834-9669-ad7f9a427fae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cfc6e-a9b8-7834-9669-ad7f9a427fae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019cfc6e-a9b8-7834-9669-ad7f9a427fae" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cfc6e-a9b8-7834-9669-ad7f9a427fae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cfc6e-a9b8-7ead-81e3-5cdd00cd5077" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019cfc6e-a9b8-7834-9669-ad7f9a427fae" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cfc6e-a9b8-7ead-81e3-5cdd00cd5077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019cfc6e-a9b8-7909-bc3b-5b4777ca0653" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cfc6e-a9b8-7ead-81e3-5cdd00cd5077" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019cfc6e-a9b8-7909-bc3b-5b4777ca0653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019cfc6e-a9b8-7460-a839-664ee7ca1577" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cfc6e-a9b8-73ad-a987-cc72827508a2" xlink:to="loc_us-gaap_AssetsAbstract_019cfc6e-a9b8-7460-a839-664ee7ca1577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cfc6e-a9b8-7ebe-be4f-e5105c0f610d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019cfc6e-a9b8-7460-a839-664ee7ca1577" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cfc6e-a9b8-7ebe-be4f-e5105c0f610d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_019cfc6e-a9b8-7459-b88d-fe58c490b216" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019cfc6e-a9b8-7460-a839-664ee7ca1577" xlink:to="loc_us-gaap_RestrictedCash_019cfc6e-a9b8-7459-b88d-fe58c490b216" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019cfc6e-a9b8-7db3-b1e8-39e266b6e0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019cfc6e-a9b8-7460-a839-664ee7ca1577" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_019cfc6e-a9b8-7db3-b1e8-39e266b6e0b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_019cfc6e-a9b8-710a-a6f2-44ff48e829f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cfc6e-a9b8-73ad-a987-cc72827508a2" xlink:to="loc_us-gaap_LiabilitiesAbstract_019cfc6e-a9b8-710a-a6f2-44ff48e829f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019cfc6e-a9b8-77e1-9b9f-f8443a3ee6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_019cfc6e-a9b8-710a-a6f2-44ff48e829f1" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019cfc6e-a9b8-77e1-9b9f-f8443a3ee6f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_019cfc6e-a9b8-71e9-aa65-33e81389e08e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_019cfc6e-a9b8-710a-a6f2-44ff48e829f1" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_019cfc6e-a9b8-71e9-aa65-33e81389e08e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockBasedPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019cfc6e-a9b8-799a-8e5e-0cc89f1ac409" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:to="loc_us-gaap_PlanNameAxis_019cfc6e-a9b8-799a-8e5e-0cc89f1ac409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019cfc6e-a9b8-799a-8e5e-0cc89f1ac409_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019cfc6e-a9b8-799a-8e5e-0cc89f1ac409" xlink:to="loc_us-gaap_PlanNameDomain_019cfc6e-a9b8-799a-8e5e-0cc89f1ac409_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019cfc6e-a9b8-7895-8444-038f3a98ead9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019cfc6e-a9b8-799a-8e5e-0cc89f1ac409" xlink:to="loc_us-gaap_PlanNameDomain_019cfc6e-a9b8-7895-8444-038f3a98ead9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_The2024EquityIncentivePlanMember_019cfc6e-a9b8-797d-97a4-622bd197985a" xlink:href="alto-20260331.xsd#alto_The2024EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019cfc6e-a9b8-7895-8444-038f3a98ead9" xlink:to="loc_alto_The2024EquityIncentivePlanMember_019cfc6e-a9b8-797d-97a4-622bd197985a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_A2025InducementPlanMember_019cfc6e-a9b8-7999-96cc-36d5be0af048" xlink:href="alto-20260331.xsd#alto_A2025InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019cfc6e-a9b8-7895-8444-038f3a98ead9" xlink:to="loc_alto_A2025InducementPlanMember_019cfc6e-a9b8-7999-96cc-36d5be0af048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7160-83bb-b2952fcfad73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:to="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7160-83bb-b2952fcfad73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7160-83bb-b2952fcfad73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7160-83bb-b2952fcfad73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7160-83bb-b2952fcfad73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7410-9f0a-23d823119698" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7160-83bb-b2952fcfad73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7410-9f0a-23d823119698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-748d-8fcb-97cdeec17ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7410-9f0a-23d823119698" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-748d-8fcb-97cdeec17ae5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019cfc6e-a9b8-7ffa-895c-8bb4e452b9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7410-9f0a-23d823119698" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019cfc6e-a9b8-7ffa-895c-8bb4e452b9e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019cfc6e-a9b8-72c0-90e4-42c200468442" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7410-9f0a-23d823119698" xlink:to="loc_us-gaap_PerformanceSharesMember_019cfc6e-a9b8-72c0-90e4-42c200468442" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_019cfc6e-a9b8-77b0-8fa0-2e28573fb5de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:to="loc_us-gaap_VestingAxis_019cfc6e-a9b8-77b0-8fa0-2e28573fb5de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_019cfc6e-a9b8-77b0-8fa0-2e28573fb5de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_019cfc6e-a9b8-77b0-8fa0-2e28573fb5de" xlink:to="loc_us-gaap_VestingDomain_019cfc6e-a9b8-77b0-8fa0-2e28573fb5de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_019cfc6e-a9b8-7271-812b-2011c1e451df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_019cfc6e-a9b8-77b0-8fa0-2e28573fb5de" xlink:to="loc_us-gaap_VestingDomain_019cfc6e-a9b8-7271-812b-2011c1e451df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019cfc6e-a9b8-762b-879b-3f465a5cc4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_019cfc6e-a9b8-7271-812b-2011c1e451df" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019cfc6e-a9b8-762b-879b-3f465a5cc4e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_019cfc6e-a9b8-7712-a86b-ed2cd2957460" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_019cfc6e-a9b8-7271-812b-2011c1e451df" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_019cfc6e-a9b8-7712-a86b-ed2cd2957460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-727d-bc9b-60d92cfea1af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-727d-bc9b-60d92cfea1af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-727d-bc9b-60d92cfea1af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-727d-bc9b-60d92cfea1af" xlink:to="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-727d-bc9b-60d92cfea1af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-7019-b5e5-b8f782b38854" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-727d-bc9b-60d92cfea1af" xlink:to="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-7019-b5e5-b8f782b38854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019cfc6e-a9b8-79d3-b7d1-4572772b76b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-7019-b5e5-b8f782b38854" xlink:to="loc_us-gaap_CommonStockMember_019cfc6e-a9b8-79d3-b7d1-4572772b76b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019cfc6e-a9b8-7485-be38-4fc5330d07e7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:to="loc_srt_RangeAxis_019cfc6e-a9b8-7485-be38-4fc5330d07e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cfc6e-a9b8-7485-be38-4fc5330d07e7_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019cfc6e-a9b8-7485-be38-4fc5330d07e7" xlink:to="loc_srt_RangeMember_019cfc6e-a9b8-7485-be38-4fc5330d07e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cfc6e-a9b8-7df4-8107-027b52f6b1af" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019cfc6e-a9b8-7485-be38-4fc5330d07e7" xlink:to="loc_srt_RangeMember_019cfc6e-a9b8-7df4-8107-027b52f6b1af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019cfc6e-a9b8-7c81-bbf9-245469ba3e5f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019cfc6e-a9b8-7df4-8107-027b52f6b1af" xlink:to="loc_srt_MinimumMember_019cfc6e-a9b8-7c81-bbf9-245469ba3e5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019cfc6e-a9b8-7e1e-a045-e21eb200b763" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019cfc6e-a9b8-7e1e-a045-e21eb200b763" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock_019cfc6e-a9b8-73cd-8519-bc06ef2bf8d1" xlink:href="alto-20260331.xsd#alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock_019cfc6e-a9b8-73cd-8519-bc06ef2bf8d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019cfc6e-a9b8-72c3-8df1-fc0f2bbaa568" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019cfc6e-a9b8-72c3-8df1-fc0f2bbaa568" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019db8c4-d0b9-7c17-bef3-97bf8fe83d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019db8c4-d0b9-7c17-bef3-97bf8fe83d5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_019cfc6e-a9b8-73fc-a099-23473a19e526" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_019cfc6e-a9b8-73fc-a099-23473a19e526" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019cfc6e-a9b8-7526-95e1-370628c84115" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019cfc6e-a9b8-7526-95e1-370628c84115" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_019cfc6e-a9b8-767a-9f44-e509c1c58f16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_019cfc6e-a9b8-767a-9f44-e509c1c58f16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_019cfc6e-a9b8-707a-b911-19830942d7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_019cfc6e-a9b8-707a-b911-19830942d7a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_019cfc6e-a9b8-729f-813b-9e8cf5c965b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_019cfc6e-a9b8-729f-813b-9e8cf5c965b3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019cfc6e-a9b8-79c9-83e7-e40a630bee3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019cfc6e-a9b8-79c9-83e7-e40a630bee3e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019cfc6e-a9b8-726e-b083-b00cd5536e04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019cfc6e-a9b8-726e-b083-b00cd5536e04" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-772e-a9b9-ee1b174dd561" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-772e-a9b9-ee1b174dd561" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019cfc6e-a9b8-74dc-bf95-efd232a42d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019cfc6e-a9b8-74dc-bf95-efd232a42d8e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019cfc6e-a9b8-7542-a51d-17df73f84ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019cfc6e-a9b8-7542-a51d-17df73f84ec6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019cfc6e-a9b8-741c-9b22-41b58417bcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019cfc6e-a9b8-741c-9b22-41b58417bcbd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7d26-8431-e40fba4d1d23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7d26-8431-e40fba4d1d23" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_019cfc6e-a9b8-73a2-9ed5-88e8195e7e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_019cfc6e-a9b8-73a2-9ed5-88e8195e7e8f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019cfc6e-a9b8-7e6c-a45e-839f033740f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019cfc6e-a9b8-7e6c-a45e-839f033740f3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019db8c6-8147-7e48-a3fc-bd6c80da337f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019db8c6-8147-7e48-a3fc-bd6c80da337f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019cfc6e-a9b8-763f-82e9-9d048723c669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019cfc6e-a9b8-763f-82e9-9d048723c669" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_019dff09-fa2b-7255-b214-b2a165978a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_019dff09-fa2b-7255-b214-b2a165978a7e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_019db8c7-67ee-7d4a-b66d-dce4c727ec6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_019db8c7-67ee-7d4a-b66d-dce4c727ec6e" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockBasedPlansStockoptionweightedaverageassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7445-8e97-1c63fcad8893" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7445-8e97-1c63fcad8893" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7685-a3ed-042d4999d31f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7445-8e97-1c63fcad8893" xlink:to="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7685-a3ed-042d4999d31f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7685-a3ed-042d4999d31f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7685-a3ed-042d4999d31f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7685-a3ed-042d4999d31f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7460-9dd4-0d011606b11c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7685-a3ed-042d4999d31f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7460-9dd4-0d011606b11c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-7b83-a880-acab8a59d61a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7460-9dd4-0d011606b11c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-7b83-a880-acab8a59d61a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_019cfc6e-a9b8-7e2f-8e8a-969d53af3202" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_019cfc6e-a9b8-7e2f-8e8a-969d53af3202" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward_019cfc6e-a9b8-7326-aecb-fcfeda5dd114" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward_019cfc6e-a9b8-7326-aecb-fcfeda5dd114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019cfc6e-a9b8-7def-b412-cd695d093cac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019cfc6e-a9b8-7def-b412-cd695d093cac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019cfc6e-a9b8-75ca-9b77-e289b62efa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019cfc6e-a9b8-75ca-9b77-e289b62efa7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019cfc6e-a9b8-71d8-878b-ded6b397907f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019cfc6e-a9b8-71d8-878b-ded6b397907f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019cfc6e-a9b8-7d4b-853c-c7f206d1b382" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019cfc6e-a9b8-7d4b-853c-c7f206d1b382" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockBasedPlansScheduleofstockoptionactivityDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7fa0-a8f5-9992ddfcd136" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7fa0-a8f5-9992ddfcd136" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7340-95ab-4d0e957e0140" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7fa0-a8f5-9992ddfcd136" xlink:to="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7340-95ab-4d0e957e0140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7340-95ab-4d0e957e0140_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7340-95ab-4d0e957e0140" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7340-95ab-4d0e957e0140_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7e12-afc6-358583b68a64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7340-95ab-4d0e957e0140" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7e12-afc6-358583b68a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-769c-8d52-eebf2c55f889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7e12-afc6-358583b68a64" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-769c-8d52-eebf2c55f889" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cfc6e-a9b8-7127-bb2f-1940c59c4052" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cfc6e-a9b8-7127-bb2f-1940c59c4052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019cfc6e-a9b8-7d24-a0ef-cfdfa81a17f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019cfc6e-a9b8-7d24-a0ef-cfdfa81a17f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cfc6e-a9b8-7c8e-b495-edfe56b16ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cfc6e-a9b8-7c8e-b495-edfe56b16ef2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019cfc6e-a9b8-7159-a2e6-7886b5be8e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019cfc6e-a9b8-7159-a2e6-7886b5be8e6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cfc6e-a9b8-7758-ab77-fca02daef8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019cfc6e-a9b8-7b1c-8d0a-41949af3a8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019cfc6e-a9b8-7b1c-8d0a-41949af3a8fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cfc6e-a9b8-7b84-9ffb-cd6957ac5298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cfc6e-a9b8-7b84-9ffb-cd6957ac5298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7cd0-9864-1160eda7b4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7cd0-9864-1160eda7b4a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7624-8791-02134ed2d463" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7624-8791-02134ed2d463" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7835-bd95-52800f78e224" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7835-bd95-52800f78e224" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cfc6e-a9b8-793b-b2ae-259b4d46a755" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019cfc6e-a9b8-7c8d-81cc-b1914b4de204" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019cfc6e-a9b8-7c8d-81cc-b1914b4de204" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract_019cfc6e-a9b8-7f28-b872-39a7f4975da8" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract_019cfc6e-a9b8-7f28-b872-39a7f4975da8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019cfc6e-a9b8-7ce8-ad74-12077109c0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract_019cfc6e-a9b8-7f28-b872-39a7f4975da8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019cfc6e-a9b8-7ce8-ad74-12077109c0d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019cfc6e-a9b8-71bc-9a05-1313d7b97a20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract_019cfc6e-a9b8-7f28-b872-39a7f4975da8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019cfc6e-a9b8-71bc-9a05-1313d7b97a20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_019cfc6e-a9b8-713a-b67e-949cd1389cd0" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_019cfc6e-a9b8-713a-b67e-949cd1389cd0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019cfc6e-a9b8-7c11-b7e0-ade2a982423f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_019cfc6e-a9b8-713a-b67e-949cd1389cd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019cfc6e-a9b8-7c11-b7e0-ade2a982423f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019cfc6e-a9b8-78b6-9b0d-a08064262ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_019cfc6e-a9b8-713a-b67e-949cd1389cd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019cfc6e-a9b8-78b6-9b0d-a08064262ba5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019cfc6e-a9b8-773a-b295-987dfb9a1aec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_019cfc6e-a9b8-713a-b67e-949cd1389cd0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019cfc6e-a9b8-773a-b295-987dfb9a1aec" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7646-85ef-496915312593" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7e04-b218-cf7553f46af2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7646-85ef-496915312593" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7e04-b218-cf7553f46af2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7cf1-a498-aa36747c9c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7e04-b218-cf7553f46af2" xlink:to="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7cf1-a498-aa36747c9c2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7cf1-a498-aa36747c9c2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7cf1-a498-aa36747c9c2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7cf1-a498-aa36747c9c2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7765-af47-31eb70672ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7cf1-a498-aa36747c9c2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7765-af47-31eb70672ec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019cfc6e-a9b8-7847-94d5-44cb1f328c04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7765-af47-31eb70672ec6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019cfc6e-a9b8-7847-94d5-44cb1f328c04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7646-85ef-496915312593" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019cfc6e-a9b8-7197-bcfb-0cf75563059f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019cfc6e-a9b8-7197-bcfb-0cf75563059f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019cfc6e-a9b8-7153-a774-4b592e9a5328" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019cfc6e-a9b8-7153-a774-4b592e9a5328" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019cfc6e-a9b8-7c30-83c5-b0bb7b429fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019cfc6e-a9b8-7c30-83c5-b0bb7b429fbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019cfc6e-a9b8-7939-aa0b-13ce51dfc5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019cfc6e-a9b8-7939-aa0b-13ce51dfc5d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019cfc6e-a9b8-75be-bd81-8069ba96852c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7646-85ef-496915312593" xlink:to="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7028-a37d-c5e946e157eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7028-a37d-c5e946e157eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-701f-8c21-93a43c1cf2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-701f-8c21-93a43c1cf2f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-756b-b19b-c5ab546afcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-756b-b19b-c5ab546afcd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7248-96dd-49b67e8dfdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7248-96dd-49b67e8dfdd7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019cfc6e-a9b8-74e0-bf3b-f41e4796e74f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockBasedPlansScheduleofstockbasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cfc6e-a9b8-7ef9-be14-986f5c36749e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cfc6e-a9b8-7d7e-b802-49e44dab7385" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cfc6e-a9b8-7ef9-be14-986f5c36749e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cfc6e-a9b8-7d7e-b802-49e44dab7385" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019cfc6e-a9b8-72c5-9181-f392a5cfa5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cfc6e-a9b8-7d7e-b802-49e44dab7385" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019cfc6e-a9b8-72c5-9181-f392a5cfa5b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019cfc6e-a9b8-72c5-9181-f392a5cfa5b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019cfc6e-a9b8-72c5-9181-f392a5cfa5b0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019cfc6e-a9b8-72c5-9181-f392a5cfa5b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019cfc6e-a9b8-738d-95f7-cf8fc58b01f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019cfc6e-a9b8-72c5-9181-f392a5cfa5b0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019cfc6e-a9b8-738d-95f7-cf8fc58b01f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cfc6e-a9b8-7ca0-b65b-444a07fb7356" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cfc6e-a9b8-738d-95f7-cf8fc58b01f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cfc6e-a9b8-7ca0-b65b-444a07fb7356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019cfc6e-a9b8-7f95-8d2d-e0a542e26178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cfc6e-a9b8-738d-95f7-cf8fc58b01f6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019cfc6e-a9b8-7f95-8d2d-e0a542e26178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-77b8-b83e-70aa7a381901" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cfc6e-a9b8-7ef9-be14-986f5c36749e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-77b8-b83e-70aa7a381901" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#LossPerShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019db9f9-cb45-7212-bb0a-5b978cdd782b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019db9f9-cb45-726a-86a8-9f414a4e0411" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019db9f9-cb45-7212-bb0a-5b978cdd782b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019db9f9-cb45-726a-86a8-9f414a4e0411" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019db9f9-cb45-7cc1-98d3-84f70850b2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019db9f9-cb45-726a-86a8-9f414a4e0411" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019db9f9-cb45-7cc1-98d3-84f70850b2f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019db9f9-cb45-7cc1-98d3-84f70850b2f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019db9f9-cb45-7cc1-98d3-84f70850b2f8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019db9f9-cb45-7cc1-98d3-84f70850b2f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019db9f9-cb45-73af-870e-e2d96690b3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019db9f9-cb45-7cc1-98d3-84f70850b2f8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019db9f9-cb45-73af-870e-e2d96690b3fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_TwoThousandTwentyFivePreFundedWarrantsMember_019db9f9-cb45-7700-96cd-a15f599fee99" xlink:href="alto-20260331.xsd#alto_TwoThousandTwentyFivePreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019db9f9-cb45-73af-870e-e2d96690b3fb" xlink:to="loc_alto_TwoThousandTwentyFivePreFundedWarrantsMember_019db9f9-cb45-7700-96cd-a15f599fee99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_019db9f9-cb45-786a-9c45-46cb08d8b641" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019db9f9-cb45-726a-86a8-9f414a4e0411" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_019db9f9-cb45-786a-9c45-46cb08d8b641" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_019db9f9-cb45-786a-9c45-46cb08d8b641_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_019db9f9-cb45-786a-9c45-46cb08d8b641" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_019db9f9-cb45-786a-9c45-46cb08d8b641_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_019db9f9-cb45-7181-9254-b30f64394eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_019db9f9-cb45-786a-9c45-46cb08d8b641" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_019db9f9-cb45-7181-9254-b30f64394eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_SecuritiesPurchaseAgreementMember_019db9f9-cb45-73ba-a28c-d5e11608bf4a" xlink:href="alto-20260331.xsd#alto_SecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_019db9f9-cb45-7181-9254-b30f64394eaf" xlink:to="loc_alto_SecuritiesPurchaseAgreementMember_019db9f9-cb45-73ba-a28c-d5e11608bf4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019db9f9-cb45-772c-b862-8fa88bc4c8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019db9f9-cb45-7212-bb0a-5b978cdd782b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019db9f9-cb45-772c-b862-8fa88bc4c8a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cfc6e-a9b8-7f1a-82b6-f3d7c2d783f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cfc6e-a9b8-72a2-bdfd-8deb0bfc0d89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cfc6e-a9b8-7f1a-82b6-f3d7c2d783f4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cfc6e-a9b8-72a2-bdfd-8deb0bfc0d89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cfc6e-a9b8-76c4-b933-d87836b9e2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cfc6e-a9b8-72a2-bdfd-8deb0bfc0d89" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cfc6e-a9b8-76c4-b933-d87836b9e2ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-a9b8-76c4-b933-d87836b9e2ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cfc6e-a9b8-76c4-b933-d87836b9e2ab" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-a9b8-76c4-b933-d87836b9e2ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-a9b8-76a9-afe4-05ba94201858" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cfc6e-a9b8-76c4-b933-d87836b9e2ab" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-a9b8-76a9-afe4-05ba94201858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2CommonStockWarrantsMember_019cfc6e-a9b8-7a9a-8536-edffffad678d" xlink:href="alto-20260331.xsd#alto_K2CommonStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-a9b8-76a9-afe4-05ba94201858" xlink:to="loc_alto_K2CommonStockWarrantsMember_019cfc6e-a9b8-7a9a-8536-edffffad678d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019dd765-0c19-7677-8fd7-b6fd90a910e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-a9b8-76a9-afe4-05ba94201858" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019dd765-0c19-7677-8fd7-b6fd90a910e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-73ee-845e-b67f6585a0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-a9b8-76a9-afe4-05ba94201858" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-73ee-845e-b67f6585a0ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cfc6e-a9b8-71da-a378-2e0c5ad16689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cfc6e-a9b8-7f1a-82b6-f3d7c2d783f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cfc6e-a9b8-71da-a378-2e0c5ad16689" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-70fd-adde-ee4dd7a1dbce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-70fd-adde-ee4dd7a1dbce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-70fd-adde-ee4dd7a1dbce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-70fd-adde-ee4dd7a1dbce" xlink:to="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-70fd-adde-ee4dd7a1dbce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-7b32-b022-9be201a7e002" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-70fd-adde-ee4dd7a1dbce" xlink:to="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-7b32-b022-9be201a7e002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019cfc6e-a9b8-7d78-99c7-1b00b4e1ba7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-7b32-b022-9be201a7e002" xlink:to="loc_us-gaap_CommonStockMember_019cfc6e-a9b8-7d78-99c7-1b00b4e1ba7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a9b8-7b54-a04d-2ec77343c742" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a9b8-7b54-a04d-2ec77343c742" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a9b8-7b54-a04d-2ec77343c742_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a9b8-7b54-a04d-2ec77343c742" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a9b8-7b54-a04d-2ec77343c742_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a9b8-7f47-9e4d-4d5436418ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a9b8-7b54-a04d-2ec77343c742" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a9b8-7f47-9e4d-4d5436418ddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2WarrantMember_019cfc6e-a9b8-70c7-aab4-56a33d292940" xlink:href="alto-20260331.xsd#alto_K2WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a9b8-7f47-9e4d-4d5436418ddd" xlink:to="loc_alto_K2WarrantMember_019cfc6e-a9b8-70c7-aab4-56a33d292940" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NewK2WarrantMember_019cfc6e-a9b8-76d2-8ea9-dfc68eef5c65" xlink:href="alto-20260331.xsd#alto_NewK2WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_K2WarrantMember_019cfc6e-a9b8-70c7-aab4-56a33d292940" xlink:to="loc_alto_NewK2WarrantMember_019cfc6e-a9b8-76d2-8ea9-dfc68eef5c65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AdditionalK2WarrantsMember_019cfc6e-a9b8-7209-9497-2d23e554cb5d" xlink:href="alto-20260331.xsd#alto_AdditionalK2WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alto_K2WarrantMember_019cfc6e-a9b8-70c7-aab4-56a33d292940" xlink:to="loc_alto_AdditionalK2WarrantsMember_019cfc6e-a9b8-7209-9497-2d23e554cb5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-75ee-8095-89bfe0ce6ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:to="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-75ee-8095-89bfe0ce6ca5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-75ee-8095-89bfe0ce6ca5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-75ee-8095-89bfe0ce6ca5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-75ee-8095-89bfe0ce6ca5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7e5d-8309-f1d6579ab03e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-75ee-8095-89bfe0ce6ca5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7e5d-8309-f1d6579ab03e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AmendedLoanAgreementMember_019cfc6e-a9b8-7ba8-9a42-2734b391df6c" xlink:href="alto-20260331.xsd#alto_AmendedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7e5d-8309-f1d6579ab03e" xlink:to="loc_alto_AmendedLoanAgreementMember_019cfc6e-a9b8-7ba8-9a42-2734b391df6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a9b8-7b1e-bc0e-be0e374fe787" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a9b8-7b1e-bc0e-be0e374fe787" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a9b8-7b1e-bc0e-be0e374fe787_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a9b8-7b1e-bc0e-be0e374fe787" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a9b8-7b1e-bc0e-be0e374fe787_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a9b8-7f92-a66c-fa05c1081630" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a9b8-7b1e-bc0e-be0e374fe787" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a9b8-7f92-a66c-fa05c1081630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019cfc6e-a9b8-7874-b1a9-a959fde63b18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a9b8-7f92-a66c-fa05c1081630" xlink:to="loc_us-gaap_SecuredDebtMember_019cfc6e-a9b8-7874-b1a9-a959fde63b18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019dba01-4a20-741f-8254-ec811e26756a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019dba01-4a20-741f-8254-ec811e26756a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dba01-4a20-741f-8254-ec811e26756a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019dba01-4a20-741f-8254-ec811e26756a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dba01-4a20-741f-8254-ec811e26756a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dba01-4a20-797d-9069-0ec3ebfa5ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019dba01-4a20-741f-8254-ec811e26756a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dba01-4a20-797d-9069-0ec3ebfa5ffc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_019dba01-4a20-7d54-8bdb-e9e345c02e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dba01-4a20-797d-9069-0ec3ebfa5ffc" xlink:to="loc_us-gaap_PrivatePlacementMember_019dba01-4a20-7d54-8bdb-e9e345c02e91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_PreFundedWarrantsMember_019dba01-4a20-75f2-b3f7-9d29d899ae03" xlink:href="alto-20260331.xsd#alto_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dba01-4a20-797d-9069-0ec3ebfa5ffc" xlink:to="loc_alto_PreFundedWarrantsMember_019dba01-4a20-75f2-b3f7-9d29d899ae03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier_019cfc6e-a9b8-746e-8673-e1d7273beafb" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier_019cfc6e-a9b8-746e-8673-e1d7273beafb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019cfc6e-a9b8-77d3-9ff6-ea42aab2fb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019cfc6e-a9b8-77d3-9ff6-ea42aab2fb0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019cfc6e-a9b8-7656-9130-287c14dcc00b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019cfc6e-a9b8-7656-9130-287c14dcc00b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a9b8-75d0-9102-852c20978d67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a9b8-75d0-9102-852c20978d67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019dba13-64cb-78e6-9b9f-a99cb06d3e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019dba13-64cb-78e6-9b9f-a99cb06d3e2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019dba01-4a20-771a-9b09-5312b1d263e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019dba01-4a20-771a-9b09-5312b1d263e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_019dba01-4a20-74a2-8f67-b746557cf827" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_019dba01-4a20-74a2-8f67-b746557cf827" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation_019dba01-4a20-7f26-97f0-f11f70b572bf" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation_019dba01-4a20-7f26-97f0-f11f70b572bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage_019dba01-4a20-7880-b32a-f389e69253a1" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantsOrRightsWarrantExcessPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage_019dba01-4a20-7880-b32a-f389e69253a1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019cfc6e-a9b8-7018-98f6-0295d28961be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019cfc6e-a9b8-7018-98f6-0295d28961be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cfc6e-a9b8-7afc-b36b-4e0ef56137a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cfc6e-a9b8-7afc-b36b-4e0ef56137a4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019cfc6e-a9b8-7bfb-aea9-0537354c5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_CommonStockSharesIssued_019cfc6e-a9b8-7bfb-aea9-0537354c5d54" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a9b8-7e2b-8921-7c7c02391293" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a9b8-7e2b-8921-7c7c02391293" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019cfc6e-a9b8-796a-b6af-de303cdd30e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019cfc6e-a9b8-796a-b6af-de303cdd30e8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019cfc6e-a9b8-752b-b20f-5ef3f7220ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019cfc6e-a9b8-752b-b20f-5ef3f7220ac6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_019cfc6e-a9b8-716c-b116-d6c8eceec8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_PreferredStockSharesIssued_019cfc6e-a9b8-716c-b116-d6c8eceec8a6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019cfc6e-a9b8-7bfe-9116-648d2036daeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019cfc6e-a9b8-7bfe-9116-648d2036daeb" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockholdersEquityScheduleofstockreservedforissuanceDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7911-a0e1-66a1b995dde8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-7050-8060-633ae92d3108" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7911-a0e1-66a1b995dde8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-7050-8060-633ae92d3108" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7f37-b59d-8a08d5a19885" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-7050-8060-633ae92d3108" xlink:to="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7f37-b59d-8a08d5a19885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7f37-b59d-8a08d5a19885_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7f37-b59d-8a08d5a19885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7f37-b59d-8a08d5a19885_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7188-82b0-68b142947c08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7f37-b59d-8a08d5a19885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7188-82b0-68b142947c08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_EmployeeStockOptionsIssuedAndOutstandingMember_019cfc6e-a9b8-78d5-8c6c-f21a1d91d32a" xlink:href="alto-20260331.xsd#alto_EmployeeStockOptionsIssuedAndOutstandingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7188-82b0-68b142947c08" xlink:to="loc_alto_EmployeeStockOptionsIssuedAndOutstandingMember_019cfc6e-a9b8-78d5-8c6c-f21a1d91d32a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_EmployeeStockOptionsAvailableForFutureGrantMember_019cfc6e-a9b8-7216-b69a-5757bafeb2b2" xlink:href="alto-20260331.xsd#alto_EmployeeStockOptionsAvailableForFutureGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7188-82b0-68b142947c08" xlink:to="loc_alto_EmployeeStockOptionsAvailableForFutureGrantMember_019cfc6e-a9b8-7216-b69a-5757bafeb2b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019db89e-6986-78dd-ab68-f7d41ff78626" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-7050-8060-633ae92d3108" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019db89e-6986-78dd-ab68-f7d41ff78626" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db89e-6986-78dd-ab68-f7d41ff78626_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019db89e-6986-78dd-ab68-f7d41ff78626" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db89e-6986-78dd-ab68-f7d41ff78626_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db89e-6986-790f-9b32-bd87598eca70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019db89e-6986-78dd-ab68-f7d41ff78626" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db89e-6986-790f-9b32-bd87598eca70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2WarrantMember_019cfc6e-a9b8-7d65-b66e-9430e2126df0" xlink:href="alto-20260331.xsd#alto_K2WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db89e-6986-790f-9b32-bd87598eca70" xlink:to="loc_alto_K2WarrantMember_019cfc6e-a9b8-7d65-b66e-9430e2126df0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_PreFundedWarrantsMember_019db89e-6986-70ad-a775-74615da526bc" xlink:href="alto-20260331.xsd#alto_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db89e-6986-790f-9b32-bd87598eca70" xlink:to="loc_alto_PreFundedWarrantsMember_019db89e-6986-70ad-a775-74615da526bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019cfc6e-a9b8-7e62-a53b-b3f651057041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7911-a0e1-66a1b995dde8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019cfc6e-a9b8-7e62-a53b-b3f651057041" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#SegmentsScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cfc6e-a9b8-763a-98c9-241bbf50d080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cfc6e-a9b8-763a-98c9-241bbf50d080" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019cfc6e-a9b8-7106-9c46-a6de6c704ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cfc6e-a9b8-763a-98c9-241bbf50d080" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019cfc6e-a9b8-7106-9c46-a6de6c704ba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019cfc6e-a9b8-7106-9c46-a6de6c704ba4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019cfc6e-a9b8-7106-9c46-a6de6c704ba4" xlink:to="loc_us-gaap_SegmentDomain_019cfc6e-a9b8-7106-9c46-a6de6c704ba4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019cfc6e-a9b8-7a8d-a69e-5debfb15fed2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019cfc6e-a9b8-7106-9c46-a6de6c704ba4" xlink:to="loc_us-gaap_SegmentDomain_019cfc6e-a9b8-7a8d-a69e-5debfb15fed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ReportableSegmentMember_019cfc6e-a9b8-7c1d-b9f6-2a11d9b53292" xlink:href="alto-20260331.xsd#alto_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019cfc6e-a9b8-7a8d-a69e-5debfb15fed2" xlink:to="loc_alto_ReportableSegmentMember_019cfc6e-a9b8-7c1d-b9f6-2a11d9b53292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019cfc6e-a9b8-7e19-b38e-1f73d571a999" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cfc6e-a9b8-763a-98c9-241bbf50d080" xlink:to="loc_srt_ProductOrServiceAxis_019cfc6e-a9b8-7e19-b38e-1f73d571a999" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7e19-b38e-1f73d571a999_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019cfc6e-a9b8-7e19-b38e-1f73d571a999" xlink:to="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7e19-b38e-1f73d571a999_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019cfc6e-a9b8-7e19-b38e-1f73d571a999" xlink:to="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto100Member_019cfc6e-a9b8-768f-8d3d-7f6fbc5fb1da" xlink:href="alto-20260331.xsd#alto_Alto100Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:to="loc_alto_Alto100Member_019cfc6e-a9b8-768f-8d3d-7f6fbc5fb1da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto300Member_019cfc6e-a9b8-77be-828b-1cf86425f963" xlink:href="alto-20260331.xsd#alto_Alto300Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:to="loc_alto_Alto300Member_019cfc6e-a9b8-77be-828b-1cf86425f963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto101Member_019cfc6e-a9b8-7d31-b242-ecf3b60b455f" xlink:href="alto-20260331.xsd#alto_Alto101Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:to="loc_alto_Alto101Member_019cfc6e-a9b8-7d31-b242-ecf3b60b455f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto203Member_019cfc6e-a9b8-7c6c-a6ee-c8d53b530f1f" xlink:href="alto-20260331.xsd#alto_Alto203Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:to="loc_alto_Alto203Member_019cfc6e-a9b8-7c6c-a6ee-c8d53b530f1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto207Member_019cfc6e-a9b8-72f9-8674-21df2e59f6ef" xlink:href="alto-20260331.xsd#alto_Alto207Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:to="loc_alto_Alto207Member_019cfc6e-a9b8-72f9-8674-21df2e59f6ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_019cfc6e-a9b8-7de7-8351-a9a027573cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_LaborAndRelatedExpense_019cfc6e-a9b8-7de7-8351-a9a027573cfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-7a62-8017-e7a7f25afb99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-7a62-8017-e7a7f25afb99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cfc6e-a9b8-7fc6-8d14-bbab10321b76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cfc6e-a9b8-7fc6-8d14-bbab10321b76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_019cfc6e-a9b8-7051-98f7-c75a8f51d50c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_019cfc6e-a9b8-7051-98f7-c75a8f51d50c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_019cfc6e-a9b8-793c-976f-f785dceabec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_019cfc6e-a9b8-793c-976f-f785dceabec7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cfc6e-a9b8-7a51-b215-96731cd70db5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_NetIncomeLoss_019cfc6e-a9b8-7a51-b215-96731cd70db5" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AmitEtkinMember_019dba27-2408-76ed-b7a7-4ee64dcc84e1" xlink:href="alto-20260331.xsd#alto_AmitEtkinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_alto_AmitEtkinMember_019dba27-2408-76ed-b7a7-4ee64dcc84e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NicholasSmithMember_019dba2a-9919-75d0-be90-a5b4aa22c214" xlink:href="alto-20260331.xsd#alto_NicholasSmithMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_alto_NicholasSmithMember_019dba2a-9919-75d0-be90-a5b4aa22c214" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>alto-20260331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cfc6e-a845-7559-941c-e87ca4915109,g:515d2a5a-b4b4-4d42-8d26-d42921144f4b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_019cfc6e-aa67-72b4-b67d-b485947d8f75_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_019cfc6e-a9b8-73f2-b531-9f9d9c8b539d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_019db851-6704-71e7-b6d5-16506bfcd891_terseLabel_en-US" xlink:label="lab_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of common stock and pre-funded warrants in 2026 private placement</link:label>
    <link:label id="lab_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_label_en-US" xlink:label="lab_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Common Stock and Pre-Funded Warrants In Private Placement</link:label>
    <link:label id="lab_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_documentation_en-US" xlink:label="lab_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Common Stock and Pre-Funded Warrants In Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:href="alto-20260331.xsd#alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:to="lab_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_PaymentsOnIssuanceCostFromRegistrationStatement_019cfc6e-aa67-7b26-b299-fc19f93b10a8_negatedTerseLabel_en-US" xlink:label="lab_alto_PaymentsOnIssuanceCostFromRegistrationStatement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments on issuance cost from registration statement</link:label>
    <link:label id="lab_alto_PaymentsOnIssuanceCostFromRegistrationStatement_label_en-US" xlink:label="lab_alto_PaymentsOnIssuanceCostFromRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments on Issuance Cost from Registration Statement</link:label>
    <link:label id="lab_alto_PaymentsOnIssuanceCostFromRegistrationStatement_documentation_en-US" xlink:label="lab_alto_PaymentsOnIssuanceCostFromRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments on Issuance Cost from Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_PaymentsOnIssuanceCostFromRegistrationStatement" xlink:href="alto-20260331.xsd#alto_PaymentsOnIssuanceCostFromRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_PaymentsOnIssuanceCostFromRegistrationStatement" xlink:to="lab_alto_PaymentsOnIssuanceCostFromRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019cfc6e-aa67-73dd-86ec-796085fd84b1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_Alto207Member_019cfc6e-a9b8-7c9c-b3a3-8f1c37843bac_terseLabel_en-US" xlink:label="lab_alto_Alto207Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALTO-207</link:label>
    <link:label id="lab_alto_Alto207Member_label_en-US" xlink:label="lab_alto_Alto207Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alto-207 [Member]</link:label>
    <link:label id="lab_alto_Alto207Member_documentation_en-US" xlink:label="lab_alto_Alto207Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alto-207</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto207Member" xlink:href="alto-20260331.xsd#alto_Alto207Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_Alto207Member" xlink:to="lab_alto_Alto207Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_019cfc6e-a9b8-714c-8199-2200133ad863_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a9b8-7485-b3e3-f40ed28f084d_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee, percent of outstanding principal, applicable on or before 24 months after initial funding date</link:label>
    <link:label id="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_label_en-US" xlink:label="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty Fee, On Or Before 24 Months After Initial Funding Date, Percent Of Outstanding Principal</link:label>
    <link:label id="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_documentation_en-US" xlink:label="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty Fee, On Or Before 24 Months After Initial Funding Date, Percent Of Outstanding Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:to="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_019cfc6e-aa67-78be-a9b0-fffa54e1a6c0_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_019db87a-f783-7ecc-a6cf-3bbebd8f8ff9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019cfc6e-a9b8-7ea3-85ff-2ed72de6692f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted and Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_StockIssuedDuringPeriodShareConversionOfTermLoan_019dd74a-a2f1-704d-9c9b-2fc4574af13b_terseLabel_en-US" xlink:label="lab_alto_StockIssuedDuringPeriodShareConversionOfTermLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for conversion of the K2 term loan, net of issuance (in shares)</link:label>
    <link:label id="lab_alto_StockIssuedDuringPeriodShareConversionOfTermLoan_label_en-US" xlink:label="lab_alto_StockIssuedDuringPeriodShareConversionOfTermLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Share, Conversion Of Term Loan</link:label>
    <link:label id="lab_alto_StockIssuedDuringPeriodShareConversionOfTermLoan_documentation_en-US" xlink:label="lab_alto_StockIssuedDuringPeriodShareConversionOfTermLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Share, Conversion Of Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_StockIssuedDuringPeriodShareConversionOfTermLoan" xlink:href="alto-20260331.xsd#alto_StockIssuedDuringPeriodShareConversionOfTermLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_StockIssuedDuringPeriodShareConversionOfTermLoan" xlink:to="lab_alto_StockIssuedDuringPeriodShareConversionOfTermLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_019cfc6e-aa68-7fce-b5af-22c443460503_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender_019cfc6e-a9b8-7621-a7b7-9248b01d106c_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of debt convertible to equity at election of lender</link:label>
    <link:label id="lab_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender_label_en-US" xlink:label="lab_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Amount Convertible To Equity At Election Of Lender</link:label>
    <link:label id="lab_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender_documentation_en-US" xlink:label="lab_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Amount Convertible To Equity At Election Of Lender</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender" xlink:href="alto-20260331.xsd#alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender" xlink:to="lab_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract_019cfc6e-aa67-76c8-a41d-c4a93f211d9d_terseLabel_en-US" xlink:label="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted &#8211;&#8232;average&#8232;remaining&#8232;contractual&#8232;term (in&#8232;years)</link:label>
    <link:label id="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract_label_en-US" xlink:label="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Options, Weighted Average Contractual Term [Abstract]</link:label>
    <link:label id="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract_documentation_en-US" xlink:label="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Options, Weighted Average Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract" xlink:to="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_019cfc6e-a9b8-7e08-b557-5133076d2c73_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants or rights outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019cfc6e-aa68-7ce3-826d-b28228735980_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to common stockholders, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019cfc6e-aa67-780b-8bca-822fd60ee6cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019cfc6e-a9b8-71fd-bab2-349066ce3df9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for issuance under ESPP plan (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_019cfc6e-aa67-766c-b904-e9aeb4bab28c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_019cfc6e-a9b8-7f3b-a1a9-661a99235e98_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DeferredOfferingAndShareIssueCostsNotYetPaid_019db853-fa2a-765a-8817-5bd7d4e33d86_terseLabel_en-US" xlink:label="lab_alto_DeferredOfferingAndShareIssueCostsNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering and share issue costs not yet paid</link:label>
    <link:label id="lab_alto_DeferredOfferingAndShareIssueCostsNotYetPaid_label_en-US" xlink:label="lab_alto_DeferredOfferingAndShareIssueCostsNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering And Share Issue Costs Not Yet Paid</link:label>
    <link:label id="lab_alto_DeferredOfferingAndShareIssueCostsNotYetPaid_documentation_en-US" xlink:label="lab_alto_DeferredOfferingAndShareIssueCostsNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Offering And Share Issue Costs Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DeferredOfferingAndShareIssueCostsNotYetPaid" xlink:href="alto-20260331.xsd#alto_DeferredOfferingAndShareIssueCostsNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DeferredOfferingAndShareIssueCostsNotYetPaid" xlink:to="lab_alto_DeferredOfferingAndShareIssueCostsNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019cfc6e-aa67-754b-9aed-93a555b5525a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019cfc6e-a9b8-7fae-89f3-aa63141e9fc7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_019cfc6e-aa68-7648-a181-ece89f5a69b3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_InterestExpenseNoncash_019cfc6e-aa67-7fb6-a3d6-355b70929fd9_terseLabel_en-US" xlink:label="lab_alto_InterestExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash&#160;interest expense related to term loan</link:label>
    <link:label id="lab_alto_InterestExpenseNoncash_label_en-US" xlink:label="lab_alto_InterestExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Noncash</link:label>
    <link:label id="lab_alto_InterestExpenseNoncash_documentation_en-US" xlink:label="lab_alto_InterestExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Expense, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_InterestExpenseNoncash" xlink:href="alto-20260331.xsd#alto_InterestExpenseNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_InterestExpenseNoncash" xlink:to="lab_alto_InterestExpenseNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019cfc6e-aa68-7124-8722-1da7a12a42b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs and discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_NewK2WarrantMember_019cfc6e-aa68-793d-a384-aedf5599d74b_terseLabel_en-US" xlink:label="lab_alto_NewK2WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Warrant</link:label>
    <link:label id="lab_alto_NewK2WarrantMember_label_en-US" xlink:label="lab_alto_NewK2WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New K2 Warrant [Member]</link:label>
    <link:label id="lab_alto_NewK2WarrantMember_documentation_en-US" xlink:label="lab_alto_NewK2WarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New K2 Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NewK2WarrantMember" xlink:href="alto-20260331.xsd#alto_NewK2WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_NewK2WarrantMember" xlink:to="lab_alto_NewK2WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_019cfc6e-aa67-7a85-9944-a815cc13b8d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019cfc6e-aa68-76c2-ad3a-13b375a4fae9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options issued and outstanding</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019cfc6e-aa68-7490-981d-51f627ef6b7d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_019cfc6e-aa67-7b04-9cc1-cbfa3e528b22_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019cfc6e-aa68-7a90-bfa7-3ab1f7fd39a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock_019cfc6e-a9b8-7e3e-a2f3-79dadf8c1050_terseLabel_en-US" xlink:label="lab_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase, percentage of outstanding shares</link:label>
    <link:label id="lab_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock_label_en-US" xlink:label="lab_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Annual Increase, Percentage of Outstanding Stock</link:label>
    <link:label id="lab_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock_documentation_en-US" xlink:label="lab_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Annual Increase, Percentage of Outstanding Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock" xlink:href="alto-20260331.xsd#alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock" xlink:to="lab_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_AmendedLoanAgreementMember_019cfc6e-aa67-77f4-9f69-ba0a188353f2_terseLabel_en-US" xlink:label="lab_alto_AmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended Loan Agreement</link:label>
    <link:label id="lab_alto_AmendedLoanAgreementMember_label_en-US" xlink:label="lab_alto_AmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended Loan Agreement [Member]</link:label>
    <link:label id="lab_alto_AmendedLoanAgreementMember_documentation_en-US" xlink:label="lab_alto_AmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AmendedLoanAgreementMember" xlink:href="alto-20260331.xsd#alto_AmendedLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_AmendedLoanAgreementMember" xlink:to="lab_alto_AmendedLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cfc6e-aa67-7093-8bbc-73e5c8ca2d5e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_019cfc6e-a9b8-759f-962f-424e9b43e712_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019cfc6e-a9b8-7229-8c3b-15d465e358ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019cfc6e-a9b8-76e2-8281-0594dc74dd6f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_019dba31-a222-78cf-b7e2-bf56702a0095_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-aa67-7c9f-a1cb-9d19c222ba9b_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-aa67-7c93-a7cc-9a4a0244ec52_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentConvertibleMaximumSharesIssuable_019cfc6e-a9b8-7b4f-8936-3c32974ead9f_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentConvertibleMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum shares issuable (in shares)</link:label>
    <link:label id="lab_alto_DebtInstrumentConvertibleMaximumSharesIssuable_label_en-US" xlink:label="lab_alto_DebtInstrumentConvertibleMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Maximum Shares Issuable</link:label>
    <link:label id="lab_alto_DebtInstrumentConvertibleMaximumSharesIssuable_documentation_en-US" xlink:label="lab_alto_DebtInstrumentConvertibleMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Maximum Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentConvertibleMaximumSharesIssuable" xlink:href="alto-20260331.xsd#alto_DebtInstrumentConvertibleMaximumSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentConvertibleMaximumSharesIssuable" xlink:to="lab_alto_DebtInstrumentConvertibleMaximumSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_019cfc6e-a9b8-731e-a07a-def733956ff7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_019cfc6e-a9b8-7c94-8215-d9dd19e34554_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_019cfc6e-aa67-7046-b6c6-81e145421bae_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_019cfc6e-a9b8-70b2-981f-b0fcc83b8deb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cfc6e-a9b8-7e4e-a6c6-5be753e80ee7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019dba30-9865-7dbe-98b5-6af97ff10466_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_019cfc6e-aa67-7319-b185-a9347b1fb730_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_019cfc6e-a9b8-7ec5-b4c8-3fb0c7c3c587_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019cfc6e-a9b8-7e00-85e2-576e94c0242c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at period end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation_019cfc6e-a9b8-7705-b59a-5b82f52fbc4b_terseLabel_en-US" xlink:label="lab_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase or decrease the beneficial ownership limitation</link:label>
    <link:label id="lab_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation_label_en-US" xlink:label="lab_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights, Notice Period For Beneficial Ownership Limitation</link:label>
    <link:label id="lab_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation_documentation_en-US" xlink:label="lab_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights, Notice Period For Beneficial Ownership Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation" xlink:to="lab_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_019cfc6e-aa67-754d-a2cd-45e48d5f67c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-aa68-70d5-a1e8-8a7ac14d1619_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019db8c6-8147-730a-9dee-4a543923a76b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of the RSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-aa68-7a74-ab69-0ebae66dedb3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment_019cfc6e-aa68-7a07-9ab7-bf2ccd898a0b_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable rate threshold for potential adjustment</link:label>
    <link:label id="lab_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment_label_en-US" xlink:label="lab_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Variable Interest Rate, Threshold For Potential Adjustment</link:label>
    <link:label id="lab_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment_documentation_en-US" xlink:label="lab_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Variable Interest Rate, Threshold For Potential Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment" xlink:href="alto-20260331.xsd#alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment" xlink:to="lab_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019cfc6e-a9b8-7647-a480-d54d1572e6ea_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_019cfc6e-a9b8-7301-b236-a35a5434e144_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_019cfc6e-a9b8-72f7-900d-7d5c8bd34121_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_019cfc6e-aa67-7c6c-bb29-806e2c20c01d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_019cfc6e-aa68-7c19-b44b-607e73453a4c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_label_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_019cfc6e-aa68-7b4f-b7b1-718588a4b6bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_019cfc6e-a9b8-7327-abe6-3975299eef5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise prices, upper range (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_019db811-ddf5-7275-9ae0-b2f20ecec4fc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_019dd75e-c9f9-7e64-8c8e-3174a6c2c9f4_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Term loan, current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_019db9f9-cb45-7af1-beba-ed8d80764841_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_TemporaryEquitySharesConversionOfConvertibleSecurities_019cfc6e-aa68-753e-a379-f9ae26a5baa8_terseLabel_en-US" xlink:label="lab_alto_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock conversion, number of common stock (in shares)</link:label>
    <link:label id="lab_alto_TemporaryEquitySharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_alto_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities</link:label>
    <link:label id="lab_alto_TemporaryEquitySharesConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_alto_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:href="alto-20260331.xsd#alto_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:to="lab_alto_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_019cfc6e-a9b8-7e5d-8cf0-76d6fc51f820_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_019cfc6e-a9b8-7c61-b057-b24a421a56d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_019cfc6e-a9b8-7415-ad80-ccb0393157bc_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_019cfc6e-aa68-7979-b3e7-b392ebc20147_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, short term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock_019cfc6e-a9b8-7980-af98-beca8356f4d9_terseLabel_en-US" xlink:label="lab_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of K2 warrants</link:label>
    <link:label id="lab_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock_label_en-US" xlink:label="lab_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC Increase For Reclassification Of Warrants For Conversion Of Convertible Securities To Common Stock</link:label>
    <link:label id="lab_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock_documentation_en-US" xlink:label="lab_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">APIC Increase For Reclassification Of Warrants For Conversion Of Convertible Securities To Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock" xlink:href="alto-20260331.xsd#alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock" xlink:to="lab_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7d95-a6fe-92d7b5cabcdb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019cfc6e-a9b8-7760-9e4f-afa639c7cdf6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_019cfc6e-aa68-7416-96e6-dc1f6e25923c_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_019cfc6e-aa67-70c7-b330-5578cd8b56d9_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_019cfc6e-a9b8-730a-873b-5da401a54c48_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Term loan,&#160;non-current</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_019cfc6e-aa67-7bd6-b913-014a58de912c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019cfc6e-a9b8-7ab6-98b7-80edb7239bf6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7255-9cde-87b184fc0654_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentTrancheThreeMember_019cfc6e-a9b8-714c-94ed-2212b3030c21_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third tranche, available from October 1, 2023 and March 1, 2024</link:label>
    <link:label id="lab_alto_DebtInstrumentTrancheThreeMember_label_en-US" xlink:label="lab_alto_DebtInstrumentTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche Three [Member]</link:label>
    <link:label id="lab_alto_DebtInstrumentTrancheThreeMember_documentation_en-US" xlink:label="lab_alto_DebtInstrumentTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheThreeMember" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentTrancheThreeMember" xlink:to="lab_alto_DebtInstrumentTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019cfc6e-aa67-7740-b8ea-10e2977c618e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-aa67-7ba1-b471-b7f441cf62af_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_019db9f9-cb45-78cf-ab33-ae55c0744b7d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cfc6e-aa67-7beb-bd33-6923752bd40f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement_019cfc6e-aa68-78c8-bd72-649d30823765_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of weighted average price for share conversion</link:label>
    <link:label id="lab_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement_label_en-US" xlink:label="lab_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price, Term Of Weighted Average Price Measurement</link:label>
    <link:label id="lab_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement_documentation_en-US" xlink:label="lab_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price, Term Of Weighted Average Price Measurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement" xlink:href="alto-20260331.xsd#alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement" xlink:to="lab_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_019cfc6e-a9b8-7ae0-83b4-da4e3e58f8fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_019cfc6e-a9b8-7cd2-baa1-241fe19e33d9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019cfc6e-a9b8-7555-a431-e00f95f95b45_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a9b8-7a71-b6cb-5027f76c8118_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_019cfc6e-a9b8-7c60-a013-0baf2bbc4ddb_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentConvertibleDiscountOnSharesConverted_019cfc6e-aa67-7597-884a-b8d610bf4595_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentConvertibleDiscountOnSharesConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount on shares</link:label>
    <link:label id="lab_alto_DebtInstrumentConvertibleDiscountOnSharesConverted_label_en-US" xlink:label="lab_alto_DebtInstrumentConvertibleDiscountOnSharesConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Discount On Shares Converted</link:label>
    <link:label id="lab_alto_DebtInstrumentConvertibleDiscountOnSharesConverted_documentation_en-US" xlink:label="lab_alto_DebtInstrumentConvertibleDiscountOnSharesConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Discount On Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentConvertibleDiscountOnSharesConverted" xlink:href="alto-20260331.xsd#alto_DebtInstrumentConvertibleDiscountOnSharesConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentConvertibleDiscountOnSharesConverted" xlink:to="lab_alto_DebtInstrumentConvertibleDiscountOnSharesConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cfc6e-a9b8-766a-b91b-9c237968201c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cfc6e-a9b8-7bc1-b5f6-a1a2318e583d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_019cfc6e-aa68-793c-ab2b-5f588e1dedce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentTrancheDomain_019cfc6e-aa67-778a-bdf3-a274813c4657_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche [Domain]</link:label>
    <link:label id="lab_alto_DebtInstrumentTrancheDomain_label_en-US" xlink:label="lab_alto_DebtInstrumentTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche [Domain]</link:label>
    <link:label id="lab_alto_DebtInstrumentTrancheDomain_documentation_en-US" xlink:label="lab_alto_DebtInstrumentTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheDomain" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentTrancheDomain" xlink:to="lab_alto_DebtInstrumentTrancheDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_019cfc6e-aa68-7d6b-9280-8631bbdfbfb2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One-time facility fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019cfc6e-aa67-7b73-bcc1-fb94c0ce215a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019cfc6e-aa67-7005-b6d0-a4ea924971a0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019cfc6e-aa67-73ed-a91b-cf11905773f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_019cfc6e-a9b8-7c72-905e-dfead9127e62_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ComputerSoftwareAndEquipmentMember_019cfc6e-aa67-7d24-87b1-d02ae4b56175_terseLabel_en-US" xlink:label="lab_alto_ComputerSoftwareAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software and equipment</link:label>
    <link:label id="lab_alto_ComputerSoftwareAndEquipmentMember_label_en-US" xlink:label="lab_alto_ComputerSoftwareAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software And Equipment [Member]</link:label>
    <link:label id="lab_alto_ComputerSoftwareAndEquipmentMember_documentation_en-US" xlink:label="lab_alto_ComputerSoftwareAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Software And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ComputerSoftwareAndEquipmentMember" xlink:href="alto-20260331.xsd#alto_ComputerSoftwareAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ComputerSoftwareAndEquipmentMember" xlink:to="lab_alto_ComputerSoftwareAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_019cfc6e-aa68-73bc-9276-ffb7140f2b3b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier_019cfc6e-aa67-7d6e-9cd0-4a34911d636f_terseLabel_en-US" xlink:label="lab_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by warrants, multiplier</link:label>
    <link:label id="lab_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier_label_en-US" xlink:label="lab_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Multiplier</link:label>
    <link:label id="lab_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier_documentation_en-US" xlink:label="lab_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Multiplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier" xlink:to="lab_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019cfc6e-aa67-71d9-97a7-523a8b206b30_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_019cfc6e-aa67-71aa-bbd5-f203abcf90db_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cfc6e-a9b8-7b9c-b8e3-93967a90dcba_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender_019cfc6e-a9b8-7eca-b9c0-9e999e3c860e_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of debt convertible to equity at election of lender</link:label>
    <link:label id="lab_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender_label_en-US" xlink:label="lab_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Portion Convertible To Equity At Election Of Lender</link:label>
    <link:label id="lab_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender_documentation_en-US" xlink:label="lab_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Portion Convertible To Equity At Election Of Lender</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender" xlink:to="lab_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019cfc6e-a9b8-7894-8619-7a33265c442e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_019cfc6e-aa67-71a4-a021-5e029d9c68ce_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cfc6e-a9b8-7bbb-a46e-d46f651a1801_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cfc6e-a9b8-7b77-8e08-ec9682d7eb76_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-aa67-7c6c-89a9-fb28f158194a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019cfc6e-a9b8-7fcc-8893-bef40181e3bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019cfc6e-a9b8-79e4-a166-410c1f7d318e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cfc6e-aa67-7ed2-a810-ded221b4628e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cfc6e-aa67-7222-89d0-72eb64c5515c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019cfc6e-aa68-7732-bc00-b4c5988b59ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate, basis spread (greater of)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-aa67-7123-b02e-46df95488393_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_019cfc6e-aa67-7fd4-ba7d-cb799d76a53d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_019cfc6e-a9b8-78d9-8f5a-2b761841dbcd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_019cfc6e-aa68-7f02-8040-981e3bae4def_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cfc6e-aa68-74ba-93f3-9cbcfd1d795c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_019cfc6e-a9b8-7b54-a905-69fddbb427cf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_019dba31-6891-7bf6-b3bd-1fe176fa6aba_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cfc6e-a9b8-75cc-ba3a-d5224cba96fb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash&#160;lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_019cfc6e-a9b8-7efc-83d3-08bf5d09cd67_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019cfc6e-a9b8-7fa3-9e27-3c717eb3e33b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentFixedRatePaidInKind_019cfc6e-aa68-789a-8886-37944fa76a07_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentFixedRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed rate, paid-in-kind</link:label>
    <link:label id="lab_alto_DebtInstrumentFixedRatePaidInKind_label_en-US" xlink:label="lab_alto_DebtInstrumentFixedRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fixed Rate, Paid-In-Kind</link:label>
    <link:label id="lab_alto_DebtInstrumentFixedRatePaidInKind_documentation_en-US" xlink:label="lab_alto_DebtInstrumentFixedRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fixed Rate, Paid-In-Kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentFixedRatePaidInKind" xlink:href="alto-20260331.xsd#alto_DebtInstrumentFixedRatePaidInKind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentFixedRatePaidInKind" xlink:to="lab_alto_DebtInstrumentFixedRatePaidInKind" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-aa67-7c84-bc56-b2e42eea2792_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-aa67-74b3-aa8d-cd2de507f4a3_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019cfc6e-aa67-7f5a-908b-0f215ccd97e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019cfc6e-a9b8-7558-b313-53091b1f3b26_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019cfc6e-a9b8-75ba-a9c7-9f9ae5a95003_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_019cfc6e-aa67-7647-97e8-0e38ae20888b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of term loan, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cfc6e-aa67-7302-a225-ae4a1a427d8f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_019cfc6e-aa68-7894-a14e-781a3aee7449_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019cfc6e-aa68-727a-864c-9aead34824da_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a9b8-7a22-9e82-cb17390a2cdb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_019db8c7-67ee-787f-a6d9-de16d68e21a8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-72bb-8905-06216b35d5c2_terseLabel_en-US" xlink:label="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-&#8232;average&#8232;exercise&#8232;price per share</link:label>
    <link:label id="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:to="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_019cfc6e-a9b8-7bd5-9386-d51935dba85c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019cfc6e-aa67-7d5e-9c7e-27a5eb0f36c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share-based payment award, stock options, valuation assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_Alto101Member_019cfc6e-aa67-7131-ab9b-46b00da41176_terseLabel_en-US" xlink:label="lab_alto_Alto101Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALTO-101</link:label>
    <link:label id="lab_alto_Alto101Member_label_en-US" xlink:label="lab_alto_Alto101Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alto-101 [Member]</link:label>
    <link:label id="lab_alto_Alto101Member_documentation_en-US" xlink:label="lab_alto_Alto101Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alto-101</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto101Member" xlink:href="alto-20260331.xsd#alto_Alto101Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_Alto101Member" xlink:to="lab_alto_Alto101Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_019cfc6e-aa67-77f9-88a4-0b03c137f630_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_019cfc6e-aa68-7f11-982d-86e4c392af57_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_019cfc6e-a9b8-7b6c-9187-1191f9ec09e9_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_019cfc6e-aa68-7d41-8437-83d77e4028b4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_019cfc6e-a9b8-74ad-9910-c51f9474c295_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_019cfc6e-a9b8-7548-934a-348c4efc9991_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_019cfc6e-aa67-7f83-aab5-65547108ed57_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_019dba3c-0220-790b-8810-20ffce707b0d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_019cfc6e-aa67-7997-862e-c0da60b0537c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, expected life</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_019cfc6e-aa67-7723-b93e-dea4f3dba399_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosure of&#160;Non-cash&#160;Activities</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_019cfc6e-a9b8-7193-9e4d-4a351d97c2d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of loan financing cost</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019cfc6e-aa67-7eb6-8b49-dfe2f756e9d8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cfc6e-a9b8-73e4-8aa6-10573faada71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward_019cfc6e-aa67-729b-bae3-3d34a7e28188_terseLabel_en-US" xlink:label="lab_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common stock (in dollars per share)</link:label>
    <link:label id="lab_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward_label_en-US" xlink:label="lab_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation By Share Based Payment Award, Fair Value Assumptions, Fair Value Of Award</link:label>
    <link:label id="lab_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward_documentation_en-US" xlink:label="lab_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation By Share Based Payment Award, Fair Value Assumptions, Fair Value Of Award, Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xlink:to="lab_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_019cfc6e-a9b8-7628-9f52-5fb109f3c6ad_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_019cfc6e-a9b8-721d-a74c-f70d1ce8b84e_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_019cfc6e-aa68-7500-a67e-519f11da891f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSU Vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_019cfc6e-a9b8-7b41-909e-ec9ca7c6b17b_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_019cfc6e-aa68-7bd8-8157-69847991e90a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_AccruedResearchExpense_019cfc6e-a9b8-7e63-9088-9671f864aa23_terseLabel_en-US" xlink:label="lab_alto_AccruedResearchExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research</link:label>
    <link:label id="lab_alto_AccruedResearchExpense_label_en-US" xlink:label="lab_alto_AccruedResearchExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research Expense</link:label>
    <link:label id="lab_alto_AccruedResearchExpense_documentation_en-US" xlink:label="lab_alto_AccruedResearchExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AccruedResearchExpense" xlink:href="alto-20260331.xsd#alto_AccruedResearchExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_AccruedResearchExpense" xlink:to="lab_alto_AccruedResearchExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_019cfc6e-a9b8-75c6-96be-5d1da8c77233_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cfc6e-a9b8-775d-9306-49538c091871_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-aa67-7f59-9737-757fab7e38ac_terseLabel_en-US" xlink:label="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average&#8232;grant date fair value per share</link:label>
    <link:label id="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_label_en-US" xlink:label="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Rollforward [Roll Forward]</link:label>
    <link:label id="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_documentation_en-US" xlink:label="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward" xlink:to="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentTrancheAxis_019cfc6e-aa67-7b7e-aa9d-f70dfb46e565_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche [Axis]</link:label>
    <link:label id="lab_alto_DebtInstrumentTrancheAxis_label_en-US" xlink:label="lab_alto_DebtInstrumentTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche [Axis]</link:label>
    <link:label id="lab_alto_DebtInstrumentTrancheAxis_documentation_en-US" xlink:label="lab_alto_DebtInstrumentTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheAxis" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentTrancheAxis" xlink:to="lab_alto_DebtInstrumentTrancheAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_019cfc6e-a9b8-77d1-a092-041140280ed2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019cfc6e-aa67-7dc2-ac38-5cac14fe5983_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019cfc6e-aa67-75b7-839b-64ac13e56abb_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_019cfc6e-a9b8-7e35-8083-97a9cb228ee5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentTrancheTwoMember_019cfc6e-aa67-7e51-b957-6a0114bbf601_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second tranche, available between October 1, 2023 and March 1, 2024</link:label>
    <link:label id="lab_alto_DebtInstrumentTrancheTwoMember_label_en-US" xlink:label="lab_alto_DebtInstrumentTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche Two [Member]</link:label>
    <link:label id="lab_alto_DebtInstrumentTrancheTwoMember_documentation_en-US" xlink:label="lab_alto_DebtInstrumentTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheTwoMember" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentTrancheTwoMember" xlink:to="lab_alto_DebtInstrumentTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_019cfc6e-a9b8-79b4-98cb-383b8160a369_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of former term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_019cfc6e-aa67-79fe-a7b6-d0e4c6305a72_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentNumberOfTranches_019cfc6e-aa67-7fa7-b18c-5ea2b5c4ddd2_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_alto_DebtInstrumentNumberOfTranches_label_en-US" xlink:label="lab_alto_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Tranches</link:label>
    <link:label id="lab_alto_DebtInstrumentNumberOfTranches_documentation_en-US" xlink:label="lab_alto_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentNumberOfTranches" xlink:href="alto-20260331.xsd#alto_DebtInstrumentNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentNumberOfTranches" xlink:to="lab_alto_DebtInstrumentNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_019cfc6e-aa67-789b-a188-cc66ba7b8cbe_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019cfc6e-a9b8-76e1-bb1b-496fa15ede79_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period for recognition of unrecognized share based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_StockIssuedDuringPeriodValueConversionOfTermLoan_019db84c-b052-7e11-9010-5e3560b0350a_terseLabel_en-US" xlink:label="lab_alto_StockIssuedDuringPeriodValueConversionOfTermLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for conversion of the K2 term loan, net of issuance</link:label>
    <link:label id="lab_alto_StockIssuedDuringPeriodValueConversionOfTermLoan_label_en-US" xlink:label="lab_alto_StockIssuedDuringPeriodValueConversionOfTermLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion Of Term Loan</link:label>
    <link:label id="lab_alto_StockIssuedDuringPeriodValueConversionOfTermLoan_documentation_en-US" xlink:label="lab_alto_StockIssuedDuringPeriodValueConversionOfTermLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion Of Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_StockIssuedDuringPeriodValueConversionOfTermLoan" xlink:href="alto-20260331.xsd#alto_StockIssuedDuringPeriodValueConversionOfTermLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_StockIssuedDuringPeriodValueConversionOfTermLoan" xlink:to="lab_alto_StockIssuedDuringPeriodValueConversionOfTermLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cfc6e-a9b8-7956-8f8a-44653c68f567_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of common stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cfc6e-a9b8-7beb-9a37-26bcc264b074_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a9b8-715d-9ec1-6f9d12a56c46_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee, percent of outstanding principal, applicable on or before 36 months after initial funding date</link:label>
    <link:label id="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_label_en-US" xlink:label="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty Fee, On Or Before 36 Months After Initial Funding Date, Percent Of Outstanding Principal</link:label>
    <link:label id="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_documentation_en-US" xlink:label="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty Fee, On Or Before 36 Months After Initial Funding Date, Percent Of Outstanding Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:to="lab_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_K2HealthventuresLLCMember_019db87a-f783-773a-90e1-bc9d49e18428_terseLabel_en-US" xlink:label="lab_alto_K2HealthventuresLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">K2 Healthventures LLC</link:label>
    <link:label id="lab_alto_K2HealthventuresLLCMember_label_en-US" xlink:label="lab_alto_K2HealthventuresLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">K2 Healthventures LLC [Member]</link:label>
    <link:label id="lab_alto_K2HealthventuresLLCMember_documentation_en-US" xlink:label="lab_alto_K2HealthventuresLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">K2 Healthventures LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2HealthventuresLLCMember" xlink:href="alto-20260331.xsd#alto_K2HealthventuresLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_K2HealthventuresLLCMember" xlink:to="lab_alto_K2HealthventuresLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019cfc6e-aa68-77a7-8123-fd63799e37c2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault_019cfc6e-aa68-759b-a103-823eed2b9abb_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate increase in event of default</link:label>
    <link:label id="lab_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault_label_en-US" xlink:label="lab_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate Increase In Event Of Default</link:label>
    <link:label id="lab_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault_documentation_en-US" xlink:label="lab_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate Increase In Event Of Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault" xlink:href="alto-20260331.xsd#alto_DebtInstrumentInterestRateIncreaseInEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault" xlink:to="lab_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_Alto203Member_019cfc6e-aa68-73a7-88f0-64d89203b66e_terseLabel_en-US" xlink:label="lab_alto_Alto203Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALTO-203</link:label>
    <link:label id="lab_alto_Alto203Member_label_en-US" xlink:label="lab_alto_Alto203Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alto-203 [Member]</link:label>
    <link:label id="lab_alto_Alto203Member_documentation_en-US" xlink:label="lab_alto_Alto203Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alto-203</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto203Member" xlink:href="alto-20260331.xsd#alto_Alto203Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_Alto203Member" xlink:to="lab_alto_Alto203Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_019cfc6e-a9b8-7c0e-acb8-5ed5e1b1fabc_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of share-based compensation arrangements by share-based payment award</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_019cfc6e-a9b8-7387-ad82-e182038a3414_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cfc6e-a9b8-7eba-89a9-9685bb4e1f64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentTrancheOneMember_019cfc6e-aa68-7c10-b2c4-467db5925995_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First tranche, funded on December 16, 2022</link:label>
    <link:label id="lab_alto_DebtInstrumentTrancheOneMember_label_en-US" xlink:label="lab_alto_DebtInstrumentTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche One [Member]</link:label>
    <link:label id="lab_alto_DebtInstrumentTrancheOneMember_documentation_en-US" xlink:label="lab_alto_DebtInstrumentTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheOneMember" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentTrancheOneMember" xlink:to="lab_alto_DebtInstrumentTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019cfc6e-a9b8-7891-a922-5c1d2afe65d0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-aa67-764f-a79a-bc924e3d8782_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cfc6e-a9b8-7495-b225-db0431db1758_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_EmployeeStockOptionsIssuedAndOutstandingMember_019cfc6e-a9b8-7578-8991-ee7969e66902_terseLabel_en-US" xlink:label="lab_alto_EmployeeStockOptionsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options issued and outstanding from 2024, 2019 Equity Incentive Plan and Inducement Plan</link:label>
    <link:label id="lab_alto_EmployeeStockOptionsIssuedAndOutstandingMember_label_en-US" xlink:label="lab_alto_EmployeeStockOptionsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Options Issued And Outstanding [Member]</link:label>
    <link:label id="lab_alto_EmployeeStockOptionsIssuedAndOutstandingMember_documentation_en-US" xlink:label="lab_alto_EmployeeStockOptionsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Options Issued And Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_EmployeeStockOptionsIssuedAndOutstandingMember" xlink:href="alto-20260331.xsd#alto_EmployeeStockOptionsIssuedAndOutstandingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_EmployeeStockOptionsIssuedAndOutstandingMember" xlink:to="lab_alto_EmployeeStockOptionsIssuedAndOutstandingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_019cfc6e-aa67-7ad3-acd3-15798d91bf50_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_019cfc6e-a9b8-7a1c-9153-2f0456fdd880_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest, short term</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019cfc6e-a9b8-76ed-999a-e5a786a8df52_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_019cfc6e-aa68-7856-9e58-0d725d42aee1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price per share</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_019cfc6e-a9b8-731d-87c2-ae572764c29e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of future principal debt payments and exit fee</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cfc6e-aa67-76a6-8164-bb0b51b0b4f2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-7dad-b6e8-193a3644bb80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-70a7-9551-557893d647af_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-7025-b295-7856e7f0860c_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentExitFee_019cfc6e-aa67-708a-a707-36dbfb3c2ccb_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exit Fee</link:label>
    <link:label id="lab_alto_DebtInstrumentExitFee_label_en-US" xlink:label="lab_alto_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee</link:label>
    <link:label id="lab_alto_DebtInstrumentExitFee_documentation_en-US" xlink:label="lab_alto_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentExitFee" xlink:href="alto-20260331.xsd#alto_DebtInstrumentExitFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentExitFee" xlink:to="lab_alto_DebtInstrumentExitFee" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cfc6e-a9b8-73b7-8775-6224ac8eda87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019cfc6e-a9b8-7f00-9192-2836854a2902_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested after 18 months</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ReportableSegmentMember_019cfc6e-aa67-7085-9284-9e903aed9504_terseLabel_en-US" xlink:label="lab_alto_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable segment</link:label>
    <link:label id="lab_alto_ReportableSegmentMember_label_en-US" xlink:label="lab_alto_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_alto_ReportableSegmentMember_documentation_en-US" xlink:label="lab_alto_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ReportableSegmentMember" xlink:href="alto-20260331.xsd#alto_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ReportableSegmentMember" xlink:to="lab_alto_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_019cfc6e-aa67-7085-804d-ec56ef9b0b7c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019cfc6e-aa68-7df0-9eeb-a89f3d2d735f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cfc6e-a9b8-7092-afa5-1a12aee731f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a9b8-731d-b27d-8652c5084c77_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_019cfc6e-aa68-78c8-85b8-be153669298f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-780a-95c9-88ab2186a58b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019cfc6e-a9b8-7352-9a5a-b14ea8b5ba71_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019cfc6e-a9b8-7c96-88c2-8f05e8fc3d55_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_Alto100Member_019cfc6e-aa67-7563-a60d-5a4ef88643ab_terseLabel_en-US" xlink:label="lab_alto_Alto100Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALTO-100</link:label>
    <link:label id="lab_alto_Alto100Member_label_en-US" xlink:label="lab_alto_Alto100Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alto-100 [Member]</link:label>
    <link:label id="lab_alto_Alto100Member_documentation_en-US" xlink:label="lab_alto_Alto100Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alto-100</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto100Member" xlink:href="alto-20260331.xsd#alto_Alto100Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_Alto100Member" xlink:to="lab_alto_Alto100Member" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentInterestRateFloor_019cfc6e-aa67-7718-a359-0c24934b3b50_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate floor</link:label>
    <link:label id="lab_alto_DebtInstrumentInterestRateFloor_label_en-US" xlink:label="lab_alto_DebtInstrumentInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate Floor</link:label>
    <link:label id="lab_alto_DebtInstrumentInterestRateFloor_documentation_en-US" xlink:label="lab_alto_DebtInstrumentInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate Floor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentInterestRateFloor" xlink:href="alto-20260331.xsd#alto_DebtInstrumentInterestRateFloor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentInterestRateFloor" xlink:to="lab_alto_DebtInstrumentInterestRateFloor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_019cfc6e-a9b8-7967-be3b-0754c14e56ca_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_019db812-4a26-737e-89bc-e22d0099b218_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Term loan,&#160;non-current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_019cfc6e-a9b8-78d2-a74f-3bddfee88965_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan,&#160;non-current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-aa68-7d51-9b03-f99bca8022d2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_019cfc6e-a9b8-7540-a674-64ef64540209_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_019cfc6e-aa67-7f24-b164-e45ebdd297c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019cfc6e-aa68-7de6-844a-9a1379d5ae17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited and cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_019cfc6e-aa67-749c-8818-781207884934_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a9b8-792a-9c7b-29e7552589a3_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a9b8-77d3-bd4a-3b394cc8a28e_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a9b8-7d38-aa26-1591a1f33b33_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019cfc6e-aa67-7b8e-afe7-cd81d3d1db38_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage vested in year one</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019cfc6e-aa67-7a48-8720-3c934abd8672_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019cfc6e-a9b8-79a9-ab72-ad4799e46184_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019cfc6e-a9b8-7800-a584-b5a17975ece0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct external program expenses:</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cfc6e-aa68-726c-b735-834bbb2c7a80_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019cfc6e-aa67-7542-aa35-4b3c13f9130a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_019cfc6e-a9b8-7319-9a71-e46f8975b018_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_SecuritiesPurchaseAgreementMember_019db9f9-cb45-70d6-8d27-e7d4db01f7e3_terseLabel_en-US" xlink:label="lab_alto_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement</link:label>
    <link:label id="lab_alto_SecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_alto_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_alto_SecuritiesPurchaseAgreementMember_documentation_en-US" xlink:label="lab_alto_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_SecuritiesPurchaseAgreementMember" xlink:href="alto-20260331.xsd#alto_SecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_SecuritiesPurchaseAgreementMember" xlink:to="lab_alto_SecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_AmitEtkinMember_label_en-US" xlink:label="lab_alto_AmitEtkinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amit Etkin [Member]</link:label>
    <link:label id="lab_alto_AmitEtkinMember_documentation_en-US" xlink:label="lab_alto_AmitEtkinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amit Etkin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AmitEtkinMember" xlink:href="alto-20260331.xsd#alto_AmitEtkinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_AmitEtkinMember" xlink:to="lab_alto_AmitEtkinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_019cfc6e-aa68-730b-9b84-d6e026a859ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise prices, lower range (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_019e02db-6a42-77c5-939c-fbc86122f02e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units vesting</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Recognition and Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019cfc6e-aa68-7fc6-85db-1aab38db2af5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_NicholasSmithMember_label_en-US" xlink:label="lab_alto_NicholasSmithMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nicholas Smith [Member]</link:label>
    <link:label id="lab_alto_NicholasSmithMember_documentation_en-US" xlink:label="lab_alto_NicholasSmithMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nicholas Smith</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NicholasSmithMember" xlink:href="alto-20260331.xsd#alto_NicholasSmithMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_NicholasSmithMember" xlink:to="lab_alto_NicholasSmithMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_019cfc6e-aa67-761b-b16d-210244236839_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel expenses excluding stock-based compensation</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_SaleOfStockConversionOfOutstandingLoan_019db87a-f783-71a0-bc12-7df296bd4a67_terseLabel_en-US" xlink:label="lab_alto_SaleOfStockConversionOfOutstandingLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock conversion of outstanding loan</link:label>
    <link:label id="lab_alto_SaleOfStockConversionOfOutstandingLoan_label_en-US" xlink:label="lab_alto_SaleOfStockConversionOfOutstandingLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Conversion Of Outstanding Loan</link:label>
    <link:label id="lab_alto_SaleOfStockConversionOfOutstandingLoan_documentation_en-US" xlink:label="lab_alto_SaleOfStockConversionOfOutstandingLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Conversion Of Outstanding Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_SaleOfStockConversionOfOutstandingLoan" xlink:href="alto-20260331.xsd#alto_SaleOfStockConversionOfOutstandingLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_SaleOfStockConversionOfOutstandingLoan" xlink:to="lab_alto_SaleOfStockConversionOfOutstandingLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019cfc6e-aa67-7301-a71f-b50cefa2f3c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019cfc6e-a9b8-7573-95cd-0cf4eb5d7b80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentDeferredInterest_019cfc6e-a9b8-78e8-bcd2-2ecbbf7ad451_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentDeferredInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred interest</link:label>
    <link:label id="lab_alto_DebtInstrumentDeferredInterest_label_en-US" xlink:label="lab_alto_DebtInstrumentDeferredInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Deferred Interest</link:label>
    <link:label id="lab_alto_DebtInstrumentDeferredInterest_documentation_en-US" xlink:label="lab_alto_DebtInstrumentDeferredInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Deferred Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentDeferredInterest" xlink:href="alto-20260331.xsd#alto_DebtInstrumentDeferredInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentDeferredInterest" xlink:to="lab_alto_DebtInstrumentDeferredInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019cfc6e-aa67-7c55-9f95-1c061f6d4a81_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited and cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019cfc6e-aa68-789d-af5e-0dc78943f40d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSU unrecognized compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_019cfc6e-aa67-7155-97da-65a17066d344_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_019cfc6e-aa67-7305-92b7-f4f7ea54a13a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_019cfc6e-aa68-7968-bdbf-900f384f8459_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019cfc6e-aa67-72ea-b4d3-08f05c61839e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-70c2-88cf-244dbc40de67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019cfc6e-aa67-71b5-970e-031f8eca5fbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_019cfc6e-aa68-788f-b163-dfb7e4d06208_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_019cfc6e-aa67-7802-ba53-16e816ac897b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of change in the air value of the Convertible Grant Agreement</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_019cfc6e-aa67-7229-9ee3-5a7b4e456afa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_The2024EquityIncentivePlanMember_019cfc6e-a9b8-726e-aa2d-4af3b90a33eb_terseLabel_en-US" xlink:label="lab_alto_The2024EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The 2024 Equity Incentive Plan</link:label>
    <link:label id="lab_alto_The2024EquityIncentivePlanMember_label_en-US" xlink:label="lab_alto_The2024EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2024 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_alto_The2024EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_alto_The2024EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The 2024 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_The2024EquityIncentivePlanMember" xlink:href="alto-20260331.xsd#alto_The2024EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_The2024EquityIncentivePlanMember" xlink:to="lab_alto_The2024EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-7956-9202-05de1cae6cce_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-aa68-7b38-a9e1-6451154c5751_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_NumberOfWhollyOwnedSubsidiaries_019cfc6e-aa67-7eaa-b0c2-dd6a8825c416_terseLabel_en-US" xlink:label="lab_alto_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of wholly owned subsidiaries</link:label>
    <link:label id="lab_alto_NumberOfWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_alto_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_alto_NumberOfWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_alto_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Wholly Owned Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NumberOfWhollyOwnedSubsidiaries" xlink:href="alto-20260331.xsd#alto_NumberOfWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_NumberOfWhollyOwnedSubsidiaries" xlink:to="lab_alto_NumberOfWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_019cfc6e-aa67-7a19-b46e-1cc31e0241d1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_019cfc6e-aa67-75ec-ab93-179768caf1cc_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_019cfc6e-a9b8-7fa8-8c8f-20b55f15e213_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7282-a363-11fa4409761f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019cfc6e-a9b8-7e1c-8d42-f3449b4e3a0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_019db851-6704-7da3-8bb6-0dee0fc14d83_negatedTerseLabel_en-US" xlink:label="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments from sale of common stock and pre-funded warrants in 2026 private placement</link:label>
    <link:label id="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_label_en-US" xlink:label="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement</link:label>
    <link:label id="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_documentation_en-US" xlink:label="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:href="alto-20260331.xsd#alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:to="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019cfc6e-aa68-79c8-ab8a-3430d2e71ed3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019cfc6e-aa68-7a31-b962-58c35eef9a2c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_019cfc6e-aa68-7f3b-979e-ae4f6c0d9800_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_019cfc6e-aa68-7a38-8aa7-35641479d237_terseLabel_en-US" xlink:label="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate&#8232;intrinsic&#8232;value</link:label>
    <link:label id="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cfc6e-a9b8-7c08-91c4-b265891b30f4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cfc6e-a9b8-7593-bcb7-a7b61f392f00_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a9b8-75d9-b4bc-6647ff5ca3f7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidAbstract_019dba33-980d-7a55-a476-f3d6d874e011_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosure of&#160;Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_InterestPaidAbstract_label_en-US" xlink:label="lab_us-gaap_InterestPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidAbstract" xlink:to="lab_us-gaap_InterestPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a9b8-7972-bf0d-cbb2c294c9d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_NumberOfClinicalStageAssets_019cfc6e-a9b8-75cd-9e79-77c79cef799b_terseLabel_en-US" xlink:label="lab_alto_NumberOfClinicalStageAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of clinical-stage assets</link:label>
    <link:label id="lab_alto_NumberOfClinicalStageAssets_label_en-US" xlink:label="lab_alto_NumberOfClinicalStageAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Clinical-Stage Assets</link:label>
    <link:label id="lab_alto_NumberOfClinicalStageAssets_documentation_en-US" xlink:label="lab_alto_NumberOfClinicalStageAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Clinical-Stage Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NumberOfClinicalStageAssets" xlink:href="alto-20260331.xsd#alto_NumberOfClinicalStageAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_NumberOfClinicalStageAssets" xlink:to="lab_alto_NumberOfClinicalStageAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_019cfc6e-aa68-70b4-9562-1c419de2b952_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_AdditionalK2WarrantsMember_019cfc6e-aa68-7fb1-b55b-842b357b2569_terseLabel_en-US" xlink:label="lab_alto_AdditionalK2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Warrants</link:label>
    <link:label id="lab_alto_AdditionalK2WarrantsMember_label_en-US" xlink:label="lab_alto_AdditionalK2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional K2 Warrants [Member]</link:label>
    <link:label id="lab_alto_AdditionalK2WarrantsMember_documentation_en-US" xlink:label="lab_alto_AdditionalK2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional K2 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AdditionalK2WarrantsMember" xlink:href="alto-20260331.xsd#alto_AdditionalK2WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_AdditionalK2WarrantsMember" xlink:to="lab_alto_AdditionalK2WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_019cfc6e-a9b8-7177-9ed7-42a0ccfd5342_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_Alto300Member_019cfc6e-aa67-7daa-8f33-5c96dd3af0b9_terseLabel_en-US" xlink:label="lab_alto_Alto300Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALTO-300</link:label>
    <link:label id="lab_alto_Alto300Member_label_en-US" xlink:label="lab_alto_Alto300Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alto-300 [Member]</link:label>
    <link:label id="lab_alto_Alto300Member_documentation_en-US" xlink:label="lab_alto_Alto300Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alto-300</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto300Member" xlink:href="alto-20260331.xsd#alto_Alto300Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_Alto300Member" xlink:to="lab_alto_Alto300Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_019cfc6e-a9b8-7ce7-a6b9-82fe5376726a_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_019cfc6e-aa68-722b-a7e3-b41fd639f060_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value reported in other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-aa67-729a-a347-392397822c45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_019cfc6e-a9b8-794f-9cb6-7cd932934083_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a9b8-7a3b-93ab-0c8aa691ca17_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed_019cfc6e-a9b8-78d7-b14d-951895e5cfc0_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final payment, percentage of amount borrowed</link:label>
    <link:label id="lab_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed_label_en-US" xlink:label="lab_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percentage Of Amount Borrowed</link:label>
    <link:label id="lab_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed_documentation_en-US" xlink:label="lab_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percentage Of Amount Borrowed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed" xlink:to="lab_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019cfc6e-aa67-7939-ba19-19195425e072_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_019cfc6e-aa67-7ba1-9bb2-24a649e7107f_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Grant Agreement</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_019cfc6e-aa68-7eb5-aac6-5c9266d6e0d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_019cfc6e-a9b8-780d-9156-360bcb8e3529_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_019dba30-e76d-7f7d-b95c-c5c8f71b6cf2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019cfc6e-a9b8-7b9c-940d-f6541988d76f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_019cfc6e-aa67-7a52-9611-732ed3654d9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested after 24 months</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentTrancheFourMember_019cfc6e-aa67-7a88-a066-01f9b1a00da3_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fourth tranche, available through January 1, 2025</link:label>
    <link:label id="lab_alto_DebtInstrumentTrancheFourMember_label_en-US" xlink:label="lab_alto_DebtInstrumentTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche Four [Member]</link:label>
    <link:label id="lab_alto_DebtInstrumentTrancheFourMember_documentation_en-US" xlink:label="lab_alto_DebtInstrumentTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheFourMember" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentTrancheFourMember" xlink:to="lab_alto_DebtInstrumentTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cfc6e-a9b8-793f-a46c-2bec1011aa97_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_019cfc6e-aa68-7658-b548-784d1bc8faad_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_019cfc6e-aa67-7763-9159-e14f33b9f29b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_019cfc6e-a9b8-7d09-aef1-e4975e606ad2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary of LLC or LP [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary of LLC or LP [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="lab_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_019cfc6e-aa68-7262-8358-3de6d6d371d4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_019cfc6e-a9b8-7bd0-982b-ddc9ab99f849_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_019cfc6e-a9b8-75ec-9f38-3ce91e7486cf_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_019cfc6e-aa68-7f9c-b7f3-767d698c2a71_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019cfc6e-aa68-744d-ad95-afe5344dd127_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cfc6e-aa68-719d-8238-e72e9f785ffe_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019cfc6e-a9b8-75f7-90a9-4109be3cad37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited and cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_019cfc6e-a9b8-7f7a-9f81-60f272286fce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_019cfc6e-a9b8-7353-a833-c19b92526535_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019cfc6e-aa68-7ff4-ba36-04f9ac5e8385_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_019cfc6e-a9b8-7b37-9cd9-5ad092a7479d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Grant Agreement</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019cfc6e-aa67-78fe-8cc5-d21b41ead533_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_019cfc6e-a9b8-774c-b433-fae7636fe02e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_019cfc6e-a9b8-7c05-abbb-ea60dad5f121_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_019cfc6e-aa67-71b9-83c9-ee317109b249_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional&#160;paid-in&#160;capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_019cfc6e-aa67-7fef-bbd1-398081b70025_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019cfc6e-aa68-7f75-83d7-9ddc82e90ec7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retention period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_019cfc6e-aa67-76ef-a250-b3fc5cc563d8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cfc6e-aa68-7b81-ac12-f9116d3f0761_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019cfc6e-a9b8-7140-ae5c-5b3691bbeb4e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period of options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_019cfc6e-aa67-77ef-87c5-efc793dc45fd_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_019cfc6e-a9b8-7902-add1-e317a35455dc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_TwoThousandTwentyFivePreFundedWarrantsMember_019db9f9-cb45-7688-b416-a3e6dfd20f51_terseLabel_en-US" xlink:label="lab_alto_TwoThousandTwentyFivePreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Five Pre Funded Warrants</link:label>
    <link:label id="lab_alto_TwoThousandTwentyFivePreFundedWarrantsMember_label_en-US" xlink:label="lab_alto_TwoThousandTwentyFivePreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Five Pre Funded Warrants [Member]</link:label>
    <link:label id="lab_alto_TwoThousandTwentyFivePreFundedWarrantsMember_documentation_en-US" xlink:label="lab_alto_TwoThousandTwentyFivePreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Five Pre Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_TwoThousandTwentyFivePreFundedWarrantsMember" xlink:href="alto-20260331.xsd#alto_TwoThousandTwentyFivePreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_TwoThousandTwentyFivePreFundedWarrantsMember" xlink:to="lab_alto_TwoThousandTwentyFivePreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage_019cfc6e-aa68-7542-8b02-c6b062519d9d_terseLabel_en-US" xlink:label="lab_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant in excess percentage</link:label>
    <link:label id="lab_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage_label_en-US" xlink:label="lab_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights, Warrant Excess Percentage</link:label>
    <link:label id="lab_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage_documentation_en-US" xlink:label="lab_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrent in excess percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantsOrRightsWarrantExcessPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage" xlink:to="lab_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7ab2-8400-e723b504b3f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited and cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-aa67-7181-8938-133e0fdd556d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="lab_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019cfc6e-a9b8-78fb-b605-35caf659f7fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019dd75a-c16f-7fcd-933d-3e714b907a41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of withholding taxes for stock-based compensation</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_019cfc6e-aa67-738a-8748-adb9487941fa_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cfc6e-aa68-71ad-8950-c6155ee5162c_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cfc6e-aa68-7d14-8deb-955265273411_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_019cfc6e-a9b8-7df9-ba84-c2fb0a63e2ab_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-aa67-7f68-b8c0-71d99b93f9dd_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee, percent of outstanding principal, applicable 36 months after initial funding date</link:label>
    <link:label id="lab_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_label_en-US" xlink:label="lab_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty Fee, After 36 Months After Initial Funding Date, Percent Of Outstanding Principal</link:label>
    <link:label id="lab_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_documentation_en-US" xlink:label="lab_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty Fee, After 36 Months After Initial Funding Date, Percent Of Outstanding Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:to="lab_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_019cfc6e-a9b8-7f91-9b69-482cc41b92ef_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_019cfc6e-aa68-7d74-9812-5bace3d2375e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cfc6e-aa68-757f-89c5-2761f768898d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_GrantAgreementMember_019cfc6e-aa67-7641-a044-c30bacec9ae4_terseLabel_en-US" xlink:label="lab_alto_GrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Agreement</link:label>
    <link:label id="lab_alto_GrantAgreementMember_label_en-US" xlink:label="lab_alto_GrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Agreement [Member]</link:label>
    <link:label id="lab_alto_GrantAgreementMember_documentation_en-US" xlink:label="lab_alto_GrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_GrantAgreementMember" xlink:href="alto-20260331.xsd#alto_GrantAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_GrantAgreementMember" xlink:to="lab_alto_GrantAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019cfc6e-aa67-715a-808f-8690e3f9e18e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_019cfc6e-a9b8-7c14-a0e4-86596ed4922e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_LoanAndSecurityAgreementMember_019cfc6e-aa67-7ed6-b8f4-da0c27627ae0_terseLabel_en-US" xlink:label="lab_alto_LoanAndSecurityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan and Security Agreement</link:label>
    <link:label id="lab_alto_LoanAndSecurityAgreementMember_label_en-US" xlink:label="lab_alto_LoanAndSecurityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan And Security Agreement [Member]</link:label>
    <link:label id="lab_alto_LoanAndSecurityAgreementMember_documentation_en-US" xlink:label="lab_alto_LoanAndSecurityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan And Security Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_LoanAndSecurityAgreementMember" xlink:href="alto-20260331.xsd#alto_LoanAndSecurityAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_LoanAndSecurityAgreementMember" xlink:to="lab_alto_LoanAndSecurityAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019cfc6e-a9b8-723c-8a6d-7bb96818a8fd_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019cfc6e-aa67-7992-a99a-af86b8938bc2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_019cfc6e-aa68-7835-8d54-839497d0f0fe_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cfc6e-aa67-7bb4-89f6-d899906b6f98_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_019cfc6e-aa67-71fb-9f59-7bf6bb9f7e46_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019cfc6e-a9b8-7e5f-8f96-a055e0c2587a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_019cfc6e-aa67-704a-84a2-553b88f7b4cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_K2CommonStockWarrantsMember_019cfc6e-a9b8-72d3-8c57-4e609e3a4f26_terseLabel_en-US" xlink:label="lab_alto_K2CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">K2 Common Stock Warrants</link:label>
    <link:label id="lab_alto_K2CommonStockWarrantsMember_label_en-US" xlink:label="lab_alto_K2CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">K2 Common Stock Warrants [Member]</link:label>
    <link:label id="lab_alto_K2CommonStockWarrantsMember_documentation_en-US" xlink:label="lab_alto_K2CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">K2 Common Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2CommonStockWarrantsMember" xlink:href="alto-20260331.xsd#alto_K2CommonStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_K2CommonStockWarrantsMember" xlink:to="lab_alto_K2CommonStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7149-96d5-90040448d917_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_019cfc6e-a9b8-7478-8b15-e1cdd8fc0716_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total principal payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-759e-a5ac-c75967128be7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cfc6e-aa67-712a-b4ff-1760ed9586b0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll, vacation and employee-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_PreFundedWarrantsMember_019cfc6e-aa67-7186-89a3-2e3a07bf92ec_terseLabel_en-US" xlink:label="lab_alto_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_alto_PreFundedWarrantsMember_label_en-US" xlink:label="lab_alto_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_alto_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_alto_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_PreFundedWarrantsMember" xlink:href="alto-20260331.xsd#alto_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_PreFundedWarrantsMember" xlink:to="lab_alto_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_019cfc6e-aa68-7d13-b1e5-84a5a76117be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and development</link:label>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentUnamortizedExitFee_019cfc6e-aa67-7833-81bf-6a329414437a_negatedTerseLabel_en-US" xlink:label="lab_alto_DebtInstrumentUnamortizedExitFee" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: unamortized debt discount</link:label>
    <link:label id="lab_alto_DebtInstrumentUnamortizedExitFee_label_en-US" xlink:label="lab_alto_DebtInstrumentUnamortizedExitFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Exit Fee</link:label>
    <link:label id="lab_alto_DebtInstrumentUnamortizedExitFee_documentation_en-US" xlink:label="lab_alto_DebtInstrumentUnamortizedExitFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Exit Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentUnamortizedExitFee" xlink:href="alto-20260331.xsd#alto_DebtInstrumentUnamortizedExitFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentUnamortizedExitFee" xlink:to="lab_alto_DebtInstrumentUnamortizedExitFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019cfc6e-aa68-7fff-9873-ff9d7026d3d4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_019cfc6e-aa67-7b98-8ded-2d47a4910378_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019cfc6e-aa67-744c-9484-0215068e94de_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_019cfc6e-aa67-7f47-92ae-e6faedee89e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accruals and current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_GainLossInOtherOperatingActivitiesNet_019cfc6e-a9b8-7a0b-90c4-77a9892a63ce_terseLabel_en-US" xlink:label="lab_alto_GainLossInOtherOperatingActivitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other, net</link:label>
    <link:label id="lab_alto_GainLossInOtherOperatingActivitiesNet_label_en-US" xlink:label="lab_alto_GainLossInOtherOperatingActivitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) In Other Operating Activities, Net</link:label>
    <link:label id="lab_alto_GainLossInOtherOperatingActivitiesNet_documentation_en-US" xlink:label="lab_alto_GainLossInOtherOperatingActivitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) In Other Operating Activities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_GainLossInOtherOperatingActivitiesNet" xlink:href="alto-20260331.xsd#alto_GainLossInOtherOperatingActivitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_GainLossInOtherOperatingActivitiesNet" xlink:to="lab_alto_GainLossInOtherOperatingActivitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019cfc6e-aa67-7ef7-989b-5a6861a0e33d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a9b8-7e45-b549-a77b72be2a24_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a9b8-7448-a20e-1e1afe844bec_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_019cfc6e-aa67-7f8d-bee8-8fbd3c63f204_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_019cfc6e-a9b8-73e8-8fad-d14a301f3015_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_019cfc6e-a9b8-7aa2-ac40-a1c4aa7dd055_verboseLabel_en-US" xlink:label="lab_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchase price (in dollars per share)</link:label>
    <link:label id="lab_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Purchase Price Of Warrants Or Rights</link:label>
    <link:label id="lab_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Purchase Price Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:to="lab_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019cfc6e-a9b8-738d-a27e-845fa03c7c5f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_019cfc6e-aa67-7a68-994b-ba6c620ca89d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019cfc6e-a9b8-75a0-8b30-6a4628327208_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019cfc6e-aa67-7ea2-a060-696fb415001f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019cfc6e-aa67-7762-936a-b5ee75c60853_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_019cfc6e-aa67-7f9a-ac51-c901c1710a31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, cost by plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019cfc6e-aa67-7e70-8d83-31aa6e9427d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019cfc6e-a9b8-7fc5-94a0-de8f162b1b01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance awards issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum_019cfc6e-a9b8-733c-af26-f0a7c129f99d_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum percentage of outstanding stock</link:label>
    <link:label id="lab_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Percentage Of Outstanding Stock, Maximum</link:label>
    <link:label id="lab_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum_documentation_en-US" xlink:label="lab_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Percentage Of Outstanding Stock, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum" xlink:href="alto-20260331.xsd#alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum" xlink:to="lab_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-753b-8306-239ec5bcc580_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019cfc6e-a9b8-7f1b-a360-f87181743265_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019cfc6e-aa67-7c87-a190-245da89bac8f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid_019dd758-dc15-7fec-96f5-fedf2a2fe823_terseLabel_en-US" xlink:label="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs from sale of common stock and pre-funded warrants in 2026 private placement not yet paid</link:label>
    <link:label id="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid_label_en-US" xlink:label="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement Not Yet Paid</link:label>
    <link:label id="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid_documentation_en-US" xlink:label="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid" xlink:href="alto-20260331.xsd#alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid" xlink:to="lab_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock_019dd74c-96b4-7537-8186-277f775ed491_terseLabel_en-US" xlink:label="lab_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and pre-funded warrants in 2026 private placement, net of issuance costs (in shares)</link:label>
    <link:label id="lab_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock_label_en-US" xlink:label="lab_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock And Pre Funded Warrants In Private Placement Net Of Issuance Costs In Common Stock</link:label>
    <link:label id="lab_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock_documentation_en-US" xlink:label="lab_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock And Pre Funded Warrants In Private Placement Net Of Issuance Costs In Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock" xlink:href="alto-20260331.xsd#alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock" xlink:to="lab_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_019cfc6e-aa68-7715-a267-779b1b733da2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a9b8-79ef-9ae9-f1d521afe6c9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_019cfc6e-a9b8-7c98-a436-61a03e28870f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Purchase and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cfc6e-aa67-7098-a8f4-3781bc72d541_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019cfc6e-aa68-7df1-9a39-b2c7f02bd4c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_019cfc6e-a9b8-7de4-a843-a3969c780f05_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of warrants in connection with term loan agreement</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_019cfc6e-aa67-74d2-96b0-e47c96133b2d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019cfc6e-aa68-72b3-bea0-9b2651925e4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of classes of financial assets and liabilities measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_019cfc6e-aa67-7b91-b959-d45377a61b15_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cfc6e-a9b8-71d9-a2e3-2819c7ea163d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019cfc6e-a9b8-7daa-986e-43e39bcafc2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019cfc6e-a9b8-73ec-9979-ed95e29c1bab_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_019cfc6e-aa68-7e26-b9b7-93fa29deba0b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019cfc6e-aa67-7237-84f4-9217a8ccc18b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares approved, initially reserved for issuance under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a9b8-76ca-af1b-2bf2d5fc6ade_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent_019cfc6e-aa68-713d-98fd-10aae8f83fe3_terseLabel_en-US" xlink:label="lab_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value attributable to instrument specific credit risk</link:label>
    <link:label id="lab_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), after Adjustments and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent" xlink:to="lab_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-aa67-7091-aba1-87bacf4ca9e7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_LongTermDebtPrincipalPaymentsAndExitFee_019cfc6e-a9b8-7dc6-87e0-190d1085c146_totalLabel_en-US" xlink:label="lab_alto_LongTermDebtPrincipalPaymentsAndExitFee" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total principal payments and Exit Fee</link:label>
    <link:label id="lab_alto_LongTermDebtPrincipalPaymentsAndExitFee_label_en-US" xlink:label="lab_alto_LongTermDebtPrincipalPaymentsAndExitFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Principal Payments And Exit Fee</link:label>
    <link:label id="lab_alto_LongTermDebtPrincipalPaymentsAndExitFee_documentation_en-US" xlink:label="lab_alto_LongTermDebtPrincipalPaymentsAndExitFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Principal Payments And Exit Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_LongTermDebtPrincipalPaymentsAndExitFee" xlink:href="alto-20260331.xsd#alto_LongTermDebtPrincipalPaymentsAndExitFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_LongTermDebtPrincipalPaymentsAndExitFee" xlink:to="lab_alto_LongTermDebtPrincipalPaymentsAndExitFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-aa67-7892-bbf9-066283c836b0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cfc6e-aa67-79be-a1f5-06252c6142c3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cfc6e-aa67-7722-9f7f-f41f80f79007_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_A2025InducementPlanMember_019cfc6e-aa68-7e47-9ec1-93ba1d628028_terseLabel_en-US" xlink:label="lab_alto_A2025InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Inducement Plan</link:label>
    <link:label id="lab_alto_A2025InducementPlanMember_label_en-US" xlink:label="lab_alto_A2025InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Inducement Plan [Member]</link:label>
    <link:label id="lab_alto_A2025InducementPlanMember_documentation_en-US" xlink:label="lab_alto_A2025InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_A2025InducementPlanMember" xlink:href="alto-20260331.xsd#alto_A2025InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_A2025InducementPlanMember" xlink:to="lab_alto_A2025InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019cfc6e-aa68-7cde-b0b1-847b76cdcbf2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount_019cfc6e-aa68-712a-a8d0-ddf40eee4b10_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum market capitalization</link:label>
    <link:label id="lab_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount_label_en-US" xlink:label="lab_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Next Fiscal Year Covenant, Market Capitalization, Minimum Amount</link:label>
    <link:label id="lab_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount_documentation_en-US" xlink:label="lab_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Covenant, Minimum Market Capitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount" xlink:href="alto-20260331.xsd#alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount" xlink:to="lab_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_019dff09-fa2b-7f03-ad7d-d4ca5d566e71_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance awards vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019cfc6e-aa67-77fe-81b1-68b909f4afcd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019cfc6e-aa67-7a01-8513-aa75240c8fd9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentFundingFeeMultiplier_019cfc6e-a9b8-7c44-af9c-788b23cc6252_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentFundingFeeMultiplier" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funding fee multiplier</link:label>
    <link:label id="lab_alto_DebtInstrumentFundingFeeMultiplier_label_en-US" xlink:label="lab_alto_DebtInstrumentFundingFeeMultiplier" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Funding Fee Multiplier</link:label>
    <link:label id="lab_alto_DebtInstrumentFundingFeeMultiplier_documentation_en-US" xlink:label="lab_alto_DebtInstrumentFundingFeeMultiplier" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Funding Fee Multiplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentFundingFeeMultiplier" xlink:href="alto-20260331.xsd#alto_DebtInstrumentFundingFeeMultiplier"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentFundingFeeMultiplier" xlink:to="lab_alto_DebtInstrumentFundingFeeMultiplier" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cfc6e-a9b8-7b4d-bc77-e5969e5c1d3d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cfc6e-a9b8-7827-8ff6-0196bbe5d817_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-aa67-7a97-b496-1206e1a3f5ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_019cfc6e-a9b8-7f58-bdf8-c7f58079ff49_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_019cfc6e-a9b8-777b-b10a-05283761a825_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_LaboratoryEquipmentMember_019cfc6e-a9b8-743c-a967-847c082d80af_terseLabel_en-US" xlink:label="lab_alto_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_alto_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_alto_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_alto_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_alto_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_LaboratoryEquipmentMember" xlink:href="alto-20260331.xsd#alto_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_LaboratoryEquipmentMember" xlink:to="lab_alto_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019cfc6e-a9b8-78e0-a5b2-36617877e75c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_019cfc6e-aa67-7549-b491-198c2e623a1f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_019cfc6e-aa67-794f-a4e3-a5441f54cdc0_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_019cfc6e-aa68-7095-a95c-b4394bd54fd4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares underlying repriced options, (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019cfc6e-aa68-7ae0-b237-8e20ec7ca3bb_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value reported in statements of operations</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_019cfc6e-aa68-7f5a-a0e5-67949ae5efe4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_019cfc6e-aa68-700d-9718-b7823960d529_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019cfc6e-aa68-744f-bf92-512f8ee8ca27_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-aa67-7510-9ba3-d4f143d084ff_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026 (remainder of year)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentExitFeePercentOfLoansFunded_019cfc6e-a9b8-74e4-97eb-68724fb5fd93_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentExitFeePercentOfLoansFunded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final fee, percent of loan funded</link:label>
    <link:label id="lab_alto_DebtInstrumentExitFeePercentOfLoansFunded_label_en-US" xlink:label="lab_alto_DebtInstrumentExitFeePercentOfLoansFunded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee, Percent Of Loans Funded</link:label>
    <link:label id="lab_alto_DebtInstrumentExitFeePercentOfLoansFunded_documentation_en-US" xlink:label="lab_alto_DebtInstrumentExitFeePercentOfLoansFunded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee, Percent Of Loans Funded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentExitFeePercentOfLoansFunded" xlink:href="alto-20260331.xsd#alto_DebtInstrumentExitFeePercentOfLoansFunded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentExitFeePercentOfLoansFunded" xlink:to="lab_alto_DebtInstrumentExitFeePercentOfLoansFunded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_019cfc6e-aa68-741e-bc39-55d6fe41a55f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-aa67-7534-a200-82d9b6137046_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_019cfc6e-aa68-7fe1-846f-3c66b7b8bb15_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_EmployeeStockOptionsAvailableForFutureGrantMember_019cfc6e-a9b8-74ec-966f-39123a35ed6f_terseLabel_en-US" xlink:label="lab_alto_EmployeeStockOptionsAvailableForFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grant from 2024 Equity Incentive Plan and Inducement Plan</link:label>
    <link:label id="lab_alto_EmployeeStockOptionsAvailableForFutureGrantMember_label_en-US" xlink:label="lab_alto_EmployeeStockOptionsAvailableForFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Options Available For Future Grant [Member]</link:label>
    <link:label id="lab_alto_EmployeeStockOptionsAvailableForFutureGrantMember_documentation_en-US" xlink:label="lab_alto_EmployeeStockOptionsAvailableForFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Options Available For Future Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_EmployeeStockOptionsAvailableForFutureGrantMember" xlink:href="alto-20260331.xsd#alto_EmployeeStockOptionsAvailableForFutureGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_EmployeeStockOptionsAvailableForFutureGrantMember" xlink:to="lab_alto_EmployeeStockOptionsAvailableForFutureGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_019cfc6e-a9b8-7a46-a842-d2514df6707d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of K2 term loan into shares of common stock</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019cfc6e-a9b8-787e-8915-3d40425dbaa5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principle amount (up to)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_019cfc6e-aa67-78b2-b752-b4ba11e0d685_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock (par value $0.0001), 500,000 shares authorized; 35,053 and 31,924 shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_019cfc6e-aa68-75cd-b5d9-7a43d2ac4005_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_019cfc6e-aa68-7b8f-a26b-e744c2ceac4d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue_019db84c-e2b7-7d5f-b9cd-ec57ee782f17_terseLabel_en-US" xlink:label="lab_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and pre-funded warrants in 2026 private placement, net of issuance costs</link:label>
    <link:label id="lab_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue_label_en-US" xlink:label="lab_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock And Pre Funded Warrants Issued During Period Value</link:label>
    <link:label id="lab_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue_documentation_en-US" xlink:label="lab_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock And Pre Funded Warrants Issued During Period Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue" xlink:href="alto-20260331.xsd#alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue" xlink:to="lab_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum_019cfc6e-aa67-736c-8372-59c1e0670fb1_terseLabel_en-US" xlink:label="lab_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum number of months of cash runway</link:label>
    <link:label id="lab_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum_label_en-US" xlink:label="lab_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Next Fiscal Year Covenant, Cash Runway Period, Minimum</link:label>
    <link:label id="lab_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum_documentation_en-US" xlink:label="lab_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Next Fiscal Year Covenant, Cash Runway Period, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum" xlink:href="alto-20260331.xsd#alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum" xlink:to="lab_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_019cfc6e-aa67-7df1-888d-a9457671cf3a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_019cfc6e-aa68-78b6-931d-75abb0dff2dd_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of debt, amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cfc6e-a9b8-7610-aed4-79b3c9cf08f6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_019cfc6e-a9b8-7570-8bba-7f35d1235871_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, restricted stock unit, activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_019cfc6e-a9b8-7455-8dbb-9d683eae5f24_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019cfc6e-a9b8-7563-8ac2-718336663b37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_019cfc6e-aa67-7df1-ab02-126e30574f61_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of new tranches</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019cfc6e-aa68-7018-9b61-fc3e520f0c11_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_K2WarrantMember_019cfc6e-aa67-754e-b159-cd6a15b175e1_terseLabel_en-US" xlink:label="lab_alto_K2WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">K2 Warrants</link:label>
    <link:label id="lab_alto_K2WarrantMember_label_en-US" xlink:label="lab_alto_K2WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">K2 Warrant [Member]</link:label>
    <link:label id="lab_alto_K2WarrantMember_documentation_en-US" xlink:label="lab_alto_K2WarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">K2 Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2WarrantMember" xlink:href="alto-20260331.xsd#alto_K2WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_K2WarrantMember" xlink:to="lab_alto_K2WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cfc6e-a9b8-7fa4-9cac-fd0430cbf4a0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_alto_ScheduleOfStockReservedForIssuanceTableTextBlock_019cfc6e-aa67-731e-9ac0-11af8c7a0b61_terseLabel_en-US" xlink:label="lab_alto_ScheduleOfStockReservedForIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock reserved for issuance</link:label>
    <link:label id="lab_alto_ScheduleOfStockReservedForIssuanceTableTextBlock_label_en-US" xlink:label="lab_alto_ScheduleOfStockReservedForIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock Reserved for Issuance [Table Text Block]</link:label>
    <link:label id="lab_alto_ScheduleOfStockReservedForIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_alto_ScheduleOfStockReservedForIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Stock Reserved for Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ScheduleOfStockReservedForIssuanceTableTextBlock" xlink:href="alto-20260331.xsd#alto_ScheduleOfStockReservedForIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alto_ScheduleOfStockReservedForIssuanceTableTextBlock" xlink:to="lab_alto_ScheduleOfStockReservedForIssuanceTableTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>alto-20260331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cfc6e-a845-7559-941c-e87ca4915109,g:515d2a5a-b4b4-4d42-8d26-d42921144f4b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/Cover" xlink:type="simple" xlink:href="alto-20260331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019cfc6e-a903-723c-a03a-8f81e9d5de57" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_DocumentType_019cfc6e-a903-723c-a03a-8f81e9d5de57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_019cfc6e-a903-77a2-b62a-c27dbe7907e7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_DocumentQuarterlyReport_019cfc6e-a903-77a2-b62a-c27dbe7907e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019cfc6e-a903-705f-b824-dc49e022f53c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_DocumentPeriodEndDate_019cfc6e-a903-705f-b824-dc49e022f53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019cfc6e-a903-7293-8bb5-908e92ff6d93" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_DocumentTransitionReport_019cfc6e-a903-7293-8bb5-908e92ff6d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019cfc6e-a903-7c6a-9b4e-f78796613141" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityFileNumber_019cfc6e-a903-7c6a-9b4e-f78796613141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019cfc6e-a903-71d2-a000-2fa0d04dc0be" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityRegistrantName_019cfc6e-a903-71d2-a000-2fa0d04dc0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019cfc6e-a903-72fa-83ec-450b4d9db988" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019cfc6e-a903-72fa-83ec-450b4d9db988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019cfc6e-a903-7d1e-8478-3baf7fd1a18e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityTaxIdentificationNumber_019cfc6e-a903-7d1e-8478-3baf7fd1a18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019cfc6e-a903-7568-b7a0-420736b2874a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityAddressAddressLine1_019cfc6e-a903-7568-b7a0-420736b2874a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019cfc6e-a903-7597-9f4d-221dd68d3a78" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityAddressCityOrTown_019cfc6e-a903-7597-9f4d-221dd68d3a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019cfc6e-a903-7fbe-b861-3f5ebb1497ed" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityAddressStateOrProvince_019cfc6e-a903-7fbe-b861-3f5ebb1497ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019cfc6e-a903-76ce-93bc-f1e0bc52f43e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityAddressPostalZipCode_019cfc6e-a903-76ce-93bc-f1e0bc52f43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019cfc6e-a903-7c9f-8e6b-c4d86016f59e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_CityAreaCode_019cfc6e-a903-7c9f-8e6b-c4d86016f59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019cfc6e-a903-760f-9db3-866270fce09d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_LocalPhoneNumber_019cfc6e-a903-760f-9db3-866270fce09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019cfc6e-a903-7bad-948f-7bfb25beaf13" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_Security12bTitle_019cfc6e-a903-7bad-948f-7bfb25beaf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019cfc6e-a903-7d2b-97c1-f3adeb3f02a2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_TradingSymbol_019cfc6e-a903-7d2b-97c1-f3adeb3f02a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019cfc6e-a903-711f-a3f8-a83ddc6598b4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_SecurityExchangeName_019cfc6e-a903-711f-a3f8-a83ddc6598b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019cfc6e-a903-7873-bade-e17a012f47ea" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityCurrentReportingStatus_019cfc6e-a903-7873-bade-e17a012f47ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019cfc6e-a903-7b4c-bf41-831a7ca66ab1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityInteractiveDataCurrent_019cfc6e-a903-7b4c-bf41-831a7ca66ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019cfc6e-a903-75e0-a50d-201fbcc68cce" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityFilerCategory_019cfc6e-a903-75e0-a50d-201fbcc68cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019cfc6e-a903-7138-a1d2-e2c2c302bfe6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntitySmallBusiness_019cfc6e-a903-7138-a1d2-e2c2c302bfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019cfc6e-a903-7954-8ea5-44b415c25463" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityEmergingGrowthCompany_019cfc6e-a903-7954-8ea5-44b415c25463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_019cfc6e-a903-733e-9d78-45c4932eb816" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityExTransitionPeriod_019cfc6e-a903-733e-9d78-45c4932eb816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019cfc6e-a903-7486-a89e-3816b58f03b4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityShellCompany_019cfc6e-a903-7486-a89e-3816b58f03b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019cfc6e-a903-7022-8850-9a025a213824" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019cfc6e-a903-7022-8850-9a025a213824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019cfc6e-a903-7b24-acde-42afae2e0a48" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_CurrentFiscalYearEndDate_019cfc6e-a903-7b24-acde-42afae2e0a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019cfc6e-a903-7717-9e6f-0fb178bc682d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_EntityCentralIndexKey_019cfc6e-a903-7717-9e6f-0fb178bc682d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019cfc6e-a903-76b6-aa23-73fdcc9c08e7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_DocumentFiscalYearFocus_019cfc6e-a903-76b6-aa23-73fdcc9c08e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019cfc6e-a903-7a39-a53d-2afde9d26191" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019cfc6e-a903-7a39-a53d-2afde9d26191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019cfc6e-a903-777a-a810-336eb0eda779" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cfc6e-a903-78eb-89d8-3b9826b10226" xlink:to="loc_dei_AmendmentFlag_019cfc6e-a903-777a-a810-336eb0eda779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="alto-20260331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019cfc6e-a903-7475-9140-775a646b5916" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019cfc6e-a903-743b-903e-6e6839aa2176" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cfc6e-a903-7475-9140-775a646b5916" xlink:to="loc_us-gaap_AssetsAbstract_019cfc6e-a903-743b-903e-6e6839aa2176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_019cfc6e-a903-7eff-951a-672d5bf26e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cfc6e-a903-743b-903e-6e6839aa2176" xlink:to="loc_us-gaap_AssetsCurrentAbstract_019cfc6e-a903-7eff-951a-672d5bf26e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cfc6e-a903-7f7d-98ec-b12f56894dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cfc6e-a903-7eff-951a-672d5bf26e7c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cfc6e-a903-7f7d-98ec-b12f56894dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cfc6e-a903-7d18-9fb7-c5c42e1bf8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cfc6e-a903-7eff-951a-672d5bf26e7c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cfc6e-a903-7d18-9fb7-c5c42e1bf8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019cfc6e-a903-79ec-add0-ea4660660ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cfc6e-a903-7eff-951a-672d5bf26e7c" xlink:to="loc_us-gaap_AssetsCurrent_019cfc6e-a903-79ec-add0-ea4660660ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_019cfc6e-a903-77a5-ae3c-37b86666ca9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cfc6e-a903-743b-903e-6e6839aa2176" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_019cfc6e-a903-77a5-ae3c-37b86666ca9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a903-746b-a9b9-e99b8826f275" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cfc6e-a903-743b-903e-6e6839aa2176" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a903-746b-a9b9-e99b8826f275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019cfc6e-a903-7ba9-92d2-59c8c1995030" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cfc6e-a903-743b-903e-6e6839aa2176" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019cfc6e-a903-7ba9-92d2-59c8c1995030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_019cfc6e-a903-71f4-935b-4e6b19c1c803" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cfc6e-a903-743b-903e-6e6839aa2176" xlink:to="loc_us-gaap_OtherAssets_019cfc6e-a903-71f4-935b-4e6b19c1c803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019cfc6e-a903-7334-83f6-75c82afcd861" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cfc6e-a903-743b-903e-6e6839aa2176" xlink:to="loc_us-gaap_Assets_019cfc6e-a903-7334-83f6-75c82afcd861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cfc6e-a903-736e-8458-c849b0dc1c14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cfc6e-a903-7475-9140-775a646b5916" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cfc6e-a903-736e-8458-c849b0dc1c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019cfc6e-a903-7d62-8eee-8af7564812f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cfc6e-a903-736e-8458-c849b0dc1c14" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019cfc6e-a903-7d62-8eee-8af7564812f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019cfc6e-a903-78e7-85fd-790b4f6ce548" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cfc6e-a903-7d62-8eee-8af7564812f6" xlink:to="loc_us-gaap_AccountsPayableCurrent_019cfc6e-a903-78e7-85fd-790b4f6ce548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-a903-7077-a235-1e3d41133951" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cfc6e-a903-7d62-8eee-8af7564812f6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-a903-7077-a235-1e3d41133951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_019db811-ddf5-789d-9427-e9306168aa53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cfc6e-a903-7d62-8eee-8af7564812f6" xlink:to="loc_us-gaap_LongTermDebtCurrent_019db811-ddf5-789d-9427-e9306168aa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cfc6e-a903-7f58-8cb7-4455e2a6c1db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cfc6e-a903-7d62-8eee-8af7564812f6" xlink:to="loc_us-gaap_LiabilitiesCurrent_019cfc6e-a903-7f58-8cb7-4455e2a6c1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_019cfc6e-a903-7400-a6be-f5036f82b513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cfc6e-a903-736e-8458-c849b0dc1c14" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_019cfc6e-a903-7400-a6be-f5036f82b513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_019cfc6e-a903-7a90-9e95-707f128ba60b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cfc6e-a903-736e-8458-c849b0dc1c14" xlink:to="loc_us-gaap_ConvertibleDebt_019cfc6e-a903-7a90-9e95-707f128ba60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019cfc6e-a903-71e5-9fba-9cfbe083f77b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cfc6e-a903-736e-8458-c849b0dc1c14" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019cfc6e-a903-71e5-9fba-9cfbe083f77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019cfc6e-a903-7108-94d9-a7f0cfbae9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cfc6e-a903-736e-8458-c849b0dc1c14" xlink:to="loc_us-gaap_Liabilities_019cfc6e-a903-7108-94d9-a7f0cfbae9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019cfc6e-a903-7f41-b56e-c132a749cdff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cfc6e-a903-7475-9140-775a646b5916" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019cfc6e-a903-7f41-b56e-c132a749cdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019cfc6e-a903-70db-a010-565b1327fa38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cfc6e-a903-7475-9140-775a646b5916" xlink:to="loc_us-gaap_StockholdersEquityNoteAbstract_019cfc6e-a903-70db-a010-565b1327fa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_019cfc6e-a903-7aab-8609-e7f3daaf0001" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019cfc6e-a903-70db-a010-565b1327fa38" xlink:to="loc_us-gaap_CommonStockValueOutstanding_019cfc6e-a903-7aab-8609-e7f3daaf0001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019cfc6e-a903-796b-969e-93513638ad3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019cfc6e-a903-70db-a010-565b1327fa38" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019cfc6e-a903-796b-969e-93513638ad3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cfc6e-a903-7c4c-8dba-1eb5b1a7b14d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019cfc6e-a903-70db-a010-565b1327fa38" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cfc6e-a903-7c4c-8dba-1eb5b1a7b14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cfc6e-a903-7dc7-8ce4-393943fdedb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019cfc6e-a903-70db-a010-565b1327fa38" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cfc6e-a903-7dc7-8ce4-393943fdedb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7f46-bd4d-026b450c7cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019cfc6e-a903-70db-a010-565b1327fa38" xlink:to="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7f46-bd4d-026b450c7cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cfc6e-a903-7568-bf50-c0b8d62be1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cfc6e-a903-7475-9140-775a646b5916" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cfc6e-a903-7568-bf50-c0b8d62be1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="alto-20260331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019cfc6e-a903-7b6f-903a-9cfdf514aede" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cfc6e-a903-79a6-a792-8035f6394390" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cfc6e-a903-7b6f-903a-9cfdf514aede" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cfc6e-a903-79a6-a792-8035f6394390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019cfc6e-a903-7344-b71c-47a7961eef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cfc6e-a903-7b6f-903a-9cfdf514aede" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019cfc6e-a903-7344-b71c-47a7961eef1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019cfc6e-a903-7b88-b7d3-5c550b553f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cfc6e-a903-7b6f-903a-9cfdf514aede" xlink:to="loc_us-gaap_CommonStockSharesIssued_019cfc6e-a903-7b88-b7d3-5c550b553f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a903-7f8a-95f6-283d66b027b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cfc6e-a903-7b6f-903a-9cfdf514aede" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a903-7f8a-95f6-283d66b027b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="alto-20260331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019cfc6e-a903-74f8-81c2-1ba727581923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019cfc6e-a903-762a-8643-8767f8abddfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cfc6e-a903-74f8-81c2-1ba727581923" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019cfc6e-a903-762a-8643-8767f8abddfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cfc6e-a903-7f87-bb66-06de0becb392" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cfc6e-a903-762a-8643-8767f8abddfd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cfc6e-a903-7f87-bb66-06de0becb392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cfc6e-a903-707e-a37e-7386e2acdf25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cfc6e-a903-762a-8643-8767f8abddfd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cfc6e-a903-707e-a37e-7386e2acdf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cfc6e-a903-7e76-a54a-f59ea64e4c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cfc6e-a903-762a-8643-8767f8abddfd" xlink:to="loc_us-gaap_OperatingExpenses_019cfc6e-a903-7e76-a54a-f59ea64e4c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cfc6e-a903-7600-b34a-3d6703353406" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cfc6e-a903-74f8-81c2-1ba727581923" xlink:to="loc_us-gaap_OperatingIncomeLoss_019cfc6e-a903-7600-b34a-3d6703353406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_019cfc6e-a903-736f-a9f3-0ba5da961754" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cfc6e-a903-74f8-81c2-1ba727581923" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_019cfc6e-a903-736f-a9f3-0ba5da961754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019cfc6e-a903-706c-b109-05b833815a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019cfc6e-a903-736f-a9f3-0ba5da961754" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019cfc6e-a903-706c-b109-05b833815a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019cfc6e-a903-7d52-963f-bdfbeae65eef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019cfc6e-a903-736f-a9f3-0ba5da961754" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019cfc6e-a903-7d52-963f-bdfbeae65eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a903-7413-b7c9-d81d45de5225" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019cfc6e-a903-736f-a9f3-0ba5da961754" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a903-7413-b7c9-d81d45de5225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_019cfc6e-a903-7f81-b34c-f59ec387e05c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019cfc6e-a903-736f-a9f3-0ba5da961754" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_019cfc6e-a903-7f81-b34c-f59ec387e05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cfc6e-a903-71fa-9b62-fa98f5c21f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019cfc6e-a903-736f-a9f3-0ba5da961754" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019cfc6e-a903-71fa-9b62-fa98f5c21f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-7258-bf07-8de5d74d05e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cfc6e-a903-74f8-81c2-1ba727581923" xlink:to="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-7258-bf07-8de5d74d05e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_019cfc6e-a903-719c-9300-35287fb5abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cfc6e-a903-74f8-81c2-1ba727581923" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_019cfc6e-a903-719c-9300-35287fb5abbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent_019cfc6e-a903-7711-9f71-c51e9c9bac82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_019cfc6e-a903-719c-9300-35287fb5abbf" xlink:to="loc_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent_019cfc6e-a903-7711-9f71-c51e9c9bac82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019cfc6e-a903-7982-bb21-20fa0e7357f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_019cfc6e-a903-719c-9300-35287fb5abbf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019cfc6e-a903-7982-bb21-20fa0e7357f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cfc6e-a903-7ba0-b73e-a3af9c586ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_019cfc6e-a903-719c-9300-35287fb5abbf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cfc6e-a903-7ba0-b73e-a3af9c586ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019cfc6e-a903-79ee-b7e4-fb8acc3896db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_019cfc6e-a903-719c-9300-35287fb5abbf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019cfc6e-a903-79ee-b7e4-fb8acc3896db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019cfc6e-a903-7add-9dbc-b8dd46ddd6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cfc6e-a903-74f8-81c2-1ba727581923" xlink:to="loc_us-gaap_EarningsPerShareBasic_019cfc6e-a903-7add-9dbc-b8dd46ddd6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019cfc6e-a903-78e3-8674-abd33041e913" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cfc6e-a903-74f8-81c2-1ba727581923" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019cfc6e-a903-78e3-8674-abd33041e913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cfc6e-a903-7b9a-943f-ef5d6745bba0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cfc6e-a903-74f8-81c2-1ba727581923" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cfc6e-a903-7b9a-943f-ef5d6745bba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cfc6e-a903-7806-977e-c01ccf651876" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cfc6e-a903-74f8-81c2-1ba727581923" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cfc6e-a903-7806-977e-c01ccf651876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="alto-20260331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019cfc6e-a903-797f-bfa1-8fbcb27dcac7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cfc6e-a903-7eae-9d10-79cc5d4d0c98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019cfc6e-a903-797f-bfa1-8fbcb27dcac7" xlink:to="loc_us-gaap_StatementTable_019cfc6e-a903-7eae-9d10-79cc5d4d0c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019cfc6e-a903-7c30-b8a0-a0b6dc8bc367" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cfc6e-a903-7eae-9d10-79cc5d4d0c98" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019cfc6e-a903-7c30-b8a0-a0b6dc8bc367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7eee-82ca-5e5dd352e51f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019cfc6e-a903-7c30-b8a0-a0b6dc8bc367" xlink:to="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7eee-82ca-5e5dd352e51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019cfc6e-a903-7b6d-b8f3-e2336a897c45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7eee-82ca-5e5dd352e51f" xlink:to="loc_us-gaap_CommonStockMember_019cfc6e-a903-7b6d-b8f3-e2336a897c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019cfc6e-a903-7fd1-94f0-1898e1ceddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7eee-82ca-5e5dd352e51f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019cfc6e-a903-7fd1-94f0-1898e1ceddf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019cfc6e-a903-7f22-87e5-2b2f219c3ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7eee-82ca-5e5dd352e51f" xlink:to="loc_us-gaap_RetainedEarningsMember_019cfc6e-a903-7f22-87e5-2b2f219c3ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cfc6e-a903-753f-a7b6-641bcc9cc1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019cfc6e-a903-7eee-82ca-5e5dd352e51f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cfc6e-a903-753f-a7b6-641bcc9cc1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cfc6e-a903-7b5a-9063-d0a72d0cc9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cfc6e-a903-7eae-9d10-79cc5d4d0c98" xlink:to="loc_us-gaap_StatementLineItems_019cfc6e-a903-7b5a-9063-d0a72d0cc9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cfc6e-a903-7b5a-9063-d0a72d0cc9c3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a903-7754-a078-e0d5753cae39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a903-7754-a078-e0d5753cae39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7e04-870a-5abda82ac354" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_StockholdersEquity_019cfc6e-a903-7e04-870a-5abda82ac354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cfc6e-a903-739f-8b6f-30d1e5472f69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cfc6e-a903-739f-8b6f-30d1e5472f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019cfc6e-a903-7b76-9f41-3e70c0517aec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019cfc6e-a903-7b76-9f41-3e70c0517aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock_019cfc6e-a903-771c-9bf9-9cae168a7f1a" xlink:href="alto-20260331.xsd#alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock_019cfc6e-a903-771c-9bf9-9cae168a7f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_019dd74d-b0a9-7ded-91b8-3890cfa06837" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_019dd74d-b0a9-7ded-91b8-3890cfa06837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_019dd74e-693c-7222-b463-6d4e53963e92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_019dd74e-693c-7222-b463-6d4e53963e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock_019dd74c-96b4-74f7-867d-89d86313655a" xlink:href="alto-20260331.xsd#alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock_019dd74c-96b4-74f7-867d-89d86313655a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue_019db84c-e2b7-7197-a3a6-46b6fbe08f82" xlink:href="alto-20260331.xsd#alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue_019db84c-e2b7-7197-a3a6-46b6fbe08f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_StockIssuedDuringPeriodShareConversionOfTermLoan_019dd74a-a2f1-769f-b806-042eb514305e" xlink:href="alto-20260331.xsd#alto_StockIssuedDuringPeriodShareConversionOfTermLoan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_alto_StockIssuedDuringPeriodShareConversionOfTermLoan_019dd74a-a2f1-769f-b806-042eb514305e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_StockIssuedDuringPeriodValueConversionOfTermLoan_019dd74b-2c11-72a4-9cd4-4737e868cd73" xlink:href="alto-20260331.xsd#alto_StockIssuedDuringPeriodValueConversionOfTermLoan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_alto_StockIssuedDuringPeriodValueConversionOfTermLoan_019dd74b-2c11-72a4-9cd4-4737e868cd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cfc6e-a903-7826-893b-08537ce70e60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cfc6e-a903-7826-893b-08537ce70e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cfc6e-a903-78ac-8e62-2c1c79817af2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cfc6e-a903-78ac-8e62-2c1c79817af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-79a8-a510-129fcaff3b96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-79a8-a510-129fcaff3b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a903-7f25-af8c-83e0531dcbde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a903-7f25-af8c-83e0531dcbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cfc6e-a903-787e-8a04-7dd3b47b1a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cfc6e-a903-7611-b9a2-60ac3fb293a7" xlink:to="loc_us-gaap_StockholdersEquity_019cfc6e-a903-787e-8a04-7dd3b47b1a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" xlink:type="simple" xlink:href="alto-20260331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019cfc6e-a903-70b1-a3f7-bf4e35a06e29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cfc6e-a903-7b8d-afd6-1d39f5b703b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019cfc6e-a903-70b1-a3f7-bf4e35a06e29" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cfc6e-a903-7b8d-afd6-1d39f5b703b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="alto-20260331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_019cfc6e-a903-7e04-8ca1-294cc5944323" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-7a45-9802-77d22b308b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cfc6e-a903-7e04-8ca1-294cc5944323" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-7a45-9802-77d22b308b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-70d6-ab01-25b90413ef2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-7a45-9802-77d22b308b5a" xlink:to="loc_us-gaap_NetIncomeLoss_019cfc6e-a903-70d6-ab01-25b90413ef2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-74f2-b865-a36aaf20b55f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-7a45-9802-77d22b308b5a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-74f2-b865-a36aaf20b55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019cfc6e-a903-77ed-9263-6eda48f37291" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-74f2-b865-a36aaf20b55f" xlink:to="loc_us-gaap_ShareBasedCompensation_019cfc6e-a903-77ed-9263-6eda48f37291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019cfc6e-a903-78cb-82dd-0277de680069" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-74f2-b865-a36aaf20b55f" xlink:to="loc_us-gaap_Depreciation_019cfc6e-a903-78cb-82dd-0277de680069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_InterestExpenseNoncash_019cfc6e-a903-7952-8360-2fc907ba6870" xlink:href="alto-20260331.xsd#alto_InterestExpenseNoncash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-74f2-b865-a36aaf20b55f" xlink:to="loc_alto_InterestExpenseNoncash_019cfc6e-a903-7952-8360-2fc907ba6870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cfc6e-a903-7e87-b459-747fbb926f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-74f2-b865-a36aaf20b55f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cfc6e-a903-7e87-b459-747fbb926f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019cfc6e-a903-7975-94ee-44cda5677b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-74f2-b865-a36aaf20b55f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019cfc6e-a903-7975-94ee-44cda5677b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_GainLossInOtherOperatingActivitiesNet_019cfc6e-a903-75c6-8a33-b4995b5cd2a3" xlink:href="alto-20260331.xsd#alto_GainLossInOtherOperatingActivitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-74f2-b865-a36aaf20b55f" xlink:to="loc_alto_GainLossInOtherOperatingActivitiesNet_019cfc6e-a903-75c6-8a33-b4995b5cd2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a903-78d9-b6de-927156e49b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-74f2-b865-a36aaf20b55f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a903-78d9-b6de-927156e49b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cfc6e-a903-7711-9284-94f22c771b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-7a45-9802-77d22b308b5a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cfc6e-a903-7711-9284-94f22c771b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cfc6e-a903-7917-a1dd-e72af4f60f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cfc6e-a903-7711-9284-94f22c771b06" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cfc6e-a903-7917-a1dd-e72af4f60f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cfc6e-a903-734f-bc3e-1261a6280acb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cfc6e-a903-7711-9284-94f22c771b06" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cfc6e-a903-734f-bc3e-1261a6280acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019cfc6e-a903-7eef-a508-f2d1e905cb71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cfc6e-a903-7711-9284-94f22c771b06" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019cfc6e-a903-7eef-a508-f2d1e905cb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-712d-8462-190e480831ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cfc6e-a903-7a45-9802-77d22b308b5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cfc6e-a903-712d-8462-190e480831ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cfc6e-a903-7e76-84de-3bf92cf1fa04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cfc6e-a903-7e04-8ca1-294cc5944323" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cfc6e-a903-7e76-84de-3bf92cf1fa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cfc6e-a903-7239-b6c6-533e04dc3af7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cfc6e-a903-7e76-84de-3bf92cf1fa04" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cfc6e-a903-7239-b6c6-533e04dc3af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cfc6e-a903-739d-b9fe-6cdc34a0b2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cfc6e-a903-7e76-84de-3bf92cf1fa04" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cfc6e-a903-739d-b9fe-6cdc34a0b2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cfc6e-a903-762d-8eed-e8bb7a528721" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cfc6e-a903-7e04-8ca1-294cc5944323" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cfc6e-a903-762d-8eed-e8bb7a528721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_019db851-6704-752e-909d-09c6ac708af9" xlink:href="alto-20260331.xsd#alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cfc6e-a903-762d-8eed-e8bb7a528721" xlink:to="loc_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_019db851-6704-752e-909d-09c6ac708af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_019db851-6704-74fd-b0bd-28a4ccce404e" xlink:href="alto-20260331.xsd#alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cfc6e-a903-762d-8eed-e8bb7a528721" xlink:to="loc_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement_019db851-6704-74fd-b0bd-28a4ccce404e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019dd755-67d9-7df2-936f-95df3aba9716" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cfc6e-a903-762d-8eed-e8bb7a528721" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019dd755-67d9-7df2-936f-95df3aba9716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_PaymentsOnIssuanceCostFromRegistrationStatement_019cfc6e-a903-7c15-9106-9cb2cec83ca0" xlink:href="alto-20260331.xsd#alto_PaymentsOnIssuanceCostFromRegistrationStatement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cfc6e-a903-762d-8eed-e8bb7a528721" xlink:to="loc_alto_PaymentsOnIssuanceCostFromRegistrationStatement_019cfc6e-a903-7c15-9106-9cb2cec83ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_019cfc6e-a903-723e-a206-0f017a2726be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cfc6e-a903-762d-8eed-e8bb7a528721" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_019cfc6e-a903-723e-a206-0f017a2726be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_019cfc6e-a903-76b9-8732-78f48925f1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cfc6e-a903-762d-8eed-e8bb7a528721" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_019cfc6e-a903-76b9-8732-78f48925f1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_019cfc6e-a903-79d2-98ed-b3f50d79b3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cfc6e-a903-762d-8eed-e8bb7a528721" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_019cfc6e-a903-79d2-98ed-b3f50d79b3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019cfc6e-a903-7b6f-9346-4af959561a17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cfc6e-a903-762d-8eed-e8bb7a528721" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019cfc6e-a903-7b6f-9346-4af959561a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-7bd0-87ab-cc96b03d17d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cfc6e-a903-762d-8eed-e8bb7a528721" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cfc6e-a903-7bd0-87ab-cc96b03d17d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cfc6e-a903-7c3b-9efc-f03bccb4073d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cfc6e-a903-7e04-8ca1-294cc5944323" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cfc6e-a903-7c3b-9efc-f03bccb4073d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cfc6e-a903-75db-ba94-df6a84122f25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cfc6e-a903-7e04-8ca1-294cc5944323" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cfc6e-a903-75db-ba94-df6a84122f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cfc6e-a903-7d26-bcf4-7fb87d94fb23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cfc6e-a903-7e04-8ca1-294cc5944323" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cfc6e-a903-7d26-bcf4-7fb87d94fb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cfc6e-a903-79e0-97f0-099e1d3ab9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cfc6e-a903-7e04-8ca1-294cc5944323" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cfc6e-a903-79e0-97f0-099e1d3ab9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cfc6e-a903-7755-a88e-7584f4b23ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cfc6e-a903-7e04-8ca1-294cc5944323" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cfc6e-a903-7755-a88e-7584f4b23ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_019dd756-e476-70e1-9a3c-6fa8d33e5156" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cfc6e-a903-7755-a88e-7584f4b23ba7" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_019dd756-e476-70e1-9a3c-6fa8d33e5156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid_019dd758-dc15-7023-b747-3949ff96002e" xlink:href="alto-20260331.xsd#alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cfc6e-a903-7755-a88e-7584f4b23ba7" xlink:to="loc_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid_019dd758-dc15-7023-b747-3949ff96002e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DeferredOfferingAndShareIssueCostsNotYetPaid_019db853-fa2a-788a-b911-580ee2b3098b" xlink:href="alto-20260331.xsd#alto_DeferredOfferingAndShareIssueCostsNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cfc6e-a903-7755-a88e-7584f4b23ba7" xlink:to="loc_alto_DeferredOfferingAndShareIssueCostsNotYetPaid_019db853-fa2a-788a-b911-580ee2b3098b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_019cfc6e-a903-7bb8-b019-4b2f59227da5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cfc6e-a903-7755-a88e-7584f4b23ba7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_019cfc6e-a903-7bb8-b019-4b2f59227da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidAbstract_019cfc6e-a903-7d81-aa39-eb31de1dcd72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cfc6e-a903-7755-a88e-7584f4b23ba7" xlink:to="loc_us-gaap_InterestPaidAbstract_019cfc6e-a903-7d81-aa39-eb31de1dcd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_019cfc6e-a903-7a7c-8746-4393b4b59340" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestPaidAbstract_019cfc6e-a903-7d81-aa39-eb31de1dcd72" xlink:to="loc_us-gaap_InterestPaidNet_019cfc6e-a903-7a7c-8746-4393b4b59340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="alto-20260331.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7cb4-a3a2-c1ccf0ca2b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_019cfc6e-a903-7713-bdc2-392801781bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7cb4-a3a2-c1ccf0ca2b8e" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_019cfc6e-a903-7713-bdc2-392801781bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentation" xlink:type="simple" xlink:href="alto-20260331.xsd#SummaryofSignificantAccountingPoliciesandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019cfc6e-a903-78af-8ebe-c6045fd3c5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019cfc6e-a903-7bc1-969f-716ecb2f846c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019cfc6e-a903-78af-8ebe-c6045fd3c5dd" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019cfc6e-a903-7bc1-969f-716ecb2f846c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="alto-20260331.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-71c1-83c5-bdb3e1d4a805" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_019cfc6e-a903-77d4-a12b-6627029f3a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-71c1-83c5-bdb3e1d4a805" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_019cfc6e-a903-77d4-a12b-6627029f3a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/Debt" xlink:type="simple" xlink:href="alto-20260331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a903-71d8-a230-256f34f11b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_019cfc6e-a903-7e1f-9a05-4cddbe05e072" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a903-71d8-a230-256f34f11b6a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_019cfc6e-a903-7e1f-9a05-4cddbe05e072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/FairValue" xlink:type="simple" xlink:href="alto-20260331.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019cfc6e-a9b8-7de8-a965-7b9eee0cceb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_019cfc6e-a9b8-7b96-8a8c-83f67ad2019f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019cfc6e-a9b8-7de8-a965-7b9eee0cceb0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_019cfc6e-a9b8-7b96-8a8c-83f67ad2019f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/AssetPurchaseandLicenseAgreements" xlink:type="simple" xlink:href="alto-20260331.xsd#AssetPurchaseandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/AssetPurchaseandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_019cfc6e-a9b8-7662-b5fd-0ddb0299a199" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_019cfc6e-a9b8-7ed0-a9d4-3139863d0e25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_019cfc6e-a9b8-7662-b5fd-0ddb0299a199" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_019cfc6e-a9b8-7ed0-a9d4-3139863d0e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockBasedPlans" xlink:type="simple" xlink:href="alto-20260331.xsd#StockBasedPlans"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/StockBasedPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-79be-ae88-a6a7050e7391" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019cfc6e-a9b8-7f15-8819-4c58b5c6c5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-79be-ae88-a6a7050e7391" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019cfc6e-a9b8-7f15-8819-4c58b5c6c5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/LossPerShare" xlink:type="simple" xlink:href="alto-20260331.xsd#LossPerShare"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/LossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019cfc6e-a9b8-7821-9c63-c8f414b7c9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_019cfc6e-a9b8-7dd6-a1ff-65fddc8ae02f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019cfc6e-a9b8-7821-9c63-c8f414b7c9a1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_019cfc6e-a9b8-7dd6-a1ff-65fddc8ae02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/IncomeTaxes" xlink:type="simple" xlink:href="alto-20260331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019cfc6e-a9b8-7fe5-b470-e0ea26260e90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_019cfc6e-a9b8-71d5-a398-0739602e87ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019cfc6e-a9b8-7fe5-b470-e0ea26260e90" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_019cfc6e-a9b8-71d5-a398-0739602e87ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockholdersEquity" xlink:type="simple" xlink:href="alto-20260331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019cfc6e-a9b8-7212-8f5f-20ff300b84e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019cfc6e-a9b8-739b-a7e8-772ac3cca030" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019cfc6e-a9b8-7212-8f5f-20ff300b84e9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019cfc6e-a9b8-739b-a7e8-772ac3cca030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="alto-20260331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019cfc6e-a9b8-721d-9407-2b34584c8b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019cfc6e-a9b8-79fa-af95-c11082233a92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019cfc6e-a9b8-721d-9407-2b34584c8b2b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019cfc6e-a9b8-79fa-af95-c11082233a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/Segments" xlink:type="simple" xlink:href="alto-20260331.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019cfc6e-a9b8-78bd-a44f-5a902c6797fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_019cfc6e-a9b8-708d-ba6b-ab1d9c07dd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019cfc6e-a9b8-78bd-a44f-5a902c6797fc" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_019cfc6e-a9b8-708d-ba6b-ab1d9c07dd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/SubsequentEvents" xlink:type="simple" xlink:href="alto-20260331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_019cfc6e-a9b8-7b6e-ac5c-c444e511cbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_019cfc6e-a9b8-740d-8d67-03e8f215ca4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_019cfc6e-a9b8-7b6e-ac5c-c444e511cbd9" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_019cfc6e-a9b8-740d-8d67-03e8f215ca4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentationPolicies" xlink:type="simple" xlink:href="alto-20260331.xsd#SummaryofSignificantAccountingPoliciesandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019cfc6e-a903-7220-9a06-debbc84dd90c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019cfc6e-a903-7869-89f9-fc09f49d6e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019cfc6e-a903-7220-9a06-debbc84dd90c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019cfc6e-a903-7869-89f9-fc09f49d6e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_019cfc6e-a903-7581-a455-1bed00f22861" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019cfc6e-a903-7220-9a06-debbc84dd90c" xlink:to="loc_us-gaap_UseOfEstimates_019cfc6e-a903-7581-a455-1bed00f22861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019cfc6e-a903-7fe7-b752-e8467e457758" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019cfc6e-a903-7220-9a06-debbc84dd90c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019cfc6e-a903-7fe7-b752-e8467e457758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="alto-20260331.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-75ec-8d83-e2f24a571bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_019cfc6e-a903-7f70-a775-999b2cdcc656" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-75ec-8d83-e2f24a571bd4" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_019cfc6e-a903-7f70-a775-999b2cdcc656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_019cfc6e-a903-7aa1-9692-0fb0eb8b77bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-75ec-8d83-e2f24a571bd4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_019cfc6e-a903-7aa1-9692-0fb0eb8b77bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019cfc6e-a903-7c11-b57f-cba36ce44f90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-75ec-8d83-e2f24a571bd4" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019cfc6e-a903-7c11-b57f-cba36ce44f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtTables" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a903-7fe5-b16b-ce1d5c613447" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_019cfc6e-a903-71ee-9764-45dd628f7422" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a903-7fe5-b16b-ce1d5c613447" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_019cfc6e-a903-71ee-9764-45dd628f7422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_019cfc6e-a903-72f2-bb56-14dea428e058" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a903-7fe5-b16b-ce1d5c613447" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_019cfc6e-a903-72f2-bb56-14dea428e058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/FairValueTables" xlink:type="simple" xlink:href="alto-20260331.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019cfc6e-a9b8-74ed-9b0e-d02053882ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019cfc6e-a9b8-7661-aebd-ee86071aeec2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019cfc6e-a9b8-74ed-9b0e-d02053882ec7" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019cfc6e-a9b8-7661-aebd-ee86071aeec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockBasedPlansTables" xlink:type="simple" xlink:href="alto-20260331.xsd#StockBasedPlansTables"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/StockBasedPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-74d7-a898-36022bddcd06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019cfc6e-a9b8-7dec-b5ca-3e4536c614db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-74d7-a898-36022bddcd06" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019cfc6e-a9b8-7dec-b5ca-3e4536c614db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_019cfc6e-a9b8-7a90-808c-70e771ef677d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-74d7-a898-36022bddcd06" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_019cfc6e-a9b8-7a90-808c-70e771ef677d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_019cfc6e-a9b8-7470-a613-c36dd9840e80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-74d7-a898-36022bddcd06" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_019cfc6e-a9b8-7470-a613-c36dd9840e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_019cfc6e-a9b8-7902-bd69-39755968947f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-74d7-a898-36022bddcd06" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_019cfc6e-a9b8-7902-bd69-39755968947f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/LossPerShareTables" xlink:type="simple" xlink:href="alto-20260331.xsd#LossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/LossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019cfc6e-a9b8-73c6-a39a-b8ecaf72367b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019cfc6e-a9b8-7d88-a992-9a9a8654fe4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019cfc6e-a9b8-73c6-a39a-b8ecaf72367b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019cfc6e-a9b8-7d88-a992-9a9a8654fe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="alto-20260331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019cfc6e-a9b8-7ac0-bbf3-e0091cf01b98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ScheduleOfStockReservedForIssuanceTableTextBlock_019cfc6e-a9b8-7de4-8042-04109af74711" xlink:href="alto-20260331.xsd#alto_ScheduleOfStockReservedForIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019cfc6e-a9b8-7ac0-bbf3-e0091cf01b98" xlink:to="loc_alto_ScheduleOfStockReservedForIssuanceTableTextBlock_019cfc6e-a9b8-7de4-8042-04109af74711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/SegmentsTables" xlink:type="simple" xlink:href="alto-20260331.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019cfc6e-a9b8-7890-bcf0-3ce5fee3c722" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019cfc6e-a9b8-7f6b-ba6b-e40a8e6b3d60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019cfc6e-a9b8-7890-bcf0-3ce5fee3c722" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019cfc6e-a9b8-7f6b-ba6b-e40a8e6b3d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DescriptionoftheBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-76ee-ba77-bcf654d69461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_019cfc6e-a903-76cf-96e4-f4403c0b4b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-76ee-ba77-bcf654d69461" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_019cfc6e-a903-76cf-96e4-f4403c0b4b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019cfc6e-a903-7905-9b2a-21940194f96f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_019cfc6e-a903-76cf-96e4-f4403c0b4b5e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019cfc6e-a903-7905-9b2a-21940194f96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019cfc6e-a903-7905-9b2a-21940194f96f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_019cfc6e-a903-755a-818a-466a92629ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:to="loc_us-gaap_IPOMember_019cfc6e-a903-755a-818a-466a92629ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_019cfc6e-a903-73da-abd9-58604fab86b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:to="loc_us-gaap_OverAllotmentOptionMember_019cfc6e-a903-73da-abd9-58604fab86b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_019cfc6e-a903-7fdf-8925-90dc5d2886cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:to="loc_us-gaap_PrivatePlacementMember_019cfc6e-a903-7fdf-8925-90dc5d2886cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_PreFundedWarrantsMember_019cfc6e-a903-71f0-800f-773fcab37f9f" xlink:href="alto-20260331.xsd#alto_PreFundedWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:to="loc_alto_PreFundedWarrantsMember_019cfc6e-a903-71f0-800f-773fcab37f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2HealthventuresLLCMember_019db87a-f783-7a0b-a215-49e6c294a345" xlink:href="alto-20260331.xsd#alto_K2HealthventuresLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cfc6e-a903-7c60-b1db-0572bff54c44" xlink:to="loc_alto_K2HealthventuresLLCMember_019db87a-f783-7a0b-a215-49e6c294a345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_019cfc6e-a903-76cf-96e4-f4403c0b4b5e" xlink:to="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NumberOfWhollyOwnedSubsidiaries_019cfc6e-a903-7b0e-9d3a-46235df0c0b0" xlink:href="alto-20260331.xsd#alto_NumberOfWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_alto_NumberOfWhollyOwnedSubsidiaries_019cfc6e-a903-7b0e-9d3a-46235df0c0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NumberOfClinicalStageAssets_019cfc6e-a903-7726-bfae-60a6e77e7f1f" xlink:href="alto-20260331.xsd#alto_NumberOfClinicalStageAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_alto_NumberOfClinicalStageAssets_019cfc6e-a903-7726-bfae-60a6e77e7f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cfc6e-a903-7b94-a5fc-b20ccf5a0712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cfc6e-a903-7b94-a5fc-b20ccf5a0712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cfc6e-a903-7d8e-971c-5d1569cda2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cfc6e-a903-7d8e-971c-5d1569cda2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019cfc6e-a903-72c3-9225-8770004bcbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019cfc6e-a903-72c3-9225-8770004bcbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cfc6e-a903-7310-891f-eac85c6ab68b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cfc6e-a903-7310-891f-eac85c6ab68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_TemporaryEquitySharesConversionOfConvertibleSecurities_019cfc6e-a903-7ede-941d-25ef58514af3" xlink:href="alto-20260331.xsd#alto_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_alto_TemporaryEquitySharesConversionOfConvertibleSecurities_019cfc6e-a903-7ede-941d-25ef58514af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a903-7a8e-94b4-f83794aafc57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a903-7a8e-94b4-f83794aafc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_SaleOfStockConversionOfOutstandingLoan_019db87a-f783-7b98-8733-1a8047daded4" xlink:href="alto-20260331.xsd#alto_SaleOfStockConversionOfOutstandingLoan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_alto_SaleOfStockConversionOfOutstandingLoan_019db87a-f783-7b98-8733-1a8047daded4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_019db87a-f783-77a5-b07c-03a51fbf9e49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_019cfc6e-a903-7044-b472-64dba675f551" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_019db87a-f783-77a5-b07c-03a51fbf9e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7635-a2e5-3271139f2590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_019cfc6e-a903-71d4-9ebd-f996d10f0850" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7635-a2e5-3271139f2590" xlink:to="loc_us-gaap_PrepaidInsurance_019cfc6e-a903-71d4-9ebd-f996d10f0850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_019cfc6e-a903-7e61-97b7-832377d510b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7635-a2e5-3271139f2590" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_019cfc6e-a903-7e61-97b7-832377d510b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cfc6e-a903-72ff-9a73-a0c39e8f38cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7635-a2e5-3271139f2590" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cfc6e-a903-72ff-9a73-a0c39e8f38cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-77a1-9a93-dee61cbe0aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019cfc6e-a903-7edc-8260-c65a1c11d372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-77a1-9a93-dee61cbe0aa4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019cfc6e-a903-7edc-8260-c65a1c11d372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019cfc6e-a903-7587-a16d-c9262e8d646d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019cfc6e-a903-7edc-8260-c65a1c11d372" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019cfc6e-a903-7587-a16d-c9262e8d646d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-75e2-93a1-585864097d89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019cfc6e-a903-7587-a16d-c9262e8d646d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-75e2-93a1-585864097d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_LaboratoryEquipmentMember_019cfc6e-a903-7fa5-8d86-c3c280dd708d" xlink:href="alto-20260331.xsd#alto_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-75e2-93a1-585864097d89" xlink:to="loc_alto_LaboratoryEquipmentMember_019cfc6e-a903-7fa5-8d86-c3c280dd708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_019cfc6e-a903-7930-9ff8-a2c7906482e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-75e2-93a1-585864097d89" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_019cfc6e-a903-7930-9ff8-a2c7906482e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ComputerSoftwareAndEquipmentMember_019cfc6e-a903-7e0c-86ff-9233863ae1a5" xlink:href="alto-20260331.xsd#alto_ComputerSoftwareAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-75e2-93a1-585864097d89" xlink:to="loc_alto_ComputerSoftwareAndEquipmentMember_019cfc6e-a903-7e0c-86ff-9233863ae1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_019cfc6e-a903-764b-af50-fabf418355ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019cfc6e-a903-75e2-93a1-585864097d89" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_019cfc6e-a903-764b-af50-fabf418355ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019cfc6e-a903-7111-94d2-76b7509259bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019cfc6e-a903-7edc-8260-c65a1c11d372" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019cfc6e-a903-7111-94d2-76b7509259bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019cfc6e-a903-700b-a2e9-ad8fc1d8fe8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019cfc6e-a903-7111-94d2-76b7509259bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019cfc6e-a903-700b-a2e9-ad8fc1d8fe8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019cfc6e-a903-7b91-b40b-0b6ef48db6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019cfc6e-a903-7111-94d2-76b7509259bf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019cfc6e-a903-7b91-b40b-0b6ef48db6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a903-7c00-8f7d-ad924dbf1783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019cfc6e-a903-7111-94d2-76b7509259bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019cfc6e-a903-7c00-8f7d-ad924dbf1783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#BalanceSheetComponentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-73a2-94f3-9a9c3db7c15d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019cfc6e-a903-782c-a48c-80b5a15131b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-73a2-94f3-9a9c3db7c15d" xlink:to="loc_us-gaap_Depreciation_019cfc6e-a903-782c-a48c-80b5a15131b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7c97-a930-e9cda1718867" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cfc6e-a903-7103-8d6a-ba149bf5caa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7c97-a930-e9cda1718867" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cfc6e-a903-7103-8d6a-ba149bf5caa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AccruedResearchExpense_019cfc6e-a903-72b2-8fab-898d9120bfe4" xlink:href="alto-20260331.xsd#alto_AccruedResearchExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7c97-a930-e9cda1718867" xlink:to="loc_alto_AccruedResearchExpense_019cfc6e-a903-72b2-8fab-898d9120bfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_019cfc6e-a903-7bf6-be2c-f6e62a628583" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7c97-a930-e9cda1718867" xlink:to="loc_us-gaap_InterestPayableCurrent_019cfc6e-a903-7bf6-be2c-f6e62a628583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019cfc6e-a903-78e1-a1ff-2a00a1d823fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7c97-a930-e9cda1718867" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019cfc6e-a903-78e1-a1ff-2a00a1d823fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cfc6e-a903-7f0e-83e8-d0fe28aae970" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7c97-a930-e9cda1718867" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cfc6e-a903-7f0e-83e8-d0fe28aae970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-a903-783f-8c61-9f23607b7e20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cfc6e-a903-7c97-a930-e9cda1718867" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019cfc6e-a903-783f-8c61-9f23607b7e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a903-70b6-9f19-228056376848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a903-70b6-9f19-228056376848" xlink:to="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-716e-a98c-6cd9ed2ce612" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-716e-a98c-6cd9ed2ce612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7609-a2e8-bf5c9f55ca04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-716e-a98c-6cd9ed2ce612" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7609-a2e8-bf5c9f55ca04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_LoanAndSecurityAgreementMember_019cfc6e-a903-7fdf-a068-25f46f9bb9c1" xlink:href="alto-20260331.xsd#alto_LoanAndSecurityAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7609-a2e8-bf5c9f55ca04" xlink:to="loc_alto_LoanAndSecurityAgreementMember_019cfc6e-a903-7fdf-a068-25f46f9bb9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AmendedLoanAgreementMember_019cfc6e-a903-74da-ba43-a2f2dac99eee" xlink:href="alto-20260331.xsd#alto_AmendedLoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7609-a2e8-bf5c9f55ca04" xlink:to="loc_alto_AmendedLoanAgreementMember_019cfc6e-a903-74da-ba43-a2f2dac99eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-791b-8926-c1426189d2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-791b-8926-c1426189d2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7f18-b4e0-0c9212108372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-791b-8926-c1426189d2e4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7f18-b4e0-0c9212108372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019cfc6e-a903-7ac4-b1ee-c4f92303c396" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7f18-b4e0-0c9212108372" xlink:to="loc_us-gaap_SecuredDebtMember_019cfc6e-a903-7ac4-b1ee-c4f92303c396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-7d03-9246-ab8a8a1f4b65" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-7d03-9246-ab8a8a1f4b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7306-b717-11a9b79d2390" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-7d03-9246-ab8a8a1f4b65" xlink:to="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7306-b717-11a9b79d2390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheFourMember_019cfc6e-a903-76ae-878c-9c54e6b5e85b" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7306-b717-11a9b79d2390" xlink:to="loc_alto_DebtInstrumentTrancheFourMember_019cfc6e-a903-76ae-878c-9c54e6b5e85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheOneMember_019cfc6e-a903-7853-a04e-96af0e461d2f" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7306-b717-11a9b79d2390" xlink:to="loc_alto_DebtInstrumentTrancheOneMember_019cfc6e-a903-7853-a04e-96af0e461d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheTwoMember_019cfc6e-a903-7d0f-a112-4ea7c3368a9d" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7306-b717-11a9b79d2390" xlink:to="loc_alto_DebtInstrumentTrancheTwoMember_019cfc6e-a903-7d0f-a112-4ea7c3368a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheThreeMember_019cfc6e-a903-7d72-aad3-99618bb48363" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-7306-b717-11a9b79d2390" xlink:to="loc_alto_DebtInstrumentTrancheThreeMember_019cfc6e-a903-7d72-aad3-99618bb48363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a903-7d92-8a0d-5e2ab9e59689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a903-7d92-8a0d-5e2ab9e59689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a903-72ff-a2da-84983cc8fad6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a903-7d92-8a0d-5e2ab9e59689" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a903-72ff-a2da-84983cc8fad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2WarrantMember_019cfc6e-a903-7ffb-a6a6-ac5745219a4a" xlink:href="alto-20260331.xsd#alto_K2WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a903-72ff-a2da-84983cc8fad6" xlink:to="loc_alto_K2WarrantMember_019cfc6e-a903-7ffb-a6a6-ac5745219a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NewK2WarrantMember_019cfc6e-a903-75f8-8ac7-a7790fad65d4" xlink:href="alto-20260331.xsd#alto_NewK2WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a903-72ff-a2da-84983cc8fad6" xlink:to="loc_alto_NewK2WarrantMember_019cfc6e-a903-75f8-8ac7-a7790fad65d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a903-76e3-8977-467b9741e04e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a903-76e3-8977-467b9741e04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019cfc6e-a903-7222-98c2-41d69591f1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a903-76e3-8977-467b9741e04e" xlink:to="loc_us-gaap_ClassOfStockDomain_019cfc6e-a903-7222-98c2-41d69591f1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019cfc6e-a903-7efe-b229-e8b0fe385b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019cfc6e-a903-7222-98c2-41d69591f1ee" xlink:to="loc_us-gaap_CommonStockMember_019cfc6e-a903-7efe-b229-e8b0fe385b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-76d7-9969-3b878e22c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-76d7-9969-3b878e22c37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7eec-a95c-ab61b1056585" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-76d7-9969-3b878e22c37b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7eec-a95c-ab61b1056585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_019cfc6e-a903-7841-8300-0e193a014b85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7eec-a95c-ab61b1056585" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_019cfc6e-a903-7841-8300-0e193a014b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_019cfc6e-a903-7b4e-8f30-d5523a6ed8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7eec-a95c-ab61b1056585" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_019cfc6e-a903-7b4e-8f30-d5523a6ed8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_019cfc6e-a903-7488-b078-2d22e676c89e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7eec-a95c-ab61b1056585" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_019cfc6e-a903-7488-b078-2d22e676c89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019cfc6e-a903-72a6-9a9c-77580065481e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_srt_RangeAxis_019cfc6e-a903-72a6-9a9c-77580065481e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cfc6e-a903-7acc-b8f2-a2b694bdce2f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019cfc6e-a903-72a6-9a9c-77580065481e" xlink:to="loc_srt_RangeMember_019cfc6e-a903-7acc-b8f2-a2b694bdce2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019cfc6e-a903-73f9-90f1-be772dbdeb65" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019cfc6e-a903-7acc-b8f2-a2b694bdce2f" xlink:to="loc_srt_MaximumMember_019cfc6e-a903-73f9-90f1-be772dbdeb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019db923-fb4a-75e5-af2b-cdd4b0c3f96d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019db923-fb4a-75e5-af2b-cdd4b0c3f96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db923-fb4a-76f7-ba6d-e2e58589b8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019db923-fb4a-75e5-af2b-cdd4b0c3f96d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db923-fb4a-76f7-ba6d-e2e58589b8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2HealthventuresLLCMember_019db923-fb4a-75c2-8b14-bc44ccdd85f0" xlink:href="alto-20260331.xsd#alto_K2HealthventuresLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db923-fb4a-76f7-ba6d-e2e58589b8e4" xlink:to="loc_alto_K2HealthventuresLLCMember_019db923-fb4a-75c2-8b14-bc44ccdd85f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-7413-b28a-27f5f53dd3ae" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019cfc6e-a903-79c7-b0b0-dbec7b12baa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019cfc6e-a903-79c7-b0b0-dbec7b12baa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_019cfc6e-a903-7a62-a74d-c236d80feb91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_019cfc6e-a903-7a62-a74d-c236d80feb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019cfc6e-a903-7350-8df5-e4609c3900a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019cfc6e-a903-7350-8df5-e4609c3900a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_019cfc6e-a903-71f8-9842-02968eef2411" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_019cfc6e-a903-71f8-9842-02968eef2411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019cfc6e-a903-7207-9632-c73fc4e963ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019cfc6e-a903-7207-9632-c73fc4e963ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentInterestRateFloor_019cfc6e-a903-72b9-8ec6-a4faa372d4b3" xlink:href="alto-20260331.xsd#alto_DebtInstrumentInterestRateFloor"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentInterestRateFloor_019cfc6e-a903-72b9-8ec6-a4faa372d4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentFixedRatePaidInKind_019cfc6e-a903-7051-a428-9f82f3fa2f2e" xlink:href="alto-20260331.xsd#alto_DebtInstrumentFixedRatePaidInKind"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentFixedRatePaidInKind_019cfc6e-a903-7051-a428-9f82f3fa2f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed_019cfc6e-a903-7b78-95fe-63da2940ed34" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed_019cfc6e-a903-7b78-95fe-63da2940ed34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019cfc6e-a903-772a-8d48-19d58ca9cac5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019cfc6e-a903-772a-8d48-19d58ca9cac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a903-73ce-b0ed-0b27228d813e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019cfc6e-a903-73ce-b0ed-0b27228d813e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentExitFeePercentOfLoansFunded_019cfc6e-a903-746b-a1a7-8f944d245625" xlink:href="alto-20260331.xsd#alto_DebtInstrumentExitFeePercentOfLoansFunded"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentExitFeePercentOfLoansFunded_019cfc6e-a903-746b-a1a7-8f944d245625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_019cfc6e-a903-7fb2-a58c-3a24270e80e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_019cfc6e-a903-7fb2-a58c-3a24270e80e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentExitFee_019cfc6e-a903-7854-bbbe-c563128510fb" xlink:href="alto-20260331.xsd#alto_DebtInstrumentExitFee"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentExitFee_019cfc6e-a903-7854-bbbe-c563128510fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentFundingFeeMultiplier_019cfc6e-a903-701a-9845-6eb96f263adc" xlink:href="alto-20260331.xsd#alto_DebtInstrumentFundingFeeMultiplier"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentFundingFeeMultiplier_019cfc6e-a903-701a-9845-6eb96f263adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a903-71d4-b87b-b19afbbc1198" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a903-71d4-b87b-b19afbbc1198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a903-7bd4-a736-77a305461ed6" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a903-7bd4-a736-77a305461ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a903-7a63-9924-64d15ea4fb28" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal_019cfc6e-a903-7a63-9924-64d15ea4fb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum_019cfc6e-a903-7ab0-9d76-b3263055e663" xlink:href="alto-20260331.xsd#alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum_019cfc6e-a903-7ab0-9d76-b3263055e663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount_019cfc6e-a903-7f18-9962-5619c6eb9cf3" xlink:href="alto-20260331.xsd#alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount_019cfc6e-a903-7f18-9962-5619c6eb9cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault_019cfc6e-a903-78c2-aa08-d8881fd8238a" xlink:href="alto-20260331.xsd#alto_DebtInstrumentInterestRateIncreaseInEventOfDefault"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault_019cfc6e-a903-78c2-aa08-d8881fd8238a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019cfc6e-a903-7fb2-8e6c-16ec10f5188b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019cfc6e-a903-7fb2-8e6c-16ec10f5188b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_019cfc6e-a903-71a5-b3d4-cb0570d46bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_019cfc6e-a903-71a5-b3d4-cb0570d46bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier_019cfc6e-a903-7ade-87d1-6512a97e03a4" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier_019cfc6e-a903-7ade-87d1-6512a97e03a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a903-7921-a367-2624ef9019b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a903-7921-a367-2624ef9019b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_019cfc6e-a903-7d17-9091-02b774eb3a05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_019cfc6e-a903-7d17-9091-02b774eb3a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_019cfc6e-a903-72a1-9cd5-be845b12f419" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_019cfc6e-a903-72a1-9cd5-be845b12f419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_019cfc6e-a903-7b30-8315-334c16033642" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_019cfc6e-a903-7b30-8315-334c16033642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender_019cfc6e-a903-72d4-a197-bc1b9b814260" xlink:href="alto-20260331.xsd#alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender_019cfc6e-a903-72d4-a197-bc1b9b814260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender_019cfc6e-a903-72ba-8090-9cc019c8cb13" xlink:href="alto-20260331.xsd#alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender_019cfc6e-a903-72ba-8090-9cc019c8cb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_SaleOfStockConversionOfOutstandingLoan_019db923-fb4a-74ec-835f-deaefdac2fac" xlink:href="alto-20260331.xsd#alto_SaleOfStockConversionOfOutstandingLoan"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_alto_SaleOfStockConversionOfOutstandingLoan_019db923-fb4a-74ec-835f-deaefdac2fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019db923-fb4a-75de-9878-6c29ce6ff4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019db923-fb4a-75de-9878-6c29ce6ff4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_019db923-fb4a-7330-8f63-a7c9afdde5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_019db923-fb4a-7330-8f63-a7c9afdde5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_019cfc6e-a903-74bd-be8a-96320e327063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_019cfc6e-a903-74bd-be8a-96320e327063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_019cfc6e-a903-7469-97f8-67f3d0d36180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-74ea-9222-39ad629b7d83" xlink:to="loc_us-gaap_InterestExpenseDebt_019cfc6e-a903-7469-97f8-67f3d0d36180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a903-738a-ab7c-2222e7391b12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-75dd-9d5c-3bbdade05684" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a903-738a-ab7c-2222e7391b12" xlink:to="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-75dd-9d5c-3bbdade05684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7a65-a485-b322ea05ac37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-75dd-9d5c-3bbdade05684" xlink:to="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7a65-a485-b322ea05ac37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-79b3-8d70-988c0d127984" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7a65-a485-b322ea05ac37" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-79b3-8d70-988c0d127984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AmendedLoanAgreementMember_019cfc6e-a903-7545-9614-51cd3f0ee8cf" xlink:href="alto-20260331.xsd#alto_AmendedLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-79b3-8d70-988c0d127984" xlink:to="loc_alto_AmendedLoanAgreementMember_019cfc6e-a903-7545-9614-51cd3f0ee8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-75dd-9d5c-3bbdade05684" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-a903-726a-b7c6-43410ede2de7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-a903-726a-b7c6-43410ede2de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a903-7b86-9160-328a60ea1ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a903-7b86-9160-328a60ea1ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a903-7276-848a-703bbae06727" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a903-7276-848a-703bbae06727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a903-7271-9560-cc2248b9c96d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a903-7271-9560-cc2248b9c96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019cfc6e-a903-75a9-9689-f5a1902c8c16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019cfc6e-a903-75a9-9689-f5a1902c8c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentExitFee_019cfc6e-a903-7f3e-8476-a0bd2306c23d" xlink:href="alto-20260331.xsd#alto_DebtInstrumentExitFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_alto_DebtInstrumentExitFee_019cfc6e-a903-7f3e-8476-a0bd2306c23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentDeferredInterest_019cfc6e-a903-789b-b69f-242b6e6a932b" xlink:href="alto-20260331.xsd#alto_DebtInstrumentDeferredInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_alto_DebtInstrumentDeferredInterest_019cfc6e-a903-789b-b69f-242b6e6a932b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_LongTermDebtPrincipalPaymentsAndExitFee_019cfc6e-a903-7546-97dc-8579106e226b" xlink:href="alto-20260331.xsd#alto_LongTermDebtPrincipalPaymentsAndExitFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_alto_LongTermDebtPrincipalPaymentsAndExitFee_019cfc6e-a903-7546-97dc-8579106e226b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentUnamortizedExitFee_019cfc6e-a903-7fcb-b9e3-f9213c6c5246" xlink:href="alto-20260331.xsd#alto_DebtInstrumentUnamortizedExitFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_alto_DebtInstrumentUnamortizedExitFee_019cfc6e-a903-7fcb-b9e3-f9213c6c5246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_019dd75c-e2c9-72d8-82ab-666a8bdafb45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_LongTermDebtCurrent_019dd75c-e2c9-72d8-82ab-666a8bdafb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_019cfc6e-a903-7423-bf42-18d7c2dec38b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7584-b3df-31f591dfd833" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_019cfc6e-a903-7423-bf42-18d7c2dec38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtConvertiblegrantnarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a903-7abd-9ef9-4bbb02ebf9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a903-7abd-9ef9-4bbb02ebf9fa" xlink:to="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019cfc6e-a903-75f5-98ca-1341a8fe9ea7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_srt_RangeAxis_019cfc6e-a903-75f5-98ca-1341a8fe9ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cfc6e-a903-75ab-a675-d3eeb53fe16c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019cfc6e-a903-75f5-98ca-1341a8fe9ea7" xlink:to="loc_srt_RangeMember_019cfc6e-a903-75ab-a675-d3eeb53fe16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019cfc6e-a903-75e1-a8e6-ef0203f960d9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019cfc6e-a903-75ab-a675-d3eeb53fe16c" xlink:to="loc_srt_MaximumMember_019cfc6e-a903-75e1-a8e6-ef0203f960d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7956-9195-e90ee39c3720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7956-9195-e90ee39c3720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7728-848f-88cb55583b88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a903-7956-9195-e90ee39c3720" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7728-848f-88cb55583b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_GrantAgreementMember_019cfc6e-a903-75d3-9499-2a2fc4ba2ec4" xlink:href="alto-20260331.xsd#alto_GrantAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a903-7728-848f-88cb55583b88" xlink:to="loc_alto_GrantAgreementMember_019cfc6e-a903-75d3-9499-2a2fc4ba2ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-7423-b969-fa581c84e07c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-7423-b969-fa581c84e07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7df6-8d18-9577f2505683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a903-7423-b969-fa581c84e07c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7df6-8d18-9577f2505683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a903-7af6-8928-3d62874c16e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a903-7df6-8d18-9577f2505683" xlink:to="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a903-7af6-8928-3d62874c16e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-78c9-8092-951ddbb0eefc" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-78c9-8092-951ddbb0eefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-76b4-b941-60def6750290" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_DebtInstrumentTrancheAxis_019cfc6e-a903-78c9-8092-951ddbb0eefc" xlink:to="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-76b4-b941-60def6750290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentTrancheOneMember_019cfc6e-a903-7416-8781-331070d04a40" xlink:href="alto-20260331.xsd#alto_DebtInstrumentTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_DebtInstrumentTrancheDomain_019cfc6e-a903-76b4-b941-60def6750290" xlink:to="loc_alto_DebtInstrumentTrancheOneMember_019cfc6e-a903-7416-8781-331070d04a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a903-7ef4-9239-91a2f78002fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a903-7ef4-9239-91a2f78002fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a903-780a-9a26-9923ce894ded" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a903-7ef4-9239-91a2f78002fb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a903-780a-9a26-9923ce894ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a903-7e4b-86a2-588b1fb01782" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a903-780a-9a26-9923ce894ded" xlink:to="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a903-7e4b-86a2-588b1fb01782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-7e76-9285-71665dcc2ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-7e76-9285-71665dcc2ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7fbf-a7c2-72fab0d8f675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019cfc6e-a903-7e76-9285-71665dcc2ce5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7fbf-a7c2-72fab0d8f675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_019cfc6e-a903-7cbc-907b-63163097a039" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019cfc6e-a903-7fbf-a7c2-72fab0d8f675" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_019cfc6e-a903-7cbc-907b-63163097a039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a903-704a-9152-1a8fcc8d694c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_019cfc6e-a903-7e5d-9252-d0728899b662" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_019cfc6e-a903-7e5d-9252-d0728899b662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentNumberOfTranches_019cfc6e-a903-7f08-a6b4-95e793516ae5" xlink:href="alto-20260331.xsd#alto_DebtInstrumentNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_alto_DebtInstrumentNumberOfTranches_019cfc6e-a903-7f08-a6b4-95e793516ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019cfc6e-a903-7f4b-afbf-96f0a4789b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019cfc6e-a903-7f4b-afbf-96f0a4789b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019cfc6e-a903-70f9-bb31-64da5be027e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019cfc6e-a903-70f9-bb31-64da5be027e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment_019cfc6e-a9b8-71c3-83a6-b9d582e0aee3" xlink:href="alto-20260331.xsd#alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment_019cfc6e-a9b8-71c3-83a6-b9d582e0aee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentConvertibleDiscountOnSharesConverted_019cfc6e-a9b8-7abf-ac76-4d3a115f2744" xlink:href="alto-20260331.xsd#alto_DebtInstrumentConvertibleDiscountOnSharesConverted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_alto_DebtInstrumentConvertibleDiscountOnSharesConverted_019cfc6e-a9b8-7abf-ac76-4d3a115f2744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement_019cfc6e-a9b8-74d9-a099-465850d2be18" xlink:href="alto-20260331.xsd#alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement_019cfc6e-a9b8-74d9-a099-465850d2be18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentConvertibleMaximumSharesIssuable_019cfc6e-a9b8-7b72-945b-0290938a3b84" xlink:href="alto-20260331.xsd#alto_DebtInstrumentConvertibleMaximumSharesIssuable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_alto_DebtInstrumentConvertibleMaximumSharesIssuable_019cfc6e-a9b8-7b72-945b-0290938a3b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum_019cfc6e-a9b8-70e1-89cf-b5a3df66f2ed" xlink:href="alto-20260331.xsd#alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum_019cfc6e-a9b8-70e1-89cf-b5a3df66f2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019cfc6e-a9b8-7233-a9fc-cd5934cac39c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019cfc6e-a9b8-7233-a9fc-cd5934cac39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-734c-95ee-742d38375d26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-734c-95ee-742d38375d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_019cfc6e-a9b8-7845-9d0e-aa1f04366ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a903-7f14-9730-eb846451025d" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_019cfc6e-a9b8-7845-9d0e-aa1f04366ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtConvertiblegrantmaturityDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a9b8-7f97-a866-893f4f2a57f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019cfc6e-a9b8-71b0-b7e1-66cc4d650e97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a9b8-7f97-a866-893f4f2a57f5" xlink:to="loc_us-gaap_DebtInstrumentTable_019cfc6e-a9b8-71b0-b7e1-66cc4d650e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-70ce-a0ca-3b6451c4b8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a9b8-71b0-b7e1-66cc4d650e97" xlink:to="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-70ce-a0ca-3b6451c4b8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7889-89a3-85c8e7a3597c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-70ce-a0ca-3b6451c4b8a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7889-89a3-85c8e7a3597c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a9b8-77a8-8635-ac7cdd9d9068" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7889-89a3-85c8e7a3597c" xlink:to="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a9b8-77a8-8635-ac7cdd9d9068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cfc6e-a9b8-71b0-b7e1-66cc4d650e97" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-a9b8-79c9-b356-8866febdb22c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019cfc6e-a9b8-79c9-b356-8866febdb22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a9b8-75c6-9e72-0c661666162d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019cfc6e-a9b8-75c6-9e72-0c661666162d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a9b8-7d20-b27b-92ab23cf5091" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019cfc6e-a9b8-7d20-b27b-92ab23cf5091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a9b8-71d9-b49a-ddcab3f8cfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019cfc6e-a9b8-71d9-b49a-ddcab3f8cfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019cfc6e-a9b8-7c80-8447-11a937407649" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019cfc6e-a9b8-7c9c-818d-5ce15c194b49" xlink:to="loc_us-gaap_LongTermDebt_019cfc6e-a9b8-7c80-8447-11a937407649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#DebtChangeinfairvalueofconvertiblegrantagreementDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a9b8-7fc8-93dc-096136a81bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019cfc6e-a9b8-70c7-a6dc-726ef9be936d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cfc6e-a9b8-7fc8-93dc-096136a81bbf" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019cfc6e-a9b8-70c7-a6dc-726ef9be936d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a9b8-7b85-8eb1-5b676bf34ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019cfc6e-a9b8-70c7-a6dc-726ef9be936d" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a9b8-7b85-8eb1-5b676bf34ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a9b8-7d24-9f13-8ff41e7e54d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_019cfc6e-a9b8-7b85-8eb1-5b676bf34ce9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a9b8-7d24-9f13-8ff41e7e54d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a9b8-7f8c-99f0-6420047ad59d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019cfc6e-a9b8-7d24-9f13-8ff41e7e54d0" xlink:to="loc_us-gaap_ConvertibleDebtMember_019cfc6e-a9b8-7f8c-99f0-6420047ad59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019cfc6e-a9b8-7571-a1ca-4656f03f4336" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019cfc6e-a9b8-70c7-a6dc-726ef9be936d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019cfc6e-a9b8-7571-a1ca-4656f03f4336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019cfc6e-a9b8-7571-a1ca-4656f03f4336" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-7674-82ee-9c056c7e49cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-7674-82ee-9c056c7e49cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_019cfc6e-a9b8-70ac-89d8-0ba0dbaaa8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_019cfc6e-a9b8-70ac-89d8-0ba0dbaaa8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019db8ea-bcdc-7d5b-9c2f-9b9af67351a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019db8ea-bcdc-7d5b-9c2f-9b9af67351a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019cfc6e-a9b8-7d29-bb29-4b79b66e7a81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019cfc6e-a9b8-7d29-bb29-4b79b66e7a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_019cfc6e-a9b8-7e2b-8b70-34d087e4fafb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_019cfc6e-a9b8-7e2b-8b70-34d087e4fafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-7311-87f2-5e67772aa2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019dd76d-2a37-7151-881f-de4d90d5ba63" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019cfc6e-a9b8-7311-87f2-5e67772aa2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/FairValueDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#FairValueDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/FairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019cfc6e-a9b8-7cdd-a664-313612d472ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cfc6e-a9b8-709b-bfa2-c42abe3d025f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019cfc6e-a9b8-7cdd-a664-313612d472ee" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cfc6e-a9b8-709b-bfa2-c42abe3d025f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cfc6e-a9b8-7088-9d87-325485569844" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cfc6e-a9b8-709b-bfa2-c42abe3d025f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cfc6e-a9b8-7088-9d87-325485569844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-a9b8-7712-9cce-c56ea3cf3e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cfc6e-a9b8-7088-9d87-325485569844" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-a9b8-7712-9cce-c56ea3cf3e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019cfc6e-a9b8-7195-85ce-28ac249d2835" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-a9b8-7712-9cce-c56ea3cf3e9c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019cfc6e-a9b8-7195-85ce-28ac249d2835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019cfc6e-a9b8-7bd5-b770-d7e89ebd996a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-a9b8-7712-9cce-c56ea3cf3e9c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019cfc6e-a9b8-7bd5-b770-d7e89ebd996a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019cfc6e-a9b8-76a8-8098-3b1aadc24d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cfc6e-a9b8-7712-9cce-c56ea3cf3e9c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019cfc6e-a9b8-76a8-8098-3b1aadc24d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019cfc6e-a9b8-7834-9669-ad7f9a427fae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cfc6e-a9b8-709b-bfa2-c42abe3d025f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019cfc6e-a9b8-7834-9669-ad7f9a427fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cfc6e-a9b8-7ead-81e3-5cdd00cd5077" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019cfc6e-a9b8-7834-9669-ad7f9a427fae" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cfc6e-a9b8-7ead-81e3-5cdd00cd5077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019cfc6e-a9b8-7909-bc3b-5b4777ca0653" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cfc6e-a9b8-7ead-81e3-5cdd00cd5077" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019cfc6e-a9b8-7909-bc3b-5b4777ca0653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cfc6e-a9b8-73ad-a987-cc72827508a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cfc6e-a9b8-709b-bfa2-c42abe3d025f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cfc6e-a9b8-73ad-a987-cc72827508a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019cfc6e-a9b8-7460-a839-664ee7ca1577" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cfc6e-a9b8-73ad-a987-cc72827508a2" xlink:to="loc_us-gaap_AssetsAbstract_019cfc6e-a9b8-7460-a839-664ee7ca1577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cfc6e-a9b8-7ebe-be4f-e5105c0f610d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cfc6e-a9b8-7460-a839-664ee7ca1577" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cfc6e-a9b8-7ebe-be4f-e5105c0f610d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_019cfc6e-a9b8-7459-b88d-fe58c490b216" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cfc6e-a9b8-7460-a839-664ee7ca1577" xlink:to="loc_us-gaap_RestrictedCash_019cfc6e-a9b8-7459-b88d-fe58c490b216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019cfc6e-a9b8-7db3-b1e8-39e266b6e0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cfc6e-a9b8-7460-a839-664ee7ca1577" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_019cfc6e-a9b8-7db3-b1e8-39e266b6e0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_019cfc6e-a9b8-710a-a6f2-44ff48e829f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cfc6e-a9b8-73ad-a987-cc72827508a2" xlink:to="loc_us-gaap_LiabilitiesAbstract_019cfc6e-a9b8-710a-a6f2-44ff48e829f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019cfc6e-a9b8-77e1-9b9f-f8443a3ee6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019cfc6e-a9b8-710a-a6f2-44ff48e829f1" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019cfc6e-a9b8-77e1-9b9f-f8443a3ee6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_019cfc6e-a9b8-71e9-aa65-33e81389e08e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019cfc6e-a9b8-710a-a6f2-44ff48e829f1" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_019cfc6e-a9b8-71e9-aa65-33e81389e08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockBasedPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-7d59-b0e5-024efbb6c8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-7d59-b0e5-024efbb6c8f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019cfc6e-a9b8-799a-8e5e-0cc89f1ac409" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:to="loc_us-gaap_PlanNameAxis_019cfc6e-a9b8-799a-8e5e-0cc89f1ac409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019cfc6e-a9b8-7895-8444-038f3a98ead9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019cfc6e-a9b8-799a-8e5e-0cc89f1ac409" xlink:to="loc_us-gaap_PlanNameDomain_019cfc6e-a9b8-7895-8444-038f3a98ead9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_The2024EquityIncentivePlanMember_019cfc6e-a9b8-797d-97a4-622bd197985a" xlink:href="alto-20260331.xsd#alto_The2024EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019cfc6e-a9b8-7895-8444-038f3a98ead9" xlink:to="loc_alto_The2024EquityIncentivePlanMember_019cfc6e-a9b8-797d-97a4-622bd197985a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_A2025InducementPlanMember_019cfc6e-a9b8-7999-96cc-36d5be0af048" xlink:href="alto-20260331.xsd#alto_A2025InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019cfc6e-a9b8-7895-8444-038f3a98ead9" xlink:to="loc_alto_A2025InducementPlanMember_019cfc6e-a9b8-7999-96cc-36d5be0af048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7160-83bb-b2952fcfad73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:to="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7160-83bb-b2952fcfad73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7410-9f0a-23d823119698" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7160-83bb-b2952fcfad73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7410-9f0a-23d823119698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-748d-8fcb-97cdeec17ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7410-9f0a-23d823119698" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-748d-8fcb-97cdeec17ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019cfc6e-a9b8-7ffa-895c-8bb4e452b9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7410-9f0a-23d823119698" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019cfc6e-a9b8-7ffa-895c-8bb4e452b9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019cfc6e-a9b8-72c0-90e4-42c200468442" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7410-9f0a-23d823119698" xlink:to="loc_us-gaap_PerformanceSharesMember_019cfc6e-a9b8-72c0-90e4-42c200468442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_019cfc6e-a9b8-77b0-8fa0-2e28573fb5de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:to="loc_us-gaap_VestingAxis_019cfc6e-a9b8-77b0-8fa0-2e28573fb5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_019cfc6e-a9b8-7271-812b-2011c1e451df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_019cfc6e-a9b8-77b0-8fa0-2e28573fb5de" xlink:to="loc_us-gaap_VestingDomain_019cfc6e-a9b8-7271-812b-2011c1e451df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019cfc6e-a9b8-762b-879b-3f465a5cc4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_019cfc6e-a9b8-7271-812b-2011c1e451df" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019cfc6e-a9b8-762b-879b-3f465a5cc4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_019cfc6e-a9b8-7712-a86b-ed2cd2957460" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_019cfc6e-a9b8-7271-812b-2011c1e451df" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_019cfc6e-a9b8-7712-a86b-ed2cd2957460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-727d-bc9b-60d92cfea1af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-727d-bc9b-60d92cfea1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-7019-b5e5-b8f782b38854" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-727d-bc9b-60d92cfea1af" xlink:to="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-7019-b5e5-b8f782b38854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019cfc6e-a9b8-79d3-b7d1-4572772b76b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-7019-b5e5-b8f782b38854" xlink:to="loc_us-gaap_CommonStockMember_019cfc6e-a9b8-79d3-b7d1-4572772b76b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019cfc6e-a9b8-7485-be38-4fc5330d07e7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:to="loc_srt_RangeAxis_019cfc6e-a9b8-7485-be38-4fc5330d07e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cfc6e-a9b8-7df4-8107-027b52f6b1af" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019cfc6e-a9b8-7485-be38-4fc5330d07e7" xlink:to="loc_srt_RangeMember_019cfc6e-a9b8-7df4-8107-027b52f6b1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019cfc6e-a9b8-7c81-bbf9-245469ba3e5f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019cfc6e-a9b8-7df4-8107-027b52f6b1af" xlink:to="loc_srt_MinimumMember_019cfc6e-a9b8-7c81-bbf9-245469ba3e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7ccd-b5a1-0f5740c4b54f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019cfc6e-a9b8-7e1e-a045-e21eb200b763" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019cfc6e-a9b8-7e1e-a045-e21eb200b763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock_019cfc6e-a9b8-73cd-8519-bc06ef2bf8d1" xlink:href="alto-20260331.xsd#alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock_019cfc6e-a9b8-73cd-8519-bc06ef2bf8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019cfc6e-a9b8-72c3-8df1-fc0f2bbaa568" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019cfc6e-a9b8-72c3-8df1-fc0f2bbaa568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019db8c4-d0b9-7c17-bef3-97bf8fe83d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019db8c4-d0b9-7c17-bef3-97bf8fe83d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_019cfc6e-a9b8-73fc-a099-23473a19e526" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_019cfc6e-a9b8-73fc-a099-23473a19e526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019cfc6e-a9b8-7526-95e1-370628c84115" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019cfc6e-a9b8-7526-95e1-370628c84115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_019cfc6e-a9b8-767a-9f44-e509c1c58f16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_019cfc6e-a9b8-767a-9f44-e509c1c58f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_019cfc6e-a9b8-707a-b911-19830942d7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_019cfc6e-a9b8-707a-b911-19830942d7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_019cfc6e-a9b8-729f-813b-9e8cf5c965b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_019cfc6e-a9b8-729f-813b-9e8cf5c965b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019cfc6e-a9b8-79c9-83e7-e40a630bee3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019cfc6e-a9b8-79c9-83e7-e40a630bee3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019cfc6e-a9b8-726e-b083-b00cd5536e04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019cfc6e-a9b8-726e-b083-b00cd5536e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-772e-a9b9-ee1b174dd561" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-772e-a9b9-ee1b174dd561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019cfc6e-a9b8-74dc-bf95-efd232a42d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019cfc6e-a9b8-74dc-bf95-efd232a42d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019cfc6e-a9b8-7542-a51d-17df73f84ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019cfc6e-a9b8-7542-a51d-17df73f84ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019cfc6e-a9b8-741c-9b22-41b58417bcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019cfc6e-a9b8-741c-9b22-41b58417bcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7d26-8431-e40fba4d1d23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7d26-8431-e40fba4d1d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_019cfc6e-a9b8-73a2-9ed5-88e8195e7e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_019cfc6e-a9b8-73a2-9ed5-88e8195e7e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019cfc6e-a9b8-7e6c-a45e-839f033740f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019cfc6e-a9b8-7e6c-a45e-839f033740f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019db8c6-8147-7e48-a3fc-bd6c80da337f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019db8c6-8147-7e48-a3fc-bd6c80da337f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019cfc6e-a9b8-763f-82e9-9d048723c669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019cfc6e-a9b8-763f-82e9-9d048723c669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_019dff09-fa2b-7255-b214-b2a165978a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_019dff09-fa2b-7255-b214-b2a165978a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_019db8c7-67ee-7d4a-b66d-dce4c727ec6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7598-9ed8-31129bffacd0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_019db8c7-67ee-7d4a-b66d-dce4c727ec6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockBasedPlansStockoptionweightedaverageassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-7b99-bb01-92186167c256" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7445-8e97-1c63fcad8893" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-7b99-bb01-92186167c256" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7445-8e97-1c63fcad8893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7685-a3ed-042d4999d31f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7445-8e97-1c63fcad8893" xlink:to="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7685-a3ed-042d4999d31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7460-9dd4-0d011606b11c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7685-a3ed-042d4999d31f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7460-9dd4-0d011606b11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-7b83-a880-acab8a59d61a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7460-9dd4-0d011606b11c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-7b83-a880-acab8a59d61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7445-8e97-1c63fcad8893" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_019cfc6e-a9b8-7e2f-8e8a-969d53af3202" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_019cfc6e-a9b8-7e2f-8e8a-969d53af3202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward_019cfc6e-a9b8-7326-aecb-fcfeda5dd114" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward_019cfc6e-a9b8-7326-aecb-fcfeda5dd114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019cfc6e-a9b8-7def-b412-cd695d093cac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019cfc6e-a9b8-7def-b412-cd695d093cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019cfc6e-a9b8-75ca-9b77-e289b62efa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019cfc6e-a9b8-75ca-9b77-e289b62efa7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019cfc6e-a9b8-71d8-878b-ded6b397907f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019cfc6e-a9b8-71d8-878b-ded6b397907f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019cfc6e-a9b8-7d4b-853c-c7f206d1b382" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-79f1-85d3-491ec03a9f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019cfc6e-a9b8-7d4b-853c-c7f206d1b382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockBasedPlansScheduleofstockoptionactivityDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-7b87-837c-e335ac0e43a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7fa0-a8f5-9992ddfcd136" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-7b87-837c-e335ac0e43a6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7fa0-a8f5-9992ddfcd136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7340-95ab-4d0e957e0140" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7fa0-a8f5-9992ddfcd136" xlink:to="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7340-95ab-4d0e957e0140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7e12-afc6-358583b68a64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7340-95ab-4d0e957e0140" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7e12-afc6-358583b68a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-769c-8d52-eebf2c55f889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7e12-afc6-358583b68a64" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-769c-8d52-eebf2c55f889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7fa0-a8f5-9992ddfcd136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cfc6e-a9b8-7127-bb2f-1940c59c4052" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cfc6e-a9b8-7127-bb2f-1940c59c4052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019cfc6e-a9b8-7d24-a0ef-cfdfa81a17f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019cfc6e-a9b8-7d24-a0ef-cfdfa81a17f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cfc6e-a9b8-7c8e-b495-edfe56b16ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cfc6e-a9b8-7c8e-b495-edfe56b16ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019cfc6e-a9b8-7159-a2e6-7886b5be8e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019cfc6e-a9b8-7159-a2e6-7886b5be8e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cfc6e-a9b8-7758-ab77-fca02daef8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019cfc6e-a9b8-76cb-a574-261a1b10e3fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cfc6e-a9b8-7758-ab77-fca02daef8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019cfc6e-a9b8-7b1c-8d0a-41949af3a8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019cfc6e-a9b8-7b1c-8d0a-41949af3a8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cfc6e-a9b8-7b84-9ffb-cd6957ac5298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cfc6e-a9b8-7b84-9ffb-cd6957ac5298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7cd0-9864-1160eda7b4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7cd0-9864-1160eda7b4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7624-8791-02134ed2d463" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7624-8791-02134ed2d463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7835-bd95-52800f78e224" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_019cfc6e-a9b8-7835-bd95-52800f78e224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cfc6e-a9b8-793b-b2ae-259b4d46a755" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_019cfc6e-a9b8-772f-a6fc-c7504161a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cfc6e-a9b8-793b-b2ae-259b4d46a755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019cfc6e-a9b8-7c8d-81cc-b1914b4de204" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019cfc6e-a9b8-7c8d-81cc-b1914b4de204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract_019cfc6e-a9b8-7f28-b872-39a7f4975da8" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract_019cfc6e-a9b8-7f28-b872-39a7f4975da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019cfc6e-a9b8-7ce8-ad74-12077109c0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract_019cfc6e-a9b8-7f28-b872-39a7f4975da8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019cfc6e-a9b8-7ce8-ad74-12077109c0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019cfc6e-a9b8-71bc-9a05-1313d7b97a20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract_019cfc6e-a9b8-7f28-b872-39a7f4975da8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019cfc6e-a9b8-71bc-9a05-1313d7b97a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_019cfc6e-a9b8-713a-b67e-949cd1389cd0" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7032-aef4-bef3aaef1b0a" xlink:to="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_019cfc6e-a9b8-713a-b67e-949cd1389cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019cfc6e-a9b8-7c11-b7e0-ade2a982423f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_019cfc6e-a9b8-713a-b67e-949cd1389cd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019cfc6e-a9b8-7c11-b7e0-ade2a982423f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019cfc6e-a9b8-78b6-9b0d-a08064262ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_019cfc6e-a9b8-713a-b67e-949cd1389cd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019cfc6e-a9b8-78b6-9b0d-a08064262ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019cfc6e-a9b8-773a-b295-987dfb9a1aec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_019cfc6e-a9b8-713a-b67e-949cd1389cd0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019cfc6e-a9b8-773a-b295-987dfb9a1aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-7d68-bb15-eb2887f7e218" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7e04-b218-cf7553f46af2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-7d68-bb15-eb2887f7e218" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7e04-b218-cf7553f46af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7cf1-a498-aa36747c9c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7e04-b218-cf7553f46af2" xlink:to="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7cf1-a498-aa36747c9c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7765-af47-31eb70672ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7cf1-a498-aa36747c9c2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7765-af47-31eb70672ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019cfc6e-a9b8-7847-94d5-44cb1f328c04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7765-af47-31eb70672ec6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019cfc6e-a9b8-7847-94d5-44cb1f328c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7646-85ef-496915312593" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cfc6e-a9b8-7e04-b218-cf7553f46af2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7646-85ef-496915312593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7646-85ef-496915312593" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019cfc6e-a9b8-7197-bcfb-0cf75563059f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019cfc6e-a9b8-7197-bcfb-0cf75563059f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019cfc6e-a9b8-7153-a774-4b592e9a5328" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019cfc6e-a9b8-7153-a774-4b592e9a5328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019cfc6e-a9b8-7c30-83c5-b0bb7b429fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019cfc6e-a9b8-7c30-83c5-b0bb7b429fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019cfc6e-a9b8-7939-aa0b-13ce51dfc5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019cfc6e-a9b8-7939-aa0b-13ce51dfc5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019cfc6e-a9b8-75be-bd81-8069ba96852c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019cfc6e-a9b8-7bdb-8ca6-0cd095b3684f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019cfc6e-a9b8-75be-bd81-8069ba96852c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:href="alto-20260331.xsd#alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cfc6e-a9b8-7646-85ef-496915312593" xlink:to="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7028-a37d-c5e946e157eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7028-a37d-c5e946e157eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-701f-8c21-93a43c1cf2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-701f-8c21-93a43c1cf2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-756b-b19b-c5ab546afcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019cfc6e-a9b8-756b-b19b-c5ab546afcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7248-96dd-49b67e8dfdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019cfc6e-a9b8-7248-96dd-49b67e8dfdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019cfc6e-a9b8-74e0-bf3b-f41e4796e74f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward_019cfc6e-a9b8-79b4-99c8-eda5bebfddcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019cfc6e-a9b8-74e0-bf3b-f41e4796e74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockBasedPlansScheduleofstockbasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-709f-9475-50a862bc878d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cfc6e-a9b8-7d7e-b802-49e44dab7385" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cfc6e-a9b8-709f-9475-50a862bc878d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cfc6e-a9b8-7d7e-b802-49e44dab7385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019cfc6e-a9b8-72c5-9181-f392a5cfa5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cfc6e-a9b8-7d7e-b802-49e44dab7385" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019cfc6e-a9b8-72c5-9181-f392a5cfa5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019cfc6e-a9b8-738d-95f7-cf8fc58b01f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019cfc6e-a9b8-72c5-9181-f392a5cfa5b0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019cfc6e-a9b8-738d-95f7-cf8fc58b01f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cfc6e-a9b8-7ca0-b65b-444a07fb7356" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cfc6e-a9b8-738d-95f7-cf8fc58b01f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cfc6e-a9b8-7ca0-b65b-444a07fb7356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019cfc6e-a9b8-7f95-8d2d-e0a542e26178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cfc6e-a9b8-738d-95f7-cf8fc58b01f6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019cfc6e-a9b8-7f95-8d2d-e0a542e26178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cfc6e-a9b8-7ef9-be14-986f5c36749e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cfc6e-a9b8-7d7e-b802-49e44dab7385" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cfc6e-a9b8-7ef9-be14-986f5c36749e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-77b8-b83e-70aa7a381901" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cfc6e-a9b8-7ef9-be14-986f5c36749e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-77b8-b83e-70aa7a381901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#LossPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019db9f9-cb45-7617-8212-973e2e1ba379" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019db9f9-cb45-726a-86a8-9f414a4e0411" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019db9f9-cb45-7617-8212-973e2e1ba379" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019db9f9-cb45-726a-86a8-9f414a4e0411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019db9f9-cb45-7cc1-98d3-84f70850b2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019db9f9-cb45-726a-86a8-9f414a4e0411" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019db9f9-cb45-7cc1-98d3-84f70850b2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019db9f9-cb45-73af-870e-e2d96690b3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019db9f9-cb45-7cc1-98d3-84f70850b2f8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019db9f9-cb45-73af-870e-e2d96690b3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_TwoThousandTwentyFivePreFundedWarrantsMember_019db9f9-cb45-7700-96cd-a15f599fee99" xlink:href="alto-20260331.xsd#alto_TwoThousandTwentyFivePreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019db9f9-cb45-73af-870e-e2d96690b3fb" xlink:to="loc_alto_TwoThousandTwentyFivePreFundedWarrantsMember_019db9f9-cb45-7700-96cd-a15f599fee99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_019db9f9-cb45-786a-9c45-46cb08d8b641" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019db9f9-cb45-726a-86a8-9f414a4e0411" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_019db9f9-cb45-786a-9c45-46cb08d8b641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_019db9f9-cb45-7181-9254-b30f64394eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_019db9f9-cb45-786a-9c45-46cb08d8b641" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_019db9f9-cb45-7181-9254-b30f64394eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_SecuritiesPurchaseAgreementMember_019db9f9-cb45-73ba-a28c-d5e11608bf4a" xlink:href="alto-20260331.xsd#alto_SecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_019db9f9-cb45-7181-9254-b30f64394eaf" xlink:to="loc_alto_SecuritiesPurchaseAgreementMember_019db9f9-cb45-73ba-a28c-d5e11608bf4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019db9f9-cb45-7212-bb0a-5b978cdd782b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019db9f9-cb45-726a-86a8-9f414a4e0411" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019db9f9-cb45-7212-bb0a-5b978cdd782b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019db9f9-cb45-772c-b862-8fa88bc4c8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019db9f9-cb45-7212-bb0a-5b978cdd782b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019db9f9-cb45-772c-b862-8fa88bc4c8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019cfc6e-a9b8-7510-8586-29bf92199a15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cfc6e-a9b8-72a2-bdfd-8deb0bfc0d89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019cfc6e-a9b8-7510-8586-29bf92199a15" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cfc6e-a9b8-72a2-bdfd-8deb0bfc0d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cfc6e-a9b8-76c4-b933-d87836b9e2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cfc6e-a9b8-72a2-bdfd-8deb0bfc0d89" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cfc6e-a9b8-76c4-b933-d87836b9e2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-a9b8-76a9-afe4-05ba94201858" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cfc6e-a9b8-76c4-b933-d87836b9e2ab" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-a9b8-76a9-afe4-05ba94201858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2CommonStockWarrantsMember_019cfc6e-a9b8-7a9a-8536-edffffad678d" xlink:href="alto-20260331.xsd#alto_K2CommonStockWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-a9b8-76a9-afe4-05ba94201858" xlink:to="loc_alto_K2CommonStockWarrantsMember_019cfc6e-a9b8-7a9a-8536-edffffad678d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019dd765-0c19-7677-8fd7-b6fd90a910e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-a9b8-76a9-afe4-05ba94201858" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019dd765-0c19-7677-8fd7-b6fd90a910e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-73ee-845e-b67f6585a0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cfc6e-a9b8-76a9-afe4-05ba94201858" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019cfc6e-a9b8-73ee-845e-b67f6585a0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cfc6e-a9b8-7f1a-82b6-f3d7c2d783f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cfc6e-a9b8-72a2-bdfd-8deb0bfc0d89" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cfc6e-a9b8-7f1a-82b6-f3d7c2d783f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cfc6e-a9b8-71da-a378-2e0c5ad16689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cfc6e-a9b8-7f1a-82b6-f3d7c2d783f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cfc6e-a9b8-71da-a378-2e0c5ad16689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019cfc6e-a9b8-79af-88ac-581a8203bd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019cfc6e-a9b8-79af-88ac-581a8203bd9f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-70fd-adde-ee4dd7a1dbce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-70fd-adde-ee4dd7a1dbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-7b32-b022-9be201a7e002" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019cfc6e-a9b8-70fd-adde-ee4dd7a1dbce" xlink:to="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-7b32-b022-9be201a7e002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019cfc6e-a9b8-7d78-99c7-1b00b4e1ba7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019cfc6e-a9b8-7b32-b022-9be201a7e002" xlink:to="loc_us-gaap_CommonStockMember_019cfc6e-a9b8-7d78-99c7-1b00b4e1ba7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a9b8-7b54-a04d-2ec77343c742" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a9b8-7b54-a04d-2ec77343c742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a9b8-7f47-9e4d-4d5436418ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019cfc6e-a9b8-7b54-a04d-2ec77343c742" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a9b8-7f47-9e4d-4d5436418ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2WarrantMember_019cfc6e-a9b8-70c7-aab4-56a33d292940" xlink:href="alto-20260331.xsd#alto_K2WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019cfc6e-a9b8-7f47-9e4d-4d5436418ddd" xlink:to="loc_alto_K2WarrantMember_019cfc6e-a9b8-70c7-aab4-56a33d292940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NewK2WarrantMember_019cfc6e-a9b8-76d2-8ea9-dfc68eef5c65" xlink:href="alto-20260331.xsd#alto_NewK2WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_K2WarrantMember_019cfc6e-a9b8-70c7-aab4-56a33d292940" xlink:to="loc_alto_NewK2WarrantMember_019cfc6e-a9b8-76d2-8ea9-dfc68eef5c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AdditionalK2WarrantsMember_019cfc6e-a9b8-7209-9497-2d23e554cb5d" xlink:href="alto-20260331.xsd#alto_AdditionalK2WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alto_K2WarrantMember_019cfc6e-a9b8-70c7-aab4-56a33d292940" xlink:to="loc_alto_AdditionalK2WarrantsMember_019cfc6e-a9b8-7209-9497-2d23e554cb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-75ee-8095-89bfe0ce6ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:to="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-75ee-8095-89bfe0ce6ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7e5d-8309-f1d6579ab03e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019cfc6e-a9b8-75ee-8095-89bfe0ce6ca5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7e5d-8309-f1d6579ab03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AmendedLoanAgreementMember_019cfc6e-a9b8-7ba8-9a42-2734b391df6c" xlink:href="alto-20260331.xsd#alto_AmendedLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019cfc6e-a9b8-7e5d-8309-f1d6579ab03e" xlink:to="loc_alto_AmendedLoanAgreementMember_019cfc6e-a9b8-7ba8-9a42-2734b391df6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a9b8-7b1e-bc0e-be0e374fe787" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a9b8-7b1e-bc0e-be0e374fe787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a9b8-7f92-a66c-fa05c1081630" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019cfc6e-a9b8-7b1e-bc0e-be0e374fe787" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a9b8-7f92-a66c-fa05c1081630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019cfc6e-a9b8-7874-b1a9-a959fde63b18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019cfc6e-a9b8-7f92-a66c-fa05c1081630" xlink:to="loc_us-gaap_SecuredDebtMember_019cfc6e-a9b8-7874-b1a9-a959fde63b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019dba01-4a20-741f-8254-ec811e26756a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019dba01-4a20-741f-8254-ec811e26756a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dba01-4a20-797d-9069-0ec3ebfa5ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019dba01-4a20-741f-8254-ec811e26756a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dba01-4a20-797d-9069-0ec3ebfa5ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_019dba01-4a20-7d54-8bdb-e9e345c02e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dba01-4a20-797d-9069-0ec3ebfa5ffc" xlink:to="loc_us-gaap_PrivatePlacementMember_019dba01-4a20-7d54-8bdb-e9e345c02e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_PreFundedWarrantsMember_019dba01-4a20-75f2-b3f7-9d29d899ae03" xlink:href="alto-20260331.xsd#alto_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dba01-4a20-797d-9069-0ec3ebfa5ffc" xlink:to="loc_alto_PreFundedWarrantsMember_019dba01-4a20-75f2-b3f7-9d29d899ae03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-75d5-a465-616722ccbc26" xlink:to="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier_019cfc6e-a9b8-746e-8673-e1d7273beafb" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier_019cfc6e-a9b8-746e-8673-e1d7273beafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019cfc6e-a9b8-77d3-9ff6-ea42aab2fb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019cfc6e-a9b8-77d3-9ff6-ea42aab2fb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019cfc6e-a9b8-7656-9130-287c14dcc00b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019cfc6e-a9b8-7656-9130-287c14dcc00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a9b8-75d0-9102-852c20978d67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019cfc6e-a9b8-75d0-9102-852c20978d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019dba13-64cb-78e6-9b9f-a99cb06d3e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019dba13-64cb-78e6-9b9f-a99cb06d3e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019dba01-4a20-771a-9b09-5312b1d263e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019dba01-4a20-771a-9b09-5312b1d263e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_019dba01-4a20-74a2-8f67-b746557cf827" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_019dba01-4a20-74a2-8f67-b746557cf827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation_019dba01-4a20-7f26-97f0-f11f70b572bf" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation_019dba01-4a20-7f26-97f0-f11f70b572bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage_019dba01-4a20-7880-b32a-f389e69253a1" xlink:href="alto-20260331.xsd#alto_ClassOfWarrantsOrRightsWarrantExcessPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage_019dba01-4a20-7880-b32a-f389e69253a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019cfc6e-a9b8-7018-98f6-0295d28961be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019cfc6e-a9b8-7018-98f6-0295d28961be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cfc6e-a9b8-7afc-b36b-4e0ef56137a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cfc6e-a9b8-7afc-b36b-4e0ef56137a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019cfc6e-a9b8-7bfb-aea9-0537354c5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_CommonStockSharesIssued_019cfc6e-a9b8-7bfb-aea9-0537354c5d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a9b8-7e2b-8921-7c7c02391293" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cfc6e-a9b8-7e2b-8921-7c7c02391293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019cfc6e-a9b8-796a-b6af-de303cdd30e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019cfc6e-a9b8-796a-b6af-de303cdd30e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019cfc6e-a9b8-752b-b20f-5ef3f7220ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019cfc6e-a9b8-752b-b20f-5ef3f7220ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_019cfc6e-a9b8-716c-b116-d6c8eceec8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_PreferredStockSharesIssued_019cfc6e-a9b8-716c-b116-d6c8eceec8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019cfc6e-a9b8-7bfe-9116-648d2036daeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7083-b829-9282aa27e483" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019cfc6e-a9b8-7bfe-9116-648d2036daeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#StockholdersEquityScheduleofstockreservedforissuanceDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019cfc6e-a9b8-71df-8243-31cecfd63989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-7050-8060-633ae92d3108" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019cfc6e-a9b8-71df-8243-31cecfd63989" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-7050-8060-633ae92d3108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7f37-b59d-8a08d5a19885" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-7050-8060-633ae92d3108" xlink:to="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7f37-b59d-8a08d5a19885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7188-82b0-68b142947c08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019cfc6e-a9b8-7f37-b59d-8a08d5a19885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7188-82b0-68b142947c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_EmployeeStockOptionsIssuedAndOutstandingMember_019cfc6e-a9b8-78d5-8c6c-f21a1d91d32a" xlink:href="alto-20260331.xsd#alto_EmployeeStockOptionsIssuedAndOutstandingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7188-82b0-68b142947c08" xlink:to="loc_alto_EmployeeStockOptionsIssuedAndOutstandingMember_019cfc6e-a9b8-78d5-8c6c-f21a1d91d32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_EmployeeStockOptionsAvailableForFutureGrantMember_019cfc6e-a9b8-7216-b69a-5757bafeb2b2" xlink:href="alto-20260331.xsd#alto_EmployeeStockOptionsAvailableForFutureGrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cfc6e-a9b8-7188-82b0-68b142947c08" xlink:to="loc_alto_EmployeeStockOptionsAvailableForFutureGrantMember_019cfc6e-a9b8-7216-b69a-5757bafeb2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019db89e-6986-78dd-ab68-f7d41ff78626" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-7050-8060-633ae92d3108" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019db89e-6986-78dd-ab68-f7d41ff78626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db89e-6986-790f-9b32-bd87598eca70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019db89e-6986-78dd-ab68-f7d41ff78626" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db89e-6986-790f-9b32-bd87598eca70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_K2WarrantMember_019cfc6e-a9b8-7d65-b66e-9430e2126df0" xlink:href="alto-20260331.xsd#alto_K2WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db89e-6986-790f-9b32-bd87598eca70" xlink:to="loc_alto_K2WarrantMember_019cfc6e-a9b8-7d65-b66e-9430e2126df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_PreFundedWarrantsMember_019db89e-6986-70ad-a775-74615da526bc" xlink:href="alto-20260331.xsd#alto_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019db89e-6986-790f-9b32-bd87598eca70" xlink:to="loc_alto_PreFundedWarrantsMember_019db89e-6986-70ad-a775-74615da526bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7911-a0e1-66a1b995dde8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cfc6e-a9b8-7050-8060-633ae92d3108" xlink:to="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7911-a0e1-66a1b995dde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019cfc6e-a9b8-7e62-a53b-b3f651057041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cfc6e-a9b8-7911-a0e1-66a1b995dde8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019cfc6e-a9b8-7e62-a53b-b3f651057041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#SegmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/SegmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019dba3a-a082-75b9-83c5-0261f3ef2adb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019dba3c-0220-763d-9a1c-dae5086d66d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019dba3a-a082-75b9-83c5-0261f3ef2adb" xlink:to="loc_us-gaap_NumberOfReportableSegments_019dba3c-0220-763d-9a1c-dae5086d66d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="alto-20260331.xsd#SegmentsScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019cfc6e-a9b8-7936-afc8-7c8a055cb9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cfc6e-a9b8-763a-98c9-241bbf50d080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019cfc6e-a9b8-7936-afc8-7c8a055cb9b0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cfc6e-a9b8-763a-98c9-241bbf50d080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019cfc6e-a9b8-7106-9c46-a6de6c704ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cfc6e-a9b8-763a-98c9-241bbf50d080" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019cfc6e-a9b8-7106-9c46-a6de6c704ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019cfc6e-a9b8-7a8d-a69e-5debfb15fed2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019cfc6e-a9b8-7106-9c46-a6de6c704ba4" xlink:to="loc_us-gaap_SegmentDomain_019cfc6e-a9b8-7a8d-a69e-5debfb15fed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_ReportableSegmentMember_019cfc6e-a9b8-7c1d-b9f6-2a11d9b53292" xlink:href="alto-20260331.xsd#alto_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019cfc6e-a9b8-7a8d-a69e-5debfb15fed2" xlink:to="loc_alto_ReportableSegmentMember_019cfc6e-a9b8-7c1d-b9f6-2a11d9b53292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019cfc6e-a9b8-7e19-b38e-1f73d571a999" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cfc6e-a9b8-763a-98c9-241bbf50d080" xlink:to="loc_srt_ProductOrServiceAxis_019cfc6e-a9b8-7e19-b38e-1f73d571a999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019cfc6e-a9b8-7e19-b38e-1f73d571a999" xlink:to="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto100Member_019cfc6e-a9b8-768f-8d3d-7f6fbc5fb1da" xlink:href="alto-20260331.xsd#alto_Alto100Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:to="loc_alto_Alto100Member_019cfc6e-a9b8-768f-8d3d-7f6fbc5fb1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto300Member_019cfc6e-a9b8-77be-828b-1cf86425f963" xlink:href="alto-20260331.xsd#alto_Alto300Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:to="loc_alto_Alto300Member_019cfc6e-a9b8-77be-828b-1cf86425f963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto101Member_019cfc6e-a9b8-7d31-b242-ecf3b60b455f" xlink:href="alto-20260331.xsd#alto_Alto101Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:to="loc_alto_Alto101Member_019cfc6e-a9b8-7d31-b242-ecf3b60b455f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto203Member_019cfc6e-a9b8-7c6c-a6ee-c8d53b530f1f" xlink:href="alto-20260331.xsd#alto_Alto203Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:to="loc_alto_Alto203Member_019cfc6e-a9b8-7c6c-a6ee-c8d53b530f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_Alto207Member_019cfc6e-a9b8-72f9-8674-21df2e59f6ef" xlink:href="alto-20260331.xsd#alto_Alto207Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cfc6e-a9b8-7ccb-9998-45014ddaa681" xlink:to="loc_alto_Alto207Member_019cfc6e-a9b8-72f9-8674-21df2e59f6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cfc6e-a9b8-763a-98c9-241bbf50d080" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_019cfc6e-a9b8-7de7-8351-a9a027573cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_LaborAndRelatedExpense_019cfc6e-a9b8-7de7-8351-a9a027573cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-7a62-8017-e7a7f25afb99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cfc6e-a9b8-7a62-8017-e7a7f25afb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cfc6e-a9b8-7fc6-8d14-bbab10321b76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cfc6e-a9b8-7fc6-8d14-bbab10321b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_019cfc6e-a9b8-7051-98f7-c75a8f51d50c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_019cfc6e-a9b8-7051-98f7-c75a8f51d50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_019cfc6e-a9b8-793c-976f-f785dceabec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_019cfc6e-a9b8-793c-976f-f785dceabec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cfc6e-a9b8-7a51-b215-96731cd70db5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cfc6e-a9b8-74c0-9052-7cb45861acf4" xlink:to="loc_us-gaap_NetIncomeLoss_019cfc6e-a9b8-7a51-b215-96731cd70db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_AmitEtkinMember" xlink:href="alto-20260331.xsd#alto_AmitEtkinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_alto_AmitEtkinMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_alto_NicholasSmithMember" xlink:href="alto-20260331.xsd#alto_NicholasSmithMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_alto_NicholasSmithMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>alto-20260331_g1.jpg
<TEXT>
begin 644 alto-20260331_g1.jpg
M_]C_X  02D9)1@ ! 0 !2@%*  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        %*     0   4H    !  .@ 0 #     0 !  "@
M @ $     0  #%^@ P $     0  "*H     _^T .%!H;W1O<VAO<" S+C
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MW0 $ ,;_V@ , P$  A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#_]#]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __1_?RBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT#_^30_^2#_B(&4?\_O_ "67_P B?KE17Y&_\/3_ /JF/_E:_P#N*C_AZ?\
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M^1/URHK\C?\ AZ?_ -4Q_P#*U_\ <5'_  ]/_P"J8_\ E:_^XJ/^(69]_P!
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M;.BOPF3]O']JOP#K$-MX]L8)&XD:TU/3&LI'C/&5V>4P]FP1GL>E?K9^S_\
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MBN69)%SDJ68%<D'@BOH[XZ?'#PE\ _ \OC/Q3NN'=Q!9V<1 FNKA@2$7/ 4
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M_P"J8_\ E:_^XJ/^(69]_P! _P#Y-#_Y(/\ B(&4?\_O_)9?_(GZY45^1O\
MP]/_ .J8_P#E:_\ N*C_ (>G_P#5,?\ RM?_ '%1_P 0LS[_ *!__)H?_)!_
MQ$#*/^?W_DLO_D3]<J*_(W_AZ?\ ]4Q_\K7_ -Q4?\/3_P#JF/\ Y6O_ +BH
M_P"(69]_T#_^30_^2#_B(&4?\_O_ "67_P B?KE17Y&_\/3_ /JF/_E:_P#N
M*C_AZ?\ ]4Q_\K7_ -Q4?\0LS[_H'_\ )H?_ "0?\1 RC_G]_P"2R_\ D3]<
MJ*_(W_AZ?_U3'_RM?_<5?H5^S_\ %[_A>GPPT[XD?V3_ &)]OEN(_LOG_:=G
MD2M%GS/+BSNVY^Z,=.>M>1G7!69Y=15?&4N6+=K\T7KKV;?0]+*^*<!C:CI8
M:IS2M?:2T^:7<]HHHK\]?V@/V\?^%%_$_4?AO_P@_P#;?V"*WD^U?VG]FW^?
M$LN/+^S2XV[L?>.>O'2O,R7(<7F-9T,'#FDE>UTM-.[2ZG=FF;X?!4U6Q,N6
M-[;-Z_),_0JBOR-_X>G_ /5,?_*U_P#<5'_#T_\ ZIC_ .5K_P"XJ^J_XA9G
MW_0/_P"30_\ DCY__B(&4?\ /[_R67_R)^N5%?D;_P /3_\ JF/_ )6O_N*C
M_AZ?_P!4Q_\ *U_]Q4?\0LS[_H'_ /)H?_)!_P 1 RC_ )_?^2R_^1/URHK\
MC?\ AZ?_ -4Q_P#*U_\ <5'_  ]/_P"J8_\ E:_^XJ/^(69]_P! _P#Y-#_Y
M(/\ B(&4?\_O_)9?_(GZY45^1O\ P]/_ .J8_P#E:_\ N*C_ (>G_P#5,?\
MRM?_ '%1_P 0LS[_ *!__)H?_)!_Q$#*/^?W_DLO_D3]<J*_(W_AZ?\ ]4Q_
M\K7_ -Q4?\/3_P#JF/\ Y6O_ +BH_P"(69]_T#_^30_^2#_B(&4?\_O_ "67
M_P B?KE17Y&_\/3_ /JF/_E:_P#N*C_AZ?\ ]4Q_\K7_ -Q4?\0LS[_H'_\
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MUE*\X7:<@C[_ /BK\2_#WPA\ ZM\0O$Y8V.E1AO+CQYDTCL$CB0$@;G<@#/
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MB?KE17Y&_P##T_\ ZIC_ .5K_P"XJ/\ AZ?_ -4Q_P#*U_\ <5'_ !"S/O\
MH'_\FA_\D'_$0,H_Y_?^2R_^1/URHK\C?^'I_P#U3'_RM?\ W%1_P]/_ .J8
M_P#E:_\ N*C_ (A9GW_0/_Y-#_Y(/^(@91_S^_\ )9?_ ")^N5%?D;_P]/\
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M_P#)9?\ R)^N5%?D;_P]/_ZIC_Y6O_N*C_AZ?_U3'_RM?_<5'_$+,^_Z!_\
MR:'_ ,D'_$0,H_Y_?^2R_P#D3]<J*_(W_AZ?_P!4Q_\ *U_]Q4?\/3_^J8_^
M5K_[BH_XA9GW_0/_ .30_P#D@_XB!E'_ #^_\EE_\B?KE17Y&_\ #T__ *IC
M_P"5K_[BH_X>G_\ 5,?_ "M?_<5'_$+,^_Z!_P#R:'_R0?\ $0,H_P"?W_DL
MO_D3]<J*_(W_ (>G_P#5,?\ RM?_ '%1_P /3_\ JF/_ )6O_N*C_B%F??\
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M /")^$M;\4^1]J_L:QN;WR=VSS/L\32;-V&V[MN,X..N#7Y8?\/3_P#JF/\
MY6O_ +BKZ3(N$<PS*,IX*ES*.^L5OZM'B9MQ'@L"XQQ4^5O;1O\ ),_7*BOR
M-_X>G_\ 5,?_ "M?_<5'_#T__JF/_E:_^XJ]W_B%F??] _\ Y-#_ .2/(_XB
M!E'_ #^_\EE_\B?KE17Y&_\ #T__ *IC_P"5K_[BH_X>G_\ 5,?_ "M?_<5'
M_$+,^_Z!_P#R:'_R0?\ $0,H_P"?W_DLO_D3]<J*_(W_ (>G_P#5,?\ RM?_
M '%1_P /3_\ JF/_ )6O_N*C_B%F??\ 0/\ ^30_^2#_ (B!E'_/[_R67_R)
M^N5%?D;_ ,/3_P#JF/\ Y6O_ +BH_P"'I_\ U3'_ ,K7_P!Q4?\ $+,^_P"@
M?_R:'_R0?\1 RC_G]_Y++_Y$_7*BOR-_X>G_ /5,?_*U_P#<5'_#T_\ ZIC_
M .5K_P"XJ/\ B%F??] __DT/_D@_XB!E'_/[_P EE_\ (GZY45^1O_#T_P#Z
MIC_Y6O\ [BH_X>G_ /5,?_*U_P#<5'_$+,^_Z!__ ":'_P D'_$0,H_Y_?\
MDLO_ )$_7*BOR-_X>G_]4Q_\K7_W%1_P]/\ ^J8_^5K_ .XJ/^(69]_T#_\
MDT/_ )(/^(@91_S^_P#)9?\ R)^N5%?D;_P]/_ZIC_Y6O_N*C_AZ?_U3'_RM
M?_<5'_$+,^_Z!_\ R:'_ ,D'_$0,H_Y_?^2R_P#D3]<J*_(W_AZ?_P!4Q_\
M*U_]Q4?\/3_^J8_^5K_[BH_XA9GW_0/_ .30_P#D@_XB!E'_ #^_\EE_\B?K
ME17Y&_\ #T__ *IC_P"5K_[BH_X>G_\ 5,?_ "M?_<5'_$+,^_Z!_P#R:'_R
M0?\ $0,H_P"?W_DLO_D3]<J*^#/V;?VW/^&A/B')X#_X0S^P/+L9KW[1_:/V
MK/DNB[/+^S1==^<[N,=*^\Z^3SG),5E];ZOBX<L[7M=/1^C:/HLLS7#XRE[;
M#2YH[7LU^:1__]+]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#/_ ,!O^B;^&O\ P3V?_P :H_X9_P#@-_T3?PU_X)[/_P"-4?\ $<<)_P!
M\OO0?\0HQ'_/Z/W,_EWHK^HC_AG_ . W_1-_#7_@GL__ (U1_P ,_P#P&_Z)
MOX:_\$]G_P#&J/\ B..$_P"@>7WH/^(48C_G]'[F?R[T5_41_P ,_P#P&_Z)
MOX:_\$]G_P#&J/\ AG_X#?\ 1-_#7_@GL_\ XU1_Q''"?] \OO0?\0HQ'_/Z
M/W,_EWHK^HC_ (9_^ W_ $3?PU_X)[/_ .-4?\,__ ;_ *)OX:_\$]G_ /&J
M/^(XX3_H'E]Z#_B%&(_Y_1^YG\N]%?U$?\,__ ;_ *)OX:_\$]G_ /&J/^&?
M_@-_T3?PU_X)[/\ ^-4?\1QPG_0/+[T'_$*,1_S^C]S/Y=Z*_J(_X9_^ W_1
M-_#7_@GL_P#XU1_PS_\  ;_HF_AK_P $]G_\:H_XCCA/^@>7WH/^(48C_G]'
M[F?R[T5_41_PS_\  ;_HF_AK_P $]G_\:H_X9_\ @-_T3?PU_P"">S_^-4?\
M1QPG_0/+[T'_ !"C$?\ /Z/W,_!G]BW_ ).>\!_]?-Q_Z2S5_2%7F^B_!OX0
M^&]4@UOP[X&T+2M1M26AN;73+6">,D%24DCC#*2"1P>AQ7I%?DO'W%E/.,5#
M$4H.*C'EU]6_U/T3@_AV>6X>5&<E)N5]/1+] HHHKX8^L"BBB@ K\#_^"C?_
M "<6?^P/9?\ H4E?OA7X'_\ !1O_ ).+/_8'LO\ T*2OU?P:_P"1Q_VY+]#\
M\\3?^1;_ -O+]3PSP/XL_:>TSPM:V'PYOO%,/AY/-^SKIGVS[*"SL9/+,0V_
M?+;L?Q9[UK>'_P!G+]ICXQ^(S=7?AO6)[N\=3/J6MK- F.F]Y[K#/@=EW-CH
M#TK]C?V#/^36/!W^_J7_ *7W%?8%?29YXJU,'C,10PV%@I1E*/-U=FU=VMZ[
MGB95X?0Q.&HU:]>3BXI\O:ZV5[_D>"?LX? S3/V?_AK;>"[6<7NH3R-=ZA=!
M=HFNI%56V \A$50J \X&3R37X!_M)_\ )P/Q%_[#^H_^CWK^G>OYB/VD_P#D
MX'XB_P#8?U'_ -'O2\'<=5Q.98K$5Y7E*-V_F/Q+PM.A@</1I*T8NR^X_H1^
M%?P8^&?@#X>6/A+P]H-J+&XMH_M1FB262[9U!=KAV&9"2>AX X4!0 /YQ_B3
MI=MX-^+?BG1=#'D6^AZY?6]J!SL2VN72/KSP%%?U$Z#_ ,@/3O\ KVA_] %?
MS$?'3_DN7Q!_[&/5O_2R6M?!S&5:V-Q;JR<KI-W=[N[U,_$W#4Z>&PRIQ2LV
ME;M9']'?QJT/P;XD^%?B31/B%JSZ'X<NK;%]>12)$\4*LK$J\B.H)("X*G.<
M 9(K\</ _P 8_P!E/]G'X@3^+OA+I'B7QI?P6\UI%/JL]I;VH$I7=+ %MQ,&
M*J5#,JG:S#;S7W'_ ,%(CK _9Z@_LW=]F.MV?VW:#C[/Y<VW=[>=Y?7OBOSD
M_8N\6_L_>#?&VK:I\=882?L\8TN:[M7O+:*7<?-+1HDF'(V[&*8&&Y!(SS\!
M90O[#KXJISU(MM>R@[7V6MM6_GMT9MQ?F3_M:EAX<L)))^TDKVW?73_@B?M0
M_M:P?M)Z1HNFOX.3P_-HMQ)+'<_;?M<C)*FUX_\ 418!(5CR>5'%?9__  2[
MN)V\%>.;1G)ACU"U=5[!GB8,?Q"K^5?-O[;?[2_P[^,$&C^!/AA:>;I&B7#7
M3ZAY1MTFD*&,)%$RJVQ0<EF )/ &!D_1G_!+G_D4_'O_ %_67_HJ2O<XFP\:
M?"4HQP[HJZ:@VY-7FNKUUWMT/)R*LY\1)NLJKL_>223]U]M-.Y\L?MW?!7QI
MX0^,6N?$,Z?-<^&?$DJ7,5]&A>**5D59(96&=C!P2N[ 92,<@@5?!7[=GQ#T
M?P+_ ,*P\>Z+8>,/#+6)TUTEW6MV;0Q^4(_.CRG"<!C$6SR237T+\</VZ_CE
M\+?BQXG^'<_A[09=.TN]DBA%S:W1EFLG^:%F(N0A+Q,I)"XR>G:M#XJ>)_\
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MA/*X1K8Y<FGN**<D_O3^?7YGV%_P3U\07&M_LVZ=9W#LYT74+VR4L2?DW"<
M9[#SL#TZ5]P5\U?LE^*O&OCGX*:5XP\=V=K8WNKS3S0I:6XM4:VW;(W,:G&6
MVD@\97:?<_2M?SCQ9/FS/$R:2?/*Z3NKWUULKZ^1^V<.QY<!02=URK5JSM;3
M37H%?AE_P4V_Y+OH'_8M6O\ Z67E?N;7X9?\%-O^2[Z!_P!BU:_^EEY7V'@_
M_P CJ/\ AD?->)/_ "*Y?XD?=W_!/3_DVG2_^O\ O_\ T;7V_7Q!_P $]/\
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M:_\ !/9__&J/^(XX3_H'E]Z#_B%&(_Y_1^YG\N]%?U$?\,__  &_Z)OX:_\
M!/9__&J/^&?_ (#?]$W\-?\ @GL__C5'_$<<)_T#R^]!_P 0HQ'_ #^C]S/Y
M=Z*_J(_X9_\ @-_T3?PU_P"">S_^-4?\,_\ P&_Z)OX:_P#!/9__ !JC_B..
M$_Z!Y?>@_P"(48C_ )_1^YG\N]%?U$?\,_\ P&_Z)OX:_P#!/9__ !JC_AG_
M . W_1-_#7_@GL__ (U1_P 1QPG_ $#R^]!_Q"C$?\_H_<S^7>BOZB/^&?\
MX#?]$W\-?^">S_\ C5'_  S_ / ;_HF_AK_P3V?_ ,:H_P"(XX3_ *!Y?>@_
MXA1B/^?T?N9_+O17]1'_  S_ / ;_HF_AK_P3V?_ ,:H_P"&?_@-_P!$W\-?
M^">S_P#C5'_$<<)_T#R^]!_Q"C$?\_H_<S^7>BOZB/\ AG_X#?\ 1-_#7_@G
ML_\ XU7Q!^W_ /"OX8>#/@5;ZOX/\'Z/H5^VL6D1N+#3[>UF,;1S$IOB16VD
M@9&<<"O3R7Q>PV-Q=/"1H23F[7NC@S3PWKX7#SQ$JJ:BKVLS\5J_H4_8 _Y-
MA\._]?.H?^E4E?SUU_0I^P!_R;#X=_Z^=0_]*I*?C5_R*8?]?%_Z3(7A=_R,
M9?X'^<3[0K^>O]O_ /Y.>\1?]>VG_P#I+'7]"E?SU_M__P#)SWB+_KVT_P#]
M)8Z_-O!7_D;3_P"O;_\ 2HGW/BC_ ,BZ/^-?E(^+Z*[WX5V=IJ/Q/\'Z?J$"
M7-K<ZQI\4L4JAXY(WN$5D=6R&5@2"#P17])?_#/_ ,!O^B;^&O\ P3V?_P :
MK]HXRX^HY-.G"K3<N=-Z-=#\NX9X/JYG"<Z<U'E:6OF?R[T5_41_PS_\!O\
MHF_AK_P3V?\ \:H_X9_^ W_1-_#7_@GL_P#XU7QG_$<<)_T#R^]'U'_$*,1_
MS^C]S/Y=Z*_J(_X9_P#@-_T3?PU_X)[/_P"-4?\ #/\ \!O^B;^&O_!/9_\
MQJC_ (CCA/\ H'E]Z#_B%&(_Y_1^YG\N]%?U$?\ #/\ \!O^B;^&O_!/9_\
MQJC_ (9_^ W_ $3?PU_X)[/_ .-4?\1QPG_0/+[T'_$*,1_S^C]S/Y=Z*_J(
M_P"&?_@-_P!$W\-?^">S_P#C5'_#/_P&_P"B;^&O_!/9_P#QJC_B..$_Z!Y?
M>@_XA1B/^?T?N9_+O17]1'_#/_P&_P"B;^&O_!/9_P#QJC_AG_X#?]$W\-?^
M">S_ /C5'_$<<)_T#R^]!_Q"C$?\_H_<S^7>BOZB/^&?_@-_T3?PU_X)[/\
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M+.H_/?\ 9=^*/[.OP<OU\:_$;1-8\1>*H')LUAM[9[*R /RR)YEPC/,>NYE
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M_#/_ ,!O^B;^&O\ P3V?_P :H_X9_P#@-_T3?PU_X)[/_P"-4?\ $<<)_P!
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MT3?PU_X)[/\ ^-5S_P#$<<)_T#R^]&__ !"C$?\ /Z/W,_EWHK^HC_AG_P"
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MU&TGT_4($N;6Y1HI8I5#QR1N-K(ZMD,K D$'@BO+/^&?_@-_T3?PU_X)[/\
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M_B%&(_Y_1^YG\N]%?U$?\,__  &_Z)OX:_\ !/9__&J/^&?_ (#?]$W\-?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[7_I4C;PJ_W&I_C?Y1"BBBOQD_3@HHHH **** "BBB@ HHHH **** "BBB@
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M(>Q!]#R#U!P1@C-?G]K/_!,[X*WVH-=:3KFM:9;NQ)MUE@F503]U&>'> /\
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M444 %%%% !1110 4444 ?$?Q+_8*^#WQ4\=:O\0/$&KZ[;:AK4JRS1VMQ:I
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MU_M__P#)SWB+_KVT_P#])8Z_H4K^>O\ ;_\ ^3GO$7_7MI__ *2QU^O>"O\
MR-I_]>W_ .E1/SCQ1_Y%T?\ &ORD?.OP?_Y*WX)_[#FF_P#I3'7]3U?RP_!_
M_DK?@G_L.:;_ .E,=?U/5['CE_O&&])?FCS/"?\ @U_5?DS\I/\ @J3_ ,@'
MX>_]?.H_^@05^.U?L3_P5)_Y /P]_P"OG4?_ $""OQVK])\*?^1%0]9?^E,^
M'\0_^1M5_P"W?_24?TX_LR?\F]?#O_L!V/\ Z*%>YUX9^S)_R;U\._\ L!V/
M_HH5[G7\JYY_OM?_ !R_-G]!Y5_NM+_#'\D%%%%>4=X4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% '(^/O!>E?$7P7K/@77)
M)H;#7+:2UF>W95F5)!@E"RNH8=LJ1[&OEKX4_L*?"/X0>/\ 2OB-X:U?7+G4
MM',QACN[BV>!O.A>%MZQVL;'"N2,,.<=1Q7VG17KX+/L9AZ,\-0JN,)WNEL[
MJS_ \[%91AJ]6->K!.4=GVL[_F%%%%>0>B?/7Q\_9K\"_M%6^BVWC:^U*R70
MFG> Z=+#$6-P$#;_ #H9LX\L8QCOG-:WP)^ ?@[]GOPW?^%_!=W?WMKJ-V;R
M1]0DBDD$AC2/"F**)0N$!Y4G)//0#V^BO6>>8MX58%U'[)?9Z;W_ #//64X9
M8AXM07M'UZ[6_(^<_C[^S%X!_:+;0W\;7VI61T 7(@_LZ6&+<+KR]^_SH9LX
M\I<8QWSGC'2_ SX&>$OV?O"-WX,\&W=]>V5Y?27[O?R122B62..(@&**)=NV
M)<#;G.>>@'L]%$\\Q<L*L"ZC]DMH]-[_ )L(Y3AEB'BE!>T?7KV/C[XS?L1_
M!GXS:]-XLODN] UJYYGGTUXXTN'_ +\T4D;JS^K+M9OXB:Y?X;_\$^/@5X#U
M:+6]6%YXKN8#NCCU)XS:JPZ,88T0.1Z.67_9K[IHKOI\99I"A]6CB)*%K6OT
M[7WM\SBGPSE\JWMY48N6][=?38^&? '_  3^^#?PY\::-XZT36=?GO\ 0[E+
MJ%+BXM6A9XSD!PEJC$>N&!]Z^QO%7A7P[XW\/WOA7Q981:GI.HQF.>WF&5=3
MSVP00<%6!!4@$$$ UT%%<.8Y]C,75C6Q%5RE'9]5UT^9UX+*,-AH2I4*:47N
MNC/SG\1?\$T/@KJ=[)=Z#K6L:+'(<B 217$2>RF2/S,?[SL?>NW^&O\ P3_^
M!'P^UB#7[Y+WQ1>VKK)"-2E0V\<B'(;R8DC5^>TF]?:ON&BO6K<=YQ4I>QEB
M96]=?OW_ !//I\)9;"I[2-"-_3]-@KY2^,G[&GP4^-.J2^(M9LI]&UR?'FWV
MF2+#),1WE1U>)V]6*;R.K<#'U;17@Y=FF)P=3VV%J.$NZ=O^'/6QN7T,3#V=
M>"DO,_-:P_X)C?"*&[674/$^MW-NIR8T-O$2/0MY+?C@#\*^X/A?\(_A_P#!
MOP]_PC/P]TE--M'8/,^3)-/(!C?+(Q+.?3)P.B@#BO2:*]+-N*\QQT/9XJNY
M1[=/N5D<67\/8+"2Y\/247WZ_>PK&\0>'M"\5Z-=^'?$MA#J>F7R;)[:X021
M2+G.&5N." 0>H(!'(K9HKP(3<6I1=FCUY14DTUH?GMXH_P"";/P)UJ^FOM#U
M#6-!$K;A;P3Q36\8/91-$\F/K(:T? __  3I^ WA34HM4UR34?%#PL&6"^E1
M+8D=-T<*(S#/4,Y4]"",Y^^**^KEQYG#I^R>*E;UU^_?\3Y]<(Y8I^T5"-_3
M3[MOP(+6UM;&UALK*%+>WMT6...-0B(B#"JJC@  8 ' %3T45\FW?5GT2044
M44@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *_DR\0?\A[4O\ KYF_]#-?UFU_)EX@_P"0]J7_ %\S?^AFOW[P*^/%_P#;
MG_MQ^/\ BU\.'_[>_P#;3[H_X)M_\G"W/_8#O/\ T;!7[RU^#7_!-O\ Y.%N
M?^P'>?\ HV"OWEKY?QC_ .1Q_P!N1_4]_P ,_P#D6?\ ;S_0_]3]_**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OYC_V
MF_\ DX7XB?\ 8<OO_1IK^G"OYC_VF_\ DX7XB?\ 8<OO_1IK]N\#_P#?:_\
MA7YH_*_%;_=:7^+]&==^Q;_R<]X#_P"OFX_])9J_I"K^;W]BW_DY[P'_ -?-
MQ_Z2S5_2%7/XW?\ (SI?]>U_Z5(V\*O]QJ?XW^40HHHK\9/TX**** "BBB@
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MOZGJ]CQR_P!XPWI+\T>9X3_P:_JOR84445^$GZT%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\]?[?_ /R<]XB_Z]M/
M_P#26.OZ%*_GK_;_ /\ DY[Q%_U[:?\ ^DL=?KW@K_R-I_\ 7M_^E1/SCQ1_
MY%T?\:_*1\Z_!_\ Y*WX)_[#FF_^E,=?U/5_+#\'_P#DK?@G_L.:;_Z4QU_4
M]7L>.7^\8;TE^:/,\)_X-?U7Y,_*3_@J3_R ?A[_ -?.H_\ H$%?CM7[$_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OYC_VF_\ DX7XB?\ 8<OO_1IK^G"OYC_VF_\ DX7XB?\
M8<OO_1IK]N\#_P#?:_\ A7YH_*_%;_=:7^+]&==^Q;_R<]X#_P"OFX_])9J_
MI"K^;W]BW_DY[P'_ -?-Q_Z2S5_2%7/XW?\ (SI?]>U_Z5(V\*O]QJ?XW^40
MHHHK\9/TX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ7_7S-_Z&:_K-K^3+Q!_R'M2_P"OF;_T,U^_>!7QXO\ [<_]N/Q_Q:^'#_\
M;W_MI]T?\$V_^3A;G_L!WG_HV"OWEK\&O^";?_)PMS_V [S_ -&P5^\M?+^,
M?_(X_P"W(_J>_P"&?_(L_P"WG^A__];]_**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX!_X*2?\F]6W_8<L_\ T5/7
MW]7P#_P4D_Y-ZMO^PY9_^BIZ^MX#_P"1SA?\:/G>+?\ D68C_"S\&:_H4_8
M_P"38?#O_7SJ'_I5)7\]=?T*?L ?\FP^'?\ KYU#_P!*I*_>O&K_ )%,/^OB
M_P#29'Y#X7?\C&7^!_G$^T*_GK_;_P#^3GO$7_7MI_\ Z2QU_0I7\]?[?_\
MR<]XB_Z]M/\ _26.OS;P5_Y&T_\ KV__ $J)]SXH_P#(NC_C7Y2/G7X/_P#)
M6_!/_8<TW_TICK^IZOY8?@__ ,E;\$_]AS3?_2F.OZGJ]CQR_P!XPWI+\T>9
MX3_P:_JOR84445^$GZT%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7\]?[?_ /R<]XB_Z]M/_P#26.OZ%*_GK_;_ /\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OYC_V
MF_\ DX7XB?\ 8<OO_1IK^G"OCKQ?^PO\!?''BG5O&/B"VU"34M9N9;NX9+QD
M0R3,6;:H7 &3P*_2/#7BO"Y3B:M7%7M*-E97ZW[H^(XXX>Q&8T*=/#VNG?5V
MZ'Y!?L6_\G/> _\ KYN/_26:OZ0J^3/AY^Q5\#/AAXRTWQWX7M+Y=5TEG> S
M7;21AGC:,DK@9X8X]Z^LZR\2.*,-FV,IU\*GRJ*6JMK=ON^YIP1D%?+L-.CB
M+7<KZ>B7Z!1117YX?9A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH YOQCJUUH/A75M9L@IN+*VDEC#C*[E4D9 (XKA?@WXYUKQYH5[J.
MMK"LMO<^4ODJ5&W8K<@D\Y-=/\2_^2?^(?\ KRG_ /037DW[,_\ R*>J?]?I
M_P#124 ?2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\Z>-_BGXF\._$NR\)V"V[6-P]J&
M\Q"7Q,P#8(8?AQ7T77Q9\5?^2Y:7_P!=-/\ _0Q0!]IT444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7)^.M:O/#OA'5-;T_;]ILX3(F\97((ZCCBNLKSWXL?\DYU_P#Z]C_,
M4 9/P=\:ZQX[\,W.KZVL2SPWCP+Y*E5V+'&PR"3SEC7K%?/7[-7_ "(M]_V$
MI?\ T3#7T+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'SIXH^*?B;1_BQ9^"K1;<Z?<7-
ME$Q9"9-MP4#X8,!GYCCBOHNOBSQ[_P G#:;_ -?NE_SCK[3H **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .(^)?_ "3_ ,0_
M]>4__H)KR;]F?_D4]4_Z_3_Z*2O6?B7_ ,D_\0_]>4__ *":\F_9G_Y%/5/^
MOT_^BDH ^D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KXL^*O_ "7+2_\ KII__H8K[3KX
ML^*O_)<M+_ZZ:?\ ^AB@#[3HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/?BQ_R3G7_P#K
MV/\ ,5Z%7GOQ8_Y)SK__ %['^8H \\_9J_Y$6^_["4O_ *)AKZ%KYZ_9J_Y$
M6^_["4O_ *)AKZ%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XL\>_P#)PVF_]?NE_P X
MZ^TZ^+/'O_)PVF_]?NE_SCK[3H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S'XR_\DSUW
M_KG'_P"C4KD_V<_^2?R?]?LW_H*5UGQE_P"29Z[_ -<X_P#T:E<G^SG_ ,D_
MD_Z_9O\ T%* /__2_?RBBB@ HHHH **** "BBB@ HKB?B7XSB^''PX\5_$.>
MU-]'X7TF^U5K=7\MIELH'G,8<@A2P3&<'&<X-?CS_P /I?#'_1*KS_P;1_\
MR-1<J,&]C]O**_$:/_@M)X4,BB;X67JIW*ZK&Q ]@;<9_.OJKX$?\%,?V=/C
M9K=IX2NYKOP7KUZPC@AU<1K;SRL<+'%<QNR;F)PHD$98\+DXRKC=.78_0^BB
MBF0%%%% !1110 4444 %%%?$7[9/[:6F?L@CP@=2\*S>)O\ A+/M^WRKM;7R
M/L'V?.=T<F[?YXQTQM[YX!I7T1]NT5\9?L=?MB:3^UWI/B;4]-\,S^&F\-3V
MT+I-<K<B47*NRLK*D>,>6001Z<U]FT U;1A1110(**** "BBB@ HHHH ****
M "BBO+/B]\:OAG\"/"4GC7XI:Y#HNF*WEQ[PSS3RGI'#$@+R.>N%!P,DX4$@
M ]3HK\4/&G_!9WP587\]M\/_ (;WVLVB';'<ZA?QV!;'\7DQQ7/'H"X..N#Q
M6=X2_P""T7AVXO8H/'7PONK"T/\ K)].U)+N0?[L$T-N#^,HI7-/92/W HKP
M[X&?M&?"']HOPZ_B+X5ZZFHBW"?:[20&*\M&?.%G@;YES@@,,HV#M9L5[C3(
M:"BBB@04444 %%%% !1110 445Q/Q,\:1?#?X<>*_B)/:F^C\+:3?:JUNKB-
MIEL8'G,8<@A2P3&<'&<X- ';45^1?P>_X*Q>&_BU\4O"_P ,X_AS=Z6_B>_@
ML$NCJ4<PA:=MJL4\A-P!(S\PX_*ON?\ :E_:/\._LM_"F?XF^(-.EUAWNHK&
MSLH7$1N+J97=4:4AA&H2-V9MK$ <*3@47*<&G8^C:*_,G]D+_@I%HG[3WQ%D
M^%^L>#G\*:O-;375E(EZ+V"X$ W21MF&%D<)EAPP8 \J< _IM0*46MPHHKQ'
M]HWXT6O[//P9\0_&&\TI];A\/_9-UG'*(&E^U745J,2%7 VF7=]TYQCOF@$C
MVZBOS#_9C_X*6Z!^TE\7=-^$MIX#NM!GU*"ZF2Z>_2X13;1-*5*"&,_,%(R#
MP<<5^GE%PE%K<****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!Q'Q+_P"2?^(?^O*?_P!!->3?LS_\BGJG_7Z?_125ZS\2_P#D
MG_B'_KRG_P#037DW[,__ "*>J?\ 7Z?_ $4E 'TA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %?%GQ5_P"2Y:7_ -=-/_\ 0Q7VG7Q9\5?^2Y:7_P!=-/\ _0Q0!]IT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7GOQ8_Y)SK_P#U['^8KT*O/?BQ_P DYU__ *]C_,4
M>>?LU?\ (BWW_82E_P#1,-?0M?/7[-7_ "(M]_V$I?\ T3#7T+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%<IXD\>>!_!H#>+_$6G:&&7</MUW#
M;97IG]ZR\>] '5T5P_AGXG?#;QK-]G\&^+-)UZ4@MLL+^WNFVCJ<1.QP*[B@
M HK%UCQ+X<\/>5_;^JVFF?:-WE_:9XX=^W&[;O(SC(SCID5-I.MZ+KULUYH5
M_;ZC CF-I+:5)D#@ E2R$C."#CW% &I17+^*/&_@OP1;PW?C37]/T""X8I%)
MJ%U%:I(PZJK2LH)YZ"MZQOK+4[.'4=-N([NTN4$D4T+B2.1&&0RLI(8$="#B
M@"U1110 445#<7%O9V\MW=RK!!"K/)([!41%&2S,>  .23TH FHKD_#'CWP+
MXW%P?!?B/3=?^R$+-_9]Y#=>43G ?RF;:3@]?2NLH **** "BBB@ HHHH **
MQ=8\2^'/#WE?V_JMIIGVC=Y?VF>.'?MQNV[R,XR,XZ9%3:3K>BZ];->:%?V^
MHP(YC:2VE29 X )4LA(S@@X]Q0!J4450U/5=+T6T:_UB\AL+92 99Y%BC!;@
M LY Y[4 7Z*XO_A9/P[_ .AITK_P.@_^+H_X63\._P#H:=*_\#H/_BZ!V.TH
MK%T?Q)X>\0B4Z!JEKJ0@V^9]FG2;9NSC=L)QG!QGKBMJ@045S4WC3P=;WHTV
MXUVPBNV<1B%KJ)9"Y. H0MG)/&,9KI: "BN:F\:>#K>]&FW&NV$5VSB,0M=1
M+(7)P%"%LY)XQC-=+0 4444 %%%% !1110 4444 %%%0W%Q;V=O+=W<JP00J
MSR2.P5$11DLS'@ #DD]* )J*Y/PQX]\"^-Q<'P7XCTW7_LA"S?V?>0W7E$YP
M'\IFVDX/7TKK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /BSQ[_ ,G#:;_U^Z7_ #CK[3KXL\>_\G#:;_U^Z7_..OM.@ HHHH ****
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M?"C]KG]G#XW:@FC_  U\=V.IZG)G992B6RNY-O)\N"Z2*1\#KL4\<]*_ ?\
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MCW\.?"&K()+#6/$.EVURAZ-!)=1K(O/JF129I16[/U4_9:_X).V'CGP/IOQ
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M@@ LY/\ 0]33,IQL[!1113)"BBB@ HHHH **** "BBB@ HHHH XCXE_\D_\
M$/\ UY3_ /H)KR;]F?\ Y%/5/^OT_P#HI*]9^)?_ "3_ ,0_]>4__H)KR;]F
M?_D4]4_Z_3_Z*2@#Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OBSXJ_\ERTO_KII_P#Z
M&*^TZ^+/BK_R7+2_^NFG_P#H8H ^TZ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSWXL?\
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MK/\ 7_!W_=U_^>GU[[_P1T_Y-C\2_P#8WWO_ *;["O O^"UG^O\ @[_NZ_\
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MCP_^R!\1M7T"^GTV^@MK/R[BVE:&5-]];HVUT(894E3@\@D=#5,PCNC\_/\
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M]._]'+7[\?\ !5W_ )-$U'_L+Z;_ .C&K\!_V-_^3J_A1_V,>G?^CEK]^/\
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MJ.45<AE/*C&.<G4:5X:'M?\ P62_Y+_X._[%B+_TMNJ_3/\ X)=?\F9^$?\
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MUX_^'"64FIWEA+ISB^A:>+R)9(I6PJO&=VZ)<'/3/%?9W_#W3]JS_GV\.?\
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MU+M>&A_4)7Q/_P %%_\ DS#XE_\ 7O8_^G"VK[8KXG_X*+_\F8?$O_KWL?\
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M_)PVF_\ 7[I?\XZ^TZ^+/'O_ "<-IO\ U^Z7_..OM.@ HHHH **** "BBB@
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MXAT7PCX?U/Q5XDNTL-)T>VFO+NXDSLA@@0R2.V,G"J">!GTH)-FBOA/X0?\
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M#O"/CO1W\.^.-#L?$.E2LKO::C;17=NSH<JQBF5D)4\@XX/2NCHH"YYGX/\
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M7K/Q+_Y)_P"(?^O*?_T$UY-^S/\ \BGJG_7Z?_124 ?2%%%% !1110 4444
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MD,8FG:,$?*[[T7=UV@@<,V?3_P#@K_\ "/PKJ/PCT3XR06:0>)-&U.'3Y;E
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MZ=+/?_!3QG:ZS:Y+)8ZRAM;E5[*+B%7BD;W*1"IL=$9Q:LS[2^*W[._[)/\
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M>N#7])G[#'[7WBWXP_!'QW\6OCS?V%A9^$;YU>YMX/L\4=K%;),Y8;FW-EN
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M^(7B/X+^#_$?Q5,/_"5:OI\5[>K;Q>1'&UUF6./R\G:T<;*C<_>!->P4BJ%
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MOQQ_X+,_\D<\!?\ 8>D_])9*_8ZOQQ_X+,_\D<\!?]AZ3_TEDH9-+XD?,_\
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M;[_L)2_^B8:^A: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR'QQ\
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M1H+>WAN-.TV.R=[R9BYCWH?G"QKEEP<90\9&?Q,_;).OG]JOXK?\))O^V?\
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M;O&XDAG"<%PAW*R@YVN2,E0I_K$EBCFC>&9!)'("K*PR&!X((/4&OS!^)_\
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M -+;JOW[^&OPK^'?P>\,Q>#OAEH%KX>TB([_ ";9<%W( ,DKL2\CD  N[,Q
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M GZ_\;?\$A?V;O$6J2ZEX7U77/"T<IS]DM[B*YMDY_@^T1O*/^!2M6U\-/\
M@DW^S-X'U>#6_$LVJ^-);=@ZVVHS1QV9*\C=%;QQLXSU5G*GH5(SE:E\T+W/
M4_V5KOQ[^T)^QY<3?%6SLM(N_'UIJMM&+&S6TC^PW:-;1S&%3@EAE@>-R;3[
MG^:?POJOCG]ECX_:?JVJZ9Y'B3X?ZLK3V4^Y%D:!L.A8<[)4)VN."K!AD$5_
M9Y:VMK8VL-C8PI;VUNBQQ11J$1$085548   P . *^7OV@OV,_@+^TJR:A\0
M]%>'7(H_*CU;3I!;7P0=%9]K)*%_A$J.%_AQDY;1$*B3=SXM^*?_  5H^!<G
MPFU.7X:Q:M+XSU*RDAL[::V\@65S*A599IMY0B(G=^[+%B . 2P^-O\ @GG\
M6OVIOC3^TSH&G:SX_P#$&L^&-$CN+_6([J^FFMO(6%XXDD5R5)>9D !YZL/N
M\?:%G_P1P_9[AOEFO/%OB:YM5;/D^=9H6 _A9Q:GKWP ?3%?HI\&/@-\*OV?
MO#!\)_"K0HM'M)6#W$F3)<W4BC >>9R7D(R< G"Y(4 <4#<HI61\6_\ !630
M;_6/V2I[ZSC:2/1=;TZ\G(&=D3>9;[C[;YE'XU^2/_!.W]K'P!^RUXS\5S_$
MBVO9-)\36=O$LUC$LSPS6LC,N]&9#L99&Y4D@@<8)(_J'\0>']#\5Z'?>&O$
MMC#J>E:G"]O=6MP@DBFBD&&1U/!!%?FQXE_X)(?LI:]J$M[ILWB'P]'(<BWL
M+^)HD]E^UV]P^/JQH:"$U:S/2_VE/VKO%O@_]E/2OVEO@#IEKJ]I?W%G+(NK
MVTS+'IUSOC,C1PS1,K";RAG>0 3D=Q\&?!K_ (*#?!?]H675_"_[=7AGPU;0
M*L/]D7<6DW$\()+B9)'=[J6%^4*.FQ<;]S XS^S/P_\ A)X0^'GPITKX-64;
MZMX<TJP_LW9J(CG:XMR"K+. B1ON!(8! ".U?G]X]_X)&?LT^*=3EU3PK?ZU
MX1$N3]EM+B.XM5)YRJW,<DH^GFX] *!1<=F?B_\ MJZ7^ROIGQ-M%_93O7NM
M$FM-]^B-/)9PW9<X6W>Y'F,"F"PRR@X"GJJ_NO\ \$L-+\0Z9^R%HC:ZDD<-
M[J.HW%@L@(_T1Y< J#T5I5D8>N<C@Y/'_#S_ ())?LT>$-5AU?Q3=ZQXQ,."
M+6]N(X+1F!R"R6T<<C?0R[3T((K]/K&QLM,LK?3=-MX[2TM(TBAAB4)''&@V
MJB*N JJ   !@#BA(=2::LBU1113,0HHHH **** "O/?BQ_R3G7_^O8_S%>A5
MY[\6/^2<Z_\ ]>Q_F* ///V:O^1%OO\ L)2_^B8:^A:^>OV:O^1%OO\ L)2_
M^B8:^A: "BBB@ HHHH **** "BBB@ HHHH **\E^._Q'O/A#\'/%_P 3M/LX
M]1N?#6G37L=O*Q1)6B&0K,N2 ?45^)?_  ^?^(G_ $3;2O\ P-G_ /B*5RXP
M;V/Z#J*_ C1_^"TGB:*Y!\0?"VSN;<]1:ZI) X]\O!*#],#ZU^IW[,/[8'PF
M_:JT>\N? LD^GZSI01K[2KX(EU"K\"1-C,LD1;Y0ZG@X#!20"7"5-K<^J:*^
M//VV?VH[K]E#X36OCC2M%37=4U;48]-M(IG:.WC=XI)FDE*_,0%B("@@DD<@
M UXS^P7^W5XA_:PU/Q+X5\9^'+71M7T&WBO(Y]/:0VTT,C^6RLDI=D=6VD?.
MP8$\+M^9W%R.US]*:***"0HHHH **** "BBB@ HHHH **** "BBB@ HHK\@/
MVLO^"EWC+]G/XYZ[\)-(\%6&LVND16<BW4]U+'(_VJVCG(*JI VE\#V%%RHQ
M;V/U_HKR[X)?$"[^*WPA\'?$J^M$L+CQ-I=KJ$EO&Q=(FN(PY16."0,X!->H
MT$M!1110 4444 %%%% !117DOQW^(]Y\(?@YXO\ B=I]G'J-SX:TZ:]CMY6*
M)*T0R%9ER0#ZB@$CUJBOY\?^'S_Q$_Z)MI7_ (&S_P#Q%6[+_@M%XVCG5M1^
M&&GSP]UBU&:)C]&:&0#_ +YI7-/92/Z Z*^(/V6/V\_A!^U)<OX;TA)_#?BZ
M&-IFTF^96,T:<N]M,N%E"@_,,*X&3LV@M7V_3(::W"BBB@04444 %%%% !17
MY7?MU?\ !0?Q3^RY\0M)^&O@;PQ9ZM?W.G1ZE<W6HM+Y*QS2R1)'''$T9+?N
MF+,6QR !D&OK;]D7]H5OVG/@KIWQ0N=)&B7SW$]G=VR.9(A/;L 6B=@"492K
M 'E22N3C<2Y3@[7/INBO&=8_:-_9[\/:M=Z!KWQ.\,:;J=A*T%Q:W.LV4,\,
MR':T<D;RAE93P5(!!ZU[(CI(BR1L&5@""#D$'H0:";#J*_&K]KC_ (*=^-/@
M/\<=7^$G@;PAI]_;^'/LZ7=SJ3S;YY)X$G(B6)D"*JR!<MNR03C&*_3[X&?%
M*V^-GPB\*_%6UL7TQ/$EDERUJ[;S#)DK(@?"[E#J=K8&X8.!G%%RG!I7/5Z*
M**"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /BSQ[_ ,G#:;_U
M^Z7_ #CK[3KXL\>_\G#:;_U^Z7_..OM.@ HHHH **** "BBB@ HHHH ****
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M>/?_ (CZ'^W=^W7X[TJ;Q7X(U(#3U,%HATZ72])L4E8>:_F7.!EBH+EG9R%
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MXZ?5-7_9,^+GA_X@Z?8./,LI+R%[BV$F3'&]S9F:)G8*<%TA!P?2OVA_:_\
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M)T-^V?H_QHT[P?\ %^R\8V/@+3=(NHHHM:L[R*PB>-46"-)+A ORCA%#< 8
MP*$*>L;GQ-_P5 _Y//\ &G_7OI/_ *;X*_;[P'I]_J__  36L]*TH,;V\^&D
M\, 098RR:6ZH !U.2,5^2_\ P48^ _QQ\<?M:^+?$G@OX=^(M?TBY@TP17FG
MZ1>75M(8[&%'"RQ1,C%6!4X/!!!YK]W?V5M#U?P[^S5\,_#_ (CL)M-U*Q\/
M:=#<VMU&T4T,BP*&CDC<!E93PRL 0>",TT*;]U'\N?[$.OZ)X9_:Q^&6L>(I
M8X;%-62)I)6"HCW"/#$S,> !(ZG)X]:_K]U/4]/T73;O6=7N8[.QL(I)[B>5
M@D<442EG=V/ 55!))Z"OYO/VP/\ @FA\4_ 7C/5/&?P'T27Q3X,U"5[F.QL1
MYE_II8[C!Y'WYHP21$T8=@O#@$!F\*U_QE_P42^(7A4_"77[?QSJVD2HMO+9
M/I=UYDJ+@;)Y1 )I%Z;A(Y!_BI+0J<5+5,^:/!T<GBGXXZ)%X:C:)]7\16PL
MT0$LIGO%\H =<C<,5^S'_!:C_D"?";_KXUG_ - M*3_@GW_P3L\:^!?&VG_'
M+X\V2Z7=:/F71]&+K).MP1A;FY*%D38"3''N+;\,VW:%;NO^"N?PP^)7Q)T?
MX8Q?#KPGJ_BI]/GU8W*Z587%\8!(MKL,@@1]@;:VW=C.#CI1;0;DG)%[_@C7
M_P D(\:_]C*W_I';UX__ ,%K/];\'/IX@_\ <?7TC_P2>^'?C_X<_!7Q;IGQ
M"\-:GX7O+KQ TT4&J6<UE+)%]DMUWJDZHQ3<"-P&,@C.0:\K_P""N_PK^)_Q
M+;X4O\.?"&K^*AIHUP77]E6%Q?>1YWV'R_,\A'V;]C;=V,[3CH:?0A/WST#_
M ((Z?\FQ^)/^QNO?_2"PK]8:_,K_ ()3> O'7P[_ &=O$&B?$'PYJ7AC49O%
M-W<1VVJ6<UE,\+65DBR+'.J,4+(P# 8)4C.0:_36FC.INPK^3'_@I/\ \GK_
M !(_W]+_ /37:5_6=7\QG_!0/X _';QE^UYX_P#$O@_X<^(]=TB];33!>V&D
M7EU;2A--MHVV2Q1,C;75E.#P00>129=%ZG[H?L3?\FF?"K_L!6O\C7RI_P %
M?/\ DUG3/^QGL/\ TFNZ^P/V0M!UOPQ^S'\-?#_B33[C2M4L=%M8KBUNHFAG
MAD"\I)&X#(P[A@".]?-'_!4WP+XW^(7[-VG:%X!\/:CXEU)/$5E.UKIEI->3
MB)+>Y5I#'"KL%!906Q@$CU%'0F/Q'Q?_ ,$6?^1C^*W_ %Z:1_Z,NJ_93]H?
M_D@'Q,_[%C6O_2*6ORK_ ."1WPG^*7PVUWXF7'Q%\':SX6COK;2EMVU73[BQ
M$S(]R7$?GHF_:"-VW.,C/45^L'QVT[4-7^"'Q#TG2;66]OKWP[JT$$$"-)+-
M+)9RJD<:*"S,S$!5 )).!0AU'[Q_+E_P3O\ ^3S/AG_U]W?_ *0W%?N-_P %
M'_VL?%W[,OP[T#3_ (<M%;^*?&4]S%!=RHLHM+>S5#-(D;@HTA:6-5W@J,DX
M) K\EOV$/V?OCSX1_:S^'OB/Q9\-_$FB:397-TUQ>7VCWEK;0J;*=07EEB5%
MRQ &2,D@#DBOUE_X*1_LH^+OVE?AQH>K?#L)<^)O!4MU-#9.P0WEM=HGG11L
M>!+NAC*!B%.&&<D4EL:3:YE<_(#X ?L\?M/_ +>D^L^)M6\>W)T/3;@6]UJ&
MLWMS=!IW D,,$ )R41@Q'R(H( /8>;_MD?LAO^R-KOAG0+GQ=%XIN/$-K/=,
M([3[(;=875%R#-*6#DG!^7[IZ]NC^#>O_M^?LTW.H>$/A=X:\3Z*=6E$D]A)
MX?DNTDF ""5$GMY &( &Y,;@!G( J'XU?LI?MM:W)I?Q5^)WA;7?%GB#QBUP
M\L=K:SZE>VJ6PB$?VI+6-TMED$F(8L@@(PVKC%(N^NY^R?\ P25_Y--7_L/:
MC_Z#%7\^O[3@*?M+?%@,,$>+M=S_ .!\U?T8?\$PO!/C/P!^S&N@>.] U#PY
MJ?\ ;5_+]EU*UELY_+<1;7\N95;:<'!Q@XK\UOV[OV _C>/C5XF^*?PJ\.S^
M+?#GBRZDU)TL );NUNISNGC>#/F.&D+.K1JPP<'!'+>Q$)+F9^X/[3L$VJ_L
MS?%2#37R]SX4UKRRO.X-8RD ?[PX_&OYW?\ @E;/;P_MAZ#',,O-INJ)'[.+
M=F/_ (ZK5^@G_!.?0OVF];LOB'\._P!HRV\56?AI]%@T[3H]?@NHHT682PR+
M;-=* VV/ PI( P.!BORA_9MU:^_9Q_;1\*Q>*)!9R^&?$<FC:BYX6-)7?3[A
MS_LJKLWT&:&$(V31_61X\U+P/I7@[5KGXE7MCI_A>2!K?4)=3FC@L_(N?W)2
M:24J@60N$P3R6 ZFOP-\<?\ !-CX2?%#7]3E_9 ^,OA[7I8U:Z.@S:A#>O;0
ME@#BZLWF?RPS!5\R'C(#2$G-?N3\<OA3I?QP^$GBCX4:Q<-9V_B.S:W%PJ[S
M!*K"2&7;D;MDBJQ7(SC&1G-?S/+\!?VY/V,/B3-XD\"Z!J\%[ LUM'JNBVG]
MJ6-W:LP)#JL<J;'VJP2=%8$ [0R@ALBEY,\;^*7P+_:._9!\3:?J'BNUO?"5
MY<E_L&JZ;>?NYC'@L(KFV?*L,@E&VMCG;BOZ!_\ @F[^T]XS_:0^$NJQ_$5T
MN_$?A"[BLY;Q%"&[MYH]T,LJK\OFY5U8J #@'&2:_&;XEZC^WS^VC>Z'H/BW
MPCK6L0:8[FTBBT<Z=91RR *\LLS1QQ!B !F20!>0N,G/[F?L%_LKW_[+7PBG
MT;Q/<QW7BGQ)<+?ZF(3NBMR(PD=LC='\L9+.."S-C*@$I%U7[NNY\!?\%JKV
M,R_"'3EP9$7796]0&-BJ_@<'\J^J/^"2VGS67[)B7,I)6_UW49TSV51%%Q[;
MHS7YF_\ !7'X@6_BG]IFS\(64N^+P=HUM:S+G(6[NF>Z?_R%)#GW%?MU^P]\
M-YOA7^RM\//"UXA2]FT\:C<JWWEFU)VNV1AZQB4(?]VA;DRT@CZNHHHJC **
M** "BBB@ HHHH **** /,?C+_P DSUW_ *YQ_P#HU*Y/]G/_ ))_)_U^S?\
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M?? NGM<>(?#*+;:K# A:2ZTUF^24*H)9[=VYP,^6S$G$8%?-/_!,C]F/Q/\
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M6KN.PD$DB;N@*J#RPR6T%&7OZF[!^TM_P58MH8[>W^#L$<42A$5=$G 55&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD[X;_P""M_P=\0>/]+\$3>$]5TN+4M3ATYK^[FMDM[=9IA"9YOG.V- =[\\
M&OK_ /8EU^]\2_LF_"W5-1;=.NB6]J23DE;/-NA)]2L8S7\E6D^&+SQM\2[/
MP9I\J076O:O'I\,DN?+22ZN!$K/M!.T%@3@$X[4VR*<$[W/Z.](_X*E_"'QC
M\:_#WP@^'OA[4=:@U_5K;2DU>5DM;?=<S"+SHXF#RO&,Y&\1L?05^1G_  5
M_P"3S_&G_7OI/_IO@K]D_@9_P3$^ 'P<U;P[XRO;C4O$GBO0+B"]CO)[CR+<
M7<!#*T=O"%PBN-P5W<^I(K\;/^"H'_)Y_C3_ *]])_\ 3?!29=.W-H?T,_LC
M7=K8?LF?"V^OIDM[:W\+Z=)++(P1$1+=2S,QP H R2> *^+/$?\ P5Z^"^F^
M+KWPSX8\(ZUXE@@NC:VUW:F%4O"&V*\,;-O*NWW,@,1C@$XK\X?CS^VU=:K^
MS-\.OV9/AA=/!867A[38?$EZF5:XF6!<V,9Z^6A_UQ_C;Y/NAM_VI_P3-_89
M&@6VG?M)?%W3\ZG<HL_AS3IU_P"/:)QE;Z53_P M7!S #]Q?WGWBNQW)<$KN
M1^PNB^+?-\"VWC;QG9'PBILA>WMOJ$T8-@@3>XN)5;RU,:_?.[ YYXK\R/B7
M_P %>_@1X3UB?1_ >@:IXS6V9D-XA2QM)"IQF)I=TK*?4Q+[9K/_ ."P/Q3U
MGPE\&O"_PVT>X>V3QM?S/>,C;3+:::J,T)]5:6:)C_N =":_*W]C"_\ V,/#
MMWK/B;]JPW&I7<3QQ:7IHM;B>UV%29)Y?(X=LD*J,=HP2025*C80@K79^N'P
MN_X*Y? #QKK5GH7C?1]3\$O>,$^V7'EW5A$QZ>9+$1(H)XW>5M'5BHR:_4[3
M]0L-7L+;5=*N8KVRO(DF@GA=9(I8I &1T=25964@@@X(Y%?RA?MH:C^QAXCN
M]%\2_LI^?IMW*TD6JZ=]EN(+4J%!BGB$_"-D%65>#D$ $,6_7#_@D=\4M;\;
M? #5_!.O79NV\$:E]FL]W+QV-U&)8XR>I"R"7;Z+A1PHH3%.FK70_P"*?_!5
MWX7?"WXD^)?AO?\ @K6;ZY\,ZA<:=-/%);K'));.8W9 SYVD@XSSCJ!TJS\6
M?^"KWP0\!>-)O!'@O1K[QM-:S_9YKVVECMK'S-P5A#*V]Y0IR"P0*<?*S YK
M\)/VO?\ DZ;XL_\ 8SZK_P"E+U^V_P "_P#@D[\#-$\+Z-KGQ3O;_P 4^(9H
MX+J=8;@VEA&Y ?RXDC59649P6=\MC(5,XI:E.$59L_7&OE[]M?\ Y--^*O\
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MO^"H'_)Y_C3_ *]])_\ 3?!7[<>!/A1:_&__ ()T>&/A=<*IDUWP78QVK/\
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M?[LD[!3[PU^+?QK^)ES\<OCSXA^('C#49(;37=6;]Z09OLFGB39$B(.6$,
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M ?_0_?RBBB@ HHHH **** "BBB@!KHDB-'(H96!!!&00>H-?SF_L^"X_8O\
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M<M_$NN?VAXWO;1Q)%%JTD7V)77HQMX8T$F#VD9U_V:_2NBBQ/M)=Q  H"J,
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M,]U\PZ@32. ?0"O?:**9FV%%%% @HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B/B7_P D_P#$
M/_7E/_Z":\F_9G_Y%/5/^OT_^BDKUGXE_P#)/_$/_7E/_P"@FO)OV9_^13U3
M_K]/_HI* /I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *^+/BK_P ERTO_ *Z:?_Z&*^TZ
M^+/BK_R7+2_^NFG_ /H8H ^TZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSWXL?\DYU_\
MZ]C_ #%>A5Y[\6/^2<Z__P!>Q_F* ///V:O^1%OO^PE+_P"B8:^A:^>OV:O^
M1%OO^PE+_P"B8:^A: "BBB@ HHHH **** "BBB@ HHHH ^7OVU_^33?BK_V
M;O\ ]!K^:S]@GQAX6\ _M:> O%OC75;?1-%L'U W%Y=R"*"(2:?<QIO=L ;G
M95'N0*_J0_:%^'>L_%KX(^-?AIX>GM[74_$>F7%G;2W3.L"RR+A3(R*[!<]2
M%8CT-?@G_P .<_VF_P#H9O"'_@;J'_ROJ6C>G)6:9^Q'CG]O;]D?P?X?O-5N
M_B#INN>7$Q%EIC_;KBX/3RU2/*Y;I\[*O<D#)K^3@K>^*_&&WP[8^3=ZQ?XL
M[2W!.R2XE_=11@<\%@JX]J_4FS_X(X?M&O,%O_%GA2&+NT5S?RM_WR;)!^M?
MH%^RI_P3$^'_ , _%5E\2/'.M-XU\4:8PEL5$'V:QLIATE6,L[2RH>4=B IY
M";@K :N4G&.S,_\ X*Z)+'^RCHZ7#^9*OB73P[8QN86MWDX[9-?+W_!%G_D8
M_BM_UZ:1_P"C+JOTD_;N_9S\;_M/_!>S^'7@&^TZPU*WUBVU!I-3EFB@,4,,
M\; -##,VXF5<#;C&>1QGQC_@GO\ L6_%#]D_5/&]_P#$75=&U%?$D-A%;#2I
MKB8J;9IF<R>?;P8SYB[=N[/.<8&7;4A27)8_"W]M[P7J7@7]K#XG:7J4)B-]
MK5UJD)[/#J;_ &N-E/<8EP?0@CJ*_IJ_9R_:-^&'Q6^!_ASQS:^(K&U:#3X8
M]3AN+F**2RNH(PLZ3*S#8 REE)P&3##@UP?[87[$'@']K+3;34;J\;P[XPTF
M(PV>JQ1"4-"6W>1<Q94R1@DE<,K(22"065OQZU3_ ()!?M/VFH-;:=JOAN_M
M=QV3B\N(_ESP61K;(..H&['J:15U):L^:_V[?B_X=^-W[3OBWQIX0G^U:%$;
M?3[.<8VSQV42Q-*I'5)) [(>Z%3QTK^@/P/X*U+X>_\ !..3PGK,)M[^U\ :
ME+/$WWHY;FQFN'1O]I3)@CL17RQ^R[_P2=TSX>>*=/\ 'WQYUNU\2WNER)/;
M:18(YL!/&=R/<2S*CS*IP?+\M%)'S%ERI_5SXJ^%M0\<_"_QAX*TF2**^\0:
M/J&GP/.66)9;NW>%#(55F"AF!8A2<= >E-(4YK1(_E:_X)W_ /)YGPS_ .ON
M[_\ 2&XK^E3]L#_DUCXL?]BSJG_I.]?F#^RI_P $ROCO\#OV@/"'Q5\7:]X;
MNM(\/S7$L\5C=7DERPEMI85"++9Q(?F<9RXP,GD\']=/COX#U;XH_!?QO\.=
M!F@M]2\2Z/>Z?;27)98$FN(61#(45V" D9*JQ Z ]*$A5))M6/YH?^"87_)Z
M7@C_ *X:M_Z;KBOW_P#V\?\ DT'XH_\ 8*/_ *-CKX$_8Y_X)N_'']GK]H/P
MY\6/&FN>'+W2-(CODEBT^YO)+EC<VDL";%ELXD.&<$Y<<9QD\']0?VE?AEKG
MQE^!/C/X7^&;BVM-4\16)MK>6[9TMU?>K R-&DC!?EZA6/M0D.<ES)G\\G_!
M*'_D[O3O^P/J7_H"U]#?\%C?BGXO3X@>$?@[:WDUMX;&D)K$\",5CNKF>YFA
M7S /O^4L&5!R 7)ZU[A^Q'_P3N^-/[-OQTMOB=XZUOP_?:7!87=J8M-N+N6X
M,EPH53MFM(5VC!R=V?8U]2_MN?L1:'^UGHFG:IINI+H/C30(WBLKR12]M-!(
MP9H+E5!?:&R4=<E"6^5@<4K:#<US7/SC_8%_8)^ WQN^$"_&'XJZI<:Q-+=7
M,+:;;70M8+*.V8K_ *2T?[W>X'F#YT 0KP<YKX"_;*T;X >&_CA?^'?V;BC^
M%-,MH;>22*XGNHI+Y"WGM'-.[EU^Z-RG82#MR.3]9Z=_P2*_:E&JOILVN>';
M.PE.R6Z2^N61H^^(Q;!V]@P SW'6O1OB#_P1N^)4-YI4/PK\8:/>VB6$8U"?
M69;BTEDU#S)#(8(;>VN%2#R_+"AI&;<&)XQ18M25[W/U0_8#_P"3//AA_P!@
MU_\ THEK^7WX._\ )R?@C_L;=-_]+XZ_K*_9B^%VO_!;X"^#OA;XIN+6ZU7P
M]:-!<2V3N]NS&5WS&TB1N1AAU0<U^-_@#_@E#^T/X7^+OASQ[J7B+PL^G:1K
MMGJ<R0W=\TY@M[I9G"*UBJERJD %@,]6 YIV(A))L_H)K^4W_@J!_P GG^-/
M^O?2?_3?!7]65?BA^V1_P3>^./[0W[07B#XK^"]<\.V6D:M%8I%%J%S>1W*F
MVM8X'W+%9RH 60D8<\8S@\4-$4FD]3X!_:%_8[NO"/[/'PR_:6\ V[S:%KN@
MZ8=?@7+&SOI84 N1U/E3MPV>$E/HX"_?_P#P2^_;4_X26PL_V:OBA?YU:PCV
M^'+R9N;FWC&38NQ_Y:1*,PG^*,;."B[OT]^$OPC3PM^SUX7^"?Q!AM-933]!
MM]'U.--TEI<!8!%,J^8J,T;<@$JI(YP#7XP>+_\ @D/\;M'^(][KOP7\8:)9
M:':WHNM'EO[N]M]1M@K"2,.8+25=\3<*ZOEMH;"D[0K%\Z:LSVC_ (+.^#=1
MU#P#\-_'EO$7L]#U"_L)W'.QM1BBDC)]C]E89]2!WKXN_P""=GP6_97^/UUX
M@\!?&J*;_A,(Y$N=*5;Z2T6ZM2H62.,(P#R1N-Q7[Q5LC(5MO[^VWPOUOXI_
M 2/X6_M.V^FZSJNI67V75WTN20VLTD;?N[F!I(H727Y4EX0!),A<J!7XK?$W
M_@CK\6M+UF>;X2>*]+US1V9FB34VDLKV-<_*C>7'+%(0."X9,GG8.@&@A)6M
M<]!_:O\ @1_P3S_91CT:UU_PKJOB'6-7=\:=9:W(MQ! BY\Z57?Y48D*N<;C
MG&=IKZL_X)H:G\ ==\*>.-9^ G@W5?"5FU[:6]]_:=[]M^T211NZ>6VX[=@D
M.X8'WAU[?GAX-_X(^_M!ZSJR#QSXCT/0-.+#SIHI9KZYP3R4B$<:,<?WI5K]
MWO@!\"/!'[.7PTT_X9> XY#9VK-/<7$Q!GN[J7'F3RD #<V   ,*H51P*$*;
M5K7/Y0/VO?\ DZ;XL_\ 8SZK_P"E+U_8;X:_Y%S2O^O2#_T6*_"'X[?\$K?V
MA/B?\:/''Q%T#Q#X7M]-\2ZQ>ZA;1W-W?).D5S,TB"14L74, >0K,,]":_>G
M2;-]/TNSL)&#-;0QQ$CH2BA21^5-(562:5C0KY>_;7_Y--^*O_8!N_\ T&OJ
M&O&_VA?AWK/Q:^"/C7X:>'I[>UU/Q'IEQ9VTMTSK LLBX4R,BNP7/4A6(]#3
M9E'<_EM_8*\&^%?B!^UGX"\(>-M*M];T74'U 7%G=()(91'I]S(FY3P=KJK#
MW K^F:R_8]_98T^=;FW^%'ALNO(\S38)1_WS(K#]*_,W]DC_ ()I?';X"_M#
M>$OBSXPUWPW>:1H+7C3Q6%U>27+"XLY[==BRV<2'#R G+CC.,G@_N%22-:L]
M=&4-,TO3-%L(=+T:SAL+*W7;%!;QK%%&OHJ( H'L!7\^/_!9?P7J5K\5_ GQ
M#,).GZGHKZ6)!R!-8W,DY4^A*W0(]<'T-?T.UXW\=_@3X _:*^'=[\-_B):O
M+87#+-#/"0ES:7,>=D\#D,%=<D<@AE)5@02*&1"5G<_.7_@DY\>? EY\#Y_@
MYJVK6^G>(?#-]<SQV]S*D37%G>-YHDAW$%]DA=7 SM^4GAA7S-_P5Y^.G@KQ
MQXA\&_"CP=J4.K7'ADW=[J<MM(DL,4UR(XXH-Z$CS%5'9U_A#+WR!S/CG_@C
MM\=M*U65? 'BC1/$&ED_NWNWFL+K&?XXA'-'P.XE.?05V'PC_P"".?CZ[UNW
MO/C;XLT_3M&B=6EM=&:2YNYT'5/-FCCCAS_> E_W>]+4V]V_-<^D/^".?@K4
MM&^"7B[QK>PF*W\2:PL5J3_RTBL8@K./]GS)'3/JI]*\S^)G[5G_  3V_:M\
M;:5X-^*OP_UZQUR[NX]*CUR>*TL'LC))Y0:>Z@OBWDQL23YB2*@R=O6OVA\%
M>#/#/P[\)Z5X'\&V$>F:+HMNEM:V\?W4C0=R>68G)9B268EB2237Y%?M5_\
M!*5?B5XUU3XD? O7+/0;S696N;O2-161;0W,C%I989XA(T8<G=Y9C*AB=K*I
M"JR%).5V?.?[6O\ P3 \-_!;X8ZY\8?AQXYDN=)T-$GDL-72/S9(I'5 (KJ'
M8C/EAM0Q#=V;. >#_P""2?C[Q;HO[23> K"\F;P_XBTV\>\M-Q, EMD$D4^S
M.!(I78&Z[7(^ENW_ ."4?[8.HQQ>'=0UK1(-*MWW1B;5+E[92>K)$D#$'_@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#S'XR_P#),]=_ZYQ_^C4KD_V<_P#D
MG\G_ %^S?^@I76?&7_DF>N_]<X__ $:E<G^SG_R3^3_K]F_]!2@#_]']_***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .(^)?_ "3_ ,0_]>4__H)KR;]F?_D4
M]4_Z_3_Z*2O6?B7_ ,D_\0_]>4__ *":\F_9G_Y%/5/^OT_^BDH ^D**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KXL^*O_ "7+2_\ KII__H8K[3KXL^*O_)<M+_ZZ:?\
M^AB@#[3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O/?BQ_R3G7_P#KV/\ ,5Z%7GOQ8_Y)
MSK__ %['^8H \\_9J_Y$6^_["4O_ *)AKZ%KYZ_9J_Y$6^_["4O_ *)AKZ%H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#XL\>_P#)PVF_]?NE_P XZ^TZ^+/'O_)PVF_]
M?NE_SCK[3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#S'XR_\DSUW_KG'_P"C4KD_V<_^
M2?R?]?LW_H*5UGQE_P"29Z[_ -<X_P#T:E<G^SG_ ,D_D_Z_9O\ T%* /__2
M_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#B/B7_P D_P#$/_7E/_Z":\F_
M9G_Y%/5/^OT_^BDKUGXE_P#)/_$/_7E/_P"@FO)OV9_^13U3_K]/_HI* /I"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *^+/BK_P ERTO_ *Z:?_Z&*^TZ^+/BK_R7+2_^
MNFG_ /H8H ^TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KSWXL?\DYU_\ Z]C_ #%>A5Y[
M\6/^2<Z__P!>Q_F* ///V:O^1%OO^PE+_P"B8:^A:^>OV:O^1%OO^PE+_P"B
M8:^A: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;T ?9%%?&_\ PS)KO_0:MO\ OV]'_#,FN_\ 0:MO^_;T ?9%%?&__#,FN_\
M0:MO^_;T?\,R:[_T&K;_ +]O0!]D45\;_P##,FN_]!JV_P"_;T?\,R:[_P!!
MJV_[]O0!]D45\;_\,R:[_P!!JV_[]O1_PS)KO_0:MO\ OV] 'V117QO_ ,,R
M:[_T&K;_ +]O1_PS)KO_ $&K;_OV] 'V117QO_PS)KO_ $&K;_OV]'_#,FN_
M]!JV_P"_;T ?9%%?&_\ PS)KO_0:MO\ OV]'_#,FN_\ 0:MO^_;T ?9%%?&_
M_#,FN_\ 0:MO^_;T?\,R:[_T&K;_ +]O0!]D45\;_P##,FN_]!JV_P"_;T?\
M,R:[_P!!JV_[]O0!]D45\;_\,R:[_P!!JV_[]O1_PS)KO_0:MO\ OV] 'V11
M7QO_ ,,R:[_T&K;_ +]O1_PS)KO_ $&K;_OV] 'V117QO_PS)KO_ $&K;_OV
M]'_#,FN_]!JV_P"_;T ?9%%?&_\ PS)KO_0:MO\ OV]'_#,FN_\ 0:MO^_;T
M ?9%%?&__#,FN_\ 0:MO^_;T?\,R:[_T&K;_ +]O0!]D45\;_P##,FN_]!JV
M_P"_;T?\,R:[_P!!JV_[]O0!]D45\;_\,R:[_P!!JV_[]O1_PS)KO_0:MO\
MOV] 'V117QO_ ,,R:[_T&K;_ +]O1_PS)KO_ $&K;_OV] 'V117QO_PS)KO_
M $&K;_OV]'_#,FN_]!JV_P"_;T ?9%%?&_\ PS)KO_0:MO\ OV]'_#,FN_\
M0:MO^_;T ?9%%?&__#,FN_\ 0:MO^_;T?\,R:[_T&K;_ +]O0!]D45\;_P##
M,FN_]!JV_P"_;T?\,R:[_P!!JV_[]O0!]D5Y[\6/^2<Z_P#]>Q_F*^>?^&9-
M=_Z#5M_W[>L+Q-\ =7\,Z!>Z_/JL$\=E&9"BHP+ 'H": /8/V:O^1%OO^PE+
M_P"B8:^A:_/WX??![4OB#HTVLV>H16B0W#6Y21&8DJB/GCM\]=U_PS)KO_0:
MMO\ OV] 'V117QO_ ,,R:[_T&K;_ +]O1_PS)KO_ $&K;_OV] 'V117QO_PS
M)KO_ $&K;_OV]'_#,FN_]!JV_P"_;T ?9%%?&_\ PS)KO_0:MO\ OV]'_#,F
MN_\ 0:MO^_;T ?9%%?&__#,FN_\ 0:MO^_;T?\,R:[_T&K;_ +]O0!]D45\;
M_P##,FN_]!JV_P"_;T?\,R:[_P!!JV_[]O0!]D45\;_\,R:[_P!!JV_[]O1_
MPS)KO_0:MO\ OV] 'V117QO_ ,,R:[_T&K;_ +]O1_PS)KO_ $&K;_OV] 'V
M117QO_PS)KO_ $&K;_OV]'_#,FN_]!JV_P"_;T ?9%%?&_\ PS)KO_0:MO\
MOV]'_#,FN_\ 0:MO^_;T ?9%%?&__#,FN_\ 0:MO^_;T?\,R:[_T&K;_ +]O
M0!]D45\;_P##,FN_]!JV_P"_;T?\,R:[_P!!JV_[]O0!]D45\;_\,R:[_P!!
MJV_[]O1_PS)KO_0:MO\ OV] 'V117QO_ ,,R:[_T&K;_ +]O1_PS)KO_ $&K
M;_OV] 'V117QO_PS)KO_ $&K;_OV]'_#,FN_]!JV_P"_;T ?9%%?&_\ PS)K
MO_0:MO\ OV]'_#,FN_\ 0:MO^_;T ?9%%?&__#,FN_\ 0:MO^_;T?\,R:[_T
M&K;_ +]O0!]D45\;_P##,FN_]!JV_P"_;T?\,R:[_P!!JV_[]O0!]D45\;_\
M,R:[_P!!JV_[]O1_PS)KO_0:MO\ OV] 'V117QO_ ,,R:[_T&K;_ +]O1_PS
M)KO_ $&K;_OV] 'V117QO_PS)KO_ $&K;_OV]'_#,FN_]!JV_P"_;T ?9%%?
M&_\ PS)KO_0:MO\ OV]'_#,FN_\ 0:MO^_;T ?9%%?&__#,FN_\ 0:MO^_;T
M?\,R:[_T&K;_ +]O0!]D45\;_P##,FN_]!JV_P"_;T?\,R:[_P!!JV_[]O0!
M]D45\;_\,R:[_P!!JV_[]O1_PS)KO_0:MO\ OV] 'V117QO_ ,,R:[_T&K;_
M +]O1_PS)KO_ $&K;_OV] 'V117QO_PS)KO_ $&K;_OV]'_#,FN_]!JV_P"_
M;T ?9%%?&_\ PS)KO_0:MO\ OV]'_#,FN_\ 0:MO^_;T ?9%%?&__#,FN_\
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MDMQ<36T/G!2$!N2H!QUP-W->N?\ #,FN_P#0:MO^_;T ?9%%?&__  S)KO\
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MO1_PS)KO_0:MO^_;T ?9%%?&_P#PS)KO_0:MO^_;T?\ #,FN_P#0:MO^_;T
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M_P ,R:[_ -!JV_[]O1_PS)KO_0:MO^_;T ?9%%?&_P#PS)KO_0:MO^_;T?\
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M_P#0:MO^_;T?\,R:[_T&K;_OV] 'V117QO\ \,R:[_T&K;_OV]'_  S)KO\
MT&K;_OV] 'V117QO_P ,R:[_ -!JV_[]O1_PS)KO_0:MO^_;T ?9%%?&_P#P
MS)KO_0:MO^_;T?\ #,FN_P#0:MO^_;T ?9%%?&__  S)KO\ T&K;_OV]'_#,
MFN_]!JV_[]O0!]D45\;_ /#,FN_]!JV_[]O1_P ,R:[_ -!JV_[]O0![U\9?
M^29Z[_USC_\ 1J5R?[.?_)/Y/^OV;_T%*\0\5_ ;5O"?AZ]\0W.JP3QV2ABB
M(P9MS!1@GCJ:]O\ V<_^2?R?]?LW_H*4 ?_4_?RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#B/B7_P D_P#$/_7E/_Z":\F_9G_Y%/5/^OT_^BDKUGXE_P#)
M/_$/_7E/_P"@FO)OV9_^13U3_K]/_HI* /I"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
M+/BK_P ERTO_ *Z:?_Z&*^TZ^+/BK_R7+2_^NFG_ /H8H ^TZ*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KSWXL?\DYU_\ Z]C_ #%>A5Y[\6/^2<Z__P!>Q_F* ///V:O^
M1%OO^PE+_P"B8:^A:^>OV:O^1%OO^PE+_P"B8:^A: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^+/'O\ R<-IO_7[I?\ ..OM.OBSQ[_R<-IO_7[I?\XZ^TZ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \Q^,O_),]=_ZYQ_\ HU*Y/]G/_DG\G_7[-_Z"E=9\9?\
MDF>N_P#7./\ ]&I7)_LY_P#)/Y/^OV;_ -!2@#__U?W\HHHH **** "BBB@
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M*[/U0HK\X/AM_P %)_A?XJU2'2?'>AW7A W#!%N?-6]M$)_YZNJ1R(,\9$;
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M"H_C_D?5=%?*G_#7?P]_Z!>J?]^X/_CU'_#7?P]_Z!>J?]^X/_CU'^IV9_\
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M !ZC_4[,_P#GP_Z^8?\ $1,D_P"@J/X_Y'U717RI_P -=_#W_H%ZI_W[@_\
MCU'_  UW\/?^@7JG_?N#_P"/4?ZG9G_SX?\ 7S#_ (B)DG_05'\?\CZKHKY4
M_P"&N_A[_P! O5/^_<'_ ,>H_P"&N_A[_P! O5/^_<'_ ,>H_P!3LS_Y\/\
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M17RI_P -=_#W_H%ZI_W[@_\ CU'_  UW\/?^@7JG_?N#_P"/4?ZG9G_SX?\
M7S#_ (B)DG_05'\?\CZKHKY4_P"&N_A[_P! O5/^_<'_ ,>H_P"&N_A[_P!
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M@7JG_?N#_P"/4?ZG9G_SX?\ 7S#_ (B)DG_05'\?\CZKHKY4_P"&N_A[_P!
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M !ZC_4[,_P#GP_Z^8?\ $1,D_P"@J/X_Y'U717RI_P -=_#W_H%ZI_W[@_\
MCU'_  UW\/?^@7JG_?N#_P"/4?ZG9G_SX?\ 7S#_ (B)DG_05'\?\CZKHKY4
M_P"&N_A[_P! O5/^_<'_ ,>H_P"&N_A[_P! O5/^_<'_ ,>H_P!3LS_Y\/\
MKYA_Q$3)/^@J/X_Y'U717RI_PUW\/?\ H%ZI_P!^X/\ X]1_PUW\/?\ H%ZI
M_P!^X/\ X]1_J=F?_/A_U\P_XB)DG_05'\?\CZKHKY4_X:[^'O\ T"]4_P"_
M<'_QZC_AKOX>_P#0+U3_ +]P?_'J/]3LS_Y\/^OF'_$1,D_Z"H_C_D?5=%?*
MG_#7?P]_Z!>J?]^X/_CU'_#7?P]_Z!>J?]^X/_CU'^IV9_\ /A_U\P_XB)DG
M_05'\?\ (^JZ*^5/^&N_A[_T"]4_[]P?_'J/^&N_A[_T"]4_[]P?_'J/]3LS
M_P"?#_KYA_Q$3)/^@J/X_P"1]5T5\J?\-=_#W_H%ZI_W[@_^/4?\-=_#W_H%
MZI_W[@_^/4?ZG9G_ ,^'_7S#_B(F2?\ 05'\?\CZKHKY4_X:[^'O_0+U3_OW
M!_\ 'J/^&N_A[_T"]4_[]P?_ !ZC_4[,_P#GP_Z^8?\ $1,D_P"@J/X_Y'U7
M17RI_P -=_#W_H%ZI_W[@_\ CU'_  UW\/?^@7JG_?N#_P"/4?ZG9G_SX?\
M7S#_ (B)DG_05'\?\CZKHKY4_P"&N_A[_P! O5/^_<'_ ,>H_P"&N_A[_P!
MO5/^_<'_ ,>H_P!3LS_Y\/\ KYA_Q$3)/^@J/X_Y'U717RI_PUW\/?\ H%ZI
M_P!^X/\ X]1_PUW\/?\ H%ZI_P!^X/\ X]1_J=F?_/A_U\P_XB)DG_05'\?\
MCZKHKY4_X:[^'O\ T"]4_P"_<'_QZC_AKOX>_P#0+U3_ +]P?_'J/]3LS_Y\
M/^OF'_$1,D_Z"H_C_D?5=%?*G_#7?P]_Z!>J?]^X/_CU'_#7?P]_Z!>J?]^X
M/_CU'^IV9_\ /A_U\P_XB)DG_05'\?\ (^JZ*^5/^&N_A[_T"]4_[]P?_'J/
M^&N_A[_T"]4_[]P?_'J/]3LS_P"?#_KYA_Q$3)/^@J/X_P"1]5T5\J?\-=_#
MW_H%ZI_W[@_^/4?\-=_#W_H%ZI_W[@_^/4?ZG9G_ ,^'_7S#_B(F2?\ 05'\
M?\CZKHKY4_X:[^'O_0+U3_OW!_\ 'J/^&N_A[_T"]4_[]P?_ !ZC_4[,_P#G
MP_Z^8?\ $1,D_P"@J/X_Y'U717RI_P -=_#W_H%ZI_W[@_\ CU'_  UW\/?^
M@7JG_?N#_P"/4?ZG9G_SX?\ 7S#_ (B)DG_05'\?\CZKHKY4_P"&N_A[_P!
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M"H_C_D?5=%?*G_#7?P]_Z!>J?]^X/_CU'_#7?P]_Z!>J?]^X/_CU'^IV9_\
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M(B9)_P!!4?Q_R/JNBOE3_AKOX>_] O5/^_<'_P >H_X:[^'O_0+U3_OW!_\
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M9A<53KTXUJ3O&2NGW3"BBBLC<**** "BBB@ HHHH ^+/'O\ R<-IO_7[I?\
M..OM.OBSQ[_R<-IO_7[I?\XZ^TZ "BBB@ HHHH **** "BBB@ HHHH ****
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M*$5ACZ[SOA.6)Q"]]1<K^<&]?FE^)KA**RKB)4*+]QM+Y22T^3?X'VQ^T?\
ML+>+_C;\6]6^(VD^)K'3;;48[5%@GBE:13! D1)*\<E<BO#/^'7WQ!_Z'72_
M^_$_^%?M'17X[@?$[.,/1AAZ51*,4DO=6RT70_2L7P'EM>K*M4@^:3;>KW?S
M/P'^,_[#.O?!'X?7_P 0?$OC+3IK>S:...WCAE$MQ-*VU8TW<9ZL?103VKY
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3]JPF=X/$3]G0JQD^R:9^*/_  42_P"3D;S_ +!EC_Z"U?2?_!++_CS^)/\
MUTTG^5W7S9_P42_Y.1O/^P98_P#H+5])_P#!++_CS^)/_732?Y7=?O\ GO\
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M:_@7P1Q1A9X&%"K449P5K-I:=&K^1]07=U;V-K-?7D@B@MT:21VX"H@RQ/L
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M_P"&.]9_Z&6W_P# =_\ XNO/_P!><J_Y_P#X2_R/6_XA?GO_ $#/_P "C_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@@]QR*S]M#G]G=<V]NMN]C9X>I[/VO*^6]KVTOVOM<SJ***T,0HHHH ****
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MYY)7TU=M>QR4,+5JW5*+E97=E>R[OR.0HHHK4P"BBB@ HHHH **** "BBB@
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M])0HQIPC3@K)*R]$%%%%8&H4444 %%%% !1110 4444 %%%% !1110 4444
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M!5Q7H'Q%\:1?#[PA?>+)K5KU;(Q#R5<(6\V18_O$'&-V>E?'7['W_(S>(/\
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MW3IY=*Z4HVL[^JOU7?R.JAF&(Q7#5:MG$.63A*]U:^_*[=&W:WG9H_,32_\
MD)VG_7:/_P!"%?M;7XI:7_R$[3_KM'_Z$*_:VOI/%;XL/_V]_P"VGQO@/\&+
M]8?^W'R9XF_:JT[PUXEU/P[+X=EG.F74ML91<JN_RG*%@NPXSCIFND\(?M/?
M#WQ->QZ=J2S:'/*P5&N=I@)/0&13\OU8 >]?!_Q3_P"2E^*O^PI>?^CFK@J]
M^EX?Y;6PT&HN,FEJF][>=T?)XCQ:SC#XVI%S4HQDU9Q6R?=6?XG[3:SHNC^)
M-+FTG6K6.^LKE</'(-RD=B/0CJ".1U%?E7\7OAQ<?#/Q?-HNXRV-POGV<AZM
M"Q("M_M*00?7@\9K[<_9A\87GB;X>G3M1D:6XT2;[,KL<DP%0T>3_LY*CV K
ME/VO='@G\(:-KVS-Q9WIMPWI'/&S'/\ P*-:^0X2Q-;+<V>7S=XMM/M?HUZ_
MDS]"X^P>&SG(8YM2C:<4I+O:]I1?>VOS7FS\_****_<S^7@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#Z5_95T3^TOB=_:;KE-)M)I@>P>3$('Y.WY5ZA\7_VB/&'@WQ]
MJ'AGPVEH]I8+$I::)G8R,@=N0XZ;L=.U7OV/M$\K1/$'B)UYNKB*U0^T*EVQ
M]?,'Y5\[>-/A]\3_ !+XPUG71X7U)EO[R:5,VTG".Y*#IT"X%?F$Z>%Q>=UW
MB[.%.*BN9K??\-3]NI5<?E_#.&67\RJ59RDW%.]E==._NGT;\(/VD]8\8>*;
M7PGXNL;>-K_*07%L'3$@4L%=&9\[L8!!&#VQR/%_VF_!&E>$?'$%[HD*VUKK
M,'GM"@"HDRL5?:HZ!N#CU)^E>D_ 'X#^*-(\46_C3QE:_P!GQ6 9K>W<@RR2
MLI4,P4G:%!)YY)QQBN+^/>J#XF_%[3_"7AEUN&M1'IZN#E#.\A,AR,_*F0&/
M^R:SRU86EG3_ +/=J:@W.S]W_+M^/F;YR\=7X:7]K)NM*HE3YE:=M/GKKOY>
M1\P0P3W,@AMXVED;HJ L3] *U;WPWXBTV#[5J.E75K"1G?+!(BX/NP K[ZU_
M5?!/[,?A2RL=%TY+_7]03;O;Y9)BF-\LK\E8P3\J#OP.[5Q?@/\ :GU#7?$-
MMH/C;2K2.QU&00>;;AU$9D.T>8LC.&4DX;D8'//2O:AQ1C*].6)PF&YJ2OJY
M6;2W:5CYNIP-EV&JQP>/QO)7=KI1;C%O9.5_\K>FI\/UT_A3PSJ'B;7=,TRW
MMY7BO;J&W:148JOF.%)+ 8& <GTKW+]IGX;:5X)\266M:!"MM8:VLA,"#"1S
MQ$;]HZ*K!P0!T.<<8 ] _9=^(NHS7%K\-;;38A:0)<W<UUN;S#D\';TZLJ_2
MNW&<12EEGU_"0YDU?5VMO?ULUMU/,R[@^$,Z_LK'U.5II72OS-VLO)-.]WL<
MK^T-\*_"7@B+1(/!&DSI<7AG:8J\LX"1[ H.XMC)8XQZ5\IR120R-%,A1T."
MK#!!]"#7Z#?%7]I#4? 'C2[\*:9I4%ZEFD1>221E.^1 ^,+QP&%>-?!?X?I\
M9/'&L^-O%<6[3(KE[B6$$A9KB=BXCSUV(.6]MHZ&O*X?SG$X;+OK&81?(E=2
M<KRE=Z*W3=)79[W%O#F#QN<?5,HDO:2ERN"CRQARJS=^NJ;=D?.6G:!KNKJ7
MTG3;F]5>"8(7D (_W0:I7=E>:?,;:_@DMIAR4E4HP_!L&OM3QM^U$/#>J2>'
M?ASI-FVGZ<QA$TRMY3E3@^5'$R!4!S@Y.>N!7?:3J&@?M,?#2^BU*PCM=<L=
MT88<^1<;2T3QN?F\M_XE)]1V!K>IQ3C*$(XC%8;EI-K7FNU?9M6.6CP+E^)J
M3P>!QO/7BF[<MHR:W47?\>OH?G'5RYT[4+-!)=VTL"L< NC*"?8D5T/@30SX
MB\;:'H+KE;R]@CD&.B%QO_)<U^DGQA\?^ O T.GW_B>T75=5MV::PM.K;R-I
ME.<JH'0.02.=HSFO0SSB2>$Q-+#4J3J2FF[)Z^7_  7T1Y/"_!M/'X.OC:]=
M4H4VE=JZUWZWNE:R6[=C\QV\.>(4M/M[Z7=+:@9\TP.(\=<[L8Q6-7Z#_"_]
MI:Z\=>,[;PIJ^C16<>H>8L,D4C.59%+A7##D$ C(QSCC'3YW_:4\+:7X6^)<
MB:1"MO!J5M'>&-  BN[.C[0.@)3=CU)J,LXAQ$\9]2QE'DDUS*SNFB\[X1PE
M/+EF67XGVL%+EE>+BT[7Z_UJ<?\ "?P-)XS\=:+I&H6DKZ9=2EIF 94:*)6=
MAO&,9VXR#U/K7=?'[X=:%X/\566C^!]*N$@^R++.099E,CNX RV[!"J,\]Z^
MA_V9OB+J/BC33X1_LV*UL/#MG"GG(S%Y)') W \#=AF/O7+>./VIM8\/>*-8
M\.Z5I%O/#I]Q+;),\C[BT9VEL#C[P-?/5,WS.IFTH4J5U36L>>R=]I/I>S6A
M]=1X?R2ED$*M>O9U9:3]G>2LM8KK:Z>NESY+\ ^(M:\'^+;+Q)H5I]LO-/+M
MY11G!5U,;@A>1PQ&>QKH/BS\2M:^)>O0:AK%BFFFRA$*0+NR 26)8M@DG/H!
MC''4GZ#_ &/]&:6^\1^)IADHD-JC'DDR,9).?^ I^=>"ZK:W'Q3^-%W96C\:
MSJDD:..=L <@-[[8ES^%>_#'8>IF=9SIJ]&*O._?6UOO/E:F68NEDF'C3K-Q
MQ$W:G9:M.U[[[I:;;'EMI8WM_+Y%C;R7,O7;&A=OR7)JYJ&@:[I*A]5TZYLU
M/0S0O&#G_> K[]^(/Q!\,?L\:78>$/!.CPRZC<0B0[^ $!*B69EP\CLP.!D=
M#R!@&O\ ![XZ7?Q7UBZ\%^,=(M#]HMWD4PHQA=4QN22.5GSD'@YQQC'-<#XM
MQDJ#QM/#?N5U<DFUWM8]2/ .71Q4<MK8VV(>EE!N*D^E[GYZ5]U_L?Z,L.E^
M(_$THPLLL5JK'L(E,C\_\#7/TKY>^+_A>Q\&_$C7/#VF<6EO*CQ+_<2>-90G
MT7?M'L*^P? __%"?LOW>KG]U<7=I=7 /3]Y<L8H3^12CC+&JOEM.-+_E\X)?
M/4/#G+'A<ZK3K_\ ,/&HWVO'W?U9\*>*]9;Q%XHU;7F)/]H7<TXSV$CE@/P!
MQ7W5\:/^*&_9XTWPJ/DFN$L;%@.NY%$LA_$QG/UKXI^'&B?\)'X]T#12NY+F
M]A$@_P"F:L&D_P#'0:^HOVPM;W77ASPXC?ZM)KN0>N\B.,_^.O3SVFJF8X'!
MQVC>7_@*T_(7"]:5+)\SS&?Q32@O63][\TSXT-A?"V^VFVD%O_STV-LZX^]C
M'7BJE?H)X4?_ (3']E6]L#^\FL;*ZC(Z_-:.9HQ]=H6O@2SM+G4+N"PLHVFN
M+EUCC11EG=SA5'N2<5[^39U]:E7C./*Z<G'?HNO0^3XCX:^I1PTZ<^=5H*2T
MM9O=;N]M!]MI]_>*7L[:6=5."8T9@#[X%5&5D8JP((."#U!K]%]<O++]G3X+
MP:38NIUZ^!1&'5[N5<RR^ZQ# 7CLH/6OSI=WD=I)&+NY)))R23U)-3D.=RQR
MJ58PM33M%W^*V[MT1?%7#4<K=*C.IS57&\XVTC?97OJ^^WXCX89;B:.WA4O)
M*P50.I9C@"OTX^*_C*]^"_PST>/P\L+W<+6UA")5+)LCB.YL J>B8Z]Z^#_@
MUHG_  D'Q0\-Z<5W(+M)W'8I;YF8'V(3%?57[4V@^,?%5WH&E^'-'N]1MK1)
MII7MX7D3?(5502H(R I_.OF>*G2KYGA,)6:Y%>3OMY?E;YGVO BKX7),?C\,
MG[1\L(V5W?K;Y23^1Y?IW[6WQ"M[I'U&PT^[M\C>BQR1.5[[6#D ^Y4_2O<?
MC7H_AWXF?!U/B'9P".\MK:*\MY2 )!&Q'F0N>X )X_O $>_R;X;^ 7Q1\0W\
M5J^BS:; S 23W8\E(USR=K89OHH)KZQ^.FIZ+\./@Q!X!M)0US=PPV5NA^^T
M<14RRD>A Y_VF%>9FV&P-/'X6.6653F5^5Z<O6]M/^!<]O(,9F=;*L=+.[NC
MR/EYU9\W3EOKO;YVL?&WPI\<>(/A[XCD\0:!IW]I%H6MYHBK$&-V#=5Y4Y08
M/UXJCX[\4Z]\3/%MYXANK'R[EPB&"!&81)& H!ZG/J3W]!@#Z_\ V6+*'P_\
M.->\7W@V)/.[,?6&TCSG/U9Z\W_96\133_$K6XKQLR:Q:R3M_M2I*K_R9C7M
M5LXIQQ&,Q=.@G*BDKWW[K;2UCYK#<.UIX3+\!6Q+4,0W+ELK1>R>]W>_DCY+
MDC>)VBE4HZ$AE(P01U!'K2Q0RSR+# C22-P%4$D_0"O5?CIIO]E?%KQ+;8P)
M+GS_ /P(19?YM7O7[+O@&VL[>\^*WB$+#;VJ2QV;2<*JJ#Y\^3V R@/^_P"U
M>]C^(:=# +'-;I-+NVM%_70^5RKA&KBLUEED7;EE)2EV479O^GO97/C6YL[R
MS8)>020,PR!(I4D>V:EL=,U+5)/)TVTFNY/[L,;2'\E!KZ8L+:Z_:3^,D]S=
MN\.@V"[MO(9;.)L*@]'E8Y/IDD9V@5ZM\1OCCHWP@NAX ^'&C6IDL /.+ B"
M)V .W:A5G?'+,6Z]<G.."OQ)74X86C1YJS7-)7LHKS=OZ^X]7"\&X5TJN.Q&
M)Y,-&7+&7+>4VNT;[>=_UM\*:AH^KZ0XCU6QGLG;.!/$T9..O# 5G@$G Y)K
M]$/A;\8-+^-PO? OCK1[87$D+2JJY,,R#A@H<ED=<Y!#$]2"".?CKQQX=7X8
M?$ZYTE4%Y;Z5=Q3Q*Y_UD)VS(K$=]I"L1WS71E6?U*M:>$Q%+DJQ5[7NFNZ9
MR9]PG1P^&I9A@Z_M*$WRWM9Q?9KTO_5CU/\ 9Z^$6E>.-0UF7QKITS6=C%$L
M:L9(,RRL3D%2I. AR.G/TKQGQ]X?CTGQ;KEOHMA/;Z39W<T4)=791'&Y0'>W
M4'&02>]?H_X$^)U]XD^%]Y\1M:LH[);=+J58XV)5H[8'G+<Y+*PKXX\?_M(Z
M_P"/?"EYX4GTF"RAO3'ODCD=FQ&ZO@ \<E1GVKYO),VS.OF-:3I^ZFHM<^D>
M[7=^A]GQ-D&2X7*,/!5K3DI3C+V?O3O\*?\ *M4M7YGS<!G@5O+X5\3M;F[7
M1[PP#_EH+>39_P!];<5]I?![PGX3^&?PO?XN^++07-]+%]HC+JKM%&6VPK$&
MX#R$@[NOS 9 !KCH_P!K_P 4'5EDET.S&F;QNB5I#.$SSB0L%)Q_TSQ7M2XC
MQ5>K4A@*'/&#LVY6NUND?-0X.P.&H4:F:XKV<ZB4E%1<FHO9RUT]#Y!92I*L
M,$<$'M7HGPCT3_A(?B7X<TLKN1KR.5QZI!^]<?BJ&OIG]JGPKH,OA[1OB)IE
MNMM=7DZ03%4"&9)HFE1I,=679C/7!P>@KA/V3=$^W_$*[UAURFEV3E3Z23,$
M'_CN^G4XCC7RBKC8KE=FK=GM^8J/!T\+Q!1RV<N9<T7==8[[=-$SHOVP-;\[
MQ!H'AY6XM+:2Y8#UG?8,_01'\ZROAWX,^#7Q2\*67A.UFFT?QC;QNS3.,F=^
M68A<['11T7Y7 'IDGS;]H+6_[;^+6NR*VZ.S=+1/;R$"N/\ OO=76?#GXM^#
M_AGX!N7T/26E\:73O$T\PW1^63E&#<$(HQF,<LPR3C&/-IY=B*63X>GA>;VF
MC7*[6<KOWK_95]3V:V;X2OQ%BZN.Y'1]Y/F3=U&R2A;52=M'Z^A](?&#X*>(
M_'MEX9T/P]>VEGIF@P-$?/9P[':B+A41A@*G=AU-? GC3PO<>"_%%_X7NITN
M9;!PADCR%;<H8$9]C7TM\2O&VA?$SX(Z1KNIZK#!XGTV7RY+;>%DG;(27$:]
MF&R3.-HP5%?(-=?!.%Q5*BX5YZ1<H\O+;6][\W5/TZ^1P>)F-P%;$QJ86GK-
M1ES<U_=Y;*/+;W6K=[Z>85^C?P1V^ _@!<>*)% D>.]U(AOXB@*1@_[PC7'U
MK\Y0"Q  R3VK],?B=X>UW2_@-!X+\-V$]]>FWLK)DMT,C@1[6E8A0>#L()]Z
MY^/:D9QPV$D[*<U?T6_YG7X54I4Y8S'P5W3INUOYGM^31\TQ_M8_$Y'#-;Z;
M(!U4P28/Y2@U]1>"/$N@_M#_  \O;3Q%IR0RHYMYXQ\PCEVY2:%F&5/.1W!!
M!R.OP?9?!CXJ7\ZV\/AB]1F(&98S"O/JTFU1^=?=7P^\.67P!^%M[J'B>XC-
MSEKNY*'@R%0L<"'^(\ #U8GM7A<783+:5*'U!)5N9<O(]?P_JY]3X?YAG5>O
M4_M5R>&49<_M%IMW?X^5[GYPIH=U)XB7PU&0URUT+08Y!<R>6,?C7W'^U9>Q
M:1X%\/>#[$%1<W V(.IBM(]@7'U=?RKYM^!FFR>*?C'HTUPN[R[B2^D(Z PA
MI0?^^PHK['^+WQ:\"_#O6K:XGT]=9\46\)6&/.!;1R$$EG(8(6Q_"I8C&<#%
M>EQ+BZCS3"TH4W.4$Y66FKT5WT2:W/%X,P%%9%CJ]6JJ4*DE#F>MDM79+5MI
MVLM_D?G+=^'M?L+?[9?:9=6\!_Y:20NB?]]$ 5CU^D7P>^.Y^*VL7WA;6](B
MM7^SM,FQC)')&&"NCJPZX8'T(ST[_%'QB\-V'A+XEZ[H.EIY5I!,KQ(.B+-&
MLH4>R[\#VKZ')L_K5L5/!8JER3BN;1W37],^1XCX3PV'P-/,L#7]I2E+EUCR
MM.S>WR?_  ;GFE%%%?5'P@5]G_LW_#/PZVA7GQ1\911S6]L9/LZSJ&BC2 ;I
M)V!R"000O'&TGKC'QA7:0?$3QM:^&SX0M]7F31V1XS; C9LD)9EZ9P23GGO7
MA\09?B,5A_88>?+=J[_N];>9]/PCFV$P.+^M8NGS\J?*M+<W1N_1?G8^I]7_
M &P)(]3>/0?#R2Z>C85IYBDLBCOA5(3/I\U>B?$K3O"_QD^#$GC^TM1#=VMI
M+>6\K >;']G+>=$S#[R_(RXZ9P17P%X5\*ZWXSURV\/Z!;FXN[EL?[*+W=S_
M  JO4G^N!7WG\4M0T3X/_!"+X?V\ZRWU[:FRB0<-)YIS<3%>H4EF/U(%?!YW
MDN$P>)PM/+U:LY+9M^[U;_K:Y^J\-<28_,L%CJV;R4L.H/=)+GZ*.F_XIVZG
MPCX+T7_A(_%^BZ#MW+?WD$+_ .X[@,?P7)K]!_V@/BYKGPPAT6#PVL#W6H&9
MG$Z%PL<04# #+C);]*^5?V8M$_M;XKVETR[DTJWGNCZ9V^4OY-("/I7T_P#&
MGX&:[\4O$=GJ]EJ\%E;6EJL"Q2(S'?O9F;(]00/PK7BG&826;T*6-:]G"+;O
MM=WT_!,Y^!<OQ\.'L37RV+]M4FDK63M&UWKZM'C_ (0_:P\6RZY9V?BC3[2X
ML;B5(W:W1XYD#L!N&796QG.W SZBMK]KKPKI%M%H_BZUB6&_N97MIRHP9E"[
ME9L=2N",]<$#H!CI? O[,&E>#]4B\4>*-3;5VTT_:([:W@8*7C^8$@%GD((R
M$4#)P.>E> _M ?%AOB)KD&E6-M+9Z;HY=52=3',\S8#LZ'[N,84'D<D]<#/+
M*6$K9M3J93&T(I\[5TG?96?]?<;9U7Q^&R"M1S^5ZDVO9IV<E9ZNZ_S\NI\]
MUI:-I%_K^K6>B:7'YMW?2I#$OJSG R>P]3V'-9M?4O[)WA^'4O'UYK<ZAAI%
MHQCR.1+.=@(_X!O'XU^AYUF/U3"5,1_*OQZ?B?D/#63O'X^C@[VYW9^F[_"Y
M]"66E^ /V:/!*ZK?QB[UBX41M*H'GW4Q&XI'G[D0[]@ "<MC/SEJ_P"U=\2+
MV[:32XK/3K?/RQB+S6QZ,[GD^X K'_:8\5S>(?B9=:8LFZTT-%M8@.F\@/*?
MKN.T^RBOGNOE.'>%Z-6BL9CX^TJU-7S:V3V26VW^1][QAQQB,/B99=E4O94:
M3Y4HZ-M:-M[[_?N[L_0/X._M"MX^U0>"O'-G EU?*ZPRQJ?)G."3%)&VX E<
MX.<'IC.,_.G[0/PTM?AWXP0Z/&8](U9#-;IG/ELIQ)&"><*2"/9@.<5YGX"D
MN(O'/AV2TSYRZC:;,?WO-7 K[ _;%\C^S/"^X?OO.NMI_P!G;'N_7;7/'!PR
M[.J-/"Z0JIWCTNDW=?UW.N>8U,XX;Q%7'/FJ4)1Y9=;2:5F^O7UTOL?#MM8W
MM[N^QV\D^S&[RT+8STS@5-9Z3JFHSM:Z?9S7,R?>2*-G8=N0H)%?>O[)NF0:
M3X#UGQ->,L"7=T0TCG:HAM8P=Q)Z %W^F*Y36OVF/#7@^ZFT;X9:!%/9+*[R
M7,K,@GD8Y9P,;VR?XW;)],5Z,^*<3/%UL+A,/SN%E>]EYW_1=3R*7 V#I8##
MX_'XOV:J)OEY;O?2R3UTU;V7G<^,;W3[_39OLVHVTMK+C.R5&1L?1@#5.OTD
M\6WFB?&CX!WGBZXL1;W-M:W%U&"0SP3VF[>%? RK;"/=3SST^+_@UX!B^(_C
MJUT&\9EL8D:YNBIPQACP"H/;<S*N>P.:[,JXGC6P]:MB(<CI-J2WV['FY[P1
M/#XS#X?!U/:1KI.#M;?NNG?T/-[/3M0U%S'I]K+=,.HB1G(S[*#74^$_A[XL
M\9Z\/#FBV+?; I>3S08EB0'!:0MT&?;)/ !-?8'Q-^.EI\)M2_X5_P##C1K.
M,Z<J"=I%/DHS*&V*D90LV""S%NO!!.37I?PM^)>I_%WP!K,\J#2-6MEEMC-;
MY**[Q9CEC#$D%2?NDGD=><#Q<=Q;CH87ZW'#J,)6LW*[5]FTEMY7/I<KX RN
MKCOJ$L8Y58WYHQC9.V\5)O?S:/A[XH_![5_A5!I<FL:A;7<FIF4*D&_Y?)V9
M.649'SCM7E-K9WE]*(+*"2XD/18U+M^0R:]!\(Z/XG^+OC33O#U_J=Q=R3LQ
M>>YD>8Q1*-TC#>3S@<#C)P*^P_'OQ%\)?L]6-MX,\":/#+J<L:RR;B0JKR%>
M=A\\CM@X&1@<Y P#ZF(SO$85T\';VN(E=Z>ZDK[OMV\['AX7AK"8U5LQYOJ^
M$BTE>\Y-V6B[OKY7\F?!&HZ!KND*'U;3KFR5N 9X7C!S_O 5DU]]_"W]H?\
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M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=,\,*=DMS'8V38ZEE432'\3&<_6N3_9+\4Z'#8:QX.O;A;>_NIEGA#-L,RE
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MDVG!*.H!/3@G'K7PC:W.K^,OB:=5TBP;5+R_U)KM+8#_ %@,OF;3G@+C@D\
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M_9JTT^1I/@6:]5. \P&&]P7E=C^(%>\?$?5='T#]GFYN] T]='MM5LX5AM%
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M6+Q5JUKXA\$?VAJ-I<R6\]P]O;N9'@8Q9W,V2/EXSVJIH/QT^#FEZ@NH>&O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'F/QE_Y)GKO_7./_T:E<G^SG_R3^3_ *_9
MO_04KK/C+_R3/7?^N<?_ *-2N3_9S_Y)_)_U^S?^@I0!_]+]_**** "BBB@
MHHHH **** "OE[X[?M>_![]GGQ3X>\$^.9;ZZUWQ,N^TL]-MOM4VTR")"ZAE
M(\QR53&2Q5N.*^G9IHK>)[B=Q'%$I9F8X5549))/0 5_/_\ LDO<_ME_\% /
M%'Q^\3QFZT'P:'O=.C<$QP['^SZ5'@]&5 \_;,J%L<FDRX1O=L_;OXN?%;P?
M\$?AYJOQ0\>RRV^A:+Y'VEX(C-(/M,\=O'A%Y/[R10?0<U\3_P##UG]D'_H+
M:K_X+)J[3_@IA_R9)\1_^X/_ .G>SKX"_P""9W[*'[/OQU^ ^N^+OBOX0BU_
M5[3Q)=6,4[W-U"5MH[.SE5-L$L:X#RN<D9YZXQ05&*M=GW9H'_!3K]C;7;B.
MUE\8SZ5)*P5?MFFWB)D\#+I$Z*/=B .Y%?;7A/QEX2\>:)#XD\$:U9Z_I5QD
M1W5C/'<PL1U&^,L,C/(SD=Z^ O'?_!*S]DGQ7ILMMX;T>_\ !]\P)2YT^_N)
M\-CC=%>/.A7/4*%)'0CK7Y(6&I?&W_@E_P#M*1Z)?WDFJ^&;LQ3W$,)9++6]
M,<E/,6-B1'<1?, 2<QR#&6C;YRXU!/X3^I"O(OBA\>_@S\%HH9/BEXPT[PZ]
MPN^*&XF'VB5,XW) FZ5E!X+*I [FM7Q7\1]-T;X0ZQ\7-$4:K86.A7&N6P3.
M+F&*U:YC"XY_>*!C'K7\['['W[-&M?MY_%?QE\3_ ([ZY?-IVG20S7[Q$)<W
MMU=ES'!&SJRQ0QI&<A1\J[$0 '*C)A!/5G[A^#OVXOV3?'FJQ:)X<^)>F->S
ML$C2[\VPWN3@*K7:1*S$\  Y/:OJL$$9'(-?B'^UY_P3(^"7@?X)^(_B7\))
M[_1=5\)V;W\D%S<FYMKN" ;I5;S!O238"4*M@GY2O(*^W?\ !)CXL^*_B%\
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M '_/_P 37T;X9\3>'_&?A^P\5>%;^'5-(U2%9[6Z@8/%+$_(92/\CH:_-/\
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M!T#%!THN2H:M'] M%("",CD&EIF84444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]_Y.&TW_ *_=+_G'7VG7Q9X]_P"3AM-_Z_=+_G'7VG0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'F/QE_Y)GKO_7./_T:E<G^SG_R3^3_ *_9O_04KK/C+_R3/7?^N<?_
M *-2N3_9S_Y)_)_U^S?^@I0!_]/]_**** "BBB@ HHHH **** /F/]L_Q9>>
M"?V5OB=X@T^8P7*:+<6T<@X*->8M@5/9AYO![&OAS_@C?X1CTWX'^,O&C*!/
MKFO"USW,-A;1LG_C]Q)7U!_P4>LKJ_\ V+?B3#9L5=(=/E;'=(M1MI''_?*F
MO)O^"2LUM)^R:J0??BU[45E_WRL+#_QTK2ZFJ^ ]+_X*8?\ )DGQ'_[@_P#Z
M=[.O"O\ @CI_R;'XE_[&^]_]-]A7NO\ P4P_Y,D^(_\ W!__ $[V=>%?\$=/
M^38_$O\ V-][_P"F^PHZ@O@/UBK\5_\ @L[X=T^;X??#GQ:T:B^L]4N[%7Z,
M8KF 2L/<!H0?;/N:_:BOY[?^"P'QJT7Q5XS\)_!'PW<K>7'A;SKW5!'\WEW=
MVJ+!!D?QI&&9A_TT4=010Q4E[Q^J/[ >L7&N_L>?#"]NBQ>/37M1NSG9:7$M
MNG7MMC&/;%>Y?&KXCGX0?";Q7\3QI_\ :Q\,:?/??9/-\CS_ "5SL\S9)LSZ
M[6QZ5X-X'U"W_8Z_8L\/:GXTTZZO_P#A!]#M)=2M;%4-P)KAU,ZH)'13Y<DS
M$DL/E4GKQ7<_LQ_M-^!OVJ? ^H>.? ME>Z;;:;J#Z=-;Z@L2SB1(HY=^(I)%
MV,L@ .[J&&.*:$UK<_!?]HW_ (*5_$;]I3PJ?A/IVD6/P]\-ZY+%%J-PUQ->
M2M#YBG$DT<2LL((W2".%G8# R"5;]HOV"/@MX%^"_P"S]IMGX(\1VGC#_A(9
MGU.]U:Q;=;7%Q(JQ[(@?F5(E14PP#;@Q958E1Z!^TU\ /A1\9_A9XET_QQHE
MFUU#87,]MJ?DHMW931QEUECG"[U 906&<, 0P(XK\IO^",?C77SK?Q$^'4D\
MDFBBVM=4BB)S'#<[S!(R^C2H5SZ^6/2EU-&TXZ'W]_P4?^,7_"HOV6?$B64_
MDZOXPVZ#9X.&Q>*WVEACD;;99,$=&*^U>:_\$I?@[_PKO]F__A.M0@\K5?B#
M=M?$D8<6-MF&U4^Q_>2J?205\6?\%)?$>K?M"?M;> _V7_",Q==(>VM)=O*I
MJ&KLCRNP'!6&V$3$_P /S].:_?#POX<TGP=X:TGPCH$(M],T2T@LK6,?P06\
M8CC7\%4"@EZ1L?B%_P %K?\ FC?_ ',7_N.K]9?V7?\ DV;X1_\ 8H:!_P"F
M^&OR:_X+6_\ -&_^YB_]QU?K+^R[_P FS?"/_L4- _\ 3?#0@E\"/=:_F6_X
M*,6MOX _;UL_%FBIY-S<+H>KOY7#?:(6$888Z,1 IXZGGJ:_IDFFAMH9+BXD
M6**)2[NY"JJJ,DDG@ #J:_E^^)'B"']L[_@HOI\7@EQ>:'=:Q8V5K,JDJVFZ
M4%:YN!ZJRQRRKG&00#BACH[G].NK:/I&OV$NE:[8P:C93X\R"YB6:)]I##<C
M@J<$ C(ZC-1Z-H6B>'+%=+\/:?;Z79H2P@M84@B#-R2$0!<GOQ6K7Y$?MT_\
M%#D^'EQ=? []GN8:KX[N7^R7FH6Z^>FG2.=GD6ZC(ENR3C !$9XYDRJLSC%O
M1'F7_!63]I;0]1T>Q_9>\$3#4]9N+R"[UKR/WGD"/)M[/"YS,[E9&4<J%4?Q
M\?H9^PY\$=8^ /[-OAGP-XF01:]/YVHZC&#GR;B\??Y1_P!J*/8C8)&Y20<8
MKXW_ &#O^"?-SX#O[?X^?M#PG4?'%T_VRPTZY;SC82R'>;FZ9B?,O"3D D^4
M?F),F/+_ & I(N;5N5!7B?Q_^-GPO^ WPXU#QG\5[I5TIT:W2S"K+/?R2*1]
MFAA8@2,XSD$A0N2Y"@D>V5_-G_P4ZU?4/'G[9_A_X;^(+Z2ST'3[;2K*$DX2
M%-0D#W%PH/&[YP">XC [4-DTXW9^?NI^(?$N@ZSXF^(OP;L]<\$^"]=NKK3(
MG@N)Q$MM<YD_LZ:[C")+^[ )C8DD*"=V-Q_H)_X)@?!#X'>%O@_:_%SP'J2^
M)O%7B*(0:I>RH$ETZ50K2Z?''DF)4;!9B<S?*_W"@'VMJW[.?P>U?X+/^S_+
MX=@@\%&U^RQVD0VF(CYEF1SEA.K_ +SS3EB_S-DDY_GWCU7XX_\ !*[]H&_T
MZ.(^(/"6NQNT4<K-#9ZQ:+GRI P#B*YMV8!\ E<D<QNI9;&W-S*R/W\^'_[4
M'P$^*?C.Z^'GP_\ &%MK/B*R2:2:SCCF5U6W<)*=TD:J=K$#@GU'%>]U_/I_
MP1U^'FKZU\3O'?QHOU8V>GV']E)(PXEN[^9+B0J?6-(1N'I*/6OZ"Z:,:D4G
M9'RQ^V[JW]B_LE?%2\SM\S0[FV_\"L08_'?7X(?LA_$;]MMOAKJ'PG_9'T)O
MLRZI+J6HZK'!;,WG7$,$*PM<7Y^S1@)""%'SG).<5_1A\=/C?\,?@'X,B\8_
M%JY>UT.[O([ ,EM)=YGE1Y$#)&K$ B)N2,9P.I%;7P?^)'P_^+OP_P!-^(?P
MPF6X\.ZL9C XA:W):"5H9-T3*K*0Z$<CD8/0B@J,K+8_"7Q/^U%_P4P_9-U7
M3]5^/%G_ &IH5W*$"W]M8SV<QZF-;W3@#'*5!*JTF>,[" :_;;]G7X\>%/VD
M/A3I/Q2\)HUM%>[H;JTD.Z2SO(L"6!F  ;:2"K8&Y"K8&<#S']O;3O#^H_LA
M_$Q?$:(T%OIAGA+@';=QR(;<KGHWF[0".><=Z^)/^",DVH-\*_B';R9^PIK5
MN\7/'FO; 2\?[JQT [.-S]F:*_!>\_X)=_M73WD\T/QFMA')(S*#>:D#@G(R
M #7US^Q;^QM\:_V=/B/K'C#XF?$"+Q7I^H:3)80VT<]W*4F>>&42D7 "C"QL
MO'/S>F:+B<%W/S>_X+&''[3?A@_]2A9?^G#4*](_X>W?M&?]$KTW_OW?_P#Q
M5><?\%B_^3G?"_\ V*%E_P"G#4*_I/H-')**NC^??_A[=^T9_P!$KTW_ +]W
M_P#\57S-^RUX_P!8^*?_  48\,?$7Q!8IIFI>(=;O+R>VC#!(9)+68E%#Y;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]._V8O\
MDD>G_P#7>Y_]&FOH&OG[]F+_ ))'I_\ UWN?_1IKZ!K^6^)O^1CB/\<OS/[E
MX*_Y%&$_P1_)!1117AGTX4444 %%%% !1110!\6>/?\ DX;3?^OW2_YQU]IU
M\6>/?^3AM-_Z_=+_ )QU]IT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3_\ H)K\Z[;X6^.?']@E[X3TX7L-K*\<C&:*+:Q5"!B1U)X]*_13XE_\D_\
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M\9/^@"O_ (%VW_QVC_AF[XR?] %?_ NV_P#CM?J311_Q$_,/Y(?<_P#Y(/\
MB"&4_P#/RI]\?_D#\MO^&;OC)_T 5_\  NV_^.T?\,W?&3_H K_X%VW_ ,=K
M]2:*/^(GYA_)#[G_ /)!_P 00RG_ )^5/OC_ /('Y;?\,W?&3_H K_X%VW_Q
MVC_AF[XR?] %?_ NV_\ CM?J311_Q$_,/Y(?<_\ Y(/^((93_P _*GWQ_P#D
M#\MO^&;OC)_T 5_\"[;_ ..T?\,W?&3_ * *_P#@7;?_ !VOU)HH_P"(GYA_
M)#[G_P#)!_Q!#*?^?E3[X_\ R!^6W_#-WQD_Z *_^!=M_P#':/\ AF[XR?\
M0!7_ ,"[;_X[7ZDT4?\ $3\P_DA]S_\ D@_X@AE/_/RI]\?_ ) _+;_AF[XR
M?] %?_ NV_\ CM'_  S=\9/^@"O_ (%VW_QVOU)HH_XB?F'\D/N?_P D'_$$
M,I_Y^5/OC_\ ('Y;?\,W?&3_ * *_P#@7;?_ !VC_AF[XR?] %?_  +MO_CM
M?J311_Q$_,/Y(?<__D@_X@AE/_/RI]\?_D#\MO\ AF[XR?\ 0!7_ ,"[;_X[
M1_PS=\9/^@"O_@7;?_':_4FBC_B)^8?R0^Y__)!_Q!#*?^?E3[X__('Y;?\
M#-WQD_Z *_\ @7;?_':/^&;OC)_T 5_\"[;_ ..U^I-%'_$3\P_DA]S_ /D@
M_P"((93_ ,_*GWQ_^0/RV_X9N^,G_0!7_P "[;_X[1_PS=\9/^@"O_@7;?\
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M_P ,W?&3_H K_P"!=M_\=H_X9N^,G_0!7_P+MO\ X[7ZDT4?\1/S#^2'W/\
M^2#_ (@AE/\ S\J??'_Y _+;_AF[XR?] %?_  +MO_CM'_#-WQD_Z *_^!=M
M_P#':_4FBC_B)^8?R0^Y_P#R0?\ $$,I_P"?E3[X_P#R!^6W_#-WQD_Z *_^
M!=M_\=H_X9N^,G_0!7_P+MO_ ([7ZDT4?\1/S#^2'W/_ .2#_B"&4_\ /RI]
M\?\ Y _+;_AF[XR?] %?_ NV_P#CM'_#-WQD_P"@"O\ X%VW_P =K]2:*/\
MB)^8?R0^Y_\ R0?\00RG_GY4^^/_ ,@?EM_PS=\9/^@"O_@7;?\ QVC_ (9N
M^,G_ $ 5_P# NV_^.U^I-%'_ !$_,/Y(?<__ )(/^((93_S\J??'_P"0/RV_
MX9N^,G_0!7_P+MO_ ([1_P ,W?&3_H K_P"!=M_\=K]2:*/^(GYA_)#[G_\
M)!_Q!#*?^?E3[X__ "!^6W_#-WQD_P"@"O\ X%VW_P =H_X9N^,G_0!7_P "
M[;_X[7ZDT4?\1/S#^2'W/_Y(/^((93_S\J??'_Y _+;_ (9N^,G_ $ 5_P#
MNV_^.T?\,W?&3_H K_X%VW_QVOU)HH_XB?F'\D/N?_R0?\00RG_GY4^^/_R!
M^6W_  S=\9/^@"O_ (%VW_QVC_AF[XR?] %?_ NV_P#CM?J311_Q$_,/Y(?<
M_P#Y(/\ B"&4_P#/RI]\?_D#\MO^&;OC)_T 5_\  NV_^.T?\,W?&3_H K_X
M%VW_ ,=K]2:*/^(GYA_)#[G_ /)!_P 00RG_ )^5/OC_ /('Y;?\,W?&3_H
MK_X%VW_QVN(U;X9^-=#UZ+PUJ>GB'49S&$B\Z)LF4X3YE<KR??CO7[ 5\6?%
M7_DN6E_]=-/_ /0Q1_Q$_,/Y(?<__D@_X@AE/_/RI]\?_D#PG_AF[XR?] %?
M_ NV_P#CM'_#-WQD_P"@"O\ X%VW_P =K]2:*/\ B)^8?R0^Y_\ R0?\00RG
M_GY4^^/_ ,@?EM_PS=\9/^@"O_@7;?\ QVC_ (9N^,G_ $ 5_P# NV_^.U^I
M-%'_ !$_,/Y(?<__ )(/^((93_S\J??'_P"0/RV_X9N^,G_0!7_P+MO_ ([1
M_P ,W?&3_H K_P"!=M_\=K]2:*/^(GYA_)#[G_\ )!_Q!#*?^?E3[X__ "!^
M6W_#-WQD_P"@"O\ X%VW_P =H_X9N^,G_0!7_P "[;_X[7ZDT4?\1/S#^2'W
M/_Y(/^((93_S\J??'_Y _+;_ (9N^,G_ $ 5_P# NV_^.T?\,W?&3_H K_X%
MVW_QVOU)HH_XB?F'\D/N?_R0?\00RG_GY4^^/_R!^6W_  S=\9/^@"O_ (%V
MW_QVC_AF[XR?] %?_ NV_P#CM?J311_Q$_,/Y(?<_P#Y(/\ B"&4_P#/RI]\
M?_D#\MO^&;OC)_T 5_\  NV_^.T?\,W?&3_H K_X%VW_ ,=K]2:*/^(GYA_)
M#[G_ /)!_P 00RG_ )^5/OC_ /('Y;?\,W?&3_H K_X%VW_QVC_AF[XR?] %
M?_ NV_\ CM?J311_Q$_,/Y(?<_\ Y(/^((93_P _*GWQ_P#D#\MO^&;OC)_T
M 5_\"[;_ ..T?\,W?&3_ * *_P#@7;?_ !VOU)HH_P"(GYA_)#[G_P#)!_Q!
M#*?^?E3[X_\ R!^6W_#-WQD_Z *_^!=M_P#':/\ AF[XR?\ 0!7_ ,"[;_X[
M7ZDT4?\ $3\P_DA]S_\ D@_X@AE/_/RI]\?_ ) _+;_AF[XR?] %?_ NV_\
MCM'_  S=\9/^@"O_ (%VW_QVOU)HH_XB?F'\D/N?_P D'_$$,I_Y^5/OC_\
M('Y;?\,W?&3_ * *_P#@7;?_ !VC_AF[XR?] %?_  +MO_CM?J311_Q$_,/Y
M(?<__D@_X@AE/_/RI]\?_D#\MO\ AF[XR?\ 0!7_ ,"[;_X[1_PS=\9/^@"O
M_@7;?_':_4FBC_B)^8?R0^Y__)!_Q!#*?^?E3[X__('Y;?\ #-WQD_Z *_\
M@7;?_':/^&;OC)_T 5_\"[;_ ..U^I-%'_$3\P_DA]S_ /D@_P"((93_ ,_*
MGWQ_^0/RV_X9N^,G_0!7_P "[;_X[1_PS=\9/^@"O_@7;?\ QVOU)HH_XB?F
M'\D/N?\ \D'_ !!#*?\ GY4^^/\ \@?EM_PS=\9/^@"O_@7;?_':/^&;OC)_
MT 5_\"[;_P".U^I-%'_$3\P_DA]S_P#D@_X@AE/_ #\J??'_ .0/RV_X9N^,
MG_0!7_P+MO\ X[1_PS=\9/\ H K_ .!=M_\ ':_4FBC_ (B?F'\D/N?_ ,D'
M_$$,I_Y^5/OC_P#('Y;?\,W?&3_H K_X%VW_ ,=H_P"&;OC)_P! %?\ P+MO
M_CM?J311_P 1/S#^2'W/_P"2#_B"&4_\_*GWQ_\ D#\MO^&;OC)_T 5_\"[;
M_P".T?\ #-WQD_Z *_\ @7;?_':_4FBC_B)^8?R0^Y__ "0?\00RG_GY4^^/
M_P @?EM_PS=\9/\ H K_ .!=M_\ ':/^&;OC)_T 5_\  NV_^.U^I-%'_$3\
MP_DA]S_^2#_B"&4_\_*GWQ_^0/RV_P"&;OC)_P! %?\ P+MO_CM'_#-WQD_Z
M *_^!=M_\=K]2:*/^(GYA_)#[G_\D'_$$,I_Y^5/OC_\@?EM_P ,W?&3_H K
M_P"!=M_\=H_X9N^,G_0!7_P+MO\ X[7ZDT4?\1/S#^2'W/\ ^2#_ (@AE/\
MS\J??'_Y _+;_AF[XR?] %?_  +MO_CM'_#-WQD_Z *_^!=M_P#':_4FBC_B
M)^8?R0^Y_P#R0?\ $$,I_P"?E3[X_P#R!^6W_#-WQD_Z *_^!=M_\=H_X9N^
M,G_0!7_P+MO_ ([7ZDT4?\1/S#^2'W/_ .2#_B"&4_\ /RI]\?\ Y _+;_AF
M[XR?] %?_ NV_P#CM'_#-WQD_P"@"O\ X%VW_P =K]2:*/\ B)^8?R0^Y_\
MR0?\00RG_GY4^^/_ ,@?EM_PS=\9/^@"O_@7;?\ QVC_ (9N^,G_ $ 5_P#
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M5=\C_:;=MJCOA9"3^ K]6J\]^+'_ "3G7_\ KV/\Q1_Q$_,/Y(?<_P#Y(/\
MB"&4_P#/RI]\?_D#\U?#'P:^(WC&PDU/P[I0NK:*4PLQGACPZJK$8=U/1AST
MKH_^&;OC)_T 5_\  NV_^.U]B?LU?\B+??\ 82E_]$PU]"T?\1/S#^2'W/\
M^2#_ (@AE/\ S\J??'_Y _+;_AF[XR?] %?_  +MO_CM'_#-WQD_Z *_^!=M
M_P#':_4FBC_B)^8?R0^Y_P#R0?\ $$,I_P"?E3[X_P#R!^6W_#-WQD_Z *_^
M!=M_\=H_X9N^,G_0!7_P+MO_ ([7ZDT4?\1/S#^2'W/_ .2#_B"&4_\ /RI]
M\?\ Y _+;_AF[XR?] %?_ NV_P#CM'_#-WQD_P"@"O\ X%VW_P =K]2:*/\
MB)^8?R0^Y_\ R0?\00RG_GY4^^/_ ,@?EM_PS=\9/^@"O_@7;?\ QVC_ (9N
M^,G_ $ 5_P# NV_^.U^I-%'_ !$_,/Y(?<__ )(/^((93_S\J??'_P"0/RV_
MX9N^,G_0!7_P+MO_ ([1_P ,W?&3_H K_P"!=M_\=K]2:*/^(GYA_)#[G_\
M)!_Q!#*?^?E3[X__ "!^6W_#-WQD_P"@"O\ X%VW_P =H_X9N^,G_0!7_P "
M[;_X[7ZDT4?\1/S#^2'W/_Y(/^((93_S\J??'_Y _+;_ (9N^,G_ $ 5_P#
MNV_^.T?\,W?&3_H K_X%VW_QVOU)HH_XB?F'\D/N?_R0?\00RG_GY4^^/_R!
M^6W_  S=\9/^@"O_ (%VW_QVC_AF[XR?] %?_ NV_P#CM?J311_Q$_,/Y(?<
M_P#Y(/\ B"&4_P#/RI]\?_D#\MO^&;OC)_T 5_\  NV_^.T?\,W?&3_H K_X
M%VW_ ,=K]2:*/^(GYA_)#[G_ /)!_P 00RG_ )^5/OC_ /('Y;?\,W?&3_H
MK_X%VW_QVC_AF[XR?] %?_ NV_\ CM?J311_Q$_,/Y(?<_\ Y(/^((93_P _
M*GWQ_P#D#\MO^&;OC)_T 5_\"[;_ ..T?\,W?&3_ * *_P#@7;?_ !VOU)HH
M_P"(GYA_)#[G_P#)!_Q!#*?^?E3[X_\ R!^6W_#-WQD_Z *_^!=M_P#':/\
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M_P"&;OC)_P! %?\ P+MO_CM?J311_P 1/S#^2'W/_P"2#_B"&4_\_*GWQ_\
MD#\MO^&;OC)_T 5_\"[;_P".T?\ #-WQD_Z *_\ @7;?_':_4FBC_B)^8?R0
M^Y__ "0?\00RG_GY4^^/_P @?EM_PS=\9/\ H K_ .!=M_\ ':/^&;OC)_T
M5_\  NV_^.U^I-%'_$3\P_DA]S_^2#_B"&4_\_*GWQ_^0/RV_P"&;OC)_P!
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MK]2:*/\ B)^8?R0^Y_\ R0?\00RG_GY4^^/_ ,@?EM_PS=\9/^@"O_@7;?\
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M_P!?NE_SCK[3KXL\>_\ )PVF_P#7[I?\XZ^TZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M \Q^,O\ R3/7?^N<?_HU*Y/]G/\ Y)_)_P!?LW_H*5UGQE_Y)GKO_7./_P!&
MI7)_LY_\D_D_Z_9O_04H __5_?RBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MB/B7_P D_P#$/_7E/_Z":\F_9G_Y%/5/^OT_^BDKUGXE_P#)/_$/_7E/_P"@
MFO)OV9_^13U3_K]/_HI* /I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^+/BK_P ERTO_
M *Z:?_Z&*^TZ^+/BK_R7+2_^NFG_ /H8H ^TZ*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MSWXL?\DYU_\ Z]C_ #%>A5Y[\6/^2<Z__P!>Q_F* ///V:O^1%OO^PE+_P"B
M8:^A:^>OV:O^1%OO^PE+_P"B8:^A: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^+/'O\
MR<-IO_7[I?\ ..OM.OBSQ[_R<-IO_7[I?\XZ^TZ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \Q^,O_),]=_ZYQ_\ HU*Y/]G/_DG\G_7[-_Z"E=9\9?\ DF>N_P#7./\
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MH#_H!7/_ (+)?\*^R** /C?_ (6-^T!_T KG_P %DO\ A1_PL;]H#_H!7/\
MX+)?\*^R** /C?\ X6-^T!_T KG_ ,%DO^%'_"QOV@/^@%<_^"R7_"OLBB@#
MXW_X6-^T!_T KG_P62_X4?\ "QOV@/\ H!7/_@LE_P *^R** /C?_A8W[0'_
M $ KG_P62_X4?\+&_: _Z 5S_P""R7_"OLBB@#XW_P"%C?M ?] *Y_\ !9+_
M (4?\+&_: _Z 5S_ ."R7_"OLBB@#XW_ .%C?M ?] *Y_P#!9+_A1_PL;]H#
M_H!7/_@LE_PK[(HH ^-_^%C?M ?] *Y_\%DO^%'_  L;]H#_ * 5S_X+)?\
M"OLBB@#XW_X6-^T!_P! *Y_\%DO^%'_"QOV@/^@%<_\ @LE_PK[(HH ^-_\
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MR** /C?_ (6-^T!_T KG_P %DO\ A1_PL;]H#_H!7/\ X+)?\*^R** /C?\
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M@/\ H!7/_@LE_P */^%C?M ?] *Y_P#!9+_A7V110!\;_P#"QOV@/^@%<_\
M@LE_PH_X6-^T!_T KG_P62_X5]D44 ?&_P#PL;]H#_H!7/\ X+)?\*/^%C?M
M ?\ 0"N?_!9+_A7V110!\;_\+&_: _Z 5S_X+)?\*/\ A8W[0'_0"N?_  62
M_P"%?9%% 'QO_P +&_: _P"@%<_^"R7_  H_X6-^T!_T KG_ ,%DO^%?9%%
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M_"QOV@/^@%<_^"R7_"C_ (6-^T!_T KG_P %DO\ A7V110!\;_\ "QOV@/\
MH!7/_@LE_P */^%C?M ?] *Y_P#!9+_A7V110!\;_P#"QOV@/^@%<_\ @LE_
MPH_X6-^T!_T KG_P62_X5]D44 ?&_P#PL;]H#_H!7/\ X+)?\*/^%C?M ?\
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M /C?_A8W[0'_ $ KG_P62_X4?\+&_: _Z 5S_P""R7_"OLBB@#XW_P"%C?M
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M[0'_ $ KG_P62_X4?\+&_: _Z 5S_P""R7_"OLBB@#XW_P"%C?M ?] *Y_\
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M0'_0"N?_  62_P"%'_"QOV@/^@%<_P#@LE_PK[(HH ^-_P#A8W[0'_0"N?\
MP62_X4?\+&_: _Z 5S_X+)?\*^R** /C?_A8W[0'_0"N?_!9+_A1_P +&_:
M_P"@%<_^"R7_  K[(HH ^-_^%C?M ?\ 0"N?_!9+_A1_PL;]H#_H!7/_ (+)
M?\*^R** /C?_ (6-^T!_T KG_P %DO\ A1_PL;]H#_H!7/\ X+)?\*^R** /
MC?\ X6-^T!_T KG_ ,%DO^%'_"QOV@/^@%<_^"R7_"OLBB@#XW_X6-^T!_T
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MH#_H!7/_ (+)?\*^R** /C?_ (6-^T!_T KG_P %DO\ A1_PL;]H#_H!7/\
MX+)?\*^R** /C?\ X6-^T!_T KG_ ,%DO^%'_"QOV@/^@%<_^"R7_"OLBB@#
MXW_X6-^T!_T KG_P62_X4?\ "QOV@/\ H!7/_@LE_P *^R** /C?_A8W[0'_
M $ KG_P62_X4?\+&_: _Z 5S_P""R7_"OLBB@#XW_P"%C?M ?] *Y_\ !9+_
M (4?\+&_: _Z 5S_ ."R7_"OLBB@#XW_ .%C?M ?] *Y_P#!9+_A1_PL;]H#
M_H!7/_@LE_PK[(HH ^-_^%C?M ?] *Y_\%DO^%'_  L;]H#_ * 5S_X+)?\
M"OLBB@#XW_X6-^T!_P! *Y_\%DO^%'_"QOV@/^@%<_\ @LE_PK[(HH ^-_\
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M0'_0"N?_  62_P"%'_"QOV@/^@%<_P#@LE_PK[(HH ^-_P#A8W[0'_0"N?\
MP62_X4?\+&_: _Z 5S_X+)?\*^R** /C?_A8W[0'_0"N?_!9+_A1_P +&_:
M_P"@%<_^"R7_  K[(HH ^-_^%C?M ?\ 0"N?_!9+_A1_PL;]H#_H!7/_ (+)
M?\*^R** /C?_ (6-^T!_T KG_P %DO\ A1_PL;]H#_H!7/\ X+)?\*^R** /
MC?\ X6-^T!_T KG_ ,%DO^%'_"QOV@/^@%<_^"R7_"OLBB@#XW_X6-^T!_T
MKG_P62_X4?\ "QOV@/\ H!7/_@LE_P *^R** /C?_A8W[0'_ $ KG_P62_X4
M?\+&_: _Z 5S_P""R7_"OLBB@#XW_P"%C?M ?] *Y_\ !9+_ (4?\+&_: _Z
M 5S_ ."R7_"OLBB@#XW_ .%C?M ?] *Y_P#!9+_A1_PL;]H#_H!7/_@LE_PK
M[(HH ^-_^%C?M ?] *Y_\%DO^%'_  L;]H#_ * 5S_X+)?\ "OLBB@#XW_X6
M-^T!_P! *Y_\%DO^%'_"QOV@/^@%<_\ @LE_PK[(HH ^-_\ A8W[0'_0"N?_
M  62_P"%'_"QOV@/^@%<_P#@LE_PK[(HH ^-_P#A8W[0'_0"N?\ P62_X4?\
M+&_: _Z 5S_X+)?\*^R** /C?_A8W[0'_0"N?_!9+_A1_P +&_: _P"@%<_^
M"R7_  K[(HH ^-_^%C?M ?\ 0"N?_!9+_A1_PL;]H#_H!7/_ (+)?\*^R**
M/C?_ (6-^T!_T KG_P %DO\ A1_PL;]H#_H!7/\ X+)?\*^R** /C?\ X6-^
MT!_T KG_ ,%DO^%'_"QOV@/^@%<_^"R7_"OLBB@#XW_X6-^T!_T KG_P62_X
M4?\ "QOV@/\ H!7/_@LE_P *^R** /C?_A8W[0'_ $ KG_P62_X4?\+&_: _
MZ 5S_P""R7_"OLBB@#XW_P"%C?M ?] *Y_\ !9+_ (4?\+&_: _Z 5S_ ."R
M7_"OLBB@#XW_ .%C?M ?] *Y_P#!9+_A1_PL;]H#_H!7/_@LE_PK[(HH ^-_
M^%C?M ?] *Y_\%DO^%'_  L;]H#_ * 5S_X+)?\ "OLBB@#XW_X6-^T!_P!
M*Y_\%DO^%'_"QOV@/^@%<_\ @LE_PK[(HH ^-_\ A8W[0'_0"N?_  62_P"%
M'_"QOV@/^@%<_P#@LE_PK[(HH ^-_P#A8W[0'_0"N?\ P62_X4?\+&_: _Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH XCXE_\ )/\ Q#_UY3_^@FO)OV9_^13U3_K]/_HI*]9^)?\ R3_Q#_UY
M3_\ H)KR;]F?_D4]4_Z_3_Z*2@#Z0HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OBSXJ_\
M)<M+_P"NFG_^ABOM.OBSXJ_\ERTO_KII_P#Z&* /M.BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *\]^+'_).=?_ .O8_P Q7H5>>_%C_DG.O_\ 7L?YB@#SS]FK_D1;[_L)
M2_\ HF&OH6OGK]FK_D1;[_L)2_\ HF&OH6@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B
MSQ[_ ,G#:;_U^Z7_ #CK[3KXL\>_\G#:;_U^Z7_..OM.@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /,?C+_R3/7?^N<?_ *-2N3_9S_Y)_)_U^S?^@I76?&7_ ))GKO\
MUSC_ /1J5R?[.?\ R3^3_K]F_P#04H __]#]_**** "BBB@ HHHH **** "B
MBN$^)_CFQ^&GP\\0^/=0P8M#LIKD*3CS)%7]W']7<JH]S6M"A*K.-."NVTEZ
MLSJU8P@YS=DM6?.'CO\ ;L^!'P]\8:MX)UJ349]0T:=K:X:VM5DB$J??56,B
MY*G*GCJ"*](^"7[3'PQ^/USJMEX#ENEN-'2*2:.[A$+%)BP#( S;@"N&],CU
MK^:S5-3OM:U.\UG4Y3/>7\TEQ/(W5Y96+NQ]R237T[^Q=\3/^%9?M ^'KNYE
M\K3M>8Z1=Y.!LNR!&2>@"S"-B>P!K^BLZ\(,'1RZI4H.3JQC??1M:O2W76Q^
M+97XDXFKC80K)*G*5MM4GMKY=3^CBJ]W<Q65I->39\N!&D;')VJ,G'Y58K'\
M1?\ (OZG_P!>LW_H!K^<Z<;R29^US=DV?$/_  \=_9U]-9_\ E_^.U]K>$_$
MVE^-/"^D>+]$9VT_6K2&\MS(NQS%<()$W+V.",BOY.Z_I^_9S_Y(#\./^Q>T
MO_TFCK]@\2^!L#E.'I5<)S7DVG=WZ>A^;<"\68K,:U2&(M9*^BMU/3_$&M67
MAK0=2\1:EN^R:5;37<VP;F\N!#(VT<9. <"OB#_AX[^SKZ:S_P" 2_\ QVOL
MGQ]HEYXE\">(_#FG%!=ZKIMY:0F0[4\R>%HUW$ X&6&3@U^(_P#P[;_:%_Y^
M=#_\#)?_ (Q7A<#93DN)IU7FM7D::M[UKKKT/5XKS'-*$X++Z?,FG?2_ZGW?
M_P /'?V=?36?_ )?_CM'_#QW]G7TUG_P"7_X[7XP_%[X1^*O@GXRD\#>,7MG
MU&*"*<FUD:6+9,"5^9E0YXYXKL?@;^S7\1?V@TUJ3P&]C&NA&W%P;R9HLFY\
MS9LVH^<>6<YQVZ]OU6KX9\.PPWUR=22IZ/FYE:SVZ=3\^I\=YU.O]6C!.>NG
M+KIOU/V+\*_M]_ 3Q?XFTGPGI1U5+W6KN"R@,MF%C\VX<1IN(D) W,,G!Q7V
MQ7XH_#+_ ()_?';PC\2?"?BS59]'-EHNK6%[.([N1G,5M<)*^T&$ MM4X&1S
MWKZZ_;A_:=O?@KX:M?!?@BZ$/C#Q!&9!, &:RLLE3, <C?(P*1\'&&;@J,_F
M6>\)X"OCZ&#R*IS\Z=];I>;TT5C[O*>(L72PE7$YM#DY;6TM?TUWN>_?%/\
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M?JE17Y6_\-$?&3_H8F_\!K;_ .-4?\-$?&3_ *&)O_ :V_\ C5'_ !"_'_\
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MRM_X:(^,G_0Q-_X#6W_QJC_AHCXR?]#$W_@-;?\ QJC_ (A?C_\ GY#[W_\
M(A_Q'#*O^?53[H__ "9^J5%?E;_PT1\9/^AB;_P&MO\ XU1_PT1\9/\ H8F_
M\!K;_P"-4?\ $+\?_P _(?>__D0_XCAE7_/JI]T?_DS]4J*_*W_AHCXR?]#$
MW_@-;?\ QJC_ (:(^,G_ $,3?^ UM_\ &J/^(7X__GY#[W_\B'_$<,J_Y]5/
MNC_\F?JE17Y6_P##1'QD_P"AB;_P&MO_ (U1_P -$?&3_H8F_P# :V_^-4?\
M0OQ__/R'WO\ ^1#_ (CAE7_/JI]T?_DS]4J*_*W_ (:(^,G_ $,3?^ UM_\
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M\9/^AB;_ ,!K;_XU1_Q"_'_\_(?>_P#Y$/\ B.&5?\^JGW1_^3/U2HK\K?\
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M$W_@-;?_ !JC_B%^/_Y^0^]__(A_Q'#*O^?53[H__)GZI45^5O\ PT1\9/\
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MQ'#*O^?53[H__)GZI45^5O\ PT1\9/\ H8F_\!K;_P"-4?\ #1'QD_Z&)O\
MP&MO_C5'_$+\?_S\A][_ /D0_P"(X95_SZJ?='_Y,_5*BORM_P"&B/C)_P!#
M$W_@-;?_ !JC_AHCXR?]#$W_ (#6W_QJC_B%^/\ ^?D/O?\ \B'_ !'#*O\
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M7_/JI]T?_DS]4J*_*W_AHCXR?]#$W_@-;?\ QJC_ (:(^,G_ $,3?^ UM_\
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MOQ__ #\A][_^1#_B.&5?\^JGW1_^3/U2HK\K?^&B/C)_T,3?^ UM_P#&J/\
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M (A?C_\ GY#[W_\ (A_Q'#*O^?53[H__ "9^J5%?E;_PT1\9/^AB;_P&MO\
MXU1_PT1\9/\ H8F_\!K;_P"-4?\ $+\?_P _(?>__D0_XCAE7_/JI]T?_DS]
M4J*_*W_AHCXR?]#$W_@-;?\ QJC_ (:(^,G_ $,3?^ UM_\ &J/^(7X__GY#
M[W_\B'_$<,J_Y]5/NC_\F?JE17Y6_P##1'QD_P"AB;_P&MO_ (U1_P -$?&3
M_H8F_P# :V_^-4?\0OQ__/R'WO\ ^1#_ (CAE7_/JI]T?_DS]4J*_*W_ (:(
M^,G_ $,3?^ UM_\ &J/^&B/C)_T,3?\ @-;?_&J/^(7X_P#Y^0^]_P#R(?\
M$<,J_P"?53[H_P#R9^J5%?E;_P -$?&3_H8F_P# :V_^-4?\-$?&3_H8F_\
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M;_XU1_PT1\9/^AB;_P !K;_XU1_Q"_'_ //R'WO_ .1#_B.&5?\ /JI]T?\
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MHKX(_5 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:KADO=4KKT>J^[;Y'[5PYFGUS+Z==O6UGZK1_P"9_)G7]/W[.?\ R0'X<?\
M8O:7_P"DT=?S U_3]^SG_P D!^''_8O:7_Z31U^S^./^YX?_ !/\C\P\*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]<X__1J5R?[.?_)/Y/\ K]F_]!2@#__2_?RBBB@ HHHH **** "BBB@#Q?\
M:&^)*_"7X->*?'"2".\L[1H[/U-W<$108'?#L&(] :_F.M+6^U6_AL;.)[J\
MO)%CCC0%Y))9&PJ@#DLQ. .YK]:O^"G?Q)9$\*?"2SD(#[M8O .X!:"V'Y^<
M2/937RM^P?\ #G_A/OVA=(OKJ+S+#PK&^K39''F0X6W&?43.C#V4U_3'AOAX
M95D-7,ZJUE>7RC=17S=[>I^%<;UI9AF]/ 4WI&T?F]6_DK?<>3?\,R?M"_\
M1.]<_P# &7_"L?7_ ("?&KPKH]UX@\2>"-7TW3;)0\]Q/:2)%&I(7+,1@#)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!PCA\<O:?S<SO?OV.B/BQF"J?PX>R_DY5RV[=_ZVZ'TE\?\ X+6_PYNH-?\
M#NXZ'?R&,1L2S6TN,A-QR2K $J2<\$'L3\VU^C_CFZ?Q5^S"-5U1MUQ)IUG.
MSL.3-&\>6^K$'\Z^??V9?A[H'C?6M:NO$UBM_96%O&BQN6"B69\AOE(Y"HP_
M&L,AXEG3RVK6QC<G2DXM]7M;YZV.GBK@RG6SFCALN2C&O%32>T;IM[7TTO\
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M .,L-]>R--<7$-W)(['+.[J2S$^I)S7W;\6/^28^*O\ L&W7_HMJ^"OV7_\
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M&SY'V [/3?YK[OTVU\R>&=>N_"WB'3O$5B T^G3I,JGHVPY*GV8<'ZU^B7Q
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M=8M']"5%%%,R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .(^)?_)/_$/_ %Y3_P#H)K\JO%/^JM/K)_[)7ZJ_$O\
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MGBG0O!OQ'L->\1W/V2PACG5Y-CR;2\3*ORQAFY)QP*^[_P#AH[X,_P#0P_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M *"E=9\9?^29Z[_USC_]&I7)_LY_\D_D_P"OV;_T%* /_];]_**** "BBB@
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <1\2_^2?^(?\
MKRG_ /037Y5>*?\ 56GUD_\ 9*_57XE_\D_\0_\ 7E/_ .@FORJ\4_ZJT^LG
M_LE?<>'?_(TAZ2_(_,?%[_D1U/6/YHX^BBBOZ(/Y!"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "OI3]E3_DJ1_P"O"X_FE?-=?2G[*G_)
M4C_UX7'\TKY_BO\ Y%M?_"SZW@/_ )'.%_QH_2BBBBOY?/[?"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /BSQ[_R<-IO_ %^Z7_..OM.OBSQ[_P G#:;_ -?NE_SCK[3H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW:?"Z CD$1LI0?\ ?-?2=% TV5K*RL].M(K#3X([6VMU"1Q1*$C11P%55
M[ "N=\8^ _ _Q#TN/0_'_AW3O$VFQ2K.EMJ=I#>P+,JLJR".=74.%9@&QD D
M9Y-=710(P_#?ACPUX-T2V\->$-)M-#TBR#""SL8([:VB#L7;9%$JHNYF+' &
M22>IK<HHH \Z\9_"#X2_$>\M]1^(?@G1/%%W:1F*&;5--MKV2*,G<41IXW*K
MDYP#C/->A1QQPQK#"H2- %55&  .  !T I]% &5KFA:)XGTBZT#Q)I]OJVEW
MZ&*XM+N))[>:,]4DCD#*RGN""*PO!GPZ^'WPXL[C3OAYX8TOPO:7<@EFATNR
M@LHY) -H=U@1 S8 &2,XXKLJ* N4=3TS3=;TV[T;6;2&_P!/OXI+>XMKB-98
M9H95*/')&X*NCJ2&4@@@X(Q7B_\ PRW^S)_T2+PA_P""#3__ (Q7NU% [GA/
M_#+?[,G_ $2+PA_X(-/_ /C%='X5^!GP2\":Q'XB\#_#[P]X>U6)61+O3M)M
M+2X5'&&42PQ*X##@C/(ZUZG10%V%<-XV^&/PW^)5M%9_$3PKI?B>&#)B34[*
M&[$9/4IYJMM/N,&NYHH$?.6E_L@_LN:-?+J.G_"OPXEPC;U9].@E"L#D%5D5
M@"#TP.*^AK6UM;&VCL[*%+>WA4)''&H1$4< *HP !Z"IZ*!MGSQ^U7\:[#]G
M_P" _BOXD7$HCOK:U:WTU.,RZC<@QVR@=PKG>WHBL>U?!7_!(_X%:AX0^&FN
M?'+Q)&RW_CR18; 2#YQI]H[[I<GG]_,2>>JQHPX:OTI^*_P4^%WQQT:S\/?%
M;08O$.G6%Q]J@@EDEC5)]C)O_=.A)VLPYSU-=[H.A:/X7T/3_#7A^TCL-+TJ
MWBM;6WB&(X8(5"1HH]%4 "D4I:6-:BBBF0%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 <1\2_^2?\ B'_KRG_]!-?E
M9XG1VBM"JD_-)T'LE?JG\2_^2?\ B'_KRG_]!->3?LS_ /(IZI_U^G_T4E>Y
MP[G/U#%+$\O-:^E[;_)GS'%_#G]JX&6"Y^2[3O:^SOM=?F?FOY4O]QORH\J7
M^XWY5^W%%?H?_$5G_P! _P#Y-_\ :GY%_P 0&7_09_Y)_P#;GXC^5+_<;\J/
M*E_N-^5?MQ11_P 16?\ T#_^3?\ VH?\0&7_ $&?^2?_ &Y^(_E2_P!QORH\
MJ7^XWY5^W%%'_$5G_P! _P#Y-_\ :A_Q 9?]!G_DG_VY^(_E2_W&_*CRI?[C
M?E7[<44?\16?_0/_ .3?_:A_Q 9?]!G_ ))_]N?B/Y4O]QORH\J7^XWY5^W%
M%'_$5G_T#_\ DW_VH?\ $!E_T&?^2?\ VY^(_E2_W&_*CRI?[C?E7[<44?\
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M?_:A_P 0&7_09_Y)_P#;GXC^5+_<;\J/*E_N-^5?MQ11_P 16?\ T#_^3?\
MVH?\0&7_ $&?^2?_ &Y^(_E2_P!QORH\J7^XWY5^W%%'_$5G_P! _P#Y-_\
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M *!__)O_ +4/^(#+_H,_\D_^W/Q'\J7^XWY4>5+_ '&_*OVXHH_XBL_^@?\
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M_P#;GY$".1AE5)^@I?*E_N-^5?IG^S5_R(M]_P!A*7_T3#7T+1_Q%9_] _\
MY-_]J'_$!E_T&?\ DG_VY^(_E2_W&_*CRI?[C?E7[<44?\16?_0/_P"3?_:A
M_P 0&7_09_Y)_P#;GXC^5+_<;\J/*E_N-^5?MQ11_P 16?\ T#_^3?\ VH?\
M0&7_ $&?^2?_ &Y^(_E2_P!QORH\J7^XWY5^W%%'_$5G_P! _P#Y-_\ :A_Q
M 9?]!G_DG_VY^(_E2_W&_*CRI?[C?E7[<44?\16?_0/_ .3?_:A_Q 9?]!G_
M ))_]N?B/Y4O]QORH\J7^XWY5^W%%'_$5G_T#_\ DW_VH?\ $!E_T&?^2?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#'J/\ AI7P+_SXZE_WZA_^/4 ?0M%?/7_#2O@7_GQU+_OU#_\ 'J/^&E?
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M^>O^&E? O_/CJ7_?J'_X]1_PTKX%_P"?'4O^_4/_ ,>H ^A:*^>O^&E? O\
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MO^_4/_QZ@#Z%HKYZ_P"&E? O_/CJ7_?J'_X]1_PTKX%_Y\=2_P"_4/\ \>H
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M^?'4O^_4/_QZ@#Z%HKYZ_P"&E? O_/CJ7_?J'_X]1_PTKX%_Y\=2_P"_4/\
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MP+_SXZE_WZA_^/4?\-*^!?\ GQU+_OU#_P#'J /H6BOGK_AI7P+_ ,^.I?\
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MI?\ ?J'_ ./4?\-*^!?^?'4O^_4/_P >H ^A:*^>O^&E? O_ #XZE_WZA_\
MCU'_  TKX%_Y\=2_[]0__'J /H6BOGK_ (:5\"_\^.I?]^H?_CU'_#2O@7_G
MQU+_ +]0_P#QZ@#Z%HKYZ_X:5\"_\^.I?]^H?_CU'_#2O@7_ )\=2_[]0_\
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M@7_GQU+_ +]0_P#QZ@#Z%KSWXL?\DYU__KV/\Q7GG_#2O@7_ )\=2_[]0_\
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M_P!^H?\ X]0!]"T5\]?\-*^!?^?'4O\ OU#_ /'J/^&E? O_ #XZE_WZA_\
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M !ZC_AI7P+_SXZE_WZA_^/4 ?0M%?/7_  TKX%_Y\=2_[]0__'J/^&E? O\
MSXZE_P!^H?\ X]0!]"T5\]?\-*^!?^?'4O\ OU#_ /'J/^&E? O_ #XZE_WZ
MA_\ CU 'T+17SU_PTKX%_P"?'4O^_4/_ ,>H_P"&E? O_/CJ7_?J'_X]0!]"
MT5\]?\-*^!?^?'4O^_4/_P >H_X:5\"_\^.I?]^H?_CU 'T+17SU_P -*^!?
M^?'4O^_4/_QZC_AI7P+_ ,^.I?\ ?J'_ ./4 ?0M%?/7_#2O@7_GQU+_ +]0
M_P#QZC_AI7P+_P ^.I?]^H?_ (]0!]"T5\]?\-*^!?\ GQU+_OU#_P#'J/\
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M#Z%HKYZ_X:5\"_\ /CJ7_?J'_P"/4?\ #2O@7_GQU+_OU#_\>H ^A:*^>O\
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MP+_SXZE_WZA_^/4?\-*^!?\ GQU+_OU#_P#'J /H6BOGK_AI7P+_ ,^.I?\
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MM_X5/\.?^@!;?D?\:\\_9J_Y$6^_["4O_HF&OH6@#SW_ (5/\.?^@!;?D?\
M&C_A4_PY_P"@!;?D?\:]"HH \]_X5/\ #G_H 6WY'_&C_A4_PY_Z %M^1_QK
MT*B@#SW_ (5/\.?^@!;?D?\ &C_A4_PY_P"@!;?D?\:]"HH \]_X5/\ #G_H
M 6WY'_&C_A4_PY_Z %M^1_QKT*B@#SW_ (5/\.?^@!;?D?\ &C_A4_PY_P"@
M!;?D?\:]"HH \]_X5/\ #G_H 6WY'_&C_A4_PY_Z %M^1_QKT*B@#SW_ (5/
M\.?^@!;?D?\ &C_A4_PY_P"@!;?D?\:]"HH \]_X5/\ #G_H 6WY'_&C_A4_
MPY_Z %M^1_QKT*B@#SW_ (5/\.?^@!;?D?\ &C_A4_PY_P"@!;?D?\:]"HH
M\]_X5/\ #G_H 6WY'_&C_A4_PY_Z %M^1_QKT*B@#SW_ (5/\.?^@!;?D?\
M&C_A4_PY_P"@!;?D?\:]"HH \]_X5/\ #G_H 6WY'_&C_A4_PY_Z %M^1_QK
MT*B@#SW_ (5/\.?^@!;?D?\ &C_A4_PY_P"@!;?D?\:]"HH \]_X5/\ #G_H
M 6WY'_&C_A4_PY_Z %M^1_QKT*B@#SW_ (5/\.?^@!;?D?\ &C_A4_PY_P"@
M!;?D?\:]"HH \]_X5/\ #G_H 6WY'_&C_A4_PY_Z %M^1_QKT*B@#SW_ (5/
M\.?^@!;?D?\ &C_A4_PY_P"@!;?D?\:]"HH \]_X5/\ #G_H 6WY'_&C_A4_
MPY_Z %M^1_QKT*B@#SW_ (5/\.?^@!;?D?\ &C_A4_PY_P"@!;?D?\:]"HH
M\]_X5/\ #G_H 6WY'_&C_A4_PY_Z %M^1_QKT*B@#SW_ (5/\.?^@!;?D?\
M&C_A4_PY_P"@!;?D?\:]"HH \]_X5/\ #G_H 6WY'_&C_A4_PY_Z %M^1_QK
MT*B@#SW_ (5/\.?^@!;?D?\ &C_A4_PY_P"@!;?D?\:]"HH \]_X5/\ #G_H
M 6WY'_&C_A4_PY_Z %M^1_QKT*B@#SW_ (5/\.?^@!;?D?\ &C_A4_PY_P"@
M!;?D?\:]"HH \]_X5/\ #G_H 6WY'_&C_A4_PY_Z %M^1_QKT*B@#SW_ (5/
M\.?^@!;?D?\ &C_A4_PY_P"@!;?D?\:]"HH \]_X5/\ #G_H 6WY'_&C_A4_
MPY_Z %M^1_QKT*B@#SW_ (5/\.?^@!;?D?\ &C_A4_PY_P"@!;?D?\:]"HH
M\]_X5/\ #G_H 6WY'_&C_A4_PY_Z %M^1_QKT*B@#SW_ (5/\.?^@!;?D?\
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M\:]"HH \]_X5/\.?^@!;?D?\:/\ A4_PY_Z %M^1_P :]"HH \]_X5/\.?\
MH 6WY'_&C_A4_P .?^@!;?D?\:]"HH \]_X5/\.?^@!;?D?\:/\ A4_PY_Z
M%M^1_P :]"HH \]_X5/\.?\ H 6WY'_&C_A4_P .?^@!;?D?\:]"HH \]_X5
M/\.?^@!;?D?\:/\ A4_PY_Z %M^1_P :]"HH \]_X5/\.?\ H 6WY'_&C_A4
M_P .?^@!;?D?\:]"HH \]_X5/\.?^@!;?D?\:/\ A4_PY_Z %M^1_P :]"HH
M \]_X5/\.?\ H 6WY'_&C_A4_P .?^@!;?D?\:]"HH \]_X5/\.?^@!;?D?\
M:/\ A4_PY_Z %M^1_P :]"HH \]_X5/\.?\ H 6WY'_&C_A4_P .?^@!;?D?
M\:]"HH \]_X5/\.?^@!;?D?\:/\ A4_PY_Z %M^1_P :]"HH \]_X5/\.?\
MH 6WY'_&C_A4_P .?^@!;?D?\:]"HH \]_X5/\.?^@!;?D?\:/\ A4_PY_Z
M%M^1_P :]"HH \]_X5/\.?\ H 6WY'_&C_A4_P .?^@!;?D?\:]"HH \]_X5
M/\.?^@!;?D?\:/\ A4_PY_Z %M^1_P :]"HH \]_X5/\.?\ H 6WY'_&C_A4
M_P .?^@!;?D?\:]"HH \]_X5/\.?^@!;?D?\:/\ A4_PY_Z %M^1_P :]"HH
M \]_X5/\.?\ H 6WY'_&C_A4_P .?^@!;?D?\:]"HH \]_X5/\.?^@!;?D?\
M:/\ A4_PY_Z %M^1_P :]"HH \]_X5/\.?\ H 6WY'_&C_A4_P .?^@!;?D?
M\:]"HH \]_X5/\.?^@!;?D?\:/\ A4_PY_Z %M^1_P :]"HH \]_X5/\.?\
MH 6WY'_&C_A4_P .?^@!;?D?\:]"HH \]_X5/\.?^@!;?D?\:/\ A4_PY_Z
M%M^1_P :]"HH \]_X5/\.?\ H 6WY'_&C_A4_P .?^@!;?D?\:]"HH \]_X5
M/\.?^@!;?D?\:/\ A4_PY_Z %M^1_P :]"HH \]_X5/\.?\ H 6WY'_&C_A4
M_P .?^@!;?D?\:]"HH \]_X5/\.?^@!;?D?\:/\ A4_PY_Z %M^1_P :]"HH
M \]_X5/\.?\ H 6WY'_&C_A4_P .?^@!;?D?\:]"HH \]_X5/\.?^@!;?D?\
M:/\ A4_PY_Z %M^1_P :]"HH \]_X5/\.?\ H 6WY'_&C_A4_P .?^@!;?D?
M\:]"HH \]_X5/\.?^@!;?D?\:/\ A4_PY_Z %M^1_P :]"HH \]_X5/\.?\
MH 6WY'_&C_A4_P .?^@!;?D?\:]"HH \]_X5/\.?^@!;?D?\:/\ A4_PY_Z
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M* "BBH);JV@9$GE2-I#A0S %CZ#/6FE<">BBBD 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!Q'Q+_ .2?^(?^O*?_ -!->3?LS_\ (IZI_P!?I_\ 125ZS\2_^2?^(?\
MKRG_ /037DW[,_\ R*>J?]?I_P#124 ?2%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\6?
M%7_DN6E_]=-/_P#0Q7VG7Q9\5?\ DN6E_P#733__ $,4 ?:=%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5Y[\6/^2<Z_P#]>Q_F*]"KSWXL?\DYU_\ Z]C_ #% 'GG[-7_(
MBWW_ &$I?_1,-?0M?/7[-7_(BWW_ &$I?_1,-?0M !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?%GCW_DX;3?^OW2_YQU]IU\6>/?^3AM-_P"OW2_YQU]IT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!YC\9?\ DF>N_P#7./\ ]&I7)_LY_P#)/Y/^OV;_ -!2NL^,
MO_),]=_ZYQ_^C4KD_P!G/_DG\G_7[-_Z"E '_]/]_**** "BBB@ HHHH ***
M* "JFH7]GI5A<ZGJ$JP6MG$\TTC<*D<:EF8^P )-6Z^+/V]?B9_PK_X :EI=
MI+Y>H^+9%TJ$ _,(9 7N6QZ&)60^[BO4R7+)XW%TL+#>;2_S?R6IP9ICXX7#
MU,1+:*;_ .!\S\2/B?\ %WQ5\0OB'XA\:_VE=VT>KWLT\4*S.HBA+8BC #8^
M2,*OX5]B?\$[OC!J>D?&*Z\!Z_J$UQ9^+;1DA$\C.%O+0-+'@L3C='YJ\=3M
M'I7R5\ O@[J/QS^(D/@/3I#;[[2[N7F&,1^1"QC+9S\K3&-#_O5P'A;Q!K/P
M]\::7XFL 8-4\/7T5RBME2);:0-L8>F5PP],BO["S?*,)B\)6RFFDI*"T[7O
MR/[XG\U9;F6(PV)I9C.]G)Z]]N;\&?U=5D>(25T#4F4X(MIB"/\ <-5_"OB/
M3?&'AG2?%FC/YEAK-K#>0-W,<Z!US[X/(]:G\1?\B_J?_7K-_P"@&OXPC3<:
MJC)6:9_3[FI0YH[-'\J7_"5^*?\ H,7G_@1)_P#%5_3+^SY<W%Y\"/AY=7<K
MSS2Z!IC.[L69F-LA))/))]37\O=?T_?LY_\ ) ?AQ_V+VE_^DT=?T5XW4HQP
MF'<5]I_D?BOA54D\36N_LK\SI/BW))%\*?&<L3%'31=1964X((MI""".A%?R
M^?\ "5^*?^@Q>?\ @1)_\57]8;HDB-'(H96!!!&00>H(K*_X1_0?^@;;?]^4
M_P *_-.!N.X9/3J0G0]IS-/>UK?)GW/%?",\RG"4:O)RI]+WO\T?RH_\)7XI
M_P"@Q>?^!$G_ ,51_P )7XI_Z#%Y_P"!$G_Q5?87_!0JUM;/]HV[AM(4@C_L
MVQ.U%"C)5NPQ7T=_P2]TW3KZT^)#7MK%<%'TD R(KD#%WTR#7]"8[BBE0R59
MQ[&]U%\MU]II;VZ7['XUA,@J5<T>6^UM9R7-Z)O:_EW/@+X&>*?$S_&SX?QO
MJ]XR2>(-*1E-Q(0RM=Q@@C=R"#@CN*_H8^-/QE\(_ OP-<^./%SL\2,(;:VB
MQYUU<."5BC!('0$L3PJ@GM@^BQZ%HD3K+%I]NCH0581("".A! ZU^#W_  4'
M^*%UXV^.5QX1MKAGTGP="EG'&#^[-U(HDN),?WLE8S_US_/\BI8BGQ;FM&#I
M>SA3BW*SO=77DK7>GXGZ1.C/AS+ZD_:<\YM*.EK.WJ]MSSKXP?MC?&[XN7MU
M%+K<V@:',Q\O3=.<P1K'V625-LDQQ][>VTGD*HXKYC?^T=2>6ZD\VZ=!ND<[
MG('JQY_6OM_]AO\ 9MTGXW>+[_Q-XUA,_A?PR8]\&=JWEW)DI$Q'/EJH+.!U
M^4=&-?O+H^B:-X>TZ'1] L8--L+90L5O;1+#$BCLJ(  /H*^SX@X^R_(*O\
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M^$>'O[4Q\,'S\M[ZVOLK[71Y'$><_4,)+%<O-:VE[;NQZ;^U3^WKHND:;=^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\
MY\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !
M_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$
M.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE
M_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\
MY\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !
M_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$
M.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE
M_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\
MY\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !
M_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$
M.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE
M_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\
MY\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !
M_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$
M.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE
M_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\
MY\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !
M_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$
M.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE
M_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\
MY\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !
M_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$
M.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE
M_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\
MY\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !
M_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$
M.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE
M_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\
MY\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !
M_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$
M.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE
M_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\
MY\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !
M_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$
M.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE
M_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\
MY\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !
M_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$
M.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE
M_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\
MY\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !
M_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE_P#/CI?_ 'YF_P#CU'_$
M.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\ Y\=+_P"_,W_QZC_AK;XE
M_P#/CI?_ 'YF_P#CU'_$.,S[1^\/^(R9+_-+_P !_P""?HU17YR_\-;?$O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'Q9X]_Y.&TW_ *_=+_G'7VG7Q9X]_P"3AM-_Z_=+_G'7
MVG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'F/QE_Y)GKO_7./_T:E<G^SG_R3^3_ *_9
MO_04KK/C+_R3/7?^N<?_ *-2N3_9S_Y)_)_U^S?^@I0!_]3]_**** "BBB@
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MPEWP8N/ ][+OOO!MT85!.6^QW1:6$GZ/YJ#T"BONWQ%_R+^I_P#7K-_Z :_
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MU^"=#U"/R[J2Q>\=>X^WRR72@^X64 CL1BOP#/P*^-P)!^'OB'C_ *A-W_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KZ4_94_Y*D?\ KPN/YI7S77TI^RI_R5(_]>%Q
M_-*^?XK_ .1;7_PL^MX#_P"1SA?\:/THHHHK^7S^WPHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#XL\>_\G#:;_P!?NE_SCK[3KXL\>_\ )PVF_P#7[I?\XZ^TZ "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5>>,?&XMAJ$&JSV:_98C%'Y4<,+KE2S<YD/.?2O&O^'9/P&_Z#WB7_P*L_\
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MS;L>IBE7YES@97E6P-P.*^'[O_@F#\,)+LR6/B[6(+8DD1NMO(X&>F\(H_\
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M&Q]/VN'E>VZZKU/R7B/A?&956]CBXVOLUJGZ/^GY"4445ZY\\%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Y59SA 6/7CF
MFU^GG[-4'AM/A?83Z*L7VR1I/MS+CS3,'; D/7A<;0?X<5\[Q/G_ /9V'5?D
MYKNUKV[[NS['V'!/"?\ ;&+>%]JH63=[7V:5DKKOW/S#HKZ?_:LM_#<'CVU.
MC+$E\]J&OA%@?/N.POC^,KUSSC&>U?,%>CE&8?6\-#$<O+S*]F>/Q!E#P&-J
MX-S4N1VNNO\ 75=&%%%%>B>.%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH XCXE_\ )/\ Q#_UY3_^@FOR)U/_ )"%Q_OFOUV^)?\ R3_Q#_UY3_\
MH)K\B=3_ .0A<?[YK]0\+/\ >JO^']4?B'CG_N%#_'_[:RA1117[@?S$%%%%
M !7[)^!O^1)\/_\ 8/M/_1*U^-E?LGX&_P"1)\/_ /8/M/\ T2M?E'BI_!H>
MK_)'[UX$_P"\8GTC^;/SB_:19E^,FN8)&%M/_2:.O:_V2=>\57]UK6EWL\UU
MH]O$CH96+K%.6P%0G.-RY) /;.*^H]8^&O@+Q#J4FL:WH5I>WLVW?++&&9M@
M"KDGT  KIM*T;2="LUT[1+*&PM4R1%!&L: GJ=J@#)]:^9S#C*A6RN. 5+WE
M&*N[:6MJON/M<H\.<5A\\J9K*NE!RE+E5[M2OH^G7S/+/V@;JUM?A#XA-T1B
M6.*- 3R7:5-N/4CK]!7Y@>'=*&O>(-,T,R^0-1NH;;S,;MGG.$W8R,XSG&1F
MOMC]I_PY\3]9LUU"!8KGPOIQ\TP6VXS(P!!FF4CY@ 2,J2%&20.37Q_\/?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/4DCN/5S[B*>']A"A%.579R=DMM_O/!X6X/IXMXJIBIM0H+505Y/5K3[GJ?
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MJR3:=ER.W3N_71/='YD5OZ#X5\2>*9VM_#FF7&I2)]X01,X7/3<0,+^)%5M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/M()9BIY44,J,;GZP45\O?MG?%GQ=\#?V:O&'Q2\"O FN:)_9_V=KF+SHO\
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M'K6N;Y;5H<-4Z<UJFF_*[;_4PX?SFAB>,ZM:G+W9)Q3[\L4M/7E;1Q_[8O\
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MW#Y-'$0H82,JC=M5*VKZ?#J<F68OB.>$J8K'SA14;NSA?1*[>DU8_+WX>_\
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M]U_Z425\E?M1>)=-U_XCI:Z9*LZZ3:I:RNI!'G;W=U!']W< ?0@BOK7]FO\
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M8.I6Q&9XBG%0A)JG'DZ?X5HNRNV_D?!]EI/B7QSK5XVCV$VIWTQDNI4@0R,
MS_,Q YQN8#/O7NG@;X^^.OA81X0\4V#7]I88C^SW!,-S;@ 817(/R@=%93Q@
M @5YY\&?B##\-O'%OKU[&TEC-&]M<A!EQ%(0=RCN595..X!%?4WC+X>_!KXO
M:H?&&D>,(-/N[M5\\++$0Y50 S12%'1L  YQTZ9R3]KQ#BZ,:RPV/H7H-:22
M;L^VFJT['YKPAE^(GAWC<JQ/+BE*THMQ5X[WUT>O?3\#J(--^$G[2.@7E_96
M?V/5K?"R3",1W<$C@["Y7B5#@XR2#@_=/3X]^$>EFP^-6AZ1?[3)9:@T;]U\
MR'=C'_ EXKZHT/6_@_\ L]>&K]-(UM->U:]PS+%*DLDSQ@B-"(LK$B[B<L<\
MGJ<"OA:R\3ZI8^*8O&$+ :A%=B]SC"F3?YAX]">H]*\[AK"U9T\71HN7L6K0
MYK[M.]K]+_U>Y[/&F.P].K@,1B5#ZS%WJ\EK64DU>VG-;]>EC] ?C-\=9_AG
MXGM?#XT*+4TFM$N1))*4(+NZ%0-C?W,YS7F.F_M3:MK%_!IFE>"8;J[N&VQQ
M1S%G9O0 1UVVMWOP8_:%T6QN]2UE-#UBU7 625(IXRW+1D2865,\@K^8R15'
MPOX;^!?P0N)/%%[XEBU?58598@)(Y9$W#!\N&+)#,,C<QP >HYKYO!X;+J6%
M5*MA9/$+3EM/5]'H[6/LLQQF;UL<\1AL=".$DT^:]/2/56:O???YV/"/C[X]
M\6^+[K1K#Q7X<D\.2V"321QR,S&59RHW?,J\ QXKYZKT#XG>/;OXD>+[OQ+<
MQ^1$X6*WASGRX4^ZI/J<ECVR3CBO/Z_6<CP?L,)3I<BC9;*[2;U:N[]6?@7$
M^8_6L?5K^T<TWI)I)M+1.R22T78U=$T/5_$>IP:-H5I)>WMP=J11C)/N>P Z
MDG@#DG%?<W@OX3^!_@CHZ^._B?=PW&J1X:)#\\<,G4)"G627_:Q@=1@#=79_
M"1_@S\/O#-FMEX@TF/5+N")[V>2^@,S2E067);*JK<!>,=\G).1XS\)_ SQ]
MJ[ZUXE\?)<3'(C0:M:"*)#_#&F,*/U/4DGFOSC.>)JF+K/#-3A16[46Y2\O)
M?UY'[)PWP32R_#K&*5.KB7K%2DE"'F^LFOSV[GRU\7/CCK_Q,N&T^WW:=H,;
M9CM0?FEP>'F(^\>X7[J^Y^8^:>"M%/B/Q?HN@[=RW]Y!"_\ N,X#'\%R:^N[
MOX0_LTV]K-<#Q@LAB1FVIJEHS-M&<* O)/85X9^SU)H5I\3['5?$-_;Z=:Z?
M%/,'NI4A0R%#&J[G(&?GR![5]/E^9X:& K+ TY14(NR<6KNSMZO34^(S;),;
M4S7#O-*T9NK)7:DFDDU?R2L]$>[_ +86L%+3PWX>C^[(\]TX[?(%1/\ T)J^
M'[>WGN[B*UMD,LTS*B(HRS,QP !ZDU^CGB[QA\$?BQ=7W@/Q)J<4#Z?(IM;Y
M9D6-RR*2T$_*<$E65N#C(SVY[PUX!^ WPFOU\6:CXFAU&[M!YD"RW$4A0C^.
M.&'YG;TZXZ@9YKY_AWB". P$<-4HS]HKM+E?O7U3O\_D?6<8<)2S7-9XVEB:
M?L79.7,ER\JLTU\FUT=^Q8^/1A\$_ ;2O!;R!IY1960Q_%]F4.[_ $R@_$BO
MSVKV;XU_%:;XH^)$N+56@TC3PT=G$X ?YL;Y'P3\SD#C/  '7)/C-?7<(974
MPN#2K_')N3]7_P "Q\!X@YY1QV8N6&_AP2A'S4>OWMV\CUGX%ZC!I?Q:\-75
MR0$:X,.6X&Z>-HE_5A7N/[8&AW2:UH/B0(3;2V[VA8=%>-S( ?3<'./7!]*^
M.(Y)(9%EB8HZ$,K X((Y!!]17WWX/^.'P\^)OA<>$/BP(;6[=0DK3Y2WF*])
M%E'^J?N<E<'H><#R^)*%?#XZCF=*#FHIQDEO;75??_73V^#<5AL7E>(R3$5%
M3E-J4)2T7,K:-]-E][ZZ/X!KNOAQX'U'XA>+;+PY8HWER,'N)!TBMU(\QR?I
MP/5B!WKZR?X!_ %Y#?)XQ9+0\X&H6A0>P<H>/S/O6Y<?%3X*?!?19])^'D<>
MJ7[X)6V8R"1P.&EN3D$#T4MCL!G-+%\8NM!TLOI3E4>BO&R7FV^WW>96 \.H
MX:JJ^;XB$*,=7:2;EY)+O]_9,J_M5^*++1?!VF> =/(26^=)&C7HEK;\*#]7
M V_[IJY\*?\ BA/V;=0\1_ZN>YAO;Q>Q\QLPP_GL3\Z^&/%GBK6?&NO77B/7
MIO.NKIL\<*BC[J(.RJ. /SR<FOL3XO\ B_PGIGP)TSP5X<UJRU&X9;&TDCM;
MB.9PD*B1W8(Q(!>, D]S7C8S(98?"83+MW.:<W^?YKUL?1Y=Q73Q>/Q^<7Y5
M3I.--/1Z_#\]'MM<^&*_0GX;_P#%"?LRWVO']U<7=O>70/3]Y*3#"?Q 2OSV
MK[G^-/B_PGI_P2TOP1X9UJRU*8_8K62.UN(YF$=NF]F8(Q(&]%Y/<U[_ !C2
ME7EAL+%74IIOT6_YGR7AU7AAHXW'2DDX4FH_XI;6^[\3Y(\ 6/B*_P#&6D+X
M4M3>:I!<QSPQ]!NA8298G "C'))Z5^@WQ?\ !WPZ^(8LK/Q1X@M?#^NV*;E#
M7,/F(D@!9'C=EW+GD'CV.":^:?V6_#WBN;QJ?%&DV\1TJT1[>[EF8J,2 ';'
M@'+C ;'3'4C(KVKQMKW[+&HZ]<S^)3;WNHR-^^EMUNF#,!C)DM_D8^X)]Z\#
MBC%SGFD(T5*]..]-<TDWT:O:UOS/K.!\!2I9'4EB7!*M+:K+D@U'K%I7;OU7
M;R,S0-0^"_[/>EWM_INM)XDUZ[CV?N'21V .1&/+W+$A(!8LQ)QWP!7SS\,M
M6N?&7QWTC7=:93<7VH-<O_=#JK.BK[ @!?PKZ,TWX0?L]?$^PN?^%?W3VUQ
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M.,=CCY5^*7_!*G]JW3M/N?%%MKVF>/KFV0N;>.\N/M\@')$8NHU1O]WS0Q/
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M^VLH4445^X'\Q!1110 5]+Z3^U1\0M'TJRTBVT_2WBL88X$9XIRY6)0H+8F
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MK9H=+TNRL9&&/-(>5E/JH)"_F"*^9M<U[6/$NJ3ZUKUV][>W!R\DAR3Z  <
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M,/*4J%)1;T=ET/9S'B;,,7",,36E)1=U=[/OW/J?0_VL_'NG6B6NK6-GJCH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDZ]2HYU)[R>FW1);(\KB'BIXVE2PE&DJ5&G?EBKO5[MMZMA1117OGR84444
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MK_@BU_R*_P 5/^OS2O\ T7<5^P/Q0\%+\2OAGXM^'+7AT\>*M(O]*-R(_-,
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MUE"BBBOW _F(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*^E/V5/^2I'_ *\+C^:5\UU]*?LJ?\E2/_7A<?S2OG^*_P#D6U_\+/K> _\
MD<X7_&C]*****_E\_M\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^+/'O_)PVF_\ 7[I?\XZ^
MTZ^+/'O_ "<-IO\ U^Z7_..OM.@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,?C+_ ,DS
MUW_KG'_Z-2N3_9S_ .2?R?\ 7[-_Z"E=9\9?^29Z[_USC_\ 1J5R?[.?_)/Y
M/^OV;_T%* /_TOW\HHHH **** "BBB@ HHHH *_-K]I3]B;QMX__ &B?"7[2
MWP.U_3O#/B?1C ]^+X3".ZDM& A?]RK%M\.890< QJH'>OTEHH'&5@&<<]:*
M**!!1110 4444 %%%% !1110 4444 %%%% !1110!^<G[7?[&GQ"_:K^+?@B
M_P!5\2V-A\-O#'EFXT[]\+V9I90UVRE5\L-)$B1H2WR8)[D']$;&QL],LK?3
M=.A2VM+2-(H8HU"I''& JJJC@!0  !T%6J*!N5] HHHH$%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!'_(\4_X9U^#?_0NK_X$W/\ \=H_X9U^#?\ T+J_^!-S_P#':]KHH_U@Q_\
MT$3_ / G_F'^J65?] E/_P  C_D>*?\ #.OP;_Z%U?\ P)N?_CM'_#.OP;_Z
M%U?_  )N?_CM>UT4?ZP8_P#Z")_^!/\ S#_5+*O^@2G_ . 1_P CQ3_AG7X-
M_P#0NK_X$W/_ ,=H_P"&=?@W_P!"ZO\ X$W/_P =KVNBC_6#'_\ 01/_ ,"?
M^8?ZI95_T"4__ (_Y'BG_#.OP;_Z%U?_  )N?_CM'_#.OP;_ .A=7_P)N?\
MX[7M=%'^L&/_ .@B?_@3_P P_P!4LJ_Z!*?_ (!'_(\4_P"&=?@W_P!"ZO\
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M ,=KVNBC_6#'_P#01/\ \"?^8?ZI95_T"4__  "/^1XI_P ,Z_!O_H75_P#
MFY_^.T?\,Z_!O_H75_\  FY_^.U[711_K!C_ /H(G_X$_P#,/]4LJ_Z!*?\
MX!'_ "/%/^&=?@W_ -"ZO_@3<_\ QVC_ (9U^#?_ $+J_P#@3<__ !VO:Z*/
M]8,?_P!!$_\ P)_YA_JEE7_0)3_\ C_D>*?\,Z_!O_H75_\  FY_^.T?\,Z_
M!O\ Z%U?_ FY_P#CM>UT4?ZP8_\ Z")_^!/_ ##_ %2RK_H$I_\ @$?\CQ3_
M (9U^#?_ $+J_P#@3<__ !VC_AG7X-_]"ZO_ ($W/_QVO:Z*/]8,?_T$3_\
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M5?\ 0)3_ / (_P"1XI_PSK\&_P#H75_\";G_ ..T?\,Z_!O_ *%U?_ FY_\
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M_H$I_P#@$?\ (\4_X9U^#?\ T+J_^!-S_P#':/\ AG7X-_\ 0NK_ .!-S_\
M':]KHH_U@Q__ $$3_P# G_F'^J65?] E/_P"/^1XI_PSK\&_^A=7_P ";G_X
M[1_PSK\&_P#H75_\";G_ ..U[711_K!C_P#H(G_X$_\ ,/\ 5+*O^@2G_P"
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M_CM>UT4?ZP8__H(G_P"!/_,/]4LJ_P"@2G_X!'_(\4_X9U^#?_0NK_X$W/\
M\=H_X9U^#?\ T+J_^!-S_P#':]KHH_U@Q_\ T$3_ / G_F'^J65?] E/_P
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M?_ FY_\ CM'_  SK\&_^A=7_ ,";G_X[7M=%'^L&/_Z")_\ @3_S#_5+*O\
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M";G_ ..U[711_K!C_P#H(G_X$_\ ,/\ 5+*O^@2G_P" 1_R/%/\ AG7X-_\
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M_P!!$_\ P)_YA_JEE7_0)3_\ C_D>*?\,Z_!O_H75_\  FY_^.T?\,Z_!O\
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M_P"8?ZI95_T"4_\ P"/^1XI_PSK\&_\ H75_\";G_P".T?\ #.OP;_Z%U?\
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M^ W_  FGBF]\2_VY]C^V>7^Z^S>9M\N-8_O>:N<[<]!UKDO^&7O^IF_\DO\
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M&V_[_)_C1_;VA?\ 01MO^_R?XU\Q_P##+W_4S?\ DE_]OH_X9>_ZF;_R2_\
MM] 'TY_;VA?]!&V_[_)_C7QU\3[NTN?C9I=Q;SI+$)+#+HP9>'&>1QQ74_\
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M "2_^WT?\,O?]3-_Y)?_ &^@#Z<_M[0O^@C;?]_D_P :/[>T+_H(VW_?Y/\
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M-M_W^3_&C^WM"_Z"-M_W^3_&OF/_ (9>_P"IF_\ )+_[?1_PR]_U,W_DE_\
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MW^3_ !H_M[0O^@C;?]_D_P :^8_^&7O^IF_\DO\ [?1_PR]_U,W_ ))?_;Z
M/IS^WM"_Z"-M_P!_D_QH_M[0O^@C;?\ ?Y/\:^8_^&7O^IF_\DO_ +?1_P ,
MO?\ 4S?^27_V^@#Z<_M[0O\ H(VW_?Y/\:/[>T+_ *"-M_W^3_&OF/\ X9>_
MZF;_ ,DO_M]'_#+W_4S?^27_ -OH ^G/[>T+_H(VW_?Y/\:/[>T+_H(VW_?Y
M/\:^8_\ AE[_ *F;_P DO_M]'_#+W_4S?^27_P!OH ^G/[>T+_H(VW_?Y/\
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MIF_\DO\ [?1_PR]_U,W_ ))?_;Z /IS^WM"_Z"-M_P!_D_QH_M[0O^@C;?\
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M+_H(VW_?Y/\ &C^WM"_Z"-M_W^3_ !KYC_X9>_ZF;_R2_P#M]'_#+W_4S?\
MDE_]OH ^G/[>T+_H(VW_ '^3_&C^WM"_Z"-M_P!_D_QKYC_X9>_ZF;_R2_\
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MR;]F?_D4]4_Z_3_Z*2O6?B7_ ,D_\0_]>4__ *":\F_9G_Y%/5/^OT_^BDH
M^D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KXL^*O_ "7+2_\ KII__H8K[3KXL^*O_)<M
M+_ZZ:?\ ^AB@#[3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O/?BQ_R3G7_P#KV/\ ,5Z%
M7GOQ8_Y)SK__ %['^8H \\_9J_Y$6^_["4O_ *)AKZ%KYZ_9J_Y$6^_["4O_
M *)AKZ%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#XL\>_P#)PVF_]?NE_P XZ^TZ^+/'
MO_)PVF_]?NE_SCK[3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S'XR_\DSUW_KG'_P"C
M4KD_V<_^2?R?]?LW_H*5UGQE_P"29Z[_ -<X_P#T:E<G^SG_ ,D_D_Z_9O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"7/_ ,;H_P"&DO@W_P!!UO\ P$N?_C='^KN8?] \_P#P%_Y!_KAE/_073_\
M X_YGNE%>%_\-)?!O_H.M_X"7/\ \;H_X:2^#?\ T'6_\!+G_P"-T?ZNYA_T
M#S_\!?\ D'^N&4_]!=/_ ,#C_F>Z45X7_P -)?!O_H.M_P" ES_\;H_X:2^#
M?_0=;_P$N?\ XW1_J[F'_0//_P !?^0?ZX93_P!!=/\ \#C_ )GNE%>%_P##
M27P;_P"@ZW_@)<__ !NC_AI+X-_]!UO_  $N?_C='^KN8?\ 0//_ ,!?^0?Z
MX93_ -!=/_P./^9[I17A?_#27P;_ .@ZW_@)<_\ QNC_ (:2^#?_ $'6_P#
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M93_T%T__  ./^9[I17A?_#27P;_Z#K?^ ES_ /&Z/^&DO@W_ -!UO_ 2Y_\
MC='^KN8?] \__ 7_ )!_KAE/_073_P# X_YGNE%>%_\ #27P;_Z#K?\ @)<_
M_&Z/^&DO@W_T'6_\!+G_ .-T?ZNYA_T#S_\  7_D'^N&4_\ 073_ / X_P"9
M[I17A?\ PTE\&_\ H.M_X"7/_P ;H_X:2^#?_0=;_P !+G_XW1_J[F'_ $#S
M_P# 7_D'^N&4_P#073_\#C_F>Z45X7_PTE\&_P#H.M_X"7/_ ,;H_P"&DO@W
M_P!!UO\ P$N?_C='^KN8?] \_P#P%_Y!_KAE/_073_\  X_YGNE%>%_\-)?!
MO_H.M_X"7/\ \;H_X:2^#?\ T'6_\!+G_P"-T?ZNYA_T#S_\!?\ D'^N&4_]
M!=/_ ,#C_F>Z45X7_P -)?!O_H.M_P" ES_\;H_X:2^#?_0=;_P$N?\ XW1_
MJ[F'_0//_P !?^0?ZX93_P!!=/\ \#C_ )GNE%>%_P##27P;_P"@ZW_@)<__
M !NC_AI+X-_]!UO_  $N?_C='^KN8?\ 0//_ ,!?^0?ZX93_ -!=/_P./^9[
MI17A?_#27P;_ .@ZW_@)<_\ QNC_ (:2^#?_ $'6_P# 2Y_^-T?ZNYA_T#S_
M / 7_D'^N&4_]!=/_P #C_F>Z45X7_PTE\&_^@ZW_@)<_P#QNC_AI+X-_P#0
M=;_P$N?_ (W1_J[F'_0//_P%_P"0?ZX93_T%T_\ P./^9[I17A?_  TE\&_^
M@ZW_ ("7/_QNC_AI+X-_]!UO_ 2Y_P#C='^KN8?] \__  %_Y!_KAE/_ $%T
M_P#P./\ F>Z45X7_ ,-)?!O_ *#K?^ ES_\ &Z/^&DO@W_T'6_\  2Y_^-T?
MZNYA_P! \_\ P%_Y!_KAE/\ T%T__ X_YGNE%>%_\-)?!O\ Z#K?^ ES_P#&
MZ/\ AI+X-_\ 0=;_ ,!+G_XW1_J[F'_0//\ \!?^0?ZX93_T%T__  ./^9[I
M17A?_#27P;_Z#K?^ ES_ /&Z/^&DO@W_ -!UO_ 2Y_\ C='^KN8?] \__ 7_
M )!_KAE/_073_P# X_YGNE%>%_\ #27P;_Z#K?\ @)<__&Z/^&DO@W_T'6_\
M!+G_ .-T?ZNYA_T#S_\  7_D'^N&4_\ 073_ / X_P"9[I17A?\ PTE\&_\
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M ES_ /&Z/^&DO@W_ -!UO_ 2Y_\ C='^KN8?] \__ 7_ )!_KAE/_073_P#
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MS]$**\+_ .&DO@W_ -!UO_ 2Y_\ C='_  TE\&_^@ZW_ ("7/_QNC_5W,/\
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M_C='^KN8?] \_P#P%_Y!_KAE/_073_\  X_YGNE%>%_\-)?!O_H.M_X"7/\
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M5X7_ ,-)?!O_ *#K?^ ES_\ &Z/^&DO@W_T'6_\  2Y_^-T?ZNYA_P! \_\
MP%_Y!_KAE/\ T%T__ X_YGNE%>%_\-)?!O\ Z#K?^ ES_P#&Z/\ AI+X-_\
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M_P" ES_\;H_X:2^#?_0=;_P$N?\ XW1_J[F'_0//_P !?^0?ZX93_P!!=/\
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MO@W_ -!UO_ 2Y_\ C='^KN8?] \__ 7_ )!_KAE/_073_P# X_YGNE%>%_\
M#27P;_Z#K?\ @)<__&Z/^&DO@W_T'6_\!+G_ .-T?ZNYA_T#S_\  7_D'^N&
M4_\ 073_ / X_P"9[I17A?\ PTE\&_\ H.M_X"7/_P ;H_X:2^#?_0=;_P !
M+G_XW1_J[F'_ $#S_P# 7_D'^N&4_P#073_\#C_F>Z45X7_PTE\&_P#H.M_X
M"7/_ ,;H_P"&DO@W_P!!UO\ P$N?_C='^KN8?] \_P#P%_Y!_KAE/_073_\
M X_YGNE%>%_\-)?!O_H.M_X"7/\ \;H_X:2^#?\ T'6_\!+G_P"-T?ZNYA_T
M#S_\!?\ D'^N&4_]!=/_ ,#C_F>Z45X7_P -)?!O_H.M_P" ES_\;H_X:2^#
M?_0=;_P$N?\ XW1_J[F'_0//_P !?^0?ZX93_P!!=/\ \#C_ )GNE%>%_P##
M27P;_P"@ZW_@)<__ !NC_AI+X-_]!UO_  $N?_C='^KN8?\ 0//_ ,!?^0?Z
MX93_ -!=/_P./^9[I17A?_#27P;_ .@ZW_@)<_\ QNC_ (:2^#?_ $'6_P#
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M/]7<P_Z!Y_\ @+_R#_7#*?\ H+I_^!Q_S/=**\+_ .&DO@W_ -!UO_ 2Y_\
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M+_X:2^#?_0=;_P !+G_XW1_PTE\&_P#H.M_X"7/_ ,;H_P!7<P_Z!Y_^ O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^\<?]SP_^)_D?CWA1_O-;_"OS/4];T>P\0Z-?Z!JB&2RU*WEMIT#%2T4R%'
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M!UR_B4DY^2"9HD_#:@Q[5\'X5^VS+-'B<=4=3V4;QYFW9MVZ_/YZGUWB#[+
MX!4,)!0]H];*UTEY?(W/V;/V?=>_:'\>?\(U83_V?I6GH+C4KTKN\F$M@*@Z
M-)(<A >."QX4BOV8T+]@O]F/1]+33[OPQ+J\P0*]U=WUUYTA_O$0R1QJ?]Q%
MKS+_ ()J>&K73/@CJOB-4'VK6M7F#OCDQ6T<:1K] Q<_\"K]$ZXO$?CC'RS*
MIAL-5E"%-V]UM7:W;:UW^1U<$<*82.!A7KTU*<U?57LNB5_(_&?]K+]A'1/
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M_0-\?OAGX!^%W[*?C_0?A_H=MHEG_9^66!?GD(D3#2R-EY&]W8GWK^?G0O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KZ4_94_Y*D?^O"X_FE?-=?2G[*G_
M "5(_P#7A<?S2OG^*_\ D6U_\+/K> _^1SA?\:/THHHHK^7S^WPHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,+)ZPU7H_P#@W^\_E/K^G[]G/_D@/PX_[%[2_P#TFCK^8&OUU^%O_!1+X<>
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M+-6T]?P+X7X9QN"KRJXG$<Z:M:[WNM=?0\&_:\_Y-K\?_P#8./\ Z,2OYO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5]*?LJ?\ )4C_ ->%Q_-*^:Z^E/V5
M/^2I'_KPN/YI7S_%?_(MK_X6?6\!_P#(YPO^-'Z44445_+Y_;X4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?%GCW_DX;3?\
MK]TO^<=?:=?%GCW_ ).&TW_K]TO^<=?:= !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWTLS\,?^'9/QY_Z#WAK_ ,"KS_Y"H_X=D_'G_H/>&O\ P*O/_D*OW.HKW_\
MB,&=?S1_\!/(_P"(:Y7VE]Y^&/\ P[)^//\ T'O#7_@5>?\ R%7Z4?LB?!#Q
M7\ OA?>>"O&-W97E]<:I/>J]A)))$(Y8H8P"98XFW9C.1MQC'/I]345XF?\
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MY]_G<]3)N$\#@9<]"'O=WJ_^!\@HHHKY$^C"BBB@#R7X[> ]7^)_PB\3^ =
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \Q^,O_),]=_ZYQ_\ HU*Y/]G/_DG\G_7[-_Z"E=9\9?\ DF>N
M_P#7./\ ]&I7)_LY_P#)/Y/^OV;_ -!2@#__T?W\HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH XCXE_\ )/\ Q#_UY3_^@FOR)U/_ )"%Q_OFOUV^)?\ R3_Q
M#_UY3_\ H)K\B=3_ .0A<?[YK]0\+/\ >JO^']4?B'CG_N%#_'_[:RA1117[
M@?S$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5]*?LJ?\ )4C_ ->%Q_-*^:Z^E/V5/^2I'_KPN/YI7S_%
M?_(MK_X6?6\!_P#(YPO^-'Z44445_+Y_;X4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?%GCW_DX;3?\ K]TO^<=?:=?%GCW_
M ).&TW_K]TO^<=?:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OI3]E3
M_DJ1_P"O"X_FE?-=?2G[*G_)4C_UX7'\TKY_BO\ Y%M?_"SZW@/_ )'.%_QH
M_2BBBBOY?/[?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#XL\>_\G#:;_P!?NE_SCK[3KXL\>_\ )PVF_P#7[I?\XZ^TZ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI\K>CT3_ #3/$SSAS!9E3C2QM/F2=UJUK\FCS7_AC>+_ *&UO_ '_P"WT?\
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MY-/_ .2/B7_AC>+_ *&UO_ '_P"WT?\ #&\7_0VM_P" /_V^OMJBC_7W-O\
MG]_Y+'_(/^(5Y!_T#?\ DT__ )(^)?\ AC>+_H;6_P# '_[?1_PQO%_T-K?^
M /\ ]OK[:HH_U]S;_G]_Y+'_ "#_ (A7D'_0-_Y-/_Y(^)?^&-XO^AM;_P
M?_M]'_#&\7_0VM_X _\ V^OMJBC_ %]S;_G]_P"2Q_R#_B%>0?\ 0-_Y-/\
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M33_^2/B7_AC>+_H;6_\  '_[?1_PQO%_T-K?^ /_ -OK[:HH_P!?<V_Y_?\
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M_P!#:W_@#_\ ;Z^VJ*/]?<V_Y_?^2Q_R#_B%>0?] W_DT_\ Y(^)?^&-XO\
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MEC_D'_$*\@_Z!O\ R:?_ ,D?$O\ PQO%_P!#:W_@#_\ ;Z/^&-XO^AM;_P
M?_M]?;5%'^ON;?\ /[_R6/\ D'_$*\@_Z!O_ ":?_P D?$O_  QO%_T-K?\
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M_P ,;Q?]#:W_ ( __;Z/^&-XO^AM;_P!_P#M]?;5%'^ON;?\_O\ R6/^0?\
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M .WU]M44?Z^YM_S^_P#)8_Y!_P 0KR#_ *!O_)I__)'Q+_PQO%_T-K?^ /\
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M_0VM_P" /_V^C_AC>+_H;6_\ ?\ [?7VU11_K[FW_/[_ ,EC_D'_ !"O(/\
MH&_\FG_\D?$O_#&\7_0VM_X _P#V^C_AC>+_ *&UO_ '_P"WU]M44?Z^YM_S
M^_\ )8_Y!_Q"O(/^@;_R:?\ \D?$O_#&\7_0VM_X _\ V^C_ (8WB_Z&UO\
MP!_^WU]M44?Z^YM_S^_\EC_D'_$*\@_Z!O\ R:?_ ,D?$O\ PQO%_P!#:W_@
M#_\ ;Z/^&-XO^AM;_P  ?_M]?;5%'^ON;?\ /[_R6/\ D'_$*\@_Z!O_ ":?
M_P D?$O_  QO%_T-K?\ @#_]OH_X8WB_Z&UO_ '_ .WU]M44?Z^YM_S^_P#)
M8_Y!_P 0KR#_ *!O_)I__)'Q+_PQO%_T-K?^ /\ ]OH_X8WB_P"AM;_P!_\
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M_)8_Y!_Q"O(/^@;_ ,FG_P#)'Q+_ ,,;Q?\ 0VM_X __ &^C_AC>+_H;6_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?%GCW_DX;3?^
MOW2_YQU]IU\6>/?^3AM-_P"OW2_YQU]IT %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YC\
M9?\ DF>N_P#7./\ ]&I7)_LY_P#)/Y/^OV;_ -!2NL^,O_),]=_ZYQ_^C4KD
M_P!G/_DG\G_7[-_Z"E '_]7]_**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .(
M^)?_ "3_ ,0_]>4__H)KR;]F?_D4]4_Z_3_Z*2O6?B7_ ,D_\0_]>4__ *":
M\F_9G_Y%/5/^OT_^BDH ^D**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXL^*O_ "7+2_\
MKII__H8K[3KXL^*O_)<M+_ZZ:?\ ^AB@#[3HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/
M?BQ_R3G7_P#KV/\ ,5Z%7GOQ8_Y)SK__ %['^8H \\_9J_Y$6^_["4O_ *)A
MKZ%KYZ_9J_Y$6^_["4O_ *)AKZ%H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XL\>_P#)
MPVF_]?NE_P XZ^TZ^+/'O_)PVF_]?NE_SCK[3H **** "BBB@ HHHH ****
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M[3/_ #SN?_ 6U_\ B*^R** /C?\ MK]IG_GG<_\ @+:__$4?VU^TS_SSN?\
MP%M?_B*^R** /C?^VOVF?^>=S_X"VO\ \11_;7[3/_/.Y_\  6U_^(K[(HH
M^-_[:_:9_P">=S_X"VO_ ,11_;7[3/\ SSN?_ 6U_P#B*^R** /C?^VOVF?^
M>=S_ . MK_\ $4?VU^TS_P \[G_P%M?_ (BOLBB@#XW_ +:_:9_YYW/_ ("V
MO_Q%']M?M,_\\[G_ ,!;7_XBOLBB@#XW_MK]IG_GG<_^ MK_ /$4?VU^TS_S
MSN?_  %M?_B*^R** /C?^VOVF?\ GG<_^ MK_P#$4?VU^TS_ ,\[G_P%M?\
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M.Y_\!;7_ .(K[(HH ^-_[:_:9_YYW/\ X"VO_P 11_;7[3/_ #SN?_ 6U_\
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M.Y_\!;7_ .(K[(HH ^-_[:_:9_YYW/\ X"VO_P 11_;7[3/_ #SN?_ 6U_\
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M_GG<_P#@+:__ !%']M?M,_\ /.Y_\!;7_P"(K[(HH ^-_P"VOVF?^>=S_P"
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MG_GG<_\ @+:__$4?VU^TS_SSN?\ P%M?_B*^R** /C?^VOVF?^>=S_X"VO\
M\11_;7[3/_/.Y_\  6U_^(K[(HH ^-_[:_:9_P">=S_X"VO_ ,11_;7[3/\
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M_GG<_P#@+:__ !%']M?M,_\ /.Y_\!;7_P"(K[(HH ^-_P"VOVF?^>=S_P"
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MG_GG<_\ @+:__$4?VU^TS_SSN?\ P%M?_B*^R** /C?^VOVF?^>=S_X"VO\
M\11_;7[3/_/.Y_\  6U_^(K[(HH ^-_[:_:9_P">=S_X"VO_ ,11_;7[3/\
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M9_YYW/\ X"VO_P 11_;7[3/_ #SN?_ 6U_\ B*^R** /C?\ MK]IG_GG<_\
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M,_\ /.Y_\!;7_P"(K[(HH ^-_P"VOVF?^>=S_P" MK_\11_;7[3/_/.Y_P#
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MM,_\\[G_ ,!;7_XBC^VOVF?^>=S_ . MK_\ $5]D44 ?&_\ ;7[3/_/.Y_\
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MG<_^ MK_ /$5]D44 ?&_]M?M,_\ /.Y_\!;7_P"(H_MK]IG_ )YW/_@+:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .(^)?_ "3_ ,0_
M]>4__H)KR;]F?_D4]4_Z_3_Z*2O6?B7_ ,D_\0_]>4__ *":\F_9G_Y%/5/^
MOT_^BDH ^D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KXL^*O_ "7+2_\ KII__H8K[3KX
ML^*O_)<M+_ZZ:?\ ^AB@#[3HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/?BQ_R3G7_P#K
MV/\ ,5Z%7GOQ8_Y)SK__ %['^8H \\_9J_Y$6^_["4O_ *)AKZ%KYZ_9J_Y$
M6^_["4O_ *)AKZ%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XL\>_P#)PVF_]?NE_P X
MZ^TZ^+/'O_)PVF_]?NE_SCK[3H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S'XR_\DSUW
M_KG'_P"C4KD_V<_^2?R?]?LW_H*5UGQE_P"29Z[_ -<X_P#T:E<G^SG_ ,D_
MD_Z_9O\ T%* /__0_?RBBB@ HHHH **** "BBB@ HHKA/B?XYL?AI\//$/CW
M4,&+0[*:Y"DX\R15_=Q_5W*J/<UK0H2JSC3@KMM)>K,ZM6,(.<W9+5GSAX[_
M &[/@1\/?&&K>"=:DU&?4-&G:VN&MK59(A*GWU5C(N2IRIXZ@BO2/@E^TQ\,
M?C]<ZK9> Y;I;C1TBDFCNX1"Q28L R ,VX KAO3(]:_FLU34[[6M3O-9U.4S
MWE_-)<3R-U>65B[L?<DDU]._L7?$S_A67[0/AZ[N9?*T[7F.D7>3@;+L@1DG
MH LPC8GL :_HK.O"#!T<NJ5*#DZL8WWT;6KTMUUL?BV5^).)JXV$*R2IRE;;
M5)[:^74_HXJO=W,5E:37DV?+@1I&QR=JC)Q^56*Q_$7_ "+^I_\ 7K-_Z :_
MG.G&\DF?M<W9-GQ#_P /'?V=?36?_ )?_CM?:WA/Q-I?C3POI'B_1&=M/UJT
MAO+<R+L<Q7""1-R]C@C(K^3NOZ?OV<_^2 _#C_L7M+_])HZ_8/$O@; Y3AZ5
M7"<UY-IW=^GH?FW O%F*S&M4AB+62OHK=3T_Q!K5EX:T'4O$6I;OLFE6TUW-
ML&YO+@0R-M'&3@' KX@_X>._LZ^FL_\ @$O_ ,=K[)\?:)>>)? GB/PYIQ07
M>JZ;>6D)D.U/,GA:-=Q .!EADX-?B/\ \.V_VA?^?G0__ R7_P",5X7 V4Y+
MB:=5YK5Y&FK>]:ZZ]#U>*\QS2A."R^GS)IWTO^I]W_\ #QW]G7TUG_P"7_X[
M1_P\=_9U]-9_\ E_^.U^,/Q>^$?BKX)^,I/ WC%[9]1B@BG)M9&EBV3 E?F9
M4.>.>*['X&_LU_$7]H--:D\!O8QKH1MQ<&\F:+)N?,V;-J/G'EG.<=NO;]5J
M^&?#L,-]<G4DJ>CYN96L]NG4_/J?'>=3K_5HP3GKIRZZ;]3]B_"O[??P$\7^
M)M)\)Z4=52]UJ[@LH#+9A8_-N'$:;B)"0-S#)P<5]L5^*/PR_P""?WQV\(_$
MGPGXLU6?1S9:+JUA>SB.[D9S%;7"2OM!A +;5.!D<]Z^NOVX?VG;WX*^&K7P
M7X(NA#XP\01F03 !FLK+)4S '(WR,"D?!QAFX*C/YEGO"> KX^A@\BJ<_.G?
M6Z7F]-%8^[RGB+%TL)5Q.;0Y.6UM+7]-=[GOWQ3_ &E?@O\ !PR6WC;Q)!'J
M2 '[!;9N;SD9&Z*/)3(Y!DV@^M?+][_P4R^!EO.(K30_$%U'GYI!;VR#'JH:
MYR?Q K\4M,TSQ/X\\30Z;ID-SK>NZS.0J+NFN+B:0Y)).2Q)R68GU)/4U]SZ
M%_P37^/6JZ6E_J6H:)H]Q(@86MQ<S22HW]V0P021C_@+M7WM3PYX?RV$5FF(
M?.^[M]R6MOFSY&'&V<XZ<G@*/NKRO][>ES]"O!/[?7[.7C*_CTZ?5;KPY++@
M(VJVXAB)/8RQO+&GU=E'O7V/8:A8:K90:EI=S%>6ER@DBFA=9(Y$;D,KJ2&!
M[$&OYF/C/^SK\5/@/>0P^/=-5;*[8I;W]L_G6DS 9*J^ 5;&3M=58@$@8&:]
ME_8__:GUOX*>+;+PMXFOY)O >IR^7<PR'>MB\IXN8NZ@-S(J\,N3@L!7FY]X
M4X6KA'C<EJ\ZM>UTT[;V:Z^3OKIH=V4>(6(IXA87-*?*]KVM;U3Z>:/Z#:*:
MCK(H="&5@""#D$'N*=7X,?K@445#<W-O9VTMW=2+%! C/(['"JBC))/8 <FF
ME?0&S(\1^*/#?A#2Y-;\5ZI:Z/I\7#7%W,D$0/8;G(&3C@=37S9=_MP_LMV5
MR+67QQ&[9P6BLKV5!_P-("OY$U^)G[1OQ[\2_'OX@7NO:A<RIH=M*\>EV.X^
M5;VX.%;;T\R0 -(V,DG'W0H%CPA^R=^T+X\\,1>,?#'@ZXN=)N$\R&22:WMV
MF3LT<<TB2.I'*D*0PZ9K]\P'A+@:&&C6SC$\DI=+QBDWTO).[]#\@QGB-BZM
M>5++:'.EULVVN]E:R/Z#OA_\9_A7\5$8_#_Q/9:S)&I=X8I-MPB@XW- ^V55
MSW*@5Z;7\GEAJ'B?P)XE6]T^:ZT/7=&G8!E+07%O/$2K*>C*P((8'W!%?T@_
MLO\ QAF^.'P<T?QKJ 1-64R6>H+&-J?:K<X9E'82*5DP.F[':ODN/?#K^R81
MQ6'GSTF[:[I]-M&GWT/H>$.-?[1G*A6ARU$KZ;/OZ-=CZ 9E12[D*JC))X
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MNS:=[:M)I*S\FC@RWQ Q4,5'"YE1Y'*RNDU:^SL[W7F?T%T445^''ZN%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 <1\2_^2?^(?\ KRG_ /037DW[,_\
MR*>J?]?I_P#125ZS\2_^2?\ B'_KRG_]!-?,GP9^*?@;X?\ AZ\LO%>H&SFN
MKII(P(99=RA$!.8U8#GUK?#86K6G[.C%R?9*[_ Y<9CJ.'INKB)J,>[:2^]G
MVE17A?\ PTE\&_\ H.M_X"7/_P ;H_X:2^#?_0=;_P !+G_XW7I?ZNYA_P!
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M;_Z#K?\ @)<__&Z/^&DO@W_T'6_\!+G_ .-T?ZNYA_T#S_\  7_D'^N&4_\
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M6_\  2Y_^-T?ZNYA_P! \_\ P%_Y!_KAE/\ T%T__ X_YGNE%>%_\-)?!O\
MZ#K?^ ES_P#&Z/\ AI+X-_\ 0=;_ ,!+G_XW1_J[F'_0//\ \!?^0?ZX93_T
M%T__  ./^9[I17A?_#27P;_Z#K?^ ES_ /&Z/^&DO@W_ -!UO_ 2Y_\ C='^
MKN8?] \__ 7_ )!_KAE/_073_P# X_YGNE%>%_\ #27P;_Z#K?\ @)<__&Z/
M^&DO@W_T'6_\!+G_ .-T?ZNYA_T#S_\  7_D'^N&4_\ 073_ / X_P"9[I17
MA?\ PTE\&_\ H.M_X"7/_P ;H_X:2^#?_0=;_P !+G_XW1_J[F'_ $#S_P#
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M_P! \_\ P%_Y!_KAE/\ T%T__ X_YGNE%>%_\-)?!O\ Z#K?^ ES_P#&Z/\
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M_H+I_P#@<?\ ,_1"BO"_^&DO@W_T'6_\!+G_ .-T?\-)?!O_ *#K?^ ES_\
M&Z/]7<P_Z!Y_^ O_ "'_ *X93_T%T_\ P./^9[I17A?_  TE\&_^@ZW_ ("7
M/_QNC_AI+X-_]!UO_ 2Y_P#C='^KN8?] \__  %_Y!_KAE/_ $%T_P#P./\
MF>Z45X7_ ,-)?!O_ *#K?^ ES_\ &Z/^&DO@W_T'6_\  2Y_^-T?ZNYA_P!
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M_P#P%_Y!_KAE/_073_\  X_YGNE%>%_\-)?!O_H.M_X"7/\ \;H_X:2^#?\
MT'6_\!+G_P"-T?ZNYA_T#S_\!?\ D'^N&4_]!=/_ ,#C_F>Z45X7_P -)?!O
M_H.M_P" ES_\;H_X:2^#?_0=;_P$N?\ XW1_J[F'_0//_P !?^0?ZX93_P!!
M=/\ \#C_ )GNE%>%_P##27P;_P"@ZW_@)<__ !NC_AI+X-_]!UO_  $N?_C=
M'^KN8?\ 0//_ ,!?^0?ZX93_ -!=/_P./^9[I17A?_#27P;_ .@ZW_@)<_\
MQNC_ (:2^#?_ $'6_P# 2Y_^-T?ZNYA_T#S_ / 7_D'^N&4_]!=/_P #C_F>
MZ45X7_PTE\&_^@ZW_@)<_P#QNC_AI+X-_P#0=;_P$N?_ (W1_J[F'_0//_P%
M_P"0?ZX93_T%T_\ P./^9[I17A?_  TE\&_^@ZW_ ("7/_QNC_AI+X-_]!UO
M_ 2Y_P#C='^KN8?] \__  %_Y!_KAE/_ $%T_P#P./\ F>Z45X7_ ,-)?!O_
M *#K?^ ES_\ &Z/^&DO@W_T'6_\  2Y_^-T?ZNYA_P! \_\ P%_Y!_KAE/\
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M_@)<_P#QNC_AI+X-_P#0=;_P$N?_ (W1_J[F'_0//_P%_P"0?ZX93_T%T_\
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MY_\ C='^KN8?] \__ 7_ )!_KAE/_073_P# X_YGNE%>%_\ #27P;_Z#K?\
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M&4_]!=/_ ,#C_F>Z45X7_P -)?!O_H.M_P" ES_\;H_X:2^#?_0=;_P$N?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >8_&7_DF>N_\ 7./_ -&I7)_LY_\ )/Y/^OV;_P!!2NL^,O\ R3/7?^N<
M?_HU*Y/]G/\ Y)_)_P!?LW_H*4 ?_]']_**** "BBB@ HHHH **** "OS(_X
M*8?$S^QO &A?"ZQEQ<>([DWEVH//V2S(V*P]'F96'O&:_3>OYO\ ]LGXF?\
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M:6WW67WL_:_X _$B/XM?![POX[+A[J_M%6[QVNX,Q7 QV'F*Q'L0:])\1?\
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MP3@O;6Y_9X>W@(\RTUF\CE Z[F2)QG_@+"OOFOB/$3%U*V<XAU'M*R]%HO\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B/B7_R3_P 0_P#7E/\
M^@FORJ\4_P"JM/K)_P"R5^JOQ+_Y)_XA_P"O*?\ ]!-?E5XI_P!5:?63_P!D
MK[CP[_Y&D/27Y'YCXO?\B.IZQ_-''T445_1!_((4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Z!_L@?\B?
MKG_7^/\ T4M?GY7Z!_L@?\B?KG_7^/\ T4M?#^(G_(KGZQ_,_3_"#_D>4_27
MY'US1117\[G]>A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!\6>/?^3AM-_Z_=+_G'7VG7Q9X]_Y.&TW_ *_=+_G'7VG0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'F/QE_P"29Z[_ -<X_P#T:E<G^SG_ ,D_D_Z_9O\
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MG-&G2=7DY7?:_2W='Q/"O$[RRI.HJ?-S*V]OT9_6/_PE/AC_ *"]G_X$1_\
MQ5:5G?V.H1&?3[B.YC!VEHG#KD=LJ2,\U_)-7[M_\$T_^3?]2_[&"[_])[:O
MPWC/PPCE.">+5?GU2MRVW\[L_6.&./99CBOJSH\NC=[WV^2/@W_@HE_R<C>?
M]@RQ_P#06KZ3_P""67_'G\2?^NFD_P KNOFW_@HF"/VD;LD8SIEB1[_*U?2?
M_!+,'[#\26QP9-)&?H+JOO,]_P"2*A_@I_\ I43Y#*/^2IE_BG_Z3(_6>OY_
M/V__ (9W'@;X]7OB."!DTOQA$FH0R8.S[0 ([E W=@X$A'82"OZ Z\7^/'P/
M\*_'WP)-X+\2LUM(CB>RO(U#2VMPH(#J#]Y2"5=<C<IZ@X8?CO '%$<JS!5Z
MGP27++T?7Y-?=<_2^,,@>88-TH?&G=>O;YH_(']@[]H[1/@[XLU'P7XXNA9^
M&_$[1LMT_$=I>Q_*KR'^&.13M=NBD*3A=Q'[N65]9:E:0ZAIUQ'=6MPH>.6)
MP\;HW(967((/8BOYK_B_^RU\9?@S>W1\0Z%->Z- QV:I9(T]H\?9V903%GTD
M"G/3(Y/B%AXE\1Z5;FTTO5;NS@;.8X9Y(T.>N54@5^T\2>'F#SVK_:.!Q"3E
M:]ES)^>C5G;?]&?E^2<9XG**?U+%T6[;7T:_!W78_?S]KW]IOPQ\'? >J>&]
M&U**X\;:O ]M:VL+J\EH)5P;F8 _NPBG*!N6;& 5#$?SY6-C>:G>V^FZ= ]S
M=W<B0PQ1J6>220A555')+$@ #J:Z/PKX*\:_$/5_[*\'Z/>:]J$IRR6T3S,,
MG[SD A1ZLQ ]37[$_L?_ +$=S\,]3M/BE\5PC^)( 6L=-0K)'9,PQYLKKE7F
M )VA253KEFQMZ\,LMX2P$XNISU9:VZR?16UM%=WYZWT.>O\ 7N(\9&2ARTUI
M?HEUUZL^W_@W\/X_AC\)_#'P_7'F:1810SD<AKAAOG8>S2LQ'UK\U#_P2RN\
MG'Q*3'_8(/\ \E5^O5%?S[E7&>98*I5JX6KRNH[RT3N]7U3[L_8\PX8P6*A3
MIUZ=U!66K5EIV:[(_(3_ (=97G_12H__  4'_P"2Z_27X(_#,_!SX6:#\-WU
M$:J=$CE0W7E>0)/-F>;/E[GVXWX^\>F:]6KY4_;;U;5M%_9A\:WVBW4MG<E+
M*(R0L4?RI[V"*5<KSAXV96]02*]"OQ+F>>5:.7XNM=2G%+W8JS?NWT2?4XZ.
M18#*J=7&8:E9J+OJW=+6VK?8^1?VP/VY5L_MOPM^"5^&N/FAU'6H&XC[-#:,
M.K=FE'3HG/S#\]?@3\ ?'G[07BS^Q/#$1ALH&5]0U*928+6-CU8_QR-SLC!R
MQ]%#,/"JU;'7=;TN)H-,U"XM(V;<5AE>-2V,9(4@9P!S7]/93PI#+<"\+EK4
M9O[35VWW:NK^2V7Y_@V8\0RQV+5?')RBOLIVT[+?YO=G].?P8^"G@?X%^$(O
M"7@NVVAL/=W<F#<7<P&#)*P _P" J/E4< =<^N5_)[_PE_BS_H-WW_@3+_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K] _V0/^1/US_K_'_HI:_/ROT#_9 _
MY$_7/^O\?^BEKX?Q$_Y%<_6/YGZ?X0?\CRGZ2_(^N:***_G<_KT**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XCXE_\ )/\
MQ#_UY3_^@FORJ\4_ZJT^LG_LE?JK\2_^2?\ B'_KRG_]!-?E5XI_U5I]9/\
MV2ON/#O_ )&D/27Y'YCXO?\ (CJ>L?S1Q]%%%?T0?R"%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^@?[(
M'_(GZY_U_C_T4M?GY7Z!_L@?\B?KG_7^/_12U\/XB?\ (KGZQ_,_3_"#_D>4
M_27Y'US1117\[G]>A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!\6>/?^3AM-_P"OW2_YQU]IU\6>/?\ DX;3?^OW2_YQU]IT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%<S;^-?!MYKTGA6TUZPGUJ'=OL4NHFNDVC+;H0Q<8')R.*Z:@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#B/B7_R3_Q#_P!>4_\ Z":_*KQ3_JK3
MZR?^R5^JOQ+_ .2?^(?^O*?_ -!-?E5XI_U5I]9/_9*^X\._^1I#TE^1^8^+
MW_(CJ>L?S1Q]%%%?T0?R"%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'F/QE_Y)GKO_ %SC_P#1J5R?[.?_ "3^3_K]F_\ 04KK/C+_ ,DS
MUW_KG'_Z-2N3_9S_ .2?R?\ 7[-_Z"E '__5_?RBBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q
M'Q+_ .2?^(?^O*?_ -!-?E5XI_U5I]9/_9*_57XE_P#)/_$/_7E/_P"@FORJ
M\4_ZJT^LG_LE?<>'?_(TAZ2_(_,?%[_D1U/6/YHX^BBBOZ(/Y!"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *_0/]D#_D3]<_Z_Q_Z*6OS\K] _V0/^1/US_K_'_HI:^'\1/^17/UC^9^G^
M$'_(\I^DOR/KFBBBOYW/Z]"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#XL\>_P#)PVF_]?NE_P XZ^TZ^+/'O_)PVF_]?NE_
MSCK[3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M==\6?%3P?;^(-6M?$MU917$LUQ&RV\=G9R+'B*5%P'D<YQGGKTK[V_X*8?\
M)DGQ'_[@_P#Z=[.O"O\ @CI_R;'XE_[&^]_]-]A1U'%^X?2G_#O/]C7_ *)E
M9_\ @5>__)%?E=_P5&_9M^"'P)\)> M0^$WA6#P[<:M?7L5T\4L\AE2**-D!
M\Z1P,$GIBOZ'Z_%'_@M#_P B-\,O^PEJ'_HF*AH*4GS;GZ#?LC:IINA_L??#
M36]9NH[+3]/\,6EQ<7$S!(H88H-\DCLV JJH))/  S7KG@_XF_";XRZ?JMGX
M"\4:7XLM;=!#?#3;R.Y$2W*L%60PL2F\*VWH3@XZ5XQ^RKH=GXG_ &,/A[X:
MU$9M-6\)V]I,.O[N>W\MOT8U^&?P?^(_Q1_X)B?M ^(O"WQ"\/3:KX?U@+;7
M0C!A2_M[=RUO?64KC:Y19&^0G'SLCE7&5+B4+MGZD?$K_@E%^RYXI\/7EIX!
ML+WP7K)C8VMS!>W%W$LH!V^;%=O-NCSC<%9&QT85\F_\$NOCI\2?#?QAU_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '$?$O\ Y)_XA_Z\I_\ T$U^
M57BG_56GUD_]DK]5?B7_ ,D_\0_]>4__ *":_*KQ3_JK3ZR?^R5]QX=_\C2'
MI+\C\Q\7O^1'4]8_FCCZ***_H@_D$**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K] _V0/^1/US_K_'_HI:
M_/ROT#_9 _Y$_7/^O\?^BEKX?Q$_Y%<_6/YGZ?X0?\CRGZ2_(^N:***_G<_K
MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B
MSQ[_ ,G#:;_U^Z7_ #CK[3KXL\>_\G#:;_U^Z7_..OM.@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /,?C+_R3/7?^N<?_ *-2N3_9S_Y)_)_U^S?^@I76?&7_ ))GKO\
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M. H  '2LCQ=X&\%>/],_L3QWH&G^(]/#;Q;:C:Q7<(<#&X),K+G!ZXS74T4
M?.>E_LA_LNZ-J8U?3OA9X=CNE;>K-IT,BHPZ%4=2JX[8 QVKZ'AAAMH8[>WC
M6**)0B(@"JJJ,  #@ #H*EHH&V?B#_P52\>:K\4/'GPZ_9$^'H-]K>H7L-_>
M0H?E%Q<YM[*-R,XVH\LLF>%0HQXK]>?A%\.=+^$7PP\+_#+1V\VU\-:?;V0E
MV[3,\2 22D=C(^YS[DUSEK^SO\%[/XKR_'*#PM;_ /"=3%F;56>5YLM#]G)"
MLY13Y7R9"C"\"O:*14I:)(****9 4444 %%%% !1110 4444 %%%% !1110
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M_GX_O8?V3A?^?4?_  %'&?\ "M_AY_T*^E?^ ,'_ ,11_P *W^'G_0KZ5_X
MP?\ Q%=G11]?K_\ /Q_>P_LG"_\ /J/_ ("CC/\ A6_P\_Z%?2O_  !@_P#B
M*/\ A6_P\_Z%?2O_  !@_P#B*[.BCZ_7_P"?C^]A_9.%_P"?4?\ P%'&?\*W
M^'G_ $*^E?\ @#!_\11_PK?X>?\ 0KZ5_P" ,'_Q%=G11]?K_P#/Q_>P_LG"
M_P#/J/\ X"CC/^%;_#S_ *%?2O\ P!@_^(H_X5O\//\ H5]*_P# &#_XBNSH
MH^OU_P#GX_O8?V3A?^?4?_ 4<9_PK?X>?]"OI7_@#!_\11_PK?X>?]"OI7_@
M#!_\179T4?7Z_P#S\?WL/[)PO_/J/_@*.,_X5O\ #S_H5]*_\ 8/_B*/^%;_
M  \_Z%?2O_ &#_XBNSHH^OU_^?C^]A_9.%_Y]1_\!1QG_"M_AY_T*^E?^ ,'
M_P 11_PK?X>?]"OI7_@#!_\ $5V=%'U^O_S\?WL/[)PO_/J/_@*.,_X5O\//
M^A7TK_P!@_\ B*/^%;_#S_H5]*_\ 8/_ (BNSHH^OU_^?C^]A_9.%_Y]1_\
M 4<9_P *W^'G_0KZ5_X P?\ Q%'_  K?X>?]"OI7_@#!_P#$5V=%'U^O_P _
M'][#^R<+_P ^H_\ @*.,_P"%;_#S_H5]*_\  &#_ .(H_P"%;_#S_H5]*_\
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M_@#!_P#$4?\ "M_AY_T*^E?^ ,'_ ,179T4?7Z__ #\?WL/[)PO_ #ZC_P"
MHXS_ (5O\//^A7TK_P  8/\ XBC_ (5O\//^A7TK_P  8/\ XBNSHH^OU_\
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M . HXS_A6_P\_P"A7TK_ , 8/_B*/^%;_#S_ *%?2O\ P!@_^(KLZ*/K]?\
MY^/[V']DX7_GU'_P%'&?\*W^'G_0KZ5_X P?_$4?\*W^'G_0KZ5_X P?_$5V
M=%'U^O\ \_'][#^R<+_SZC_X"CC/^%;_  \_Z%?2O_ &#_XBC_A6_P //^A7
MTK_P!@_^(KLZ*/K]?_GX_O8?V3A?^?4?_ 4<9_PK?X>?]"OI7_@#!_\ $4?\
M*W^'G_0KZ5_X P?_ !%=G11]?K_\_'][#^R<+_SZC_X"CC/^%;_#S_H5]*_\
M 8/_ (BC_A6_P\_Z%?2O_ &#_P"(KLZ*/K]?_GX_O8?V3A?^?4?_  %'&?\
M"M_AY_T*^E?^ ,'_ ,11_P *W^'G_0KZ5_X P?\ Q%=G11]?K_\ /Q_>P_LG
M"_\ /J/_ ("CC/\ A6_P\_Z%?2O_  !@_P#B*/\ A6_P\_Z%?2O_  !@_P#B
M*[.BCZ_7_P"?C^]A_9.%_P"?4?\ P%'&?\*W^'G_ $*^E?\ @#!_\11_PK?X
M>?\ 0KZ5_P" ,'_Q%=G11]?K_P#/Q_>P_LG"_P#/J/\ X"CC/^%;_#S_ *%?
M2O\ P!@_^(H_X5O\//\ H5]*_P# &#_XBNSHH^OU_P#GX_O8?V3A?^?4?_ 4
M<9_PK?X>?]"OI7_@#!_\11_PK?X>?]"OI7_@#!_\179T4?7Z_P#S\?WL/[)P
MO_/J/_@*.,_X5O\ #S_H5]*_\ 8/_B*/^%;_  \_Z%?2O_ &#_XBNSHH^OU_
M^?C^]A_9.%_Y]1_\!1QG_"M_AY_T*^E?^ ,'_P 11_PK?X>?]"OI7_@#!_\
M$5V=%'U^O_S\?WL/[)PO_/J/_@*.,_X5O\//^A7TK_P!@_\ B*/^%;_#S_H5
M]*_\ 8/_ (BNSHH^OU_^?C^]A_9.%_Y]1_\  4<9_P *W^'G_0KZ5_X P?\
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M ,'_ ,179T4?7Z__ #\?WL/[)PO_ #ZC_P" HXS_ (5O\//^A7TK_P  8/\
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M  %'&?\ "M_AY_T*^E?^ ,'_ ,11_P *W^'G_0KZ5_X P?\ Q%=G11]?K_\
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M5_X P?\ Q%'_  K?X>?]"OI7_@#!_P#$5V=%'U^O_P _'][#^R<+_P ^H_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#?Q*/^&F]"_P"@+<_]_$H ^FZ*^9/^&F]"_P"@+<_]_$H_X:;T+_H"W/\
MW\2@#Z;HKYD_X:;T+_H"W/\ W\2C_AIO0O\ H"W/_?Q* /INBOF3_AIO0O\
MH"W/_?Q*/^&F]"_Z MS_ -_$H ^FZ*^9/^&F]"_Z MS_ -_$H_X:;T+_ * M
MS_W\2@#Z;HKYD_X:;T+_ * MS_W\2C_AIO0O^@+<_P#?Q* /INBOF3_AIO0O
M^@+<_P#?Q*/^&F]"_P"@+<_]_$H ^FZ*^9/^&F]"_P"@+<_]_$H_X:;T+_H"
MW/\ W\2@#Z;HKYD_X:;T+_H"W/\ W\2C_AIO0O\ H"W/_?Q* /INBOF3_AIO
M0O\ H"W/_?Q*/^&F]"_Z MS_ -_$H ^FZ*^9/^&F]"_Z MS_ -_$H_X:;T+_
M * MS_W\2@#Z;HKYD_X:;T+_ * MS_W\2C_AIO0O^@+<_P#?Q* /INBOF3_A
MIO0O^@+<_P#?Q*/^&F]"_P"@+<_]_$H ^FZ*^9/^&F]"_P"@+<_]_$H_X:;T
M+_H"W/\ W\2@#Z;HKYD_X:;T+_H"W/\ W\2C_AIO0O\ H"W/_?Q* /INBOF3
M_AIO0O\ H"W/_?Q*/^&F]"_Z MS_ -_$H ^FZ*^9/^&F]"_Z MS_ -_$H_X:
M;T+_ * MS_W\2@#Z;HKYD_X:;T+_ * MS_W\2C_AIO0O^@+<_P#?Q* /INBO
MF3_AIO0O^@+<_P#?Q*/^&F]"_P"@+<_]_$H ^FZ*^9/^&F]"_P"@+<_]_$H_
MX:;T+_H"W/\ W\2@#Z;HKYD_X:;T+_H"W/\ W\2C_AIO0O\ H"W/_?Q* /IN
MBOF3_AIO0O\ H"W/_?Q*/^&F]"_Z MS_ -_$H ^FZ*^9/^&F]"_Z MS_ -_$
MH_X:;T+_ * MS_W\2@#Z;HKYD_X:;T+_ * MS_W\2C_AIO0O^@+<_P#?Q* /
MINBOF3_AIO0O^@+<_P#?Q*/^&F]"_P"@+<_]_$H ^FZ*^9/^&F]"_P"@+<_]
M_$H_X:;T+_H"W/\ W\2@#Z;HKYD_X:;T+_H"W/\ W\2C_AIO0O\ H"W/_?Q*
M /INBOF3_AIO0O\ H"W/_?Q*/^&F]"_Z MS_ -_$H ^FZ*^9/^&F]"_Z MS_
M -_$H_X:;T+_ * MS_W\2@#Z;HKYD_X:;T+_ * MS_W\2C_AIO0O^@+<_P#?
MQ* /INBOF3_AIO0O^@+<_P#?Q*/^&F]"_P"@+<_]_$H ^FZ*^9/^&F]"_P"@
M+<_]_$H_X:;T+_H"W/\ W\2@#V3XE_\ )/\ Q#_UY3_^@FO)OV9_^13U3_K]
M/_HI*Y3Q7^T'H_B#PWJ6AP:3/%)?0/"KM(N%+C&3CTKCOA5\7--^'NBW>F7E
MA-=O<W!F#1LJ@#8JXY[\4 ?=E%?,G_#3>A?] 6Y_[^)1_P --Z%_T!;G_OXE
M 'TW17S)_P --Z%_T!;G_OXE'_#3>A?] 6Y_[^)0!]-T5\R?\--Z%_T!;G_O
MXE'_  TWH7_0%N?^_B4 ?3=%?,G_  TWH7_0%N?^_B4?\--Z%_T!;G_OXE '
MTW17S)_PTWH7_0%N?^_B4?\ #3>A?] 6Y_[^)0!]-T5\R?\ #3>A?] 6Y_[^
M)1_PTWH7_0%N?^_B4 ?3=%?,G_#3>A?] 6Y_[^)1_P --Z%_T!;G_OXE 'TW
M17S)_P --Z%_T!;G_OXE'_#3>A?] 6Y_[^)0!]-T5\R?\--Z%_T!;G_OXE'_
M  TWH7_0%N?^_B4 ?3=%?,G_  TWH7_0%N?^_B4?\--Z%_T!;G_OXE 'TW17
MS)_PTWH7_0%N?^_B4?\ #3>A?] 6Y_[^)0!]-T5\R?\ #3>A?] 6Y_[^)1_P
MTWH7_0%N?^_B4 ?3=%?,G_#3>A?] 6Y_[^)1_P --Z%_T!;G_OXE 'TW17S)
M_P --Z%_T!;G_OXE'_#3>A?] 6Y_[^)0!]-T5\R?\--Z%_T!;G_OXE'_  TW
MH7_0%N?^_B4 ?3=%?,G_  TWH7_0%N?^_B4?\--Z%_T!;G_OXE 'TW17S)_P
MTWH7_0%N?^_B4?\ #3>A?] 6Y_[^)0!]-T5\R?\ #3>A?] 6Y_[^)1_PTWH7
M_0%N?^_B4 ?3=%?,G_#3>A?] 6Y_[^)1_P --Z%_T!;G_OXE 'TW17S)_P -
M-Z%_T!;G_OXE'_#3>A?] 6Y_[^)0!]-T5\R?\--Z%_T!;G_OXE'_  TWH7_0
M%N?^_B4 ?3=%?,G_  TWH7_0%N?^_B4?\--Z%_T!;G_OXE 'TW17S)_PTWH7
M_0%N?^_B4?\ #3>A?] 6Y_[^)0!]-T5\R?\ #3>A?] 6Y_[^)1_PTWH7_0%N
M?^_B4 ?3=%?,G_#3>A?] 6Y_[^)1_P --Z%_T!;G_OXE 'TW17S)_P --Z%_
MT!;G_OXE'_#3>A?] 6Y_[^)0!]-T5\R?\--Z%_T!;G_OXE'_  TWH7_0%N?^
M_B4 ?3=%?,G_  TWH7_0%N?^_B4?\--Z%_T!;G_OXE 'TW17S)_PTWH7_0%N
M?^_B4?\ #3>A?] 6Y_[^)0!]-T5\R?\ #3>A?] 6Y_[^)1_PTWH7_0%N?^_B
M4 ?3=%?,G_#3>A?] 6Y_[^)1_P --Z%_T!;G_OXE 'TW17S)_P --Z%_T!;G
M_OXE'_#3>A?] 6Y_[^)0!]-T5\R?\--Z%_T!;G_OXE'_  TWH7_0%N?^_B4
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M?,G_  TWH7_0%N?^_B4?\--Z%_T!;G_OXE 'TW17S)_PTWH7_0%N?^_B4?\
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MR?\ #3>A?] 6Y_[^)1_PTWH7_0%N?^_B4 ?3=>>_%C_DG.O_ /7L?YBO)O\
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M2C_AIO0O^@+<_P#?Q* /INBOF3_AIO0O^@+<_P#?Q*/^&F]"_P"@+<_]_$H
M^FZ*^9/^&F]"_P"@+<_]_$H_X:;T+_H"W/\ W\2@#Z;HKYD_X:;T+_H"W/\
MW\2C_AIO0O\ H"W/_?Q* /INBOF3_AIO0O\ H"W/_?Q*/^&F]"_Z MS_ -_$
MH ^FZ*^9/^&F]"_Z MS_ -_$H_X:;T+_ * MS_W\2@#Z;HKYD_X:;T+_ * M
MS_W\2C_AIO0O^@+<_P#?Q* /INBOF3_AIO0O^@+<_P#?Q*/^&F]"_P"@+<_]
M_$H ^FZ*^9/^&F]"_P"@+<_]_$H_X:;T+_H"W/\ W\2@#Z;HKYD_X:;T+_H"
MW/\ W\2C_AIO0O\ H"W/_?Q* /INBOF3_AIO0O\ H"W/_?Q*/^&F]"_Z MS_
M -_$H ^FZ*^9/^&F]"_Z MS_ -_$H_X:;T+_ * MS_W\2@#Z;HKYD_X:;T+_
M * MS_W\2C_AIO0O^@+<_P#?Q* /INBOF3_AIO0O^@+<_P#?Q*/^&F]"_P"@
M+<_]_$H ^FZ*^9/^&F]"_P"@+<_]_$H_X:;T+_H"W/\ W\2@#Z;HKYD_X:;T
M+_H"W/\ W\2C_AIO0O\ H"W/_?Q* /INBOF3_AIO0O\ H"W/_?Q*/^&F]"_Z
M MS_ -_$H ^FZ*^9/^&F]"_Z MS_ -_$H_X:;T+_ * MS_W\2@#Z;HKYD_X:
M;T+_ * MS_W\2C_AIO0O^@+<_P#?Q* /INBOF3_AIO0O^@+<_P#?Q*/^&F]"
M_P"@+<_]_$H ^FZ*^9/^&F]"_P"@+<_]_$H_X:;T+_H"W/\ W\2@#Z;HKYD_
MX:;T+_H"W/\ W\2C_AIO0O\ H"W/_?Q* /INBOF3_AIO0O\ H"W/_?Q*/^&F
M]"_Z MS_ -_$H ^FZ*^9/^&F]"_Z MS_ -_$H_X:;T+_ * MS_W\2@#Z;HKY
MD_X:;T+_ * MS_W\2C_AIO0O^@+<_P#?Q* /INBOF3_AIO0O^@+<_P#?Q*/^
M&F]"_P"@+<_]_$H ^FZ*^9/^&F]"_P"@+<_]_$H_X:;T+_H"W/\ W\2@#Z;H
MKYD_X:;T+_H"W/\ W\2C_AIO0O\ H"W/_?Q* /INBOF3_AIO0O\ H"W/_?Q*
M/^&F]"_Z MS_ -_$H ^FZ*^9/^&F]"_Z MS_ -_$H_X:;T+_ * MS_W\2@#Z
M;HKYD_X:;T+_ * MS_W\2C_AIO0O^@+<_P#?Q* /INBOF3_AIO0O^@+<_P#?
MQ*/^&F]"_P"@+<_]_$H ^FZ*^9/^&F]"_P"@+<_]_$H_X:;T+_H"W/\ W\2@
M#A_'O_)PVF_]?NE_SCK[3K\[/$7C^TUOXF6OCN.T>*WM[BTF\DL"Y%ML)&>F
M3M.*]X_X:;T+_H"W/_?Q* /INBOF3_AIO0O^@+<_]_$H_P"&F]"_Z MS_P!_
M$H ^FZ*^9/\ AIO0O^@+<_\ ?Q*/^&F]"_Z MS_W\2@#Z;HKYD_X:;T+_H"W
M/_?Q*/\ AIO0O^@+<_\ ?Q* /INBOF3_ (:;T+_H"W/_ '\2C_AIO0O^@+<_
M]_$H ^FZ*^9/^&F]"_Z MS_W\2C_ (:;T+_H"W/_ '\2@#Z;HKYD_P"&F]"_
MZ MS_P!_$H_X:;T+_H"W/_?Q* /INBOF3_AIO0O^@+<_]_$H_P"&F]"_Z MS
M_P!_$H ^FZ*^9/\ AIO0O^@+<_\ ?Q*/^&F]"_Z MS_W\2@#Z;HKYD_X:;T+
M_H"W/_?Q*/\ AIO0O^@+<_\ ?Q* /INBOF3_ (:;T+_H"W/_ '\2C_AIO0O^
M@+<_]_$H ^FZ*^9/^&F]"_Z MS_W\2C_ (:;T+_H"W/_ '\2@#Z;HKYD_P"&
MF]"_Z MS_P!_$H_X:;T+_H"W/_?Q* /INBOF3_AIO0O^@+<_]_$H_P"&F]"_
MZ MS_P!_$H ^FZ*^9/\ AIO0O^@+<_\ ?Q*/^&F]"_Z MS_W\2@#Z;HKYD_X
M:;T+_H"W/_?Q*/\ AIO0O^@+<_\ ?Q* /INBOF3_ (:;T+_H"W/_ '\2C_AI
MO0O^@+<_]_$H ^FZ*^9/^&F]"_Z MS_W\2C_ (:;T+_H"W/_ '\2@#Z;HKYD
M_P"&F]"_Z MS_P!_$H_X:;T+_H"W/_?Q* /INBOF3_AIO0O^@+<_]_$H_P"&
MF]"_Z MS_P!_$H ^FZ*^9/\ AIO0O^@+<_\ ?Q*/^&F]"_Z MS_W\2@#Z;HK
MYD_X:;T+_H"W/_?Q*/\ AIO0O^@+<_\ ?Q* /INBOF3_ (:;T+_H"W/_ '\2
MC_AIO0O^@+<_]_$H ^FZ*^9/^&F]"_Z MS_W\2C_ (:;T+_H"W/_ '\2@#Z;
MHKYD_P"&F]"_Z MS_P!_$H_X:;T+_H"W/_?Q* /INBOF3_AIO0O^@+<_]_$H
M_P"&F]"_Z MS_P!_$H ^FZ*^9/\ AIO0O^@+<_\ ?Q*/^&F]"_Z MS_W\2@#
MZ;HKYD_X:;T+_H"W/_?Q*/\ AIO0O^@+<_\ ?Q* /INBOF3_ (:;T+_H"W/_
M '\2C_AIO0O^@+<_]_$H ^FZ*^9/^&F]"_Z MS_W\2C_ (:;T+_H"W/_ '\2
M@#Z;HKYD_P"&F]"_Z MS_P!_$H_X:;T+_H"W/_?Q* /INBOF3_AIO0O^@+<_
M]_$H_P"&F]"_Z MS_P!_$H ^FZ*^9/\ AIO0O^@+<_\ ?Q*/^&F]"_Z MS_W
M\2@#Z;HKYD_X:;T+_H"W/_?Q*/\ AIO0O^@+<_\ ?Q* /INBOF3_ (:;T+_H
M"W/_ '\2C_AIO0O^@+<_]_$H ^FZ*^9/^&F]"_Z MS_W\2C_ (:;T+_H"W/_
M '\2@#Z;HKYD_P"&F]"_Z MS_P!_$H_X:;T+_H"W/_?Q* /INBOF3_AIO0O^
M@+<_]_$H_P"&F]"_Z MS_P!_$H ^FZ*^9/\ AIO0O^@+<_\ ?Q*/^&F]"_Z
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M?_B*/^$!\"_]"YIO_@'#_P#$5UE% ')_\(#X%_Z%S3?_  #A_P#B*/\ A ?
MO_0N:;_X!P__ !%=910!R?\ P@/@7_H7--_\ X?_ (BC_A ? O\ T+FF_P#@
M'#_\17644 <G_P (#X%_Z%S3?_ .'_XBC_A ? O_ $+FF_\ @'#_ /$5UE%
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M?_B*/^$!\"_]"YIO_@'#_P#$5UE% ')_\(#X%_Z%S3?_  #A_P#B*/\ A ?
MO_0N:;_X!P__ !%=910!R?\ P@/@7_H7--_\ X?_ (BC_A ? O\ T+FF_P#@
M'#_\17644 <G_P (#X%_Z%S3?_ .'_XBC_A ? O_ $+FF_\ @'#_ /$5UE%
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M?_B*/^$!\"_]"YIO_@'#_P#$5UE% ')_\(#X%_Z%S3?_  #A_P#B*/\ A ?
MO_0N:;_X!P__ !%=910!R?\ P@/@7_H7--_\ X?_ (BC_A ? O\ T+FF_P#@
M'#_\17644 <G_P (#X%_Z%S3?_ .'_XBC_A ? O_ $+FF_\ @'#_ /$5UE%
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M5>X@CE8+Y:G +@D#/:O=/B7_ ,D_\0_]>4__ *":\F_9G_Y%/5/^OT_^BDH
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MD_\ A ? O_0N:;_X!P__ !%'_" ^!?\ H7--_P# .'_XBNLHH Y/_A ? O\
MT+FF_P#@'#_\11_P@/@7_H7--_\  .'_ .(KK** .3_X0'P+_P!"YIO_ (!P
M_P#Q%'_" ^!?^A<TW_P#A_\ B*ZRB@#D_P#A ? O_0N:;_X!P_\ Q%'_  @/
M@7_H7--_\ X?_B*ZRB@#D_\ A ? O_0N:;_X!P__ !%'_" ^!?\ H7--_P#
M.'_XBNLHH Y/_A ? O\ T+FF_P#@'#_\11_P@/@7_H7--_\  .'_ .(KK**
M.3_X0'P+_P!"YIO_ (!P_P#Q%'_" ^!?^A<TW_P#A_\ B*ZRB@#D_P#A ? O
M_0N:;_X!P_\ Q%'_  @/@7_H7--_\ X?_B*ZRB@#D_\ A ? O_0N:;_X!P__
M !%'_" ^!?\ H7--_P# .'_XBNLHH Y/_A ? O\ T+FF_P#@'#_\11_P@/@7
M_H7--_\  .'_ .(KK** .3_X0'P+_P!"YIO_ (!P_P#Q%'_" ^!?^A<TW_P#
MA_\ B*ZRB@#D_P#A ? O_0N:;_X!P_\ Q%'_  @/@7_H7--_\ X?_B*ZRB@#
MD_\ A ? O_0N:;_X!P__ !%'_" ^!?\ H7--_P# .'_XBNLHH Y/_A ? O\
MT+FF_P#@'#_\11_P@/@7_H7--_\  .'_ .(KK** .3_X0'P+_P!"YIO_ (!P
M_P#Q%'_" ^!?^A<TW_P#A_\ B*ZRB@#D_P#A ? O_0N:;_X!P_\ Q%'_  @/
M@7_H7--_\ X?_B*ZRB@#D_\ A ? O_0N:;_X!P__ !%'_" ^!?\ H7--_P#
M.'_XBNLHH Y/_A ? O\ T+FF_P#@'#_\11_P@/@7_H7--_\  .'_ .(KK**
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MD_\ A ? O_0N:;_X!P__ !%'_" ^!?\ H7--_P# .'_XBNLHH Y/_A ? O\
MT+FF_P#@'#_\11_P@/@7_H7--_\  .'_ .(KK** .3_X0'P+_P!"YIO_ (!P
M_P#Q%'_" ^!?^A<TW_P#A_\ B*ZRB@#D_P#A ? O_0N:;_X!P_\ Q%'_  @/
M@7_H7--_\ X?_B*ZRB@#D_\ A ? O_0N:;_X!P__ !%'_" ^!?\ H7--_P#
M.'_XBNLHH Y/_A ? O\ T+FF_P#@'#_\11_P@/@7_H7--_\  .'_ .(KK**
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M_P#0N:;_ . </_Q%'_" ^!?^A<TW_P  X?\ XBNLHH Y/_A ? O_ $+FF_\
M@'#_ /$4?\(#X%_Z%S3?_ .'_P"(KK** .3_ .$!\"_]"YIO_@'#_P#$4?\
M" ^!?^A<TW_P#A_^(KK** .3_P"$!\"_]"YIO_@'#_\ $4?\(#X%_P"A<TW_
M , X?_B*ZRB@#D_^$!\"_P#0N:;_ . </_Q%'_" ^!?^A<TW_P  X?\ XBNL
MHH Y/_A ? O_ $+FF_\ @'#_ /$4?\(#X%_Z%S3?_ .'_P"(KK** .3_ .$!
M\"_]"YIO_@'#_P#$4?\ " ^!?^A<TW_P#A_^(KK** .3_P"$!\"_]"YIO_@'
M#_\ $4?\(#X%_P"A<TW_ , X?_B*ZRB@#D_^$!\"_P#0N:;_ . </_Q%'_"
M^!?^A<TW_P  X?\ XBNLHH Y/_A ? O_ $+FF_\ @'#_ /$4?\(#X%_Z%S3?
M_ .'_P"(KK** .3_ .$!\"_]"YIO_@'#_P#$4?\ " ^!?^A<TW_P#A_^(KK*
M* .3_P"$!\"_]"YIO_@'#_\ $4?\(#X%_P"A<TW_ , X?_B*ZRB@#D_^$!\"
M_P#0N:;_ . </_Q%'_" ^!?^A<TW_P  X?\ XBNLHH Y/_A ? O_ $+FF_\
M@'#_ /$4?\(#X%_Z%S3?_ .'_P"(KK** .3_ .$!\"_]"YIO_@'#_P#$4?\
M" ^!?^A<TW_P#A_^(KK** .3_P"$!\"_]"YIO_@'#_\ $4?\(#X%_P"A<TW_
M , X?_B*ZRB@#D_^$!\"_P#0N:;_ . </_Q%'_" ^!?^A<TW_P  X?\ XBNL
MHH Y/_A ? O_ $+FF_\ @'#_ /$4?\(#X%_Z%S3?_ .'_P"(KK** .3_ .$!
M\"_]"YIO_@'#_P#$4?\ " ^!?^A<TW_P#A_^(KK** .3_P"$!\"_]"YIO_@'
M#_\ $4?\(#X%_P"A<TW_ , X?_B*ZRB@#D_^$!\"_P#0N:;_ . </_Q%'_"
M^!?^A<TW_P  X?\ XBNLHH Y/_A ? O_ $+FF_\ @'#_ /$4?\(#X%_Z%S3?
M_ .'_P"(KK** .3_ .$!\"_]"YIO_@'#_P#$4?\ " ^!?^A<TW_P#A_^(KK*
M* .3_P"$!\"_]"YIO_@'#_\ $4?\(#X%_P"A<TW_ , X?_B*ZRB@#D_^$!\"
M_P#0N:;_ . </_Q%'_" ^!?^A<TW_P  X?\ XBNLHH Y/_A ? O_ $+FF_\
M@'#_ /$4?\(#X%_Z%S3?_ .'_P"(KK** .3_ .$!\"_]"YIO_@'#_P#$4?\
M" ^!?^A<TW_P#A_^(KK** .3_P"$!\"_]"YIO_@'#_\ $4?\(#X%_P"A<TW_
M , X?_B*ZRB@#D_^$!\"_P#0N:;_ . </_Q%'_" ^!?^A<TW_P  X?\ XBNL
MHH Y/_A ? O_ $+FF_\ @'#_ /$4?\(#X%_Z%S3?_ .'_P"(KK** .3_ .$!
M\"_]"YIO_@'#_P#$4?\ " ^!?^A<TW_P#A_^(KK** .3_P"$!\"_]"YIO_@'
M#_\ $4?\(#X%_P"A<TW_ , X?_B*ZRB@#D_^$!\"_P#0N:;_ . </_Q%'_"
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MIO\ X!P__$4?\(#X%_Z%S3?_  #A_P#B*ZRB@#D_^$!\"_\ 0N:;_P" </\
M\11_P@/@7_H7--_\ X?_ (BNLHH Y/\ X0'P+_T+FF_^ </_ ,11_P (#X%_
MZ%S3?_ .'_XBNLHH Y/_ (0'P+_T+FF_^ </_P 11_P@/@7_ *%S3?\ P#A_
M^(KK** .3_X0'P+_ -"YIO\ X!P__$4?\(#X%_Z%S3?_  #A_P#B*ZRB@#D_
M^$!\"_\ 0N:;_P" </\ \11_P@/@7_H7--_\ X?_ (BNLHH Y/\ X0'P+_T+
MFF_^ </_ ,11_P (#X%_Z%S3?_ .'_XBNLHH Y/_ (0'P+_T+FF_^ </_P 1
M1_P@/@7_ *%S3?\ P#A_^(KK** .3_X0'P+_ -"YIO\ X!P__$4?\(#X%_Z%
MS3?_  #A_P#B*ZRB@#D_^$!\"_\ 0N:;_P" </\ \11_P@/@7_H7--_\ X?_
M (BNLHH Y/\ X0'P+_T+FF_^ </_ ,11_P (#X%_Z%S3?_ .'_XBNLHH Y/_
M (0'P+_T+FF_^ </_P 11_P@/@7_ *%S3?\ P#A_^(KK** .3_X0'P+_ -"Y
MIO\ X!P__$4?\(#X%_Z%S3?_  #A_P#B*ZRB@#D_^$!\"_\ 0N:;_P" </\
M\11_P@/@7_H7--_\ X?_ (BNLHH Y/\ X0'P+_T+FF_^ </_ ,11_P (#X%_
MZ%S3?_ .'_XBNLHH Y/_ (0'P+_T+FF_^ </_P 11_P@/@7_ *%S3?\ P#A_
M^(KK** .3_X0'P+_ -"YIO\ X!P__$4?\(#X%_Z%S3?_  #A_P#B*ZRB@#D_
M^$!\"_\ 0N:;_P" </\ \11_P@/@7_H7--_\ X?_ (BNLHH Y/\ X0'P+_T+
MFF_^ </_ ,11_P (#X%_Z%S3?_ .'_XBNLHH Y/_ (0'P+_T+FF_^ </_P 1
M1_P@/@7_ *%S3?\ P#A_^(KK** .3_X0'P+_ -"YIO\ X!P__$4?\(#X%_Z%
MS3?_  #A_P#B*ZRB@#D_^$!\"_\ 0N:;_P" </\ \11_P@/@7_H7--_\ X?_
M (BNLHH Y/\ X0'P+_T+FF_^ </_ ,11_P (#X%_Z%S3?_ .'_XBNLHH Y/_
M (0'P+_T+FF_^ </_P 11_P@/@7_ *%S3?\ P#A_^(KK** .3_X0'P+_ -"Y
MIO\ X!P__$4?\(#X%_Z%S3?_  #A_P#B*ZRB@#D_^$!\"_\ 0N:;_P" </\
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M O\ T+FF_P#@'#_\17644 <G_P (#X%_Z%S3?_ .'_XBC_A ? O_ $+FF_\
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M O\ T+FF_P#@'#_\17644 <G_P (#X%_Z%S3?_ .'_XBC_A ? O_ $+FF_\
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M O\ T+FF_P#@'#_\17644 <G_P (#X%_Z%S3?_ .'_XBC_A ? O_ $+FF_\
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M$M-^'FLWNG:)8VMQ%&A22*VB1U)D4<,J@CBJW[.?_)/Y/^OV;_T%*ZSXR_\
M),]=_P"N<?\ Z-2N3_9S_P"2?R?]?LW_ *"E '__TOW\HHHH **** "BBB@
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M*>J?]?I_]%)7K/Q+_P"2?^(?^O*?_P!!->3?LS_\BGJG_7Z?_124 ?2%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5\6?%7_DN6E_\ 733_ /T,5]IU\6?%7_DN6E_]=-/_
M /0Q0!]IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOC(X-?SQ?M5^%/#G@C]H3QKX:\)1);Z5;7:/%%$ (XC/#'-)&@'"JDCLH4<
M# Z5^J?_  30N+N;X":M%<<Q0>(+I(2?[IMK9B![;B?S->)XIY3A,1E=+-Z,
M.6;Y7M9M25]?-::^IZG &8XFCCZF6U9<T5==[.+Z>3-3]M?]J^^^"%A:^!O
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M (CKA?\ H&E]Z/V)HK\=O^%C?$+_ *&C5/\ P-G_ /BZ/^%C?$+_ *&C5/\
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M?\1UPO\ T#2^]'[$T5^.W_"QOB%_T-&J?^!L_P#\71_PL;XA?]#1JG_@;/\
M_%T?\0KK_P#/Y?<P_P"(ZX7_ *!I?>C]B:*_';_A8WQ"_P"AHU3_ ,#9_P#X
MNC_A8WQ"_P"AHU3_ ,#9_P#XNC_B%=?_ )_+[F'_ !'7"_\ 0-+[T?L317X[
M?\+&^(7_ $-&J?\ @;/_ /%T?\+&^(7_ $-&J?\ @;/_ /%T?\0KK_\ /Y?<
MP_XCKA?^@:7WH_8FBOQV_P"%C?$+_H:-4_\  V?_ .+H_P"%C?$+_H:-4_\
M V?_ .+H_P"(5U_^?R^YA_Q'7"_] TOO1^Q-%?CM_P +&^(7_0T:I_X&S_\
MQ='_  L;XA?]#1JG_@;/_P#%T?\ $*Z__/Y?<P_XCKA?^@:7WH_8FBOQV_X6
M-\0O^AHU3_P-G_\ BZ/^%C?$+_H:-4_\#9__ (NC_B%=?_G\ON8?\1UPO_0-
M+[T?L317X[?\+&^(7_0T:I_X&S__ !='_"QOB%_T-&J?^!L__P 71_Q"NO\
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M (CKA?\ H&E]Z/V)HK\=O^%C?$+_ *&C5/\ P-G_ /BZ/^%C?$+_ *&C5/\
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M?\1UPO\ T#2^]'[$T5^.W_"QOB%_T-&J?^!L_P#\71_PL;XA?]#1JG_@;/\
M_%T?\0KK_P#/Y?<P_P"(ZX7_ *!I?>C]B:*_';_A8WQ"_P"AHU3_ ,#9_P#X
MNC_A8WQ"_P"AHU3_ ,#9_P#XNC_B%=?_ )_+[F'_ !'7"_\ 0-+[T?L317X[
M?\+&^(7_ $-&J?\ @;/_ /%T?\+&^(7_ $-&J?\ @;/_ /%T?\0KK_\ /Y?<
MP_XCKA?^@:7WH_8FBOQV_P"%C?$+_H:-4_\  V?_ .+H_P"%C?$+_H:-4_\
M V?_ .+H_P"(5U_^?R^YA_Q'7"_] TOO1^Q-%?CM_P +&^(7_0T:I_X&S_\
MQ='_  L;XA?]#1JG_@;/_P#%T?\ $*Z__/Y?<P_XCKA?^@:7WH_8FBOQV_X6
M-\0O^AHU3_P-G_\ BZ/^%C?$+_H:-4_\#9__ (NC_B%=?_G\ON8?\1UPO_0-
M+[T?L317X[?\+&^(7_0T:I_X&S__ !='_"QOB%_T-&J?^!L__P 71_Q"NO\
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MZ/\ A8WQ"_Z&C5/_  -G_P#BZ/\ B%=?_G\ON8?\1UPO_0-+[T?L317X[?\
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M(7_0T:I_X&S_ /Q='_"QOB%_T-&J?^!L_P#\71_Q"NO_ ,_E]S#_ (CKA?\
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M^%C?$+_H:-4_\#9__BZ/^%C?$+_H:-4_\#9__BZ/^(5U_P#G\ON8?\1UPO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X
ML\>_\G#:;_U^Z7_..OM.OBSQ[_R<-IO_ %^Z7_..OM.@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /,?C+_P DSUW_ *YQ_P#HU*Y/]G/_ ))_)_U^S?\ H*5UGQE_Y)GK
MO_7./_T:E<G^SG_R3^3_ *_9O_04H __U/W\HHHH **** "BBB@ HHHH *_
M'_@H)\3/^$Z^/%SX=LY=^G>#H%T] #E3<M^\N6^H8B,_]<Z_<CXD>-;#X<>
M=?\ '>IX-OH=E-=%2<>8T:DI&/=WPH]S7\L>LZM?Z_J]]KNJRF>]U&>6YGD/
M5Y9F+NQ^K$FOW'P3R3VF)JX^:T@N5>KW^Y?F?E'BGFG)0IX2+UD[OT6WWO\
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MXD>.!L69PN/PK^ECXZ?%C1O@O\,M9\<ZM,BS6T+)90LP#7%XZD0Q*#R<MRV
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH _3/]F7_D0+S_ +"$G_HF&OHFOG;]F7_D0+S_ +"$
MG_HF&OHFOY#K?&_4_P!!\/\ PX^B"BBBLS4**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /BSQ[_R<
M-IO_ %^Z7_..OM.OBSQ[_P G#:;_ -?NE_SCK[3H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD4PMWU*>. 2,-P0N<9(&,XK[L_:\_P"1#TC_ +"2_P#HF6OCGX0_\E0\+?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#],_P!F7_D0+S_L(2?^B8:^B:^=OV9?^1 O/^PA)_Z)AKZ)K^0ZWQOU
M/]!\/_#CZ(****S-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ^+/'O_ "<-IO\ U^Z7_..OM.OB
MSQ[_ ,G#:;_U^Z7_ #CK[3H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S'XR_\DSUW_KG
M'_Z-2N3_ &<_^2?R?]?LW_H*5UGQE_Y)GKO_ %SC_P#1J5R?[.?_ "3^3_K]
MF_\ 04H _];]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!1$!^>[]*G_8Z_Y!GB?_ *[6O_H,E>+4G*7"J<OZ]\^DHTX1X[:AZ_-TM?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH _3/]F7_ )$"\_["$G_HF&OHFOG;]F7_ )$"\_["$G_HF&OH
MFOY#K?&_4_T'P_\ #CZ(****S-0HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^+/'O_)PVF_]?NE_
MSCK[3KXL\>_\G#:;_P!?NE_SCK[3H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S'XR_\
M),]=_P"N<?\ Z-2N3_9S_P"2?R?]?LW_ *"E=9\9?^29Z[_USC_]&I7)_LY_
M\D_D_P"OV;_T%* /_]?]_**** "BBB@ HHHH **** "BF22)$C2RL$1 2S$X
M  ZDGTK^:/XB_M??M&?M$_M8R^"/@'XXU+0= US5HM(T>&SF,<(MHV$1O' Y
M(<!IV)Y"G'84FRX0N?TOT5\9?MP>,/&?P@_8\\7>)_ ^NW5EXAT.'2(H-2RI
MN27U"T@D=B5VEI$9@W'\1Q7YI?\ !/K_ (*#>.M5^*/_  JK]H/Q))K-GXK=
M(M*U&[V*UK?_ '4@9E5?W=QD*,YVR!1T9B"X*#:N?OU117Y9?\%3/C3\4_@M
M\/\ P1JGPL\1W/AR[U+5+B&XDMMN9(U@W!3N5N >:9,5=V/U-HKP;]ESQ-KW
MC/\ 9T^'/BSQ3>OJ.KZMH=E<W5S+C?--)&"SM@ 9)]!7\_?Q:_;M_:;^&?[4
M7C:UT[QG=WF@>&/%^J0Q:3-Y?V62SM+^1%M6^3<$,:[,@[@.0<TFRHTVW8_I
M]HKS_P"%?Q+\+_&'X>:#\2_!L_VC2=?MDN(LXWQD\21.!G$D3AD<=F4BN[FF
MAMH9+BXD6**)2[NY"JJJ,DDG@ #J:9!+17\P?[3O_!1SXV>+/C+KMQ\%?&-W
MX=\%V#_8M.CM1&!<1P$@W3[D))F;++G&$VJ1D'/])_@"^N]4\">'-3U"4SW5
MWIMG-+(W5Y)(59F/N22:5RY0:W.MHK^>/]L?]HW]JG2OVVO$'P3^#WC:_P!.
M@O;W1-/TK3XGACB%SJ%C:$*'E7"[YI2268 $DD@5N3?#_P#X+)Z<!=PZI?W+
M1G.U=4T9_P#QUY,'Z<_2BY7L_,_H HK^=;2?^"A7[;?[-WBRW\/?M,^&FUBT
MF?+1:G8)IMT\*$!VM+FV1() /[Q249XR*_<_X(_&OP%^T#\/-/\ B7\.[MKC
M3+TM&\<H"7%M/'_K()T!.V1,CC)!!#*2K D3)E!H]:HHK\)/^"EW[9GQ4^'W
MQGTSX5?!;Q1<Z!_PC^GB?5FM-A:2ZO,2I&^Y6XB@5'&,?ZPYZ4VQ1C=V/W;H
MKX%_X)R_M#:U^T#\ $NO&>HMJ?BSPS>S6&HSR;1+.K'SK>9@H YC?R\XY,;&
MOOJ@4E9V"BBOR!_X*M?'GXO_  1_X5=_PJGQ1=>&O[:_MO[9]FV?OOLWV'RM
MV]6^YYCXQ_>- XQN['Z_45^8G_!-_P#;*N_V@_!UU\.OB1J N/B!X90RF9]J
MOJ5@6PL^% 'F1,PCEP.A1N2S8_3N@4HV=@HK\.?VN_VD/CCX$_;P\*?#/PAX
MPO-+\+WUQX>2:PBV>4ZW4ZK,#E2?G!P>:_<:@<HV"BOY9O@E\>?^"AG[0_BJ
M[\%_"GQ]J.JZM963ZA+%)<VEL%MXY(XF;?,$4D/*@P#GG., U]):GX,_X+'>
M'+235_[3U*]6W4NR6]_I-U)A1GB'<6<^BJK$]A2N6Z7F?T#T5^(?[%O_  4A
M^(_BGXI6/P(_:2MHVU/5;EM/M-3^SBRN8M0!*K;7D"A$!=QY:E41ED(5E()*
M_K/\;/C#X1^ WPSUOXI>-I&73=&B#>7& 9;B9R$B@B!P"\CD*,\#[S$*"0[D
M2@T['JM%?SQVW[?G[?'[1&O:A_PSOX06STRS;'EZ=IHU!H%<DH+BZN@T7F$>
MBQ@XX6MCP?\ \%+OVH/@A\0K;P;^UGX2\VRE*-<;[$Z=J4,+\">$+M@F0<G;
ML^8C D6E<OV3/Z!**RM"US2?$VB:?XDT&Y6]TS5;>*[M9T^Y+!.@DC=<\X92
M"*_F[\7_ +07[;7C_P#:Z\;_  ,^#OCR_P#M7_"3>(+/2['SK>"*.WT^>YD$
M8DE4* D,)QEN<8ZFFV3&%S^EFBOP U#PG_P60\(0-K4.J7^I+ I9DAN](O6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'Z9_LR_\B!>?]A"3_T3#7T3
M7SM^S+_R(%Y_V$)/_1,-?1-?R'6^-^I_H/A_X<?1!11169J%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'Q9X]_Y.&TW_ *_=+_G'7VG7Q9X]_P"3AM-_Z_=+_G'7VG0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?M;)^T;\+AX8\778?Q]X/BCAO]Y^>^M?NPWH'<M]R;'23YC@.HKYR_X+.?\
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MA_P6>D\+#P3\-XIQ&?$AU"]:W/'FBQ$*B?WVF0P_B..]?IY^T'^T/\./V;/
M4_CKXAWNP'='96,1!NK^X R(H$)Y[;F/RH.6(XS^%?PA^&/Q;_X*8_M"S?&7
MXJ0M8?#S1YTBG",RP);0G>FF69."SMG,T@QMW,YPS(I'V"GOS,_9[]AVVU6T
M_9(^%D6LAEN#HL+J&!!\B0L\'7MY13'M7XF_ 75-,T;_ (*T:WJ6L7<-C:0^
M+_&N^:>18HUW1:DHW.Q &20!D]3BOZ4[&QLM+L;?3--@2UM+2-(888E"1QQQ
M@*B*HX"J   . *_E-'P6LOVA_P#@HCXW^#^HZI)HMOK_ (O\6;KN*(3/']ED
MO;H81F4'<8@O7@'-#"GK<_IH\0?'/X+>%=-FU?Q%X[T.PM(%9V>74;<<*,D*
M-^6/HJ@DG@#-?SR> Y8?VHO^"F]OX^^$EG*GA^+Q':ZV\X1HP++2O*,MQ)W0
M73Q<!L$M*%(!.!]97G_!%KPR\#+I_P 5;R&;LTNDQR*/JJW*']:^78M7_:)_
MX)5?%BR\/WT]EXB\&>)6^U.D42B'4H(BJ2[9&4307$((^7<4!8$AU-)E02Z/
M4_I7O+2UU"TGL+Z)9[:Y1HI8W&5='&UE8'J"#@BOY_/V =2E_9Y_;N^(/[.,
M[.NF:W+J.G6RL3EY-*>2YLY6/^U:B7ZEQ7[V^%?$ND^,_"^C^,-!D,VF:[9V
M]_:N1M+074:RQL1VRK XK\"/B+<#PS_P6.T^ZL>3=:OHZ,J]5^VZ3!#)GZAR
MQ]C39%/JC^A6BBBF9!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q'Q+_ .2?^(?^O*?_
M -!-?E5XI_U5I]9/_9*_57XE_P#)/_$/_7E/_P"@FORJ\4_ZJT^LG_LE?<>'
M?_(TAZ2_(_,?%[_D1U/6/YHX^BBBOZ(/Y!"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH _3/]F7_ )$"\_["$G_HF&OHFOG;]F7_ )$"
M\_["$G_HF&OHFOY#K?&_4_T'P_\ #CZ(****S-0HHHH **** "BBB@ HHHH
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M]O\ ]J']J[X=_LO?#V+QAXED_M+4M75UT;38& DOY4522&Y"0IO4R2'(4,
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MT-K?^ /_ -OH_P"&-XO^AM;_ , ?_M]?LO\ K]E/_/[_ ,EE_D?SE_Q"C/\
M_H'_ /)H?_)'P[17W%_PQO%_T-K?^ /_ -OH_P"&-XO^AM;_ , ?_M]'^OV4
M_P#/[_R67^0?\0HS_P#Z!_\ R:'_ ,D?#M%?<7_#&\7_ $-K?^ /_P!OH_X8
MWB_Z&UO_  !_^WT?Z_93_P _O_)9?Y!_Q"C/_P#H'_\ )H?_ "1\.T5]Q?\
M#&\7_0VM_P" /_V^C_AC>+_H;6_\ ?\ [?1_K]E/_/[_ ,EE_D'_ !"C/_\
MH'_\FA_\D?#M%?<7_#&\7_0VM_X _P#V^C_AC>+_ *&UO_ '_P"WT?Z_93_S
M^_\ )9?Y!_Q"C/\ _H'_ /)H?_)'P[17W%_PQO%_T-K?^ /_ -OH_P"&-XO^
MAM;_ , ?_M]'^OV4_P#/[_R67^0?\0HS_P#Z!_\ R:'_ ,D?#M%?<7_#&\7_
M $-K?^ /_P!OH_X8WB_Z&UO_  !_^WT?Z_93_P _O_)9?Y!_Q"C/_P#H'_\
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M ?\ [?1_K]E/_/[_ ,EE_D'_ !"C/_\ H'_\FA_\D?#M%?<7_#&\7_0VM_X
M_P#V^C_AC>+_ *&UO_ '_P"WT?Z_93_S^_\ )9?Y!_Q"C/\ _H'_ /)H?_)'
MP[17W%_PQO%_T-K?^ /_ -OH_P"&-XO^AM;_ , ?_M]'^OV4_P#/[_R67^0?
M\0HS_P#Z!_\ R:'_ ,D?#M%?<7_#&\7_ $-K?^ /_P!OH_X8WB_Z&UO_  !_
M^WT?Z_93_P _O_)9?Y!_Q"C/_P#H'_\ )H?_ "1\.T5]Q?\ #&\7_0VM_P"
M/_V^C_AC>+_H;6_\ ?\ [?1_K]E/_/[_ ,EE_D'_ !"C/_\ H'_\FA_\D?#M
M%?<7_#&\7_0VM_X _P#V^C_AC>+_ *&UO_ '_P"WT?Z_93_S^_\ )9?Y!_Q"
MC/\ _H'_ /)H?_)'P[17W%_PQO%_T-K?^ /_ -OH_P"&-XO^AM;_ , ?_M]'
M^OV4_P#/[_R67^0?\0HS_P#Z!_\ R:'_ ,D?#M%?<7_#&\7_ $-K?^ /_P!O
MH_X8WB_Z&UO_  !_^WT?Z_93_P _O_)9?Y!_Q"C/_P#H'_\ )H?_ "1\.T5]
MQ?\ #&\7_0VM_P" /_V^C_AC>+_H;6_\ ?\ [?1_K]E/_/[_ ,EE_D'_ !"C
M/_\ H'_\FA_\D?#M%?<7_#&\7_0VM_X _P#V^C_AC>+_ *&UO_ '_P"WT?Z_
M93_S^_\ )9?Y!_Q"C/\ _H'_ /)H?_)'P[17W%_PQO%_T-K?^ /_ -OH_P"&
M-XO^AM;_ , ?_M]'^OV4_P#/[_R67^0?\0HS_P#Z!_\ R:'_ ,D?#M%?<7_#
M&\7_ $-K?^ /_P!OH_X8WB_Z&UO_  !_^WT?Z_93_P _O_)9?Y!_Q"C/_P#H
M'_\ )H?_ "1\.T5]Q?\ #&\7_0VM_P" /_V^C_AC>+_H;6_\ ?\ [?1_K]E/
M_/[_ ,EE_D'_ !"C/_\ H'_\FA_\D?#M%?<7_#&\7_0VM_X _P#V^C_AC>+_
M *&UO_ '_P"WT?Z_93_S^_\ )9?Y!_Q"C/\ _H'_ /)H?_)'P[17W%_PQO%_
MT-K?^ /_ -OH_P"&-XO^AM;_ , ?_M]'^OV4_P#/[_R67^0?\0HS_P#Z!_\
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MWB_Z&UO_  !_^WT?\,;Q?]#:W_@#_P#;Z/\ 7[*?^?W_ )++_(/^(49__P!
M_P#Y-#_Y(^':*^XO^&-XO^AM;_P!_P#M]'_#&\7_ $-K?^ /_P!OH_U^RG_G
M]_Y++_(/^(49_P#] _\ Y-#_ .2/AVBON+_AC>+_ *&UO_ '_P"WT?\ #&\7
M_0VM_P" /_V^C_7[*?\ G]_Y++_(/^(49_\ ] __ )-#_P"2/AVBON+_ (8W
MB_Z&UO\ P!_^WT?\,;Q?]#:W_@#_ /;Z/]?LI_Y_?^2R_P @_P"(49__ - _
M_DT/_DCX=HK[B_X8WB_Z&UO_  !_^WT?\,;Q?]#:W_@#_P#;Z/\ 7[*?^?W_
M )++_(/^(49__P! _P#Y-#_Y(^':*^XO^&-XO^AM;_P!_P#M]'_#&\7_ $-K
M?^ /_P!OH_U^RG_G]_Y++_(/^(49_P#] _\ Y-#_ .2/AVBON+_AC>+_ *&U
MO_ '_P"WT?\ #&\7_0VM_P" /_V^C_7[*?\ G]_Y++_(/^(49_\ ] __ )-#
M_P"2/AVBON+_ (8WB_Z&UO\ P!_^WT?\,;Q?]#:W_@#_ /;Z/]?LI_Y_?^2R
M_P @_P"(49__ - __DT/_DCX=HK[B_X8WB_Z&UO_  !_^WT?\,;Q?]#:W_@#
M_P#;Z/\ 7[*?^?W_ )++_(/^(49__P! _P#Y-#_Y(^':*^XO^&-XO^AM;_P!
M_P#M]'_#&\7_ $-K?^ /_P!OH_U^RG_G]_Y++_(/^(49_P#] _\ Y-#_ .2/
MAVBON+_AC>+_ *&UO_ '_P"WT?\ #&\7_0VM_P" /_V^C_7[*?\ G]_Y++_(
M/^(49_\ ] __ )-#_P"2/AVBON+_ (8WB_Z&UO\ P!_^WT?\,;Q?]#:W_@#_
M /;Z/]?LI_Y_?^2R_P @_P"(49__ - __DT/_DCX=HK[B_X8WB_Z&UO_  !_
M^WT?\,;Q?]#:W_@#_P#;Z/\ 7[*?^?W_ )++_(/^(49__P! _P#Y-#_Y(^':
M*^XO^&-XO^AM;_P!_P#M]'_#&\7_ $-K?^ /_P!OH_U^RG_G]_Y++_(/^(49
M_P#] _\ Y-#_ .2/AVBON+_AC>+_ *&UO_ '_P"WT?\ #&\7_0VM_P" /_V^
MC_7[*?\ G]_Y++_(/^(49_\ ] __ )-#_P"2/AVBON+_ (8WB_Z&UO\ P!_^
MWT?\,;Q?]#:W_@#_ /;Z/]?LI_Y_?^2R_P @_P"(49__ - __DT/_DCX=HK[
MB_X8WB_Z&UO_  !_^WT?\,;Q?]#:W_@#_P#;Z/\ 7[*?^?W_ )++_(/^(49_
M_P! _P#Y-#_Y(^':*^XO^&-XO^AM;_P!_P#M]'_#&\7_ $-K?^ /_P!OH_U^
MRG_G]_Y++_(/^(49_P#] _\ Y-#_ .2/AVBON+_AC>+_ *&UO_ '_P"WT?\
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M&0?^08:^AZ_G.H[R;1_8=&+4$GV"BBBH- HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^+/'O_)PV
MF_\ 7[I?\XZ^TZ^+/'O_ "<-IO\ U^Z7_..OM.@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /,?C+_ ,DSUW_KG'_Z-2N3_9S_ .2?R?\ 7[-_Z"E=9\9?^29Z[_USC_\
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MP.-\LA9VQQECCBO2Z*!W=K!1110(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .(^)?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\]^+'_).=?\ ^O8_S%>A5Y[\6/\ DG.O_P#7L?YB@#SS]FK_ )$6^_["4O\
MZ)AKZ%KYZ_9J_P"1%OO^PE+_ .B8:^A: "BBB@ HHHH **** "BBB@ HHHH
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M_P!!JY_[]I1_PS)H7_0:N?\ OVE 'M__  GW@7_H8]-_\#(?_BZ/^$^\"_\
M0QZ;_P"!D/\ \77B'_#,FA?]!JY_[]I1_P ,R:%_T&KG_OVE 'M__"?>!?\
MH8]-_P# R'_XNC_A/O O_0QZ;_X&0_\ Q=>(?\,R:%_T&KG_ +]I1_PS)H7_
M $&KG_OVE 'M_P#PGW@7_H8]-_\  R'_ .+H_P"$^\"_]#'IO_@9#_\ %UXA
M_P ,R:%_T&KG_OVE'_#,FA?]!JY_[]I0![?_ ,)]X%_Z&/3?_ R'_P"+H_X3
M[P+_ -#'IO\ X&0__%UXA_PS)H7_ $&KG_OVE'_#,FA?]!JY_P"_:4 >W_\
M"?>!?^ACTW_P,A_^+H_X3[P+_P!#'IO_ (&0_P#Q=>(?\,R:%_T&KG_OVE'_
M  S)H7_0:N?^_:4 >W_\)]X%_P"ACTW_ ,#(?_BZ/^$^\"_]#'IO_@9#_P#%
MUXA_PS)H7_0:N?\ OVE'_#,FA?\ 0:N?^_:4 >W_ /"?>!?^ACTW_P #(?\
MXNC_ (3[P+_T,>F_^!D/_P 77B'_  S)H7_0:N?^_:4?\,R:%_T&KG_OVE '
MM_\ PGW@7_H8]-_\#(?_ (NC_A/O O\ T,>F_P#@9#_\77B'_#,FA?\ 0:N?
M^_:4?\,R:%_T&KG_ +]I0![?_P )]X%_Z&/3?_ R'_XNC_A/O O_ $,>F_\
M@9#_ /%UXA_PS)H7_0:N?^_:4?\ #,FA?]!JY_[]I0![?_PGW@7_ *&/3?\
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M#_\ %T?\)]X%_P"ACTW_ ,#(?_BZ\0_X9DT+_H-7/_?M*/\ AF30O^@U<_\
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MGW@7_H8]-_\  R'_ .+KQ#_AF30O^@U<_P#?M*/^&9-"_P"@U<_]^TH ]O\
M^$^\"_\ 0QZ;_P"!D/\ \71_PGW@7_H8]-_\#(?_ (NO$/\ AF30O^@U<_\
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M+KQ#_AF30O\ H-7/_?M*/^&9-"_Z#5S_ -^TH ]O_P"$^\"_]#'IO_@9#_\
M%T?\)]X%_P"ACTW_ ,#(?_BZ\0_X9DT+_H-7/_?M*/\ AF30O^@U<_\ ?M*
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M71_PGW@7_H8]-_\  R'_ .+KQ#_AF30O^@U<_P#?M*/^&9-"_P"@U<_]^TH
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M#_\ %T?\)]X%_P"ACTW_ ,#(?_BZ\0_X9DT+_H-7/_?M*/\ AF30O^@U<_\
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MGW@7_H8]-_\  R'_ .+KQ#_AF30O^@U<_P#?M*/^&9-"_P"@U<_]^TH ]O\
M^$^\"_\ 0QZ;_P"!D/\ \71_PGW@7_H8]-_\#(?_ (NO$/\ AF30O^@U<_\
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M !=>(?\ #,FA?]!JY_[]I1_PS)H7_0:N?^_:4 >W_P#"?>!?^ACTW_P,A_\
MBZ/^$^\"_P#0QZ;_ .!D/_Q=>(?\,R:%_P!!JY_[]I1_PS)H7_0:N?\ OVE
M'M__  GW@7_H8]-_\#(?_BZ/^$^\"_\ 0QZ;_P"!D/\ \77B'_#,FA?]!JY_
M[]I1_P ,R:%_T&KG_OVE 'M__"?>!?\ H8]-_P# R'_XNC_A/O O_0QZ;_X&
M0_\ Q=>(?\,R:%_T&KG_ +]I1_PS)H7_ $&KG_OVE 'M_P#PGW@7_H8]-_\
M R'_ .+H_P"$^\"_]#'IO_@9#_\ %UXA_P ,R:%_T&KG_OVE'_#,FA?]!JY_
M[]I0![?_ ,)]X%_Z&/3?_ R'_P"+H_X3[P+_ -#'IO\ X&0__%UXA_PS)H7_
M $&KG_OVE'_#,FA?]!JY_P"_:4 >W_\ "?>!?^ACTW_P,A_^+H_X3[P+_P!#
M'IO_ (&0_P#Q=>(?\,R:%_T&KG_OVE'_  S)H7_0:N?^_:4 >W_\)]X%_P"A
MCTW_ ,#(?_BZ/^$^\"_]#'IO_@9#_P#%UXA_PS)H7_0:N?\ OVE'_#,FA?\
M0:N?^_:4 >W_ /"?>!?^ACTW_P #(?\ XNC_ (3[P+_T,>F_^!D/_P 77B'_
M  S)H7_0:N?^_:4?\,R:%_T&KG_OVE 'M_\ PGW@7_H8]-_\#(?_ (NC_A/O
M O\ T,>F_P#@9#_\77B'_#,FA?\ 0:N?^_:4?\,R:%_T&KG_ +]I0![?_P )
M]X%_Z&/3?_ R'_XNC_A/O O_ $,>F_\ @9#_ /%UXA_PS)H7_0:N?^_:4?\
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MD/\ \77B'_#,FA?]!JY_[]I1_P ,R:%_T&KG_OVE 'M__"?>!?\ H8]-_P#
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MX3[P+_T,>F_^!D/_ ,77B'_#,FA?]!JY_P"_:4?\,R:%_P!!JY_[]I0![?\
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M !=>(?\ #,FA?]!JY_[]I1_PS)H7_0:N?^_:4 >W_P#"?>!?^ACTW_P,A_\
MBZ/^$^\"_P#0QZ;_ .!D/_Q=>(?\,R:%_P!!JY_[]I1_PS)H7_0:N?\ OVE
M'M__  GW@7_H8]-_\#(?_BZ/^$^\"_\ 0QZ;_P"!D/\ \77B'_#,FA?]!JY_
M[]I1_P ,R:%_T&KG_OVE 'M__"?>!?\ H8]-_P# R'_XNC_A/O O_0QZ;_X&
M0_\ Q=>(?\,R:%_T&KG_ +]I1_PS)H7_ $&KG_OVE 'M_P#PGW@7_H8]-_\
M R'_ .+H_P"$^\"_]#'IO_@9#_\ %UXA_P ,R:%_T&KG_OVE'_#,FA?]!JY_
M[]I0![?_ ,)]X%_Z&/3?_ R'_P"+H_X3[P+_ -#'IO\ X&0__%UXA_PS)H7_
M $&KG_OVE'_#,FA?]!JY_P"_:4 >W_\ "?>!?^ACTW_P,A_^+H_X3[P+_P!#
M'IO_ (&0_P#Q=>(?\,R:%_T&KG_OVE'_  S)H7_0:N?^_:4 >W_\)]X%_P"A
MCTW_ ,#(?_BZ/^$^\"_]#'IO_@9#_P#%UXA_PS)H7_0:N?\ OVE'_#,FA?\
M0:N?^_:4 >W_ /"?>!?^ACTW_P #(?\ XNC_ (3[P+_T,>F_^!D/_P 77B'_
M  S)H7_0:N?^_:4?\,R:%_T&KG_OVE 'M_\ PGW@7_H8]-_\#(?_ (NC_A/O
M O\ T,>F_P#@9#_\77B'_#,FA?\ 0:N?^_:4?\,R:%_T&KG_ +]I0![?_P )
M]X%_Z&/3?_ R'_XNC_A/O O_ $,>F_\ @9#_ /%UXA_PS)H7_0:N?^_:4?\
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MD/\ \77B'_#,FA?]!JY_[]I1_P ,R:%_T&KG_OVE 'M__"?>!?\ H8]-_P#
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MX3[P+_T,>F_^!D/_ ,77B'_#,FA?]!JY_P"_:4?\,R:%_P!!JY_[]I0![?\
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MK*C(H#%G"\D?6O3?V<_^2?R?]?LW_H*4 ?_4_?RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#B/B7_P D_P#$/_7E/_Z":\F_9G_Y%/5/^OT_^BDKUGXE_P#)
M/_$/_7E/_P"@FO)OV9_^13U3_K]/_HI* /I"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
M+/BK_P ERTO_ *Z:?_Z&*^TZ^+/BK_R7+2_^NFG_ /H8H ^TZ*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KSWXL?\DYU_\ Z]C_ #%>A5Y[\6/^2<Z__P!>Q_F* ///V:O^
M1%OO^PE+_P"B8:^A:^>OV:O^1%OO^PE+_P"B8:^A: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^+/'O\ R<-IO_7[I?\ ..OM.OBSQ[_R<-IO_7[I?\XZ^TZ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \Q^,O_),]=_ZYQ_\ HU*Y/]G/_DG\G_7[-_Z"E=9\9?\
MDF>N_P#7./\ ]&I7)_LY_P#)/Y/^OV;_ -!2@#__U?W\HHHH **** "BBB@
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M>L7WAWP!XF\0:6P2\TS3+VZ@9@& EA@=T)!X(# <&OPC_P"'@O[37_0;L_\
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MR;PXS;'457HT[1>SDTK^BW^=K'R>9\;9=A*CHU*EY+=)7M^A^XM%?EE\(O\
M@I9H>NZI;Z)\7M!305N&V_VE8N\MLC$\>; ^9$7U97?_ '0,FOU'M[BWO+>*
M[M)5G@G57CD1@R.C#*LK#@@CD$=:\//N&<;EE14\93Y;[/=/T:T_4]7*,]PN
M.@YX:=[;]UZHFHKRGXQ?&;P/\#O",GC#QQ=-'"6\JWMX@'N+J8C(CB0D9.!D
MDD*HY)%?E3XH_P""GGQ+NKZ0^#?">DZ=99P@OC/=S8'<M') O/IM./4]:[^'
MN!\RS.#J86G[JZMV7R[_ "./.>*\#@)*&(G[W9:O_@?,_:RBOR#^&W_!3K49
M-4ALOBSX6MTL9F"O>:0TBM"#_$;>9Y"X]<2 @= 3Q7ZQ>'/$6B>+M"L?$WAN
M\CU#2]2B6>WGB.4DC<9!'<'L0<$'((!&*YN(.$L?E<DL93LGLUJG\UU\GJ=&
M3<183'IO#3NUNMFOD;5%<EXZ\=>%OAMX6O\ QGXSOTT[2M.3?+*_))/"HBCE
MG8\*HY)X%?E'X\_X*?:\]_+!\,O"%K#9(Q$<^KN\LDB^IA@>,(?;S'^M7P_P
M?F&:7>$IWBMVVDOO?7R5R<YXEP> LL3.S>RW?]>I^Q-%?B3H'_!3OXL6MVC>
M)O"NBZC:@_,EK]HM)2/9WEG4?]\&OTV^ 7[2'P__ &A-#FU#PH\EGJ=CM^V:
M=<[1<0;NCC:2'C)X#CZ$*>*Z\^X"S/+:?ML33]SNFFEZ]5\U8YLHXOP&.G[*
MA/WNS5G\NY] 4445\:?3!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '$?$
MO_DG_B'_ *\I_P#T$UY-^S/_ ,BGJG_7Z?\ T4E>L_$O_DG_ (A_Z\I__037
MPI\/_P!H"3X965]HB:&-1$UP9?,-SY6/E"XQY;^GK7J95DN)QLW##1YFE=ZI
M?FT>'GO$F"RRG&KC9\J;LM&]?DF?I%17PY_PV1-_T*:_^!Q_^,4?\-D3?]"F
MO_@<?_C%>[_J#FW_ #Y_\FC_ )GR_P#Q%;(/^@C_ ,DG_P#(GW'17PY_PV1-
M_P!"FO\ X''_ .,4?\-D3?\ 0IK_ .!Q_P#C%'^H.;?\^?\ R:/^8?\ $5L@
M_P"@C_R2?_R)]QT5\.?\-D3?]"FO_@<?_C%'_#9$W_0IK_X''_XQ1_J#FW_/
MG_R:/^8?\16R#_H(_P#))_\ R)]QT5\.?\-D3?\ 0IK_ .!Q_P#C%'_#9$W_
M $*:_P#@<?\ XQ1_J#FW_/G_ ,FC_F'_ !%;(/\ H(_\DG_\B?<=%?#G_#9$
MW_0IK_X''_XQ1_PV1-_T*:_^!Q_^,4?Z@YM_SY_\FC_F'_$5L@_Z"/\ R2?_
M ,B?<=%?#G_#9$W_ $*:_P#@<?\ XQ1_PV1-_P!"FO\ X''_ .,4?Z@YM_SY
M_P#)H_YA_P 16R#_ *"/_))__(GW'17PY_PV1-_T*:_^!Q_^,4?\-D3?]"FO
M_@<?_C%'^H.;?\^?_)H_YA_Q%;(/^@C_ ,DG_P#(GW'17PY_PV1-_P!"FO\
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M_)H_YA_Q%;(/^@C_ ,DG_P#(GW'17PY_PV1-_P!"FO\ X''_ .,4?\-D3?\
M0IK_ .!Q_P#C%'^H.;?\^?\ R:/^8?\ $5L@_P"@C_R2?_R)]QT5\.?\-D3?
M]"FO_@<?_C%'_#9$W_0IK_X''_XQ1_J#FW_/G_R:/^8?\16R#_H(_P#))_\
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MW_0IK_X''_XQ1_J#FW_/G_R:/^8?\16R#_H(_P#))_\ R)]QT5\.?\-D3?\
M0IK_ .!Q_P#C%'_#9$W_ $*:_P#@<?\ XQ1_J#FW_/G_ ,FC_F'_ !%;(/\
MH(_\DG_\B?<=%?#G_#9$W_0IK_X''_XQ1_PV1-_T*:_^!Q_^,4?Z@YM_SY_\
MFC_F'_$5L@_Z"/\ R2?_ ,B?<=%?#G_#9$W_ $*:_P#@<?\ XQ1_PV1-_P!"
MFO\ X''_ .,4?Z@YM_SY_P#)H_YA_P 16R#_ *"/_))__(GW'17PY_PV1-_T
M*:_^!Q_^,4?\-D3?]"FO_@<?_C%'^H.;?\^?_)H_YA_Q%;(/^@C_ ,DG_P#(
MGW'17PY_PV1-_P!"FO\ X''_ .,4?\-D3?\ 0IK_ .!Q_P#C%'^H.;?\^?\
MR:/^8?\ $5L@_P"@C_R2?_R)]QU\6?%7_DN6E_\ 733_ /T,5G_\-D3?]"FO
M_@<?_C%>,>*OC2_B;QQ:^,SI MC;-;MY'G[]WD-N^_L&,_3BC_4'-O\ GS_Y
M-'_,/^(KY!_T$?\ DL__ )$_4JBOAS_ALB;_ *%-?_ X_P#QBC_ALB;_ *%-
M?_ X_P#QBC_4'-O^?/\ Y-'_ ##_ (BMD'_01_Y)/_Y$^XZ*^'/^&R)O^A37
M_P #C_\ &*/^&R)O^A37_P #C_\ &*/]0<V_Y\_^31_S#_B*V0?]!'_DD_\
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MZ*^'/^&R)O\ H4U_\#C_ /&*/^&R)O\ H4U_\#C_ /&*/]0<V_Y\_P#DT?\
M,/\ B*V0?]!'_DD__D3[CHKX<_X;(F_Z%-?_  ./_P 8H_X;(F_Z%-?_  ./
M_P 8H_U!S;_GS_Y-'_,/^(K9!_T$?^23_P#D3[CHKX<_X;(F_P"A37_P./\
M\8H_X;(F_P"A37_P./\ \8H_U!S;_GS_ .31_P P_P"(K9!_T$?^23_^1/N.
MBOAS_ALB;_H4U_\  X__ !BC_ALB;_H4U_\  X__ !BC_4'-O^?/_DT?\P_X
MBMD'_01_Y)/_ .1/N.BOAS_ALB;_ *%-?_ X_P#QBC_ALB;_ *%-?_ X_P#Q
MBC_4'-O^?/\ Y-'_ ##_ (BMD'_01_Y)/_Y$^XZ*^'/^&R)O^A37_P #C_\
M&*/^&R)O^A37_P #C_\ &*/]0<V_Y\_^31_S#_B*V0?]!'_DD_\ Y$^XZ*^'
M/^&R)O\ H4U_\#C_ /&*/^&R)O\ H4U_\#C_ /&*/]0<V_Y\_P#DT?\ ,/\
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M^A37_P #C_\ &*/]0<V_Y\_^31_S#_B*V0?]!'_DD_\ Y$^XZ*^'/^&R)O\
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M .1/N.BOAS_ALB;_ *%-?_ X_P#QBC_ALB;_ *%-?_ X_P#QBC_4'-O^?/\
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M./\ \8H_U!S;_GS_ .31_P P_P"(K9!_T$?^23_^1/N.BOAS_ALB;_H4U_\
M X__ !BC_ALB;_H4U_\  X__ !BC_4'-O^?/_DT?\P_XBMD'_01_Y)/_ .1/
MN.BOAS_ALB;_ *%-?_ X_P#QBC_ALB;_ *%-?_ X_P#QBC_4'-O^?/\ Y-'_
M ##_ (BMD'_01_Y)/_Y$^XZ*^'/^&R)O^A37_P #C_\ &*/^&R)O^A37_P #
MC_\ &*/]0<V_Y\_^31_S#_B*V0?]!'_DD_\ Y$^XZ\]^+'_).=?_ .O8_P Q
M7R]_PV1-_P!"FO\ X''_ .,5S_BO]JJ7Q/X=O_#Y\,K;"^C,?F?;"^W)SG;Y
M(S^='^H.;?\ /G_R:/\ F'_$5\@_Z"/_ "2?_P B>_?LU?\ (BWW_82E_P#1
M,-?0M?/'[-#;O =ZWKJ,A_\ (,-?0]?'M6=F?H<9)JZ"BBBD,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /BSQ[_ ,G#:;_U^Z7_ #CK[3KXL\>_\G#:;_U^Z7_..OM.@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY;7R[B6 ()Q<&3/E,N[.Q>O3''4US'_!1+_DY&\_[!EC_P"@M7TG_P $LO\
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M?0ZJJDXODWZ'\I6O:YK7C#Q%?>(-9F>]U35[AYYG.6:2:9MQ]3R3P/PK]?/
MO_!,OP1+X.M9OB#XBU1/$ES"KS+8M EM;R,,^6%DBD:39T+;EW8) %?55G^Q
M;^S'87<%]:>!X4GMW62-OM=X<.ARIP9R#@CH1BOH;Q+XDT/P?H%_XG\2WD>G
MZ7ID337$\IPJ(O7ZD] !R20 "2*_9^*O%:IB8TJ&3<U.V^BN]E%*S>F^GH?F
M'#_A["@ZE7,^6=]M79;W;ND?R^?%OX<ZE\)/B1K_ ,.=5F6YGT2X\H3*-HEB
M=1)%)MR=N^-E;;DXSC)ZU^W7_!/3QIJ/BW]GBWL-3E,S^&M0N-,B9N6\A4CG
MC!/HHFV+Z*H':OQ5^-_Q';XN?%CQ-\1/*,$6L71>"-OO);Q*L4"M@D;A$B[L
M<9SBOV\_8%\ :EX$_9XT^?5HF@N?$UW-JXC8898IECBA)]GCB60>S"OK_%2;
M_L"C];M[5N'_ (%9\UOQ/F_#Z*_MBK]6_AVE]U]/T/R\_;M^*=Y\1/CUJVC1
MSE])\'DZ7:Q@_*)8\?:G(_O&;*D]U1?2NW_8\_8WT?X\Z'J7CKQ[?W=CH5M.
M;.UBLF1)KB9%#2.7D20"--P PN6;/(V\_$OCO4YM:\<>(M8N&WRW^HW<[MZM
M+,SD_B37]!?[$6DP:3^S#X*2%-K74=U<R'NS2W4K9/\ P' ^@%=7&N/JY)D%
M"C@GRR]V-UZ-M^K:_$Y^%L'3S7.*M7%+F6LK?-)+T5_P/QA_:H_9[F_9W^(B
M>';2[DU'1-3@%WI]Q* )3'N*/'+M 4O&PY( !!4X&2!]P?\ !,GXJ7EPOB3X
M.ZE.9(;9!JVGJW\"EQ%<H">Q9HV"CN7/<UJ?\%1M)@D\.^ =<V?OH+J^MMW^
MS-'$^#^,?'XU\C?\$_M3FL/VG?#]K&VU=2M=0MW']Y5MGFQ^<8/X5E5Q$LXX
M1E7Q.LU%N_G!O7YI:^K-*=&.6\1QI4-(N25O*26GR;_ ^M?^"HWB+4K;1/ /
MA2&1TL;^>_O)E'"O):K"D6?4J)G_ #KY&_8I_9Z\,_'SQYJD?C664Z)X>MHY
MY;>%_+>YDF8K&A<?,J#:Q8KST (SFOU$_;=^ &J?''X:VMUX6"OXB\+2RW5K
M$[!!/#(@$\(8X4.VQ&4DXRN"1G(_%CX+?&KQS^SOXZD\2>&4C:;:]I?65RI,
M4\8;F-\$,K*R@JRD$$=P2#S<"UYXGAF6$RV:C7CS+L[N3:?SCHGT?H;\6484
M,]CB,=&]&5O2R5OP>K7;U/T'_;+_ &.?A)\/?A/=_$WX:6DF@W&AR6RW%L;B
M6XAN8KB98.//=W616=3D-@@-E<G(^1_V%_$>I>'_ -IGPI%8R.L.K?:K*YC7
MI)#);NX#>RR(C_\  :M_M$?MG^/?C_H4'A&?3;?P_H*2+/+;P.TTEQ*GW/,E
M8#Y5.2JJHYY.<#'T9_P3P_9WUJX\2P_'OQ)$+?2[".>+24+#?//*IBDF*CI&
MD;.HSRS-D<+D]M\5E_#5>&>5.:<E)*[YGJK15^KO=[NR]#EMA\;GE&650M%.
M+=E9:.[=NBMITN_4_9*BBBOY;/WX**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH XCXE_P#)/_$/_7E/_P"@FOR)U/\ Y"%Q_OFOUV^)?_)/_$/_ %Y3_P#H
M)K\B=3_Y"%Q_OFOU#PL_WJK_ (?U1^(>.?\ N%#_ !_^VLH4445^X'\Q!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?IG^S+_R(%Y_V
M$)/_ $3#7T37SM^S+_R(%Y_V$)/_ $3#7T37\AUOC?J?Z#X?^''T04445F:A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!\6>/?\ DX;3?^OW2_YQU]IU\6>/?^3AM-_Z_=+_ )QU
M]IT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNB,H]SM'I7[:^(O^1?U/_KUF_P#0#7\K?@GQ7J7@3QAHOC/1VQ>Z)>07D7.
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M^)?_ "3_ ,0_]>4__H)K\B=3_P"0A<?[YK]0\+/]ZJ_X?U1^(>.?^X4/\?\
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MJ5H\SC>^MUU]'^1^NXCPQA'(EFT:UY<JG:VEGTOW7YZ'YZT445^AGY$%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /TS_9E_Y$"\_P"PA)_Z)AKZ)KYV_9E_Y$"\_P"PA)_Z)AKZ)K^0
MZWQOU/\ 0?#_ ,./H@HHHK,U"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XL\>_\G#:;_P!?NE_S
MCK[3KXL\>_\ )PVF_P#7[I?\XZ^TZ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \Q^,O\
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MTE=+TZK[SISOA# X^?M*\?>[IV?S[GXL_#?_ ()G>/+_ %2&X^*>NV>E:4C
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M3E^#J*K3A>2V;=[>G3\ HHHKX0^M"BBB@ HHHH **** "BBB@ HHHH ****
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M.R!?5\'E--\\:D;S:^)+1ZMW=W9[)=C]=*_$>**6XF2"!&DDD8*JJ"69B<
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M*GQ;\(Z9X%^(.J^%='>62SLO(V-,P:0^; DAR5"CJQQP.*_3;X4_\DR\*_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?IG^S+_
M ,B!>?\ 80D_]$PU]$U\[?LR_P#(@7G_ &$)/_1,-?1-?R'6^-^I_H/A_P"'
M'T04445F:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\6>/?^3AM-_Z_=+_G'7VG7Q9X]_Y.&TW_
M *_=+_G'7VG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'F/QE_P"29Z[_ -<X_P#T:E<G
M^SG_ ,D_D_Z_9O\ T%*ZSXR_\DSUW_KG'_Z-2N3_ &<_^2?R?]?LW_H*4 ?_
MT?W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH XCXE_\ )/\ Q#_UY3_^@FOR
M)U/_ )"%Q_OFOUV^)?\ R3_Q#_UY3_\ H)K\B=3_ .0A<?[YK]0\+/\ >JO^
M']4?B'CG_N%#_'_[:RA1117[@?S$%%%% !7OW[,O_)7]+_ZXW7_HEJ\!KW[]
MF7_DK^E_]<;K_P!$M7B<2_\ (OQ'^"7Y,^FX+_Y&^$_Z^1_]*1^C_BO5;C0O
M"VL:W:*KSZ?9W%Q&K@E"\4;.H8 @XR.<$?6O@D_M=?$?_H&Z3_WYG_\ C]?<
M?Q%_Y)]XG_[!=[_Z(>OQUK\Q\.\EPF*HU98BFI--6OZ'[=XO\2X_ 8BA'!U7
M!-.]O4]W\1?M(?%3Q#;M:#4(],AD!#"RC\IB#_ML6=?^ L*\*=WD=I)&+.Q)
M))R23U)--HK]<P66X?#1Y</!17DK'\_9GG.+QDE/%U93:[MNWIV/N[]G+X,>
M&[OPW;^/?$]HFH75X[M:Q3#,44<;%-Q0\,S$$C<" ,8YYKVOXF?&CPE\*OL^
MG7\4EW?SQAX[6W &V/) 9F) 5200,9/'3'-8G[-GB;3]=^&&GZ;!*#>:.7MY
MX\C<N79HVQUPRD8/J".U5/BW^S[9?$_7(?$,.KMI5VD(AD!A\]'5"2I WH5/
M.#R01V]?PK'8BE6SBI'-IM0BWWT71:=&NVY_4F682OAN':,\@IQ=648MO35O
MXG=V3:?1O3;I8S?AK^T='\1O&5OX4BT V*3QRN)VNO,(\M2V-@B7KC'WJ]%^
M./\ R2;Q-_UZ_P#LRUE_#/X0>#?A04,4XO-9OR8A<S[4D?"EVCA3/RC:I8@$
MD@<D@#&I\<?^23>)O^O7_P!F6N"O/!2S2C]0BU3YH[WU?-OKK_PQZF%IYE'(
M\1_:LU*JXSVMHN71:)*_7Y[L_,GX>_\ (_>&O^PG9_\ HY*_8ROQS^'O_(_>
M&O\ L)V?_HY*_8ROI_%3^/1]'^9\3X%?[MB?\2_)GXB'K77_  ]_Y'[PU_V$
M[/\ ]')7('K77_#W_D?O#7_83L__ $<E?L&._@3]'^1_/.6?[U2_Q+\S]C*\
MS^%7Q)TWXF^%XM8MML-[!B.\MP>8I<=N^QNJGTXZ@UZ97Y$?#'XBZI\-/%,.
MNV.9;9_W=U;YP)H2>1_O#JI['V)!_GKAKAO^T<-B.3^)'E<?_)KKYV^\_KGC
M/C+^R,9A/:?PI\ZEY6Y;/Y7?R;ZV/>?VG?A1=Z9JLOQ'TG?/8W[*+U22Q@EP
M%5LG)\ML >BGCH0!\@U^S5A?>'_'7AJ.\MBFH:1J\!X895XW&&5AV(Y!'4'(
MZU^8WQF^%=[\,?$K6\0:71[XL]E,>?E[QN?[Z9_$8/<@?HG ?$SJQ_L_$Z5(
M:*_5+IZK\O1GY#XJ\$JA/^UL%K2J:RMT;Z^DOP?JC]'/A3_R3+PK_P!@RT_]
M%+7YY?M'_P#)9O$/_;I_Z2Q5^AOPI_Y)EX5_[!EI_P"BEK\\OVC_ /DLWB'_
M +=/_26*O X"_P"1SB/27_I:/J_%7_DG<)_BA_Z1(^U?V:_^2.Z+_OW7_I1)
M7S#^UU_R4C3?^P3#_P"CYZ^GOV:_^2.Z+_OW7_I1)7S#^UU_R4C3?^P3#_Z/
MGHX<_P"2CK>L_P PXQ_Y([#?X:7Y(\S^!'_)7/#7_7PW_HMJ_3/X@?\ (A>)
M/^P9>?\ HEZ_,SX$?\E<\-?]?#?^BVK],_B!_P B%XD_[!EY_P"B7I^(G_(S
MP_HO_2F+P@_Y$F+_ ,4O_2$?CK%YHD5H-WF*<J5SD$<Y&*^O/ _[5'B+1+.'
M3_&^EMJL4("_:XSY<^T< N&&UV]\KGOD\UX7\'O%EGX*^(VC>(-1;;9Q2/%.
MW]V.9&C+''.%W;OPK]2O$F@Z/X[\+7>A7LGFZ?JL('F1,#P<,CHW(." PZC\
M*^@XYS7#TJE.AC,/SP>O->S6NMM.BL]]3Y+POR+%UJ-;%9=C/9U8Z.'*FI:7
MC>[V;NKV=M;' ^%/CY\,/%TT5G9ZK]BO)B L%XIA8L> H8YC))X #DFNX\8^
M"?#GCO2)=&\1VBW$3@['P/-A8_QQOC*L/R/0@CBODR']CLC4E-QXFW6 ;)"V
MV)BOH"7*@^_/KCM7V+K.LZ1X4T2;5]9N1:V-C'EY'.>!P!ZLQZ #DG@<U^9Y
MQ0P5&M3EE-64F_6Z?2SLMS]JX=Q.98C#5H9_0C"*\TU):WNKM*W>_P M#\A-
M3TMO"7C&YT>](E.D7S0N<8#B"3:2!Z$#-?LH"" 0<@U^,OB[7/\ A)O%.K^(
M0AC&I7<UPJGJJR.6"_@#BOT8^ 'Q4TWQMX5M-!O9UCUW28EADB=OGFCC "S+
MGELC&_T;KP17W?B/EU>KA:&):UC\7E>VOI='Y7X.9QA:..Q6#4K*;3A?KRMZ
M>MG?Y,_/[XF6D]E\1/$UM<Y,BZE=G)ZL&E9@WX@@UZ/^S):7%S\7M-FASLM8
M;J23'388FC&?;<X_&OLGXD_ #P?\1]5&O7,LVFZBP599;?:1*%& 75@<L!@
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MS7I?Q?\ 'NF^ ?!5_?7,RB^NHGALX<_/),XV@@=<)G<Q[#W(SMB991/$PP^
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M (3)Q]C*VZC[O>]U=ZZZ7[&G_P -':N>1\/=7_[Y;_XW7P-XLU,ZUXIUG6#
MUK]OO;B?R6^]'YLC/L/3E<X-?KIXQ\7:-X'\/W?B+6YEB@ME)520&EDP=L:#
MNS'@?F> :_'G4[^;5=2N]4N?]=>323/_ +TC%C^IK[;P[=&HZM:C0Y%HK\S=
M_+7M^I^:>+ZQ%)4,/B,5[66KMRQC;I?3O^A1HHHK]//Q **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^U/PC\>ZC\3_ (>:-X\U/PW>^$Y-9B\]-/U H;F.)B?+9PA(7S$PX4X8 X8
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q'Q+_Y)_XA_P"O*?\
M]!-?D3J?_(0N/]\U^NWQ+_Y)_P"(?^O*?_T$U^1.I_\ (0N/]\U^H>%G^]5?
M\/ZH_$/'/_<*'^/_ -M90HHHK]P/YB"BBB@ K?\ #/B?7?!VL0Z_X<NOL=_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'Z9_LR_\B!>?]A"3_P!$PU]$U\[?
MLR_\B!>?]A"3_P!$PU]$U_(=;XWZG^@^'_AQ]$%%%%9FH4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?%GCW_ ).&TW_K]TO^<=?:=?%GCW_DX;3?^OW2_P"<=?:= !1110 4444
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M(YKG;<ZE./>*!55AZQ&OZ#M,TVPT;3;31]+@6VLK&&."")!A8XHE"HJCT50
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ML13IXJJZDDO=ZNW5'XOXUX6K5P-!4H.3Y^B;Z/L<517>?\*N^)?_ $*FJ_\
M@%-_\11_PJ[XE_\ 0J:K_P" 4W_Q%?M']I8?_GY'[T?S;_8V,_Y\R_\  7_D
M<'17>?\ "KOB7_T*FJ_^ 4W_ ,11_P *N^)?_0J:K_X!3?\ Q%']I8?_ )^1
M^]!_8V,_Y\R_\!?^1P=%=Y_PJ[XE_P#0J:K_ . 4W_Q%'_"KOB7_ -"IJO\
MX!3?_$4?VEA_^?D?O0?V-C/^?,O_  %_Y'!T5WG_  J[XE_]"IJO_@%-_P#$
M4?\ "KOB7_T*FJ_^ 4W_ ,11_:6'_P"?D?O0?V-C/^?,O_ 7_D<'17>?\*N^
M)?\ T*FJ_P#@%-_\11_PJ[XE_P#0J:K_ . 4W_Q%']I8?_GY'[T']C8S_GS+
M_P !?^1P=%=Y_P *N^)?_0J:K_X!3?\ Q%'_  J[XE_]"IJO_@%-_P#$4?VE
MA_\ GY'[T']C8S_GS+_P%_Y'!T5WG_"KOB7_ -"IJO\ X!3?_$4?\*N^)?\
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M^]!_8V,_Y\R_\!?^1P=%=Y_PJ[XE_P#0J:K_ . 4W_Q%'_"KOB7_ -"IJO\
MX!3?_$4?VEA_^?D?O0?V-C/^?,O_  %_Y'!T5WG_  J[XE_]"IJO_@%-_P#$
M4?\ "KOB7_T*FJ_^ 4W_ ,11_:6'_P"?D?O0?V-C/^?,O_ 7_D<'17>?\*N^
M)?\ T*FJ_P#@%-_\11_PJ[XE_P#0J:K_ . 4W_Q%']I8?_GY'[T']C8S_GS+
M_P !?^1P=%=Y_P *N^)?_0J:K_X!3?\ Q%'_  J[XE_]"IJO_@%-_P#$4?VE
MA_\ GY'[T']C8S_GS+_P%_Y'!T5WG_"KOB7_ -"IJO\ X!3?_$4?\*N^)?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB@ HHHH **** /.?B_\/[7XK?"SQ9\-KQA''XDTRZL1(?\ EF\\;+')_P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!\6>/?^3AM-_Z_=+_ )QU]IU\6>/?^3AM-_Z_=+_G
M'7VG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'F/QE_Y)GKO_ %SC_P#1J5R?[.?_ "3^
M3_K]F_\ 04KK/C+_ ,DSUW_KG'_Z-2N3_9S_ .2?R?\ 7[-_Z"E '__5_?RB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#B/B7_P D_P#$/_7E/_Z":\F_9G_Y
M%/5/^OT_^BDKUGXE_P#)/_$/_7E/_P"@FO)OV9_^13U3_K]/_HI* /I"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *^+/BK_P ERTO_ *Z:?_Z&*^TZ^+/BK_R7+2_^NFG_
M /H8H ^TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KSWXL?\DYU_\ Z]C_ #%>A5Y[\6/^
M2<Z__P!>Q_F* ///V:O^1%OO^PE+_P"B8:^A:^>OV:O^1%OO^PE+_P"B8:^A
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ^+/'O\ R<-IO_7[I?\ ..OM.OBSQ[_R<-IO
M_7[I?\XZ^TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \Q^,O_),]=_ZYQ_\ HU*Y/]G/
M_DG\G_7[-_Z"E=9\9?\ DF>N_P#7./\ ]&I7)_LY_P#)/Y/^OV;_ -!2@#__
MUOW\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH Q?$>C+XAT&_T)Y3 M_"\)D
MW%0XQG&1G\ZY7X<?#^+X=Z7=:9#>M?+<S>=N9!&0=H7& S>E>B44 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5XYXI^$-MXF\:VOC-M3>WDMF@;R1$&#&!MP^;<,9^E>Q
MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5@^*-"C\3^'[_0)9C M]&8S(!N*Y[XXS^=
M;U% ' ?#GP)%\/=$GT6&\:]6:X:XWL@0@LB)C +?W,Y]Z[^BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /'-=^$-MK?C^V\>-J;PR6\UM-Y B# FV*D#=N&-VWTXKV.B
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .;\7^'(_%OAN^\.RSFV6]55,@7<5VL&Z9&>
MGK65\/O!,7@'06T*&[:\5IGF\QD"'+@#& 3Z>M=S10!__]?]_**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH __0_?RBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /_T?W\HHHH **** (IIX+9/-N)%B3*KN8A1EB%49/<D@#U/%?-W[1G
M[57PV_9AC\*/\0;;4;QO&%^VGV<>FPQSR"15!+NKRQG8"RK\NYLL/EH_:T^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __2_?RBBB@ HHHH
M \A^/'P9\-_M _"C7_A)XLN;JRT[7H51I[.4Q31/&XDC<=F"NH)1@58<$5\6
M_'+_ ()N?#7Q7^RQ9? #X.6UIX?U30[V#4;'4KW<SSW8Q%<RWDT:-(YFA9N
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M?^V:(1[$5^0?QUUS7/\ @I9^W9I?P>\%7<A^'G@V26V^UPG=&EE;NO\ :.H
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MX-?\6_$NXN)/ 'AR.6Y6VC+1!-+AF\NQL$8',;3%C)*PPS8E(*L01^Y/BO\
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M:_F0_;]_:2O?VY/CAX3^ _[/T,NN:'I-TUM8M&NT:GJ=P=DEPN>EO%&N%=L
M+YDA^0@@ _4+_@D%I%[IO['-E>70(BU76]3N8,C'[M62 X]?GB>OFS_@K?\
MM(ZKJUWHG[&_PO:2]UGQ!-:S:U%;?-*YF=?L.G@#JTKE977@X$79B*_0O5]=
M\$?\$_\ ]CFS_M"1;JV\!Z3%:6\>=AU'5)<X51U'VBY9G; .Q"S'A37X(_LT
M_L3_ !:_X*#7_C;XZ^+?%Z^&UN=48M?SV;79OKV7,LRQ()8MD<"L@') R$4?
M*< '] O[+/[+GA_]G[]F^R^"\JQS7VIVLLFO7"#/VF_O8]EP0>Z(N(H^GR(N
M><U^2G_!%C6KKPU\6/BY\*M0.VYEL;6[>/T?2[F2VDQ^-T ?PK6_X<A^)_\
MHM$7_@FD_P#DVO"OV!?#M[^S?_P4KN_@KJ-^+UU&L^'WNA'Y*W"Q0F[C?86;
M;YAMT(7<<$@9- ']/]>/?'/P5\)_&'P]U"\^,OAVR\2^'_#,4^L-!?1"6.-K
M2"0M( W 81EQGT)KV&OA[_@H]X^_X5[^QG\1[Z*3R[G6+./1X1G!?^TI4MY0
M/^V+R'Z T ?C9_P28_9[^'OQW^(7Q'\6_$_PO8Z]HFBV5M!#9W4(DMH[K4)V
MD#1H> 8TMV4>BOCO7UW_ ,%0OB)X?_9;^ 6@_LY_ G3;?PA!\0)[R6]BTU!
MJ:?"$^T( N"INI)$5F'5$=3P:]/_ ."-W@'_ (1K]EN_\93QXG\8:[=3H^,;
MK:S5+5![XE2;\Z^-/^"SEDB_'[X57^O(1H,^DF*1OF&1%>LUP,KSQ&Z=.>?I
M0![5^QS\/_\ @FY\)OA1H=_\3_%G@?Q5X\U>UBNM4EUFZL[Q;2:9=_V6"&<O
M'&(=VQG"AW8$DXVJOPS^W5>?L^?"3]H+P-\:?V-?$.D&8M]ON;309XGL[*^L
M)8VC98X3MB2=6PT0 0[6P,,17[(VG_!+#]A>_M(;ZQ\'SW%M<HLD4D>LZ@R.
MCC*LK"XP00<@CJ*^+OB)\'?^"7GPV_:'T?\ 9HN/AOXDUWQ?JUQ86P;3+^>>
MTMY]0<+''.TFH1NI12LDF(V"HP/)R  ?<7_!2']I+6/@/^R]-K'@VXDT_P 2
M^-9H=)T^93MFM5N(VEN)QW#)"C(K#E)'5ATK\YO^"?GP[_8'\)_#.S^)/[0_
MBSPEKGCO7FEE.G:Y=VTT6F6X<K'&UK,Q1IG"^8SNI9=P5<88MZ[_ ,%O[*_;
MX=_"V_B3_08-4U"*5NPEE@C:(?BJ2?E7LGP2_P"";?[$'Q(^#O@CQZ?"TVH2
M:_HUA>RSQZM?A7FF@1I?E6<!2)"P*X&T@C QB@#\[O\ @ICHW['OV?PG\4/V
M7-?\/V_B07IM;^Q\,SVZ1^4$:6*[\FV($3QNFTNH&[<,\@&OW:\$?',6?['N
M@_M#^.6W2P^#;;7M0R GFSK8K-*$'_363(0#KN&*_+#]IOX+_P#!+K]E7Q7H
M7@CQS\._$6N:WKT#7,5KHFH7%S)%'O$<9E6;4("#*VX1A=Q.ULXXS]P?MY>&
MK/P5_P $[O&?@[P1:OIVFZ%HVCV%I;NQ=X;*VN[2+RV8EBQ6!2I)8Y/))ZT
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MOI]]XSU2'3_#GAKQ-IFGK-<-B&.31T3$;MT"O>HRDG"C=\Q !- 'ZJ?LV_\
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MBO=5EA7EG:YD2UM<#US',!ZYK]S?A5X*@^&WPP\(_#VV $?AG2;'31MZ'[)
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M/XH?LN:_X?M_$@O3:W]CX9GMTC\H(TL5WY-L0(GC=-I=0-VX9Y -?HC\$O\
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MY?M#?$G6O!-R7\!?!?P[JEU!< %X6MM,1GDE7!"E[RX'R'KY*AL'RR*_4?\
MX)$^*+(?L8S3:E<I;VGAS7-5CFED8*D4:I%=.S,> JB4DD]!S57]CW]E#_A4
M'[!GC&QUZS\KQ;\4/#VHWFI*RXDBAN;*5+.U;N/+B?<RGE9)''85^*_PV_:A
MNOAQ^P_XT_9\\+S./$7Q \2MO$62\>ER6EO'<XQ_%.T20@?Q(TG<4 ?7WP=T
MB]_X*1_\%!-6^+'B"W>?X;^!Y(IXX95/EFPM'9=.M&4]#=2AIY4/!'G#/2OZ
M3J^*_P!@C]FF+]F3]GO1_#&IVXC\5:[C5-<?'S"[G4;;?/I;QA8\9QN#L/O&
MOM2@#\B?^"O'[1^N?"?X.Z1\*/!M\;'5_B(]Q%>21G$J:3;JHG12.4\]Y$3/
M=!(O?(Z3]AC_ ()[_!?X??!KP]XN^*GA"P\5^-_$UG#?WAUBUCO([%;E1)';
M0P3!HT:-"!(^TN7W?-MVJ/AG_@LMNM/VC/A7J.OQE_#JZ0FX $[C'?.UTH[$
M^68^/>OZ*M,U'3]7TVTU;2+B.ZL;V&.>WFB8-')%(H9'1AP592"".HH _GD_
MX*Q?LJ_#7X(Z?X.^/GP7TJ'P9<W6JKIMW;:8/LL N?*>YMKF"*/"PNGD.&\L
M*"=IP&!)_5[0[OX<?M"_L@^#OBC\?O#UCXFL8O#UOXCO8;V!6A2\M[)C<3(C
M<+UEVGLK5^7'_!9CXO6WB_Q7X"_9M\(O_:.JZ?.=2U"WA^=UN[M5@L8,#_EH
M4:1BO7$B'O7W%^UF7_9K_P"":6H>!#<*U_I_AG2_"H=.!-+<+#97)7_>C,K_
M $S0!^7?_!)C]GOX>_'?XA?$?Q;\3_"]CKVB:+96T$-G=0B2VCNM0G:0-&AX
M!C2W91Z*^.]?T?\ @#X;^ _A7X>3PE\.-"M/#NC1R/,MI91"*(22'+MM'=L<
MFOS*_P""-W@'_A&OV6[_ ,93QXG\8:[=3H^,;K:S5+5![XE2;\Z_6J@#\_\
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M^@H _=VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH __3_?RBBB@ HHHH **** "OR(_;[_8(^-G[7/QE
M\,>*_"VO:%IOA+0],AL9(;ZXNH[SS&N9);F2-(K66,[HV0+F09*\X'-?KO10
M!6LK.UTZS@T^RC$-O:QK%$B]%1!M51[ #%?E5_P4)_8:^-'[7WQ!\%:EX-UW
M1-,\,>&K*2&:/49[J.Z\^ZG#3O$D-M,A!BCB"[G4E@0<#!K]7J* *6FZ?9Z3
MIUKI6GQB&ULHDAA0=$CC4*JCV  %?E7_ ,%!_P!ACXT?M??$?P7JO@_7=$TS
MPMX;L7@FCU">ZCNO/N9]UP\20VTT9!B2(+N=26!! &"?UAHH \G^*WP=\*?%
MKX/:[\%=95K70]:TXZ>##C=;A /)DC!XS$ZJR@\$J >*_$?P-_P3_P#^"C?[
M/=QJ_ACX!_%#2[+PYJ<_FLT=Y)"DAV[1,]M-;2B*4J &,98D!1N8*,?T(44
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M?LVZW^RQ\ +'X8^*KJRO=?DO[S4+^;3WDDM7EG<+'L>6.)VQ!'$&R@^8$#(
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M8>(/B5\1H?">M7<:3'3K/3C?M;;@&"RSM<6X\U<X=44J".'8<U^E7[?_ .Q
M?VP_">AS^&]8AT/QAX4:X-C)=*QL[B&Z">9!.8PSI\T:,DBJ^WYAL.[*_&OA
MGP=_P6?^'VE6W@G2-3TK6=.TU%@M[RYGTNY;RD&U?WMPJ3N .\BEO7TH ^/_
M -I[]E_X]_\ !.VR\._$WP%\:+N_L]2U 649M6GTZX6<1M,-]J9YXIH2L9#[
MF(R5#*0U?T5?LY?$;5OB[\!_ 7Q,UZ&.#4_$FCVEY=)$"L8GDC'F% >0I;)
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M^R;H'[(GPI;P19WXUK7-5N#>ZMJ(C,2SSE0B)&A+%8HD&U03DDLYQNVCZ\H
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M;^.K/1;75I;F2.&>XDM+JUCN6\Q[5AY4L-Q &QMW^BY4LN^OWIHH _"K4O\
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MYK6DT@"R*\9*^9%(  Z;E)(4@@J*_+WPO^Q5_P %2?A9I"?#?X;?&#3K?PK
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MXH\1?$VT\7?%C4;]'O[W6+N\%A!8)%(/(@<6\\TKF1D(+)&BJ-JJ.=W] -%
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M+?;_ "+VPG2YMI?+<QOLEC+*VUU*G!X((/(H Z.BBB@ HHHH **** "BBB@
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M:M\._"S]KO6/VG_'.AW7B!K^ZUF]AM[>1(Y4N=59P7+29&%CED7 ]17ZM_\
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MIZ_#;P3_ ,$HOB'\2/%UE\9OVJ_B8^H^*KJ[AOKS3;.W%Q&%C=9!;&Y=U15
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M<UKQA\#=>U^[\5^'[&74+:"[DAO$U$6Z&4PQI;V\3B:11B(H2"V 5.<CZ_\
M^"8_CCX\>*/@1>>'OC]I6L6>K^%]0-G8W6M6T]O=75BT2/&&-PJO*8F++OY.
MW:#R,D U?VW?V._AC^UKJ7A"W\6^/3X.U?PYYZ0QJT,IN8+UH]R^1+(A#[H@
M$=>O((; Q]Q>"O"NG^!?!N@^"-)>22Q\/6%KIT#RD-(T5I$L*%R, L549..M
M?SN>/?\ C(;_ (+&Z9H:?Z3IWA?6K.(*>56/P[;"[G5NV#<12#'^UCJ:^I/^
M"JO[47Q/\'ZWX2_9?^"]W<:9KWC:".XO;FT8QW<D-U.UK:VL$BX*>=(C^85(
M8@*H(5F! /UZO?'?@?3-371-1\0Z=:ZBQVBVENX8YB?01LP;/X5\;?M-?\%%
MOV?OV7_$0\$^)'OO$?B<1I+-I^D11RM:I*NZ,W$LLD4:%EP0@9GP0Q4*P)^2
MO"?_  19^#[>!%A^(7C+6[OQM=P[[B]LI(4LH;IQDB.&6%I)45CR7D#..?W9
M.!\G_P#!*OX<^";?]J3XI?!SXB^%M'\6W?A^QNF@OKVV2Z%O-I.H)9R_9UF5
ME43^>&+8W (H!P3D _H3\!?$O1/&_P +O#7Q6N$.@Z9XDTVSU-$U!XXW@CO8
MUDC61MQ0-AP.O7WXKIY/%?A>'1F\12ZQ9II*<->-<1BW&#MYEW;!SQUZU^2G
M_!9?QK;^%/V:O#'PYTS;;'Q+K<(\E %3[%IL+R,JJ, !96@P!P*^2?V7?^";
M'Q=_:'^$OA34OCUXSO?"OP_LH'N/#NAVBH]P\%\[7+73!OW4)E,FY6=))67
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M>X\.Z':*CW#P7SM<M=,&_=0F4R;E9TDE9< [$5!7SY^T-\&O$7_!-/\ :?\
M!6O_  M\57>H6=Q%#J5M+(!'<-"DYBN;.Y6(A98Y%7!PJAE;& 5S0!_6'111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '__6_?RBBB@ HHHH **** "O
ME7]N#Q]_PK7]DKXI>*4D\F;^Q9[&%\X*SZEBRB8>X>8$?2OJJOR[_P""LVC_
M !/\7_LYZ7X!^%OA75_%5WK>NVS7L6DV-Q?-':6L4LN9%MT<J#-Y6"1C@]Z
M/F;_ ((Q_!GPSJWPN\?_ !(\5:)9ZK_:FK6^F6QO+>.?8NGP>:YC\Q3@,UT
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M!^,/ _B'Q/\ "_7-06'^U]-TJ[NM.MYY,+;ZE%+'&\:QNA5;E-V4 RWS1$$
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M&OZ"_@?\=-!^,WP$\/?'A(3I6GZOIKWUS$[;OLSVQ=+I-V%W+')&X#8&X '
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH _]#]_**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH __1_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$_9SLO UM\%[AM L-<-XU]JXM(;O][#Y?E6P-Q')'&2K,YXW-CY2 K9^H/\
M@G[\8/BW\<_V:M&^(/QFA7^V[JZNH8;M8%MOM]I$P$=R8HPJ*6;>GR*JG9N
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MCN[&Y"AC%,@)&<$%64E6'0G!  /?**** "BBOE+]I;]LGX.?LHS^'K?XK'4
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M./@7]HGX<V7Q1^'3W#Z+?RSPI]JA\B8/;R&-PR98=1D$$\?E7L% !17Y7_\
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M_%_1-6@M?C3X7T[Q-HSNHEGTU6L;Z)#PS*&=X9"!R$*QY/!<#D?T%?"/XM^
MOCCX!TOXE_#;4EU30]64F.3!22-T.V2*5&^9)$8$,I^HR""0#TFBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BOYL?%?\ P4%_;@L_VRKS
MX;Z0WE6<7B=M+MO"KZ;;$2VOVGRXT:8Q"X)DCP_G"4#G>N$XK^DZ@ HHHH *
M*** "BBB@ HHHH ***_E \6_\%3OVTM*\5:SI=EXOM$M[.]N(8E.DV)(2.1E
M49,.3@#J: /ZOZ*_DLL?^"L_[:MI.)I_$VG7J#_EG-I-H%/_ 'Z1&_6ONW]F
MO_@LM!KFN67A3]I70+71X+HB,:]I0D\B)R< W-HYD<(?XI(W.#_RSQDJ ?O-
M14%K=6U[;17EG*D]O.BR1R1L'1T<95E8<$$'((X(K\8?VR/^"LD'P:\=:K\*
M/@=H5IXBUK0I7MM1U/46D-E!=1G;)!%#$T;RM&V5=S(JA@5 ;K0!^TM%?RZZ
M%_P6;_:EL-36YUO1O#6JV1;+V_V.X@;;Z)(ESE3Z%@WT-?NK^Q_^UYX&_:]^
M'UQXK\-6DFC:SH\J6^K:5-()7M99 6C9) %\R*0!MC[5)*L"H(H ^M:**_G9
M^+G_  4-_:B\8_MB:C\$?V=O$%K8Z#<:_#X>TU6T^UNMTJ.MM/<-+)&S&,RB
M23.<"/'IF@#^B:BOQ1_X*<_ME?M!?LS?$KP=X8^$FOP:;9:KHS7=R);&VN3)
M.MP\>X&9&*_*HX'%?F</^"KW[;8.?^$QLS_W"+#_ .,T ?UOT5_,+\-O^"S?
M[17AW4X_^%D:%HWB_2SCS$BB;3KO ZE)8R\8_P"!0G\*_?[]G/\ :1^&7[4'
MP^C^(/PSNW>%'\B]L[A1'=V-R%#&*9 2,X(*LI*L.A."  >^45\K_M;_ +6/
M@7]D?X;KXU\5P/JFIZE(UMI6EPNJ2WEPJ[FRQSLBC&#))M;;D  LRJ?P?US_
M (+.?M1W^JO=:)HGAK2[$.3';FTN)VV=A)(UR"Q]2H3Z"@#^HBBOR"_8C_X*
MDV/[0WC.S^$?Q<T2V\->+-3##3KRQ9_L%[*B[C 8Y6=X92 2F7=7QMRK;0WZ
M^T %%%% !17Y7_\ !43]J#XR?LR^%? 6J?![5HM)N-=O;V&[:6U@N@Z0QQL@
M G1PN"QY&,U^.'_#U[]MO_H<;/\ \%%A_P#&: /ZWZ*_EH\#?\%COVI_#VHP
MR^,+31/%E@.)8I;0V<S#U26W955O<QL/]FOW=_9)_;*^%_[7?A2XU7P@)-)\
M0:2L?]J:-<L&GM3)D*Z. %FA8@A9% /9U0D"@#ZZHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***_"G_ (*=_MG?M0_L_P#QDT+P7\*-1;PGX<ETJ*\6
M\^PVUU_:%RTL@D DNH95 B"JI1<'G<V0R@ '[K45X/\ LP^-_'WQ)_9_\"^.
M_BA8#3?$^MZ;%<WD*Q^4"6)\N7RS]SS8PLFW^'=C QBO>* "BBB@ HHHH **
M** "BORO_P""HG[4'QD_9E\*^ M4^#VK1:3<:[>WL-VTMK!=!TACC9 !.CA<
M%CR,9K\</^'KW[;?_0XV?_@HL/\ XS0!_6_17\JG@S_@L%^UOX>U2&Y\32:-
MXJL@P\VWN;!;9F3/.R2U,15L="0P'=3TK^B3]E[]H[PA^U-\(]/^*?A&%['S
M9'M;^QE8/)97L(4R0LZX###*Z-@;D9254DJ #Z'HHHH **** "BBB@ HHHH
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M/S)F8J@)SM7 )Y.3@U]'4 ?A=_P7"_Y$7X5?]A+4_P#T3#7 _P#!*/\ :=^
M?P/^"'B[P_\ %CQI9>&]1O/$$EW#!<^9OD@-I;IO4(C9&Y&'KD=*[[_@N%_R
M(OPJ_P"PEJ?_ *)AKX3_ &'O^"=NG_MA?#G7/'EWX[E\*MH^JMIHMTTY;P2!
M8(IO,WF>+'^MQC!Z9SS0!XM^W?\ $CX3?'#]IW5O%/P!TXMH]_':VWF6]J8/
M[2OQE9+B.#:KYD)51N4.Y7<1EJ_J$_8Z^'_BCX1_LJ?#WP/XPC:'7-)TD/<P
MR$EX))W>X\A_>(2",CL5P#WK^</]KO\ 8<^)'["-WX9^(WAWQQ_:UA>WA@L]
M4L4DTN_L[U$,BC8DLA7*ABKI*?NG(7C/[2?\$S?VJ/&/[2GP0UZP^)%Q_:'B
MCP3.EI/?857N[6XB9K>64+@>:"DB,0/FVACEBQH _+?X?_\ !8W]HO3O&%IJ
M/Q(M=-UGP[$MPT]C8V:VTTS^2_D(LS.WEKYVS>V&(3. QX/UQ^P7^WS^T5^U
M%^TU+X3\;BPM/"9TR^NS9Z?9;(X9(C&(LSN9)>-V.7P2>G05^-O[%O@CPM\1
M_P!J?X;^"O&NGIJNB:GJBK=6LI/ES)'&\@1\$$J64;AT(R#P37]I>DZ1I.@:
M=!H^A64&G6%JH2&WMHUAAC4=%1$ 51[ 4 ?BM^V__P %5/$7P9^)>J?!KX&Z
M+8WNI>'Y%@U/5M2#SPBX*!G@MX(WC^:(D*[NQ&X,H3C<?C[Q%_P4'_X*7_#J
MSL_&WCW0Y=*T#42C6[ZGX:-K8R!N559C'&QW#D#S-Q'(]:G_ &I/C;^P=X*^
M/>N^)/A[\,;SXA>,[;7)=1OM6N=;N;72FU-;DS2>5"IE\^(2@@C"1D<*63!+
MOVCOVW_VQ/CQ\!?$OA[Q=\$ET;X?:O% UUJXTC53';I'<1R12+=R.+=3YJH
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MKPI\6_ACXY^)FG^,_!NM:%INI:-;7:/J%A<6D4MQ93,J1HTR*"Y6=S@<X!H
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ML8?M ?M*? 6W\3WW[//PY@\82:PUO'?7CZ-?:G) (0Y2$26DD8C5MQ8J?O$
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M_P!E-G_]/35_61^T[XAU/PG^S?\ %+Q-HKO%J&F>%]8N+>2/AHYH[.4I(/\
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MB^+7AN\TC1? ;)+86^HVLENUWJK\PNJ2JI*6P'F$C_EIY?7YA7QS_P %%O\
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MK-)-)]^1V8DEG)//6@#Y)_;]_;]LOV1K'3?"'@_3K?7?'^NP&ZA@NBWV6QM
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M^/\ @H_^WI\?/V8_CGH_P]^%LVFPZ5=^'[;4I/M=G]HE,\UU=1-\Q<87;"N
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MQE\--.T2TL_#-OX;U"VAL(856"*..V<IL3& R, RMU# -G/- 'P-_P $Z_\
M@HGXC_::\1ZA\)/BY8VEKXLM;5[ZQO;)6BAOH8F EC>$E@DL88,"K;77/RJ5
MRWX>_M?_ +27QT_:#\0:5%\:+6*V3PS+?PZ;Y=BUENCG>,29W??_ -4G/;\:
M]-_X)53S1?MP^ XXW*K-!K".!_$HTVY;!_%0?PK[<_X+D_\ (6^#G_7#7?\
MT*QH ^7_ -AC]KW]IOP#J7P[^!G@>PBG\"ZCXCM;>>0Z8\\GDW]Z@NB+@<#
M9N?X?PK^J^OS3_X)*_\ )EGAS_L):K_Z5-7Z64 ?A=_P7"_Y$7X5?]A+4_\
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MH ])_;K_ ."I/BKX)_$O5/@I\#]'LY]5T,)%J6K:BC3HEQ(BR>5:PHZ@F-6
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M"A0/ZLJ_ +_@M_XWT61?A?\ #F"9)-5@.H:I<1@@O%!((H82PZ@2,LF/78:
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M@=PLKJS ?PJ3VK\&/^"./P9D\=?'W6OC'K$1FLO 5DP@D?G=J6IAXD.3]XK
M)B>X8H?2O>/^"V'QIX\#_L_Z7/\ W_$&IHI_W[:R4X_[;L5/^P?0U]\_\$R?
M@K_PIO\ 9-\,R7\'DZSXT+>(+W(PP%XJBU4YY&+98B5/1BWJ: /RR_X+;_\
M);/A]_V+TG_I7+7Z:?\ !*NW@N/V'O!<<\:R(]SJX8, 01_:$_4&OS+_ ."V
M_P#R6SX??]B])_Z5RU^G7_!*7_DR'P3_ -?6K_\ IPGH X?_ (*)_L/?"WXG
M?!GQ/\4?!GA^TT+QYX4LY]56ZL84@^WP6JF6X@N4C"K*S1JQC<@N&"@':2I_
M(O\ X)+_ !8U;P!^UGI7@V*9O[(\?6MSIMW%N(C\V")[JVEV]"ZO$8U/4+(V
M.M?TB?M5>-]%^'7[-_Q)\6:],D-O:Z#?QH'( DN+B%H8(AG@F25U0#U-?RR_
M\$W/#]YXB_;5^&5O:([+97=S>RLH.$CM;2:4EB.@)4+SU) [T ?L+_P4M_8S
M_:)_:G^)'A+4_A?%8W'A[P_I+PE;R]%N5O;B=VF*H5/!C2'+=\8[5].?LK?L
M5_"OX,?L[Z9X)^)W@[0]2\07=K++XBNKN""[\V64LSH9Y$_U42810,* -WWB
M2?O*XN+>TMY+JZD6&"%6>21V"HB*,EF)X  Y)/2OYQO^"B/_  4K_P"%BPZI
M\!/V>[TCPQ+NMM8UR(D-J2_=>VM".1;'H\G68?*N(\F0 _-3X36UHO[7?A&U
M^%[/+9)XWL5T=AN+M;KJ2?9V)Z_<"DD^^:_J'_X* ?M3>)/V3/@A;>.?!VEV
M^IZYK.J0Z3:&\#M;6[20S3M+(J,A?"PD*NY<D@G(4@_"O_!+W]@#6O 5[9_M
M)?&O3_L>LR0D^'](N$Q-:+,N#>7"M]R5D)6*,C**Q9L/M"_L%\6_@_\ #GXY
M^";OX>?%+1H]<T*\99&A=GC9)8_N2121E7C=<G#*P."0>"00#\S/^";?[?GQ
M0_:E\:>)?AK\5M-L/MVEZ;_:MK?Z?"]N#$DT<$D4R,[J6S,K(5V\!@0>"/U^
MKYQ^ '[)WP)_9DBU,?"#P[_9ESK.P7=U-/+=7$J1Y*1^9,S%4!.=JX!/)R<&
MOHZ@#\+O^"X7_(B_"K_L):G_ .B8:[?_ ((H1H_[/'C<.H8'Q3(.1GC[#:UQ
M'_!<+_D1?A5_V$M3_P#1,-=U_P $3?\ DWGQM_V-,G_I#:T ?7W[6O[$7PB_
M:4\ :O:C0++2O&T=O))I>LVT"07*72+F-)W0*987/RLKY !++A@"/YG/V&_B
MAKOP2_:T\ ZO;N]O'>ZK#HFI0[BH>UU&06LJR#OY;,)0#_&BGM7]D7B3Q#H_
MA'P]J?BKQ#<I9:7H]M->74\A 2*"!"\CDGL%!-?Q-_!NUNOB3^T_X,ATZ!Q+
MXB\6V+A$'S(MQ?(['CH$4DD] !GI0!_6A^UY^UIX'_9%^&Z>,O$T#:KJ^J2-
M;:1I43B.2\G5=S$L0=D,8(,DFT[<J "S*#^"MY_P5+_;M^).L7EU\.;6VL[:
MVQ(]IH^B_;UAB[>8\RW#\XY;*@G.,=*Z?_@M5XAU.]_:0\)>&9G<:?I?A>&X
MAC/W?.N[RY$LB_[RPQJ?]ROUR_X)C^ O#7@G]CCP/?:%;QI=^)DGU34)TY:>
MYEF= 7/_ $SC1(P.@V^N20#\[?V7O^"P_BNY\7Z?X,_:;TZQ.DW\RV_]NV$1
MMI+-W8*'NH2S1M$"?G:,(R+SM?I7[9_'GQSJOP]^!'C_ .)'A9H9-2\.^'M3
MU2R:5?,A,UK:R31%@"-R[E&0",CO7\R/_!6;P!X9\"?M>ZC/X9MX[1?$^EV>
ML7<<7"_;)WEBE<KT#2>4)&QU9BW4FOVBT3Q#J?BG_@E#>:UK+O+>2?##48G>
M3EW^SZ=+"K$]RRH#D\G.30!^6WPW_P""RGQ\T6_U:[^)FF:=XCMSITJ:=:VM
ML+-1J+/'Y4D\H=F\E$\PLJC<QV@%<[EY+6?^"IO[>.@ZG:>(]=BLM+TS4?WU
MK:7.A^39SQY!Q%))B9TP<9$Q..^>:\[_ ."67P^\'_$3]KK1;+QIID6K6FD6
M%[J<$$ZAXOM5N%$3NAX;86W*#QN /:OWQ_X*7^#/#WB_]C/Q_-K=O&\^@PP:
ME8S,!O@N8)XP&0]BZ,T9]5<B@#8_8<_;*T+]L'X=7FL/8IHOBSP[)'!K&GQN
M7C4RJ3%<0%OF\F7:X ;YE964D@!F^(/VW_\ @JIXB^#/Q+U3X-? W1;&]U+P
M_(L&IZMJ0>>$7!0,\%O!&\?S1$A7=V(W!E"<;C\A_P#!%;6;ZU_:7\5:'&[&
MSU#PK<RRH/N^9;WMIY;M_NB1U'^]3OVI/C;^P=X*^/>N^)/A[\,;SXA>,[;7
M)=1OM6N=;N;72FU-;DS2>5"IE\^(2@@C"1D<*63!(!!XB_X*#_\ !2_X=6=G
MXV\>Z'+I6@:B4:W?4_#1M;&0-RJK,8XV.X<@>9N(Y'K7[ _L$_MM6G[8G@S6
M&UC2H]"\8>%GA74K:W+-:RQ7._R9X"Y+ ,8W5D8L4('S$,*_(?\ :._;?_;$
M^/'P%\2^'O%WP271OA]J\4#76KC2-5,=ND=Q')%(MW(XMU/FJ@#,I!S@#)KI
M/^"(\TJ_&CXA6ZN1$_A^)V7/!9;N,*2/4!CCZF@#Z7_X*/\ [>GQ\_9C^.>C
M_#WX6S:;#I5WX?MM2D^UV?VB4SS75U$WS%QA=L*X '7-?*WC'_@L'^T3XD\.
M:/HWPL\/V=AJ-AIT#ZSJ<MH;N6:[5!]HDA@5C#!;[\[=X<D8)*9*US'_  6C
M_P"3K/#W_8H6'_I=?U^T7_!.?X?>#/!'[)'@#4?"VDP:?>>)=.BU'4IT7][=
MW4N<R2N<LV!PHSA1PH H _)K]G7_ (+'?$[1O%,>G?M(VEOXA\,SHX>]TVU2
MWU"VD52481HR0RJQPI4A",[@W!5N-^*?_!8#]ISQ7K%]J7PHTRQ\'^&+:79#
MNLQ?W&UC\AN9YMT0=L=$10.GS8W5\/?M2>%=#T7]KSXC^$](MEL]*3Q7>Q1P
M0@(D44MT3LC4#"JN["@# & *_KW\3?"WX>Z/\"]>^%>C:!:6'A1=%N[-=/AB
M58!"8&!&W!RW<L<L6^8DGF@#\T_^"=W_  4@\6?M&>-Y_@S\9K.SB\1S6TMW
MI>H62&!+L6X#2P2PY8"0)ND5U*J55@5! +<K_P %)/V[?CM^S5\<M&^'GPT;
M2ETFYT"UU1_MMD+F7[3-<W4+$,S# "Q+@ >O/-?E9_P3.GEM_P!N'X8/"Q0M
M/J*''=7TVZ5A^(-?1'_!:/\ Y.L\/?\ 8H6'_I=?T ?MCX:^/'CS4/V")/VB
M[MK9_%\?@N]UT'R<6QO(+665"8@WW-RC*[NG>OQG^&/_  63^.VC:GJMY\4]
M.L/$5I_9TRZ?:V=JMF/[1+)Y+SR[RPA5=Y8*I9C@#&2P_3+P;_RB1N/^R9:I
M_P"D,]?BQ_P2R^'W@SXB_M;Z1IWCC28-:L]+TZ\U&""Y7?$+JWV>5(R'Y7V%
MB0&!&<'&0* .UU;_ (*S?MM6NLQ:M=2Z7IEI=#SH;%M(5;9XF/&QI29F7L")
M?QK]Y/V'_P!K.Q_:[^$3>-)]/CT?Q%H]R;#5K*)F>%)PH=)82WS>5*IRH))4
MAE);;N/S7_P6+\/:/J/[)UOK5W:QO?:-KUBUK-M'F1"=9(Y%5NH5U(W '!*J
M3T%?./\ P0VGF;1_C';,Y,4<^A.J]@SK>AC^(4?E0!]+?MY_\%);#]EW6U^%
MGPUTNV\1>/#"D]VUVS&RTV.9=T2RI$RO),ZX<1AD 0JQ)W 5^:L/_!17_@I+
M:: OQ5N-"DF\&L PO9?#+C2"I. ?M:HO&>,^=^M?#7[4^O:QXD_:W^)^JWT#
M:A>GQ=J<,=O*K2%TMKQX(8"JX8@(BQX!S@8%?I9/^WS_ ,%&+G1)/#<_P$LW
MTF6W-HUH?".L^0;=D\LQ&/[1MV%/EVXQCC&* /T+_8+_ ."AFC_M:&[\">+]
M+B\.^/\ 2K873Q0.39ZA I"R2VP<ET9"1OB8L0"&5F&[;^EU?R-_L,_"OX\_
M#[]KGX9^*[_X=^(M,L8M6$%S/-I5Y#!#;WD;VTK/))& J*DA)+'IU-?UR4 ?
MA=_P7"_Y$7X5?]A+4_\ T3#70_\ !%[Q%X?TC]G_ ,:V^K:G:V4K>)Y'"3S)
M&Q4V5J,@,0<9!YKGO^"X7_(B_"K_ +"6I_\ HF&OR8_9T_89^.W[4?A34O&?
MPKATZ33M*O383&\NQ;OYZQ)*=J[6R-LB\YZT ?='_!8WQ1\ ?$'BKP1'\.;G
M2]1\;0K>'6;G2VCD(MCY0MX[J2+*M)N$A0$ET7.0 RY^P_\ @BSX7U_2?V>?
M%7B/4HGATW7O$#M8[QA95MH(XI94]5,@,>?[T9':OP6^*'P,^)_[*GQ'TK1_
MCAX+@E?"WD5G=3/+I^HVZL5($]C-&Q7(PP25'7C<!D9_K&_8[^-G@+XT?LV^
M'O&_PWT.+P_8Z=;O82Z+;*JQV%U9J/,MXPN 4.5>,X!*.I8!B0 #X#_;?_X*
MJW7P:\<:E\'O@-IEGJVNZ*[6^J:M?AI;6VN1]^"WAC=?,DB/#L[;5<%=C8)'
MQC=?\%&O^"D/P]T^V\=^.O#K1^'-0*&WFU?PU+::?+O&5$=PBP%MPY&)#D<B
MOS0\ ^+_ !D/C%I'CW2-(3Q?XI&K+J<5C<VTEZE]>^;YV)((BKR[GY*@Y-?J
M7\3/VT?^"A?Q:^'WB#X:>,?@9'/HWB2RFLKD+X5UGS%65<"2,O.RK)&V'C8J
M=KJ&QQ0!^P'[$O[:_A/]L/P=J%W;Z?\ \(_XL\/&)-4TQI1*NV4'9<6[\,T+
ME6'(#(PVMD%6;G/VZ/V\/#'['^BV&CZ?IZ>(O'>O1--8Z>\ACA@MU)3[3=,O
MS>67!5$7!D*L RA21^1O_!*CX=_&GX;?M96=WXF\#Z]HFD:OH^HV-S=7NFW5
MK;H-JW"!Y)8U49DA4 $\D\5X!_P5,U[4M;_;=\>VU\[F'2(]+L[9'/\ JX1I
M\$I"^@:21W_X%0!Z1-_P5-_;P\2&\\3:#):0:39%GG6QT1)K.!>N'EE65U '
M=I,XZFOT%_89_P""INH?'#QYIWP:^.6DV>EZ_K),6EZKIX>*VN9U7<()X9&?
MRY' .QU;:S838I(S^D_[,'@#PI\/OV=? 'A'PO:0QZ:NAV,LFQ5VW,MS DD\
MSX #-,[,S$CG/I7R!H/_  2<_9P\,?%G3_B_H&M>)+'4-*UN+7+6RBN;);&&
M:"Y%S'"B"R\P0(P"A?,W;!C=GF@#Z$_;%_:[\&?LA?#F+Q7KUL=7UW6)'M]'
MTI)!&UU,B[G=W.2D,0*^8X4D%E4#+"OQ!T__ (*1_P#!17XO7M_K?PF\-FYT
MS3WW3P:%X=EU*"W7&0LTK+<.N1R274GJ,#BG_P#!:G7M2O/VE/"GAZ9W%AIO
MA>WFAC/W?-NKRZ$LB_[PB13_ +E<]^SE^V+^W#\'O@]H'@7X.?!ZWU/PM:++
M);7R^'-5N6O#-(SO,\\$Z1RL6)&X#H .U 'V#^Q__P %:-=\<_$+3OA-^TAH
M]GIMUK5TME9ZQ8HUM%#<N=B17D$KOM#O\OF(5"D@,F,NOV7_ ,%(_P!I3XE_
MLN_!30?''PL>SCU74_$$&FRM>0?:$$#VMU,VU=R@-NA7DYXS7\XGQH\&_M0?
M''XGZY\6/$?P?UG2=7\02QSW,.E^']1M[7SDC6-I%1UD8-(5WN2QW.6;O7[#
M?\%8]2U;6?V'_A/K&O6\EIJ=]K6CSW4,RE)8YY=(NVD1U;!#*Q((/(- 'RWH
M/_!8C]HBY^'TOABV\/V&M?$34M19;:\2T;[-#9&*,)'':1/NFN#+YARQ"J-O
MRODA>2\,_P#!6G]L7X=^,UM_BK966M6T,B_:]+OM-&FW*QM@D1O$L;QOC[ID
M1QSRIKZI_P"")?P^\'W'AKQ_\3KG3(I_$MM?P:;;WDBAI(+4PB5TB)^YYC-\
MY'+ *#P*I_\ !;[P9X?CT[X8_$&&WCBUN6:_TV650!)-;*D<T:N>I$3;MOIY
MA]: /L']IS]LKQ7:_L>>%?VD/V8E6]G\2ZC:0K'/:&\>&)XYQ<0R1(>)(9HO
M+8@D @X)!!K^7J^\>^,+SXMW'Q/NHU'BJ?7'UAT\DA?[0:Y-P5\GJ!YO&S\*
M_H__ ."+VLWVH?LM>(--NW9X=*\57D5OG[J1R6EG*47_ (&[,?=J_#OQ/_R?
MYJW_ &4V?_T]-0!^]G_!-O\ :C_:&_:0N_'Z?'.RCM8= 33#8-%I[6(9KDW/
MG EOOX$:<=OQKY6_:S_X*_:[X>\9:E\/_P!F>PL;BTTJ5[:?7[Y#<K<31MAC
M9PJRIY8(P))-X<<JH&&/["_M.^(=3\)_LW_%+Q-HKO%J&F>%]8N+>2/AHYH[
M.4I(/]QL-^%?RZ_\$Q? 7AKX@_MC^#;'Q5;QWEII*7FJ1P2\K)<V<+/ <=_+
MDVR =/DYXXH ]AM_^"H_[>GP]U&RU3Q[!;7-C>'S(K?5M#%G%/'QD1O"MNY
M!&"&..,Y'!_=;]C/]L?P5^U_X"N==TBU.B^)-$:.'5]*>02&!Y 2DL3\%X),
M,%8@$%64C@%J_P#P4&\ >&?B!^R%\2(/$EO'*VA:7/K%E(_#07E@AEC=&ZAF
MP8SZJY4\$U^%W_!'/Q#J>E?M9SZ+:._V/6] OXKE!]P^2\4R,P]59, ]1N([
MF@#Z1_;9_P""D?[2OP+_ &G/&GPH\ SZ3#H.@M8+;"XL1-+_ *18V]PY=RXR
M=\K8X&!@5Q-Q_P %9_V@OBI\;?#7A;X7:;:>'?"^H:M8V8A-HMYJ%Q#+/''(
MTKN71&<$D+&HV9QN8C<?CW_@IW_R?-\3O^NFE?\ IJLZ_J6_9V^&'@#X5_"+
MPOH/P^T*UT2T?3;2646\85YY7B5FDFD^_([,22SDGGK0![A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_4_?RBBB@ HHHH
M **** /BW_@HE_R99\5?^P;%_P"E4-?RS?LM?M,^+?V4?B3<?$WP9I=CJ]_<
M:=-IIAU 2F$1SR12,P\IXVW Q #G&">*_M2\0^'/#WB[1;OPWXKTNUUK2;]/
M+N+.]@2YMIDR#MDBD#(XR <$$5XS_P ,G?LL_P#1&_!G_A/:=_\ &* /YH?V
MA?\ @J#^T/\ M"^ K_X9:G9Z/X:T#5@J7JZ7!,+BYB4AO*>6XFEPA8 D1JI.
M,%BI(/U/_P $B/V5?B(GQ/7]I'Q?I$^C^&=.T^XBT>2Y3RVO[B\7RC)"C?,8
M4A+_ +S 5F90I;#8_=#1/V<OV>O#5W'J'ASX7^%M*NHFW)+::)8P2*P[AHX5
M(/O7LH 4!5& . !0!_)A_P %:O\ D]/Q'_V#=*_])4KJ?AK_ ,%;_CS\*OAC
MX;^&'AKPIX:FM/"^G6VFVUQ=Q7DDCQVT8C5I!'=1J6(&3C SVK^D[Q=\!/@7
M\0-:?Q)X\^'/AOQ)JTJ)&]YJ6D6=Y<LD8PBF6:)W(4< 9P.U<W'^RE^RY$ZR
M1?!WP:CJ<@CP]IP(/L?(H _DW^)GQG_:A_;K\?Z;INLB\\6ZE&Q33M(TJV*V
MMJ)2 S)#'D+GC?-(Q. -S[5&/Z.?^"=W[&L_[)OPQO;CQ@T<WCSQ<T4VJ^4P
MDBM8H-WD6D;CAMF]FD8<,[8!*JK'[H\->#O"'@NS;3O!VAV.A6KD,T-A;16L
M9(X!*Q*H)Q[5TE '\UW_  6W_P"2V?#[_L7I/_2N6OUM_P"":_\ R9%\+O\
MKTO?_3A<U]-^-_@U\(/B9>6VH_$CP-H7BN[LXS%!-JVF6M])%&3N*(UQ&Y52
M>< XSS77>&_#/AOP=HEKX:\(:5::'H]BI6WLK&".VMH59BQ$<42JB@L22 !R
M2: /P!_X*Z_L=?V5?G]JGX>6.+.^>.#Q/;PKQ%.V$AO\#H)3B.8\?/L;DNY'
MQ-_P2P_Y/F^'G_7/6?\ TU7=?UP:SHNC^(])O-!\0V,&J:9J$3P7-K=1)/!/
M%(-KQR1N"KHP."K @CK7FGA3]G[X"^!-<@\3^!_AMX:\/:S:AQ#>Z=H]E:7,
M8D4HX2:&)77<I*G!Y!(/!H _(O\ X+A?\B+\*O\ L):G_P"B8:[K_@B;_P F
M\^-O^QID_P#2&UK]7O''PP^&OQ-MK6S^)/A+2/%EO8NTEO'JUA;WZ0NXPS1K
M<(X4D#!(P2*G\$_#KX??#339M&^'/AC2_"NGW,QN);;2;*"QADF*JAD:.!$4
MN551N(S@ 9P!0!V5?G=_P4U^/GQ4_9Z_9WMO%'PDF_L_5=7UFWTR;4!$LS65
MO+#/*SHKAD5W:)8PS*0-QQABI'Z(UA>)?"_AOQGH=WX8\7Z5:ZWI%^FRXL[V
M%+BWF7.</'(&5AD \CKS0!^*/_!)_P#:T_:!^-_C[QA\/?BOK4WBK2-.TH:E
M!?7,:>=:W N(X1"98U4LLRNS /G'EG;@;L_N77G_ ,/_ (4?#+X46-SIGPR\
M*Z9X6M;V02W$>FVD5J)I!P&D\M5W$ X&<X' XKT"@#\+O^"X7_(B_"K_ +"6
MI_\ HF&OS+_90_X*"_$W]D;P3JW@;P1X=T?6+35]1;4I)=1%P9%D:&.':ODR
MQC;B,'D9R3S7]9GCCX8?#7XFVUK9_$GPEI'BRWL7:2WCU:PM[](7<89HUN$<
M*2!@D8)%><_\,G?LL_\ 1&_!G_A/:=_\8H _E$_:6_;&^.O[96KZ'IGC>&U2
MVTZ4KIVD:-;2)$;F?"%PKO--+*XPH!<@?PJ,G/[W_P#!+S]F/QO^SS\#/$.K
M_$NP?1_$?C>Y6Z:PEP)K:SMHBENLP&=LC%Y'*'E05# -N _03PC\'?A%X N?
MMG@/P/H?AN?&WS--TRULWQZ;H8T.*]&9592K#(/!!Z$4 ?QG_P#!/7_D\_X4
M_P#85;_T1+7]E5U$]Q:S012&%Y$95=>JDC 8>XZUY#X<_9S_ &>_!^MVGB7P
ME\,/"^B:O8,7M[RQT6QMKF%B"I:.6*%74X)&01P2*]EH _B,\+2>(/V4_P!I
M+2K[XI>%#J&I> ]82>]TF\S&+CR&R&5W5@0PQ)%)M93\K8(-?H;^UQ_P4Q\3
M_M2_"K6/A/\ "+P#>:5H4]NEUX@O+C%Y.EI!*CX B4I!$) FZ9R2<A0$ZG^A
M+XA_ WX-?%IXIOB;X(T;Q1/ H2*;4+&&XFC0$MM25U+JN23@,!R:C\/? ;X)
M>$_"^H^"?#?@'0M.T#6%"7UC#IMNMO>*.@N(]FV8#/\ RT#4 ?@+_P $2/\
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M#SPW=0SW45BDD\?VJ7,=N;J[< %N6$:*$!^9BK;05_J \<?L[_ ;XF:L=?\
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MO7^&O@W1?";:EY?VHZ1IUM8&X\K=Y?F_9XTW[-[;=V<;CCJ: /Y"+_0OC?\
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M_,BJXCR ?*C5%C3(!(7<0"Q%?C9_P48_;?\ VH?AQ^U#KOPS\ ^)KCP?X?\
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MDG_L_>T\-PB*"66!WE\W&2%<-C:K$?GC_P $H_@MXK^(/[4^@_$*VT^0^&?
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MXG>,/$>J_#G2[">&(ZI=SRVE]?RLJ(L*RG;)Y(#L[+G8P53RU?G/_P %._\
MD^;XG?\ 732O_359U_7UI^GV&DV,&F:5;16=G:HL<,$*+'%&BC"JB* %4#@
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M=^#O@3\$/AWK'_"0_#_X>>'?#.J^6T/VO2])L[*X\I\%D\V")'VM@9&<' H
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MP3X!\$?#708_"WP]T"Q\-Z1$S.MII]O';0AW^\^R, %FQRQY/<T =;7X>?\
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MVG>)M*\Q9OLFIVD-[;^8F=K^5.KIN7)P<9&30!^(_P#P0Y_Y%OXO?]?>C?\
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M'?\ R?[XA_[*;=_^GIJ_?[_@J9^R]XG_ &A_@IIGB#X?63ZGXJ\!7,UY!9Q
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M'>L?\)#\/_AYX=\,ZKY;0_:]+TFSLKCRGP63S8(D?:V!D9P<"@#X0_X*^_\
M)G-Y_P!AS3/_ $)Z^4O^"&O_ "#OC+_UUT#_ -!OZ_<KQ?X(\&?$'1G\.>/=
M T_Q+I,CI(UGJ=K%>6[.ARK&*970LIZ'&1VK(\#?"GX7?#!;U/AIX.T;PDNI
M&,W0TC3[>P$YBW>7YOV>--^S>VW=G&XXZF@#^:#]IW_@H;^UYX6_:;\::7H'
MBJ;PWIGA/7+S3[+24MH#;_9[.=HXS,LD;&4S*H=F9CG=\A"[<?TO?"CQG+\1
M_A;X.^(<UN+23Q1HVGZHT(SB)KVW2<H,\X7?CGFOYZ/C?\+/C7_P4-_;#OM
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MRYS%H.G#!<?W3]CA+XX^<GG)S7]>%K:VUC:PV5G$L%O;HL<<: *J(@PJJ!P
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M;,!G_EH&J]X(^#'P>^&=]<:G\-_ N@^%+R[C\F:;2=,M;&66($-L=X(T++D
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ME*307$:RQ2*>JNC@JP]B*^<IOV+/V29[W[?)\(?#'FDYPNEVZQY_ZYJH3]*
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M !P * ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#__U?W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZT_X(X?$/4_%O[+VH>$-4E\W_A#-;N;2UR<E;2Z2.Z53])9)<>V!VK?\#_\
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MC_\ LT^!_B1?W N-7N+,6FJ-P&.H61,%P[ <*9&3S0/[KB@#ZBHK^7K]I?\
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M_"_XX:WXZU?Q=HFN_P!A6]]X:N=2M'M$DO+>9KEXK.&:)(_](C3RB8TP XY
MQ0!^_P!17\X7_!-S]NOXU>,/VEM/^&_QK\9W?B/2/%EG<VEFMX8]L&H1@3PN
M"JJ<NL;Q =V=:_37_@I?^T)XA_9[_9KN-4\#ZF^D>*_$>HVNFZ=<Q;3+!R;B
M>10P(_U43)DC@N.^* /T(HK^??\ 8P^-W[5/CW]G?]H;X\>./B#J>HVWA+PS
MJ-KH9F\IDCU2*T>[>X4; -\"K#MSD?O#D5\/?"K_ (*6_M@>%=;OS+XENO&]
M_J]D^G:?:WZ+/'!>7$L?EW"0Q(&EE4*R1IG!9\D,!M8 _KIHK^2[XG?&C_@J
M!\'O[/\ B/\ %+Q!XN\-6NJRCR);M5CLC*?G$;VP4P1L0"1$\:G /RX!K]</
MV//VV/''[5O[./Q'TN>+R?BWX.T>Z\I[",(;YYK:7[%<PQ=%F\Y-KHHVAMK
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M\9;;7Y/$#SP3:DB'PT+. 6C1M+M^QJGE^:#CY ^_S<\ELU_6?0!YS\8=1O\
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M_@J!^WAX]T?XM6_P7^!'BN]\/0^#PW]LWNF7#027&H2@?Z,9(R"4MTP&&?\
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M?B#6[NXU19KR]E:>>017TR(&=R2=JJ%'H!BONROSI_X)3?\ )D'@C_KYU?\
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M/AI^T<NO>,=>\5ZYI'A82:&LES/=W,-]);WWEFU7+.)6D1-NP;BP7'.*X?\
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MV\E[:6<=NKK-'(3(T=Y(X&%/1#S7S#_P1L4M^UEJ2ABI/A;41D=1_I%IR,T
M?U-45_*IXH_;+_:__9O_ &H;GP/\2_B'JFN:3X+\0I%?VLXBVW^FI,KYVA 0
M)[8AUQC&X&OZ8OB-\3-!^'WPF\0_%R>9+G2M#TBXU965OEGCBA,T80]_,X"X
MZDC% 'I-%?S-_L$_M'?M@?M&_M2>&_">O?$G5;KP[8M+K&L0CRA$;.TPWE,
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M?M5?\%$_@;XUMS\2O%WB?P]J\RK=1VFL18MYXMWWEMYH_)9"05.U<<%>",4
M?U[T5_-1XK_X*7?MC_M*:=H_@']F_P )76DZU!91MK5QH=H^HW4\Y^5WBW1R
M"TM]W()RX/\ RUQP?FKPC^WW^VU\ /B8;7X@>)-6U.?2KD+JF@^)%9BZD M&
MRRJ)8"5(*,A7'!P5." ?U)_'B3XC1?!?QM)\(H_-\:#2+S^R%&-WVORF\O9N
MPOF \IN^7=C/&:_%W_@FM)^WI-^T)=?\+ED\9?\ "$BPNFU,>*Q?>09\ 0"V
M^W# F\W!/EX_=AMW&*_6CXO_ !1N+K]D7QA\:/AW>26$UQX*O=>TFYVKYL)D
MTYKJWDP=R[ERIP<C/K7XS?\ !,C]J_\ :*^,7[3L7@[XF^.]0\0Z*VCW]P;6
MY,?E^;%Y>QOE13D9..: /Z+**_GW_P""J?[4W[0?P6_:(T/PC\*_&]]X;T>?
MPS:7CVUKY85KB6[O(VD)9&))6-!UQQ7SBG[9?_!1/]H_PIIFB?!.RUTV'A73
M[>UU.^T*T:YNKV\CC'F7%S=K%E9)3EEAB*\=G(W4 ?U+45_*_P#LF_\ !2/]
MHKX??&+0_"OQC\27GBOPIJ=]%INI6^JJ)+NS\V3RC-%*P657B8Y=')#*"N V
M&7]]OVQ/VHM _9,^#MU\1M2M1JFJW4RV.DV!8H+F]D5F&]@"5CC16=SZ#:#N
M9: /JJBOY6?!WQU_X*?_ +9.MZKJ?PCUG5YK;3V'G1Z-+;:-I]KN^98A-(\*
MLV.0KRO(1R<BNQ^&O_!1;]K_ /9=^+1^'G[4L=UK^G6LL,.I6&J0Q)J%I"Y!
M-Q:W$2CS3L.Y=[21R#A67.\ '].M%9.@:[H_BC0].\3>'KN._P!+U:WBN[2X
MB.8YH)T$D<BGNK*01[&M:@#^-/Q'^US^U_>?$+4_#GAWXH>*[BXGU2>TL[2V
MO[EY'=IS'%%%&C$LQ.%55&2< "NTU[XH?\%.?!&FS>)/%>H?$W1--LQOENM0
MM]4@MHU'=WGC" ?6OGWP-J^F>'_VJO#^OZW<I9:=IOC2TN;F>4[8XH8=25Y'
M8]E5023Z"OZH_'?_  4$_8U\*^&+_5+_ .(VE:]&D,G^@:<WVZXN?E/[I8D!
M7+_=^<JG/S,!DT ?DY^PQ_P5"^+]U\5/#WPE^/\ J*>)]#\3W46G6VIR0QPW
MME=7#".#>\*HLL3.0K[UWKNW[\*5/]'5?Q0?LM_#SQ!\:?VHO!>@>"]-:(3Z
M[;ZA,L .RQL+>X6>:0L!\JQ1C"DXRVU1RP%?U:_MB?M1:!^R9\';KXC:E:C5
M-5NIEL=)L"Q07-[(K,-[ $K'&BL[GT&T'<RT ?55%?RL^#OCK_P4_P#VR=;U
M74_A'K.KS6VGL/.CT:6VT;3[7=\RQ":1X59L<A7E>0CDY%=C\-?^"BW[7_[+
MOQ:/P\_:ECNM?TZUEAAU*PU2&)-0M(7()N+6XB4>:=AW+O:2.0<*RYW@ _IU
MHKPCXN_M#_#[X1_ C4/V@M0NAJ?AN"PAO;(VS F_^V;1:)"3_P ]FD0!L84$
ML> :_FTUG]NK]OC]JCX@R^'_ (2:AJ5@\_F2VVB^%X?+,$"XRTDZKYS #&Z2
M20+D\!<@4 ?UA45_)[IG[<7[?O[*7Q!AT#XMZCJ=[)$$FGT;Q1#YHN;=B0&C
MG8>< <$+)%)MW Y#8*U_2)X&_:/^'GC3]G6S_:9:=M.\*2Z1-JUUYGSR6RVH
M<7,)V_?>*2-X_E^\P^7J* /?J*_EO\9?\% ?VV?VL_BI_P (/^SI]M\/6EY(
MYT_2-%2/[7Y*?\M;J]<!A@<NV^.)<CCH35\1_M'?\%-?V+?$NBR_&?4-1DLK
MUF>.VUQ[?5K&^5,;XOM<+R,& ()$<ZNN03P>0#^IJBOG;]EG]HKPS^U%\&M(
M^*WAV(6<UP6MM1L=_F-8W\./-@+8&1AE=&P"T;*Q )P/YT?B[^WY^U)\._VI
M?&=K!XZU"\\.>%_&6H1II&Z**WEL;'4746A81$JC1)Y9."<'/)H _JWHK^5O
MQQ\>O^"H?Q6\.7OQ^LCXFT'P.BM=1-HL#6-A!:+\V^-$Q--"HY,SF08!+/@<
M?7'_  3<_P""C7Q'^(GQ&L_@%\>]177)M:20:-K#QI'<BXA0R?9K@QJJR*Z*
MVR0C?O 5B^\%0#]-_P!L/]K#1OV0?A]I'Q UOP_<>(X=6U1-,6"WG2!D9X)I
M]Y9U8$ 1$8QWJK^QS^UWH7[8/@O7/&&A^'KGPXNAZ@+!X;F9)RY,2RAU9 O]
M[!!';KSQ^ W_  4BOOVLY_B!XJM?BJNM#X5Q^*;K_A'3>1!+#</.%O\ 9W"@
MM^XW[>3\N:\2_9?U#]N6T\-:M%^RHGB!M$>\7[?_ &/"LD/VORU \QF5L-LV
M]^E ']DM%? G[<_[:$'[('POTF>RLXM7\=^)@\.F6DY/DQ^0J^?=7&P@E(RZ
M@(&!=F ! #$?A?X5^-__  4Z_:@N-3\4_#;7O%.KVNGR[9VT0KI]E"^-PA40
M^3&S!2#LRSD$%LYR0#^LNBOY@/V=O^"HO[1'P7^(D?@C]I2>Z\2^'H+LV>IQ
M:C;B'6-+8/LD<,$21VB.2T4P8G&U2AYK]G_V^OBMXH^'_P"QKXN^*/PGUU],
MU-$TF6QU&UVL?)N[^VC+1E@PP\4A&<=#Q0!]P45_(W\/O^"DW[9MEI&N>$-)
M\27GBCQ%XF:UAL+F>!+RYL1%YAE%I;B(J\LVY1N96VA3A=Q#+^W'_!,V^_:<
MU3X<^+]2_:=7Q FK3:M']@'B&*:"?[,(%W>5%,J,L>\]E SGWH _2IW2-&DD
M8*B@DDG  '4DU_-)^U)_P5N^,7B3QSJ/AC]FV[A\,^%K"=K>WU$6T5U?ZCL8
MKYP^T(Z11R=8T6/?CEFR=J_T4?$GPWJ?C'X=>*?"&BW:Z?J&N:5?6-M<N"5@
MFN8'BCD8+R0C,&..>.*_)']D;_@E1J_[/_QQT?XL^/?%&E^*;30HYWM;2*UE
M4K>.FR*;]X2N8\LR\9#;6&" : /S'\-_\%+?VY_A=XBMY/%OB.75H_EE?3==
MTV%$FC8YSN2*&=0<$ HX%?TG?LJ_M&^&OVIO@WI?Q5\.VYT^69WM-0L6<2-9
MWT 'FQ;P!N7#*Z-@$HRD@'('Y/?\%N_$W@5])^&W@\>3+XRBGN[W*X,T&FN@
MC(<]0LTP!0="8F]*]B_X(KZ#K6G?LZ>*]:OHWBL-7\1RFSW# D$%K!')(OJ"
MWR9]4([4 =K_ ,%!?^"BL/[,4Z?"SX7VUOJWQ#O(%GGEN/WEKI4,O,9DC4@R
M3NOS)&2 JE7;(*JWXF:7\9O^"BO[25[?ZQX-\1>.O$B1R9N/[ :[@LH7(R$*
M6 C@0XY"X!/85X5XRU;7OVD_VF-1OI9PVI?$/Q/Y,+=5C^WW0A@4?[$:LJJ/
M[H%?VB?#+X;^$/A#X#T7X<>!+%-.T30K=+>"-  6VCYI'( W22-EW8\LQ)/)
MH _D]\+_ +;O[=?[-?C!=*\7^)==>ZM2DEQHWC".>Y,D9Z*RWN+F-6QP8Y$/
MH<5_2A^Q]^U9X3_:W^%2>.]#MSI>KZ?*+/5]-9P[6MV%#91NKPR [HW(&>5(
MW*P'+?ML?L9>'?VQ/!&DZ#-JD7AG7]$O%N+75OL8NY%@9666V*^9$QCD)5L;
MQAD4XZY\Z_88_8+U3]C37/%FIR>/E\5VOBFVM86METTV0CDM7=DD+&XFW8$C
M*!@=>M 'Z-T5_.%_P43_ &Z?VH?AI^T_KOPQ^'?B2;PAH'AF.R^S1V]O S79
MN+6*X>>5Y8W+@M(4"@[ %P5W;C7[3?L=?%3QA\;/V:/ ?Q/\?0+;Z_KEG(UU
MLC\I96@GD@6<(.%$Z1K+@87YN !@4 ?2]?R9?MA?M8?M,>$/VH?B=X7\+?$[
MQ#I6D:9KEW!:VEMJ$T<,,2-A41%8!5'8"OZS:_BO_;E_Y.^^+G_8PWO_ *'0
M![=?^,O^"I_A_36\1ZG<_$ZVT^W3SGN)8=2:!(P-V]R4*A,<DMQ7T'^R%_P5
MA^+7ASQOI/@O]HS4D\4>$M3FCM7U26*.&^T[S#M69GB"+-"I.9?,!D"Y96.-
MC?T"6WQ;^%?AWP=9ZOKWC'1]/LK6SB>6:>_MXT15C!))9P.@K^,W]HS7_!OC
M?]H+Q]XC^&-N%\.ZSKE[-IJ11^6'BEF)5DC !42$[E7 (! P.E '] 7_  5[
M^,7Q2^$?@WX;WWPM\6:CX6FU._U!+F33;E[<S)'%$4#F,C< 22,^M?CKX+^-
MO_!1?XD:;/K'P[\2?$7Q386LIAFN-*_M*^ACE"ARCO KJK;6!VDYP0>AK]&?
M^"PUEJ6G? WX$Z?K))U"U-Q%<$\'SDL[=7S_ ,"!KV7_ ((F_P#)O/C;_L:9
M/_2&UH _*'3/V]/V]O@CXCBM/%7BO5UN80&?3?$UEYGF(?[ZW,:S ''WE=3[
MU^]'["W[?/A?]KO2KKPYK-C'X=^(&BP+->6"/NM[N'.UKFT+$OL5B \;9,>Y
M?F<'=7TG^T?^SWX$_:4^%VK?#KQM8PS27$,AT^]9 9]/O-O[J>%\%E(;&X#A
MURK9!(K^1_\ 9*\::Y\&?VL?A[K<+_9[BP\06^G7BYX-O=R_8[M#Z_NY'Q[X
M/:@#^CS_ (*F?$;QY\+OV7O^$H^'.OWOAO5_[<L(/M=A.]O-Y4BS%DWH0=IP
M,CVK^?OP-\?_ /@H+\3Y+R'X:^+_ !_XLDT\(URND2:A?F 2Y"&06X?8&VMM
MW8S@XZ&OW0_X+$?\F@_]S#IO_H$U?E'_ ,$QOVL_@_\ LKZM\0;SXM7%Y;Q^
M(X--CM/LELUR2UJUP9-VTC;Q(N/6@#CO^$C_ ."KO_/+XM?^ .L__&Z_H:_8
M*O/C!??LN^%;CX[KJZ^,_-U$78UV*:'4=@O9A#YJW"K)_JMNTL.5QCC%>"_\
M/>?V-O\ H(ZU_P""M_\ XJOT?\)>)](\;>%=&\9^'Y&ETO7K*WU"T=U*,UO=
M1K+&2K<J2K D'D=* .7^+OQ5\'_!+X<:[\4?'=U]DT;0+=IY2,;Y7^['#&"1
MNDE<JB#/+$9('-?RS^*_^"J_[:.M>)M4U;P]XU3P_I=W<RRVNG0Z9ILZ6D#,
M2D(EGM7D?8N!N=B3U]J]D_X*-?M.>(?VLOC?I7[-OP6\S5O#NB:BME;QVIW+
MJVM.WDM*#G!BAR8XF^[]^3)5E(_.S]HOX/2_ +XQZ]\(;F^&I7/AU;.*XN%&
M$>XFM(9YM@P#L$DC!,\[0,\YH _N&LI'FLX)9#EGC5B?4D9-6:SK61XM(AEC
MC,K) I"#@L0O &>.:_E!TK_@IS^V=-\9;;7Y/$#SP3:DB'PT+. 6C1M+M^QJ
MGE^:#CY ^_S<\ELT ?UGT444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]?]
M_**** "BBB@ HHHH ^+?^"B7_)EGQ5_[!L7_ *50U^'?_!&?_D[34_\ L5M0
M_P#2FTK]Q?\ @HBI;]BSXJA1D_V;&>/:YA)K^2KX._&[XH_ 'Q7)XW^$>N'0
M-;FM9+)[A8(+@FWE9'=-EQ'*G+(ISMSQP>M ']TU?CO_ ,%K?^39?"/_ &-]
MK_Z;[ZOR _X>=_MS?]%.D_\ !5I7_P B5]A?M=_$WQQ\8_\ @EK\%OB1\2-3
M.L^(]8\6SFZNS%% 9/(.L01_NX$CC&V.-5^51G&3SDD ^C_^")<23_!?XD0R
M#*2:[$IYQP;10>17Y&::WC#_ ()[?MEVU[K.GQ:S>> =1E*Q>8%2^T^ZBDA#
MHZ[MC26\I*Y!,;\,N5(K]<_^")B.?@K\1RKF+=KL0#X!VG[(G//''6OP^G\3
MZ_\  WXY>)9I3X<^)NI6UU=VL]UJ=I!XATW4'ED#-<H+@.&D9AD2#YP2PSRP
M(!]H_M\_\% ](_;&\->%OAE\//"=[I>FZ?J"ZA*]Z8Y+NXO?*>WBBBC@+@(!
M*_.XLY*_*NWYOV7_ ."8OP%\8_ +]F*WTKQ]:2:;KGBG4[C7)K*8%9;1)XH8
M(HI5/W9#' KLIPREMK ,I%?A]X%_X*/_ !0^$>I1:AI'P>^'6E7W.+BW\-'3
M+HJ>H62UFAQZ?=-?MO\ L2_M]>%OVS(=;\$ZIH;^%?&&E6AN9K2.<W$%S9L5
MA>>"4HC*4D=0T;#*[E(9^=H!^2_[0W[;GPJU'XVWZ_LT? [PMJ6M?VPTL/B+
M4-,-]J6HZF;C>+JUAB*$-)-\T9?S'?()52<#4_:)\4_\%5_%OP&\3ZK\<-'&
ME?#6:"%M4CDMM'MI!$;B/RP8B3>J1+L^Z P[\9KXBUOP?\9OV#?VC=+U3Q%H
M:IK/A#4!>:?)=PL^GZC"C$)+&RD;XY%S]U@Z'(.UU('UA\?/VU?VL?VU?A+X
MATKPYX.3P_\ #OPY;K?>(Y].WM'*D3J46>ZG(&T/M98(QO8@D[E7Y0#TC_@B
M03_PNWX@+G@^'DX_[>XJ^2_^"G?_ "?-\3O^NFE?^FJSKZT_X(D?\EN^('_8
MNI_Z5Q5\E_\ !3O_ )/F^)W_ %TTK_TU6= ']8/PBTC2M"^%7@_1]%LX;"QM
MM(LDB@@C6.)%\E3A44 #DYK^0CX!6T.F_MW^!;*Q7R8+?X@V,4:KP%1=350H
M]L<5_83\.%*_#WPNK#!&EV0(/;]PE?Q_?!%2O[??@Q6&"/B+9@@]O^)JM 'U
ME_P6EN;V3]J7PY;3Y$$/A*R,(SP0]]?;FQZDC!^@K]H_^"<.DZ+I'[%GPR70
MXT1+NRGN9V48+W,MU*9BQ[D-E>>P Z "OD'_ (*Y?LG>,OB[X>\/?&WX::7+
MK.K^$H);+4[.V0R7,NG.QECEB0?,_D2%]R*"VV3<!A6K\H_V;/\ @HC^T7^S
M-X'D^$/@JRTS6M,^T2M9V^J6L\T]E-.272#R9H3AI#O*.'^<G&,D$ Z[_@K7
MH6BZ)^V/K$FCV<5FVIZ7I]Y<^4H42W,B,KRL!QN8*NX]SR>237](O[(__)JO
MP<_[$_0?_2"&OY ?VC-,^.,/Q'?Q3^T+!=0>+_&5K%K;B]PLYM[DLD.Z(?ZD
M!8]JQ$*8U 7:N,#^O[]D?_DU7X.?]B?H/_I!#0!]#5_$O\+O^3P?"/\ V/=A
M_P"G1*_MHK^$W6/$6L>#/C#>^+-"D%OJNA:]+>VKL@<1W%K=&6-BC @X=02"
M"#T- ']V5?SP?\%L_BKH&J^(?A_\'=*N4N-3T)+O5-21&R8/M8C2V1L='94D
M<@\A2AQA@:^*]1_X*8?MU^,K=]#LO'4L9N%*L--TJQCG(/\ =DCM_-0^Z,I]
MZ7X"_L!?M0_M2>,5\0>+-.U'P[HNIS&YU#Q%KZ2K),';+O$DV)KF5^<$?(3]
MYUH _5C_ ((ZZ.G@3]EKQK\3/$P-CIFH:S=7(G968&RTVUC$DH"@DJK^:O )
MRI %?>7P_P#VO_V7OCQX@/PR^'?CNVUW6=4M[C;:10W,4CQ)&3*5:6%%RJ9/
M7->N> /A'X'^&?PLTSX-^%++[/X9TNQ:P2%CN9XY ?->1L?,\K,SNV.68G%?
MR<_&+X ?M&?L"?&N/Q?H$=]:6FAWKR:%XGMX/,M;B%@0HD.&C5VC8I+!)U^8
M89"&(!]U?MB_\$G_ (=_!KX+^(/B[\(_%6K32^&(A=W5CK+6\ZS6^]5?RI8(
M8"CH#N 96#8QD'FNC_X(\?M/?$;Q)XRUS]GKQMJ\^MZ-!I3ZII+W<C32V;VT
MT44EO&[9;RI%FW!2<(8_E W&O@KXV_\ !1O]J#]I'P&WPB\0OI]II>J-$EU%
MH]E)%<7^QPZ1R,TDIP74$K&$W8P<C(/Z:_\ !)']CWXB?"S4-<^/OQ3TJ;P_
M<ZSI_P#9>D:?=*8[HVTLL<T]S-$P#1!C%&L8;#$;R5"E2P!^XM?RY_\ !7']
MH?QMXR_:!U+X%0ZA);^#_!*6?^AQMMBNK^XMDN7N)0,%F03") V0NTE0"[$_
MU&5_/3_P54_8>^)OB#XEW?[27PIT>X\2:?K%M;IK=G9H9KNUN+.)8%G6%1N>
M%X8T#; Q1E9F^4Y !XAXW_X)6^*--_9*\-?'/P%J=SX@\93Z=#K.K:,$3R_L
M-U$LZI9!1O::W1OW@+-YO/EA2H5_F+X<_MM_$7P5^S#XY_9CU"6:^TC78(5T
M6Y$A672I/M<4MS$&SDP2Q"3"@_)(<CAFQVGPH_X*8?M9? WP5:_"_3;ZQU#3
M]$C^R6BZQ9&6YLXH_E6%75XF*QXPHDW;1\H^4 #Y>U3X??&_XJVWBOXY'P=J
M%YI/FRZGJFI6>FF#3XC/(6=U\I%A506)(085<L< $T ?J]_P17T;Q?KWQ7\?
M>/=1NKNZTC2M%CTW=-,[Q?:;VYCF4 ,2"P2W;I]T'G&X9_HQK^=C_@D-^UOX
M+\%RS?LQ>,+2WTFY\1Z@UYI&IJ-OVN]F5(S:7!_OL$40-T)_=_>*;OZ)Z /Y
MKO\ @MO_ ,EL^'W_ &+TG_I7+7Z=?\$I?^3(?!/_ %]:O_Z<)Z_,;_@MNI_X
M77\/FQP?#T@S]+N2OAWX1_M\_M1_ WX?V/PP^&/BB'2M!T]IWMXFTZSN'1KB
M5I9#OGA=CEV)YSCITH _J2_;.^*N@?!W]F7X@>*]=N4@DN-*N].L49L-/?WT
M3PV\:#J3N;<V!PBLQX!(_F9_X)E>#[_QA^VE\/\ [+ TMOHDEWJ=TXZ116UM
M)M=O8S-&@]V%<CK$7[;/[;?B>T;6+/Q'\0;N$GR<VQAT^U\W + *D5I;AL#+
M?(#@9/ K^A7_ ()[_L*P?LE>&+_Q+XSG@U+XA^)(UBNYK<EH+&T!#BTA8@%R
M7 :5\ ,P4 80,P!]O?%'XI^ _@QX(U+XB?$C5HM&T+2TW2S2GEF/W8XT&6DD
M<\(B@LQZ"OY8/VI?VL?C/_P4 ^*6F_#CX?:1>+X;-WLT/P];?/-<2X(%U=E3
MM:79DDD^7 F<'[\C4/\ @I7\=OB3\4?VE?%O@;Q1J;-X<\#:E/I^E:?%E+>)
M8_E:9ER=\TG\3MDX^5<* *\$_9\_:J^*/[,=QJ6H?"B/2[74M5 2:^NK"*ZN
MA",'R4DDR4C)&YE7&XX+9VK@ _IF_8&_8@TC]D?P3<:CKTT6J?$'Q+%'_:EW
M&,Q6T2_,MG;,0#Y:MR[\>8X!P J@?9_CWX;^ /BEH1\,?$CP[8>)M)+K+]FU
M"W2XC61<[74.#M89(##!P2,\U_-G\'/^"I?[77C/XN^!_!^NZSIDFFZ[KFF6
M%TJ:9"C-!=74<4@5AR"58X(Z5]N_\%E/&_QL\'>!/ 2?#W4M1T?PG?7-\FM7
M.G220;KA1#]CBGEB*L$8&8JI.UF'(RJT ?KEX$^'G@3X8>'X_"GPZ\/V/AO1
MXG:06MA EO%YCXW.50#+-@98Y)QR:[*OQ?\ ^"-7QC^)'Q&\ _$+PCX[UF[U
MVS\*W>G2:?->S/<2QK?I<>;"))"S;%,"LJDX4L<=:_:"@#\?/VI?@=_P3P^.
M/QKU3Q/\8OC'_87C"!8M,N["VUNPMEA>T_=A&BGMY75QT8;NO85].0_\$W?V
M-X? +> ?^%>VLB-!Y)U)W<ZH7VX\[[5G>),_-@83/&S;\M?D%_P5"_8F^)NA
M_&#7/C_\/]%N?$'A+Q4RW=_]BC:>;3;P(J3&:- 6$,I'F+( 5!+*VW"[O"+'
M_@JK^V!IGPV'PW76K"26.V^QIK,MF6U=(PNP'S=XB,@7CS&B+Y^8L6^:@#P'
MX#W&I_"7]L?P7;^';QYI] \96NGK+%P;B$7PM95^DT192/1C7ZQ?M^_M)?MP
M_#;]I36?"GP.U'6;;PG!9V$D"66C0WL(ED@5I<3/:RDG<3D;CCIQ7S5_P35_
M8D^)/Q&^,7AWXX^/M&N='\$^$[N/5()[V-HI-3OH")+98%?#/&LH61Y<%"%V
M DDX_J,H _EV^%'[7?\ P4DUOXI>#M&\2:KXADTB_P!9TZWO%D\/6\:-;2W*
M)*&<62E04)R000.<BNX_X+;_ /);/A]_V+TG_I7+7]*-?S7_ /!;=3_PNOX?
M-C@^'I!GZ7<E &K^Q;_P3%^#'[2?[/'A[XO>,/$NOZ=JNKS7T<D%A+:+;J+6
MZD@7:);:1\E4!.6//3'2O>/B+_P1Q_9]\'_#[Q/XMT_Q?XHFNM$TN]OHDEFL
M3&TEM \JJ^VT!VDJ <$''>OJW_@E,I'[$'@@D8S<ZN1[_P#$QGK[%^./_)%?
MB!_V+VJ_^DDE '\G/_!-?_D]WX7?]?=[_P"F^YK^Q>OXZ?\ @FLI;]M[X7!1
MD_:KX\>VGW)-?V+4 ?Q/_MI?\G;?%_\ [&C5/_2AZ_M8L_\ CT@_W%_E7\5/
M[::L/VM_B\I!R?$^J8'UN&Q7]JUH"+6$'@A%_E0!\K^)/VY/V4_"'C:\^'/B
M7X@VNG^(]/N_L-Q:26]WNCN0VS86$)3J>N['?.*^9?VF?^"5OPG_ &@O&GBC
MXK6GBK6=!\8^(BDO+6]QIJS10I$N8/)6;:0@W8GZDD<8%?GG_P %2_V+OB=I
MGQAUC]H?X?:-=>(/"WB5([K4OL41EETR[@C2*0R1IE_)D""02XPK%@VW"EO!
M-*_X*O\ [8>B> 5\!#5M-N+B"W^RIJ]Q8[]415&T,7WB%I%'\;PLQ(RQ+9)
M,/\ 8:_:$^*?[-?[37A_X;?VO+)X9U;7XM!UG2VE:2R)GN/LK7$:'(62%V\P
M.@#,%VD[6(K^KCQ[\-_ 'Q2T(^&/B1X=L/$VDEUE^S:A;I<1K(N=KJ'!VL,D
M!A@X)&>:_E]_X)V?L=?%7XQ?'+PQ\7O%&D7>G>"?"^HPZS/J5ZCQ_;[FU<3P
MPV_F#,Y>4*9&'RA-V6W%0WZ*?\%D_&_QM\'^!/ 2?#W4=1T?PG?W-\FM7.G2
M20[KA1#]CBGEB(8(P,Q52=KL.1E5H _7'P)\// GPP\/Q^%/AUX?L?#>CQ.T
M@M;"!+>+S'QN<J@&6; RQR3CDUV5?CG_ ,$<O&OQH\9?"KQJWQ'U#4-7\-65
M_:QZ%=:A)).Q<I+]MBBEERQC0B$[02JLS8P2:_8R@#\?/VI?@=_P3P^./QKU
M3Q/\8OC'_87C"!8M,N["VUNPMEA>T_=A&BGMY75QT8;NO85].0_\$W?V-X?
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M )#&^<_)(42 >F\#BO[.9$25&BD&Y7!!![@]10!_&Q_P3M_Y/3^%7_82E_\
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M5EGMQ&&#*3AE1"I&.<YK]I?^"8O[1/C+]H?]G)M0^(EV=1\1>%=3FTB>]?\
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M6>."_@6YM7=.5\V%OED4'G:V5.,,",@_H@G_  5M_;,C18X]:TE54  #2H
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M)EO\)?"P#V^B7&D+/<;=K75W)=H]Q</[R2$D#)VKA1P!7RU_P1 _Y*1\3_\
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MWA+022>I)L(:_FN_X*ZJ1^V7JQ(P#H^ED>_[HBOZ4/V8/^3:OA+_ -BCH/\
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M_8M^(5YX<U+]K*XT6RN+6.ZATF35M<?1&D0F-IUC*75MYP4["<[MFX=-W/\
M-)\//B-^U1_P3L^*&I[=%E\.:G>1_9;VPU>V>73[^.)MR,I1U64*<[)89. S
M -AF!L?$SXH_M2_\%&?BAI,?]@MKFH6$9M;'3M&MI(["Q29@TDCM(\GE[RH,
MDLTN,*!D!0  ?MK^V'H_PB\"?\$R/&/A[]FBZLKCP+;/916\NF:BVIVZK/K,
M#7(6Y,LQ?,KLK@N<;B. ,5^%_P"QJW[7,/C37;C]CY)6\1+IX74&A33W<632
MJ<?\3 %0#(%SLYR!GBOZ6?AQ^QOHOA[]B5/V2O$UXLSZCI-S!?WL2[U34;R1
MKDSQ!MNY8)V!CR 2$7.#FOYRM+@_:B_X)K_'8>([G1GTZ]M?-M#)/%)+H^LV
M<A!*K*A02(VU7 #K)&RC<%92M 'TI\9/@W_P5K_:!\,6W@[XO^';SQ#H]G=I
M?0P/_85OLN8T>-7#V[1OPDCC&[!SR.F/T9_X)9? OXY_ +X;_$/PK\9?#4OA
MM+Z_M[VP26>"8REK=HYR/(DD QY<8YQFOR&_:/\ V^?V@?VT;/0_A?IWAZ+2
MK6*\2YBT_0DN)[R]O K1IN;<SLJAVVQHHY.6W$+M_<#_ ()P?LX?$;]GKX#Z
MO_PMIY(O$_BRZ:^ELI)O.:RMTA$<,3D,R^8?F=PIXW!3RIH _G;_ &#=&TG7
M_P!L#X5Z7KEI%?6;ZPDC0S*'C9H8WEC)4\':ZJPSW%?UR?M":7H^M? ;XC:7
MX@1'TVX\.ZJLX<94(+60EO8KC(/8C(K^*+X6:'\0O$?Q"T+2OA1%<2^+S<B;
M3%M)!%<_:;<&93$Q9<.NS*X.20 ,D@5]U?&S_@IK^U1\3_AEJ/P-\:6FFZ']
MKB^PZO<6]E-;:E<HORRPRK)*T<7F=)52)">5&U25(!RG_!+RZO;;]N3X;K9Y
M/G_VM'(H. T9TNZ+9]A@-]0*^[_^"Y/_ "%O@Y_UPUW_ -"L:G_X)'_L>>.=
M"\93_M+?$G2)M%LK:SEM- M[N,Q7%Q)=#9-=A&PRQK%NC0D?O/,)7A<M]!?\
M%??V=/B%\8OAYX,\??#G2+C7KGP//?I>V=G&9KDVE^L),R1*"SB)[<!@H) ?
M=C 8@ ]:_P""2O\ R99X<_["6J_^E35^%_\ P5%OM1O/VXOB+'J!8"U&E10J
M3D+"-,M67;Z!BQ;'J37H/[#G[:'Q_P#@7XL\&_LX:=9V3>'/$/B>RMIH-3LY
M?M=L-1NHH+@0LLD14X)8!U8!LG':ON+_ (*M?L/^._B+XBM_VC/@_I,NNW:6
M<=IKNFVB;[MEMLB&[BC'S3$1D1R(H+!41@"-Q4 _7']G'1-!\._L_P#PXT?P
MS%'%ID'A[2S#Y:A5</;(YDP/XI&8NQZEB2>37\FG_!0/1="\.?MF?%+3O#$:
M068U-)]L2A%6>XMXI[C ' /G.^?>O8?@]_P4\_:;_9^^&=O\&+&PTK48-!1[
M6RFUBUN'OK&/)Q#\L\2L(B<(LB': %.5 44_V1_V.?C+^V'\88/B)\0[&]3P
M;=:@=3UW7+Z-HQJ!>0RR16Q8+YTD[94LF5C!W'^%6 /VG_X*'7FH:C_P3<U_
M4-6S]NNK#PU+/N.3YKW]DSY/<[B:_//_ ((D:/I-W\5OB+K%U9PS7VGZ3:+;
M3NBM+")YF$@C8C*[PH#8(R!@U^G'_!4J-(OV%?B%%$H1$?1@J@8  U6TP /2
MOS9_X(?J?^%A?%%L<#2]/&?K/)0!_1C1110 5_$Y^R%_R=S\)/\ L;M(_P#2
MR.O[8Z_B=_9 4M^UU\) HR?^$NT@\>UY&30!_;%1110!_.=^W_\ M@_ G1_C
M7XE\(^"/@SX7\9^,-.F%EK'B+Q!9?:M]W;(L)ABB0QNY@"",N[XW+M"%0&:E
MXC^(G_!7CXA_";7M9O?#BZ)X%FT>Z:^CDL-(L,:8;=C,%AO3]IVF'.-J[O[O
M-?''[<'P0^*/[.G[4?B3QQJNE2?V/K?B"ZU_1-2>/S;.X2>Z-TL;-ROF1,P2
M2-L,<9QM92?IWQ?_ ,%"_P!L/]L3P-JOPB^%'@>WTLW%A</KM[I(E=_L*1DS
M@S3OY=K$Z9#;F+MD(K9.& /%O^"2Q(_;4\-@'&=-U;/_ ("O7I7_  6C_P"3
MK/#W_8H6'_I=?UYI_P $E_\ D]3PU_V#M6_])7KTO_@M'_R=9X>_[%"P_P#2
MZ_H _</]@#2-*TC]CKX6)I5G#9K=:/%<S"%%3S)YB6DD?:!N=SRS'DU_,-^V
MM;0:=^VI\3X[)!"O_"2SR_+Q\\CK(S?4LQ/U-?U%_L)*5_8]^$H88/\ 8%J>
M?<$BOY??VY%*_MK_ !/##!_X2%SS[["* /TQ_P""Y5S>B;X-69R+0KK\@YX:
M0&P!R/\ 9!X^IKZE_P""..DZ+9?LF7.IZ?&@OM1\0W[7C@?.7BCA2-2>N%CV
MD#H-Q/<Y[;_@I[^RYXD_:0^!UGJ'P_LSJ'BWP/=/?6EH@!EN[69 EU!%DC]X
M0J2*.K&/8 685^ _[-'[:_Q[_8M?Q!X0\*V%G/9ZC<"2\TG7+:?%O>1@(TBK
M'+!+'*44(P8D$ 97(!H ^U?^"VFA:+8_%_X?Z]9V<4&HZIH]PEW.BA7G%O.!
M%YA'WB@8@$\XXZ 8_4;_ ()9_P#)B_PY_P!_6?\ T[7=?S8_M3:Q^T=\1]=T
M7X[?M#V<]G+XZAF.CI+']GC6RLF5=MO;,2\4 ,F4W<R$E\L6+'^D[_@EG_R8
MO\.?]_6?_3M=T ?H+7AG[0G[1'PS_9G^'US\0OB9J'V>!<QVEI%AKN^N,96"
MWC)&YCW)PJ#YF('->YU_$C^U1\=OB3\?OC#KOBCXC:FUX]E=7%I96R92ULK6
M*5E6*"/)"CC+'EF/+$GF@#VOXC_$O]H__@I?\>['0]$TYY\,ZZ7I$#M]@TBR
M+ 23SRD8Z;3-.PRYPJC_ %<8_I5_8^_91\(_LD_"R/P1H<PU+6M1=;K6-39
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M>-=!\0V<6H:=>:/?)-!,H9' @<C(/<$ @]00".0*_E)_X)@?\GT?#'_?U?\
M]--Y7M6J_MS_ +<7[:?A.?X >#]$L<ZA;%=5NM$M9K>>:SC3,OVJ>6=XH(G"
MGS-@C#Y\L<-L;Q7_ ()@?\GT?#'_ ']7_P#33>4 ??G_  7+_P"/SX,?]<_$
M'\]/K[#_ ."0NCZ38_L?6&J65G#!>:EJVHM=3(BK).8I?+0R,!EMJ@*N2<#@
M5\>?\%R_^/SX,?\ 7/Q!_/3Z^U?^"2"D?L7Z$2, ZIJI'O\ Z010!\:?\%R;
M[457X.::"RV$AUV4@'Y7F3["HR/558X/^T:^EO\ @C9HF@V/[*FH:SIT4?\
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M_P!Z*!=I]IJ_9S]M;X/:[\>?V7_'GPO\+*LFM:E:PSV*,P3S;BQN(KM(@S<
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M_KII7_IJLZ^U?^"'ZG_A87Q1;' TO3QGZSR5\5?\%._^3YOB=_UTTK_TU6=
M']7_ ,'=&TGP]\)O!NB:%:16.GV>CV$<,,*A(T40)P /S/J>3S7\=_[9EEIO
MAW]KOXJ6_A?%O!;>)+V2(0_*(YFE,CA0.FV0L !TQQ7UAX>_X* _MK?LD^"+
M?X!^)]'LDGTZT1=,NM;M99[NVLYDW0&"6.=89XD5AY)82*H 0Y4!1YE^Q1^R
MI\3OVM/CE8>-O$UC<S>#K?5!JOB#6;I"(KMA*9I8$=L"6:X<%6VYV!B[= "
M?N[_ ,%2GFD_83\;R7">7*TFBEU_NL=2MLC\#7YU_P#!#[_D>_BI_P!@W3?_
M $=-7["_MK?![7?CS^R_X\^%_A95DUK4K6&>Q1F">;<6-Q%=I$&;@&4Q>6"<
M ;N2!R/Y9?@K\;?VBOV%/'^L:CHVAMHFJWT'V*^L->L)A&ZI)N4E"8G#*P.U
ME8<$]0: /Z.O^"BWQV^"?P6^$NE+\7O!5I\1+O6+UVT71;U%,#75M$0]S(SJ
MX1(5FVDA2Q,@4  EE_(GX"?M'?MW?$.UU;3/V-/A=H7A/06N_,N5\/Z-;V]D
MMP4 'FW.H2-"9=BKG+ XQP 17T)_P4,^&GQ>_:@_97^!W[2>BZ1_:E_INA_V
MAKUGI\;$Q1ZO;6L[3PPEG<Q1/$P< LP5@Q^568?$O[*?_!1WXL_LR_#27X,^
M$O!VF>(1)>3SV+W"SK<)<7. 4=(6!F&X<*-K=MV,8 /FC]K1OV@6^..LM^T^
MBI\0S#9F]"BRQY?V=/L__'A^X/[K:/EY_O<U_0;^VT2W_!*QF8Y)T'PAD_\
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M]O\ _8Y\#^/_   D7_"80V5IK^FP,RQK,UW;K]LL=[D*A8XVDG'F1*"0I+
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MR 2!D#Q#II/M\LPK^=OX ?M3?&C]F.YUN[^#NL0Z3+XA2!+PRVD%UO6V+F/
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M&L6KV,%\BG(6>)90#[!@:TJ* *=CI]AIEN+33;:*T@7D1PHL:#Z*H JY110
M57NK2TOH'M;V%+B&089)%#JP]P<@U8HH S]/TG2M)C:'2K.&RC8Y*PQK&"?<
M*!4M^;T6-R=,$;7@C?R1+GRS)@[-^.=N<9QSBK=% 'X _!3]CW]IG]J_]I6V
M_:6_;*TD^&M(TF:":'3'1()+DV+YM[2.V+.\5JK M(TOSR#(!8N77]_J** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JVUE966_[';QP>:=S
M^6@7<W3)QU-6J* "BBB@ HHHH **** "L2^\,^'-3N!=ZEI5I=SKTDF@CD<?
M\"8$UMT4 -1$C18XU"HH   P !T %.HHH *AN+:WNX'M;N)9H905='4,K ]0
M0>"*FHH IV.G:?I<'V73+6*TASG9"BQKD]3A0!5RBB@ HHHH *RKK0M$OKE;
MV]T^WN+A/NR21([CZ,02*U:*    8' %%%% !1110 4444 %%%% !1110 44
M44 %%%% !6;J.C:1K$:Q:O8P7R*<A9XEE /L&!K2HH IV.GV&F6XM--MHK2!
M>1'"BQH/HJ@"KE%% %>ZL[2^A-O>P)<1-U210ZGZ@\4EI96=A"+>Q@CMXAR$
MC4(OY# JS10 5!<VMM>0M;7<23Q/PR.H93]0>#4]% &3IF@:%HI8Z/IMM8%Q
MAO(A2+(]]H&:NWO_ !YS_P#7-OY59HH _C/_ .">@+?MH?"D 9_XFC'\K>6O
M[&)_#V@76HIJ]SIEK-?Q_=N'A1IEQZ.1N'YUJ+%$IW*B@CN *DH **** "BB
MB@#*NM"T2^N5O;W3[>XN$^[))$CN/HQ!(K5  &!P!110 4444 %%%% !1110
M 4444 0W%M;W<#VMW$LT,H*NCJ&5@>H(/!%0V.G:?I<'V73+6*TASG9"BQKD
M]3A0!5RB@ HHHH **** "LJYT+1+R\34+O3[>>ZCQLF>)&D7'3#$9&/K6K10
M 4444 %%%% !1110!^&7[97P$_;*_;)_:2_X5#)ID6A_"#PG=V\UKK!C$5LT
M=U!&TMP3(_F75Q'N>()$ BD$';DN?V1^%WPY\-_"+X=^'OAEX0C:/1_#5E%9
M6_F$&1UB7!DD( !>1LNY &6).!7>44 %,DCCFC:*50Z."&5AD$'J"#VI]% &
M-I_ASP]I,S7.EZ7:V<SYW/# D;'/7)4 ULT44 %%%% !1110 4444 %%%% !
M1110 4444 %4[W3[#4H?L^HVT5U%G.R5%=<COA@15RB@"AI^E:7I$/V?2K.&
MRB_N0QK&OY* *OT44 5[JSM+Z$V][ EQ$>J2*'7\CQ4ZJJ*%4  #  Z 4M%
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M0ZI:0WD:G(6:-9 #Z@,#5^B@""WMK:SA6WM(D@B3A410J@>P'%3T44 %%%%
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M /NVBOX9=8F\>^*_BU?>$O#E]=W.IZQKDMC9P"Z,8DGN+DQ1)N=U1=S,!EB
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MC26.Y"+\J&1' <#"[U8J%4@#[PH **** "BBB@ HHHH **** "BBB@ HHHH
M**_"/4_^"LOQ1TW]I2[^"?\ PA&C2:7:^+9/#WVGS;@7#0)?FT\S[Y4.5&[[
MN,]L5^[E !1110 4444 %%%% !44UQ!;J'N)%B4G +$*,GMS7Y ?\%4_VSOB
M'^S[8>'/A5\([W^QM>\46T]Y>ZDJJT]M9*WDQI;ELA'E</F3&Y @V$,<K^,_
MP>_8O_:R_:\TN;XF^'[5M5TR::6'^U];U$*;B:+[ZH96>9\$X+;2N[(W9!P
M?V.45_&5!XQ_:W_8%^*O_"*R:GJ'A+6--\N=]-DG^TZ9>V\ARK&(,T$T4F"-
MR_,I# ,CJ<?UB?LV?&BR_:&^!OA#XQ65M]B_X2*T+SVX.5ANH)'M[F-2>2JS
M1N%)Y*X)H ]QHHHH ***_F+_ ."R^M:QIW[4_A^#3[^>UC/A&Q8K%*R*2;Z^
M&<*0,\4 ?TZ45\H_L,3SW7[(7PGN+F1I99-"MBSN2S,>>23R:^KJ "BO+/CE
MX^O_ (5?!GQQ\3-+MH[V\\*Z+?ZG#!,6$4LEI TJHY4@[25P<'.*_,K]AO\
MX*3_ !"_:H^-K?"SQ5X1TO1K,Z7=7RW%E).9!);M& I$C,"I#G/0].>U '[$
M4444 %%%% !1110 4444 %%%% !117\QW[=W_!1GXR^-/BUKGPE^!>O7?ACP
MIH%Y+I@GTIVBO]3NH7\J23[1&?,6,R K$L17<OS-DL H!_3C17\;OB;Q!_P4
M _9W&E^.?&>L^.O",.I2?Z/<ZA=WH@FEV[O+E65VC+E03Y<JY(!.W@X_H&_X
M)P?MDZU^U?\ #75K+QZD2^-O!LL$-_+ @CCO+>Y#F"Y$8^5')C=9%7Y=RA@%
M#!5 /T<HK^4/_@J_KNMV/[9OB*WL=0N+>(:=I1"1RNB@FU7/ (%>:^&_V(OV
MZ?$/@+2_BOX0\/:AJ.B:I91:E9S6FL6QN9+:5/,1T@%R)RQ4C"!-^>-N: /[
M!J*_DN_8Y_;Z^/'P4^*^@^%?'/B2_P#$?@O4+^*PU+3M7G>=[19I!$TT$DVZ
M2%X"=QC!"-@JR@D,O]:- !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!__]+]_**** "BBB@ HHHH ^+?^"B7_)EGQ5_[!L7_ *50
MU_/[_P $KOBE\._A%^TK?^*/B;X@M/#>DR^';VU6ZO9/+B,\D]LRIN/<A&(^
ME?T!?\%$O^3+/BK_ -@V+_TJAK^7W]C_ /9@OOVM?BI<_"_3_$$?AJ6WTRXU
M+[5+;FZ4B"2*/9L5XSD^;G.>W3F@#]N?^"AG[=G[-'B7]FWQ3\+/ 7B>U\9^
M(/%<<-M##8AY8;=4GCF:>6;:(QL"?(H8L7QQ@$CX$_X(W>%=:UC]JF]\2V<;
M_P!G>']!O&NY1]P-=/'%%&Q]6.Y@/]@GM7TOX?\ ^"')6_CD\5?%W?9*P+QV
M6C[977N%DDNF5#[E&^E?L'^SO^S5\*?V8/!'_"$?"S3FMXKAQ->WEPPEO+V9
M1M$D\F%!P/NJJJBY.U1DY /Y%OCKXEO_  9^V-\0O&&E)'+>Z%X\U:_@28%H
MFEM=4EE0.%*DJ649 (..A'6OIGXM?!+_ (*.?$WP/J/[3/Q0BUF?1A"VIO%)
MJ"P2VMD/WAEBTU90T$,:_-L6-6507*XRU>'^/55OV^_$2L,@_$V[!!Z$?VTU
M?UW?&R-)?@SX]BE4.CZ!J@8$9!!M),@B@#\'_P#@DG^UI\4-3^+<G[/WCW7K
MOQ%H6LV-S<Z9]NF:>:RNK1?-=8Y),OY4D0?*%L!E!4#+;OHG_@J)^WCXS^".
MHV7P(^#%[_9?B/4+-;S5M50!IK.WF++%!;DY"3.%+LY&40IL(9MR_EI_P2N_
MY/D^'_\ URUC_P!-=U5#_@J$E^G[<GQ(-_\ Q'2C$>QB_LNU"X_D??- &W\-
MOV-?VZ?VCO!*?'#0[J\U&VOS+-9SZIK31WU\48JSP^<Y.&8$!I&0-U!*X-=_
M^QI_P4$^-'P ^*EC\-/C9K-_K7@J6]&F:C;:O(\UWH\@<Q&6*28F1%@?_6Q,
M2NT,%4-@U_2'^SQ/HMQ\ OAO-X<9&TMO#>D_9MA!41"TC"CCC('!]Z_DS_X*
M&SZ)<?MH_%63P^R-:C4T5RA!'VE+>);GIQD3A\]\YSS0!_3%^WK^T'XA_9J_
M9MUOXA^#%C_X2*YGMM-TZ2:/S8H9[ICF9DZ$QQ*[(&RI<+N!&0?YS/@3\+/V
MG?V^_%GB%(/BE%)J^D1Q7$H\0ZQ=+),)2^T6T$23$I&4^?:BI&"OJ!7]*?Q4
M^$/@/XW_ +,>G_"SXUWZZ5;:KING!KLS1P2V^H0Q)(LD32_+O5U.5(^9=RG@
MFOYZOB!_P2W_ &G/ ]W-XB^#]UI_Q(TFRF;R;W0+Z..\CV<@O!(Z%9<$$I"\
MI&1S0 OPS^+?[8W[#/[01\ ^*;S5M:TK1KZ"#5]*:2XU'3;FUG5',ML2#M<Q
M.KQN@5@<*ZD!DK]5/^"QWBGQ+X6_9M\*WWA;5[O1Y[CQ7:Q226=Q);N\9L+U
MMC-&5)7<H.#QD ]J_(OX.?\ !0#]KG]ESQPGACX@ZCJ?B#3=)F$.H^'?$AD-
MRB\91)KA3<V[JIR@R4'&48<5^G7_  6$\1Z;XP_8^^'/BW1RS6&M^(]-OK<L
M,,8;G2[V5"0,X.UAF@#\I_V>?%W[<GQ]\/7W[.WP0UW5;NPN+MM5U2[%[)"\
M:2QQP!+F_D?='!B/*PH09&+?*^ %YGXC:!^V%^PA\3=.37?$&H^'-9N4^V6E
MW9W[W-E?1JV'!R3'* V!)'*GIN7!4G]9/^"(<^G'X7?$JUCDB^WKK-H\B KY
MPA-OB,L/O;"P<*3QD-CO6'_P7#N-'_X1/X46LC(=5-[JCQ#C>+?RH!*?7!?R
M_;(H _3']D;]H1/VG/V<]$^*=Q#':ZM-%-9ZI!%_JX[^U^278,DA)!ME1220
MK@$DC-?Q_?!?XB>-_A1\3] \>_#:%;CQ1ILKKIR- ;G-Q<Q/;KMA7EW'F91>
M06QE6&5/]$/_  1B6\7]E3QBTW_'NWBN^,6>N?[/L0WX=/QS7XL?\$]U5OVS
M_A2&&1_:I//J()2* /0/CS^S]^W_ ."_"1_:"^-TFM&S>6)[B[EU@7%S9-<,
M%B,L4<S- I9@@  "$A"%)"U^G?\ P2%_:I^(WQ4@\4_!;XF:O/XAE\.6L.HZ
M7>7<AENDM2XAF@DD;+R*C-&4+$E0Q7.T*!]T_P#!0V-)/V+OBJLBA@-+0X(S
MRMQ$0?P(R*_%W_@BC_R<KXP_[%&Y_P#2^RH ];_X*9_\%!_B/H7Q'U+]GKX'
MZS-X<M- "1ZSJMD_EWD]VZ!VMX)E.Z*.(,%=DVN9-RY"K\WQQ8?L,?MXZU\-
MD^/-M'>RQSV7]I1PMJS?VQ):E?-$BQ%]VYD^<1E_-/0)N(%?/_Q^\JW_ &S/
MB$WC#FW3QWJC7N>AA_M.0OC/\)3I[5_:O#)#)"DMNRO"ZAD92"I4C(((XQCI
M0!_./_P3<_X*&_$Q/B=HOP%^-VN3^)M#\3RK9:7J-_(9KVSOGX@B>=SOEBF;
M]V Y9E=EVD+D5^H'_!13]K#5?V5?@G%J/@TQ_P#"9>*KDZ?I3RJLBVP5-\]T
M8VX?REVJH.1O="P*@@_S/;[2]_;.\SP(5:UG\?YTLQX*F-M5_P!'V[>",;<8
M_"OU:_X+EI>?:/@S(>;79KX7VDS89S]1C'T- 'YW?!;X-?MD?ML^(-8\4^%-
M;U'6I=*=3=ZOJNJRQ11SR#*Q)(S,Q?;R%C7"+C.T%<^<_M0ZM^T=IOB'2?@_
M^TK+<W&O?#^*6WM)+V3[1<-:7;+*O^E!F^T1<9C<DD E"?E"K_0#_P $<I]'
MD_9'GBTXI]KB\1:@+T+C=YQC@*EL<_ZK9C/85\*_\%NI],?XM?#B""2%M0BT
M6Y,ZJ5,RQ-<?NMX'S!20^S/&=V.] 'Z;?\$OV9?V#/A^RG! UL@CJ#_:MY7X
M*_L%?%#XEZY^V'\,-.UOQ;J^H6MUJC":&XO[B6.0>1*<.KN0W//-?O3_ ,$P
M/^3"_ 'TUO\ ].MY7\[O_!/7_D\_X4_]A5O_ $1+0!^]/_!37]M3Q%^S#X-T
M?P3\,I$A\;^,5F=+MU63^SK&'"-,J-D&61VVQ;@RC:Y(R%K\B_@W^Q[^W+^V
M%X7;XU0^,'CLKN61K.]\0ZQ>K->O$Q1FMQ&D[!5=2@9MBY&%X''=_P#!::._
M7]J3PW+<<V[^$;(0'M@7U]N'UR<GV(J#]G[]D#_@H#\2/@[X9\:_"#XLOH_A
M#4X';3[./Q-J=HL")*\;IY$"&.,B16RJG&?>@#(^ /[9_P"TE^Q?\=Y/A%^T
M'JNH:GX;L=02SUS3M3F:_FLHW Q<V4S,[!51EE548QRH>%RRN/UH_P""GW[4
M_C;]G7X*Z''\++M;'7_&]X]K'J(02-;6<47F320$_*)6+1JC$'"EBHW ,/QT
M^)/_  3X^/TWB^\E^+_QB\#/XI=8OM+:[XK<Z@5$:B+S#=1>;CRPNW=_#C'&
M*_<?]H3]F7P!^T-^S3X,^&'Q:\56FB>(=)T^RGL-8AGB:,7\-HL4LB"0IY]O
M(6RP!4D;6!4@4 ?@K^S]^S%^U#^VYI&O?$+P]\3;2YO](NC%+#KFMWC:C)+L
M202!$CG98V#[5D<J"P*CH2/<_P!AW]H?]JCX'_M*:1\#/B1-K&L^&=0U@^'M
M0LM1,]Y'87+3FW$UM,V[RQ'-][:WELA8D9VLOBOC+_@F[^V-\))QXO\ AS:I
MXQL+?>\&K>$;_P V7"DCY(@8KDMD$$1HX!&,FO0?V3O^"EO[0GPE^(^D^!?C
M1JUWXO\ "EQ>1:=?0ZOEM2T\M*(GF2X<><SQ'[T4S," 5&QCN ![%_P5:^ _
M[13>._&WQT2XE_X5.D6D1-%_:7[OS=D%M_QY;_\ GX(.=O\ M>]?G)^R[\!O
MVBOCKJNOV'[/5Q+;WFDPP2WYBU+^S<QRLRQY;>F_E3QSBOZ1/^"JG_)COCW_
M *[Z/_Z<[:OSC_X(?,H\>_%1"?F.F::0/832Y_G0!]W?M!?M$^,/V&/V)_ -
MGK BU#XH7&EZ=H< GD-U&M_#:K]KNI6)!E6':><G=(R9RI)K\:O@W\"_VX?^
M"@$NL>/8?&<\^G64Y@DU+7=3N8+,W( D,%M%;I+C8&#$1Q+&N1R"<5]I?\%R
MH[_S/@U,>;(#7U&.@E/V G/U7I]#7Q[^R1^R_P#ML?&+X4-XK_9\^)C>&?#$
M6H7%J]C'X@U#3MEU&J-(S06R-&"RNASG)&,T ,TGX\_ME?\ !.SXX+X%^(VL
MW>K65OY$UUI-[>27^G7^G.Q ELI)23$6"L%D0(5==LBG:R5^U'[?OQ.3Q#_P
M3V\1_%3X;:M<V=MKMIH-]8W=O(]M/]GO=0M&'*$,I9'VLN>Y!K\=OBW_ ,$^
M_P!J&XUVTE^._P 8_",NM?9@+9O$OBR=KK[*'; C-Y%O\O>7QM^7=N[YK]!_
MVB/!^L> /^"/S^#->U;3]<O-(L]'@-[I5P+NQFC76X/*,,P #J(]JY Z@T ?
MC+\#?C+^V)XC.M_"'X(ZYK^L:MXS6W^T?9;B>:^2"S\PD13L_P#HT3&7][("
MN0%4N%)#?O!^P9\./C9^R7^S[\4_&'[25C-!>6LEQKJPRZA#?3O:6%EYDF98
MI9D4L4( +9[D8Z_$O_!$!5/Q&^*#D#<-*L #WP9Y,_RK]Q/VD?C+H/[/_P $
M?%GQ:\1V7]IVFAVHVV>0/M4]PZV\,))! 5Y)%#'!PN3@XQ0!_,#HGQ-_;._X
M*$?&_P#X0O1?&5U;7.II-.+**]FT_1M.LHN69HH,Y5-RKN*22N2 2QYJ'X[?
M"+]KW_@G[XI\/W]]X[N+5=:\]]/O]$U.Y:WE:V*>;'+'*L9R!(I*NA1@>"V#
MCU;P#^TI^W_^V1\2KSPS\"KVV\,LD3W$L.BV]KIEM8VI8#,MXRFX()V@ R,S
M'[J]<>;_ +='P*_:W^#^D^#]0_:<^(X\<0ZS->+IT"ZK?:B+22%8C*2MU%$D
M9<.HS'G..>@H _H/_9,_:@N_C'^R'9_'GQI$G]JZ-9ZA_;"6PPLDVE;R[HH^
MZ9HU63:!A2^!P!7\X5Y\;_VF_P!N;XWV'@[5?B$NA2^)KF5+*TN-1FTW0K("
M-G6,)'N&2J[%)5Y)&(!+,:_:_P#X)'PZ5<?L57]OKHB.FRZWJR70G($1@:*$
M2!R> NW.<\8K\_/CI_P28\3?\))J.H_LL>*=)\::,P:>+1I]0ACU6W7."BR'
M$$J*2 )'>,\@$$_,0#PWXJ?"#]MS]@/QGH-U8>+;USJJRRV=UH-Y=7=E-]F9
M/-BG@EC0'&]"4DB*-D8)P<?TG?LY_&ZX^*O[-WAGXV^.;9=!N;O39KG5$9'A
MC@DLGDBN7"2?,L9,3.H)/RD<GJ?Y<[7XM?MT_L1>)+3P_JVJ^(/![ ;X=-U4
MM=:;<1H0&\F.;S+=U_A9X3D=F!Q7[V:/^T;>?M7_ /!.;XE?$ZTTY=)UQO#'
MB/3[^UA8O$EW;64GF>23\VV2-E= <E2VW+8W$ _&CXL_M9_M3_MW_&^/X:_"
M"_U'2=%U>ZD@T?0M/N6LD-M%N?S[Z1'7>PC4R2%V*)@[ ,<V/C#^RM^W3^Q'
MX:M_B\?&LO\ 94-Q#]JN_#VKWCBTFE8"/[7%-'!N1W(3.UT)(5OO 'Y&_9:^
M'GQ<^*?QBTWP5\#O$G_"+>+[V"Z:VO!?SZ<VR*)I)46>W#2 M&K?*!@@'/%?
MH]\0/V O^"A5QX0U&+XI_&>QD\+%4^VKK/BW4FT\J)%*><+F+RL"3;MW?Q8Q
MSB@#]/?^"</[8^J?M7?#'4[/QV8AXZ\'RQ0ZB\,8BBN[>X#&WN50?*K-L=9%
M7"AEW *'"C]&:_ _]@7]F+XC_!=?C#/I/CGPMXIN=<\(W5M:6_A76UO[R._&
M3:R$(J&/DL%?/WB,5\3_ /"DO^"K?]WXA?\ @\N?_DJ@#^LBOYGO^"GO[5>L
M?M!_%6Q_9<^#K2:GH>AZ@EK.MI\YU;7&;REB3'WXX&;RT'1I2S<A4:CPSXG_
M &Z_V8/V=?C-XT^+TWB.SO=6@TC2=(NM=U"6[-L]Y-,ES+:AYI-DJQ' 88VL
M5;G %?#?['7[0W@3]F7XH2?%?Q=X(D\<:K9P-'I2?;5M([.:7*RW!W03%Y-A
MV(> H9CR=I4 ;^V'^SE'^RYXY\+?#.XN?M>L2>&K'4=6E5MT9U"ZFN/-6+_I
MG&%6-3QN"[B 6(K^KO\ 9 _Y-2^#O_8HZ'_Z115_*/\ MI?M/6W[6OQ?M_BE
M:^'7\,)!I=MIOV5[H79)@DE?S/,$<77S<8V\8Z\\?N3_ ,$S_P!M^R^--KH'
M[,\/@^329O /@^W9M4:^$RW7]F&TLCB 0H4\PR[_ /6-C&.<YH _(S]L#XZ?
MM5:3^UQXVLK_ ,6>(=$U#2M=N(='L[2[N;>..R68BQ^S0QLJLLD6Q@0O[PG+
M9)-?U9?"R]\6ZE\,?"&H^/X?LWBBZT?3Y=5B*A#'?O;HURNT8 Q*6& .*U-2
MO/!4>OV-KK$^GKK;C_1$G:(71&3_ *H,=_7/W:ZB@ K^&2U\7#X?_'Z'QZ;3
M[>/#?B==3^S[_*\[['>^=Y>_:VW=LQNVG&<X/2O[FZ_A[\*>'-(\8?M.:/X2
M\00FXTO6_&%O8W<09D+V]SJ"Q2*&0AERK$9!!'4'- '[&?\ #\RW_P"B+-_X
M40_^5]?"G[<?[?<?[9>@^%-$3P,?"/\ PC-S<W'F'4OM_G_:$1-N/LT&W;LS
MG)SGM7[H_P##JK]A[_H1+C_P<:E_\D5^5G_!4G]D7X"?LT^$_ 6J?!SP_)HM
MSKE[>PW;/>W5UYB0Q1L@ N)9 N"QY7&>] 'V9_P1-_Y-[\;_ /8T/_Z0VM?7
M7AC]@7]D3X1>*H/B_P"%/ SVNO>''EU&WF.I:A/LE168L(IKAHR>3C<I .#V
MKXK_ ."..N6OAC]EKXE^);Z.6:VTG7KJ[E2%0\K)!IUO(RHI(!8A< 9&3WKZ
MO^"7_!1S]FW]I/X@VGP>\'PZQ%JNMPW/E+J-I%!!*L,322)N6=SN,:L0,<X-
M 'Y0?MK?\%2_#W[17P;U+X,?#KP=>:39:_);&_O=4DB,BQ6LR7"QPQ0EQN:2
M-<NS\*" I+97[$_X(_\ [-'C;X6^#_$WQC\=6PL#XWBM(=+MBRM+]B@+N\[[
M2=OFNZA5.&&PDCD5S?[='_!-K]F;P'^SYXJ^*OPITN?P=K/A6W6\"K>W-U:W
M2>8B-%(EW)*5+!OD*,OS8R".*^>_^"+?Q<\7VOQ:\3_!6XO9;CPQJ.CS:M%:
MNS/';7MK/#'YD8)Q&)(Y6$F!\Q5,]!0!Y[_P5)^,/[1?AK]J_5_#_P#PDNM>
M'?#%A;V,F@Q65W/9VTD#V\;2SIY3())/M!D5G.6!7;G"BOWH_8L\0?$SQ5^R
MW\._$'QA,[>++W3R]T]TI6XEB$TBVLLN0"7DMQ$[$\DDD\DU[QXEOO!-HUF/
M&%QIT+/)_HOV]X5)D&/]5YI^]T^[STKJ: "OXK_VY?\ D[[XN?\ 8PWO_H=?
MVH5_%?\ MR_\G??%S_L8;W_T.@#]3-._X+@P6&GVMC_PIAG^S1)'N_X2$#.Q
M0,X_L_C.*^8?VQO^"FD7[6'P>/PI3X<MX7/]H6U_]L.KB]_X]PXV>5]DA^]O
MZ[^,=#7Z_:-_P2R_8CN]'L;NX\#3M+-!$[G^U]2&6902<"X]:^&_^"CW[#7[
M-'[/G[.9^('PI\,2Z1KG]L65IY[ZA>7(\F992Z[)YG3G:.<9':@#/_X(<?\
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M3(NJ2^&S]EW$!C$MW 9@N>2<^63CL*_3#_@K;/HD7[%VOQZJR"ZFU/2EL Q
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M[5'C;Q79S^?I&F7/]CZ80<I]DT[,0=#_ '99!),/]^@#Z2\*_LA_VK_P2_\
M$?QQ-EGQ&^NIKULX7]XVCZ<7L)$]0H,EQ.?4(I^OTY_P1/\ C3Y=UXX^ &J3
M_+,$\0:8C'^)=EM>*,]R/(8 ?W7/K7P+HW_!2+]HK0O@_!\"["+0O^$2@T<Z
M%Y#Z<&=[-H# X=O,^9W4DLV.6)/>O#?V3?C))\ _VB/ _P 46D,=CI>H)'J&
M/XM/N@8+H8[D0NS*/[P![4 ?VYUY9\<_^2)_$'_L7M6_])):]0BECFC2:%Q)
M'( RLIR&!Y!!'4&O+_CG_P D3^(/_8O:M_Z22T ?QA?L_?!'7_VAOB,GPO\
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M)V?\$[8?V>XK;XR?%^*.Y^(]U"PM+0,)(=&AF7:RAAE7N74E7<$J@)1"<LS
M'T)^WEIC:)^P;\0M&>3SFL-$M+<N?XS%/ F[\<9K^;7]AS]IS1/V3?C+=?$[
M7]$N-?M;C2+G3?L]M*D4@:>6&0/N<$8'E$$>]?TQ?\%$O^3+/BK_ -@V+_TJ
MAK^>G_@F+\%?AA\>?VBK[P5\6M#3Q!HL/A^\O%MWFFA N(I[9$?=!)&_"NPQ
MNQSTZ4 7_P!N_P#X*!3?MA:=X?\ ">C>%/\ A&?#^@7,E[F><7-U<7#H8U)*
MHBQHJLPVC=DG)/ %?L1_P26^!]M\*_V?K_QA+K6GZSJGCJ\2ZG&FW<5Y#:16
MT>R&VDEA9D\]2[M(H8[=P7J#GRG]MS_@G5^R5X%_9W\8_$[P-HS^"=:\,69N
M[>:&^NIX+B5654MY(KJ65?WI.Q2FU@S DD#!^!_^"/WQ*\4^&OVI(OAY87,K
M:#XPTZ]6\MLDQ"6SA:XAGV] Z[&0-Z.1Z8 /HC_@L;\4/CWX/^*/A#0?#FN:
MKX?\"W.D+/"VGSRVL-SJ0GF$XEDB*[WCC$)5&)"AMPY8U^@?_!+KQC\7?'/[
M*>GZU\7[N\U&Y74KN'2KS4&>2XN=+18O+=I)/GD F,R*S$DJH&< 5]Y>)[OP
ME::;O\9S6,.GEU&=0:)82_.T?O?EW=<=ZV[5[62VADLF1K=D4QF,@H4(^4J1
MQC'3'&* )Z_DO_X*U?\ )Z?B/_L&Z5_Z2I7]:%?R7_\ !6K_ )/3\1_]@W2O
M_25* /FOXF_"KXF_LH>-O OB^RO);635]-TOQ/X?U: ; WGQ1S[1U'F6\C>6
MZGJ,,1M<9_?'X@_M.^'_ -JO_@F5\1/B!8>7;:Y:Z2+/6[%#S:W\<L6_:"2?
M*E&)(CS\IVD[E;'J7Q*_9:T7]J[]A+X?^"W$=OXFTSPOH][H5Z_'D7JZ?%^[
M=NHBG'[N0<XX?!9%K^8O0?'OQ+^!W_"P?A?-')IR>)+2;0=?TRY!&'MY=REE
M[2P2H=K>A=>C&@#](O\ @BC_ ,G,^+_^Q0NO_3A8U_3G7\QG_!%'_DYGQ?\
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ME/,7=\A'S8/I7Z*?\%OHI8/^%(03'=)';Z\K'.<L/[/!YKV3_@B.RGX*_$)
M?F'B",D>QM(\?RKR7_@N7_Q^?!C_ *Y^(/YZ?0!\*_L_Z9^W'^T9\*[/X&_
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M-!'F4LR[;<1 KV;=QDFOG6*SN?VZ/^"@DT:%[C2_&GB5W9AG*:'8]\]BMC
M.GS8'>OU=_X+6P0VOP ^']M;1K%##XC"(B *JJME.  !P !T% &C_P $3O\
MDW?QM_V-4O\ Z0VM?LM7XT?\$364_L\^-ESR/%,A(]C8VN/Y5\C?M0?"3_@I
M#K'[0OQ U3X8CQO_ ,(I=:O<R:9]@U>>&U^S%OD\F-;A0J8Z */I0!_2A7\E
M_P#P5J_Y/3\1_P#8-TK_ -)4KZ@_8Y^%'_!1+0_VEO NK?%\>-!X/MKJ9M1_
MM/5YY[/ROLTH7S8WN'5AOVX!4\XKY?\ ^"M7_)Z?B/\ [!NE?^DJ4 ?T<?L8
M_P#)I?P@_P"Q6TG_ -)DKYG_ ."K/P;\-_$7]E37?&UU:)_PD'@)H=0L+K;^
M\6*2:.*YA+==CQL6*]-R*>U?3'[&/_)I?P@_[%;2?_29*^0O^"LWQ_\ "?P^
M_9QU3X1)?Q2^+/'AMX(;-'#30V44Z33W$B Y5&$?E*3]YF^7.UL 'YI?\$8_
M&FH:)^TQKG@Y9RNG^)?#]P9(?X7N+*:*2%_JB-*![,:_J"K^9+_@BWX U/6O
MV@O%'Q#\G.E^&-">V>3TN]1F00J/K'#,3]/>MW]J#X2?\%(=8_:%^(&J?#$>
M-_\ A%+K5[F33/L&KSPVOV8M\GDQK<*%3'0!1]* /Z4*_G>_X*I?ML?&#PS\
M7[K]GKX7:_<^%=(T2TM)-3N+"0P7EU=7<8N%7[0A$D<21/&-J%=Q+;MPV@4/
MV.?A1_P42T/]I;P+JWQ?'C0>#[:ZF;4?[3U>>>S\K[-*%\V-[AU8;]N 5/.*
MI?MO_P#!1[XEM\:?$/PA^ FGV&DPZ#?R:1-JC6$%]J5_>P-Y$HC\])$1%D4Q
MQ[4+G ;<,A0 >*^)_P#@GY^V[H7PBG_:%UCQ4DLUIIKZO=V/]KW;:O!:)%Y[
MEF*>6TB("S(LQ/&!EN*^JO\ @DS^V/\ %;QQ\1+_ . 'Q3UZX\36,^FRWVDW
M=_*T]Y!-:% ]OYKY>2-XF9AO8E"F%X8XX/Q1^S)_P5/U[X6^(/'7Q)^+$NB:
M3::3=WM]I5SKMU'/):Q6[22PF"QB>W)9 5*,X'.&P*^9O^"2_P#R>IX:_P"P
M=JW_ *2O0!]>_P#!5W]LKXP>$OBLGP ^&.O77A;2-.T^WN=2N+!WMKRZN+L,
MXC^T(0ZPI$4^5"-S,VXL H'R-:_L1?M97?P(C_:E\*^.;+7+ Z;_ &O)!INL
MW<VJQ6RQB60,1&(_.B7)DB$Q92"HRWRU^LG_  4$_89\ _M,:]'X[\+^-M+\
M)_$;3[:*SFAU*Y1+.\@3+QB<+NEBE4/\L@5LKA2O1A^,/C']ES]NC]CQ[OQG
M:Z?K7A_3K ^9+K/AV^:6U$:_\M)FM'WI'V/GH@[$8- 'ZO\ _!*3]I_XY?$C
M4?$7P:^-4NH:Q_9%@-3TS5-2CE-T(TECAEMY9Y!^]YD5T+DN/GR67 7Y/_X+
M$?$#QYX9_:=\/Z7X;\2:EI-F?"EE*8+2\F@B,C7MZ&?9&P7<0H!.,D >@KZ1
M_P""9W_!0GXG?&7QZ/@'\;)DUW4;FUGN=+UD(D-PQM5#O;W"1JJ./+#,L@ ;
M*D-OW!E^0/\ @M'_ ,G6>'O^Q0L/_2Z_H Y'P#X#_P""AG[<W@/2G\/:I=KX
M'\*64.E6;7&H-IUC<O9QB,G!8O=7#8/F3.& 8E=R#Y1Y/\&_VGOVD_V(OC3)
MX;\47^I-::'?"UU[PW?7#3V\L2D>8(E9F1)2GS131G!^4Y:,D'^DS]@*?3KC
M]C?X4-IDD4D2:-&CF$J5$RNXE!V\;Q)N#CKNSGG-?SR_\%8+C1[C]M;Q6-*9
M&FBLM*2\*8/^D"TCX;'<1[ <\T ?TE?M#_'VR^$?[,GB;X_^'5CU..STF&\T
MS?\ ZJ:6_,<5FSX()C,DR%@""5R <U_-3\)-'_;1_P""B7Q%US3[7X@7<HM(
MA=ZA-?ZA/:Z7:I(VV...UME9%+D':D<6#M)8CDG]I/%G[2<'[*__  3E^%7C
MO6-(AU_6+_PWX<TS3K"Z_P!1+=2Z>DJ-./O;(HXF=@.2P"Y4MN'Y:_!CXE_\
M%(OVT->UD_!_Q,OAW3+ QK>3Z>MMHEA:F0DQQ^9!']HD;&X@9D<#DGD9 /!O
MB$?VP?\ @GI\7K+PW>>-KFSU'[/%J%N;*_FN]+OK0R,@WPS!5==\;*R21AAC
M(QD&OZ+?&/Q@N_BI_P $^?$WQJTAFTG4-<^'^I:E_HLK*;2\_L^4R+%("&'E
M3!@K<'@'K7\V/[<'PB_:*^#WQ T'1/VDO' \=:[?Z6+NUN5U"\U$06IGD3R@
M]Y'$R?.K-M5=O.<YS7[E?"?_ )0_WW_9/_$?_HN\H _ /X+?M!?M2:/XKN-%
M^$WB/6]6\2^*K.31[>))KB^N5%P\<C-:HS-LFQ'@2!244L05.&7[S\%_L.?\
M%#;_ .'/C"358M0T_P 1Z]=Z3/;R7GB&+[5+%#]J:<O(ES(R\R)N5R&)/3@X
M\R_X(_*K?MAVY8 E=!U,C/8_NQQ^!K^K.@#^$F^\&^.;7XMW'P^NW8^,H=<?
M2Y'\_<W]IK<F!CY^>3YW_+3/^UFOZ9_^";?[.O[3?P(N_']Q^T1>27":TFF+
MIJRZI_:1!MS<F8CYW"9\Q/3/X5^"7BE@G[?6KLYVA?B;<$D]L:TU?V(^//&6
MC?#KP1X@\?\ B)F72_#>GW6I710 OY-I$TKA02 6*J0!GD\4 ?RL?%?]JG]J
M3]M3]H1?AU\-/$E_I>F:SJ<UCH6D:?=O86RVP9MLET\3+YK")3)(\A;;\VP!
M<+47[0W[*O[7_P"Q'I6D_$_5/'3-8WMZELNH:#JUZLD%ZZ/*JRB1('^81OAA
MN!Q@X) /;']MO]LO]JKXO6W@7]G:SM/",VI22?8=/T>UM(IH8$4EI)]0G3S!
MM3)=U:-3T"9(%0?MD_L[?MS_  V^#EMXX_:2^*(\4>';C4[:V&D_VS?7I2[E
MCE=)&@EA2W^0(PW*Y(SQP30!]]_ 3XQ_'/\ ;@_X)_?$'P7IUY]H^*>BW%OI
M<%['<"RENHA+;W$4\DH*+'(8Q+&Q& VS/5C7X#?&_P  _$?X7_%+7? GQ;D:
M7Q;I30K?,]S]L8M+!'+'F?<V_P#=NG<XZ=J_=/\ X(>_\B/\5O\ L(Z9_P"B
M9J_,3_@IG_R?%\4/^N^F_P#ILM: /U>_X)O_ ++_ .UI\)?BS+X_^--[++X1
MO_#DL%I')K'VX>=<2VTD)$ =]N(T?D@8Z=Z\-_X*7_M__$^R^*.I?L[_  .U
MFX\.V&@%+?5=1T]S'?7=](H9X(ID.^..+<$;9M=I P)V@ _OI\/V5_ 7AMT.
M5;3+,@CN#"E?Q@?M)6FL/^UO\3K26Y%GJ4GC76%$[.8ECD?49=LF\<JHR&!'
M0<B@#[8/_!.K_@H)I'@5OC%;ZX\>LQVINVTN'6KL:\$ WE<*OE&0#GRQ.7S\
MH!?Y:^I?^"7W[?GQ!\=>.;?]G3XW:O)K\FH6\AT#4[G+WGG6R-+);7,W64-$
MK,DCY<,I4LVY=O%?\,$_\%2CR/C7+_X5VL?_ !NO,_V4OV)_'OPY_:8^'_C1
M_BC\/M2DT?6(99[33_$:75_-'DK-'%"(PSR,A8;<CWH _IQK\+O^"X7_ "(O
MPJ_["6I_^B8:_=&OPN_X+A?\B+\*O^PEJ?\ Z)AH \'_ ."9?[;'[/\ ^S/\
M(/$_@_XMZO=:=J>IZZ]_ D%E/<JT#6L$0):)6 .Z-N#7CO\ P4I_;:^'W[65
M_P"#O"_PJTZ\_LCPN]W,][>Q"*6YN+L1H$BB!9E1%CR2Q!=FQM&T%KO[!'_!
M/7P/^UY\,M?\=>*/%6HZ#<Z1J[::D5G%"Z.BV\,V]C("<YD(XXP*\M_;$_8\
M\>_L%^.?"OBCPEXMN-0T[56DETK6;56L+VTO+4J7B;RY&VL%=61U8;QN^4;3
M0!^V/_!*+X!^,?@G^SO>:IX^L9-*U?QMJ)U-+.=2D\%FD210>:AY5WP\FT@$
M*R@@'('Y??MH_MV?'/X^_&^]^!OP!U6^TKPS!J1T2QM](E:"[UFZ\SR#))-&
MP<QR29$<894V$%P23C]@/^">7[3/B#]IS]G$:OXEN8YO&OAF:32=0EP%,\B1
MJ]O=.HX!E1AOQ@%U<@ <#^57X/\ A?QSXM^+OAGPAX#U4Z!XMU34HK2PO7N9
M+-K>\D?:A\^(&2-MYP"HSDT ?H)\1?V$_P!O/]GCX?7OQN_X2QBNF0_;-2CT
M36[PZE9PH,O++\L2NL0Y<Q2R;0"W*@L/TF_X)>_MS^+?VA8=7^#WQ@O%U#QA
MH%J+ZQU 1B-[ZP1EBD$^W"F:%W3Y@ 9%;)&Y&9OD37_V!?\ @I;+H6I1>*?C
M2CZ*]M,+Y;SQ=JIM3:E#YPG$D>SR]F=^[Y=N<\9KI?\ @G7^R5XQ^#?[3>E>
M,Y_B-X'\06::?J$%S9:%KR7]])'+%\I6%8U)59 C,<\ 4 5?^"F/_!0;XEZ3
M\3-4_9\^"&MS>&M/\.[(=7U.Q?RKRYO&4.\$4ZG?#'#N"L4*NT@8$[1@_':?
ML4_M[R_#<_'HVVIB!;3^T@C:LPU<VH7S/-$!D\S.WY]F?,]$SQ7@_P >V@M?
MVS?B#)XP4/;1^/-4:]##Y6A&IR&3@\;2F<=L5_:F6LY;,NQC>U>/))P8S&1U
M]-N/PQ0!_/S_ ,$M_P!NWXJ>*_BA:?LZ?&#6KCQ1::W;W#:-?WKF:]M[FTB:
MX:&2=OGEC>)'(,A9E954':<#['_X*:_MJ>(OV8?!NC^"?AE(D/C?QBLSI=NJ
MR?V=8PX1IE1L@RR.VV+<&4;7)&0M;GP2^.W_  3&\1?%/0=!^!=AX9MO'5[+
M)'IDEAX3GT^Y$GE.9!'=-81+'F,."3(N1D=\5^57_!::._7]J3PW+<<V[^$;
M(0'M@7U]N'UR<GV(H X3X-_L>_MR_MA>%V^-4/C!X[*[ED:SO?$.L7JS7KQ,
M49K<1I.P574H&;8N1A>!QN_ ']L_]I+]B_X[R?"+]H/5=0U/PW8Z@EGKFG:G
M,U_-91N!BYLIF9V"JC+*JHQCE0\+EE<:_P"S]^R!_P % ?B1\'?#/C7X0?%E
M]'\(:G [:?9Q^)M3M%@1)7C=/(@0QQD2*V54XS[UPOQ)_P""?'Q^F\7WDOQ?
M^,7@9_%+K%]I;7?%;G4"HC41>8;J+S<>6%V[OX<8XQ0!^J?_  6*\6^(?#?[
M-/A/4_".LW>E27?BJT1IK&XD@:2)K"]<*6C92RDA6QTR >U?CA^SSXN_;D^/
MOAZ^_9V^"&NZK=V%Q=MJNJ78O9(7C26.. )<W\C[HX,1Y6%"#(Q;Y7P OZ??
M\%8+#4M+_8<^$NF:S=0WVH6FLZ-#<7%N_F0331Z/=K))&_&Y&8$J<<@@T?\
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M;\%^!/A;=Z5\+M.L="T&"QN;BRBTF.."U7SD:;S(1" @WLV_<O4G-?RJ?\%
MOV+M)_8\\;>'K/POXAEUW0/%D%S-:)=A!>VQM&C5TF,>U74^8I20(F?F&WY<
MG]A?^"5WCKQ%XR_8>\0:5KT\ETGA34-5TJR:0EBMH+.&Z2,,>2$>=PH_A7:H
MX % 'Y)?\$[/B9\1]=_;/^&FEZWXKU;4+*XNKT2P7%]/-$X%A<,-R.Y4X(!Y
M'6OZ'/\ @H#JFIZ+^QU\3]4T:[FL+VWT^)HY[>1HI4)N81E70A@<''!K^:C_
M ()N310?MM_"UYG"*;R[4$G'S/8W"J/J20!7](?_  4:N+>W_8J^*1N)5B$E
MA B[F"[G:[A 49ZD]AWH _)K_@C9XZ\;^*?V@?&-EXF\0ZCJ]O%X8ED2.\NY
MKA%<7MJ-P61F ."1GK@FO-O^"T?_ "=9X>_[%"P_]+K^M_\ X(G?\G%>-?\
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MPC^ OA+X8Z5\.;O5-<\+:-::8L\U]'#:22VT(C\PA8V?:2,[>"1QD=:^7?\
M@K5_R>GXC_[!NE?^DJ5^MG[,_P#P3X_8^^(G[.'PX\8>,/AY%?:SK_A_3KR]
MN1?ZA"\MQ/ KR/B*Y15)8DX4 >@H _#']E;X83_M5?M3Z;'XJUK3-%BU36/[
M7U,W%S%:M<[[CSY;:Q@=MTLLI)5$0-M!W-P.?[,J_C9_;T^!O@+]FK]I/4?A
M_P#"G49Y-+M[6SODCEE\R>PGG!?R#*,,=H"NA/S!74$DC<?Z@?V)OB)XD^*W
M[*OPW\=^+YGN=9O]-\NYGD^_.]I+);><_JT@B#D]R<T ?4M%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]/]_**** "BBB@ HHHH
M ^2/V[_#/B/QC^R/\2O#7A+2[K6]7OM/C2WL[*%[BYF87$3%8XHPSN< G"@G
MBOQT_P""37P+^-OPY_:=U'Q!\0OA]XA\+Z6WAN^@%UJNE7=C TKW%J5C$D\2
M*7(4D*#D@$XP#7](5% !1110!_);XR_9O_:'O/VWM<\56OPN\4RZ)/\ $2YO
M8[]=%OC:-:MJ[2"<3^3Y9B*?.'W;=O.<<U_4C\6K&]U3X5>,],TV![J[N]%U
M&&&&)2\DDDEM(J(JCDLQ(  Y)KT&B@#^6W_@FQ^S[\>_ O[9'@?Q1XW^&OB;
MP]HUI%JHFO=1T:]M+6(R:;<HF^::)47<[!5R>20!R:_17_@I?^P'XF_:,GL?
MC'\'8XI_&FDV@L[W39)%A_M&UC9GB:)WP@GC+,,.P#H0-P**&_7VB@#^2SP'
M\2O^"FW[/WA-O@SX-T;Q;HVDP-*L%JWAUKMH/-8F3[+-+:RLJLS%AY;[03N7
M!.3[%^Q=_P $T/C)\1_B5IGQ/_:(T:Z\-^$]/NEU">VU3*:EJTZMY@C:!\R1
MQL^#,TP5F4D*"267^G&B@#XR_;P_9DU#]JSX!7?P^T"\CLM?TR\BU?2VGXAD
MNK>.6/R9&'*K)'*ZAN=K$$@@&OP*^#_B3_@HE^PO<:QX0\+> -6@T_4+@7%S
M:76C2ZG8/<!/+\V*XM@5+%0 3'-AMJYS@5_6%10!_)KI'[*W[:?[=/QOG\?_
M !+\,WOAP:W-;C4M:U/3SIEK;6T,:Q+Y%O((WG*QH%58PV6QO906<?I3_P %
MB]"T_P +?LB_#WPSI">58Z1XETZSMT_NQ6^F7L:#\%45^T-?E-_P5Z^'WCWX
MD?L[^%M%^'GAK4_%&H6_BFVN)+;2K.:^F2%;&]0R-' CL$#,JEB,9(&<D4 ?
MAC^R[X6_:Z\*Z!JW[1?[+0O)WT.Z_LG48=,B^VW1CDC6?,MBT;K/ <#D*Y5A
MNPN U;VN?#']O+]MCXF6NH>-?#FOZYJY5+1;S4=/;3-.L85;D%C%#;PJ"2S*
MHWL<G#-U_8S_ ((]_#7XB_#7X3^/+#XB^%M5\*W5YK<4D$.JV4]C)+&MLBET
M2=$9E!XR!C/%?K[0!\W_ +,/[/\ IO[-'P"T/X1:;.+^ZT^"66^NE7'VJ_N2
M9)W48!V[CLC!Y"*H/.:_G%_85_9P_:&\)_M;?#3Q'XK^%_BC1=)L-2:2XO+[
M1;ZVMH4\B0;I)98511D@9)') ZU_6510!\G_ +<_AKQ%XP_9*^)?AKPGI=UK
M6KW^F!+>SLH7N+B9Q-&VV.*,,[M@$X4$U^1O_!(;X)_&;X:?M!^*M:^(W@+7
M_"NGW'A>XMXKG5=+N[&&29KZS<1K)/&BERJLP4'. 3C -?T144 ?@U_P4E_X
M)R^/OB)X]O?V@/@)8#6KO5TC.M:,CJEP9XD$8NK4-M5PZ*OF1YW[QN4/O(7X
M2M/B]_P4]TGX=K\!+32_&<6B16G]FI:CPY*;U+3;Y8A6Y-J;D*%^52'R%X!Q
M@5_6E10!_/K_ ,$Y_P#@FW\1?#'Q&TKX]?'_ $S^P(?#S_:='T:9E:[EO /W
M=Q<(NX1)%G<B$B0R %@JK\_Z0?\ !03]E*]_:N^"/_"/^%WBA\7^'+G^T=(,
MS!(YGV%)K9W(.T3(?E/ $BIN(7)K[JHH _C\^$W_  \+_9,\0ZMH'PO\,>*O
M#UYJ;I'=VBZ&^H6UP\9.QT62WGA9NH$D7)' ;%'QR_9'_;CUVYTGXM?$[PEX
M@\8>)?'(GN+E+2QN=1O+-;?RTC6\6UB9+<NI_=0C&U%QM7!4?V!T4 ?"7_!.
MCPAXL\$?L4^"/"OC31+[0-;M!K'G6.H6TMK=1>;J5W(F^&55==R,K+D<@@C@
MBOPB_85_9P_:&\)_M;?#3Q'XK^%_BC1=)L-2:2XO+[1;ZVMH4\B0;I)98511
MD@9)') ZU_6510!^;G_!1K]BC4/VL/ FE:WX#DA@\=^$?.-DD[".*^M9P#+:
ML_17W(K1,WR@[E; <LOXK_"KQW_P4>_8VLM1^'7A/PCK^GZ9/.TQM+K0Y-1M
M$N& #26TPC=/F &?+D*$C)!/-?UET4 ?R>?"_P#8D_:]_;-^+USX^^,FGZGH
M%IJUQ'<:QKNNVS64DD2[4V6ENZ(781KLB5$$2  $J  ?V$_X*,_L4:]^T7\(
M/"D'PD2/_A(?ANLR:=ITCK&MW9SQQ1R6ZRN0J2 01E"Y"G!4D9R/T_HH _E3
M^#_QK_X*/?LC^&I/A'X=\!ZN-(MIIFM[74?#US=I;RSMND:VFC5=RLY+ !W3
M)) Y.=7]FS]AG]IK]I#]H"W^,'QO\.WGAK0;C6?[;UJ]U:U^PRWLGGBXD@@L
MW$<G[]LKN""-%).20J-_4O10!\]_M6?!:;]H;]GSQI\'[2Y2SO=>M$^R2RY\
MM;NUFCN;?>1DA#+$H8@$A23@]#_,5X-^!_\ P42_90\;7VJ?#7P3XIT?5Y(F
MM)KC1]..K6T\.\-@F&.Y@D7<H89&1[5_7S10!^;OQD_9E\6_MF_L3^!O#OQ#
MN'TKXHVVE:;JR7.H0&V>/6#:@7,-W"B*T2R[W6150%'VMM.S:?Q)^'-A_P %
M$?V%/$>L:9X,\'ZWI\.IE%NXDTMM7TNY:,D1R)+$DL6\9.&1PV#AN.*_K8HH
M _DF7]GK]N[]O+XM1^*?B)H6I6T\Z);OJ^MV3Z5IME9Q$L(X4,:;E4N2(X49
MF9BS<EFK]J/VP?@+JOA3_@G%J7P$^%FE7_BB]T.RT*RMK>QM9+F\NS;:A:O-
M*((5=R6VO*X4$*,GH*_3&B@#\%/^"._P<^+GPR\=?$>]^)/@C7/"=O>Z;8QV
M\FK:;<V"S.LTA98S<1H'(')"YQQGK7ZL?M>? V\_:._9W\7_  ATN[CL=2UB
M&&2RFFR(ENK2>.YB#E0Q".T>QB 2%8D D5])T4 ?R%_"?1_V]?V)OB)JL_@;
MP#K=CJ5]&;&ZC;19=2L;R.)\J8Y(T=) K<J\3]#C."0>E_:,^!/_  4,^.&G
MZ1\<_C+X5UO7KS5)I+*RT>ST^>6[T^W1=^\Z?:Q,+6%S\H,F)'89<'AC_6?1
M0!^4W_!.GX(^)G_8;\3?!SXL:!J?A6;Q/=ZY8W%MJ-I+9W2VNH6R0&58IU1L
M$%MIQ@D5^1@_9U_;J_8+^,,_C#X:>'-1U-K83VD&KZ38-JEC?64A!(FBC60Q
M!MJDI*%964%2<!C_ %F44 ?R:_%ZY_X*"_MZ:[X>TCQ7\.=2F31#.+)(='ET
MNQA>XV"5Y;FZVH"WEK]^7 Q\H&37]"G['7[-,?[./[..D_!WQ'+;ZMJ%P+FY
MUAHU/V>:XOC^\C7=RR)'MBW$#>%W87.T?6U% '\J_P"T'_P3W_:7_9>^*_\
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M_A!K<WA%])LY"=$TN^OK3[46D$H\R-)5#X"[EW#'!QSD_MY^Q5^S)\,?@_\
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MN:VN[/1+ZXMYXG;*O'+'"R.I'0@D5_7+10!EZ'%+;Z)I\$RE)([>)64]0P0
M@_2OSM_X*K>!?&_Q$_98/A[X?^'M1\3:K_;FGS?9-+M)KVX\M%EW/Y4"N^U<
MC)Q@9%?I-10!^%?_  1Q^$/Q8^&.N_%.X^)7@O6O"4>H6VD+;-J^G7-@)VC>
MZ+B+[1&F_:&&[;G&1G&17Q;_ ,%%/V>?C]XW_;)^(GBCP7\,_$^OZ-?/IIM[
M[3]&O;JUF$>F6L;^7-%$R-M=64X)PP(/(-?U344 ? W[6?[+6L_M/?LD:/\
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M5&95X"DC%?V044 ?'OC[PSXDO/V"-<\'6>DW<^OS?#B:Q33HX)&O&NSI)C$
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M4ZL_AZWP$@TWQRGAYK8:<+'^P)S<K:A?+$"W)M?M*Q[/EVB0#;Q]WBOZXJ*
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MKS2:UI-S9V\\]L +:)6N8D1W\]T?9R2J,<8!(_JDHH Y+_A / G_ $+FF_\
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M+QRL5+<;U4$J"6'M_P"R]\!])_9L^!_AKX1Z9*MW-I4+27MTJ[1<WT[&2XE
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M_@D)\-_B'\-/@1XOTGXC^%]4\*WUUXDDGAM]6LI[&:2+[';+YBQSHC%-P(W
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M^_X)@?L#_$3X)^)KCX]?&>V71]6N;"2STO2"P>YMUN&4R3W.W*QN47:D88L
MS;PK "OVUHH _!+_ (*1?\$X_B%X_P#B#?\ Q_\ @)8#6Y]:6-M:T:-ECN1<
M1H(_M-JK;5D$BJ#(F=^_+*'WD)\%6_Q _P""G5G\/6^ D&F^.4\/-;#3A8_V
M!.;E;4+Y8@6Y-K]I6/9\NT2 ;>/N\5_7%10!^$'_  3-_P"">?Q&^&/C^W_:
M#^.>G_V%>:9!-'HND2,KW0EN4:*2YN I*QA8F94C)+DL68)M&[Z\_P""C7[%
M&H?M8>!-*UOP')#!X[\(^<;))V$<5]:S@&6U9^BON16B9OE!W*V Y9?TCHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%? .TE"0#@@XJIK/B_PGX<FCMO$.M66F2RKO1+JYB@9ESC(#L"1GC(K\B?\
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MQ7=U=10V\@8;E*RNP0Y'(P>1S7\T'_!:/_DZSP]_V*%A_P"EU_7/_ ;]@?\
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M5X(MX[OQGX@T_0()<[)-0NXK5&V]<-*R@X[U%X6\?>!?',4DW@KQ'IOB".(
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M?P,8Y&&_(*?>#+C< #^XZ'QKX-N/$3^$+?7K"77HU9VT];J)KM57&YC &\P
M9&3MXS735^)7_!/K_@G?\=?V>/C/%\:/BMJ>D+'-IEW;-8VMS-=7HGNBG^M;
MREAXVDDK*^3CW(_;6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]6/^^*R_V;/^"5\O[27P<T'XNZ!\5K.PCU<2K-9?V8UP]I/#(T;PR.MROS#
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M?M*_M#?M Z/XW^#W@[^W]%M?#EI82W']H:?:[;F*[NY739=7$3G"2H<A=O.
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MC98@853U].: /V?_ ."@?/[&?Q7S_P! @_\ HZ.OQ4_X(H_\G*^,/^Q1N?\
MTX65?N[^V#\/_%OQ4_9G^(7P]\"6/]I:_KFFF"SMC+'#YLOF(VWS)F2-<@'E
MF ]Z_+[_ ()>?L;_ +2'[.OQP\2>,/C'X0_X1_2+_P .SV$$_P#:%A=[[E[R
MUE5-EK<3.,I&YR5"\8SD@$ _,W_@IW_R?-\3O^NFE?\ IJLZ_<K_ (*#?\HU
M=;_[!WAG_P!+K&OSV_;M_8'_ &L_C+^U;X[^)7PV\"_VQX;UE]/-I=?VGIEO
MY@@T^V@D_=W%U'(N)(V7YE&<9'!!/ZL_MC?!GXD?%/\ 8AU7X/> M(_M7Q;<
M6>APQV0N((-SV=W:R3CS9Y(XAM2-SRXSC R2!0!^7/\ P0__ .2B?%'_ +!6
MG_\ H^2O;O\ @M]_R33X8G_J+WW_ *3K70?\$K_V2OV@?V</&/CW5_C1X6_X
M1VUUFPLX+1OMUE=^;)%*[.,6D\Q7 (Y;&<\9YKU+_@J=^S;\:/VC_ O@72/@
MQX>_X2&\T;4KJ>[C^UVMIY<4L(56W7<T*MEAC"DGVQ0!Y/\ \$K= U#Q7^P1
M\2O"VDA3?:QJ^O6=N';:GFW&E6D:;F[#<PR>U?GG_P .@?VQ?^?30_\ P9C_
M .-U^T/_  3'^!/Q5_9Z_9]U;P/\8-#_ + UNY\17=_';_:;:ZW6TMK:QH^^
MUEE09:-Q@MNXR1@C/Z*T ?D7_P $S/V,/C3^RMXA\>:I\5XM/BA\06MA#:BS
MNOM#%H'E9]P"KM #C'K7ZZ444 ?Q.?LA?\G<_"3_ +&[2/\ TLCK^V.OY=OV
M</\ @G1^V1X#_:+^'?COQ9\/_L&A:%XBTZ_O;DZMI<OE6UO<I)(^R*[>1L*"
M<*I)["OZB: "OY+_ /@K5_R>GXC_ .P;I7_I*E?UH5_/)_P40_87_:F^.?[3
MVL_$3X5^"O[<\/WECI\45S_:6G6V9((%21?+N;F*088=2N#V- 'N/[/W_!+S
M]E;XJ_L[^ ?'/B*SU>#7/$V@V%]=7-KJ#)BXN(5=VC1T>,<DX!4@>E?CA^T%
M\+_''["O[4-UX?\ !FNW,-WX=FM]3T35%_=RRVDP$D1< !6*D-%*,;'*L-NT
MXK^LC]F;P;XB^'G[//PW\"^+[7[#K>@Z!IUE>VXD27RKB"!$D3?&S(VU@1E6
M*GL2.:_,_P#X*G?L7_&+]HGQ;X%\=_!#PV/$.HV-C=:;J:_:[2S:.&.59K4@
MW<T(<%I9\A22.,]: /1_VP?'\G[0O_!+;5?BCX?3+:[I>BZE<PQ D(\&H6QO
M(^_RP2))D^B9K\%OV.?V6;?]K;XAZE\.%\9V_A#4+2P:^MO/MC<F[\MU62.-
M1+$=RJV\X).T$XP"1_0W_P $_?@1\6/!'[+6N_L__M.>$UT^SDO+^V@M)+RU
MNTN-*U*)6FC)M)I0O[UYLY93\V1ZU^67Q9_X)8?M4?!+XB#QA^S1=R>)-/L[
M@SZ9>6-]'IVL60.<"0220@LH.W?"YWCDHN2H +7Q=_X)2>$/@-X9@\8_%OX^
MZ?X=T>YNDLHYY="N90]Q(CR+&%AN'8DK&QZ8P.:^E/V6?A#X#\(_L:?M,:)\
M&?BE!\4$UG0KY6-GIMS8?9KA=-N1Y6RX)9VG5@,KTQCK7QEX@_8X_P""FW[2
MNMZ98_%VTU.ZMK([8KG7]5MUM+,/@-((DE=LD8W&.)G(&#G K]\/V.?V4?#W
M[)?PB_X5W97W]N:GJ5P]]JM\T?EK<7$B+'M2,EBL2(H502<\L<%B  ?SC_\
M!+'Q5X?\*_MG^$'\0SQ6R:K!?Z?;RRL%475Q;L(5!/&Z1AY:CNS@#DBOZ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!_]#]_**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH __1_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_TOW\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]/]_**** "BBB@ HHHH **@
MNKJUL;:6\O9DM[>%2\DDC!$11R2S'  '<FORA_:A_P""LOPF^"'B:W\'_"_3
M(?B?J,1?^T9K6_%M8VI&-L:7"PSK/(>=P0;4Z%BV54 _66BH;>7[1;Q3XV^8
MJMCKC(S4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 455EO;.WFCMI[B..6;[B,P#-_N@\G\*M4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%53>V8NA8FXC%R1N$6X;\>NWKBK5 !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !156.]LYKB2TBN(WGB^_&K NOU4<BK5 !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%5K
MF]L[((;R>. 2':OF,%W'T&>IH LT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4455M[VSO#(MI
M<1SF([7",&VGT..AH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '__U/W\HHHH **** "BBB@#RCXX
M_"'0/CU\*O$'PC\47=S8Z5XCBCBGFLRBW"+%,DPV&1'0$E .5/%?@%_P4O\
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MC;D8LKA%N&XZ!D+$'C-?0'[$7_!2_P <?$#XHP?L\_M.:5%I7BF\F>SLM16
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M\0A^QU-^TK^U7KT;QS"\U5)$M8;4PZ7"1% @CA5 \DSHS1]W\Q%':OS.N_\
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M@5^QCHZ:E>073V(U5;7^T+J\NHF(D^PP?-%Y*X/[R1'W %@%4!CY=XI^)?\
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M/M*Q;&&W&[S1GH*^ZOVBOVIK;]CC]GW0O%/Q5F7Q/XZO+6"RAMH-EN-1U5(
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M:\_^%/P[TOX2?#7PS\,=$N9KRP\+Z?;Z=!-<;?.DCMT"*S[ J[B!S@ 5Z!0
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M&><R^>W. @ +;Q\HH>/_ ([_ /!8+X,:2WQ-^(_V^RT"(H\[2:9H]Q:1(6
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M*\_9[L8])T2RD,<@T^SL8K. G!$;WNJ!]TH4@E4<,0<[ "* /Z2Z*_FTU_\
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M>-BK#.H6PX(Y'%?'W_!%74]2U/X-_$&34KN6[=-?B"F:1I"!]E3@%B:^NO\
M@I7_ ,F0?%'_ *]K#_TXVU?&_P#P1'_Y(Q\0_P#L8(O_ $DCH J_\%L=4U/2
M_AU\,GTV[FM&?5;X,89&C) @3KM(S7P5\"?^"</[3W[0/PGT#XP>$?'ND6.D
M^(DG>"&^U#4$N$$$\ENV\16TB#+1DC#'@COQ7W/_ ,%O_P#DG'PO_P"PM?\
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MQ#FL(=)C2ZNYKF>=;*T2X<K!;VMI 0BYVL0!M&$)9BW7^D?]E?X+:O\ L]?
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M6UDFO>-_$"R'3-.9]L4<<?#7-T5(<1*QPJKAI&!52 &90#[PHK^;CPE\:?\
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M?!'C#X(>(KY[K4/#MPNKZ>9G+R-97>(YT4DYVQ3*K'WFK]NJ_EB\,RG]@O\
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M2Q0QF&ZBF8L\*/(,I&0-JGDCMDU^&G_#GW]L'_HI/AW_ ,&6J?\ R'7]*5%
M'\4?P<^$'Q;^-GQVA_9^\,^*%L]>FGO[<7-Y>7*V8;3HY99"6C1Y,,(F"_)U
M(SCFOT,7_@D!^V&C!T^)7AY64Y!&I:H"".X_T.O'O^"?_P#RDQL/^PEXH_\
M22]K^K&@#Y(_:V_:H\,?L@_""/QGXBA&KZ[>%;+2M-638UY=A,LS,066&,?-
M(^#C*K]YEK^?SPM9_M[_ /!2[Q+?W<&NW \,V=QMGDDN&T[0+!G^98DABR9G
M5".B2RA2"[?-DZ__  5F\>:W\3/VQO\ A66GJTL7A"ST_2;2 '*R76H(EV[@
M=F8SQQG_ *YBOZ2O@9\(_#GP)^$WAGX4^%HE2S\/V<<+N!@SW!&Z>=^F6EE+
M.?<X&!@4 ?@;=_\ !%+XYZ?8#4-"^(NA3:M&"PC9+NW3>!P%G5';GU*"O)O
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M,X]":^C_ /@BS\$=)T_P%XJ^/^IVH?6-7O7T6PD< F*RMECDG:/T\Z5PK?\
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MW#?9%D4/+-C($FT(G#*7/W?U&_:J^ @_:9^!VO?!DZW_ ,([_;<ED_V[[/\
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M8Y9W<Y9W8EF)R237\Y'_  6L_P"3H_"G_8FV7_IQU"OZ;=,_Y!MI_P!<H_\
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MXFZ7;^;J_P .+L73%1ECIUX5ANE'^ZXAE)[*C5^3GP6\9>$/B'_P5+T?QOX
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M;_P1 GE7XB_%"U#8BDTJP=AZLD\@4_@&/YUYW_P6;\7:IK_[2_AKP,DADLM
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M=T75+G6;'PZMPL5U=A!,XN+B2X((C 4!3(57_9 K^>+]HS_E,=I/_8[>"/\
MT5IE?OG^R-\9_%/[0?[/_A?XO^,-&@T'4/$(NW^RV[.8Q%#<RP1N/,^8!UC#
M#).000<&OP%_:SN8?!__  5PT_Q+KTBVNG0>*?!NH/,YPBV\,6G[W)/0+Y;9
M/M0!_497\PO_  6L_P"3H_"G_8FV7_IQU"OZ>J_F%_X+6?\ )T?A3_L3;+_T
MXZA0!^_O[0'P?LOCU^SUXH^$UX%\S7]**6KO]V*]B42VLA]DG1&/L"*_$?\
MX(T?%>]\&_%?QO\ L[^)BUHVMPF^MH)?E:/4=,)CN8@O9WA;<WM!7]%&F?\
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M\$T?VKKSQ_'H'VW33<WL5A=W44C:?JVFW;$[1,A&V8+M++NW1N.0R_>_H?\
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M#^LXS;O#K=OGT=&LWY^H;CZ&@#]GOV9O^3;_ (4?]BGH7_I!#7QU_P %</\
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M>B21Q7 NO[+2&..)+:..2YDB(@4.0I R02!70Z[_ ,%EOV3=)E:+3=.\3ZT
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MH^IZ]IFFVLZ?/&UEIB1)=7"E<[HL133*1U3![U_21^U;_P FN?&'_L3?$/\
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M_P#KAJ/_ *<[JOB7_@M__P DX^%__86O_P#T0E?;7_!,W_DQWX7_ /7#4?\
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M.PF\J/Q/X@@CNE'_ "TM[2&6?8?;SA$W_ 17S]_P0QZ?&S_N6_\ W)5]+?\
M!8[X?:GXL_9<L/%FEQ&7_A#=<MKRZP"2MI<QR6K-QZ2R19]LGM0!U'_!([X=
M:3X1_9#TKQ?;VBQ:EXVO[Z]NIL?O)$MKA[.%2>NU5A)5>@+,1]XU^BOCCP9X
M?^(G@[6O GBNU6]T?7[2:RNH7&0T4Z%&QZ,,Y4CD$ CD5^97_!('XN^'?%_[
M,,/PNCOD_M[P+>WD<UHS#S?LE[.]U%,J]3&7E=,]F4@]L_HS\6_BCX2^"_PY
MU[XF^-[Q+/2=!M9+AR[!6E=1^[ACR1NDE?"(HY+$"@#^;/\ X))>(=:\ ?ME
M7_P[GEV1ZWINIZ==PG[IFL")U8#^\IA< ^C-ZU^B_P#P6H_Y-7\,?]CE8_\
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MJP(_4=0>#S7XT?\ !:;XP^'+#X5>%O@C9WR2>(=7U6/5KFV1@S16%I%+&IE
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M3]GS5OC=^S>WB#PI9_;/$'P_N6U:.-!F66Q,92\CC'<[=DN.I\K R2 ?B/\
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MAWXG^&(;BWTKQ-9QWMM'=JJ3K%*,J)%1W4-Z@,1[U\W?\.[_ -BS_HE6F_\
M?RY_^/5]5>&?#7A7X<^$K#POX:M8=&\/Z!;+#;PJ=L-O;PKP-SDX50.23[DT
M =/7X#_\%(O^"A$7B.*__9=_9UN6U6?5'^P:WJMEF3S2[;#IUD8\F0R'Y)77
M(()C7.6(YO\ ;E_X*)>)_C-K[_LS?LD&YO[759O[/O-5T]6:YU61SM-K8;/F
M$!Z/*.91D*1%DR?8/[ G_!.'0/V=K6S^*?Q:A@UGXES('ABXEM=%#CE(3R)+
MC!P\PX7E8^,NX!M_\$T?V*;K]F?P'=>/?B+9I'\1?%T2K/'D,VFZ?D.EIN''
MF.P#SX.,A%_@R?SY_P""W5O>+\7?AQ=.?]%DT*X2,>DB71+_ *,E?TC5^(O_
M  6N^%-]KOPR\#?&#3U+IX5OKC3KQ5&<0:FJ-'*WH$E@"?604 ?JG^SC-;W'
M[//POGM!B"3PMHC1CT0V,)'Z5Y5^WQ-;P?L<?%E[D90Z)*H_WW=%3_QXBO'O
M^"7?QTT'XL_LL^'/"@OTD\2> (O[(U"U9AYJ01,PLI N<^6T&Q0V,;D=?X:\
MK_X+ ?'+0O!?[/'_  INUOT/B/QY=6VZU1AYJ:=:2B>29P.51I8TC7/W\L!D
M*V #Y]_X(:V]VMC\9;MC_HKR: BC_IH@OBQ_)EK]\Z_(S_@C;\,M2\(?LV:O
MX[U6)H6\;ZQ)/:AAC?962"W1_7F83#Z $=:_5SQ!KVD>%=!U+Q/X@NDL=+TB
MVFN[NXD.$B@@0R2.Q]%4$F@#\=?^"Q?[1_\ PA/PQTO]GSPY=;-8\;XN]3V'
M#1:3;O\ (A[C[1.N >ZQ2*>&KW[_ ()=_LZ?\*+_ &;['Q%K=KY'BCXAF/5[
MW<,216K+_H,![_+$QD(/*O*X/2OQI^%6D:U_P4@_;^N/%/B6WD;PL;LZI>PO
MRMOH6G,J6]H<< R_NXGVXRTCN.]?U;HB1HL<:A54   8  Z "@!U%0W%Q!:0
M275U(L,,*EW=R%5%49+,3P !R2:^8?AA^VI^S!\9?'LGPR^&WCRUUGQ&@E*6
MPAN81.(06D^SRS1)%/M4%OW;ME06&5!- 'U)114<TT5O$\\[K''&I9F8@*J@
M9))/  '4T ?@9_P6N^-NR#P3^SYI5QS*6\0:HJG^%=]O9(<>I\]BI]$/I7L_
M[$W[6G[%'[/7[-/@WX=ZG\2;.VUP6YO]67['?%AJ%Z?.F1BMN0QBRL.1P0@P
M3UK\M+?39O\ @HE_P4)O(+BXN$\.>(M4F9IH"%DM] TR,K&4+*RQO)#$H!*D
M"63)!R<_K9_PY@_90_Z#?BW_ ,#[/_Y"H _)S_@HA\4?@]XI_:<T?X]_LW>+
M8=7N;RWL[N[EMX9X7MM5TQPL4N)HX\[HDA(QGYD8GJ*_J#^"OQ.TKXS_  E\
M)?%31MJVWB;3K>\**<^5*Z_OH2?6*0,A]U-?BO\ M7?\$G?@W\+/V?\ QA\2
MOA+J7B"\\0^&+4:@L%_=6\T$EK ZM=96*VB;*0;W!#=5P1S7HW_!%SXU_P#"
M1?"[Q3\"]4GW7?A&[&I:>K'DV&H$^:B#TBN%+-[S"@#YI_X+=?\ )7_AS_V
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M.GC2(%M+*_@C;]]_HXX2X3(=\$^8"SX7:<_G!_P5062Q_;NEN]4^:T>ST25
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M_9F\ ?LJ_#*'X<^!/,NFDE-UJ&H7 'VB^NW 5I' X50JA40<*H[L69OHNB@
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MK:)7S.@98YIII)%SF25#G@!4Y9OWEHH ^._V%OV?/&?[,?P L?A5X]O=/O\
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M_"#^,)&TW4+&0W&EZK#&))[&<@!B%)4/'(H"R1E@& !R&56'U%10!_/#H/\
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M@7>_";X,:KI6C76O7,*:G/JD]Q C:='F1XHFMX)VW22+&&R #'N4]<5]?T4
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MM?T33]+T32?L+V^KW-W"PN&N))6DC6"UN$PR,@))!.T C %?#6D?\$@_VT]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXYZE\ OV6/%'BCP[>-8^(=9:'1M+F0X>.XO2=[H>SQVZ2R(>S** /D3]L/\
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M=KX.0%Q^CO\ P3?UW5O$7[$WPMU#6G>2XBLKJT4N<GR+*^N+: ?00QH![ 4
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ML-T'CBB5U $RL%P2>17ZC*P8!E.0>01WK\.?^"W_ /R3CX7_ /86O_\ T0E
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M>58<J0""" :_EU_X)M&Y\ _\%$;+P7X;NGGTR63Q#I$T@/\ KK.UM[B6,OC
M(,EO$W3KB@#^JB^OK+3+*XU+4IX[6TM(WFFFE8)'''&"SN[-@*J@$DDX K\&
M?CG_ ,%F=5@\83^%/V:/!UIK=I!,8(M3U=;B7[:W3,%G;O#(JD_<+2%F'5%/
M%?7'_!6KXJ:E\./V2[W1-'F:"Z\<ZE;:([H<,+5TDN+@9]'2'RF]0Y%>!_\
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M7D?_  ^W^-G_ $3[P]_W\N__ ([7])36UNQ+-$A)ZDJ*3[+:_P#/%/\ OD4
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MCR>(?ASI^H^*-+BF:W>ZTSPM%=P+,BJS1F2*V90X5U)&<@$>M?J%_P %?/\
MDSB^_P"PWIG_ *$]<E_P1@_Y-0UO_L;;_P#]([*@"I^P;\:OV^?B!\8]1T']
MI_PYJFF>$TT:XG@GOO#YTJ/[<D\"QJLPAB!8QM)\A)R 3CBOH']M#]OSX<?L
MCV,6A"V_X2CQY?QB6VT>*7REAA8D">[E"MY:'!VJ 7<C@!<N/MCQ;XGTKP5X
M4UKQEKLGE:;H-E<W]T_]V"UC:60_@JDU_)A^S3\/]=_X*!_MI3ZG\3KB2ZLM
M0FN-?U[#L"+"W9$2UC9<%4):&W7!!2,Y7E10!]":1^VY_P %0/VC[F\U3X)Z
M3<6^D>9Y9&AZ'#+:0GM&;N]CG^;N<R@]\ <4:U^V;_P5,_9R:UUKXRZ7=3:-
M'*$)UK0[=;*0_P#/-KNRCA.3V_>Y/;/2OZ5= T#1/"NB6/AOPU80Z7I6F0I;
MVMK;HL4,,48PJ(BX  '85-J^D:5K^EW>B:Y9PZAIU_$\%Q;W"++#-%(-KHZ,
M"K*P."",$4 ? O[%?_!0GX>?M:1/X5O[0>%/']I&TLFE/+YL5W"@^::TE*KO
M ZO&P#H.?G4%J_0NOY'/VP?A3J_[!?[85EKWPCG?3=/5H/$7AYMS/Y$3NZ26
MKEB2Z*Z21E6)W0LH;.XU_5I\/O&>E?$;P)X=^(&A'.G>)=.M=2M\G)$5W$LJ
M@^X#8/O0!U]%%5;Y9WLKA+4XF:-PASC#$''/UH \P^,OQP^%_P  ?!T_CGXJ
MZ[!HNFQ9$2N=T]S*!D16\(^>60_W5' Y8A02/R%^ O\ P5A^)/QR_:7\-?"J
MU\&Z3I?A7Q-JCVL4CFXDU"*UVNR%W$HB,F%&[";>N/6OG+P+_P $KOVO?CEX
MO3Q+^TSXF;0;=CFXN=0U :WJLBYSMB5)9(QGU>8;?[K=*\*_9_\  ^B?#+_@
MJ#H_PZ\-^:=*\,^,[_3K4S-OE,-J9XD+L  6(49( &>PH _K5KRGXU?&?P#\
M /ASJGQ0^)%\;+1]+51A 'GN)G.(X($R-\CG@#( &68A06'JU?SD?\%L?BIJ
M5_\ $;P-\&+:9ETW2--;6[B,'Y9+J\ED@C+#N8HX6V^@E/K0 GB3_@LE^T+X
MO\0W-I\%/AII<>GQY=(;N&\U6]\M3]]S;2VZ*#W&PA>FX]:]L_9L_P""Q5OX
MM\96?@7]H[PU9^%CJ$PMTUC36E2TMYF8*JW5O<-(\:9X:42ML_B4+EE_1?\
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M6\N,)&H"EF.<DMS@?UN_##_DFOA+_L$6'_I.E '<T444 %%%% !7\T'[4?\
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M. %RX^V/%OB?2O!7A36O&6NR>5IN@V5S?W3_ -V"UC:60_@JDU_)A^S3\/\
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M*>Z99")0.J)$^WHY4\5\I^!?^"WOA?4->ALOB-\+[G1=)F?#WFG:DM]+"I.
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M2\.WNIZEX?TS4=:LO[-U"ZM89;FU+!S;S.@:2+<.#L8E<]\5L5#;3?:+>*X
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M^SS&]%-?M3H^KZ5X@TFSUW0[N*_T[488[BVN('$D4T,JADD1UR&5E(((X(H
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MCV=VJE[A(/))81-O4KORS1D9%?I_!/#<PQW-O(LL4JAT=2&5E89!!'!!'0T
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M8_@#KG@*Z\%:S,;V%)+F^2X_TRQ#-);,@BCVMMCDYW'E=N#FOU%H **_.?\
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M1V5?K;7Y)?\ !&+_ )-/UG_L;+__ -([*OUMH *_F^_X+=_\E8^&W_8$NO\
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MIX(!X/6NCKYX_9;_ &>]+_9?^#VG?"+2-8FUVWL+BZN/M<\2PN[7,ID(V*6
M"YQU.>OM7C?[:W[<W@']DCPL;0>5KOC_ %2$MIFCA_N@Y N;LJ<QP*1P.&D(
M*I@!G0 Z;]LS]L'P1^R5\.)M:U*2._\ %VJQR1Z'I.[+W$X&/-E (*V\1(,C
M<9^XOS$5^//_  2X_9Q\8?&_XX7_ .UY\3_-ETW1[^YO+:>9,?VIK=R7,DJY
M&"EN7+LPQ^]V*,[7 Y;]F#]D+XR_\% _B3<?M&?M)ZE>1^#;F?<]P^8IM4$3
M'%K8ITAM8^5:10%'*QY?<R?TK^&/#'A[P9X>T_PIX3T^'2='TJ%+>UM;=!'%
M#%&,*JJ.@'Z]3S0!^*__  6^O+I/AI\,=/13]FFU>^E<]@\5NBH/Q#M7V]_P
M34MX+;]B'X71VY!5K6^<X_O2:C<NW_CQ-?-__!9KP/J7B+]F71?%VG0^;'X4
MU^WFNV'_ "SMKN*2WW_3SFB7_@5=E_P2(^(UGXQ_9%L?"*RH;[P/J=]I\L>1
MY@BN93>Q.1UVMY[(I[[".QH _0?XK6\%W\+O&%I=$"&;1M01R>@5K=P?TK^<
MO_@BE>74?[2WB^Q12;>?PE<R.>P:._L@GZ.U?NO^V9\1;/X5_LM_$OQ?=2I%
M*FBW5G:[R!NN[Y#:VX [_O)%.!V!K\;_ /@B%X0O+CQW\3?'IBQ:6.FV6F"0
M]Y+N9IBJ^N!;@MZ97UH _HKK#\3>)O#_ (,\/ZAXK\5ZA#I6CZ5"]Q=75PXC
MBABC&69F/  _7H.:Q_B'\1/!?PI\':GX^^(6K0Z+H.D1&6XN9SA5'0*H&6=V
M.%1%!9F("@D@5_--\<OV@OC]_P %.OB[;?!7X):9<:?X'MIO-ALG8QQ^5&V#
MJ&JRKN50N<K'\P0D*@>0Y8 YS]I#XL>./^"F?[5.@?#GX1V<H\-::[V6D>:C
M 16SLIO-4N@,^6K!5.."$5$QYA(/]-GPD^&F@?!SX9^&?A;X8W'3?#-C#91.
MX >4QK\\KXXWR/EVQQN8UX1^R#^QY\._V1_ O]A^' -4\2ZFJ-J^LRH%FNY%
MY"(.?+@0YV1@G^\Q9B37UW0 44TLH8*2 S9P.YQ3J "OF7]L7XU+^S_^S?XV
M^),$PAU.ULFM=,YY.H7A\BV('?8[B1A_=4U]-5_/3_P6M^-OVO6?!?[/NE7&
M8M/1M>U-%.1YTNZ"S0XZ,B><Q![2*?J 6?\ @BE\&7O-5\<_M!:O"7%LJZ!I
MTCC.99=MS>N"?XE7R%!'9V'K7?\ _!:SX,?VKX+\&?'G2X-UQH-PVBZBZC)-
MK=YEMF8]ECF5U^LPKY7\'_\ !(#]JS4?#&F:S:>,M T-=4MH;MK*6[U".:!I
MXU<QRK':LGF)G:^"1D<$C!K6U/\ X(X_M836$RS^//#E^JJ6$!OM1;S&49"@
M/:!<D],D#/<4 ?L/_P $\_C7_P +S_93\':]>W'GZSH,1T/4R3EOM.GA45W/
M=I8#%*Q]7-?"/_!;_P#Y)Q\+_P#L+7__ *(2OGO_ ((S_&*X\'?&#Q7\ ]?=
MK>+Q7;&\M(9>"FI:9N\V,*>C/ 7+?]<0*^A/^"W_ /R3CX7_ /86O_\ T0E
M'VU_P3-_Y,=^%_\ UPU'_P!.=U7W;7PE_P $S?\ DQWX7_\ 7#4?_3G=5]VT
M %?S??\ !;O_ )*Q\-O^P)=?^E-?T@U_-]_P6[_Y*Q\-O^P)=?\ I30!^Z/[
M,G_)MOPG_P"Q2T+_ -((:_%/_@N-/>-XG^$5LX_T2.SUEXSZR/):B0?DJ5^U
MG[,G_)MOPG_[%+0O_2"&OS8_X+0_"2_\6_!+PI\5M+A>=_ NHRPW80$B.RU5
M41I6QV6:&%?^!T ?</[!]O96O['?PECL,>4VA6[G Q^\DR\G_CY;-?6U?D;_
M ,$A?V@M#\>? )?@GJ%XJ>)O $LPC@=QYD^F74K313(#RPBD=HFQG8!'D_.!
M7ZY4 %?R:?!4?V9_P5:6#P^H,$7Q#UN&(+P/LYNKI&P!V$1-?TS_ !^^-?A3
M]GOX3>(/BKXOG1+;1[=VMX&<(]Y=LI\BVBSU>5\#CH,L?E4D?SA_\$I_AYK_
M ,7_ -L23XLZR))[?PC#?:S?7)!V27^H!X(D9NS.TLDH'?RVH _I;\9_&#X2
M_#B\M].^(?C;0_"]W=Q^;##JNI6UC))&#MWHL\B%ER",@8SQ7&_\-3?LQ_\
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M  1H^"W_  B'P.UWXQZG!LO_ !Y?>3:LPY_L[32T2E2>F^X:;/J$4^E?)O\
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MP?\ ')'_ $ M3_\ 262OYW/^")__ "<AXS_[%.?_ -+[.@#^FRBBB@#\O?\
M@KY_R9Q??]AO3/\ T)ZY+_@C!_R:AK?_ &-M_P#^D=E76_\ !7S_ ),XOO\
ML-Z9_P"A/7)?\$8/^34-;_[&V_\ _2.RH ^TOVTY[RW_ &2?B])8#=(?#&J(
M?^N;V[+(?P0M7XT?\$0+>R;XC_%"[DQ]KCTFP2/CGRWG<R<_54K]_OB7X*M/
MB3\.?%7P[U"0Q6WBC2KW2Y7')1+V!X&8>X#Y%?RQ_P#!/+XMG]D_]L";PO\
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M&_VQ?%DO@F>"UNO$<]Y?PSZ@TB6]GI=DHBMA*8TD<8C$,0PAR[#. 21]>_\
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M6\,Z9>BYTZ_T74[61HVS%.EO-%)'(.Q^YE2.S'L37[(_\%0_^3%?B;]-'_\
M3O9U^+W_  2HM-/T_P#;JN+#29/-L;;3M:B@<,'#1(RJAW#ALJ <CK7[0_\
M!4/_ ),5^)OTT?\ ].]G0!^6W_!)[]C3X4?&?2M;^.?Q4M$\11Z!JC:59:-<
MQA[+S4@AG:XN%.1-Q,%2-AL&"6#$KM_7_P#:V_9Q^%/Q&_9N\<>')?"^G6MQ
MINCWE[IDUM:PP2VEY9PM- T3H@* N@5P,;D+*>#7QS_P10_Y-J\8?]C=<_\
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M%I& [D+?6H)_44 ?J1_P5?\ ^3)/&'_7YI'_ *70UYA_P1B_Y-/UK_L;+_\
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M=4ET'5O&"W=Q>ZC;G9=0V=L418X).L;2N[$NN'4)A2-QKYX_9;_X)+:%\5/
M.C?&']HCQ;JDM[XNMX=5AL--D1)!#=H)8VN[FXCE=Y75@SJJJ5)QO)S@ T_^
M"L_BC]ECXJ?"O1_&?P[\7^&=?^(&D:I#"SZ3J%K=7D^G312+*DGV=V+HCB-E
M+9V<A<;FS]G_ /!+"_;Q?^Q#X:TCQ$BZC:V-WJ=B([A1*C0+=/(J,K @J-^
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M&B@#\M/^"M7_ ">YH'_8%T?_ -*IZ_J%K^7G_@K@?L_[:^@SS_)'_86D/N/
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MUM42VTR2YD(N;9W*R/Y\$(&$D91C).>>E?JA7X"?\$@?VI?B;XI\9:W^SO\
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M75X+&6XM88X#/97<<F4FV*-Y21$,9/W07 ^\:_2?]C[_ )-1^#W_ &*.B?\
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MQU_8:_X)G?LU0:-<?&CQ!X@\/IX@:=;'$]Q=M,;8(9?EM;24J%\Q,E@!R,4
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M8_@A_P +5_9>N_&.F6_FZU\.9QJ\149<V3 17J#T41E9F_ZXU\*_ _\ ;/\
M^$5_X);>--#EO]GBWPI,WA73LM^],6M;WMI5/8PQ&YV>@MQ0!X3X3@/[>_\
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MO\0_ _\ ;1\9>.KCXC>./A1XU\2:Y>W:WEU+J'A[4IA<NK [9%\@ QX 78,
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M=I6JZC9M83R2^%;RZ#6[2)*5"S6S*#OC4Y SQCN:_L-HH _F@_X:M_X+!?\
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M+]AWXK-\2OV:QJ'B?2E>2.TO=&A-Y=-:.P;[-J%@$9G!"C<51XR5# JV O\
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MOV2M!C^#D?PZO=8L-.=X[*UUS1-0NC;+G/EVTUM)"7BSRH#.H!^7C J#XW?
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M"*_F 'RKA4 7<<HX"AMI&X_KI10!_+]X+^-7_!4O]DS3_P#A ;WPEK>K:+I
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M=C=M;&<'']'=% 'YZ_\ !,CX%:O\#/V7-+M?%FESZ/XF\47ESJVHVMW"T%S
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MM&_ '1+W7=&N=4NM7L+O3[9[[[+]N+FXL[RWB!=8\2/'N(VM&1AP^0O]-=%
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M'[ ?C/7].\&^"M4>WU K#=A-+GU;1KTQ9,4T4T*[=P#$@JZN 2KKP5']8]%
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M?#&N_#GP#K_BK38?"EI:R7.E:7=7T*3I?WSM&TD$;JKA75BI(.&!Z&OZ*:*
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M>#[MM7@TNZDTY;>UCT_SY3=+&80D7EN'8MA2I!Q@U_1C110!_/[^VS_P3_\
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M#\)_V2?VB/\ @H\OQ'\ ?"'XK?#?4T\')-%8WVKZAX<O8)8K2*(@-)>#9 "
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MF422M&@" Y55.[EMJ^'_ /!<W_5_!3Z^(_\ W&U^_=?@)_P7-_U?P4^OB/\
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MK)=+7[5?:?'+]^SGM#N>YAP2H*K(&0?O K8)_I6HH _F[U[]O[_@IAXZT1_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&Z)X]\<^.M/TC1O$EG#?Z8TK.9[RUN$62.6&U16N'4JP)(C^7/S8->7^ _\
M@H9^QS\2-?M_#'A?XDVG]I7DH@@CO;:[T]99&.%59+N&)"6/"C=DG QDB@#[
M0HHK%\1>)/#WA#1+OQ)XKU.VT;2;!#)<7=Y,D$$*#C<\DA"J/J: -JBO@36O
M^"GW[$.AZ@VFS?$9;N2-MKO:Z;J%Q$/<2I;E''NA:OH#X._M1?L__'[S8_A'
MXWL-?NH06>T4O;WBH.KFUN%BGV#^]LV^] 'O=%>1?&#X\_"/X!:/8Z_\7O$D
M/ANPU*<VUM),DLGF3!2Y4+"CMPH))Q@>N2*_F9^ W[0_@GPQ_P %);WXO>*?
M%TEM\/)/$GBN[2]D-P]N;6^AOUM&\E59\.TL>T;,C(R!@X /ZPZ*\#^#O[4/
MP&^/^H:CI7P?\70>)+K28DFNHXH;B(Q1R,55B9HHP<D$<9KT'XA_$_X>?"7P
M])XK^)GB*Q\-:3&=OVB^G6%7?!(2,,<NY .$0%CV% '=T5^>Y_X*F_L.#4/L
M/_"P9-G3S_[(U/RL^F?LN[\=N/>OLCX<?%;X;_%_P^OBGX8>)+'Q-I;$*TUE
M,LOEN1G9*H.Z-\<E' 8=Q0!Z!16)XF\1Z)X.\-ZKXN\2W0L=(T.TGOKVX8,R
MPVUM&TLLA"@L0J*3@ GC@9KP_P !?M;?LW_$SPYXB\7^#?'NGW6B>$A VJWL
MYDL[>T%SO\HR2721#YRC 8SR,=2,@'T717SC\'OVMOV>_C]XHU/P;\(?%J>(
M]4T>V^UW216MW%&D.\1[A+/#'&_S,!\C'KGI6Y\8/VE_@/\  *.%OB[XUL/#
MLUPH>*VD9IKR1"2-Z6L"R3LF01N";<\9H ]RHKX,T#_@IM^Q'XBU)=*M?B3%
M:2R.$1[W3[^TA;)P&,TUNL:+ZEV7'4\5]Q:3J^DZ_IEMK6A7L&I:?>()(+FV
MD6:&5&Z,DB$JRGL02* -&BBB@ HKYM^%G[7W[-WQKUR_\-_#'QS::UJ.EV,N
MI748BN(!#9P.D<DS//%&@56D0'YN^>@)'DGB?_@I=^Q/X4UJ30;_ .),%W/"
M^R22PLKV^MU]Q/;P21./>-FH ^[:*\M^%'QL^$_QRT%O$WPE\467B:PB*K*U
MK)^\@9LE5FA<++$Q )"R*I(Y KM_$WB/1/!WAO5?%WB6Z%CI&AVD]]>W#!F6
M&VMHVEED(4%B%12< $\<#- &W17SIX"_:V_9O^)GASQ%XO\ !OCW3[K1/"0@
M;5;V<R6=O:"YW^49)+I(A\Y1@,9Y&.I&6?![]K;]GOX_>*-3\&_"'Q:GB/5-
M'MOM=TD5K=Q1I#O$>X2SPQQO\S ?(QZYZ4 ?*'@'_@J'\,?'O[3G_#.=IX6U
M"UBN-3N-(M-9>5#'-=P-(GS6P4.D4C)A&W%OF&Y%&<?I[7YX^"-1_P""=[_M
M67B>"(M''QODU'4;>81VUX)QJ,(F^W%0Z?9EEPLN^1<%OF^8YY_0Z@ HKYD^
M,7[9/[,WP%U$Z)\4?'MCIFK+C=8PK-?7D>1N7S(+1)9(MP.09 H/8UYMX'_X
M*1?L7^/M4AT32_B/;:?>W#;475+:ZTZ(GMF>YBC@&>V9 : /N2BHX9H;B%+B
MW=98I5#(ZD,K*PR""."".AKQ3XR_M(?!+]GP:0?C'XIA\-#7OM'V'SH9Y?.^
MR^7YV/)CDQL\U,[L9W<=Z /;Z*^<OB#^US^S=\*_#FB>*O'WCVPTJP\26<.H
M:<I\V6YN;2X0/%.EK$CW'ELI^\8P,\'GBO5?AM\1_!WQ<\$:5\1OA_?G4_#^
MMQM+:7)BE@,B([1D^7,J2+\RD?,H- '<45S7C+QCX9^'WA75/&WC*_32]#T6
M![F\NI Q2*&,99B%!8_0 D] ":_EA_X*=?M#^"?C+^T!HOBGX*>+I-8T*W\-
MVEI+-:FXMXQ=1W=W(ZE9%C)(21#G&,$<\4 ?UAT5\E^!OVZOV3_B5XMTSP+X
M'^(5KJNNZS+Y-I:I;7B-+)@MM#20*HX!ZD5]9.Z1(TDC!$0$DDX  ZDF@!U%
M?#_CS_@H[^QE\/-5FT/6/B/:WU];G:Z:7;W.HQ@]"//M8I("1W DR/2N_P#A
M!^VA^S!\=]470?AEX_L=0U>3A+&X6:PNY3C)$4-VD3RD#D^6&QUH ^H:***
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MT&HK@?AU\4_AS\7?#Z>*OAEXCL?$NE.0IGL9UE".1G9(H^:-P.J. P[BN^H
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M']M+K=TP2"SO8;C3Y9G/1(OM<42RN>R(S-[4 >'?!K_@H_H/Q>_:BN_V9(?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME_P6OT?3OA_9V'Q4\"7VI^+K&!8I+G3YX4M;Z1% \YQ)AH&<\LJJX!R5XPH
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MD^#_ (/^"M#U?4_"NGZ:FI3K86MQ+!/J-U/+$HE,:E&,,42E,_=\QO6OL?\
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M_<;7R5_P2_,-U^WW;7/AD;=)\G774?\ 3HT4@B'YE*^M?^"YO^K^"GU\1_\
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MJO\ V&O%_P#Z!>5_03^U;_R:Y\8?^Q-\0_\ INGK^?;]B3_E*MJO_8:\7_\
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M?!#XG?'SXJZEX+^$OCH^ ==@TB>\:[6>YMFGMXYX$> /:X<Y9T?:>#LSU H
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MFS#[2<KD'B?^"(_Q.UJ^TGXC?"'4+DRZ;I;V>KV$3')B>Y,D-T%ST5BD1P.
MVX]6-?M%\8@#\(_&X/(.AZE_Z2R5^ G_  1$_P"2L_$C_L"6W_I2* /I_P#X
M+4^//%?A_P"#?@GP5HMQ-:Z3XHU2X;4C$Y19ELHT:&"3'WD9Y#)M/&Z,'L*Y
M7]@?]AK]B?XP_L_Z)XU\26:>._%-_$QU9'U*X@;3K@NRFW^SVDT1CP ,-("S
M_?4A6 'ZN_M!_L^?#?\ :8^'-S\-/B;:R36$DBW%O<6[".YL[J,%4G@<A@'
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M_3?J%?GE_P $8_\ D[+7_P#L4]0_]+;&OT-_X+4?\FK^&/\ L<K'_P!-^H4
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M;3_@M[X3'@E9;[X9WI\7B'!ACO(AIK3@8W"4@S*A/.WRR1]W<?O5Y5_P3Q^
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M)/$-K%>MI\=S+96^GQ7"!XX6\DK(\R@YD)<*&^4+\I9OAW_@L&LL?[8EL^I
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M/%UV9O4@V-EL/TP"![@U^P% '\F?_!,^+Q!;_P#!03PY!XM\_P#MR-]?6_\
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M2/\ L-VW_I,*\R_X+F?\?7P7_P!SQ#_/3Z /HK]F?_@FG^RWKGPI^%/Q?O\
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MZ]XZ^&V@:UJDY!EO)]/@-S(1_?F"AV_X$374?#[X+?"'X3K,/AEX+T?PLUP
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M.3F$*(S^*U^=W_!9W1](\/\ [.'P]T70;&#3=/M/$BI#;6T2PPQ(+*XPJ1H
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MJ?#CP!H?AR_*E/M5E8017.T]5\X+YF#Z;L5['0!_,+_P6L_Y.C\*?]B;9?\
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M,)(2Z;7^<$;FW_H__P %J/\ DU?PQ_V.5C_Z;]0KT+_@G/\ #[P)\2O^"?\
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MK*'3M-T^&.WMK6VC6&""&)0L<<<: *B(H 55   P!B@#\^/^"EO[*VN?M-?
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MRJ1N0U]I_#_]GGX$_"J]_M3X<> -#\.7Y4I]JLK""*YVGJOG!?,P?3=BO8Z
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MDJ_"'X3IX(?X9CP7HI\(2;"^C'3K<Z<YC974M:E/*8JZ*P)7.Y0>H!K7\&>
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M9/7T[XK^%GPQ\=Z+9>&_''A#1_$6D::RO:V>HZ?;W=M ZJ45HHID9$(4E05
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M+?BOP#\4O"UU+I=_)'!K.EDB.[M[BV#>3<6Q<B-MRN>X65"K!\!2?O?XQ?\
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M HHHH **** "BBB@ HHHH **** /_]?]_**** "BBB@ HHHH **** "BBB@
MHHHH **** / ?CO^S!\$/VD]*M],^+WAJ+5Y+$,+6\1GM[RVW')$4\15PI(R
M4)*$\E37P'=_\$6OV6KB]-Q;^)/%UK"S$F%+VQ90/[JLUB6 ^I)]Z_7JB@#X
M%^#O_!-#]DOX,ZU%XDTWPS+XEU:V97M[C7IA?"%T.0R0A8X-P."&,992,J17
MWU110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'Q?^SS^P9\ _V8O'5[\0_AA%J::M?V,NG/\ ;+S[1$+>:6*9@J[%YW1+
M@DGC/K7VA110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7SS^T=^S%\,/VI?"FF^#OBFEXUAI-Z+^ V5Q]GD$PC>+EMK KM<\8ZXYKZ&H
MH \S^#GPF\)_ SX;:+\*O PG&AZ DJ6PN9/-FQ-,\[;GPN?GD;''3BO3***
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /_T?W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001999480-26-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001999480-26-000012-xbrl.zip
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MUW]]<777H /<3BU8_I=/_,LOG_BC1Y8V'WS1]!?)<><&_:6BZ<[,(/,+$T
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MV5N^-G$_?OF5FM94-],>FQ4T"X_XM+CZ=;MV@!%T32?V/ %(1/=%]'LN8*I
M-CH(.R!S\@PW.-1-?_[BA4.\,->+3"9C5E#4#/[,]32TZ( =TI?J_YCK@8'D
M3(<M_S'+ WT1R&$+(C#XGC(%&7P";,/GL4YMB7$U3;6:+V_^MJ@XEV\.5[#X
M]!E37,$GP)?MHBG E&.M(</_!?=%OX7+U&*7-IE-L/A+\#EXR:>%?:>#01$
M#-PB=OV=H<\1/LC_99N=-87;61QGN^RL)=;.VC7?0MU]9VT!=K; E.WL3-DN
MCBD[ H!A <&%D6YWWSOS\<2U O^HP<O>9F BZNYWBII.TL#$-%G *#* 74 6
MWG,%WB6X2]9T!LX?&+7#-QV,K> R^!Y\M$<7+&/^K"^?4E\10B-<23Z0MXKC
MJ=Z)@WRH:3IZ-.#U$5V[,2_)#"W^4P%__\3!_T!= IZ4=D5L4S>?G5.!N]PX
M<< /5=6;>@8&J>_<";7Q.IM.\&DO],94K2D]&5R(8&SO:6M[-Z!/6:,)8$O)
M>_<#SD7_B8"LO;LVYRBT14#<WCVWDS=S1,#2WAW+4U96^_%XY5-W>8_A?Q4)
M_U/W?P_J@!4)^%/W?(_M@!6("^74G>'#"?["/$-E[T[O60K^XN!_ZI[Y@05_
M<8 _>8_[Z(*_.%R<ND-]N/#4D<[?3]UQ/DYXZDC(.G7_^?CAJ2,A[M2=\ .'
MIXZ$I5-WU0_EI1282Z2<O)=^!"^E0/@W3]TS/ZB74B3@3]X]/[*74B0NQ'75
MP]3M1V+0NS&3[8MXN+F_V[,V;F%%7*.311LO7;J+-FZ*Z\8?"2D+&20+<-Z)
M^,5UT3?#^>Z%VD/#L%Q\]-T,%?%Y,H-PF<E\<YE,=':ITB\$#N)ZP)N)]=[6
M7V#C]P91F7[=^QF_W*@I&<_X%R[="4/BNKJK,<1*>>YM>NV9&M5^)[8-TG3O
M >\XR'>2X.+ZK1M _C?EKQ3^F&#YIF=3Y]NWRWT#7:[)W4* +J[C*@+0ER51
M'.P;)%'\TETD44M<UU8X7<&<J6P86KIT)PR)ZP,+I2N60+Y3[=XINKI'T14<
MZ(64@K9.T94]DJY8 OMF2=0K1!()ZP3?VQ9LQ)V#)C#=H:EA4&Z&S_AUCIUG
M8KCZ1D86:TLP#Z\YE0!<2]A3:''!7V"61DM8KSH3^(.+KSW;U%%,P877^AL3
M6"?# <*ZS6*CH$@N$-:-SBZ$\!#&<ZG]:(W=5\+0<'K*0%C/^@3P4&0S#&']
MYUPBZ1LE#IU8AG8SG=G6"_.F3T8MM(7UD 7'09%\(*S+_)6.W!O8F<U:$\9M
M48N8@)-'JGHV+'CX;-,L4:3,+_YFF<\@W::X@"2VV6NIAC_N%<?8IK4F%W((
MVA;.0V=X7$3P$V]>%L-SZN_7EF<7A>B2P@JC,&$C#"MQS%J24HVA^CSQR\J@
MY68A^!4NA+&]!+DS-Z5NE<1U6.(2+D"S/7$]O5HE<0E%7,*%GG8@K@E@NR0O
MH<A+N+!:J1B/0%S)]C,1>6UH/Q._=)=#OK:P@<6BW:S3Q$]'V(!CR:R')P9A
M(Y_OC1CVTQ*F<WI1U3/%KP"-X3IG%'X]A(U81E_S$E@9?14/OP6>DW:$B[Z6
M/%QT(*$C7! T[+M@$,>Y&_NYX'?V P[]6LBB]7\J"K=AB;;_YI0"@L--BE@H
M[ML)P<(%(DLF+AS'PD4#LS+Q+7T]9SXN4AD+&V?[SL>SX5TWYLQ+8:GE*Z[>
M9E1UJ?8$3'@J\.\*&T?+#_\'W?EY#4+U!C9H4\=] (8Y&3P(&\+*CX=[6U?I
M/RR#N+H!.SD9%)11)GRI8[L7#\1\]I&,'[^3-WWJ;9)I)V:H%.AM=(4+21W-
M&'TOU%-@O*E[>O&FDGK$D3VG%\TZ_VAE@;U#NL)&LMXQ?@NL]^^6@2R!<"Q
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M](RX/_K@P96M1ANY&OQQS^"1_L?:D_0!,=C]+"E-I>Y?X4YT=M(]PY/N?0L
MON"0KZGS<0NNC8$&(>,S<<BU_9)K3Y-KXZ;.OSW'U<=ST1D96(=(!FR#2D15
M@9%M@MR(I&VC:DO]5@*RK*7^X$Q! L!;[$ A 3-,8?_S*FIR>!RH/P39L_1L
M6Z_N)/BY#HJ=LK5I=*R;+*&.1:,Q"*? -E>LD/TL?PXN6WU!<,7J!097HCJO
MK%AF!1-KF'0"SZ>F!$9)W!*IGU#:2K=?[W7DW-&U1NY ULJTE7JOW2DFNJ;4
M&\V"8F+%[F_]D\3(DRY*]GQ+9U-QBDX*UPA%1\U$Q_#PG>'V<,DD1[GLO,3/
M-FG>]B70\K-ESU/B.>PB1N6J?U$4VE$:E<%MFADD;L5=T1[!NQ-^CZN,Q[/#
M<5Y.8I ).IUMK$N5-Q6FEE+W:(L\$5:\2G?0WCTC!G#YC8'E,G!;-S#DQDIQ
MT0\DQFMB"U5PVE-#(OHX+:S)@IF@S$V+Q2(]A\<E .J\ECJEXL^RV;N,.;[\
M58=7PVLE$[9EH;)XT1UF')C$5'5BH'^$N9]X,9M#1FS-D;"J0-=6)>8T/Y"/
MJ=$&Z4@QL=QT^1:5Q/+:\HTEL4IS74WL&AKLBQ\_9V$W9T(-(Z!2Z0/0'@M^
M\?*M9)0)T(W!YG_"<H\<!SUZ*#BW>8*07B,,%^FNA9:]:.%W\83NTR2LKP4*
M92D=SF)-8IA!&<\)D:QH_"(6+<(=>\_G3]_ =S+GY-3C72J.54N.9TQ' H'/
M2-?L- HPY)DZ9R..SLH2:RD5$%&J#L:^\TOEYO8ZY4":89HA^I$](C9L<Y'S
M@'1JFL6Z$.(#P3X#2PN>U0CYL%T9--O51K]9[;?"'.5@J>N*0/:)K,SQ_;)[
M8''= ^/-06<6MR(N;(KGPB]T9;M0__6-Z!8R<BS#<U??XJ^KAN;_A=RJR^R-
M_I<V)P/_VU6YZ@-6I);6!#-OK]1NV"MU8D<+?*:UD4W)SQH9PTLOB/%*Y@Z"
ML&RH*N3Z#M50U4=B;Q&)>0I5]EF8E;*QK(;\8:4H, EFK.85HYUZHZ!2_EZS
MWFT5<_S8J?>;ZQ=UT$C4HE80/VLTG9+OR3--"U8N[KI?1!7PX<LGR<%>EI"8
M8-OE$998NG9/;%>ZD6K2=1A;N3&YC0E/3!&=.0HVMR]VR%K;O6!K](-GZ":6
MMU_45@8Q]NH.[ ?_:2_;&?^=RN#&I5-)KL?0'TY=<:0//TSB:;I+M8\K*.$\
M&G&LZ$]6.S%<RB6[GC.[]GH^NRIUZ3LQ08<BE_[%D;[JCNKQCFV8>3<TB3%W
M=!86BM@:C$:-A]SQF@?J>(;++KF;4;Z>-$/YW'G\Q-"O-$H6/V<<RUC]QWB\
M69?^CD=8NLL"-(QIX0LC^(P\;UB.AP'CX<CR7 F[H%-7>M"=GR4C"X_D9KOD
MY/-&<J"M6W46L+$!28R+[VU+I1HR;LFFPF,P'YN6$8M]1RPP[XV'+#!FP9O[
ME?&*]\*1F%80!"R^T6?P:I@P906*I305'W?-;LF@YXWD;L"@PSKS1*1KHKJ6
M73*G^'@KF?/,D=QL1/'#'V:LC]TC,7C:V=4?GN[.XPU"T&'YX5#>U)*IVI*5
MQ<=RR<KGCN1F%";\2L>$Q?)_S# _E)JZ9<=8N&17X3%9LNNY([D3Q0*_P\-!
MXXXI*-I8$+]D4^$Q6++IN2.Y[[-INYXYM%@RJ#BX:_9*!CUK)+<4GT$[=>GJ
M;:*/]-3L[I(OQ4)9LY^'+SOE(=J>#]%:[<K@$2!&W-+R%)^! %FMM6E?67H*
M1*HEK;8J9PWXCM!B#[O07: !=3W\Y#8@ZX=IX%@=OXI2LM P>]6=L ^J4^53
MA*D]==A??IO"RZ6FA/[7.,!T^;M7NOR-YRQ_8WGV0G]#1X>-$^Q-,*8V#D)U
ML.2<-5+]>SA!GC<5QK[XUV!'2G*C]G=^ W8F6#%*E3V=31ZU3%;<P?HB.=[(
MT36=V//5U9/OL\0/!X&5-7YEC=^J&K],8N^XY7VR@IVQ[J\N;X;?I-N[IROI
MX>JWX</7F]O?I.N[A]_AS]JWN[N_X>?'I^'3U?>KVZ?'E,E":W9Z2"7+]O.T
M412RAK;+5U29I">ZR1J\OQ);JQF6]=/O]!)4IA"6\NKQ RH0S=B?QG-<>\X[
M4.OFBV6\L-[86#GO8@*\K3L_^?4>R%H;7X'Q\3K(82/^:,MO-L* %7T[EF _
MKF6C=2.-<8"TOT[>:R15\&/;G&#*5>Q9-GV&;>&7N/*904S0819K> ^"&OY^
MMH@!_\$.$"Y]UO&KL8?&&O8%AR>$'VW\[.'A'>O S8(53)'XG7+@%2:>V57#
MMR"DD&-8<V"N&[#5MX7-<S0/=X6-!E#G<%A-658Q_WOD-R>37%!X&GP'*UB-
MH[KT.Y4F!+ P(MB\!\#JK+N>MU &V.$T5H"+REMZ2_1M!H#A%0IL&;#2?_.F
M/O".&\"2-:6P; ?!-+<\W &H#C;@=+[N?2.J$K\UT3Q IO1J82<AUIN<.&%/
M9'@6SO-S$W;"B!HZX&#Y:UA"XBN45%- 0_(A^),.:$Q^[QG:\I<:=4!*+7]+
M'5>?ICR: V_Y6T8"B2=/2<)8FB(_)RRA@%*7?T :2WQG,6HC1N('F^) WN37
M#+G+7SL38B0>X4S2 .0B&24>\*K'[@<N"+Y>>((_4,($_F1)]KQK$) (IPKX
MF0N'P/;C-B=\#6#&V8^<)(67R[BC&!\$PO*G:;V:OH#D?S.165V4EWQ8!X?#
MF"?W^$.?@'XDSE'(OO"3AU*7%QI5X^*)]3%7)\@X? 5\D '2KZVS\0>:/F96
MM2N-;6O*6H&%$B_#\WQT@-!!>0=,I_.A*(C<=0+K>K6PX((<).L(] X*/NQM
M9@ =N&RH036AG-(&_V4P1!9,ZW9K.42H*/6DO7D HF$<TOE\^!8[\/;/B^X&
M<TL1DZS'/=,+X $")LSG*NJ&9T0]IU([JG)#DH2/E-@HV>$W#:C%L&:(,7X7
MF2)5V52%]S,E[[B@N3G! V$'W[I(HO[S@7-0\#ZS1<!OV*Y.L[UGIF=O;K_&
M><7F0S@L,%'8  PN+3Z75+)G*B$CW<"D)I\&R R0C4/K0.;8E!L]^@A$CJ^/
MT+8A+J,*8&+5PJ5A<\(T\VAJF<^.&]@:*&/ 1- 905DS?^(*-UE\Z111$1@8
M*I!IB?Y]HI_AVT<_H#LPL_#OT#YD]# #GL:V@[K%S%V;HQPU&5B$8\]F#!SB
M+B8YDOC;!D4EMHMB=JX&D->1ZU3+B<P;YJ59(S1C6-<\YMOH9O Y)IX92;P
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M8A2\3(+S/DTX]&SF,AI@]F+@*8#3R,1 8(%FB#YP4R+E C_N4,8:A*0-/S*
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M9':!U#$T-?S/540:0_>2V/8<(/$/8GBT(O$(''AL;^Z%Z4UKFL5B#_A8X"R
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MS);G##UW8MF ;2VO@=-= ]/TM6V,41>V-M[\L-I(:8"8^()/XP,#('S;Y[Q
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M;P1T0&(\G<.]30/K@P$2V\W+RED/>]0A:=NM[ 1)<5WZCE)O;TK@Z8N3O_-
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M!<RHVPB"W"&X+/>OZX7AWW_V\VU6!/*R\.^N0^_:2F6P<TIB+CSM4R&6!%=
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MG3/+(-$- +?@NE_O8]=%/ &7 <0)_)5RS]-#[!X'R.P_P-* ,IU4&47> ^D
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M,_RP#7Z'5!HR ,=EO%G",EX>*89"I"%ZD#[8&1%*03$32Y;8%>BK'+"P0-D
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M0'CY]D5\Q'9>J=;?I IPV5SL?V7G([S/-5<'=VB#YA9<X";UE%ZUUUGI0YR
M:F=!LX _.X(H=CRD/9YB!^]0J?8;C7P>_=$5>TL63+%WT4"2\\%Q'XI]D9KV
MH-A[;#Q72H!V2;,_9M3L)R,U>H'4V(]6;ZT(;.RHU;&-YSO2ZHM0W$6K=QH'
MUNJM3<Y]\5J] ^Z(TNA6%3DYGR)=JW]:ROC9S+$9D[GPX&=]EG(O3,\0Z+0P
M_1!4R9L!]AB=(@Y5%C]$]%H&GA$YR;RNCI+,Z^HHR;RN1V\ZQ0,.(,;8&Z3H
M%5+P#J;2?R6.SO@UGG2V,0$L^R[9\^_&2SN<\W]3=ME,V64SN<M566@<(BEP
M4L3)35N9]YY.6"LP=+IGZ@M)_*R43)_F2<^7)N0%)\)0U!QT1FP>P,7'VAH3
MQ#PI*J)X4##P$##U'?],UC#F^#N=Q8*_/TQ6)\"R+!F\AXS 27CD]]MP>!^E
M<!!,.4)MA^?=F&"%SXAR9F/\]HCZE=A@V/UJP7_"YUT/'W\-SQ!3K[^T-,:_
M;CR19/AX&5L%9@KP(RJV '_3?/T&"_GS\\P5B79UN,K@2 @RRF)N#Q<1OD40
MASLU=-AWD/&HQO-7-RJ/9=GR;LLKVJO+*\I*B;)2XL3*"<I*B5R5$JOMEW0[
MK[G&YFFNR;Q/F49P;/V_C<K'=-FHEH_GU"6,@""="PQ04%IH-1&>-A;=!Z S
M%MYPI/3E:&.FACFJ$CP,)#U^%QWLSW23'5<'"A[/GTG4)"-(\?6GXEDF&#4F
M^H(&QI4\FS=?C%UO4DQS0^< @S,(F#'1[0C,OMN>!I)CTDPB A'A+]#XB&A8
M?$J"9&@ <;>=71:E5?(@;D1F.&';S\CT(70D^G!!B8B'B"E<,G$D'M19!6P\
M!N/)$]@S8FQ8KXX0T,R^>M'@?L0B"QKQC6A06>#C@,"R8AK4"3:@#20BYF/K
MIL9<K9<P]RW8.JOFD.C;C$=[0^'I&:A+,,(FS2FQ)9;L,_<3OOC$O4Q%2(+I
MZ$MJLZ*S6,B>L<;8LERLN6?Y;KS\T/$5#@.?GRCIN]/+0CM%]Z8X])%- ,"T
MIKH+ &=')LYV=H,SL3Q#0_2!"Q4XJ__VS'BCOK3%^@9#NBUB:CYY\!1[WH<
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M 1-_^(V)Q;H,C$&](%<ZR# NU[),CX+^=8T@YXD_0,,'Z-$#F/CASTBF1[V
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M!AR^0W-GY4'<*F'DA*+GP'+P GML>5./MS75Z,P&^D@9-_-.S*X/!69Y#"/
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MCA$,+Z[&.M654XC@!BU9@H:DZ2WRA6:EN*\-=O1'N6!'WOE10B?7/L@6H X
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M%#P4%#Q,FH*'IN"A*7BH_]:>H^!AQRK6OK8:8G"BCD>JBK\4H25O'1O5I)J
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MV3%3N\2\+AQ48LPI(Y4FX1*ZBA4A!).-E:,!X H'8<W3O$HF3PLV58T/&%%
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ML$Y85VYY:H1&D2GM4^DHYZH 7]-):QP.IS3PY8##U(IJ9_*WRLC'C)F_Y,1
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MR%T6\H Y]E65F<?4RMX.2#>+0CY="+9D4RE$_(09AKX]BW@\%_.4E;SEI><
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M?-N2G!?IC5@XLEG'#D/.S5U@Z&:PI"PLVQ+I5O ,36B;L1PC33BZRKK%-Z*
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M79KT\25U&U24Z?*\SPC137-@7_; ENYP8[NMQ%:XX7%8KN8HNL#G"!N^28U
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MUQBTX !T'DP?4*!U:'_6JXI.=IOH9!.=W"$Z60-9R)-98ZFDFAC$A59>2.Y
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M0M^49QK]_^U]>7/;2++G5T%X/2^D%Q#-2Y1H;T^$+=O3FK$MK>7>WOUK R1
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MQC<'W4E_U*:AW ;*''%8R)%'6V6RQ;-M,;9JQ-S_E"P%(_L'BY3HCA\ JZ"
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M@E:%=E)2:.92(&&=P@GK?R84;,*9'C]C%]+Q%G"FK%\!KY_[*14TEL _*:
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M@#M4KK^<J;"#K.]'$9#"J!UG[S%^@:T=#/@DH:T\HEAU>@3CG1"P)=("S/:
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MP 9I,)9T"?K TK '%A;LV\!&9G,GAB_2R'K=:;?:6P]RV+).PS'<&IR,'VX
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M;>8*-*GQV LD2:OBB@H'D8?7W.8=N'>4G$8^6,Y#Q(.C!6&FG6V-0!W%M+Z
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MWHWT8"/N@YN_%/.B1F&#7NNXU/-D-512$32!(##"U$?$:SQWS<]SVEH']E
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M9"+/J4)).Z3&Q//("S(A!L1=&?C?QFX;]$Y3<ST^$NS:$RZPB44:8;-V/Q1
MY8WJJK%37*%=VF&_W#NNVVW=S3'V4(?S9+WET.U5["TWY,YRP-'&<+:V=.:R
M.8N*O0*7B,7%UVD<)6F.^U# %F."H,_Y^O"%QX-E0E@FJ]4]'^_A?%_H,0JN
M$@%ZX(D6>JS183JSA,#JO#%H^@0QAN@@7G,8]W\8>%WR*^60_$D54B>U)"!8
M% 8 =5DCN8SPH]B[1%3\*$;-^,J'^:E+UURNISU/!C'5_0OA)1E*+FY'4"T^
MFZ-XF*-("M?(1J0L?='@%!"SBG1Q5/SQRG!G$-)>;-WI@M&*0$$,X1J.U2%6
MMG)@A$(1A:XW\<+5;1\.E)TY#AQ_UI#  Y  =RPH7D>P$T 1]9.I.E;SF,<(
MIC.2<!\<(U #V6C"FLEF3& HA" EC+-+5E>;PWN P]-'AE),8QBSBR9:4(>?
MO/UC5/061-JZ0(LU\#TT&_+3)2L"GN'SA;^: [S? Z3#F""H%K?#"J?<&D 9
MA\ 'DT62>G(]J5O.B#L4(LY=FL8@,6UKZF.K 7;*$> V(H5JG.,$ 38#PQS,
M/S1]%83<681N;J3PXTIA)TFBL4_2C@&D*5+L@&$!K'C,.4OAHMG_^]]_ 7XU
M81V=,:/,$DKM@8@X$6XK/#NI-YZ&L(1+O[DECW1*E+#&L)]\1"+6"BI*00D1
M*W%A,#BRY=_A$3:']E"LK:!=*I=F-)MY,?K356.Y/$)JRJN";6A+3SKZ9X*8
MHF)'(!:O/\I,^/[E>VI+>T-T!XP]:KFG1N-F'U=.L)&;^DE2D_Z@[N#<U-''
M, HLAL,9#OFB8)W6I1=ZY'0TG=4*[Y]B[VI7://*X0HRS6$G,]QNC]N[D/.>
MXC/<L5&\_\F4O.+%KN(BJZ@9M7]%\W XK0_]UNG"MBXCQ.S/6U;S4Y@GM[ N
M"1!9L))U9)%PD9GS*B^X1!P*6HU&^"_:)RQ+Y><D0C$ KT<D!&?O$N:,#5P2
MAZ#(DY;UHP )KCJ-Q(Z?>)6^?V,/BBMF=I1'QI9PH*F;TS4B#T_]N=$6GFFX
M21#&!.%NDR#<) CO8((PY?5.H\!%7'&,KXZ  ?AXW=R\C9/9,C+Q#-Y OV .
MYX%^ ^S$%;3Y6&NBB#+OA6-109'?'] +N)D;\,2Q$>'E&*[C8L<&[!7C<-F_
M[AI2B44NTV]9'PM<6>>WID:.$S>7OW+\  _+E@502#MO Z;;;/#"5&O:A)O<
MB :GZG.5)]$P?%/GIZ=Z^8PMX=C2)MI!>&ET[M,,<SZ-7!>G\Y.S));R"!)N
M,S0..)1 O;KANT0UX"COG ^"9)R69X8-8#+Y>)2!,JHC?F;CBG(?0-4(H/@N
M+<_@;4PR*R2%/K3B:9U.<H&EVF6QC"K[[W)96.&T4]D??NQR,CNU+N!.'-SC
M/<)<(#^$M8%&0(V1\)X*/8G+R32-;*7_Z2Y$*?#L&3<]Y%QHI93;K"(L65O2
M*4R]G]0&[8:D9C%TI716@[04FSA7L&IJ:1UA@R,8\(T,%7OP#MYA7()7W:>6
M]Q2SN+-0C;.D$A0W.U<"EI0::GODS1FXG&=\C1U\4:M"_B"[/-))+BZG& 38
M)9CNBBWSYG8%"M:?^PS$V671H1.OUKN5$PJ>X;W,3T]E-# 14S=H,WXFQM3*
M\!DU<Y&^7M=$UT1JUSZU%T/FM>(E=)NKCC[#"WA5E1=?XXPR%%FQ9.V<E?+D
ML-&1GU9GE]4^I[G4FR\*.>XJAL%R2A<S'.HLSHE*TA#=S&KAG+3:I/@/JF;R
MI FR4GQBI'TBMS+(BG/R0'6=KDGZM/82S[.^@9AYJKWNUVYG15P!=P>C,N4>
MHBY*%?H757Z;6:]HB:K\O40I-* 5!8EWC7U[N&.FGUC_*P/1"4KOPOKNH:V]
MKQWZ 56#CC4/T.D_4\]Q_^*?X7V88,L7V*<Q]C+E[ADP^%?LKH8N___M>]>V
M=8)^_R@.?4<WT_)#GXQB?@_*""26P:%*<"89J45'0H.2#.ZV>VV:3-[I1N?S
M<0M-; :O"]+,)>AFP20QC1[JW(TN,;N^L,SEV>7-Q5C?X$\7H!,4#'T5SG("
MT!M<S'ET/;OP&LJ+FZ&:J!_&"%FQFZO9(AE]$EH75_F@]/J*9E\[D;5H>$;'
M(GP2U< UC.(9^4E0EN)JE:[*5%-J=IGXRL&MOZ!PX<)PS"&-4IXH_AXDOAO%
M[&D%&9__*H4#+ _%26^&[B>AR&(TV8NO?&7CB%(@B7(Z4UC7RV%)-ETIM6IV
MB:$>+749G'.9MQT2PG-03Y1^AG[$!IK-#;@P.9,4LG+J-4L*KN,$=9[,'OYL
MF1^S>6>80:A(HFJJ9.$N)L@6^K<6/?+&2N].>,#4OI_A_WX]*Y"$260K:R@5
MW;2L"S(.\PDQ33R1W%M'BM2Z675[O8[]-$6+@.A247;. -F89/(D2M(B"+$K
MR'S)]4Z3(+$+64:=855+P\^HR>=&C(]I/#.>$K8?BUUEB*\:DO-:M2H+]KC2
M+CJ=1Y.KO]1 ['$8,QX:];!CEW>A3W8A:(4E-!)VS DW]Q&PW'>,#J K3@;)
M)C(88OG@T,9$3T,*5BBWNY;8B*WL;'E:?8V"U=:S5M3(4!C<Z[<4[TGI_06R
MS<*?(;4FC_/Z!HEB%,UK7;%@9KM@3LI/X,332.HUT%-_E;N62/[K61=?G]=%
MY!V_;<F546+G3>Y@4Y-V,V[E9SI"C-H7G5.S?&1K[Y9TJ?:Y!77E4>-^Y!U(
M00!%UZ8ZY,"7L'O8W)*?FJL0&'=I51>*' RV-6>E2E_.P:/=35NX05N]T7C?
MIF\1MO:>&T.K<94C-9%&LD3+KD7AT/:[#R)CJ%-U]YWU19T0_.J,#EF;1/1,
MM_.N\CT[V9RPF@VI+2C59UVD#I*F:_W!37W]=%'C-:_M'@IJR4?@8L0:N^W.
M,-=-=)M0ZK8< '%<><NWEC=$Q2Q5,U"U/^46HOCEAPB$)%Z['W&6I)ZG^RQ_
M :T02$W_^)]9B)TO\SVF\=77M@$>@B%<F +;7(X8\62@+= QT282-I;9[;5@
M6-<P9?0D*J<.*M@(&2_UQ;V.XL"]]M&4DL3!@Y''WG#9'6.QN@U]0O%>VCN7
M<[<Y:JHVENVI,(!%,K/,Q08%5L71B)V:\7'YE*@!&2S',W'4R!K%^#L4!QDW
MXK79G(PCC'_,ITY 3F-59#46;OOU^ZD.W[)G/4O8:YQ1X0;8D*G*>)LGB_'4
M=](8DR93G[EP^?#E\KC6.4U6M-+BZK2_>U%8 GG^0Q14)'DQ\A%SE?@M;U@Y
MAQ_Z178NFEFZD56<X;'Y,^:3U$"6-$X*4:MNM>I\2Z95QBA5:$]+QT[JI5YC
MCG!/7- )HXE?XV7>QOB$/70J>-XRHS,Z'>.REU@;?[RB]W'./@QF:O\R*UG/
M*Y!L47D\F$94SB,3-^^98YU__-2'-4_]D9]&G/B!YV&#E71ML>H)#/;]EQ]G
M!YUVQ^: D+HZB$IC*T-2/I._\(LF)0-3,GI-2D:3DK%%2D9]6*3AMM2R4G_B
MVH7XJ'JB\)FK0^84Q_1NYD'DIYJ;%+V48+M$\3P2+V7.<8IL-Q?Y\CN;$U5!
M.D\SF![Y>9RYEZ7^V*;JJ.DBP-2'L60_.I=AE."?&?E _Q0G@Z'@H9.RBDEK
MF< \4'-=<;URGH5G\%RM+L /9/J@P3C&H[F53 X.M4&KUHJ0NNB2)YD0>XG*
M-SQWXI\^V(8AF6Y'[\AO=8M3WDS$-:*_=9#;]Z.>G( X!XIZIOJ)JC$,E^FM
M0F>1O5A26M3GI^&X11NR%[[Y^<:QWE^!D8!^*G65X)KA,_LTHOQJ&UWG456=
MZY Y#SGRHB!@RT&MM:#_A-:W[]T/%0I0A?X#1V'ZD]1,9 KF95>O@K=^2A+O
MQCJ9>C,?*/0?M']?@4'^M-F!R YY0XFZFV6B)G@K2Z5%Y&>XBI\R$IDG%IBM
M^*:O<X$*YB!R7^$X9*(2)TZ>DPGTP[N"6Y$@]-,R"%N-EWD;BSD;IY'X1*K8
M#('?>*D&[JQ@+;PS);Y"'YY/G7CFC(E_. 'P#S?#5$5T'7])W1:1JH^7=X*%
MU.B /F'O1,C,AE^AP)5PR!4<1TJ07&$*,+[F!7D<+,_4DGO0XT100QKK$FIM
M!$6QK$^]X42^2C3<#Z$#(;>#.P"&"9@;^"P;*, 4..E1NVA(YL,&IU'K\6-J
M=.@O02,XA^<28)[/Z<:J(/*&-Y:*-%!6+-_8?'=*MU9_\<&/C"NH/K[M]M$-
MH!NXR04$J[65OY%T<#5G&@SO9I* Y<XB%;-087P:Q.; !5]!70?BARA232<C
MIW*+F%[CP]8[\Q$F;&S*R$NO/2]4'T<) K!A=L67+R?TFX\88<+WZ77L34A_
M^N9E,2PI]69:;^*H#:?L:5<T)<YU!BMV-G<W%I0=\H9R8CFO'M@/L4^MNT@6
M01$KA(#H$G99YB?P$MC!"@/AJ^=^O]EA3G#AS=,\HE%E)/P[@G\4$CTJ@^6:
M_FE'EM@"?WH2M5ANBPH+GVWG[-2Z/%<\+)G5]^GJY"D7(@K(6V  3*N1E.\
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M_7.FV'O@)!F2(;#J[O@U4& !A$LC[\U2H 0%.MYI)P [^"Q249/E=YE757X
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M0^0%"O.)]/WY\%DP%^\.XBZGRMR#D^.,5CB[<-&O 5:;=QQ2V3%3%00[][G
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M#<0J\"D$=<)Z"]Y&[%-8!A!C-)G+)\3VQV;3T,6J'99)26N(M=&34I964LU
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MK9LW8%.E(5K%@@ACBV@<B.BQ.]5W0S:JLTZ0V#* 37!'E@?->-108K3A!*2
M (Y#0;&YLAW5 Q=H/0F>(-MBQTCHYO/\Q25J_OC-_P-02P,$%     @ S#NM
M7$3OBO%62@  R/H# !4   !A;'1O+3(P,C8P,S,Q7V1E9BYX;6SM?5F3&SF2
MYOO\BMK:UT47[J-M>M92*JE'-JI*F:3JWGUJPZGD-I.1'21US*]?@,R3C. 5
M "/(S#;K+&:28GSN_@%P.-P=__Z_OU^/?_KJZ^FHFOSE9_0G^/-/?F(K-YI\
M^<O/?WQ^"^3/__L__NW?_OU_ /!_7GU\_].OE9U?^\GLI]>UUS/O?OHVFEW]
M-+OR/_V]JO\Y^JI_^C#6LU#5UP#\Q^*?O:YN?M2C+U>SGS#$_.YC=^_6?X9(
MV6"Y!UI2!@1C"BB*+/!26$T58@BJ__7ESPPQAS73P%!# 744 ^DP!_&%P@A1
M&JA9?.EX-/GGG],/HZ?^IRC>9+KX]2\_7\UF-W_^Y9=OW[[]Z;NIQW^JZB^_
M8 C)+W>?_OGVX]_7/O^-+#Z-E%*_+-Z]_^ATU/3!^+7HE__SV_M/]LI?:S":
M3&=Z8A\>$!_O9O?_\#$:]LORS?C1Z>C/T\6_?U]9/5L8:*L(/[5^(OT&[CX&
MTI\ PH"@/WV?NI__X]]^^FFI.5W;NAK[CS[\=/ORCX_OUI&.)K-?W.CZE]O/
M_*+'XXAX\0VS'S?^+S]/1]<W8W_WMZO:AU;T=R(G4"S!^9_IVW[IC.DJ JGM
MW'@0_^HGB>(9,39]>W?,]]\%G ]Z/IYE1+S^W5GQ5M=ZE%/!:U^= >WBB\"U
MOS:^S@GUR?<^PGD'<A5A^DH]GE43/Z^KJ1W%.=?_R5;7ORQ@OJXF+HKN77PQ
MK<8CEV;:3[/X,TV]TRI\FE7VGU?5V,6)^\V_YJ/9CS\F>NY&\6/;I4K/!6DN
MAF0Y^O]GI^<]DC;2:C09I9GJ??SU]J%)HJ/+[;_/?/RNY<1V!V]<V2<?&J=I
MM;KGP5@;/U[\]1_S*?BB]<T_[I\=Y?'OXLOI/QZ6*Q5G4&'BBJ0@)\!!+;"#
MUBI+UEDTO6-ET%.SX-'M(R*?,/O%CV?3N[\DTRQ9U8YBJ?0,<GW69NQ79?+:
M ^40!$)9RQR-4BE92J8%@J?R/-#HHKZ3['8$[[40A;JZSFK/695-C4M+1= _
M_U35D<[1]XIO+::5/]MQ%<? 7WZ>U7/_\,=J,HNL?C->/#".;/\EO<C&A.5P
M>EU=W\3!&0?;Q??1FG(L@<!(#8&&ACLKC25<E")&$Z",/-G@'&S@S0&&;N-,
M9X4W4:@C&U8P_;I8UG8"]8\5=R43&QH!961!J[NU@0/=#5>5TGI?E/#> XFM
M!LPSYPC#GJ%PNE1XXLD.C@D;E5V  1'.=359N%Z_+1S<M363NRAB(,!C0KB6
M2EC*,EM_#41.RS?M"M;-GL$X54[-KIL:=C7UA7,+)>KQ!SUR[R:O]<UHIL?-
MX()#0-$  9)*>F2]<R&WZ[L1T#E0()_&"XS\CWX6Y?/NC:XGH\F7:0LJC($4
MG@%L<,#Q/1*"R\R#9B3G0( ,.EZW/.X\$5@[OYZ/T_[[<G;EZR1Q[:_2 OG5
MOYO$';MO!LI( #K.6X!39-+FR2*;>XNP,[ASX$<92ZQ3AG2E3,12>SWUO_KE
M?]]-UJ,U'ZOQ^&U5?].U6X7+$0)&:0PXU)'=!BNB<Q-G3XC'IT_F^$1)DQ3P
M/AZY0Y^N=.VGE_-9.C=)AU&KV 2CT:,6$GCH6.2ZU9ZH<C[G&I[C<Z.H,=L=
MTVZ6*."4K$N]-K]"&A=+&.=7;9R6.,K+:/8PU2J*\V9$1ZT7<%$6B-Y-IW/O
M?IW7D9@??#VJW)*OBS<O;Y+^IV^^^]J.IGY- 40%( T/@$"'/*,"!YY[#MD?
MY3/@43FK%?!K6A#_38_G?B? 1G"@ D6 > $M9$AH;X]#LW:0SY)EF6RV3C)Z
M*,G26>@_+CZ\>WVGG2C]1V_'>CH=A=$RZ^,R_%W7M9[,IO'-U]7D-EOG,BQ?
MST9F[#]Y&^6<C?ST<_5H\5Y;JY$%R@0%5%RE$9=:!*2WG0X7QGB>3!R28=?Y
MRHHNOA_]=%:/[.+L/G[L(BGQKW4U76QFG!/4 0.U L)Y!Q0R$A"IH T:<DGR
MGR<>@O0\27E$ZZUSCG</3O^_^72VR 3Y7+7$31<BI 0WE^(D?C)=#+2+B;N;
MZ2_#X_G_3B0/N"(6"(PQ,#3NKKFCGA'%B5<X>T@[NQCGS=:^[;Y.9=%IN4\#
M+R6#IGG^?D*/4#_4_NT\)2W=K0KO)A_JT5<]\Q_&VB["0K_[V66X^_>OJVGZ
MS,JJD,2*:P$W% @:!)!<.""5DYP@PAG;;;DOA_$\N3HDPZ[S57;B:[L8S0[V
M JR1$:S'1@"!E ":: XHC]LVXZ$,$N_$PGV??,;<*FJ$=<:H[HQI\2\>^[F?
M?7W]OM*3.WIKH'% 42UQBV\DY !2[ U#E$"V-8GUH">?.V-*&:$AKGMP^'\3
MV@67-Z$U -NH$H$UC7L?1P$51'C)I76"=*%,ZY.?'V7R&*&!,IW/ @YW#3_Z
MJ+;I:!8WV/77D?5+2>,.O?JR-.?]+/I8E1+SN.02 Z!D1%@OH.=P,/N#W60Z
M3_X.DA$-E.]\[-&6!/ ^[M 77N1G_?U#52\L.HL;>3.?I9SES]6'*/1DMH9?
M6R ]QVD$6Z$D$CKDWO%VA'S>A#VF/1OXV/EX)&)\ +R*1FD)-$,0(*R"U2$0
MHWAF=CT!<-Y<.5S7#98_^,SBD"2!@!G0049N$@\90<X:UU!L=Z1TC1))!U)X
M(#6,FW/GB*'"((UU9@G;D@[^_9<5NK^/OW8M0OS53VT]6L3+JA GJ5?SZ6CB
MI]-?4\+B>'I(G>&VK\Q82K@7^ES5@G,S';F1KG]<AO>CZU25^'ZDS6A\FQ*H
M)S\NZ]LWXNP]FT0S7HUNWK?E>D%*0612G!NH,YH+%AA#N2G5$7/G@66OO)N/
M4WSV,"2-%5G<!J"XIR!0"HF%AIK5 $)WS65!?K3*QV-R<^V\Z?A&'DQ]Y;W
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M9/:2V-W1G2UE,AGD"+/+XA*9OU5C/5LTOVXI_I R]9^6 #N,/1?<2E6:-8W
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M,BJ ("DEFGC/LQ-GD#<]=39?]UN>-NJ^1$Q_--$3.]+C1[+O,-TA'S?EFC-
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M;A>+TP942@'%K06$.V8\U %2N9-E6Q]QNB;-H[4"$_'2D8@?;IJ$$(= $F.
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M@(0+@@1)O3U.-/$P_,^3QGT8OX')A<YG=QB3CX7YF,[!I@_)/>N=-"Q0!F-
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M"!H;(#!CP&!$XP^-.%-":C&84/T&.9XGM_LD0T/-59Y2[ Y"W;M[#7+%E4@
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MQ2WKR^JM?3L&$1)Y*N#:2H@0,,+#N!QZK)7$%).A92>V"G-BDW]6SI4[0>Y
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M,5@)D8K=W8/JI8)WP::]*F$LT6T:IA)!G_>;4JI*J(#PCV5$6[$[A9F?>(.
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M7KAK/<<3,8L^Y2]K,4@YV^(%CLA$F340[VC4S)F(?IJ"8JZEG+AD$A-Z'+&
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MDR>D6=O><0;D/>\YX[,"20 +@&<_!1ZZCUFQMTAK3BA..LO%WCF\G*8?FL>
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M%3X<Z7-:'I^>)V0\DAKJ#K9K<_!^@DW($EG<",H.4\3.-/&R:]S\G/L1X:Z
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MH<@SA;MP9MA/K1NCD,-[FJ!V\(& *16HANV^X3+?U2*JDS@)"L4D9JP0HHC
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MH!7-GIC0^>R+<8 @D;T9,M'; BIO>E^XDLG<-.QU?]0QRC4NZZ*\?(6>Z?6
MNZU F^#/T_NK4K>=N195HN2S[!IRF-0KIC?WQ=E>_Y8_;%I@;)0XH!A_C#!
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M??IBU9#2F$G#.P7LP#QJ@XEX/3@(?3I*0[O09K7+.=\CS<K\QVP1"[O"YQJ
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M_3E)<Y[PX:F#+5?LTI9MQ+SPBP&+:^RZO=M1TSL)"&5MXE-(ZU'01KI*U/[
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MK@V0#^IE0J,CSX=!\[R$:'2:%^/WH)%O'Q/[D99F/&%CKTZ]D01\27I[_!A
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MF41Q(YP#Q[TH?$J1?8FU0P8!GE^OC;0NM7#+Q"QVL14]>*7ZB"7^Q7,8"I&
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MSN31[("*:X64FA)BQO<<C4SK?PKP&SD$?/T&,BJ^&U2I^C:@$_8,6,1'$>8
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M=#;8<!J)LT4?_?.I16I,ST4Z$JG/!5"?<\'+DY/^HD[\OE:Z49@8<86]PM<
M#RPJ7AA<G7$RW1FL-OK[#)?<SWE/1D;.;X)QHSM=U3NMG'VFX4\IW9"&S![H
M[%^+.L D;^M%>%D>@'*H\]"?>6?JIS*D[R.6HNQ;^.[A@*O6Y[[K0[]O4$/
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M8TG<_."8=D&SUV\J6,^1DT6+PSYZ_)*O^?K=^T '%D"R/SEP#,9+$RRH"HF
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M?K:#H=F'J"&WYU\NYCN!GKLZ#8J KOWFCI+"(^LQVZ%8S-Q0U]R3M-(ER=C
MMLOK3QHG5^KLLJ.CO&0R>G@3WR]\]>99?L>F,:U&Y _OS4#5,(74;CLJ9/>R
M Y]M?(UEID8?><EK,BO(M+QAC-/68&F+]C?NK5+:J)KWHYRW4.M@Y5N$B0)F
M!7-_=*Z,CTF@VE!RA* DJ7@Z::Z["+$6/A..WY^-+CJ_18'LX9T&<+_2YTC
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MT2@&?>@>_0K,=((<4C:XYJRZ5B,?*MEFO./^^;X]JZ'1-;6=T,M&4F(\F\O
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MP4%QA ANCWQQEA UV71NEZR+3;_PAQ?_EO+6Q/]1^O;VJ]Q^4G7%<G9>0%#
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M&,R0+/+ZD>T4H_4>N"Q$G^V; C0P6=:JTM:0+CL[[MPEG*Z(@7)BI?*\#]4
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M_\#/40?B$>G[IRH@AV-P]-O_.%0JT$%C',_;X"< F5\G@'AUZC?$@5($Z@1
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M3ZV83P!XGH!A*HO!NL^FS504O^]?])+;E%=B^GB^ . $T.GK-#EG3(W^A4P
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MSPGN&5=LSY8TQB2VN&1 ($REE4M;LN/]*$O;F5U= P^MW-(1\:VL$RDS' *
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M#,=&C#B"DWS[J';%25;L6-QIL;X6G-]PS7;;=K>)C8-;C5<&79E(WH4)>I!
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MUTI4^2[M%T0F3I?P*#C*W,#1"'NH@?"!PEPP>&BMM&\E=G-W0R(%K'X(A%,
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M#^7PP%?0(0J@M":"+$LT&VOBMU,1+!MQK&+?T'V:<<-4]>:=."9-7)=Y.'8
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MUJ2L0*P^!3"<"57^ .O2E\"!J:*(.QJ"]#)NL&;+1N#6,)<SN@W$Z_,>?J8
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M]DV(%XT'G1M+"9*OGNFR[_<-;\Q?20F.@JDD%WS?K_'LU7N29A47\DSD"P2
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M#Q<2;^3[WFH/[UD;+$=H=Y!&(!^[KV?6,=RA>NJJVL9TL5<8G]^Q:#T9T=X
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M.0H@_N4_T$,2ZQ"D$-;FV =;F@;508B?#K>(]QJ09"AXB\K'!U. _U79[U(
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M])22HG6Z'YU:-E)E28JI!(L\P-&&IOO4?0L?8ZP4MBC;VZ%=A"AZCZ /VB@
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MJG,KQ)0MD&AHDX4':GY[J/*CO/]NDHV4XK=38O6GA2-W9II"2)^:^%95KH^
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MPV[>_?HR\>,WCB+E_)-#)O*M2\#TVWX@'5$6W0SVE^8Z:!(["AM57 <9!Q[
MIRVZ#'3Q@A91^"J>"F>N'=)XL0!JWUYJQWB(O_=N3/?8MZP?^4CH>5EU37Q&
MI_N.XY(X\<8'K===,B(6@BK;.2=^J"1EK229R!E^P[SOC[[$W%%[K58F]'I
M,9KVYJCZW(W7&J"G@A,P>4?4-)BQ6<LEADH$<@D@WE1).ZT)0F\W85B=%8*&
MHQ8>T=QJ^:G%GJG1\?.',N14Z6,_.>D24!,T17I4] )0,>B:K-7DK'+AK6PB
ML,127SII]LZJP8Z;WU?/U^TL:-J2,+DVM#\8;/V,B[;SH7J!!L=T\0?O02W#
MY+XQ%YZFY/-?/:/ OF?(0B'A<I0C*"9Y;KZI\]N4R$YSF(5L)G7(R*IM\D:2
MJN\GZS(\ZW)<+"[XGS_Y4D^LT[M?Y$-"-X-Y;6[/_S#*Q@^(N;9X>L51$S6L
M=)C,)0-*I :Y@_B0,FY;NTJ6HA1+5@+UVZJ\R;>8/7LLZ[[,[+#NK,,G%ZF=
M6)21^;+Q1A4Y?;.R][I&DN.:GS#DD/&2)SD?OEARZ[DENNS>@A.-JPYZX\$E
M+/!SI5/\-A.?IQF[5\*+>^/!-]>7D6S^/C FB$[#J-&-U=84O_MX0<110G;5
MXPKVXX12-0A:U0@Q7F+N_TI%1+/"I&8W8S>]#^&>S:;,DOHF!+G#I[V_,.D!
MS3A$'=F.7Q$Y\K.Y29S4+7LPR\:85':,GI!3C[J$4*G.,_U\S*/?&\.CS0Z]
M"\!X#;QK@UONE*Y;_O3\X'WNB>F7'@U/_>I>>R1H[('S2-<)V5"L;N@)XFY-
M"=]VZKQ(@>GR6Z.\6LJL.CFA4L'E>"!I5/X2$ _A#UC2./PJ]+U%;"])CCWS
M;F,K0-'3T&&FU8UKL$K^--91'K;I).RUP;'C!PN?QDL_2UKRC%%D<-;1-(AI
M0;0H$/DO 0(3PN#T W=FC/$^P:1KQ]45K=;\A.[TO?#*]"4 ZM(-+< %=<#N
M$1QP+2010N5?RT6M!S.<(C]W[MO5=E108!0_AS0A_U \I:C_=PEPO@3<9S=[
ME_:BBL4>W\CM2+LD,<0E=#\+/J9H4B/"V6U2HL]$S88/J7(U;K+(AXS+*I"'
M?5<M=(XZ]OKQY8NA94;T]("5$EV"F692Z1.UZQP3_Q W#W4)ZC!N@I>68 /+
MOIQE8#ZPQ8/PD^7,X;@85QXB&E[M%I%AUSAK9:V3\,KH&G/2^PQ#1[&)-'L)
M-"7EM_)[Q]HCRHMXZCU3GWY'7QW#,PV)ZT#"[IF/;)S4?E3]5+F)?=GTSFE4
M/*4N3==]S^F!="^5>9^X<^\1B=R+7U(HA2X6RO"4^NK:I-6/1]G'M!?7U0Y*
MD>$P6H(47JLCU?I>388+L$<:WR0Y).X ,XNPW/;6&X&9  +?(:0OOM6@=E#1
MYMM1LWE5WM6Z;H^NU5\"6D],S'#KV,40$C.!8O50B;L 7S#6K*W8Z0TSDU.]
MU7XSCSG&\X^XCEB\=(Y51$'RTL920$MAK&>36?_> FK:9/S8V9Z@252)+HE;
M\8:NG";[Z55J,DYHS*IM_8,^PH=@BB*(079+V72=Z-K40/L0\I>08_=MWUP1
MAKMAUXI\V;4A5,NZ-'/^HMT/2 \:LT7L?KF'J>\SU/'9J$)CH<)XP9Z9!UW#
MP?*J3<6;O]JQ4&FPB);+TKOL2GI+U9:O'Y)E9YX8FOR60K?+6AH)B#"LYUOF
M#0RXN 4=^.B.(1/;L?8R9!;W6+Z:!PZJ6LZA3P(^Y VX^93XM>:\ >?!K_L2
MZ# W>J.X7G/Y[_D\9B5$74L,(>%B/:ZRXVN:.X ^I9+#7JQ?>,V\*$:2@P8W
M__D$7;C0WY<T3QMW/<C<^-$SS/9#1.#Z\DQBEON4A@+_('C$[30;QJ"?(F<K
MAC/QWFBR.,U93%8;%"--@NXE=DJU9CYD-VSGH5OEDSIZ$*RH]8WT]Q) )^JB
MJ%+$)9Z7&; ,?!)GU:#QW9[98$C-_1DE)[+]&$RA+  >JL41WAXQ1S"G2E ?
M;(ZZZ)VBY\%TS7)V.,HEE]WOV*"(P2'SW97OF-^&0NZ/2)QMY!.1.]8/'KP1
MGS'\?G0]Q=5NX/<1$52",%@BO<DV01J<&_4M?;$;WF',](/'I^S"W O#?7@C
MTCKU$M#"WL(4<C?^Y)CV+H,]2!-I%8X<-W G(=O/]+S<I1]NOJV.M[&$6L$%
M3NLP]IF\43"Q?V.6(GLB6*V-F_]H'Q50DLZI!;?AT8N,S32X/?/:>H2NE4,W
M(RXE3!%CH?;H>JHGTZ,/<.I43N:V[D!+K>@?!Z^$^0R\OMQ+2<UH85A\F3&'
M]Y<@4WEGNGGD]/-U,?=MA[*DB6EA"\>9 7CBZ8#?T@ZL8W$G;<9NHIF29*Y!
MDPM??$EF>G2F@@M:;B"4E8+]+2Q&']? JZK[*F(2^YALRN-*Y9<^'7(J*1#U
M\-&=OASTA+3R?_+F <8)KY#TMR.J5"M#.090Y#.MX3S#6\;=NC>B"OIDRUW8
MQ\!CRFH1!-U;X6UC?WY)713P:Z69[E=O+RSR7@(HUC/T5!B.U#IN0!'G,D0)
MW-9[$\1]B-U]+XM99N6AJA_O\]0I-GAM/*FNWVGVJ,ZI[^UAF'F&O]<SV<JJ
M?*=N8DV;/7%9NBTVDXL[/=#A>G).$#J\BQG&R1!^S!2P/U^"VCVJ2S\D<F:^
M>2*+*GN[<;!?U%]=)Z.Z-P+S52Z:N 1\H.(<7U"B[.P3R8D-=5SC%XI26#+\
M/%PT:!V)%]3!H7IT0^C]2:/C+_R<'857FTLI,X'3 P$C$G3-*$X1>8?K)FW6
M#+CRNF4ES]G.LQL-]4T-'^"5T?-SEP!JI#Z\_ 9T':_U>D29CG@G>NFB>4OX
M:*>X,I+R%F^&EX>8]7<->Y#^#0B'7]+2$_\L8<46\ZJDZ;K=([>SF?7-9JFN
MK\2!&W%EF7U:M[^=:(C HN3="$6N11W*-"/P)4X\+/K;SES=2<+S2\"NPL=>
MG&7&!>7%-V419P3MHQ$;W$S;B?FG]"R=T([>.Z^?D(N(6QPB4^#VPO?.+; M
M!6,B*Z-EZXW*Z;.KHBNCUY13#B\!/8A/&7O=HG>G-X_-FQF-)U-+KG4_EF _
MGTZO5'I&CBOS+V+^G.KV/%4*Z7"S=J]F_I!X3X[P0+2W,[Q":G\*Y:+O*&BF
MH(H./*OVO\)UD#,=XT"YV30A3[>ZOJ(^A=.W3BWNW>TV5V9?XQZO.G+EW%J4
M,Y)Z@W'D/4FD)O(-JB%EITC@B?WKII1,=DU,S%$[^3>F#0C-^1-':[J)QWBU
M*"GIB5EMT/NXF04*:FO05WHRAX1@\;M/^]K6"_SI=LCP;UH?.R<X&DN/3F\T
MROD89K_R4AS\N/T/MBL62IG8I^0N,<#_1M!^?--.K/HQ0L%$8]'.X0+:,ST!
M@;$^+%,#I6QJ(^VSLU)RRK>(Q$:$TF1J;#YXZZPF)[*@=VU^43.AJ[5TG9SW
MUY%2N%0F6)_4MP ,U\<?K=7)A[&HY#'MR]$/^5X#85BO'/[[NEG\Q),4,6 _
MB@,1>4IWZ]T>,#XOI*5A'E&XAVLXY$Y-P]!-Y[4+_ESL$3F*#KU;_9,2X2/&
M&J6&:+BS-P6@&K %R3E=09U?5_1L;;)6U+!.W?  4_3@AT")AI7SCX+ XZ]X
MRX5'A'2?0J',,DE)"]./&\T?]Q'ER]7G?,B<K559O]!_$[D57PGGFC52D)EI
MI20+%Y+: CZ<[>T30KK=M&%+"HMN"M^_67/IA?.+\Z:J0SK,W@[U@O($97"S
ME\,U*[!@J7A/45\6)OE^8BV&RA*S3EDH$4/<.']*E*PA^"U?EU>T5^(T?B'5
MZ*!LP=^5&!S0D73SV$:N.P#Q,;\^NE>9/6E,V7-3.E/L8D_*77";;O;!;](?
M7.O2^9[\EN,56'T(0EG5#+.QB6]OQBJ*)/S,7A[=D/&Y\)-?_SH^).MVUX3M
M].?K+P%VDZ..9JTM4._6WL[:29FZIM9>-ZYSL::!YU/#KS"&DX$ZQ3^&)ANA
M66@)W@7U/(<WLPG?$L&!I+[&=RRZ'X\0]ZS%V]+\7DK&^?X(FWSB1Q\(L")]
M+3<PORA4E,*<%U>[A9E?-Y@6*M^W[/\3',"TFD7K]@&Q[-MWV!TH@<UZA??Y
M5?\*I!":LF>W#A_Q48RRO!52\+%S&4] V?_D.0UP/1GM4_*>:$G+'HYQ\SZ_
MD':K<I(>G1F(V4YA9@6J B;D+[CP+FN1^#P,^WITN9!*RV!-6?>X3<+P]>/,
MNE (;<D'SGE=Q4,""H/^^)80OUQB18%/__!6M:%1P+V'"4<=,NLE7AY$GK'=
M7Y\C]>NHY.T5=$KGU\U6K*TWWU54EJ +;Q\_3BQ/#JFIVVWT.U1<&-89EWH@
MMG%<.?]D\[&JI\3V-[3!$BB\50B?TZPHESM5-WLM+7F0@CN2K-V1QIOYN$\1
MH W]A)=9+BCJ<-$B,5P".F-9AB2*!*AF5)0U)?A<HA*_"$T]K&+<:K^^@BX@
M"A/2BHE6.(HJQ1^2L>;3=K42%BNY3=U?5V/$N!AX=Y,"V /:\!YS%G%A#[8\
M.G]T&%=Y-IE,5Z<NF"BG"6)HR\L5-NE[Y(QB3_.8IA7<&'A.#MX3@K#Q[3O@
M)4,6RXR>[RY^/(5VU ENIY#L=#D[9J#LCK6!LT, E"^XGTJ$2XE12F0QH0_Y
M#!<7CX5'MTJ.-2O!B^>L^A3$ G;?!<3H\<USWEHY^-2VS'NMM1._UP6F@@T;
M2R_0XGCB:1NS*DHK7;D$D(^L?8&*<5.RS$QL*[3DFV\EFE49QMIG9[#<?D6-
M2:U[=6X*'!P/PGY]G; 06SMKI1?F#AK2GG[?U-IJLN_0SA+WJ7R#&F@\5OXA
MI9["W_J)%PG'D R&$H4OOE\"EFR=(S'Q[([245)/^^YUY7=L4T :.+^@%@"8
M]7(*N=^G5<N]G>>BX3F*:3JC)O:94/KYV4*-_8D^XU<Y368ZH&E.Q<E3>[BQ
M?U%PC_Y*L7.)0F%SW*N]S_\,VDH'1)$[CEZ>3>5F*J?EBVLQX%!E63QEY^+=
M/NPM<AW2J#"-Q>!=XX<]VZP_]XOXGL":C=6Z=%DVX7<43?RP5N;SPKQ?N&":
MY!&38M6BBLF]7/]5O=OQ_ZNBE[#882Q!&,-RI#EX*_9.U##]F2>9<<T_(E8Z
MTS+*A[Z""=15:8QJR(%-)DI<"N)*!P2[]?IQLO /,^5S7X1S_304=O?@+[XT
MC-702-);S6I=JV@3B?F&>*MBY7;;/U18>>',:G3F$T*R#:OH,[1MRW#F@0_O
M)5W#2<I#+P&1.P^,)ERF"W]5;\[^GK&3Z__!3IZ@OOY^R'D0]H TBK:6QV?7
MA4I!601EC^C$WB3Q,_=7\KN7,WG>O/[.-LLC+L?HMEBO<4>SE1!O??FL9VUT
M;5J@SRG'L6!G<Q5=G"DUX1*PH%%P_]L"TM7E0_FQR:R5" RB9WT).-?TM]#"
MU74UW%,/=<&,E^4UBWTC8YC/!KYG)^-OXLA'-T!$<:C/K?0002 C4?M]76/!
M'T$/1@S-XS\>USW>L9>>WLAD!N1TM,SIWC<(NYTJ<,?31RB/HZP5@=--;7=7
M<FJ(A=!N\O7$SJT=ZUFYK(\ [PSD;DD?7]5:.1U86=!ZWLLET%ZNF/4.!CF=
MUPL3&7V#%N&N&Q46,51\CJE(&6F@JWC6QEF(I8.\;6'M!-:$1QZ),II-;9YI
M9VSXI5%1F;X,]I]4I68-DC,6S$JL=J@5N 3L./PD)*M.>/.,24676 AN!23N
M?$_)BVG6H?*E5L5V/)7;J(LK;([1\<G0NJM[HX]%/WLFY;1:<\=\ &SPS]U2
M)ND%I87$<262VE='>F6BB6=^(2<#0:\>+,=,3DFM/B?/YL<QWB]@^C!GTW^G
M+,^Q,"4X]Z'0G][_3N4%D8&A0<*Z?3M^[Z!;Y^*FCC V@EVY/[ZL^?SOR8W^
M3VM,+K:W.5_,\O+.+2O=L(4P$F;Q@KTH^C2-\3\F+-H=VEP57 +!$PP:QB;D
M'J>UR#\Z7M:9YW($UA[EV[C4[X7^/3<QM:@4A^#I3$ADB_1O+K8?M->6/'4M
M/SH_Z%T0P85OKQ>*1&(0MT\#X\I8M=A*F3KW*X#-*5^;O@P])V_C3,R!W^Y"
MYT7V8'&XPI_C/W8H\S0L@@[KTMQ09W#*T"Z;_3D*D3*'Y['<@8E5.CIG/*G$
MA2!PZZ(X:;0VPZ>HNTS;^]!0O/MZ<FB/XOI34XPWEPU"WVNAF;&QZ=R-B="(
M/>A.,_8+C+9L&E :[=C-#!=.-9JY%C<'D-VP+("U?WES$<>232E8SX7XJ7;0
M>^=M:U5,250,FZV^CD: C#OR+W":4R->%V=?A]6*4145^1P43SRH?;6^D<ZZ
MCQS>O!#$U2;^]/<[=M)28AFUR-8\>96JOARJI3D*MOL2RI:4^Q06W&K2);"X
M[=Y9Y.;(U6I!\E7>ZU $$?G&NVM\-.G3AITA8PY#=:":\"YX3?]D@BD4$<0T
M@?'T=5B]'DDINP56(SXF%-GA4:H3$!"V1>1&?9W* ?:U.14V(8%)\%VQOCRC
M(B9D ]<,I&SEFU-_'-]Q]M&>1*0-(9U](#M%SZ*ND5BT<"&=@<A(14=)X[JT
M]TC9.6:7;Y_OA=FH"VGT]:@!KCFW8^=NZZG=7&!6,6I<70U<(%F#)X9_8FB'
M(\28@TW1O,^'$=E!M56[3;.NF1M>& 20X FZ21@SP\W16K/2I'/&)"?9#AGP
MHAV93Y"U) %X-\VYM".)#=B4L\DJ*+T-Z>D:@P4!#Y!)MBDP'J*M1JKX0[2/
MG8*N'OG X@;0_/Q@^4$7D(S R*Z\UW4<8C3QT#ZGXZ_G"PPRPROEM3S%P\2A
MOSK.R,@*J9;6:R$A6>CFT<U18Z*;WP@;&T-PYX6%9%=/;I'V>6+RM$H=7'K'
M6:24^/O_/LC%@K^#:$&.%O'LA*'9CHSR6/8O@1\37ORWMN3]_-SRCOA-?7&Q
M(=E>W6RXHRZ-(XR1D/;8\4Y9-4M*M5^8).!Q4U7>#ODW;AG;\8PSH:H(CWL]
M4"UFM21M+T&%POCX(8(:E:Z(62HX\OB7_FH*%CM6<W8),,\ALTA=8,)S;P.=
MJD9=U\.9%]GHQ9?1#]^V5E]DM7+X.RUVREP"&)IMK^DR%&6X=/5SR&+KK$:U
MJV,8?S^"/O'HNZXW 7+>HV?7BPO/-5<K++E3XOXN(%WMN1F[D<;AC,<8;YD
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M?Q*:=;;S ^S=7R8KN,O<T>FV7([!R1$[V=-6-PL$F%7F_?NL2OZE[NJZ;:W
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MS<;2OYY0[O?=9L#0M8!82^O'_AF[^\E-I";??>62BR1OW5K"P>O);,\,NV0
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M(B1BE8QT5I*.#5]LL?$.O"#\C#I_< RGP@Q_"D3%O&MSU%[]Q]LX6Y1:<@F
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M-3NZK8B6FCI!;?/B(OSBKLKOL[JR6%/';:?DU.O0B)A2) /!$Z^5"KZU_(%
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M+]0V;@=?"0H<%WBZ\/Y^4H89C6]'^H6E4D\(%JCQJ^[B.I!-4HDSWS_<W[[
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M6A[^)EYZY,%+O>6*Y";%KI]?;:\FE)MYL]NA<8>4$?7P%,&S8#)($@1@=>U
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MWOOK*O;5P7AMTOFKQTHV=];_+_;>.ZJI;NT7C:\%I4@7J4%I2B@*TJ1$1;J
M]$Y40'KO+5&1W@0$I$8$1&JD(RUT! 2D1D!*$GI-J %"<O/N,\YWS][[?N?<
M\YT]QG?/N>\?:V2L-<;*++]G/O/WF^N9\X'A\H@W@@[3TG"]TG5X)H3DCSQL
MG<CELU]QI0VDFVW QH?$78(93A?CWY-UVB*/;HT6+#N\C/ @V7IT,KALT8F4
M1;%_]:OP\E"_?JG%C177&.Y"_4/2?"B;H[%:<R#?S<1\WWBKH@C>Q15JGB:Z
M4'5BN6NN.->BKSFL@TPZ8R0JG>5#+X?HMUA)MLV)5X^+P[<ME$Z=(]OZIN@Z
M>G9>HYRR_1$NB"6^;FMF?&0GF-4RP+M;VF U<SOU9EI\PA3?\P@UM4</J2),
M]!\NA$&:(%_GMZB^$)T)WM[Y 578+1XA7+[*Q:[!HPK7 JKO.8G^Q^R61\+7
M=R?:>WDX>L4[1:"7\G-$Q8.E$=6-(T6KC6Z^N"*N 4XK]-VGB\7EY:&N?^O=
M)FM1/,UA-$$(5X%;:Y7'^^;FA#3,.A5NNQGP\39+;_#')HUYQ1TBKI_5@QUH
M*%9+!M#=J,(UD]2BB?J[%F9]$^7HN/.*'61 35ZJP<@'&7E/R)LY+MQ\+$D@
MH&+^ 6ZKL.<;PFFW[OOX3IK95;/9G,2)C%\+M,F>*5JOFZ43;"(#-EW5J,VG
M)YOJMG<>I^=OU$9V9WN*L-J][>C,_9S>LHFHJIJH)ZGM/T3#9X"'CGB[_2"_
M5&R6NIN K%XPRZ&P;E&&-Y=CRLPRHG!DU-",[]GJ BOO(D,0@_.Q'Z$8)X])
M;[=HDM>-YN#*-#E\4VWQG3\AP&XJOMTV/$=&3-4P.RXLCL%Y!TD02MQB*WN(
MN4=@Q,ST-HXA\I.UV9<$,N<<WC?-1"CR^1C;<;.FG]]!Y7?SL#U?>V;]/-78
M]P:K7Y;.FMM8?%J.4=.ZIRW%$CZ+/MNCMDP.$IUL8=;9L8[<#&?1@\3 OX3_
MBW).<:G]]^.CK*OQXB0-,B *MM$/.[N 6KD'80[Q7M"ZODF\79QUV:T@68-%
MA27KPP7 \N,7LOL($X%^89M*&GJ-@MFC&=W'PU31LA$))F_3)!K=;A<6(DKK
MC9&2!X]BB.5D0$34GSLVE)EA"U+U9 !'/HF##RMT1JM-8123\T2GUC'2#2B8
M!%7>@1&CCWN):K2EI%##TWP*F827&)HLN1/OJ?7HGES/(@/.E2,)$T#<") =
MO/K"G7CISVT;AK N<0H]'?X>ND,&)-$3$MA-B"?%1VID0 K8\ NB?Y[@D!@'
MW[\K0SIO <.7@-&?E"1@/[OF"72N9$#/%TJ+(8ED /S=*85^W 3BN200QP<&
MVY1'@M!B/4@J\A]+ZWS\Y^Z5O&@DCF.&#(BG*'0&)) , -\X0I(>@S&R=I"]
M]:)9(.G)F?XG) CV3\7]4V_\6^.C8%T>_<B5"=U&,#'CI% %:DP&_'-I=(SX
M%%*$(!G0YNQ.DE(C/B+"B,3(.3+@F('2%G0J;+@$[@,[ECS0_'_3^8F$< +E
MU6/Z%C)@EV(<C)W"E,XP4EJEW-JOI[(>6_QSB?\ !YX&3P;L[0*#R8!%91)?
MA!$9H%02.D*Y&YX0!NW6_U.)?X\'A@U+!JPL*AU1K#'R+_#_ O\O\/\"_R_P
M_P+_+_#_ ^#_TSIPVS\TOC1^0HF/,&8^B<'S%!6S'UQ_8B>P^\GR>H+!DB%-
M^^%_6S4D1G;IWQKV]G^V863 _Y?ZY:]!\?_C0?$7^'^!_Q?X?X'_%_A_@?^_
M$_A&*\AKX,7L#3+@8!/V 3%$!OS]N\,3T/LA1I/[:_OE!E:.6VXFMM&+%A5+
M^_T]EXET?U<OE7]HV0RRVH0853]_R)1.!CSNA#Q"+;I'D,2)JKCXV+56GDFZ
MPIID=K,+=UHM7Q4L86U&U$),'O[WNIZ1#/@+N[\&[E_@_P7^7^#_J\$_ DX=
M8>:[Q#D(Q-4YH8G!+?B48/K G0[X_=3V_INY$L$HGN?H91FZ1[XKLM/"VX,4
MD]!0RW\?T)*&];R'JRD>U'3K7Y=&(9O) +YMCEN?6B^?/?U?"=?ZQ_BEUG\\
MANH_/QSNW[GH[_X/<OKYPO_]Q/0?Z<DC_QS0A/B12+@=V36\Z0YP@-"4V77W
M1FUK+TV'#4^)?/]5ILCSTI@'GWDF@U@F P[["!ED (WRX2L\3[ZK>%:1P]"]
M+ 6N1.$?J7X&OQ5ZU*A&PJ$Y:&F-@^9I*=N6::VLE1H8-U2MG1"=&0H12Y5%
M!A4U[6X0'/?DAW^!T-R1W<!85+T2;]VI3G2>8[JH1YD$0F!=JLPAM+\Y07&T
M51N/#*\%1\[)3#8#H=WB/C1K6V8]AFEO'N6AIKY>!SZB@U9"VZQ%"5*X)K0H
MJ1@SS+[:J-."T5I),Q5S_Q@1L+7ES7)K=?-ZR)Q-7()R&.0&:79X@0Z"-2$*
MSE\]V );5>/IWDO,2H7_\/\#U$"5W-Y<Y;<=;_,\MZ 6.O;>GA"3K1+=.40_
MY?6ENV8KP'VI?&G#%@KYL+CON%@#4M6:MJJK0#BZ'IF%;IXA".?Q-\&Q$*IF
M<6P5>ANQQ>J&G]ZF[?:X^RLPIBN8P7DTY.]#I4#(A0_SS H#[BQ$OM;TY;<5
MB!<%E+YUC5A2^ZJD!PBJ1$P &6'?D<5D *IL_N0<8L5:M ]6O>?48-LR 4*H
ME9S6'0-K/98=#WZTYO@=U,)+*$,_@YB!VC_[6QC;.0+%/EX<4MA1P0AJ[SQD
M[&ASA6(Y5.C>L]AI""E%#5)-P))6(LD 9F+B#X5;9$!@.8GU.'=0A<5DS^PT
MFG"%#+C(1!G02911]]4ND?1F8A].9!H@*9#X*572%CJV0@W"<7KBQW*<PZ>7
M3"G&* K1( /:19#888SNF<\H+'46]F0%N:NB1F0A _:_P,/M@+N& T0#,F#4
M%EICLN=^:A/0L=<#J_&/%ZN WUWSCWSRVOM=TJ]$_M<'OB^5-IU/U!%+,]BM
MLD,8%^G&S._D4?$HWT>4DJYM%%]V[^)"]07<>"3.;9T_JZ:;A=I5BNTVKS+5
M?&HA!U4_N_5G>D:B^%A$$@8<>X2[(FZ-/17L^T4_JQJ5/-2WO33BO5K@+W72
M"3D/:Y<5=W6#V4?6OTJ4&#-K3GAZ?]LVN@>V( +:R20D,M[U!=G+1NIM@<15
M/I$!DNL$<7KJ0+N+5TMV)K8#A[L1D1S@;GBD^<HKWX:)O G763X_P ?[\W?Z
M6^,2SM-_OL\,&=">+>^.'Y\T<7B1.SLMQW!@HAQ!M:H"LT@EY@=L'Z+T\;U1
MM9Q,=+63^?XB*H$7>5[:]=;10>$++\7R33/I3DM33V1\2*?B#03Q:W=P.N&0
MFNU6S?E4"G G=\]20IX'8A%3,VTDWG&+'XVGC#5)T7TO*U.W_&5.G]S\'3H8
MR@CA@+9?VYN&#D#9<[TTAZ7S16Q&+BZ6)G85@^,#@$1%^G;@/M\ZF,!,3S!9
M_D5B[K&15+!3:$V7>+N84U8>*.^&LC\">K[%B$ASGH_(E2@"O;]VA%();=$=
M#VK#FT2*A#Q'A]ITF.?W<:?5VWO:R#]JYV>T[!F14^5]-6.ZL+!PB!B$$8*
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M3+X6"Q;/J5?2PI:T7O*N^;K<'/N8@,"K==Z'' (C%9Z7.9I[7*!QMGJ$N?Q
M2(@Q/WSQ (-\-JP@,[ 78-!MQ\IWT=6E!N8WZ*N+JSRN,.HA_*CS[EQ^^AZ>
M-1%Z6K1$@%,<=KOJ@3@=A/33LSM/P<O:S/':5R=5!4\?_M0WK?<;PO.'ZZB<
MCH $@7Q(:#7FOC@Q\#A(S_UD(RNG@2ACCT,,PO\@WB4DXNW-K63:.026O_E[
M"O(\?F2CZJ:E+?^<P5]D$W1"?9;:"GAXJA0B!:&W>I*>N5U\JVE\)2XDU_-I
M*8OMKDT4[1]!R8.OF\YY'H)HTFP9^\Z*I+14Q$[NS3A_&AT@ 0C*]!#N;(6!
ME#0V]P'#B93U@W$BYUF^P@W/!=V$7%G<./Y8ZVJI]ST*,]$Y$EUI@UTO,#_S
MIS@S;Z+JF((&3HO$(-UH4$+07_>]PR1SEK:NK.!U;KSBR/<0E("I@KE!IM1,
M";6LR*[YR&L=*UW3+C=IFJ0Z:K>JF/3RA0 #/.KM2^,+7"7%1$.A;B7J28&W
M6;-41G4_O,1W1-WXAHV>[S8,>SB/Y-."618].DN::_D&H.4:(*N*0>OAX48'
M3*GP\27G^T,Y:-!,X1@*NJ&[!O]$!N ,@%&-+Y'88;H0Q='M-#_<1//>W 7>
MJ&UQ:M?X2J(SU_/*7[('%=ZD*^4+I_'V6.LBS&2B="[WZ"*%;?AA\&\]$=CK
M[TFL>/$WQ'/8^9C<&U9L[9G:DTW%LTJ0 ?TV-CGQ>^6['X<T_)\I:L,>D0%5
MJ#8:\-0>N@;*D_NX$54KPV9>V$^?^AD4'GUEL9<![3V>YD+WBTL!$MMI&_A'
M_^WAS()T\=R*W10KYJ9ZA(4D(N+KP9X+>MD@_&,.L<8X1K=T>F4YD<@RT,'&
M8=(]2]5SFV=&.UB388=TT/T^CA_XUDM%GV)=4DI\CKD<A%0$@=ZHT>(YIM34
M'!5XSK:Q^N7-NW",PZ*7HA^V K0_?)A#H+$Y?4"\!^_H,*R9=(%L!=D-)*;)
MA^M+RW$=>]V>_C4DZ\+TT62O$PN/M%8B&&"H?A)="ZP<,L.KB1$J-RR+OP?8
M09)0#;8O%-<\7DK2Y2R*"Y4JF2=9MOKIX).M]$=).6*1702G8V.W:F&/9DYD
M6LF@S$B+Z\8B=(I23^76FVNYUPB,G@O#M<+KK:(-;R[G70B$V]<GV6<^\?TE
M+<R\OA"$PIJTP:A^!QQA9<(4A-R!F>*U6N[W@BRZ,&8SI/-,=XF@MXXA>EAM
MZULY.U*S^B%J'"D"$YW83U^./YR>@U3/?^W=S"D/$7%L%29JUIX*12&>WS$U
M;:69:A>DZ1.4K'.D&J@O$5/VZC;YF:H IEY,O:59DJIA51'?5PH2Z^_?(6YZ
MJOHVA$F%&^G\C$=,]LGOS&[8[.?^2;_#3OYEFZC_*;G\_ZWBH"5$K3^I+09X
ML@LG QY*'1MAX ?&<#/PH>9IXE6*,'2DUX"J+2N)P[XG%)7![GGNZZG '@._
MWU!A>7I.)905)[DP%(\W'C-IF'#?%AG*QGVZ_(BAXT'7BH>B-*K6"5YU[4VC
MZYC#R<38O(C+,[.W4 MUJO[KX1?^".#W0:3UXM/.TUFA2[6+01 UE-5P8S]1
M;M"SP11[9W_L+<+5:-_5=5>)YE.9U;3E+RMMFT!.94^W+:ZH3MJ*2-J"H#=W
MC3;6F;6M@'2W:C8[8DZ\%Y";9\"N>&IL5]#9XDEH1DI_[>ZC[73[DQ[YU\</
MCU7EP]:LP[#@*>^..79<6B6&T_7%KF/-C$8%(Y=:;>8]D7,=*U2LNX1<B3;]
M+@61HIVY&<4SW89V@G<FJD/$YW:%:G:MH[Q8W?S8-SPKB\DLE.?L??/M,@>.
MEPCIZF"N],FO0_V?%&ZGGF>0:+GD_'/(FRC]Q]TT@2G%FF]+'CO4-MYF.M=E
M/V-?;H_.CQ/T8\[.4[C4 QSLC$J<#+B%)&0.MIPE[-M3G<IWU3/DSKDV4I#Y
M6&42#F2HJMM<ER(#W*K75M \0:D3_&3 UBH9D('S9=V&*IW!%4(7Y,U\36(4
M39Y$IN6.I]U"SB5+G+]UP,?K+X5./3#EZHD0Y!FCEQ)8#)%V?/_BJU%H@EC6
MVR;P6.,^-6@4RAP@.(!AB]\DBG[YK>%\L?_)LGIE\_6?#3T+:OPF* CN.P\]
MI29+9, 2&QG ;*WDWAT@0F>DQBA8Z+PY!Q]5"HLDT$C\6%509;K2+>\T.F%V
M<  &WT+\O';V3H&O9@OE_GHK-2KQ[-(W1?=#Q::$V0+<2E1R8.1LS/IY#OBI
M0QR!#&@%O4D$+GG[':8=Z!(331C12H$Z"G,]I.3$8SBKGE5D')$* P>L*S_!
M*Z:8-\7U8)=CC+A'>JE^^W*W52BU-H8'&+TIUM$HJK8 PC%?:V\9^I2J]&CY
M3&12W_I4>^<_>[?\__'7B<&A(<6-%, V.K#'A2$HB":T'[YKF'@68 F[AX!C
MD,?74&0 C5+]*XI'\0XG SC FA3/1(* ZSO^5Y3Z/R6UV?CG,Q7^T\^P^/>N
M/6 <<O?)P?S)"I 4K[E(!MB#CX5V8:C-^1-J$S-\.DDCMXD,L,22 2/%EO"_
M?60BZ9Z<95'<M": //8_=Z!*&<W.%8*%0;:5D[E4ZN]^+QZ+@,5GH0_M!.M7
M2\,U5.;$NOJIS34L(VB"@TW?7AL1N8M04:'.7Z5BE6(QK'NJI\+RZF_'<63#
MVTE,C=FS5@YIDCJ] G/3@B^"5@0T-JRX63V*;Q$I_\*8MKXH?7AX^*Z\I4R+
M5F.$\=&7DW/=VBJLHO->R=3?QXG@CQLJ.M6?9R#OUPZC]"U#9<+,]PW>_K;"
M;-Y6D7II4#E6<R9VSOFS>;?C9;DI:A%G^*=7PDLL^N^S_)\EF_.6^$^'1A2=
MJQTO_]3T=E??T(P-K'K!J/^6=I$/'4359BV7Y^<]_<%\Q[3)BQ%7ZL-O?C_Z
M==%%3T5NL&].!Q.G;ZQ.:4;RFW_12M%5/@R$2!'9#!3[>T\&G%Q!]"-8R("2
MFI,^"CTS64?\_<9*2*HUY=?(\8#RBBVB ;=#4GVWG[X(M<$<$:/6@WKWU( J
M+";[#XEO_ER7#9TYY89]E^PB PZF*8/G87+K,"(.;(,XOA0 )S69DP&K$B9?
MB0[X,U1G.&X(R?ZRQE6MKRD.-J#E'WWDN=XL<?IZ1HJ([PY@QW@WUC@2=2;)
M@#8#,"* 6;(P#%UR/7.>UAW&OSQ!,OFV5[2EAT.=RAC$8GA2KHG67F*T#N?B
M7PA)#N6B!1Y&EIH,YI['^>5AAUE_!=CH]->.D7:?V*HP[6[#9JUSB\ZW0&N<
M.:PCL0@:W<^6J4UC4K&>D<KO^GAI$R+'/?I#/9Q[21=".%/0J:U%H67OLXR:
M4]%JUH^F>^8%%14Z9)+6:G@>(F""6$3IDG>A'NF00VWH%+:@"%7K]P2&SUL,
MK:$^(3T-YG(:I5J0O6-#.[;!$;'Y:R2>49%]1>$;=(5Q6BR:\L)QWNNZ^L&Y
MSLE_R^O9VPTYI&NDC!Q72ZOA+O@6./[$OW-6V'+&<?*(:2Y50;$]<4FWP,D+
M-JU4:E74G7@LJ"1,!GQU19%BG0B: ?=K*@T%+ (;!H;-? ]^GVG6/7_42L5*
M"^[4UN0QT9L0UYI9A#XRV82_1BYJX,B L[ M\+XF"FL'[2-PDA[#*=/E+Z4Q
M,N!Q.30#4X1S"$+V 6,(S"1\]'[B\G!&*X@TDGL+1Y5P0$^]UFB7T]WRX6WI
MX+*[DHO&C2'4^3>_N(S!$62 \W[R%B_>^NV-U]\O.6O0L!P(RG EYMO_0D5#
M1R&[I@?#1Z[@_<S[N)*#W=RK Y77J26+M>;>OYC1+O)+:X*#X0&QV<\EGSR^
M;7)D(\>?J6VF45#WYS>DL=7IH52,HO"\V4@%TVX/7J;WIL_SG[C "SR7%<+:
MEY&*9("C>WA=+BWJ&5XU_'KDD\F<SJY\&KHVSBCK=DN[5YO*?FV(QY2I7<.7
M/VCG[8H73GEIMN/*:7BT!N 0?/MD9;(E]C!YC&\<RK"^6T65W+VUS3>,2Q+.
M9R0# "\1;_LGGN3+FYKVXUW5)K2<CTM)]NMROXL]Z6F;7?(=>\2T^O60$M8Z
MPSM6>OC>38HT$H#]N6-%!G(B4+H?V7V_;)H^0BK4:_::AL^&?.Q[XZ%)!QM[
M #:;20XQN#.53M(DI5.<IAMR7\MDU;X+<BPT)T0!UFJ'%!6TAJ>F-JN]-6!_
MG0Q8>[*(B\F/>&BM%U1,(<4:T7@72"T9$*<<IA3];&WULQ$XPX98.@ME)XTJ
M7<?/Y5T-*YF1CBW1>=151K*5E".QAMRF#;[$M7\ADSA:U,N?I%[5U<U]V<Y.
MEC?AX06?FZU'P#8Y7R>W.Y'\C??FEZK!M_N;38;N'.3?KPTM"/J<5CH!0FRH
M0K\'#+2?R"2$*/JB![UN\+-1^[5>(A0 _1X+Y=\FGO!<83UFQR"O6A/4NC(3
M(VIY[,<^.\2>>[40B@(<VG72VT#*YJ\J/ 3'A%#E.1^I2<Z9JX["S5A<O0E?
M!5NOGY75?-\D\<] 'K^&SA=U;:OAU1/PE%FFS4@EQ"32=+WF;JW$<8O46$TZ
MD?[GF7@/;44$2#0_2]]ZMZX%*^ +4W,.JEZFS.Y()W#FO\IA_N]XT3\F:.6)
M1RL)!/BK)UU(TO!+5B^PO>=!.FCG"3<,@P00=0B).!3:K]BQP&F.2ZMO&[W7
M]F:.5MA-6++)79]^"2(#[<L4FB'=L':^^DU;K*\?KB'X+(P,X)ZW3-RZ44X&
MN!#-)O0L?,R]E!W@N NT6)R?$Q$KU=Y[9RCM6G[(N_#9G%IW$C78]KOWE24%
M&1%?_I9"\S3M@GVMX1&X%L$94]26&,WQ7NEZ*V[1SY^M:"!VR^^=B[]-N$JR
M1+?IX=!< )4L(A?I 'Z;!J2KS5)4[CR-2"H-S.)[8=HN$B#R.E% _9F)G.)#
MA9<-NF^A=),*]MARX3'M\&E.BZBB;Q_HTZ[G>_S06+W2P^(OM=^[%5YF$9K5
MV?A'@\S%Y6^^VU\ *D+K_C:KSARR=NDK+!X-FO$]CGLJ33-J]DMG_O?ORJ*R
M/+;YN!,+6>][Q;P=#[1HTD HGBE4)#@?:N+*$\J+"6$6XULVWV(FK[MBF3XU
M;J?&5IY[S7Z.:@5RGZB!K!EO#L70#"KQ1TP@7IJF25W.-;^KPDM[[IU$Z&#H
M[*GXJOX:&4#-<R+-,%QF^?M),F-.WEWJ;,]W[%=Z6P+WF: #T'/O'((2YAD@
M>3.>/OB6T1W23?6S7RM5YQ..I1(XE18'*WWY=(PX:O1C6I)G6V,-?6P"3*9M
M9:GU2ZGU_+,+99R_.;,TM@ +DW!+K(>1O<-A<S1CS9ST79!S/75?S]-H)MUU
M$(C GN-_H#'M95)T@>M@8[<^+.1V<<!\UR0/V^A7,7&XP\NA<:.+.3/<J0^E
MCMBM8<IL$0%?UEB#YPOKOQU'!'=\*+LD+<L^K9_Z+=!7?WG$8B7OAQXDR!G*
M=I:K=&7&PC3@\^#!H+GA5:->N*2X]ISU8C1+]@*/;G&[E+\JSK[-/>&^% X7
MD3LMEN<<MPFYZ1![OC+.:9#S!A\53\[#=@0COD6 WFUU> JF6+,5NF.SAD6G
M^ANL#S#KSDR3AC/FG6><(0/[XT32IQI?5XD-E0F$C_//BX-O=RWZ61;=HV.D
MZ:$JH3^0M%!Z(ALN-+<)+SA2&ZJZ6.!R6>*\I-BR^J?^SQ, XN#:N"WU8;4+
M*8W18*3?@&#HZW+<'!8.PBZ9S,7QZ9KUZ_2#<3[V[2PF\TIL88<^A&&!WLB:
MG(LUH2HV]@_X+,PT$VA47_BI@N"-4P?M@$S"#@88)A9R#DNGW%$O$4@A3,]L
MTJ_OW?2]&I_02Y7T:[FJOR'B>N9HIPY3^&.$H]]V?/4<0VE89R>[3IG3:$K]
M/>OA:IU)>U:5T.(%]]=SEW&PMP:]9 "[[71%Z<UI.3OUL+-N7]U<#<ZPKQ[W
M&0++D?0;9$ U,-'7M)G/'5WY7&IJ=R'-]-IO]95/94GJIG>WFM@5?&412O7L
M^CINX>SC;V7>&V>ZN_I6;J";Y<JPVB\J6=8,BW$=VGOR6SXIM2>A,_#+>M9]
M^&JT/Y'"+%@$4K,3E=*_W,B<F-\!7.60YBL5XCJZX#\8,!LJ3<6IRZPJM=K4
M8YZ/\7Y254?/J"!VP]S3#X;*76WY[%C?V)/O7+!6R;Z](Z#^XN%$SM $UTD*
M),"<R$^0Q(5UUIT@NM:8GR(; ,QB1P:\@*J'U%[]D@-WE I>>4+8 MBZ71<2
M64T#"D6PR.!++TT+! RK;SSUDB^6X\'4M]XB/IE0NK7Q=<,\CN9EW<_+?&^D
M16+.B5CD;NJ"'ZY97_)/Q]X-B/%Y+D,MW9QME17:1(J<]!AR37]V)]53RK'D
M0VSAY3X9EL:^?5CHOE(_;BMQ<Q;O,)SG$&34S!:5]89?<"@T/WYUX-6O;8G0
M'A"&#(B!GLM"U\=5--\;S8KZHVQR]]UY!8G0T0?;EX5#U;]C6NP/37$)126$
M,P7CJ+6BU<J!5IV8W4'V>)MA[PB1T#N2X_;BAWDHD0-XC'Z[/>\[1[]WTW)<
MKV]6?^]4FGM)GW?!#\$L&(?[UOSUGE._S[';>,XQY.#X&*C=95"4@%Y]&1##
M6&0"3Q,#I6=*;QV=3;L%LVW6H\LYQ,]OM()0+NA<F09A#H>)PVYGGF4^#UEV
M;WAAB"+,]W!C(W9>],7IXT3!+H#P#O_"N;;S"B9K]9V0*\IL;?+B]+._*?I-
MK<1Q=\#3L^TV]_(:>Y4Z(&H>D)NCJ[GKK,M ZK_/.AW@)7I??H*J/[COF2-V
M-ON:Q+?9N*.']6,Q>U6Y-SQ[L,(]V>LR('/A0[U&Y/"^8AP9\-9P]S>2_O[X
M:B%-O<S+)7GI\M8<Z_Z5CGT3"INO$6]W/=\19(=,4&#)-<ZY%\O=1=VC/O;C
M0D%E)7^XT!L)5?5>UET5:'C*\K[G^+6;"<.M:X?VBY;*G82X:E8104&4^:S+
MV-1'1#'I$A$ X9P1CPUY9DW'(K/-:U"Y77?P8M98 9\TX/WF;LI>[]O]VR%Z
M&%=0Y]=%Z7QOE@L))15MDK V55TT)(@T0@)! "$*8T0V]/"^Z@3;YA?F1+&A
MB^?&@]SZ$0VBUE2L+WTG-,V@C-.%.BV?ZF$H^_&3H0M]=RK2^*1_\ UJQECO
M[&ELPM/F@UK35?U*\?D+B9UF6<JXA&AN8EI7:4NV7MGS2,LA,D 2?AB!WC&N
M^?/$U,M0H;FB"*+!)X$"5)<:>W.,W$U_MS^BU82G5M6YCJA8C[$J+PA4E]'X
M@6F8C&3+Z>%]/DS/LQ+859Z!8SD3T29_4MUJJ ">#%BH179F?9$B ZYNW^<F
M1MSE9!IT%9-@]NP3;F,JR,8]W-0=K#T!8[.*\":;'5)6>O66&D5F0T.=*??<
M>2S6NX!#K:%G&5">51Z9R=I2!+-I^5EJ>+-#Y;=GG\S@-UKUY:CCP!R=-S!F
M8P-.DSTR0IHZH@?!%BOE";G""_V^U9FR+M]N]30;C@:KKM77[H^2 ?*B]!^^
M(%J(:FC@% H-K??WQDQ8# S4[]T8&[%6J8]Z!=B=B%IAG^7S)O(:?\[#-2V0
M =V(/ZR<*2W8XJMLBK9EZ*.NL;"/]P_4[QZC2IAJOP"T3CQ8?_.T6%C2<,GN
MQV0F&0!9\DXAW?"[W?C^>=3G]9Z=),W=JF/WI97RQ&%-D,'C$011N71J-<@0
MZCJ[7TRK]:LZFS:WS5?HZW+KQ+@23P@=0>#3M!:>6D[J[,6:%Y_5#],XM[M=
M[(Q/>;:]@GDFMI>G#D3X\S2Z^[VF[YJX#_\\#HD,=\:B]2G%Z0!9%C=33WQ=
MC\4G@+3"U5\?7\Q( ' E:_N:(UXKV.4Y:E0XFTM-Q,?%?:D:9E:ED150&PS[
M3E4;NH=+F%G0C?<5Q(/?U# ^+W6\P,S5GH39.T>-N<O7%<1U9Q&H'',LCIGO
MH><DH%=P1='/ZJK"M)N]GM<;?T_CQJ-S,NIMA#Z?4\ T9],SHKI?D!":B<+Q
MWX[WG<Z2Y\>/]I3H.IYYT+!%=7E_FY\ZE0IH<O\Q6[[F!O>/U(,X!)Q?4 MK
MED'?P%-AN3[?>O)"SV%SI$!]WOO'U%Y-? ^##7O[!9R4#YR--&!]LS6QTQ4]
M\JQ:YGTZ\TQ44JP'.)@K0F6XU(;[>TEI#\OQYZ_[]OIW9[L==U'Z=T@\QD\_
MXS_$^-A)!?2XC59/KXF*+X=(F9]<G,RQJ5A#-;8@IS=%MY\G8WC @4RR8MGX
M/3&58%@O(NP.4:*U=N*>4*"/MDH&@[J_ M.7X32+AN?)18@+/!ERL&K4F_UA
M3J*R%K?;+VO'P[0Q2VUF6]"SR^-<# 'V5 BG_<)<=,DS@?A8MVONPV.H/*Q:
M./Z]MZE=BH;1LI:5<6/1<CFB2-D&VYM XB ,*;*'7"F*#2Q_G.M3ZD;1DC>H
MF13$YV;"-EL:,X\IJ@_;FH$>I,=HDR+1SOR5U5\3KO>K:EQZ]/K7KL;P8-@^
MHD2!%2?4-EW?(2H=^G((Y*I/^FZI 3V-[:IFYG6Y9G31AI<6=S<E$U^\8OJD
M6CQ/NG! $5%6BX+H\JUN>,R!Y0<K#<?>Y,C/3:LTG-99UVT<P7-K3&;O^Q6?
M"JWZ)Q&<Y$UW$M#,UH,L*:JF^(;^V4NP:(#>N*<E_=8-RC1)NFA!STPPEG2V
M"[W]QCFT.U5@VLJ,QO95F[2JQYV[[6WK'9ZN]S]$/2_1S^8BL0DX_UKX(?M'
M+1?W$SLNE?LE.=_&!?PYB8FIMQ#N!"$<U#TFJ&LG6-+<8=IOS/.F37#UBHOG
M(L,50+*'A[P7:%HJ-/C0'.=70&+GX4DQ<O:[J^W-E)%JRB6SPY]J^B[H_?7]
M_8IL?R:#0BMTL4&J1KEYS,Q$7<(31)@PJJ/,->AGH8[.B+>KMU*=AHS=!!RX
MV@I$*:CY']+]T1&JBF6_?<&5[]SZH[#7VXY2+32FN+E\P92*:0V;0 9CA\+K
MS[C<J'@64*OIT0>B0#151QAF)ZS1*J\&F7DE9TGB^^?;/1<BO7?XF4I8OM*D
M].I!X% QO'$YUIUAEI!E:>L\,)A%K)U^=?/"TTLZ &H05YAB>6)VB2I<5,"W
M].A;:KT%'Q2$#I$VTF2Q-QIJJO:S7@&U%K=8#PQX9_T/0LW6_NLZL"SAKTBS
MOTG+_\5(L_'_IS7@9>)#K/CE@"<SXC&U ]S7YZXQT,Q\*">.?OC-_,-N-KY3
M=DA"T>%\P:=B)XZTG *SOB_K*#TS<Y7X/9T-+N>&</:7O+3)@+YU3R.?1 8'
M)=X$C1INS1G]A)NLT].V'VXKO-)D#COX2!?TY[(_*'M,P0;-[;2SR2']S0;F
M]=!=>&[YMFW'@;Q>=-M.MZ0^'A'F$]P[=A :U-&SKG M)OC+IR1_VKC2.WR\
MBYZCKRK']"PA1!%X)&S_WAJ$P$U%!K"I_</]@TV_]T;.\C.*JI.@+:6 [?+/
M5B,#S%1J!K-F&A>"8ZH?_)>U"1 3JFN.LW5\:<2EUEDK_A%=AY;#2OSRHTBZ
MQCO=$6/MWS&OI%?_S6BJI>*=57&'<+%RQ/S,6MH=VCY/;V%E)GIC_QMJ&(?S
M.C'H9E$\&(U($..OQIG$WDMDT+TL@E\[.CQR>^6A)2+617N"\OYO#M$SMBXO
M7VVDJYISKC\\\;F*D4I>-@RG>:?^=.C!T#G9PWOGBE7TQVI%Y4VJ$_5&W3ZU
MU*;+"[Z>5)]Q%/;H5Y?E#0L;?U'Q\YS*LW62,*[UM?!#A/.U()>JBD6MK"CT
M2TLLK_P?JL$3.;I6(_<L[HU+Q3^:ZYE\Q&J7:Q@C_9(=(/GN"B^3W$<Z<U L
M&1">@MLA1>2 R(#S'\D S.H_/^%.&(WI&%700\,9-/C-KR+LBQ5X)<MKN[Q9
MJ5Z9\G&=W[&HN?Q?>JG*-R?X$6ZKZ# RRI?356R<*[#>@/_N2H6,W'EP/,!9
MS]JQ@.A D$?,QX,>X>?"BJVK71@LG-*J-2&G>4R/I@Z[@ZS./?OT;8>!4-^1
MRQ0!@K-N&)N+R-#JR[1\2YBR>M5';6MWX?701==_B*,Q^:]Q-+?^</H/?(V2
M38RF#!.B,AE@;4 95()(X68#4LG8AA"I#U*"_'>#G5NQG<AC#N512-)Q8NS\
M+E_Q!G"0*Y1%#S)"M7M93X7EW)'[IB\9P#O,3'%GSI"S2YK39PCDHN8(;/,&
MA8OG5L+^;FW>&+452@;<-*9@\IS^K." 4.A^+ RE4#1UM?U63I*Z/8F-#"AB
MSSH%A6B2?HXM$7Q+M;)B&<9,TQ1JY 9Z#QYY@:>$JE _P:PAP:ZXE?;T5MYW
MI5:,B].JL 1T^_3=W^(B<VVHQ?#RB8GW&[[VDNT2]LX]W::VSQ;B&+O-6R>E
M7+6-I$!3VQ-7#;7XU,\I945WATK;H+>$"61 N;<YW6S/3&OC,1F0@9<#QWZ(
M$S,Y8*,9U_@R="J6;CQ1D1MU-#]5LKU,!F!%9%!5]U!L#+-]?)4#\HW)/W2+
MA:2.W/]AS1QT"*$XKEI[2J>CP"<70S?^/*8],0:YR4GILT_3K08)3&83+$T4
M4#3M9PDV@@1WIOD@^(DF^ ;H4+=M?I>? ".U'\)/!)SQ54A;(AVEZW0CR8!-
MH"/E=>,6."LX3'F"I'X\_P=L[JY2$G'JN/-4 ]9G@P+/UI !HPX;':6;8(HH
MN-0J$%"/>5F*" A6E?%C [GQO=?^PVWJ#SZ/71#M';XDRTC*O]HE1F<6C@K6
MI)U(M:H>)1MEX.>='IDR;YJIM81*:W?)<LB%7M1O-G@:/S%Q:'6MJ!L/O+S\
M(7N&:17]>;Q$<SBU8"RENFETSE\>^>M((Z<6S.A<Z$GKT>G".9$3^T[IM2KT
M4^OKLT_N*HGM9P$K=+)O!([F[Y\G Q*6FY!_! !5",'H 1C=JE/(E^A _I#
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MC4)$?JC<3Y]'3<G;AZSO8&-W%I"+'U&Q[>#& ;O8XN;?GRG,+VD?*D ZE8N
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MTO=LSI4E!I"W*E'&'5&Z'E$UW083C/6R"QZ4W1YGCF/Y)AY&RH==&/-*LJ[
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M9ZI/L^?#H.Q7<,)DAFH*<"&F7?* /$@!MHUV",XW.""A6\@(%.L+5""<6=D
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ME?KH\?><-;W[^1QL7=3#4:?5-;8#<_8[BU;W&F1@DB$EWU)\OX?T$5GO0X#
MII^1OZ14ASX>4);X\.1B1S^;-/.1J:]H=[>%A5OQ/1QMMC$W"ABXT=M.D+XE
M(CMFN@7$#'\BP8O9:X%P6;3/Y3GY%-]I&:M&YTW?+WHT-=L3P+-?&G3B])M.
M%TQ1&1_S"T\QV!BBM#)F5<YQ!A4%.5KO6"#T=7CD*V]UQ-HSJ]",QRE<_O)O
M.TSD3#5N#A^Y?X6#\ O+U?DJJ>WWB04Z?$A11^D3_@L#3UU=C#6^;2T&F=_(
M+DL4_+C=#@>3CY7A]RD G3&^QEFR[80U^A86'L!&ZWLB;#.[,GI.*:JX(N92
MC$IS9(! HA'P>$9,;MMW-N;$3_))[%3"+(C%(D)/_%:%?\\@QR\^SI\"49H#
M1HRGEE78?%+?&JA+G]Z?(56QM.M'@+!W11KIB8HXVZD E9VJ5-M3%KVA$C:Q
MQ7I#2D5'$;5C@J(RWRA :RE5%UD.)#A1^&O?X/AO7M0T#AXUQ8'7HU+4QH$[
M]+EONOE\\'JT:+0I86QN9A>ASGDW:_V\YL;+^?BF[J5<'^H#_ >MJ=-'B<S!
M1@'LN,3R"(_#M.A+-DK7^A4F8CH;[H3H-]C:K"*_Q^\:XS<(2EX1;0>(=B2_
M.F9"PFZ$P?E]^.;F4D^B*'=$0HVZ0<+3(_6C[^#--O#Y,65I"F#CFT1.W6$\
MF-Z%D#XUGB9_,Y>9[/073+TSLEUITCCH>J/XBTBG0ZQ.7%F;/N\P]AF?Z#E0
M''BF%+7Y-(.; I0V]E( O8,@U> GQ/$,'%55!RA O!#>;9O:^^TU;XC'Z*SF
MJA.UMZRDC$8Z<E\C"]YT#K$&7VLXO48!' @2<;TL!WJD]A9G=[&E^03W3OH+
MC1D4(*0*UCV] Z( S<\I &[Y]/'KDS^AHM3')%,CK-8920+034UT#4V7*< :
M"^&:.?D;'"!*8\<WVEAF*RJ3](<;!Q-;?I8&CVC5-P1KE2+D%"8G\F3P<K^+
M+9(^P'A@0ZA34 D,)!CB3."/R6W(H8Z3GQK9Z<[@B4RE>6>!M-&=$S,;^^PO
M] ]P5=3H0_>&F*<VR _$CYIY>Z#?[!HP)8[/IV]+WG%4EK$;?310D1MXV]A_
M[2I3TL1HR9 U$X$=UCP"J>P,@FIBG- \VK,QJ^+?BT9$5NFFDQO!4C4VRO=7
M(A^0G/8*=ZE=B+^%IT9J#[S!V]>0P>"92,2F3N-Y^/<GOPNT!HD_D3'8K/+E
M((!@3:_@JPESZ?8=(QFR26U]A;_R]*6T'U3Y2]E%.Q/:-I=(UE=>CRH@OX##
MID$H1_C$].[K1CP8RWO_\P!1B+F\N(AS5-_>941VE74#N1BQY.%>Z?_0?]WH
MEF3<]*!$&^ND1:^3++0F(?:3EOS# '\%D %$G(R&ER8UZX\E67VKU\1V,,TW
MC#B/C-C5UQ#46,7WWUVO=$ND57G%^/*\?N$/HAN>JJA'ETE%JK1>-R@ !NT/
M.T^U[5,_KZBL_7AE/+F0NZS)EABG=7]M2T=$,+*0-3TSC?: EHH9(I74&Q/4
MO:0ML)"VFO:-<")H7JIQG'6C*._'QTTQO\:GMU.M@N6.&6JLM9%B"3I08^QH
M,\*?_S)N*?SB+?^1%J_BV>?2'IZ*5Z\?"1CNFJ=M;EF( 4;G0436^*:4I=VE
M-G"8^PW<KR/CH]K!A@S:)=S$?6/]&X^,]:8R'AU\-=[@'#O0(SC#OM7"5_.Q
M14Z[;C?AF+Z7&I4#3S^@$S?/'3-;8+QY)M.$SN]<^=7+&FNMN+R9D-48@@9Y
M>O0YT0[?/J>4RG("K1Q!MX/U279AL%F\B'"JN1!]],'=-P:TSPK:[Y^0Q(OS
MHPJ]AG;SL53#T'7Q"\^=>%OGHY"6:L7 _O6ER;=M+&7AY% BT\P:U^Q&P#7P
M$?Q+CH#;7R_-E%6KT\ ]CQP].E?3H;VL+;BEANSE<$9WZ'/"F[FV90?3B4RX
MRXLJV@)"]PQ+-?W-Z-6LN4S"]-VK;JB<\(*LMA/N$-U(463E=H(<[*NI^P\\
M9,W-<>NFI[CE"3ET9ZRGO6@W0=K%Y#'H<HO6W9D $M]H%X(?_@A$S50J/".=
MH9ZX"ST[.SZZ\JLFNDI552>8#97#:HSX/EV5ZQL]<S:(DRU_\"9U_E  O]WI
M"J[5#8P^8RM]:LDO ]G"[$_<;KX.D;T\U/3DA<1Q:H*JHH9,1<TDP"L$*0"'
MZG%]+*KM=+('.N0B[_W)?G.KJ[[3MLH[4JL.6F=9;= 740;G(KJ"Y6]*[S_A
M<D\K;>K07M=_18:B[$9J2 C43#YU&EH]R#HAT#::4AGS5EYKK>218NX[V@^F
M3QU4:%0_OP_TB-#<%E)GOW?U7V7?R$[,ZBA.NED5*!O-Q+W,WJ6OCYM\3_I2
MML[ )W>0 [41*%$IO+<;C<^?D>3'0VX/U0L7^-9BIK;Z8J%A62W>3VN^?,S<
MU 06&Q6S&JTMA8*I+F6-2]1]:K>V:F0-WD9(@<(CHXU)T>]!]G9(^[["Q>F4
MB7TZ*H&[T"NK"&J>GNDEB1$JJ<-8($J_YYS.UBZ=;U5\"+O_+35^#6()O8G?
MP69;8B^BLAW-EQ#>/C;*4IV[3@D_UH.,;+,8%52TCZ#D?R(3^[PT3T2V:W*9
M&!I&53T95]J%)^^9L83*_ZBC5:9C4&\QK7.<-K:OB",>0>G6"Q/4B!>&ZB6R
M'??&]Q+<G6Q=V?-W+>(K!V5,N.^'R@M\%#1=C.(8:..3NWDUTL9:[_EN]7)R
M9PO4/KP[S]#K?GM-#N*JJ\N( XGJ-8.C\52O=9.%K&-%=0R_BR3DJ;*:^S\8
MMJ_O="BVI;HDU&OQ+;;P_8_XATEY18MDJN^)51V$R=FMF=W[T&A(LO/UI::3
MXW6F(Q(7AY1//!K7T=Y,K7DGTS%$:N,V4MU_I/1@"R*@=VU46MO-34#W4I'9
M9)B=G4V<MG*<_CT# XA-PN-WENP*4E\K]]9)9OM3OFV??_1G%49^7'!.['XE
ME+?R8V?C=8;HUWI>''^K->XL>NS2^6@/;UGE5-VV'M2EAZEQ;DU(:E([F]W(
M3-6=5JH_2X(3[5"7/B)Y56:^7'YH9EHL>C&AXLFD3]Z/@\N<.(&S;Q]F<)U@
MD*]:V+@X.:Z;DV2S<P7E0 $"Q')B3G$*?*JH[29B.+J=X)6>K1%,+YTOB#>8
MP&>-8[IO[C@RG/-E)XEO^8=O?L3;)ZE/UH!-4+=B?%CGK-WDQZ\$0H<A*Q=1
MM-_)PL2G./NV,=7>EQJ(G/-TE]X_,HKM<N0-.'^V##CKISP:;:#NV\%$JWE"
MS_ ]QYF24&*K=-^5,SUHUO#4M].F)(?ZQ-?J[*9F3?]592C_3VRO+E?C[#'T
MH?7R&6PC,A"P=M0C8[_KC"<^S3WX$5KD]GJ8Y-3_,>M3ZZRCP9UK65G5 T)(
MWY/U=JJ-%W2\PJ/UQ*VJ)NN<OHK;M!Z0BV=]'TU8?\TCR)#>2["G<NPF&N:L
M/>OQ$OY8]$I<Y^V<_.=N*Y6!(+&R/"%Y)9D"IQ>$['R<9Q14;ZY!1P72[OGA
M8%TD4(QLZ8:1>=3D'&7\JE2AP[N _RSN9.FLGMU$&P]=YYCK&M.9G.]QSI=S
M67IFWQ)SHC57[E>8N+4,&I'"PQ<JBYTEQB?NCWLM;Q;OA.G53!%'/5$^&W#I
M/)QK9+WN7+J>!X+#FG>E+>RAZ?=8C(Q@$!-/P<ZC5YZ%C2?P07,LP(]NCUDK
M]57BJG=8D-=\IU[73+Y :8>FC:45!PN=^N#N2:;XRH3&M2B!9(PQO*@@;C=U
MRVH+,NH^[H$>9\$T-CP^\.TH<W[_]A0UZ T[_XC%>5DNIBE\P84LXK5,:-&>
ML2B^VQ@<'BI!?*?9RTM_U_*<>S"P^6.OY$CX4G;\0]&<]QIB_2OJ*#A$NIRU
MS3O(9/+VK<EOZ?,[^AZ-Z*K6N3BMQV:/'D4'7BU+.Z5YSE^1U7HL!S8 X=R.
M,*K0LU]SRVQ)?9>=T+3W7$[N6QCR5%95A^UWZ V=!AEQ3^VTL9=N$2URER3,
MKC?L6YCNE/[*D,"WXG@[1D+T<<>H::WS7F:8X9F)-&*+5%VP]WZYM;TZQP>N
MXSJ!WB+-ZB]UIF,3Y:2088C*-B/WI)<3\+!E?C9\'P[4+.OTX:=Y:W&<[_>+
MMU)D=O6EV++'M#C@;?"S9%%\QJ">*@6P\'*VG<VNNA4@\/F2GP+]9XD Z^OJ
MSW6%FFLSQ@9BY'S$T[&8VQW78$B^6\.RU=*5=>8$;ZKUMT[&\ \X$6X0'Y15
M!?=/0,:8&4JS2''#LT8/3CY"'\G[P[#V_9MA-8?C4G",XEU0L-^K>F4P]@S5
M@FXS1;@;%95Z@+$*\.0U.5"%7 =OG;>S/8[&8=%$X\C(-VV3,\JAK_D\^48S
MO/0[5 6PJA\]D$R3I'!<MD-DAN5S8N1U 3;QDUI\<S)?!JS8R](DY'721-4U
M+'+9XW>L[ICO[RH6:QD76C]_^])%K_+GAL>FBECK''V;KUR;7(9(Q<B"WLV[
M8BYWAC<71-Z;OK" -K(#4IFO!VLE['>#\97%YBIO:T?'LF)?5H]E17.=HP!5
MA?6@/2WDZ:RR#.V MV\7-"2*&[X-N:0KOI3-:QN+/"_VK*U/^.6H]+>&@YV5
M'^[22ES/S=[-QW<+#CED-=QL9?Q%O#*GS^%U=74*#[F7JA_;B(U< )&VGV;#
MFUZ7/ KOKSQC%!%T*\67_^,$2VB^SI-<4?GNIT/ED&L^2\1KG1TLPCWDD0C/
M/7+OR0T2K>LO:WM,# B/[BBCQVD@50X"/FOT50FI%K+1J?FVC(+4G\V6/3W+
M[3Z0?:;QER#Z'F];<O!%?C1K:%KV6'?EGJ7X5Z@Q[EYGH\Q@YE>B7H%O6<>X
M>J)\H%0;QX".Z!>'G-G[T7?$T1]+:C^;WWMK+_]AKMS)^-?WK9\VA8:!OX92
M#1)_R5*%#'MH'8!!AV>HX/I3C\5BTN^M5;T</&X3TQU\KJ3 B*\M_ Z- ,)\
M:UFD,"A70<,]W$5)MM(ZW3]8L5+D3KI")3=46S:^:M0*9O\SI"7]ZDKK=/EV
M"C62[;U5@Q,BGM:!.#CR&R?$\^U<^:AT%WO_Q?S2?&HQ?"YJ,6L1LP4A6)32
M<93<#4:K1?C5[P*//GHQ89:BR'S'SV'7,*0XDZG=(63R<=<-FF9#M68Q#9]=
MI'7\;BT^>& MYO;@ *$ZZ0HQ))TL@ZW8A+[D/6V>(])2D):J5W>M3BDO:Y.J
MO20=)*OMNQ_\/ FWU75.OC6R?(3D'-DT<?I],@X+&40<6\3UOYYA(D$P:_-A
M?.H?8M:*:[V*$U1M1,%RPO(FO; 'IHOJK9V"F]JGQB/;/FX?Q8H/*+OBW#L1
MIXPF\!$&$O:?I2J#;MT]HFAKFMCYJ"W6VLFZ^L1C8ZGR8NO*MP77UD!!Y@3?
M P2X WI/\ZP^2U"KN[R!GJC>E*'+J&NO'LL=;$R'9.@40P4/['61HAERTM_8
M+-L:;W#..6!,JQC$"O7"YV.<M%\02,ZSE>\>SE5'G>M:E[L0TKPN]V#TC8%U
M6]E3O@(?>XW+5JO(?9#22<$O IK+N#:]FT[N2A:5R.HWIN\A4"/<>N[L-:S,
M8C[J9K1\%B?FC.E\8/#UAKL*S7>]7=SZG= .)3W?S8WYK+3R[#T\?%17RI6)
MLHJ5'"(#J>%QY>5/5LJK5KK3Y0*)-A@P[7*(.;9A^CN21S:T>Z%3LJN-[<J%
M3_.O^Z6-E34Q*D[MM7V=H<HWG[MLK%?MQR4839;>D.QY;?30Z"10I"-RWUPG
MK\K <J1RK;@.XD/;:?+"Y&S?IC#,H@[24(5*'O;2[8 )8F4_'*"#D*KM7KAK
M%_4O*\!?METY$WO?PZ!?VHHK9,,.'X'3U/Z,:T"/IYHV5D4OW^ $7WG^D8N!
M0\.(;H9QR]S83N-D8/"]-YI'6<U,FEKNW O7<;9(&2<14F?+%3_=S5-0N!?Y
MMH876KT]89R["@L@#YC'M*%9S!W-(:W?+U]ZP1$8]GCH38CFO:#(=QT_OXKP
MNOD]UWRRG]UR#_:5IZJ8F9^_;I3'N74QT8P8M%04?&]ACK314U6O1+@+O?.U
MF*WGUUKEBT@ZT[JHR,]GK^)J.577XGQ&@O,(ID2]AJ#9\A#]H5[FXQ>"QD9_
M>)>L( I&FVW'-!X&O=\Q#LF3("WNH4R*7\(*4W$G#:+:?5_>K_UJ[A/F;%MA
MM1KC0"J4X;6 AZ3(1N3?B5O>LE(7800$U4\7E=&,>4J!8BIA,)...LP)I[:#
MMRFH4,G'J/HDFIR$LF>*--]IOC/3W-_9L92)JS_&>O=MR?K$FN=$%_Z.-$8]
M96XA/-+;YG&<SY@'S/7@L^D@HBR/F"! S7&X0'WBB[5_O81U^=]K09=]/CR@
M\U]Q0&?D;TM!SU( O"A=^T+UJAGN@N[Y)(>*^:<OHW;$C=]0@&G!T7@*T"PD
M,1NRJV=VX5QE1\/'NKERNB %:J;]$5F <D+334.ODY)5A;ST=2/0#;4#+K;^
M5T:TG37'6>D)MP?\5+J0_O"9J"F9 ".\Q!R81IK6/=/)R2=R\]SP ^,[X.FJ
M^*W<X6]0Y@,(F?$A!;BHC0.19RC @6<Y$D0!_&_ NXN>0':EIRG +YE<'WHB
M>ROY=CP&3&JF -L;]M9@"G TD +$WQ]&K=JC*,"@DXZB/Y[%'^Z,^"Z 08?
MY)^8[ZV29IU(]BV-UTQK'5X,"SW-2VC^7/5&E.:1?5OL$B/-./C;(LH)]1@U
MMJ)-2E%E=$"=++ZA6_")8(=\'D!6E3G^UKN(Y87:4;?M?5;M^90#D_!+MPMD
MB^!R$*P^:E\K)(P"3.&$R3$RI NC6QY40@0*\#;4"T':8(/_W((,2K"*52UM
M?:, =.G4D4K'KI";]B '=\7W F:1Q'@$(P7X+M9) 6X)P5BHLK:'S^=!%2G
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MP$P^Y&BC*%1LA,R#UYPE48!0WC;.-9<EZ_O.Q9DV/;?S7:\-*L=^8G[GT/6
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M=';2]?9PR=KZ98&4?8G ,]56JSGM2I\$[4$2# 5ANU^)GZC#7?C+/,8?[M3
MU1D[@1 V&-Q>^0G)JA\QK']:LV/ 8_]5"OESKF5*<!!J,YLNW%[+W#*G-U)\
MKJ$J5NO\[.?K%_BB%4PX<#%K.(*0W)H>MFH*S+QOX#71@A;J>+-9G<2W(F*@
M4E@Z>^L]>R$_;<%\T"6GS9#=QZ0&\D58YQ5M+.]<9R"R\@2O>L+@&0@)=&_H
MYA5)GDN9@MC$;C4SM_C*'N>[3Y7<U>^3XPKG4.,LN_-X7L(UK\;>IFG6^6&(
M<4.9[HXNDVVZ(;>@UZCWU8MG*IP[\U3:H:\Q:/REI&9>/38S*.O,]*DGKVHB
MW[U'65@H/2,%QG6JM,YX[-LH_$+HAX'MT0%@;O!,)J@"3I1$1,@:JL]TN=K4
M--2\\"H6"OZ&\OAP?YVPLAGX/&?-ZLO:HM0/RW=#*P('1F6U%BOB/M^B,%RL
M.:\%>:UN1LZ&/)+NVD$N=6+2XB2)G-*W%=5(V)$7'$D_SHI]UZ4 ;\*0/Q^A
M,EQ?BWK@4&3&;@R$]SYFZ0YV*K?(2EMD0:\*0>N8N)[C%NQ^G+\CF+VV_( [
M*UPT^7\>;/Y?:WR:_ZC0Y3?(WU]7<9N=)D:=_R791>QLW]AG'=Z)68Q6I:8<
M/P/VC_ZSMZH=MO_9Q'_IC]TCZ\121Y@I9C%AR\I7E" &[S8$[\RZ$0<;X>$4
M8-X"0KQT,$5+S2#[N8@.)"I,?!]*GO[/%!96_7.FB/R;S8\__^D7+/V=1OL%
M=I7JD:5'X2MI\ ,9\7A2VN\EQ&YJ7\KA/T6M[#L@^Q=?;9#<8RB 1NYS>#F"
M&+\/7MEU)=&)T%)&_R9SI&$X>DKC.G*),--71VZ9QAI8Z<\F5BP.-8-9Y2R^
M:TU? MNCDKX,37SZ(IU?:3?#7/<"^9.Q'H*I7MW 0N9\%Y,^0N]A*QM1'EEA
MG/UF_/=S K6,WQT+^AJ;<)0VC?]==X]MB\F/;32;ETVK]=6!RU"9N1,7AZP&
M)6^$K2)GHI?'[T:>]6P7*Y,=O=MZ;L9/\T(^7K.)S(B'YZ33-UF#AHAR'ZY%
M7:D<DKA0[M<S<PQ^F4/]AQJ0]GCFE>G=8\=$/JC]7@I=HCI$%6Q,"TP T:'*
MB=4(R7;:LW9-_SCF6#6R%^?=^:)N*5HFMCK#0F*+_X[3P,<LOYJEJ6MX;6PA
M1KV]<KI-_YA#HVA&M]FY>..A8F2&H$VBD>/<\\S8N&/25@L-]9QO-)V<>%J9
MQ5A9 6-C [\">H"FZ4ANEM]GDY?([%^JYP9+MB5>]9S0U1N^X'79V<7&+#-#
M]-AHM-8/#H\'6F)-_O(RV>J FRH3W@F[-%O/98(Z213/]3+G'3']K"?6P<21
M_.94\;G7IZX ;X[WBU& ".CI&33HE[ :;BK@(4;E4E<9*=ZP,GR3Y8IT);$F
M(>GY_,R<@,S0@)IE*W8Z6%EFIH]SHM6:9=#YFL0%]#/__A:&->>LD^T3CPW$
MLM;M+CT[IBV<7]PCDLG"""Y;6NUI*X<*8%\+Q]UYG?=[Y5,?;XL:BR>'<06"
ML==__Q*^]T3D[-A<K?#J!@&,MS>I&"7*87M;>4SR'YY+G%H?4B_S]WIL'<,7
MVU94I'3J.O)15CC=,Z0<;KIY.O#W[:3E.-[F<<TP:];0Z;NEP8M:G5G*X6;P
M(^*#(IF7O="!8'NP'PP8/FV*A;0VT&H."RCH%OK*3EX^C>J]W+>"YUE7ML52
M@"8XZPM\14RH*N\05-_F:);#VHZNO.LC;36QLX8O/$[X:ZCU'S^[4I+U^L<"
M%#0#.0I5&43<P+*$5&R<<"S3&:HL278\D79"W*_X?#2'^J4;'R4BWP"KX@59
MX4<?X.-;IKAQB?&7 S!K%X8LAH0I@)F3[U%/*3!AH*<H#^EFS6%/. OKV>7Q
M&UYKY/!Z<2=':C*OY2?#/"NOZ'4* !T=?''WVIAY3P_Z3D5XJ[Z_DH63QW$^
M Q&M 4T:8R, 6 5*/#M4:;'@-I7+*BR=Y+-#]7H?VL7Z$\?3<^0^7>HI*CP7
M[>%QDN/=L0XU0?MX*RMVAG\?R$DVZD">H@ZDRH4N*?_^#H:UXO]P(!5QB!:6
M0!3KAL0.*!1V?$#9P-.1.YR[4D]V?%<K6]CM%E5]"^/3:".WK(/XW%IY6AD#
MHZBJ>P8X"0 OCB#4 5NG%,XPC.^%%37<181KH:/GST>?*^K"A*M3I+\)1JOU
M]/CX,Q1)'H,JXGVQF/ZY.WCOV2C)EMVDY\?M0G3+_'L4!&D=/.^STLH"W +R
MF#HQ$::W'BK2>B/;$PV\9A7!%$ ?%:[K$^$4.G+?+MA8!-?-ZU\2G1-LR'!N
M)M(T@@*T2I"_(+:UZJF^W?\$F )$FM89J*U[Z1.O3J]23=FMB!80_MP0!<"W
MOX!QX+FQNDTI;; +6'#K!HN7CW&8&=O&G4%GB<L<? _?ZC+KS$C-1&XJCN8/
MJ%D%/9N2Q=M@IS'&%29P5F7Q7'S&F:N/].[T\)9RJ^AX%TSH?VXN60P_"EW(
M)7>!RQ:CH+71""RR->Q95(/9]D\AQJ9Y#C,.OW/;39C&X,K*RM*JZ/X>]NKJ
MH!N:?$]8634!L4B /C/_9Z8S0AGV#<ZS"K:G 'YD<7RLFTCTP?BWXNWAN:O+
M<N<ZGV9Z,B[YO+I0N@:A@S<+D.F>\)_".Y9 G^,$GU:3E6,??F)C27/<C2;D
M=B_M;;%Y+Y=FG^1!Z<#$B>QX*URG1CEVK]WYF.2I7R-<H"?^QQ\GRFCO7G4E
M#;T7=I):4M'SK#T9E(V'W!PBRLP2M%:O-8A-B5M8> 4+!#,8"3ID#Q@!HNRY
MN5%/1+*2:?ZX4^-_O=&SXB3)VM2<&[[2 R<='5VP#QL8%[]1H-\G?'TUX2#O
MK_^-AWVA )NBRXB= _BVH6E-:PUZ^(KNZ=X^IU\^KIOV7]S@)^%/9FS]E^;K
M[NPV]A.L8/:+J 3)/=[-[)XD0M2^Z5H[QP&(J$X5HQH%V)>C $]@ZA3@%#?\
MJ_WO]TP@0LE&J!^N/3%BD'6Y!4@UNP$%8#6C %_!9#T*,!Y"5+.E -<1^]1I
M[ (3V#>D &XH,>5\^.?I!-@/ \V_>C((1Y-$.@:?1Y!J\#$+NJ0.XL?-7/(<
MS)C@I@["<2!^WYTQ/TWZ"&\[!MGF_OU%=G<) _YKMNSP-A/X-@LUL8/OOC\D
M>DCTD.@AT4.B_V2BCIKTCH8L'\1WEQLOX0LI@%#O[^I$*7!RL C55Q51@)\@
M"G"1 JS=))^CYD^9Z-\7;%2K\OQ!V\C[WQY"^IP5@P]'DU]3/9HK>1B,H94\
M8/Y]QQ7!'0?Z@[?!'YTMW,6$@S'BX -ZZI\HPEWJ&YA1/Z4IP.\;E-!M\#^(
M:_[17>1$^#\B &8E_B%A_C]ZC'(1R29?**?^"R=2D]-*%KQ?+SD O*E/_D'4
M/&1ZR/20Z2'30Z;_ZDRU'KUE?GO.5WQWL7X/TTF,3X>3&V*V_KZ_BSVB<,;6
M")&9^V\^],">( /OBO"E  ]%X=NW9;8E#GW_(=%#HO]J1!OC20DVL3!1MAXU
M EVGP7K"@:ZZ]SXR#&3>:M1*8'(7AZ3L4JV$OL5YK.,#M[>E<//%><>)N-%J
MA/3O^X^DP"Z':QC_7]8POO[[&D:]:SN<3UEXA@1;::U-SUVMEDV5J[C2U@5M
M,SO&I)67S8P;J=G .T*.4 !T="X%@%%'<6Z89EN"8VN4> WY&K[4254BU-W?
MYT+!L[E0)@J@JIA$.@BA #%WZ;]6F*(AV,%&.@J .*M+)MVD )T?*4!P E:2
MB%^&["V#R"IJH!L#$!5XJPZ>BPSUD"3L4+6%/YO,8]J$VIK+AT]_A.-W %\F
M=>@.!3@A/@/9QPVC-H;!Q%<QA[0.:1W2.J1U2.LO:?&G_Z.U!1-P!!GLI03!
M-N9GF8U-Y^R-;-Z($G0[RKSB=S],N_,KSRSY%-0,N]1*8MO3&W$N64S$S/7?
M<XDM"_I>&- PO"0PZ*<ZD]7XZD]OU?PS>>" ,WQ_Y:^E ?HS==J?YN)+R+\1
MQY]DFLGRW@&9@?J3- S^)%4_U:!#6H>T#FD=TOK_,2U\.09)3)*0)-<Z4H"#
M,\@[?WHP1 4_VED+#E,5&/-JZ> >[!];,XM3-Q ])27A=P:ITNC:XP>^<2C,
M0UJ'M YI'=+ZEZ/UE]_".980?^)4F(!#=2(8O)):7F4$V=C[GFU?O7C-42#T
MG&!TCLX=5;^O],9__BH.U<-&8#:"B;2S=>F@^U5U*8XE4\\>:(V]K'#+/%H?
M[IZ@4OCM_Z[\Z)#6(:U#6H>T_F^DY1T3 Y^?K9@^( U2@#2/W738*WQJ9ZUJ
M)<YPJ)/S4W\5YQZG^U7%C^^*:_2:@/;G+].@TY:F7U'_$K[M7]3E'M(ZI'5(
MZY#6OPHM)?@_J-)//T<!HC/8<*8!.Y(LOT:2!GY87RBX5MIVBL/#1:>G,W-;
M9@KVISHH W^L!--&?8/QXR4M44E&WRI"+Y<L331JTKL[W\U6W@48T10@2!^[
M1/;CG(ZE #S;8B*T:/CL/:("!<BDJYZ'=\3@C2C 2?A/&N=]$ YY(\M/>8_,
M 6Y%'  6,$VBPR'\$'X(/X3_L^!MRM[8B:84>_^=AANMZM7!BU.#]E'?[AC[
MI[&B#:R=L"S-UAPXR1 9WCX?O?!=AQ)BI2.-H&1B'BW"T.FGY%^?D*]/W;6G
M +'Z5 K((0J0%>>GHO2OW/=#^"'\$'X(_X_@3@N2H5,\7RM0$2FPH+RQW(9
M]&-^]BY#P6>\C=X<>[Y0,YPI63<QB0)87:, ).:[](-@;#Z9CP)\/3*Q"9[3
M)(K!0\#;0!4Q!C_ZWD"-WX<",")FT21  B5 O@9OR?M=KDJ-R;6+ D2]XF"G
M64(=P@_AA_!#^'\_W%*S#1["?VRP_D31LN++*+J&OGJZ[-CK/6G1FC(;,DLH
M3O!\V@H%V%F%O\MD8<.?F(DYCD]JX4H:7T\^L=;F.:B!/"<8R'I+;65($-'1
M4/V79A0-MD/NL[JB5H4DR6'!C4&9+"I_;9C!?VF3&QC#@:WIOS3,V7_YL*\?
M#^&'\$/X(?R_"QX(M9WM.]DYYX*875$2P0P]KAN:<V!_R-ASSPN\\7BQL>BO
M'[]?]]<EH_^5(MI#^"'\$'X(__MP51@^&[O1K"CIY^&KKSLP4U7K?TWT0D#"
M175Z;M7@O/^M0W2#?WOE\3]N_A:%#MQLWH:R;V9O2M'%9*+-'2V/_\P*5_OO
MO!G)#?37]Z5YRZVB*<"%C'QJIZD_J N]0O]UR5!K/8(T!>C**X"/_J(  ]IJ
M("T#=7;@7[&9MB,XX/,UCO"=(7UJW]I]\R"<4&,*$+>02P%&]< 4X"8[S6[Z
M_V8-U?^VYKW1'K,OK$@!2#Z@1?&OA6C8)7BWPB@%6/E. :ZH\7O_S?:]G3__
M\D^_>.OO-:C9W/2^O+,<&?4"M73V]\!X[9'O\.I1M6Q2<K\3XOCU?[?&VG]7
MHW]'M*6JD'T)587DJ1/BB:DP0>%W78-X,LJ.JF6&M>B_OR1[EYXR]+=FHB E
MB)21\- ]?YFMB+/*37E(ZX>8)D^BG6K3$3T+9 38%1*&P"+)P!-SJYQ&ZVS,
M&)=.(.T6PV.Z=0O^8*''JNOBP]W/N^?<7GSZ-.4LN047RF].L9D+:AUNTW7X
M7?H=BFZ+":, 7%!C'!,&% IU(N5Z.O,C?:[A;I0KAKZ7",T&9%6U6I"SD$?P
M9J5&J2>O-#O$D30K!X&CG#")BL>!^@+R%KUJ@YW^;7,O8$]PPVO\"9NF39(!
MM3&=X- W>)8[;R8V*NIJO(.O@&*9SO3:@\5OV]PD[SSCY\0=*\?N=:1 PHIH
M HRP.]NF(L4)%RP<:9\^_)70RG([G-S2MQEY4?*XA>B'N#C_H<J-+C(>T6?F
M8AO:^LC13KHA+:-A=Y'(3;(RT0S5MJ(UM)6_,/Z(@0(\^P9GQ,?HX4*"7R X
M'="+]YUD/TVI37YQS_1 -[((C.3AN(@1!PC2J]^7?_"0I:+D> JNFC@BAM:?
MW%V,[@/U)!&%8%1[EMF^1#ZJ30':3;=[":J6/ZRA#'AO#T]Q]+7:8^_ZU]N3
MWTV<%XSO%AX>W=R##.W]<<T]_6PG*6(<0H[7A Q8RQE&/GOGR;&+F(>)SQIK
M*^LYH<I0TCGX:L%8J"@NK?2*IAZ7@:VM_+D(1X9ST8&FF_L4X#@D'/[SBC<%
M>,T&QQF3'M8*A@YTO4]X?93US?5EAB(D7G,;='!L C[]E@(P$H=>?U[G5E%\
MD\[B^&5H:J2Z&^'>#A50[GGV]LGF\[S!/12U-S%_ZHW!GU^RRT5D%QL90>]&
MU04/LON#5R=.5[*+=)NL7H%HPILE7TPJ'@QA;EJ/MS\SV'[#'%JBUCY].P#R
M]=VZ2.Y-(;/.TH9AB,3HN*.K2](J3":P2\RXC]]BS=E>J.]GZCC9"NW7>,PK
MKPV-*Y\ENA9.7=7&G!#EUFL+O%KYXX&_W',&>8'/R)\V<_H=$ 8B$U8&':UL
MN8H38' NSNI,]W@VDQ NI766YI(^8V;&=]4(_J"L6RN7S'UK%4\9!VHQ"+P_
M>K(23TUJZ.CQ[SWF7*--^5FK/ML/0L\RFG6> =?)&8K$86[#?81LP#OH+6)X
MX@4$YV+%@U\^\O<BGI<W?!N-JYQ"A!W<^HD.N7H0OYNVE:JC:-X_A71&*^*;
M"390%WR-CP=[[8_Q8R'2($F]H;1FGLZQQPFRW5<ZIZ8FM.?%HL47Y<@#PQD6
M^<H3>==K-9727B]W(D8:ITG!%,!N4GC.,V*#J#=W_S:9"]L= ^4>KTYZ_CCG
MMJ:J^<=+,Q[[FAHRA-[LGRER(14_7_@>Z3@AVS)VH]W5F:V5363UHQ^@ZM^(
M#I4G2':)42W%S*?NS^.[3T2AJQ,OI[=J-O?E&&RDP^&6[::.*LA"N'BAY'+G
MYL(,(@)R6I5ONC/?2Z!M].!6Z=Q"N-WFNY/HTW9R$#M#\5VY7752E0V^P<<5
M.X$QU+3'+&G(5KO1G&U\_\E%[![9K*_B].O-JI.R::++J*<L8_HM8'9EED*O
MH9842UG^:X,/X]:$JJ)LY%;8UKWL&(&7MJ Z]ZUC3?V#ZC!&1_.2[/=/$E-&
M8I[M>HZPY6#UN,=QO;S'-.]]]Z?A:!!3@' ^$#:\MB]6+#DB^:'0"[4UEFQ4
M&#/[P_+!4I_>]L]1*T49DA5H))=CB:H,GJXXI=FD8*B/ZVM2I0WSIMBV]NY:
M,CTA[ABDI8$3E51ZQGLP7\R8(\U"_YL#>NKG2)261@Y_E!6T)7]ZF9/'.*TV
M.-^=([V(]D7<EQ4^A\:B+VJTRT\68-?@S7=+UD,BH:<?7827\S*%,5M$]Y$=
M>*NV^^71YGMXS1!4Y15L\];FU,$X07SMA3>?9AKIYO%+II(RQ;EK=:6_4)7Z
M:RM9OWB<I_T:Z9Y<(-Q_^V[=X]VSD=UNXHUO:#:M5]Y^[ 8]B2ZF6TNW2 5P
MAZ21IVSZH.628K=38D,NADR1_@S-]%]'968IP-@*)KH.2P$L\+F7XR\FST:Q
M?2N)6AA_%]1_1BRW-K;V=OR>WW= X>D,2.@K:EZ.&G2-MD$.SB"754&SRMDG
M0C) +&>&W0;U<H5]/(;T[X3,F*%9[8Q7-"H=Y46?)@Q6'GCN+,/-=@S)Y%[=
MTIKA'>[$\<%^N11'RS6MN2A=Z2LJ !#W9!*J\'L&X19& ^#V=<5B+3?/=H8C
M'PPQB;8R,#A2+>RCS8DQ'*0[F=_TDLO51+;+/]8D[VS,5X*SW)^^:IDM>"2T
M>P\^WVC?/ VB *X4()1\==1EVS70$ST;P]RTQN?)*L(U^N2D<D?L:X?KRP6I
M]UGJ.S/W389V(_#[MMZ[/V$7\'Z];^#>^99=@=')FL]S?%C#N_"26#S1"%\X
M&Q.RNL9NWK?J=OO7WN#D\ZVKA-!OH6ANY.1&. 4H$VY&G29>'(:>GXTY_MV1
M)R$]M2K9T\DE[$72E?-7-MZQ7+V["CQ;G7@MO/$@YM?3B2M=>)B1%%MK7E]=
MV4O3RODI)*1W !1L^_W2J'R4Y:.BT<L]:U8;MLY<Q-.+D+'3NTLC]<X8)<F@
M:6[;<"M-@X><Z059ERXZHB?]7ZB==M_6O%LC;WA<J7!' Q6G9%&8RO31]>F"
MPV6)R<?1MX2LSIXT?AM]_>AC'G+R4U7)HNGR0#BOK;JC:6N(B1<%"/PA5!J;
M#=H=YN#87PJOY]!E"LV%T)TT-MC\7/RVUJ*2X VRG]UC'VXSR-?D$/\L/KGA
M4KU-TH\$.VU,Q)ABZ4-=R)Q$?J]XTT_[,F<-!NPX-W>DU*(9N2!S=LSL"VH_
MCH.2N1 5]IT3A%9?<)L55#=NNFZXY(*:OJ6@RT?Z3V>0 BA4PS?7=0\5#;O/
M=?6QBRFF"HZ"L1'25]:U!5/(061&6#>8GBB##=#![H77"S\L6JY-?_M\V=,T
M\9=0<\8+YA6^(KF.TOA*60X!WD;<Q48"B#D["&N4;>B?MI#]4J\.>F<CSW9I
M&?VF1?<J&F<LQ%@?&UU55[9:L4)UE,RPY\2C)!3L(E[8LF*P46Q:&X-DID[3
MLB^9T^;Y\E<%"VAUHW,?_[@C5=1  =PK&O3U1RIZ]>RUTR\7N6*BO2Y&+@B&
M&S-'YWVV/1=.?D!6@BKH!Z*XH ;877IOB8J(LJHUX6G9P8(^&IO)^FK+C*44
M4A(%\'^)WUQI1]'0AVS,7]6?U=TONEOZHV-<K;P]_N<'#34E.L"T&Y_=\ETN
M("]UYD)6KE-.44I<[<N?A+V:;4O:MC.((K1$>W<5TFEYR*)PEP((;"B*9*'H
MP%;_F=(R_^CVZK_90])@CX'\+KUUBFH)J!' P7$DFH41ZH$+:7WG>LV9<;SG
MOE!:EU[;<VE[&B_Q"Y$/7IF6Q\W+1T(7]%F<<GVM8M(P=\1:;(VR33DG<U:+
MD"5+RS(<^[T4X(0S3I(,?8$B;,G]VV[Q">I[\+_@>XNN9!4(-6PX-2>]!JK'
M3^,CDR6W="D #56:L"@#2!H*.S)-31.7.JD_HJ3AOW>M%S<*_=Z^2!4XS.Z/
M[8MM\E\(FALLA]A#["'V$'N(/<0>8@^Q_[W8/W_Q]>XDRE2WH?9Q@Q1@X\LT
M\55]+P2/PL2PXC^P<$U?=TBJ6F,2ZX@6^"(L_L82@;SV'SZU?.#_0$D<8@^Q
MA]A#["'V$'N(/<3^+T5/&<3[%"#.'4D!1DO)CQJ%*4!P%3[I]_E3"&D_E0+$
MF,B%@AU1H?R" R7;X@05!8F-NQV+\KDG:;8O&DKC#?[')R0PYNIC5)\DD9Y\
M?,=S]1L%N""Q1PK,I0 #4J-?*_<=9Q Q9!DL9\+EF&SS[]U'AZ[-H_DB)\:,
MM>@>&T2*K%G%_"EJB\&'<",<2+,4@#5>B.P(GP%C]0<*Q+>2_OH;EN8A[!!V
M"#N$_?-@U@U8W3ET9*. UQ"9=?+E>(^X:[FNK/-<+.0Y!VUB;+#"=HFE)\T<
M=MO6.LNRU/15^IA]N/<=259F&:[+CDJ2GL@I7V]U=M,.4';0?V+K$.C/NVE&
MVS-4*$!\\!!\94^7[#8Z_N*?OCGK[S2:13 W?#YY!;73#R;Q)'23_[) 04GY
MG"0Q7L637--) ;(-:\!C:+(V$;%#D"/[OZ6A#/_MUAIDBR1>9+0-C==ME+;P
MXNFQVE4]4<DJ3R^PEO30]EU,EK>.+V,LI-I:$J>:/(-D7.&7'+&PC8YPE)GO
M;.PZ54/[8P[PE"$BO<K;:I,BZPT*O:K-X%<)9G4IF^X37])[JU1>R]-^0HX3
M.;I52JY^4-35>=([ IE'[B$2\=DI/LK7I$I?]4T>2.)E"3$C"/Q%X594N4/C
M)7R^-R?_@=%@\9E(T.53%S\+#$M?LUD.;A0D5<+.4H"66M)[HK;K46NKZ/K>
MP@DW/Y,MB<OT#X391':/?*8 1\C#D+-D'B^[T>8I>IRNXRN5Y-BLU\[.@LT)
M7Z)UNYD4A-YEW)_+G*&QM&]#18)8&Z6FQY81K#L!19..N&M26E^O,PD^G0@G
M+U[K0@LH=,HO.^U8(D.D>106H#U%F%]]YMUU8Q9)NN8'3D@3F$],/];X:LI]
M'K>XM+,;MDYUT\4'O_)NP7K@S0J-%^$M5MA'<TU[91N-6.>!H.L*KJ63G(EL
ML)C%S&U&\?5I5G@7*I\:311-'] @F^#?A3'V1'%J'''@DN IF93G52L[F'N4
MF.7(X&/7N1=9<,I' 3D=\U>@%NCM;M6\=!T#ZS5=/>@4*HJ\M=-/UZ=:GJ@N
MMW%S$BZ!8@)UI\/UI\L1Q#>@$-"NI"/\0.\L7$J&!/Y=W$(-Q@?_WD -/7Y=
M\S@PC0:O>\%QX"Z\*R-XR@D>!+,O-U#G(([ ,+ C\.9;J/EY5_ JMPT%R*ST
MI48_1\NH7,%AX)TA;;*IQY8]D5V7?$=CB]R<"#Y@,AV$8W4E\5OX^-\G(A$+
MGI AA0UB+#4(H@.3Q(3_'_;>.ZK)[_OSC1]4D"+2!8&H@ BA*$60%A4! 0$!
M*=(B3<0(2&\A41"0+DA16I0J4B(=(1!Z[[WW(B604$(@;?C.K#5K_7XSL^Z=
M.W/OS%IW_CC_9*V3)SG/?M[[M<_>Y]E++[3(23(T "<-</@-6,Q%KB/#T6G/
MB!MXQMUW)@NM?-^;MGZXYCP# P"HK9N85!I@FM1LELE*R4:[._D*CHU*+QA%
MA&O%DHX7X[+O&^^RP) ?CK)**Q>/W4=6C\A#AVH@XR_-PPE3N@=:6R@R!\*@
MLH*2F5OWGO4>Z04ZP4@I^7GD'=:AYV8+WB<F9W^EDYAD"PXCZ^)2]U]6$U+
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MXP-9S_S))Y-';#L;.$.(/J))8M?Z[$9'<#LIWTS1^1SP2J.6G@9XP+7/@UU
MS6PO5$Q$<H_NQCW559:<VL);_D!T3:7@4%6(Q90 B4$_4(?:35M2(?;1^)@!
MR;14MGI3$>44829ZT3CZ^%W^21M5*R6>-&MP7]W5F:H'=]HRX32$]';L-OW/
M*L']=^V45_7S:8 ;3'''?? ZF.Z_>@\M T_WD33 0_D3CC-/TOEHA7( ^>GW
M@GID1@;_ E_!#U":P\_LGC#^+"L2=$QW\NEV5B3@_XS_/09HTV#*F*H3?P9]
M3''K20?606(D<427$?AHR9T\W("(I %6+2%DB=-Y.AH@OI^'_)IR-@UT J,N
M_)_V3_]/VC^-_1?<3'?00V54QLM2V0Q"JN!T92F.Q]&NP8KT]#L^CHZ)IP<W
M(H*:;"$)R/+\%A-B-3Z[>9[^SZ<>>U\OD7HZ(<KE6=[\"^%SLY'/@4;*$[OA
M'9"I:TL;6/IE2R '<<)\W.762/&%G#N3!F[\Y^@J0@D];F+S;;_U=Z[PQ-Z/
M6W3:"<15+])'NJ)MEZ[U&3\;=2VV&%"*'M0I;=\M:3O_[+$Z^WN'+^U:GI J
MW(* X\DK+0E);DJ=4:!S[Z'%"2BH8^W;QB7[NR<5[EQ&!+'<!G2A67X:9MZ"
M!@B3H'P%_WU<=>:JHU!452O6-O!D^*+U7DL<^\-%"(-Z/C%J1[8!*>=I)<OT
M=10-#4]*#'_)N2K($M2D 7=6C_)4\A8RM'NU,S)N5)5QI+9>?7G1B9[5ELO;
M+1013_XR"9G?5 JMRL_O'C_V\<@9>H*6T;YVT51P\3WT%(XSB'M+O0WC'B$C
M'"MN5>?PSIG%\\^_>)%- [Q_PHM@/(%":(#@=[!+$T=S6M9?3"9V%HS^I*XV
MN7F^_MWZRF--B.5U+YMGZ(4(.E[1XB P+FZQ.HS*0E9S"VL0P& PPT^_U%:2
M2[OD[#;VLN0,'__P3*9S]6A=QVC@>:(]>L=#>9=F")^#S+1J,;^TVG &+/;[
M6Y7V%K,)UD"3JLP89,]<4/$2Z\S"2G4P#)1-5-:P%MX\%<GA-J6Z9,MEFM0R
MC'A>TM0'=#6B&A!+4^!SF+^J9U$O8_F9E8F#__T'I/2!5OBU]C9U'AZY*K0K
M+)DN6+87Y-'2I=$PK':;!@B/@P^!9X<PN$LT !$+SX1W 'G)]OB1)9.-:)BK
M9-B/BX6JJ91D(4[X\W?-VTD2L^OJ_4&@=LR_O\YISR*BB941]@\.1F7$><]A
MUV+:5E.*CO>UA+.TC10[+]Y>MJZ)?NG2[SF0OP%SRGB'A7'D)QNM%7BC)"NV
M"PCHNTD;S]VMB%OI@^4CJ:>'8%X:8#$+LN^A@"0PEY[!C$7#&=L'OT!T(%N1
MIYLY- "H]A2UHK7S E>^@HQ!=F1*C,FGJ3[2]2ON-A]PXU>V[32NLO2W5#DX
ML)^N0[Q'E!M\ #L]\:Z!L045V,3X%T][_M1ESH7W"C-P=(== 8_?\\R< U7+
MK41?L+D6:W:1\BN:>]I&4@'5N=9#-.8Q4/$[$=G9$VVHS4M&ROY]0R90ZC"O
M]+26US] \3R-R2Z^R_7_2-^R?$VE8&.72<]\$V[9==-+\"8Z5C%2+F5A)#O+
M:T]\Q*^BE8^SC^7'P+>"""Y)P^U+:^%%%8CP5' B*POQ2QN0E6P 799FF=?+
MW@YXVI:5I/;B9KQ'45'1'2T3QY</>9D9A,W^<H>?L80\L=HV3\NYF.BI/2:U
M8IVWZC_((T3,X.I>/9ZI"#@'R<5P(QSV/M  O*)(([QFL*1\5"S$<&1F9^+I
MG,)]0$XX_ZO']A!)"*+I#IRG2]%%H>VT]<I&4I++FIWJ-_MH5M(ZQJ>X8U8A
M]9%,[]]*^3F%8QVEF?'Y\-6*&K!*S]KM1?%YZ?+J^<P4TD ?(A91<=P&CCM0
M9XUV7:X:=@'VANB5JW.5J=VMK^;V!_+_L^/^I4)*SX<&*#/;Z2B!^>!S\_*+
MIG19/QS^45^8NV(HQ>@A:>?*))M.#SKF3'@B\I BCS,C<Y03$+AB<D#L;WEI
M#K3?38%'2]P+[_[Z6':P@35?T=>@JBM<>+1PZRDN67[P=A8%_?*'_/<(0T6&
MFB%E-P& 4\:#<@PGSAPFU.20>.)5B75 C4G.' 1YCV*[T> VTU8*5!ZID+2[
M\"509+5>3KJ-\]GCSX^"%5?.F3Q_*1X+ 'C]DY,526:FP/[E"$]:"&@:X L4
M3P-00N*HT3I4MT/I$Y9-&N (ST,- YU^(\8MJ@HM(SX<Q0&V#PS<\K>?G7!H
MO^W^(K[+DNAD]LQ#N>#4K)6 Q.E)?S#U?3;75D+\C+Y<=EO!U$]$7Q,QV,%%
M,@B;=7_?C3-Y;9=FE%A2A,I-H+#V$%="[_J1391JO(J2,N9JJ^#A9F'4(1J
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M[80=!J8!7I(,*.R5Q"E(&?SBF7V)MIPY*=8*&F (!$GT*R#S":+VM?9LSM,
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M7N!]&Q>F"MN!G&A&W*T_60@G2D:)W<'9%VICJJN"NN*1":8=*OQ\9#\<*W:
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M8G3O49L]:8"_/Z%KP#C,E6+X=>*6]F$!<ZK--^"4RTQ%FK;T=<(K%<&M"T%
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M<*2XA1(T[(@ 6Q#9CQT9G^X;X5"X?['YA*C[Y^7/N6=IOC =RF.*2 ^K(\C
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MFP%GUWTQFYL4,NG&K*$G-"_6HW8_U41?,1B5VL6DWD+BP+%LWT/K,%KBDL7
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M";.I&\\<C!D\6*BG41=@L_$D)A0N!N.#AF]PH3OP?Y3EX%[A?;Y9/_S)*:.
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M0YJ?G:Y7%U5_UA8WWC >.=>T/4)]#N2@%JF#W,(H*0[%2)O;@&PBVC3:]\9
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MRA*I@?H*)4/K,!?])DJ(R'IO;'OFX*?0'$2[B]#'18\63*&DEY%3S3/QP<3
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MPV-H<@ [(\==^/1.D]MHD66%XR\0Q_ZMBM&O:<YDR>8-TDV&.G\/SE6-;7Q
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MTF[>6^\U.EYTQ]SQ88PJZZ.X^3ABWDCY4Q7],;9CXO(/FJ+,C-ORZEF5JT*
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M^[L[?L>EFK7 IX5!B)4.,-3D_R+O_AMWK"WT+?0M]"WT+?0M]"WT?R#ZKUL
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M87;7R4GY4]P_S!PKHP(94% N,8)= SHP>QQ[LL* EMFY($EK@F5B>7Y:$E(
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M1]T0_%DD31;UZ^._]>\MLLZUA@[\.%.UCJAKAX6-XG.KCB!_M&<BQY[\7*H
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M%*ERW8^1BTO)Y+8I=].>#23/X\UG1*RG;%+ZZ%>&\ZH@&*$M$O&],<*V&W$
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MDMT]6!GS)B.0B5 RDZP#:P;#2(>P6[SS+?*>LBX+IK$W+.Z$#Q9+OX\KU[_
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M</)U;;@Y6&VB+D\R(4ACJ4#UB<R:SJ-CA,=KQOUG3I;$CCZTC;PSQKEZ<U+
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M63FRTNG2H][?V!6W F,D&1"0&%C8B5BKQ5F7Y>QPO^0>Z);;P54CL\<JN22
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M!;\6V7O!7J"P%NB=='#['+BJ@O+,PB92F&F^L[PK94Z&W'BM.0,'.>%[BV!
M XFH1S&!#E0@R/URLDR(_(JB<4%2L8J6GW2:VNR+>>5S;=]F-00+'K0PGDM
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MTGQY6J:UF&'RV6G/1,E#2Z+;%%W,A.CTK$4EWP%I:_S&,Q&REWH5&0%U(5
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M.MF9XR<C>?+'O2^@\^<:FBD#*$"8$$D%BS<@/]A!$>9@YFTDUT]MBSB?[^^
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MRMR&X-+,1G*&CB!S-SU2Q.WBZ$$[CSH,-L5V?*Z&;=IL/,T07 JNVD5LG0$
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M@Q<765 < \'N0PWM<H]8?_BTN/XY[PVFA=KE$MHP\_%X<^.YC22<A94F(EV
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M3#LRN'&#H=L-I@L[S]'F0T>WVZN/O<K%RQZ'_K9=NH[5?G:?@>X*F!U*??=
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MI_Q$OP##A!M/D]8*>HLF9LZMZPGBY1Z>%WJCDC!IT(:Z="Y;&_8SK)]IZPM
M)P/$V4YV&X%KNT'22V#[CP8)G/?:1E :I/*9RY8_M&F/!![0#\<3@^D"WJM-
M!7[!Q"=.V*0?_@'WS;ZJ_F!1&8?,G%+J87<_@>E7GRJZAJ5]P 9LL".^2X)?
MHZV(U)I]VS*1:9GL9?_OA3J[<6QV;BN\F)]ZEX?OGO$_.VPV-._LIRSL'LZ1
M[.8>)\<9ES]H"U(XZ60J0^RG<SDS0&<"Z4OJM&[[%?75!B92OQ%1]$YN5@;(
MBCB^.$X5K*7[S-&^0BE)F#'H9##=*@</IL6)LM-S\&\/-A\,+4-J0HG7?N;]
MV1QAV*W,IX=[>^RSW,)S8:^Z6&I5?W-/<MAIZ) UDQ[C-P[]U&Y6('D5!A;X
MBM[U<LXI*194N&T\4ED."N&YWK*$S;)4O;)%9E*A\!C'%=R1XV@>ZP]3-P_T
M&$=<&&SS7/PMHZF"[!RR.+]I?M ]OZG_MV2<1ZJL^="75EX6E8YYT+G4,&4B
MEMQ':]:W)EEVF)&]:2E67<4//GRYJZ[E#U'56J@QF9K0V(XYLI<I(@):.\'R
M6$PSP5G7&E!$K9FR=Z&._8)4H%O]<13C8E-:H2IZ@VVLX'"<F$)0>\QD;'("
M2M/G(/\=FC\M%7%(>W6%>+P=<D1MR?+UM2%=M4<B[I3$T(=+CN=S5T2DM71$
M[ X^M<#D0-R0$V)&M.SMGXUA"X-'RTG2^RHB0CR'TL4CEJ(FT$TGV/FLICV/
M<]5A?\EQ%/<Z]2C_Z,<5D<N )Q1E0(S.IRZ 7I/PNWHTVQ5U/#*7;/?;XD1C
MW769K\GAAXQ87GY OU_9RV=.5]:L60E]^MP-U$)6KCHW#N?SB>]FI.5A#_5[
M?<.!7S<]*%<GBKM6@8AN) _B)( V'F5ZE&4@"S9:G_WCG4K9:Y,7>XM:Y=IK
MU]\>[;*6%>\"2[INS(0?Y<.^P0!R,^C5/2: 3SQ2?W[J!>E"[F6$@O9=#$+=
M[@J+U!$G=%99V].Z[P^D4IOIC43M9X\V6+#M4XG2WY?;[!]+]ZT>%HTW\;I^
MIRON)<N!A8!I]_!3]_SV6H!>XNZ".O6XS,*TZSG "NY-_-A<^>ZUP9<L_W4I
M_:;$346KH?.7*CXI-W#^-I[]4.;N&N#I3JZ=QZQU$RT7YCJ8,?3Y+*O+U16G
MA]J:#=.XTL>K&14J 3=,4_KEHJ;?]^P2FCLQK3R C'=;WQ3V&+"U\!HPO'!,
M[=F=CN6OV<%)ZS]SY_,*Q'>WN!&[PQ?M^*[T$-&X-+I5&F&#"6X&B)ZSC.D%
M [*H<*H620AOUH4] +3U:G$+W4RSJO[\;%__ONG]HSQVMY[<$"\!7>00V)^A
M7$/V5L"9H:'<!,H #<-W]AXQ*WDG!B@%2BBB(7RA^VJ$*%N$(#P47V;?/4>\
M;(TC+YB-7=Z/CM@Y4*S+RE7\,TUW\R,O#%KEG Q;X%-^]UA7?IMY)IRAF)^S
M2K38J8Y9\4;4U:%J%Q/SS]5U,>M)/EZW?_X.$S'76H/6:J^6N5&N4J715X:E
MDR B ,PB^.WT6:&'=;0?)>6_)%JNZNK8<W1'2C% >B;D>)(I:K65@)S4Z[YW
MT_O*:-GZ-D:'5RXA^0IBW%NZ5JDA]I'P'A0&@8%JU QWT-=W*^F'_9FAP1\?
MN$\;16Y7.%$;F:CK7*:+/F@79H#>GF?FZBNBD8BWS#2DBEW\UJCZ9_$!AIYA
M"<W$$AVP>[I_ED9/O/5D@(JXS^=,G"!5=L%U"<K@! :H5EP;7"OQK2L556Q0
M]N-5?E]-=<8A:5S;>>?=LV[$TI57$?4YR[YF.\Z^?G[N?MSISQ4#_0/BQ6VZ
MWO+R'A*PNPBZ>@@DS@+-A!)MD!,(2-*L1"9AHUU9RE#JYST$?5:N=71-&OR[
M1R* ^8FR!S?H[IW=XZ$>MR83TCI.32*^(84WXOPR+!=]A'95H^J33C]SU]0V
M?'CKMC1B/S%ZV6XV16,W?9"B7+JR+Q2M*L@ =9Q+K,F\^UV&;^9R\L6;X>>C
M[A\R/[B .52/!)SFN+ _[PUBB6Z!#%#G> IB#%QY)9-B!S]3#026^*7!$,I6
M5[@M FY%>M\>Z%1QYM14:.5+>[5S *O+ .'[<KD9H+RW2.;,]F !FH9TY@W$
MD&_VNZPRA\[BG^/WYB;[T6I^3P0=T+Y*CS_S'>60FM\1+ME9@%0NM_:!GX+9
M&_6(\5=&"L94J?J9G+7WNZ2?( :#Y%KE^#\):QS3U><DW_&HW&NAH; _%%T5
M&*!/X_$,T+9R-AVU\D]'?\DX3:%SP41;S!$<T]_*^V.K%1?FU*,Q50T 9/+Q
M9\N+D-UU_.]Q*A]S4C16L.7=S]>*7GS9-Q@K],S0/7%CW<(&$9?ZU. 0FP^R
MU4K+H:I_HJ$[1?-Y*FV[ =9*/WDNL>$3F,CF?A-)Y4.9AVF338;5G75&J\.N
M_'CPLX(+ 1%.E# E\PPY*>1E)?_/OD': ;?\PQH)X/U-- -DK+5WO)@!ZCF_
M0-N"?ISC^],"&(BF-Q8Q0 -6"/ON/[VQ=X7L0P1C0]^W5 BH!P;*?N"YR??A
MXCV_;>R1<OY?A ^?4RUG?J^-@N.!\<@2>U;C:Q%IRS]S?E+$[01FD6T?_[Q&
M>/Y="0/T]#J2Q/]?!P0H9N0,,!UAMF&V%4@^JTF',QV'!;EX[Z']$V:(;2!
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M@1TPKY]&?!CD4FWV.L&DQ_R6B4SM_)MLT&A>LR?M-0/DAXH 5\OX]1&CR)L
M[*YS6/7'NS]J;"G0K!]L&BQU:,5-]LNAXU5P$])&%$(0 -\$8A>4(WSS8"%C
MEGWU D<2RB]H/,[;_!H"TI5]9B21#C>A7*//(@]C/>8$?"2Y26,II2OGT#&J
M3NO"VR_]?VP2^)Y8-EKIRZNUAD>RZUF%"JU2*)?@JK0B?:WW0 ->:W1T/:MP
MAA;EJ^;O44,#$CV5\HRWW%PLNB_'425HI=5KQPG+5 'H^0%]4R1;;115*+C
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MFV+D [2:9A;FOZH!9XJ.&O;#G5F#^J>M"KE#A*N!\D\""J_?VV.3F6XY>T\
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MM.4Y&VRZ^?1SJC%*03UF",YBQ.(Z56@!F#/03*ZR,PCTJFUHC6: ;9ISYJ[
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M1!T!@HAMMZ-M>G. AXMQXVV\4V%OYFLU7SN:+C_A?"39'WH!_1T%1&BLFQV
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M_>W=]A %V;^[$AO>4*H_:U#\[LMRZ/%.[R.>A&-XDZ]QC/\XH^NDA%A,_WH
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M"71,ND)*2A#'+8X_JO?;D>GFW+AT(5V[^I.XEL5;*OS>NYT/-"B^C!TQZ,,
M^=JO<4[K&JDZS;3-.JKO:OA,[[A\N-2.B RJ-8@Q>%_9%ZW,R@163"090CE@
M(L-V"W%W!,L2]: 'U3K;SN(EUN[[^U?""[,9'G)5!*&8OSF;^CP]_^0;780I
MI+5PQ-^%L#N 8(FZOO JD\=FI-BH\MOT5:Y1I=QS&X+LV94M)N,#Y\=_07+U
MP,0;($P%.9\T6K8.68XGN(:+![SX[EU4U5EPAT^Z-YAC/75^UOC$]ZLYR:?3
M8\QWV)-^\T@,%?.6X!&\SN;5/YU-V_0*"J9.FO/T<LAEZDK&U0!NLA!XN*^3
MS.)K85"7IZZ^F/:V^<)S C'$%9E,T_??\SU4B:J6_YEO6L:V%F:V-UPAWZ$4
M>OJ_WER\)(_4A!IFUPF(K[KT];XS&!7=#E.J$^+L;$!<8J(DKCH=@2L M66A
MF<B\R5"AS)'L@<)1-XO\"=,>/;W=%ZV?NH?H#OI&)85\$O5R),2>.K=B%63^
M,WSK O4"%-*"W:)6TC1)II]>[O1K:@:V<_YO^4NX+<?,=T)H,K^"07;40&PV
M"]A]R@24!6DOHPE<0?>#*8-*VT)4;<H0^ 1L>L.KIRLN0K$C?4UE6U]OP7YS
M5^ ]^^<$KE9ACP%^U3&:'54>,6AOK/T#2-PGE*$;%,'<JQX&;2*RX(NG]QK5
MMG(M$R\LR6T':&=B>]MNLG\ -Q_MXL.#ED3P\3 1D[YH']M9'ZIW7>VX:$IC
MH][3FSEQ:ZZW:H84-T:=4A0RHMU,!5EH'QFSQJ?;Z T(W-N",O9 [_S?5I9;
MCYR*3W"K8!R=2Y9QZ5>.W_UTGIV=O?B  X$KPQ)O0F*UUF!69#\*6@*FL6'_
M0#;R[Y:[]):E-_)!5:K^]PT81"U".D@5@[I?MIBWGA2#\,.*,:81XC(S\POV
M%S_-92T%H$?B]N]TL7D];IQSE+(COQ=M6OP H#%-!P)7>+$LME\)3<*27Y)L
MW2^0$AH6EANV7T4$-&1@[;J[N[JO%D3P]=]W2Q5Z=L[GA_$PO8=Q+,J*7ME_
MS(98@H=75/TL[$ZL]#%:*:YO'69U=A%^5OY YF7:WPD^0-59H'0,<.G13?:)
M0T S<L#-BOR0"=_GB'GNI?/[3C/&<[IT=)[!\D1P6+#\2(5%3A=7>@VGZ7GW
M? *$> N\> @81;1CAW>Y?B" FK\_&;@2=VH.C+WKU+X,^"O%YMK9QXDM1X0E
MQ]@>8_DNS?I/@LDMX4=;.Q >8HC[FNQ0!W?M[N:YWC#"A>;P\+O3EH$\SY0.
MA(F]4VB9<45+7O2$D.NIU+'?EYG:FGBP+D+CQQ(*G\+55Z)\Z&F&H<#XQIVJ
M7,36KY3J5KW$.]V.VSLREE>S>Q 38C>53PO?B[G X\#@Q%,C&%,._[R2MLU)
MB5.]VC[@8C+1U2I<)?M<OX$C#MFA8?Y!LDR%$[<'W,T09/F*8(5SPKC)3RC0
MRBAU2NB#^7\WGG/Z*L@T:E3#[W>^G%6.</US'@ 0,K&S.YKG[D#2!#Q'49(,
M+<TQ9N;!=9#$R=1**QMCU?E.I%U7LUVFQ'.-;7M+V6!QZ8%T7"-N^#RHB9EP
M:$A+V0 B8XV#8D3( C#FX#H@/ET;OI65J_==?M7]R+,J7I+>8RN\=47:V_.,
MG\;92^,7QC;,\IAXM4Q'HGPT):'.25O5)(W19=.Y=W&6 >[S$3+VBKK=R,B(
MN^'IYS";-O8J L'.C'CE<N"@S5'U$#6P+RB-P3U'LR/5$>JEU"BOM);1;]#A
M$8\>E7#T?H7&3?_E_59\]D,S^IBT9V<!+FMZ=S&4'#*/\D(M'5A1((2T$H/5
M*'=W[$,!WUWY@B;UD3?FWWJ;1[Z?DK\6+OTWEE7Z&+R/R0\R8/]=BN+W3,0#
M8+K>(4#*^"3E\\)PJ<)9S)LOV/81KM8EGG<K+JLN:KEF^,L9KXVY=GCR4NG'
MZ<51["1M?/6@#2],?QV44H)F:+6XQ-=L^H?J+A9]*[64XU8?>I/>//(^IB5^
M[W?3X]<Q%\!2/]=DYVC<!".E(8%A_\:UG\ALW[T5;?ESJ^/<:D YV1XV)ZX"
ME7J3SRR&#M\A1V7%)$C?M^*B0M]&6<VV9=RQ(^DOWFOW5W1)R96(A%QXPSNS
MO)SM]M4=(/?U],+F<4&6OZ'4$&;L+B+P588.GB0$'I%<02P<D>!XG;(6+(M9
MXPY]+N][[X2C8EIYCMW>*[,37Z ;=;M+90RN?4(@[P21ZD)!59F_GN1#%G@B
M6GQEY7QYPGBR,,M!N&\M$9/NB,<_RH%QX'MEBY[#J&9L4CNTY*4C+&]42HY/
M_<\_]-=AP7->N6NKG-Z<72GA\F(<M^TNQQ@?O$X%T X!]&[4/756\O"43L.U
M87L(+VQFN%;^L4.36,%:9 3O>F#0VRO^V'VYQFO\6-4 =)3E&\9'+-&A[.0/
M*^*!*?.N$!Z70$N$3N@A0,\TF:>N9<-%N->5]X2HD.C8#?#1?7W47/1A<*Z5
MM8JDZ(+2(/R]5TLU* EOK\@;^\E\:B]>.1N9:*DXTFI]1E2KY17&T?]O"O@*
M8PG;TI%%=8V21B0M.&>1]9JJ5Q5?56(%]_E5:Z8JEE6.<9O*&JC>_7KZ[.<5
M4$--.?![]0"*> -!448E/O*B>%5%^;03Q^(*S'B$$MMK(Z""&46&S^7BM)-6
M+-/;'HX99%UHS#)C)IHA##EX"  9"A":@+ 2JUD:.YZZK7%PZ^+3!<ZW[GWU
M=;IKR[#M4C8G4<&,*(: Q/,.2_K^ZQAC?7J/,6O4-7JE,8M;E#SE7LW/;G]R
M=8W3IW#%(]B:+_CHK2+.X>/!>#AB<B:=]?WYR0U7"-'2)A/"_5N3"_8=)S+R
M_A$PI3NL3K&I96-C;=JWV,S#7Z,BV?+;\P\5IFH&D !+,32<<<L$-+EU""!:
M0Y8]R?$DX7S];1?2P[5HUAO9R$+)E7\)'^_U'RQM?SSG(G=>XGI"R\7\NV<1
MOD=374G@UO A[D NBO?QZ2@EW"=C)Z?G<6NV'-.3AI]BQ,UEWN2\TQHI96>=
M_T7Z3OY(+SX$!$YB1 B!*5&Z1.JH_470D-$-5<>[+24W(^_G"W,PILA/XU:_
MW9T)_,#_P>Q\.? 9 I?]Q.@0,(+%A!+*QEX^U);_XO3Q\U@VLGL;_^*=<8_,
MLVC1A>U#P#:("H:IDHLIM]Y&G2&-4OR;N":AX;PGY\-S?#YTIDMQNF9_@-WW
M=DW_&C&V!:$J_@"U* T5$$U?4N;;/]GCUC8QR>DCK9]M9>4?6 FERDO8"N1:
M71C=KOC%9+83Q.HM5:;44*&P')^,-V:EN<XD)4@Y/#BU.LY?'EJ :%EQN?Y.
MF]^*PZTE8EQW&]7J0!, CG0#T<_A8/B\L586@3VM04-XA]OQ3>DF:YBP8=&.
M1J.=?.&'@:53&;>N-:E5^,-';YF(=7_.JJ0D6?1_T9UPW'VT?8/3O]'_FT1%
M,>>S-SF=._5OXHQXX*<H20S.<.JU*" E(WH]<!%%L'UB5A;=9;^VLPDU>/_*
M^Z3ZU_NIC@$5M[5.QMJPJMA\@O0+,B43NI FH$JNH]#7K;5'RCI\T,GMZDHW
M!EVL)%("-1X+G[!X[9#*#?7'A<IR<@Y\>,$*Z9(2(B*3:'SX!LU!AD!SUO6I
M-I<'#6K;KT4M[B9<?IW^]07+;*[-;<N&?TR^4QH!$Z^!,-IXU C]SBBJI1 -
MM>%9@HR?2]L6"<=X?17>-R;Y[3FAS[\4 7AU)&(X71>VLX8T>6!-@UCNWC-X
MA.0O'@*0_V>Q5[UX:?E>+_9AG\7"-G^*/-=6@R*A\IEDYWOVU-_.RH"F$0@&
MQ P *=Z%0JUG6K\BANPRS,5V(;!J]J7&]YYWG6W=W6PKHAI;T]Y>.469TVDQ
M:,M["^3-5,#?0P#Y+I$=C4A$'/\-X:0%DBZ1LC+N1M9J_N$+U5T)B6CMN9PS
M$93SWDY&&:4%?'XZ.!Y2B!)%X0H. 8*]<J2 ]77PEM/Z\RC)\# =)K?YN%H;
M%;5IO9P>"PSFNB:?L,QP_!!K@FL]R4)-8&H']H<HH@UP>9*<BII1 S\$I^ME
MX$LNT!:0<027+MO8#!)F['A?<XCQS:V_-VW8LQ%>\!,T?J+(UA_BPC6*"W%C
MJN'WR[/\T]>NN+K=H(T'&]3<W.O:# ( 5&+>OC4*206H[K&3UYC8@J!YT>M0
M#\IXHR[-M'_BFAR\:)216:;>OHK&N#_W[,J%5EFLM^=J?927"57^#%!XLO#K
MCR!@]FJ&\/E9E1H X"Q $B"XR>3=6*93>@5IU4<C,$B\<1(1BX?7OOF)N#\O
M<+O/WQZ:?/MJ(J=GQJGEP0M@G9YD:5Z62:&_+_%E%$5SFN"=P2=JQN+$\-$^
M@TO3ZFG/Z[<,+1LQRV;W/78[E.OG3FPH9+++YT;HT@69>GKR/HAH88.Q(@B_
M8BL[W:^S[.XR-+!K&?BGR(2A7N9'/<_V[SMQ&U)["&CYOF5 -"#?:L_='R!K
M;<(5>K(^=,W_X6]9NRAU/?@X5_:HC5W&)3^>+<J)_A$FF:L@<*_ S=^WU:GN
ML*3A)_JQO5?PVZ !."C]$]G_\N:>05$[IZ63$@S?5J EE\9Y"IM3=#%@_;<$
M#CD4R$T[27'!3R88\V9Y%^&7;9$.TNRE=_:M#=8S]BV<S;8+SJ\+;0K>9(%D
MNVO18^#:$,2@20,""N2 .O,@$QR<9G0Y&WPZN]VN#O.TG75_.UK0P.>K]_ZF
M6(Q!(N%"TP*&.71C4;A7B%;-_P38+.'_'>"YF?\>8(__%N#*HP!_BMXW!< @
M6Y^(F8$QAP  #4C,W7-4ZB-NO#RM'^(B?-;HZ].)D"F1HXG!KML?WF1:L*?N
MHY8ER*;$\.U(XAJ(XQ<RHP+ZY&I#Z)N'*:!B?^\@85/87O_]VS4L"R$O$NZ&
M=()=F= ?6RI&ST#AWB).MNE0H$0J@?$2F( [(>'1_0SMC_M1)U;\J3J&94KV
M/ 3_IZGF$. )HBA^0PV )2Q)R'7]Y(4Q,-^W??<S(I]R,9\CTU.J!6Q2 I2"
M1B(::V,^[17()&TF"++@(6V(+3JN"0/%F]42J\<D\!V]JD8-*^>UG=9,RU0(
M9V$*(5?.X'.*0K1S* =XFT4'!I<=\1AWV8DH=DI7-9#+L/&+3$^N@LEWM4.
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MPMY2\QE DT0"O'V*&64X8Q7\#I&$\),$79_[O7TKZL(Z CA*7,+V>CLJ=7A
MMA:XWIR]^3WDXM=7ZGOO_!R&YIE*P(8F]-:(!7Y::312M$TA[;T("',@=3?Y
MY'$1V8GM&,_8R1L7'7;=F#CSC7KTV@5,4Z#*H:,)?1!;*1723C,PQ[CBF^BK
M]MADG[@ET=9[+X[MZ8D1.VW%V'<. 4(P^ RZ5'3>4+TF%%J_M.)D-8H(#Y8P
MPU:(KS%5!0#LK4F1!XZ  31?XB$@T_@BU%AJWO!<N149^^YGWNJ*96@8)T]
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M,[H4X\"QIU?XE*/\;: LN_#^)]4B,0ZUG-<UF+<75NF *1,I.:H>3;D0%SB
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M.Y#)[]\N"PH_5KBD\35$Z $K_DA0'VP?;Z38N)!$MFZ1H-&)7?B)DBZ=!XW
MSUFLR.4M]NZSONNL%T[<>7&\:56<5DFO ^/*W,]3BJA7*9'D0GJ9H74US !M
MK\BYF['YD1\ZH7B+[=?7BAU-T;T-^P&O6PNA#IOFRQ(VT\;8QG%!=7_VDD<_
M;)XEB#Q*L IMNYM3&FP"^FBS?>\UFFK/]&*W*BCF"B/#%N*))?B_\D@O 5,?
M'ZY/<$^UQK<_1G&U*@.G.-ES(*]0Q&^()0@C,5 ,@7M<=@CX\(]VEUZ&>HCE
MI:G1&_]D81!C%R47DL49OYSZ$M?6KF;:=LTY#89,W[_G66 Z\$?H'U.F OLH
M;H> JS-.AX"!GD!B.1!&"67JRBQZL;$84[8-E_$]B@Y%BV"2$G6Y_:\Q[<B$
M4D?$MKR3)W_]XUNM&M_88M:-V_^EJ#4/2WS23EY/%_;VC"D/L50J%]KWV:JD
M6OZ$M$.&1BG5KW^(P"5;J='HU"NPGW+CY+#+TW7FH].N3><OW%D^@0(= J#J
MX>L'V^W4>V5+5P86D&L2E/#7JY:>P>!\P\<A[:\#^[N[E]M]%C>G7%[Y/TT8
MG=Z:9:%6 M&[3P_$R\CJJ(Q'EF' OV2W:TM5AP"4AS6V\HD"'!1E>K09G28T
M;2SR\( !)!5TEZK.J'EWI1(85O;O"A[<['*2R5R5E/-_<TQ!03L/)6K E*IF
M61F,BY0DXJ\Q$$^49XU-G3-%*OJBM5YDD923!W)6.$QO>;%L=<0?:=:'? =2
M!@#@DQ-J0:/[UPGGUX\7/<<IG\ZU_'$\ HT<1<0O%!?_Z(!?_.(S>SK!Y<$?
M _OGS><!9O*KN=%UQ!X&]W'2E5&'0X!$%"?Q&.+4.!Y[;.UG1W'"?FTPZT1$
MA&[/9$AMO(K+&(?7C2 KOG%1<H,5@V..:OCK$, COH^OS@PKZ7N\.3,Y\\<R
MP%_CT7**6$A"1=SQC[Q/!+/?L1N4B$J#.G1)3=M(JD7U%IUJ#!L>A0/GU1Q&
M+\+:D>\Z<@C%IIU=G9E:SL="'IM]I,B5-V6A<'E22O2*^C:@<)0<9?D5M,-9
M/REW/II_W;FM*V:D1203:O&M\U+_N7:Q4P*M&V-L+$0'FE :V8\(&42=7HJZ
MW4H2?E4'RR,4-+R%3$)#9/?4RY,F_)NW;E+N:,D&*'V#. /H$4=O81C3[IJ4
M!2(_2"HJF*3X#,.H?+N*?I#S7&UY*V@KA?6JJ%=ZG0;O!;8GWJA+OTC<Y'#F
MC\RCM.(M*%!2(-KXS+R$2Z:DG&OOC)Y+&J0M5FBV8.3YP=_(EJ??S^_PP->^
ML ^6M7VG"4S@%K8AZU2;9"R_[B& ;^FA\,4H9[^S/POM<US4^"S5RK=+IQ^O
M.-O+[PZNQZ8RHE&!P"4?/'+K.VEAN.PX@P?[$#/WN;;:><45\7 R4"=N<X]@
M<2_!>#(0 %)1/1T'O_<) <FGC6^"2#EE1,>G,8@WC@_@2J9C:QD>Q#:QX)_M
MW]H"/2!K,<8_.I@=4(%_/+8F$TY B1KB'3Z>B:Q^*S+VT5;2,%O["S^\_9\V
ML6X Q0/VSDI@2%!,*Q[^\JEX$#0A5+%9>+9A9/F;;V7XW6;5<Q&<'C7L1JJ8
M7W^+F)?L^H7Y/H+%[ Z!.*+D'OYK9V15+CDM+YGI&W9GUAI8R+%FNFL#&)WE
MP!^'@!%C/:+/T]PS40Y-/_^IV'STCPP3>H<XN)[>15.M;AH.9#LJ5-PO0[,@
MA16.!F*:")Z;QBK=/8G_]JU;D2)\"1GSE_P"W.:$3.AK[U_M?0D64XVW ^/>
M((3ZC:-L*3_QV,5U7$K_C,[$OI=P77A ZZ D>NW5A['@8%'PCVR3G_(Q059Z
MN&5! '!) I56QJ6F*U,!@<U<1<Z*9JM_G?7/]3"_>>J]!#@AG/A):,32D+?%
M5#;1X3972T[VI=.GS*] TN9!Q*N[L>,X[+M-]_,DMK4S9\M^_^B?D,R=C(]3
M%Q<.%36RG>S,S&S_BB):3*8@^ QU2=4$I:UF@I'3GPSN87)XH?VK-Q$>;5TS
M@9ZMSUP"SEM4[R/Y!C[4 OB7 /1#0*/V"(J/(04[-P\6A558?7GY#H#JBYM]
M\7L@?Z$!?A\Q>!OA-RD,GUP3GS(6C%+LNXC(,+PGL6(=>8K'*/-%P[=X#B.%
MSFPM.5P^Q]=[Y'=$<!R6:)ZA/2;%$S\&;AM+_X,FE25[4OW(\_PC4G/?;^(#
MJGI2PXN#;':#VTY\B%M<,0$_:O,/-24)ETDUX.F7L7>:2PR4VO,54YH7>)_6
MTGA\6X\??X[CM32J^YORI9>/5,+@1%,#*8A!*:[9/T ^F/Y(^,7(&SG#2GF(
M2NQG__>=*2SIK@,?J))/A$Z>;1R'])>U([)0>$?X)P@_+2@W0E_\<<(3];+S
MZ%G2<_5#P)YV)0!^FCD*#"Y1]@\!Q\5(AX QL:02:'5&J!,R>^_4I@C("YD>
MK?X]R*@ 5=%G?F?F4:1]_UPCOJ7C,JN589KXL1LGG))/E[Y8V!]G$DD[:6S8
M9JF.C*#44BUH]K,.-V9V_QBX24T%B6]LNG"(XP:API=RONJK#N#\5]!V3HFF
MC4542\2@2[^B1O5;G;7C%!#^5\6WFHG+E3!90YP;5NN%=LZW(>"EERT A&FQ
M?==K:+/A/\57@35H"7\?9+Z"G9\/VROITX\;KNVAXB''^T]'L1(5"H>;$OY=
M?7(CQV=?S]BW45&:O91P9=]2%>>5=5<04,[R,[RP !/]XN"@A<-_N\+W_N,?
M-?&AY\@ [QCP<R!FS#2+W,A,M JEH0L:BF[2#\4#D[[FKCZS$7KY0E7W;WI+
M=UV%1-R;.H")O)1I-!7![/8M>O%]I&HE91@]OT^.:/13O/3'KB6=Z=[F2/HT
M_G^?OZ_[;*^O:V;\>W&?GLKCX[JVLMT]UVB8#_'P+'6-5$=<?\9">TOSI0"I
M9HA!#;CL#Y2 L3BL_0^(Y^%,LD=_BKBHAKOA>[\P">NMABX6U?U3 ]HRYI#"
M?R;TE_TZ#[!MFH.!7#3(%P)5QUVZ':O;'^*_\]H[<>/T']D+.;-Z)[ZQ-'^*
M.BHTX6.M@/)H$GAI*K0C<G/:NDB:OY7>P"HT>>5KT0ES#_/K"\>9G7E!.MZ4
M@+I'W16@5*UO.1MGU$'U<VUD#&1;D9D7O/*6;%,XCXZC=IK5Y>91_.QF;MN5
M^GF:I=NR*BQ3!V+O+<WR1_<]#$$H'-84WN1Y0W% 8XQ;G[R)/YY/[QLIKQG_
M8+:UPFLC1-N&W;&B'.T<"*20FMQ^_:-/)A@+4*SGIN?!I0:.7M["Q#'ARU81
M6A4Z><:XY^ AN?1_B.U[S/NK(9H/@N*=JT?!L<8J\PO.1%L(1O_<IL,I9$D@
M^R?Y;,M -A[!J:P7(9>X8^/C34!?,FQ1LVHZ=1?:)6]L&!A8A6G*SUP<$U?>
M='H>P]ZE2[2A"=PA)Y# VP)4'6>H^X4NZ"X_S(,1S4_>)FVX_>5#ZVCW7VQ.
MO6_O.7&Q5<H:?@N^MJ8RUW_AZ/TVV,<FI5\;P1%U?CJ@K4<^/+J@XU>XK] L
M4J/^JK>3_+/1%M2'^( ;<Q< C"0="!,"#2UK,P2&^W6F=-U,,Z?\H37+-N>,
M2UU#A"?Q[@F0IP@0&)=U"."BZ1-#G4E) ZN1D!X2)&G+:U:]O"=78F36M%OL
M^KG*OMX;BCEFLLH6ZC&VW^68\H"B",XT-H15X$R_)_6#?9W1I4WX:).EQ56H
M_<SRJIMCFP4I49^KZ4Q*F@;CQFKYGI:)+L(?N[B+S]J&UL(N8]']1L:\<[0+
MW]^<J[MRIBON3\5*_]46&6"W--]"DW3BP-B*.Q>QL0P'.?'#F&/:W5(MRN@>
MM-ID+WM:QSY'3=DU_1C:]OYZ \*@U.B_;>@?_5DLCGCS<TUDOI[ %6&7-=PQ
MM!,6L*C/9W&.,7^Q^%_>T:DWMZ)LB' D7G,)@>M;'2UJ@F$X=C0#_$7'PN7U
M[[0W--3S:W!%3,O]3;#P.%8CXQ0+H#_I(V%C?W^R?F1M/G(QK/'UV(..@AW1
M#:4O9A^9/!+E?U0^S!3EL[N$&+DR:"P?N<M'>6&6^ZGZ)Y^YJO.;NF[M8+46
M4W%AUU.Q1<0K0EP#9;F]1_M)G"C&:VR.<!G8A$L/J7W%8$?3[TV"VJONX%RY
M1$=GRUN.>^XFGR_0E\Z#F-\>5&&<IBABR6\HE<10@F9"&T)XE0(?_5G>W]=A
M]2I0+Z]&X07*QRD__RH#YK&X<DR9G>TKZS\!HLA(G\#H(8"[5Y?DC.>-KX+E
M6;?.3NFR9^K'&2S.6\R;K=S4.\W;%TUI++41HKA+BO6::C1[%U\+6L@(%D6*
M&D04/AZ<E'RR\+6:)@P9[6 (THM[SQ&_7U_VB[)J&#)\QG)GR]E/4TZE9H#%
MZ\%9]F/]EO1"!*X$)()X@'C:+SC;;P3[?#"$ FZ51V;Q_GB<FA5$A!BXML^<
MH,\JWE'\YF.IX#5@P'?S)OOO<_@F"8KFJ*]:*7#A-SU,>B"G7N-U-X>-]:BB
MWR,C:$W3UWUR(D67H$E1+-L&XQH0^,#4QC_<!LFO9ALJLSEVQ 5?H$-]0II/
MM8S)-O(*75'U!#1"_]VCE_<K3Q!=<,@TAK+SDEYE1/FBI7KEVXKQ[ZOOK]I/
MM51_:J]Z=-)<QM*HAG6JG8D_@4/SKZDC_]JK<OR6CKF,KR.O9*)TTE_7P*!C
M<';2:YU27I+PR\:W)YO?]23^8'EQ_^_UQ0W4RT/ 4A+Y#"6+&KUY<7<,BVE%
M8^:J2A>F,<LNY7N[2D%LN1&R>"E5J./$6]DW5_E% 24A*S[;PU0I%_A .(.+
M,LE4SLL.K?K(R8>O-QY1_?L^R!0Y7[B;>8K87>M@?F7QW-U% &BF?76U,J&M
M$#FCT-ZKXO0U)TZ6B2B9 *D-E/ A( "R/$98& [$: ^6G3@$^*PBK@D7-U06
M+OL4B&K*4MWHRT.I]^43.,7K]#CPW0L_) \29\@C].RV#-61A59*,%R1$F[1
MUU<PH%G$TIW)W>69?DW4W_/Y7_9OQKT+^W;$'O(58A8:O%SH1'_^R#J RN"S
MYC\$V+>7V1Y3[.'S]95MC45._-WANRG9.<QDM49UU1&&Q,)]V",CYYE;N3)=
M\VNP#16@F(PHSN%[ )+*09,A(;<+V;<-H*1C#O-^3=MA%]J4W3FSEG6^9NH:
M>^_+FIV\YJZ5Q*XBY@ (*VL-WX(26\D\4S0$2<!T(8PG.*!MRFBV.";ANC#F
MX2>#9-H;".I%1^B!F<'"QAB-KV*XD*%/P9,<UA^W&2[71<IW^ *OA-:OZGY,
M[]HYWCQ9'O@$P$B%3FKV:T0IS^B>>[WIKC.EKBO\TU^OPO_TF%1.6RSJ&LV$
MWG,(\ 6E0]J4MN5\J;R,2?&G&+<FC%G16QNV41#2K3NB4%4G9;^AX<V]WCD0
MK+XD/^:2._*H1L9UBG0_KXNDU1A<.@]]0K/XG\S##MFH,.$,;@M/=@I\JO,_
M!RMORX>8ZT#5KA_MX+N3?>GK*?.;#QM?U?IB3"NPF\A;3B[F,=.??YV&=N*\
MGL=HW6#7I5'^4R[Z#,V)7H* 1KN0I2A%;RW?/LBSCO#USMPB.;N[7 YX5;J(
M^ICM.I!TX)GQ.2,FW.<G@J+.GH5X!_;1Y*7PKUD72JDN>/J*@.$+-BG?X$95
M,&L O&6<@.(>KM!/KIQ7F[&\(4YJE!->9P_4VEF\L-[DW/#_/3W_?O]_E/<.
MDV5M^H--?/]9Q./+)&8H$ZNB[,)KG%9,>2O]U6+,@[Z\V5 M,<A/3BBX(!04
M]%;,1?1XJ EH7O+_X\3F?[7_:O__:Z##^?_#]NU\1  0A!AJI^?VGX%5RN]Y
M,]"EHR*?N29K/3XH2N$WV*)5-]_2F!@3U_K@$"! @U O_(2S4%SP;A"TPY.U
M'K^%9E\]?9%/DI7UMR>*A%=/UVA'.,I[QC.]OO=_IIW$B)\;B#UCAP!^0[O7
M3ILH3'%[?Y%?H/IZF<=/8D2CY[X@3ML-8+'IL)RUM$NQ9687XL>-*131S9_I
MU!T^'KTU!24X'Y4HE1M@"),42XSS&MT4/K^J<7&[^L757/?;2*Z*E43,^Y]\
M&5SOV(0V^A?*@<J4C'4P&WP2P1EE3CJV-Z3*PSK4<0=KU/[,DB.D-WG=%!/[
M+430AS7T9#'M&@5"BF1PZ3-3^\3L'_]P?&"*7[\0A=6F4Z_)Z!V?[#5!\+,\
MO]R=B"&M0I6I42W@>PLA*I#J$"4_UW^1\7GM(N5.^8T"3%7?O8ZI-P8W5R[)
MVO ;(+AZ1OFR[EH.-@UI+I60G]);#P$>@=P/46R:#+;-4EFDU=\ _Z<%^C7$
M2:V$;/EYDI7DR/6;6OD[+KR7 ( GAX!M,%41/@,Z#O8Y!(A$.9 .MET(T2$\
M*AB=/$OS?JO(T=XB]:<GMVO6H6)!H9Q_0W-2CTI,R4[&GHBG@BD]A.,?(D(H
M96YG*T"$CIF[=F:3Y06^27@(/WQ^3>SHI!SX- KX>S*9:7\E:IU^:&U">4MP
MJR(VW<4$A7,6V]%A_OP36ML8.9Z@\(#09KD[^W L?!AR,I#!!V<:6AZ:0/WB
M1/7#G)^O]\@8&.8,OFM6/K)+KDCTA).<UI;77:Y\C,FH,NMGQ -@+*AE@2;(
M?LE:>'+T8D U09-'SJBQEFGJY\D;:!_P8]AZN$.BF>MVU.GXYF>Y-E\U1X!+
MN^2?1U66%R=((OBD3) C4>C%CP!W],OM4Q;+=DUM$QE3Y2&/_R9#?*4C4BT:
M$R=P!]OA3#Y;9!(/ 2@1)4TT&AL! 7X9W^?R]__6F^EO5,E_-2_M[HR+ZY6A
MO^D]G)_U:]%A99*HAZCE.^3W1*&Q 2P /OD/F:@6=77*M,;54/].D5S&_"T0
M)D"Z/6Y5[%F CY)<QK"2-*@1U&R^K89X.!GS+WQD>9EM^L]S#>^9,"M8N*CP
MWJ*J]F47]1:+K^: 7(=@ZT_(X/\<K5[4BY(X! 1F)6*/J3OV]?4Z&^?+LAXH
MSC5^S ._VY.2C3ZV@7)'W=-<0MZA%S!549\V'IO<*-=%.K[]\5]CS3U_XEAX
M"%]4S7)Z,B%31ZGBK/=I/D@A!!FXM4^]25$B3R+I#7 .F-GZJ![Z]\2O8"\_
M3/RE\'N!DG57C-Z83RH3I)>S/7F&57D!X/+GKS-%IT5MY8-CWKX]"S@-8"^O
M7G@/;BY#'P*R4.+]4@_75.CE49Q'I[3;=\P6?YY&;S6I*12P)2II/V]R'&\O
MO?S6'*3*:]'45,-:1O))WC*4Q+OYH#&URUZOG5PA-T+33?TEKM$. =U5J)<V
M%+GJ)$T:@GHMZ@IEHB&KS;K*-U=,7JZ2W!J&@D=?NW*69@T?9ZQ.P^90]U')
M&,AP'U.NC5QDM-[MOB_L[-6&#-<R1^@\WL]/%?*1N1LA]NX\8*.?B1!QIE&\
MI*0AS3BFTS66@3'39?CB(2 EK,5XO-9YPB>4;*#,=\\[U<L<,"Z_^'[P="J
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M9M-7*4V!@K-7P4$^XTKW#"<6'\9]W&MLKL5Q9"L,Z[? L6'9N^RKAN2=[3H
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MEQ= ^3!\<7%XF?WH9C/,)X\4AN'N*#&ME)9^H%+:FR +A-!) 6P$UNN901%
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M6"US^SKM)$6U*2P.TO.INMY2?"ZMYT;7F4Q>U1C6JNP/6GPQ '.+)4R!-GD
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M,]RD<S>[>T\ZV:2O.:#A@J?K/1,=7A;F-6\*7R") KXBWP3'.K <" 7?.DC
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M?<U78$>N5OF6B4=SBSJ&9Z^MLM/G6-6_'C^Z2)Y>I MWBB"&9I[?!B5IX@Z
M'RW[#5R@Y%WNKQ1!,,L_2*2?O_&;R?IGE:K:US$L.MS&EOK"ATOF@:#<]\ZM
M#*P$=LF*XHVZ'O70W;PAYYJ?F25=/_O7SIZ_%";>-ZQ8LE$TW_*'VD)G N8P
MDC.U< L>MF04'8ZR;*D="W[UH/"N2_ 'S]P"G;16U_1+%[OP#;OHM:9N+;UW
M9&[$5RNE9),ZVA&BM.9DLFKC0WEC^Y5K>SM*TML+A<7Q#Q0V4:!B21<9(@8W
M(QBW'0"<+N63.4MXN3MC.OY/HM+L% Q1SG6]HN]VG^P/,\\C">80W#-2%O6]
M.O0$F+!<VU4(5UJ:=JV-=IAA"\VC+6&RQ50]#'G%Z9S5G']J %DK2Q'8ZLQS
MT6H!P\AG?X3:VH1J'AO^&9:E/CL_B*Z@)C.Y%MJ[/0Z;]Q"+<U'][=W*%1^9
MOTE7(TR?B&(DRT^HI-]<Q_U<I!N#13W22?N]WQYGC:MQ)UI_&I[:*2:KAO]<
M-FZ'IFI!TUMXPV\JGP@O,;'_5EU9T/;0\%;-W;1S,3/9ET;*>#]P]45LRC'N
M7H6!9V 4?H7%3AH*242U/0JF&K1W<WYZ:5[\\/6IF)],I764E2(W8NO)7?1<
MQHP5"46PP+L1ZB")\]QQNS\39?S,C<V?3JQ5->H+O_+\'.QYJ@C.T1?!VIJ+
M/(* (L:P&#1>BM!] [0B"BT^$KG^2IKO>+F.<EGQ1'/=]G%>$^EL>P'AQ5?:
MURV?1DT-(PG&:%:X(^B^@DHJ0*921,M]' **BQR=BS8$A02SS.Y[JLH;I:G(
MG;4)NR"V* )L'IYL!\I/);6(P"]/(+AH0QIY*E]!A%?M^.^RZ8&VE/K!TS&3
MXGVH1E?+>?W/%:[O <X%A7!'&FL*V=Y') B5CCM)9([5L?*]?P?#\99#R[^Z
MHZ_*P4*DFSTN[)A\:ZS<9T_9>V 8R9KPZQG1CX0&HUZ'[XBDO<4N*T2$''VV
M)F2?/Y@E/?C@M)1?Y"]U:@1B!,()%R4J+-JFPGE6.#2TYR2=Y5<G)8_\N>G8
M,7I9^LK#[J0)>Y9UX[>& %()2;C&]4<O(QZZ1=>T^[[-Z$U.;,80*,-,01FW
M0_9^(ZEJ\[8D9GU(+I9@E_%'#4+^*WB!>N0.#>;??&+9<8AY(9PTV;DZ7-/?
M'\56EKOJ5M]H*AT'J=\1E,5%>MZ?.D%[B5VLA&S[0/?._<#N,TT0O2F\VDL9
MCQ&J\!/@'J&[VR9FYPJ1T5=P!\TP_*3IC*)';)W)5X4B]_@;/HR;:/ T%I]V
M +"M+*$I\E#QA8@6;8)AH[RI@I>YL9F3M-6W[=%+5[O/;#Q(-ST[38%0Z['?
M=EO.(*?;E7<<8CM%N#KI-'L/?[72X8OK%$4\'*-AJWUU=L,!WL#:X?U7@*1B
MMMQ%JT\J)\)WAG",RU[YQ'RZ5DE&G%FOV[:? 8MN"O4R3:L8KCU6$N5IE9MQ
M2N=4D6,DFX!%1.4V*#,"\A/+!P^+((FSM4\.! 6=/'&;@36KZTW:J,FJI1!4
M]9SXSS]+Q+##',DZL'TE0N<B^0)X74GK.#O*O:IZ#&4_49R$3#=(XLZ\>$J2
M(2C&L?PA7<T?1='G*&62PW!-F6PX_C>*W[X]V/97LZ7#W/5*S.058XD?L#18
M90*>@7P5?A1#U-W;W"&L<0F;?E!O#IO**(+=>:!_BO,FS^DW68D3&$%Y!!$@
M\3.09*.QB^7(FJ$VI+CA4B .V=H;Y<LY\0GCK[O[\ XPW9$B%B=U06S3)S_,
MVZ66[$U$KL CO3?+EC,.RXXJ*_T^FM >]%/+O"/1(^X >."1]$*%BWGKS,D8
M%ET6]%H)Z0T1C<\E.\'"D=9@/L&%U$9NKQQBUQ2QB/]M<CKO3)]FONJUL<!;
MGC+GSM<T'0#A4S^\/Y=QB?G ""8'0)*+(/%7$O+E_'HD,A&_A!GW7ZW]:[8/
MZ\LIE6M=E__T\X4N@Y<LT,47,$PWGI%\#1[5#(81]5;,\TT2+C=A+7T]E+[M
M+!4PP9Z?7^'5,-)5P"^ <M[=!T BK-I[<U]/BJ*:C5/R)KL,]FO>2UK9+K$W
MHSQ.1QC$%E#HDCE&[0#HQ6U 20IW(/M6OK!2%,$.]4>-+B3<!9\= "\M]/F0
MK2I0/R1=P->Z/"6R_ESNF+S9N]10TU%#%J^H YR56G-"3V"0[YTB@V 0Q"R4
M<!.*LUV$X2^N6,1),*!,$PR&'5K]XSH3"V"[*:)1"6=7NZ[_<11C9V?]@5V,
M/P"V&0_WO\.T(+1'$;#G4((5]H]>8-+"[[&K!\"8]0O@8=S]PR*]U)<M\G!_
MPE1<BY!O7:$XH>55F=U,HOGK^3M"W/TZ]WM&F_*O>#-E5I;./ ^XK0D9Q\[F
MD'X2T)O()3*'UF0K_/+*BTC-?(LQ!_,LPR,OWJ[]R%_C">A[C58YY\H:YP5[
MC?0.C)< 0%M"2ML^5SN>=>I*S4.-47O#9C>7")?37MF^>I3T+Z:*WPHCI[8/
M3YPZ>IW(6?(1,5NH73LN_D5+S<$Y]SV44OW8SN \V^;HU5_0^9=<9DA0G@N_
MMSQ4!Z+;95AJ_ 2]ZYVAETPWRZ=$ZWH5DU1+&9_7-'1+3\U!*VTI C%;RYBT
M&NQC5(W@"\_B.P7C27YO?VJ<>E67MPJFBY8Z+[A?G;X5K&V66<POWKZ[0[(C
M<,4C1!&#*"Z=TTN./B\K4ZY4O?CBGO3K["O[DJ<908KI@Q8MS,("E$+$; O[
M,(T7,;7 HZ.^J.:LT7YM0JJQVNR!M7_!FO!'DG%&HU0$RPV]7X"X'"-)@<;:
M1#:%!X.^[S)B:4RUR;!CX>UM4VQE/9-*VJ4-V5$1]R\LZUQA^%[B0-&@/F]1
MA]\"CQ.%:'Q#L16GNQ/UNM4_SBB9+__A$S@+K_T.&NN6[?=07_^.0G,CVJ'<
MZC]7%8+>A;/2UFX8L434K(4R<3XOH!SNY]5!]BX< %\_O4.NWQMFWO"<P@<2
MO],C),;7@FSAQXW#P2^GWWCF7>GSDF5_N-*&?-$5.2X6^YQO)PCV0N^0AO8C
MAD5LXW6,(<DUY0I.1(ZI&2OC3$?1*#-]=I1O=G"Z_G:EA%T:@^6+#HRHX^]J
M&NN+ T!&E<A':_19V ^I0?>B02E8.P0 MY;WTNBBY81/:./$]_C@6?O@E3#A
MITJKA3:V6>YWWU+D6#MXF_%2:@S[AX4T5ZGO:'*4<-!T92@)"5'7]L'#=1%7
MPB[AM!5\%)?K^*YU/@&L+WIYR3*^ZT0@*?##0L!PJRF*\_VEH9DRH]K1&I.U
M;7_T5GG:?%%D4*WS*=G^)"?JN-S6F#3O+<0;NG@RUS%X%^Y'D@1S@MYHMZM_
MM1&\]J-K^NP6?NDO",E%PP.Z9;N"IO#D?W81(4+Q LM< C_SB',NH(6A[^Z2
MK(Q"RM-LP1?&>WF2/PIG=Z:8@!O#!\!B&:RNF\ZN>&9;B3#SFHDE5^GL;NM1
M;+5LN!UU?5[@\;O%N-OI+>_]]MFH3_]V#"$#;1S)=K=%-IR_F>77Y-2DJH"F
MH&96M,L)#4+XJ:P$]M02(+MH11E46(C645VVF%'9Z2IXT>QM1X@O<E>/:UVV
M%LHIKB&>^?7QXXG\5W(E[Y-!#(T%N2Q^'2H(OTDHW//7BE+2VO.^9?HZSZY*
METWQ^4JI96%,],6,) C!&H537OJ./[V,9(:]4 D\%N[>F=\(KR-,GVG,N5:)
M]7'F-<Y$_'YUB9'WV$KAT?MZ4/I++J?-%"K5MQ Q[2]$N%C#S^+<Q;R45/'$
MU]]7'9_UCF3V/&"8EI)(5EC&ID2>3DC"^M-'' RTMHE2LEV6*?+5*A-PY]]O
MSJIG>L Y>4&WC S!@!&+419'D&V5-</XDX275?X7?)-XR]$S)UC57.Q6?&\:
M_/XY&0U5@"ZB4(2; Q:D%*(KJ$HLZ!JZ3GS8H6+^%C:C8!A8&L'68N(BXS5S
M07_T2(G[^PK<8V#A\*/X@P-@96>QFQI$9-X9^[D]1 J-:#Y*]J'HU0R_#7-6
M[19YF*PE5I,I;N _]T#K3U9VR93Z/GUDCM*);<90+.3W4 =DR.(E5W8+*[+5
M2$\&SD5]03E/$%J$);@_Z[#)V1 2:DS[QA%Z__Z]'4D'QZZON9?S(QC$]:]K
MHBZ#%^G/B:>^@FNNF/&#0QP)R3JJBLO:J\DCBENN27\=RQ9,N".8ZK$9K%V)
MD;^^M']8'AH.1BU^@I!N6R1&(K*87*2)QXJB./"TN2G>=O^S/:_G']BH,VK;
M L\KF79@F2B"=1JCZ3#27UE0(^MN7M'-FC&TK-VX?,WV[,DLPCG-B\Y?(O.D
M"TU?<OWXO@+K\!MBI@TA-,'JQ:=N#0TC%/52/ZW@[#/ASDLU48DG\N7MC[.:
M]/2@>X9 611^CW@ D)*IKVR7L!WV:D5%YF]=YNNK*QU]KPUOXLSBH?,75PK(
M^1TY_2'T5G=^:JB_O=U/R(FJW+"O4<Q&O,7R0!<SL-OA]Y#3S%8' .X6 ]F-
M'(R8EQ"F9NPZ<D LQL8Z7+2G7OM^"-[+[&87W+CZ\"U]]MCNCRD]%.$,3\Y(
M$1T"0?E _-+RY8AE_V-F)FK/)(>TIM>3U)^S37$IEBF4,C:9/@]17SL\*WD@
MZB9=G/DO2,S"M/\*3MQMTO8(HGWD*6D]P[8N8BI.#TQKJA;BBP1 *&G?FIGZ
M+,%#^/3F_(^R5]/],IW.&)6OG[,M5!>! =5J5=Z+0\4 XBX=50FWYBZO)&2H
M;<7"Q&J>Z2K#)DU3S":""41'I\&R>@,=%=4_#RXPNY?Y>[7=O6F$]/7;83.@
M1\AUQ*"$,%A=0H$-JZ-Y[39$;#""#7Z> @/9T^UJ0I)K%RR/YO]UTHCATI]G
M=>P!0^K[4?^!"E.6#POR44+ RP1C!_#%?:)WIXV+4(8M9M1F!"WV\NFKJ)R3
M3HPOFJ:@EK"B?[CU,C41>MO^ +@[=[F3= [LA$L= "QO;&X*^C$^_$ZM?"O\
MN9#C&1Q-JBZ<_L:X;PW!H#<?7(<NW5VG0^A8Z &P[#>G)P>_04"WP>(=#H#.
M#/[KUQ.6R">4BWWN#<B_7^55S&3KZ[2\"%1SZJ]AN:!+7?D+N_9TCMM&?\#V
M0T0Y;:*:PDG ;/9^]$75>.R8+GI@JFJ;TB?F%<IZW?(T8X29 CYZ1$A:U9P3
M-?AZZ=A)1J+Q8?W!,L0,2H3B>W\)-?.]E31Y^^&6K[M;B=F'#3-6=V6%NF]W
MO=?<6$M[F,='"5B*0 +I$VBX\IBPAV=8:GIX72',L&5L*WAR5/W"BNSI(IP4
MZ[?@!;XSI)].L-:,6<=6[-%FSP^SB$XD<-K9&)9\07A#)(U4&Z5SKL%SUI_E
MV#DSCK[TF9.>Z4?A<^1 N"NX140OZZ4LHW',2W3-KT!]P''&W]]_\$54B6YG
MP9#"A]3\C[_ L!#V>I?SJ<D K:E9EPAM14B#;F[$Y+$;CDA6V _3<K:FC#E%
M&V4N''MV[)Z&<7_LWCV#'["A[]U(4#&A\V%49YB(T.;JZYGU??Z@")LI#&EM
MR[+Y^YWZ1$PN-V+D2>B//*9<">IR!N_&OC*%YU+?=I>OX/)/DZH*7_[MNIV?
M9YB2+?8<)-V[7W7"<^E!Z$Z0C=<Q)U\.S^G4PM?8ALT+C;#C'O2]:G[W2]:D
M()CIWOJS3(G6H46&ITO8P^7(?,)"QST#HI5YY932X(Q,Y7CPV%LG-<7(#D)B
M,N\Q@8*+0M0<6 E* AN XKN#JD0E8'V59]*Y5*TF:E,>:JT-;DSAJV8P^><;
MXDV&J=^";Z)',LLXA6W'D;70S3!"$:EQ1,T<LGQM:C^X\6C[D%]$<3./\]%<
MC=[C$8O/(ZZ'5MYX^<OZX@;GU&83^6PX%^D:0::(L+<T7_S^3F1 <6GONY[]
M#\,#\D/2YR^ULG-_?A7:UBP@>_'[2P#2M;J7 7>+( :L+#\<OZ-CK5>_WUZ2
M?8D^G:KWUBM\^\TXL.*]!!N#'G[,*:*^POJR82$EW=IR>+=AOFL:'(*%DZ<*
MOGW]\SF/#/*4B&-%*'Q$* 6U5GX >&H@J;KJ2'M(S59B"/0XC:Z=^)O-7S=U
MEOH6"DV>5?J6$9_NL[EZYN0!<+]B(0Y Z"(FD01;?%C[O,IX"X3VA22H*5AP
M"^VOAX7'KP;(I%5T#0IX6BCR/))^UIYNK=\.R</3L:CT ,"4M,\9]=\B;@I.
M:6@F?$E>L!GN?&[5W74ED'6V >")$5Y)_78/'D4[GK*HS $WH%921-V7R\*W
ME-2>-$](Q;C8F#V[8+]X86NUMTY?"_Z<V(DT/-P%$PB$>R\S;\81);EX';L5
M?!R<]CN?9+0;1+C&V\V)EGJUINZ7Y>KPZ0M"W:&SD%98[0$0_3%D3G)\O45Z
M1.1"R,,SWWB%)?2OFO$17(Z?:[6+-K"Y>>%H"R<]/C-H\R@(U N:'@EM7XBK
M]JWX88N U(V_(3NC<*=5!T)"^."=74)W%:*9G:8.=^080[DW(FWQWGHI/ELD
MW4!];/(J\U<]LTX552YKC\^Z1LO:!=.'B5UTJ309'D7K9..BGL6^9*-ITW_L
M1(PXD)Z^7,=RU%"A1I]BNF;417\H":ZM[=S8[L9)"#\MD'NU\"*I]J_HXVXO
M8G>#2"1J@YX,HA_)@3B!CMEM,LO@!S=&S5)2/ET2\BF/>V.S=J.BR(@]?2>]
MA(5_];J1+H9V?(#0_EF"A?J$PK ,85NWJ1/!)*GU;(6(CJ>*/GNW)EV9;94O
M?^[(Q]!28< 62PFA/J=Q(49=1&L)F$[JT9!G9L>OD:H4JQR_.O:TL]\ND+%E
MB&;(UW9D/+GHRO@-"<ILX9^N('$KK32EC&6-I[Y^'T&]Y1&)M4X)N;-N+?;7
M(M)F2#WQ@G.U%0:P)T&HT61BX"-L]4*;Q4QW6S:HO23XN%$];KQK>2DUVT*W
MH^/H@N)HM;8KN]S@!"28O8!4 -#\L(MU=,!UU(,@IS_)TG+[87]I(MC!#(*M
M&>A.'+KZ8O,U4<6LS*?@\<5CHN7R^V814M+$-2.B0M;PFY0-?2J=',7,TE_^
M7?#A 7![%[5OJ_30@N!-\AG#WH&!IX5BX$=XU8@<3R)K:0D/0 F;5YPE495L
MH>F>,K*;C &M\G*,0\@[!P!X)B!N!3;=U$["<@7RCG4C^92^54PJO43.^Y[7
M9XI,>& [)"W-M#VB?>%4'I8+;D] =>JQ@LA%;*++R93-282VT/:/D7.21G65
MV1=2OT/;I5-;=2\%K+>UQ%!?0&]GI,*$6S1]H!S-%DOF[NV15_)/__;[V72B
M?*6N&G,1=3?[).Q\](SP][/]LS(M^$-W\A'1C%//B*$)$_!O0D5LLHI@. ?'
MCO-BY_1)/T3D=JT!5H!ZF$5B1._Z7^M8DN $<C<$>1'%UD"MT)'DHG*%0O:#
MK])2Z6&:A=WVTE*FQM7"J.*PP<"VK3\Z$)8#8'K/[0 HN?*2"P_I<.$AE*3L
M_@C.$/2I<YA(W;AI%C7K\^MVB.YEZ>0^XTH!"@;9:GD >,!8: -8WF"H($6U
MAC9(R$]WKP^IO.F@K3![L_#!%5-I0\F^C\F('_-"K/Q<&WU8 +N(H6F.>,#B
M#@!.UZ?2$ZY:\>_N"Y]LOF$B&<_;7LJKTIOA'!^MU_"WD\OL)EJD:'WWP\.<
MGY8T$F1*]#+8TSOG/I",@P*.ZRR?5[A25"7Y"#:$PM,YK>Q#8A"M2W2!RHGU
MQRXF2T":*\&C*S">P?3,C1;)<^WUW!^5_-V^]F]HFMS*FC/!PY*@&&7*B[W.
M(;)P(')7"Z#UWE5S%G4@O$6Y?9AV7,#U^[(VV_)(5U:<CS:P9>(V1.I""386
MT]U+>VUFXJ(K4VW.,N*,UR?0V.H0?XT1IM"D(,5 12'N#CV[6)8Y<6ZFP3;@
M=!(M&4X/>TD:G7B[5!P ZT>P,LC%ZD+-D># F>I+A"L[IR::C=$&TMS? LFZ
M3V[JC#Z:8AT2R=:N?\E%Y]@Q<O174#N40-,&M=]?&W,,=]F8O3FV5QEX5NF*
M277'2^JX_2E>X,*<E$3)<\@LBL8:0D0O!N*/?X!+@+;%OC:3$H*.!D'W2V=[
M[ZM_G=(@?GW.(.TF:?U$#@B0%IR+ >@48#&A$-*<TX$5:+YE.3G)9GZV1X_%
M*-M7-O/1="Y/ZOXQB=K];F(W291: /7)$&A?R4B6$- LV+1\HQSB'W+?:Z<3
M\M6^.4&?;,R0^%4H>AH .%=(#N!($/DRG($0UJ4P=S&X#,OC:#(EV&/7E3-K
M<;KFK>Z"9MX0CT>OK.\)V7=[^]_AIY>4.4"N=BWO6#BDQ/#->H'.<7]?/V!6
MS-+HW'NMG U3Z9QL4^F"]5)&L(:**=K!WH6E<'\7I1B'-^SV+S<MQ!9J@X_H
M/.$7M<*KFNAT\^YP(.3JE/_*8#]>_D'Y6@>GYI%G9T\.JER*C3;Y""'1P3FG
M'WQW +@K3=%2T;@%4 &VF5 *MR*DHXA;2UVY2@= <K/*.^]W#K@KHT-1;WL.
M@*:0*T<+S7Q%7YXXW\1[+_H&<R>68 W#;72O9*0&0QXACZOS? !MC;:5 [RK
M9$Q^BU_?..=V9?;%3Z8'K@R3QO>,;MBNHCNQ\7HG074BHQ7HM_PIUGXD;]KY
M]0/)@JCP[^'5PW]]>79<C%?E@OI^&;TKU=249LMEB]0,8LKR5/R66IK0Y[O9
MTXX;&E6.M?/O*6T;V>^S\SY'/,[XX[OZ^T\</(@NR 3I_9HX[)>;,'(W6P2@
M89H%RGP;F=O$F9TGSPJ.ME\?+@\(D$'PRKG5VH8%>MXP17\.3,02;#-PD&7C
MC(S'6"\DRRS.?J[/=>QU]J"YE5V3V_,+::+]1Y\$;$]J*@PZ-T[A21@DX0 P
MI^;+-(#EH8IPL7D^NQ#?L!H/^R$/R2=2QCM;GK??57]7U(<]$Z!L@+*D>FIA
MRS&*G9XD-5WOJ/-7/W]^DD98P6!96(3.R!>CK;-MRJKNW)^N?)@U%0O2%Z]!
M$:RPLPN+"<GX76S:/"3>6"KJQ_Y\*LYIM..ZYI41%BXRNC9__+!RZ!'*?<("
M_CC!W0#L71)^@ZF>Q'\+Q3Q[JO3K9&ARN%VJMT?IYW-=J^V<+.A5NN);I[Z"
M^F9DV$APUE-?M@@AVQC\BDTC@]_-7AU7(S7N3$)TF?(_]I]TSGI^4GA(UX]D
M13O.I59%Z[KY)MW>;4K]EKX%:['D7:Z[= D8K2=#S<8N%J-JL%W*_X.]]PYJ
MZNW:A8,@"$COO0M2I0A*BZ@T$0$+58B*U A1Z0()@O0. HI"4!!$P-!10$(O
M(B =0DL"T@,):(BD<,)YOF^^.<\[9[[G=_X[,^^_F3W9][[WO:YUK;6OM1;J
M5H<49P3H3(H.C'?IE<;)QK<UU]UY#*)J(?+W/JZL)5%CJ @@V(:1UH_D&.]U
M._.\P15T.[.J/E59D6<@3/_SJD*"@4P*]\-LG[D<@* 'R]_CA,\S.H:O'<L_
MJRM@ZXG@;2Z2FD-"D,$2ZDJGF\CK>9]#4"SF2YSV0<16RV"F:C)MKTL4?J#$
M^*KUN%2&MH#D#4H>1,3K-DX%3\UDXG0BA7!;IUU;^U[[2[U].FM[XTE:SF_@
M]C?ZF8DGN(XD_SX",$/'GP4ECD%676"XN5.I];G^V_Q&$PKYN@E\^_7W180*
M$&/(JTCT*]H)_'0TS#V=<<G;GO!A*3$K\I9MP46?'8_7/X6 OX=U+-K7=0]7
MX%T:=!X>9:B-MD$=V,&[= DHC<3?+48/=BY\ 37>V.M1R5D7M5&RF-G\X5*N
MPT!EI\TA12-<\6)$-WI .!)_TT6WX0/,*S)G1VX?/1<2>;)%T[9=;V?%KW7Y
M@N$TEN4%$EV[5,^<@TGGZ<-6J5R;-KP21+P]NB+8NSCVDU$1];! +L.PTCQ7
M[M)MKR=JO5-DE64DG?;R'P$Z1.J'P$XAN7O67%UV!@.#R-D_!A9W$G><;,4+
M;SP%+X_\XY1>#-U:AZDEQEK0\>-S@-U-T=-TM2G;')USTA%,!'._:/_\O06P
M%.=?DJ4]A;12 C \;^>W92&HX5O@<XR==,+]\U]N%X&3^__WNG<CU.E6WH%/
MIZ;_RYVCE!C_6A]/VJ/UM_%0WT#EUZ%J)"\?:@%&0[SO\=:#DOI@A\8/ABL)
M619)ICFN_-3Q5G5^):FJ);S%;K)H4S=L]H8&YU:=SH$;T\3:*"9SIJ6AL'_'
MKT/QK9F"]\O@J[8J*Q 2'1!3?SL)86!=K\Y8GG?D?/?IKMDI#7[>4^]>5&\R
MI=2Z3]]'T"/J:+7U)I3Y]N[RB* 54YP!-7+L9,<).R\?'@7M:369NVG+$A]/
M_$LJ=*>9='XYU0I]T.ZG-6(_'>@ CKQEC^10JVKH)^-=NL00K^7-X[W\/J$_
M]W;(+8LA2$K3%/YXS [<;QDI$1I4C%\MLIT;JB#YNE@;NRXKRWTQC6K$]'?'
MRV6"\B49"+"4^%XUN;YFLXQ"#8+%9-ZMI-Y5E-5$V[?]B&U+)E,WUY$!VZ?@
M/QI8+UPQ?37LI 8\N5N*P] =KW7Q-X37R=KCJ5!G\\BK"F6TI4C8K+W%')>8
M@('K%?<D #6*F@CS@['29J"<$^HXNNF0S"E.F&5>WWSW:PJNM3&UV 629^SW
MZA5F,S$7Z0J]51BNCGX/.>H'Z$G:>*$.R0XM\OM5H,3)2L&9NXZ)'XX %C5-
M7Y[NW'VXFU/3WMZ.$*5OY.T( ](X?HY86]="T'O^!\=G,?D[TJQW=?/ NKFA
MR:3!G]LPJ_>3MKPR0#$K%/$&B"Z#[44L\2&W2NGQ<FF%/N"P AM"$<@F?B3%
MEON*IK=K<&K$MYXM4=*ZH;.+4RDJ"E";2)&/EIZ15P*]?.Q*R#]8FHFGL=5A
MEQ*. +PZ\!=2]48-"=G=M]1*WU0Y]1$?N5D\X=>S\U>Z6GE9KE<(+'"ZA'?P
M$$<VCC# >W791$.Y\9#HWU\"%Y35U"=1\G;D6<]89R</(S=+X:SM^2SPWU/4
M3X%J0 P0YT'@LL0KB49^?HXU>%TI*)7CUSBT9I:Y7)10\,G@Y(DHX <8Z:P4
M[BQ!@^A*.EM$6L:XS_9]VH1*QUCG(*3)ET])3FUZHEI>,B^P[07T@O=NC-/8
M5<B7YB)TOXYYCOUN&1&[NV1PIH38HJ96:?BQ4]:E).;'V\'6W( :!T9P]A[U
M^*-A\:MYVF A^Q<E=RU2[1"QL*+E1ML%X+4]+I)L4Q<7P)<F1!CI_@:ZW-!&
MT"TH[_#P"3=\X*16M'>UY$J+K*[G1=4B3<!I](,HXP7J2YCO4,!M:G(9]0/0
MQ\CR@?ZCYI0F!]9'N7/H:(CR*6SB"16#1KF4H!!IK_-_P=A=D@H+SH\0W[L7
M&D!\@G_K',@K8MSGX55F7%=AQ7L$$(_AE9%^>OGJB36F)F?R&QH[$.'K#-IN
M>.=C?X,PMV6L5!>WCE@(?=_07. .J4Q(,QI#BB+=N5",Q)<D=@@V?'=V#?-#
M\ERV(SAT%R%EUC:Q$G59O$36RE*.I\)?]385R["MQ+AMPP#KH)NK#_P%33^Y
M<ZG^"!"311R3J CW1X6O'TXPU"0*7F0S>WQQ9E1]9_@;^%  OY1.D<,NG7",
MN/XS2&DG0J_<\?,'CID+-K7U4$_B3HO#+N/W#!- BL->.OEFZ#3Q._6S1BOP
M$\6*I!%^/Q(SLQ8GEJK8]8Q^9OA_B0V^+O5I^J25+2R,<CT"M(*)+336%O2(
MH"^\^O<2F[&B]V%ZO M.="I+IJTI:PKMM.1Y>4O\>U63'B?_L@AS%-#(6(&.
MXRY' .^EQ", MUBG5.T1(':YMO;+Z^7Q!X)<G\!ZGXH*>@4TA!5,8&IR#XHK
MJD4^^P[2V.+)3RD<A,C&3,(1H(MGH1BPMW'8FW5X?KG310P3.J7JQ<2LV?P'
M3?QK@W78'B4[0;M@?'R]SSS2WOD< 4Y1$.IP;(&L4'Y/<=##^3$_CY1F08>D
M>UJL3%IOX29Y-#:ZW0I"=)2 X"- G+-BSQL)KB&K\)?:/OHO5)[>&I:I>GOI
M[][$"TT-.8:\XUX85670,1AGD-1L'TT4JE<0(:_C<S[W<@4Q(Z,"$N./*[TO
M^RIJH1XI5C,$Y=R2.BZONK4,2U4W!)(-2#=5Y+NS7&9\GKELZ4<UV3/^*"AX
M>*M)6EO5(L9P>BL]GL*"-R#F4V-WC<6@PX_RN:);;4I=YS8R:P=HS\/6ZK>S
MB^N^G UDS?!_%'V-]X,E[8DZ18!\G]8.Y%4WM /?+R<9V#9P>5&K3B)1@14S
M$CF-K 62B][SGQK[Q)XS*E=> )#!Q]E#@3SB.Y+U,HFB0K8.?6! 5O)(/2_F
M4[\Z%I3L."<2NDQ%":)"F++.245)F Q!\100J1@8#_/B$H[PQ//7W!TL(SF3
M7<=6<MB[5PT4OS9Y7H^^C;$4$1%WV =]@"X".:#G2'/7C[/?P!B4>=I*DG#]
MP53]]-=J9-RHQ+Q@DU-KXO?ZE,>&Q3$I^)-02L3#"4/&3]#V-KTVTFV")7K6
M6-+WBOE>2!CX0?/#Y!//%8=UB]CNT.Z9B65X,^XC:*PX<B3T)Z@>A&,V%HLP
MR;LF>AWE^F>#K!#=(5,H\4:X%BFW>E&""N[& =$?@0V@KG24I$8<7-1S] A0
M\UN*AT/C+O<&5DAP].Y?/=ZKY.%SKP,-HS5G5EM!M%-D>CP:ST*-"@)2/[BF
M4P0-T @*W=/7,^<1O*['>+XAL'6+S)KQ^^H_MO#8:%]@??[-J0GN#*"]; U;
M-I+"K#UO-2$PND8V>\4'D@O,T-$7DZ;.Y$0=R#PVLH:>IO4A\;8P%)W39E.+
M*6KXWM5(637./:S5M^M=98!1GZE/'CE7=A6LHF3MMX=+*VFCR(9IBH(4WDH#
MX-P5WM)=>/%<Z-,CP"IU9X$'.:X "8MX%<*Y!?P6N(0W78I)+0Z]T@>OURWV
M=ENVA6Q;:Z=H1L^H]<R"[.3CY%G(H]5%G&O$I>..,0L1HH3>#_APM.YKKPIP
MLTI#6WD%*"YW"K4225+#I$[_R)+KJFN<?.S@?B^3D$IWX& :VQ7\@4TC82FM
M57^4%&"KY+<Z23FO5@I7)^3PS,NVNSQ>>7 ELQ\QQ 4@(7NO+ MF+B_(6=@(
MD4I\!\M[W /\%#9!;G_;@N6C91'J:RL?+YX_S"-H$X]+/V(ISJ1(+%=<H29)
M1/Q0+U&UM/8K.\;5Z\>=G,?R*:W;%?)^\:E)!9_?U?0 H.W0;F0C\L41X!&0
MQ5<H^!!&D:.IX@F)YZTU/_!^GC69?>)/T;[\R_$IHQQ'5<:=-[A-FCL0G2/%
M2=.AZ%(K*W<HUNC(\*MCYR.E[&J^-G\;]Z_R^^GG\H)+ON93R@!;%.M*H<IA
M0!'7:@N-'7($4*C#'%"3QV ;=QL.Z5#"5-$4O4R4Q-\-Z*V5F]_$Q !,I%!\
M?YB16O1P_-\R7V4@_#707RTIIB/ ]!2"3A-9UQGCCTN%:%U+[%#%"!$"L$>*
M.10Z?IFP%JNZ-FF_V<L?@\,[E^=BV5^F*'\?$JU)[5<75F+Q48;)'D_KH(/4
M>0@ .O7,(>;!:V2M820XH'2AYTL"948VO,(G^+<Z@B?5QK965W_Z=R+Y3NB2
M*2F(K$>Q)'A^T[H" 1<M]3[O/V&5G. L+"N"?JT0=,G(&J:*Q%N/<"V&)A,G
M21X0[[1!CY" <!6E"Q8XOS,O<^6*%"[O3V08_&3!(2C\9&(;Z1M93:^K AA;
M=H.'5.1;%48DFP3!:\1LE*153QP!/C\XEEFVQ5-?''=7$*($4%]5&6M0[+\T
MI-NZ%)CZ*S2]<&G/)?I?\HMZZV>2%0#*1_Z[OG*$QAJ.&00*T]K+,1*FK]7.
M#Z8&]WK:M,I]#4E,&'DLC(TRYB ==ZV'4(NABI1+D%/009I0VO?O6*]TZP1'
MX_+*Q4_1(<*W6^_EG*34IR:E?6[W_%JA05*6P@WB]7J(*/.^(\!I\^ 4QL&R
M+5&K]>ETUD>0V&7'FK?<PKU;TS%SOX")H#ISG >9@W+=1F0C5S^VC"*WU]H,
M2PI,< ,+IDYF!U@VY&JM.[F=C>J7Y_[^-)(91%("4YQ:?Q91$301;[C@HT#@
M>;4=VZ&23>ZJ 9L+<8U/&-<&;W)WMZ8PW\V^)#4!ZY1*,A8E3>)'NI "AM(/
M:?T$A?>NE^L M7U9=Y8S3EP*G=?2915A84H#$PR(= 8:C02W21)R/]"C=Z)7
M=<V7^K$/X3Y_R"MZ*D]T_.)T'U<HA]U+895?%'_ZB5F82G5?/@*\L#_6>*8+
MABX3G1,VH/SCK2J(D0\NO1(>U<V._O(Y#YU$9A\FH>OT?IB0OU_+4?Q+H=_F
M 8F]"\0->P1CGB%]6C08M%;0.&^!SLO)6AT6#.4T^/O4+X,3KFCXY))D%]TT
M3II3OQE+;NHZEZ7?:_Q:TVK\T/ZP,4X56VBL)1=JO] /2.'N$_>2BR%7D45H
M,S0V*H)R,N#SAF"9*>%,PFA7Q8:-=$;[WHF;CO!HO&4<6_<)MMK,=C40C8T#
MS76:<HF:T29O@K4*_>7';@5WK,TD>6NH<@^*%0>=GM&$WWE:%@W&M]!.K6$E
M;*Y1*]=&_21H?57K0H2[1>3X@=!2L_N;E:]8/LZ;!UR2LJ#]$ZT2UA^(KJ3C
MO5"/36J;*+ZI$Z<[WM4F-'$>+*;)6N\R=!DKXI5V4=3AZ7H*.DOPO)AVZ@^S
M9<(NA7^79O,&&T(-'$/^GO0"331MX_!=[5)L-)Y0D DI\IWS>FYZ*<I*J2E%
M942ENW+,6G$I<S91X6WVB#/@KR*12D4^0CX$2^AU2G*-5_U9DMJJ%OMXKUF-
MZ")VJ4<P/-;, ::9DWMA,L_ *1D @/2GGZ8SJ9M'  A++DQ<5;?Y"!"OL\'0
MDD[FCHR6F2C)$\3(I\=,#!;FK,#PM_T>' 'LJ4TT&=-GV^[C>58-36879WDW
MIG9C?Y_>&?GC#AH_ FQ/HKG82'S$8+Q0-,7(@\W'YYV3"+_TV2<*W6S[@]*]
MPC^V?W2G6>HP4(*@HTN":L87*7X$4$^+&,L8EF#TW34RUYQ71_V!:>#B.6'F
M6PW56N<L6)Y3/U L2'D8J1@D1P,LL<V@E<P9B]FRJ9_O9W9\'FNQ?--L0_[I
MQV3XZU><?RB/H;-N3/B^+B J&6O^G"+BJ4/ELYHL<7'QD*_4[*_0R'V](ILG
M8^[1CEA,)ZDV?BOW@=6FQP?^2S[(Y_C_R ==_U_YX"4I+E(+C:V#[!)QG]!:
M*$Y]&Z$H6, 49U,SZ[0Q4KDYUHWLD^Y.L!#/R 1\[5";:H@X>3SUE5H*Y2-M
M:K!#QVF<5G,6P56X%I_=XBU;YEYYQY6S(NUK[E=;6O3_(-*. /^,O:N\HY8;
M@LD>T&FA1:E)J )%Z%MU&WX[H(NC-QOS[2:K1]+3U%\_QG7F)D4L4T[[J1\!
M%G48J#H1UTB#?BS;'5A$.H@=(3WAWH2O(GXK&=YT$_*N7,3R;F0\%@:L6TC_
MNL$)QLMA=BF"-L28T9T_X<B$_.#76.$TN++/U!3Q_:B0K5?Z8%:8P. K.\/.
M?J2V1$7.@ ?9@?BHFM ;2W=M!20X!B*YGG?(L1/_GM2V*!9IMNCBE-K:6'LW
MGN?[ISFK'VAQ=^GI7TL4WB5,7[3Q&;HGLL]<QDDNN8[_QND>V":A-B+Z.7XP
M,/D3X#F=._(J)[YV]-'#0B<@.O\(T&C>!T?%]-!IOP>I0:VUV3C1W>^)CT!J
M4@?_S4'5YSEW_4,,'!B<9@A;V2 ^NJO%.RVE-4GQHR?4#<_3(_U./K7-=V-C
M(M;H.J\^(6.(]HNUX*%89(RXP^\J" 3BPQ3<6%-YKO,=#\_E3Y]2   T0)\!
M)$@/-3H,D \-;!(W"+Y<)ZXV3X3 (8[0\<>/!+>""=+U^X:%8JNL38,L)&]&
M7/[E3TNAGKE) (HX'0RQG](Y(F2E&6AY=#18;[GV!T&2S2^GOC:\:\%"4R8C
MJ'HS#MGTOW^"7'$FF1X!0,]&:,D-_S.7<A8V4!O:0NMC/[[(EF4*CK?C9MEV
M(-QF2"?E_JO"& .A\"S?'M=)1S79?9WTQ]3&MFI^E Y;<9RH^5HO?:+[-%K2
MJ.+ AL9&#YC..!$<:!TUL(W;YRDET!%X75\W".75=RO"@/0@M]87[V0%[=R#
MU?6M7"841Y#\ V31[E-1P/>[)&5(*M++:G<V&S1&L?KH?5B6\@M\O\CT=/70
MQ[Z M5YG"Z)@UH5N$TKGXUCHW5P/EGT#VJE13"3L-O5C$(AOYNKRM9\48&!3
M'0.Y>OIF=T9W'WGX3H'Y$[%G#@/P>JYM3;(Y=$B?WUB5;N&DN.<Z Q#J._<
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MXW41'0;<>8H[;?JXE+C/!L75+7H;)*KVH-'F]"",\\VOF8;<];70[M<+!T>
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MV)WAN=09I1>)M21_QV(7QQ:M*LH%A67LP^2#V1*2M)P2T8"+\K\1:V(T-GI
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M?:-\'8>[*\]M]=D$;$I)@$Y8'X7-4PN9&(\<%9-JG;@T06G2;$.4 /.-*"W
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M#ISFG?;+#89!F-B!1>I@G(9:N"76RL4_X6VF;:8%$+F"[#F'=A\3)C-27G&
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M;N]-'_WMR467K5D_P (:X'"ACJ)N-WMP4+%!%#-/$7/+]A$L**@\Z]_#<3;
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M,&@Q4',+I]%&$'><[5(JFXH\-^VK-_>&\UO*^<1SMZ]V%$L_%!<-*0>LN@&
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M>L?#C,1!5[O5]^:L%G:9KCXXPP">%6P;%\^E]8M%D%X(J(0FYXS%+Q.536E
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M<OM<8[[[UC:+!#,2-X@E)^??1EO*VOE\V5=](!P+_*+<H_]FSY\TH,D%R70
M$:9.B(W6O_$JE.TZOM&"69@8#O:[+^%5^=WM:'7_52.SUM'E5H+-!)67\@+M
MAF+P^KJUQ O>Q^YHWFRYAU\TKM!W3WRQ=N&16HX14_!-[@@Z"QI43J,!:S0
M8?#W)O\N#; P=YJM&X0<R19JT!=1JHP&E$[8Z&INKY)T[X;%DAT"\.C>B:V&
M1?'U*?$K]=XM'>[[UWXX0_YQ54-\/_1=' W\\OA@NN8_9:.,C45<72\RFVA)
MXPV!O_T6\5=WC_0LXFG P8@M#9ATF([,H5OFH9XPB.IW9 ;#"? K]3F[U_!E
M@R6>;V%7G3Z:Z]LWJ77I;3\I<CT;QO6)?5B4XHJOVR;ACW>W[Z"38'SXV3X]
MJ1D?Q@2_H!VQ3Q.;)TX*1&09\+?_,E+X!HNYM#);/<:DJ3+L$R@V(E!Y8[S;
MU?5^#!N,U_B&/O0SG'Q\DLH!P5D\#>GBI[RLP,=VM95O465:6UK1)'M[<X_V
MFOX />>]4KO+YX49S[Q:*3R@Z,VF]I&T(\=:_GQO35P!G;%A!_D7)S8YI\<?
M&GZ^-=@S<?L?@P\.MBQ<;-(I3_.(5P$RG7#&8)$?D_%5U-X[*&IB7$<=>-*/
MG#^6BM[VS*(!)C[>!T^&H%QZ8F3SEN9_%6/)#.00STW8#U79VB^7GEOE&J_I
MU;JIWR/#E(3J@?-T01$7)MW&NR3^9EMJ48&J[W/F31MB!D5/*;QQ^1?;M3+"
MG8]B\6<&(N\A>URZ1 9P8W,H<S"12:<.P5G5)V.:\J)A"CE>Y@0*#"[0@&[O
M[Q;@2>,!C6:"?#\\9K8Q\A<5PQWR2<V?*6=;J?:=3F/U\R=8N/)/QOY"$?QL
M2I-9'1>(-FV:O?#D.V> *Y(IU'I2X=T]V20KEWLBQ]0@TE+%[YU8R6P@%+]O
M*W42S]HWQ@.Z6_$U7=Z]]J\KAJV#:__O%4,).C"DDLS(@B"*Q!DY.8*S@&"&
MW<N_T?4_ABHT]=EPQRU6;K\XH?[(#LMD?,$]*V75^0P\A&Q"-^NDEYX\:/$&
M#.R)/);?MZ0V75W:I$T79&%G7;(YU ?>V\X8!0][] EBOLFV+&C^9L7Y<80Y
M#>;!EJ0(:>GNM1NA,#//"#_)SQ#J[T=59\B&89*MVTXD.8Q3;1EKKS(7>W8K
M-\:A0UJ&^K+A!8W. QGW&JGL-C746:1PI*P3PAPL6(7P;:)Y@CK8L0F;N8$C
MGA%(1863O0T%#>'2.CKG0E2L8,V!*/S-Y51H"VK[@#"Q:HOW2VG6%<<.)3YH
MB3A1LQI;4URH&)3V8Z'#:,!%3<:L.5WAZ&Y4 .78QI^(N"QGEI=E]H;N[E[)
M$BJ7DR5N%*<H%)]FN,T#,!ZKW,ICB<5%G(N ]+<'M]24+YZ;J_'%FJYD1$A=
M9%2$/#C->/0)_'LH=AF4)VRM6%>LC"4LL\*;.CV?E ][,T_5^,DUEZWV6_GN
MK"L2$SZ9( 8,+0/V<GM.O:\#95I[=D7"DHGQN:M,(;?ZL$CV;XX&<AOB]W.(
MOU0Y[,_ (Y[Y3JC<W<%TU+<%DCZAZ_VV7[2B_:!L,.4?ZUK:#FWI5,J+.1J0
M-CNNK9=: CXQ;QT/XA2YL*@W?MG QX>_C\M$6\$H2B']'OU7<M(7DHY9P_N(
MZS2@-L^&FE>]=3A"_)!%?#9)QS,D!$01'T[57:!C0]AC2;4_.P_Y9-^_G^3_
MDHGED[0/L YZ$2N>8)!2")F)E*<41@+@LD,[P3A53Q1T=IKQ:Q%/WC$P:FAO
M_V<PYL+^J9Q3(9BD2K7K H#6L0^/_K^N1C"01ZE?X'AK/]XPG3[,[#.XEZ3"
M(<ZGL 1>P+WDDS)N9*EHW\E_TEC6Y<T]LV/L#]=EH #9/-^"4D$#/$B3)!VR
MKIY4\D"KY4!Y6.3'$^S2B3>->YF3Y$*LL_%, 3&F.I?4*<'@"/$.)9]ZPBMS
MJ_ "Z([=L;_Y7J>L/?_ZTQU^J$VVI0[T,+&V#WO8@WZ&YI#)@\<Y<D_ E(C/
MF;Z4?^OSVHN>_!PV;4>@CE]@Z :7L5)E;ZF?M)>[/ZCY-7O="M- 0N8_[43+
M#1'#FU._O0I&\)LCY5"-\4-P,>H@2C)WR!R[V[39KNW@V1Z7C>R:_O1)8UA<
MLJPD*/@F^ZV//1*SQ%9'OU7(4R1;Y(F%Y&4H"+U,4.]-+3:WN-;\P9]59!'F
M&Z /375J<4]%!)*\D3T7$8J$L5ZJ:*X%23A!=BI8\MR,VP>5.3OQ>5:4?YJ&
M?XK5_!J#0#WLC#K>:9N9%!RF0X35$]Q0.#\F,QP[S%B6O^S@U?A H$BT;3B/
M[%V189\^+I7 YW,BU"JR,A;"#D(OM>);8YK,H)"?+?GD?$D].B+;D@?/D4XD
M6@D'UKMUKV5:G.I\0"(:4G*:=9U)D20Z%?W1=5;RU89&T7G&@L\QNM6!4^]D
M#XL@W_\7>^\9U62TKHL&Z2"$WB$H5:DB18K$1A,A(DH5HH+T*E*4F !*;X("
M"E*DB'2D2I'041#IO82$)B60 (9@"B>LL^X=]^R]S[AKGSO.'N?'_3'_9>3[
MYIQO>9YOON\S%0@#E'RJ%'4\E^M@-UY"';<5XFGPM=;3[-2\X=I%)X9?-A5=
MI92/K\H[%J[<1LG?ZU4XC$:#R1^I).J/8P - !TXK,(CB<5+P1T0L4_9H,0V
M$#&TF[7P.L'SS&=WJXQ'DW3)"]=D8UOKEF!EX5@'C>(P,L?#)0+QF1-Z06>N
MD^9['T>EZB+5][TU;[S.>I"OHM2EN3)7M[+RQ(W^Z#G-(?1I#H'N. 8\$(<<
M ]RMMWS)_(?46VO[U*Y,5^JK/X>(EVT,9"YB<#FB\SKN&(!>CX9=+#WR!LX>
M?)/]U;_<#Q. :+*D$!J8#/W\%"K_Q>9L %GCWW5VGUP(/X1#=E,Y*94:NV*H
MZ?Y,&OW=]ME6;LB565P<5;#%H,9^6K_ZXOC1UESU*GA<+KR-CZQ,?-!8@AOK
MF-5ZE7'G0M;'?S9$[:H,DO3<D2Z$N99+\_[C4R88($=(0$^F<Z9*7%V9F2LD
M:W?.L4.\6^E/TI5^!/<5T!L$CA84B/+@6+ [D&\&QHZ7>Z5TL%4%#/&;_U%V
M->B7LET/%HM<GLD_8C_*BMTW9VD7TH,CK=\1=9=R.W*CGW>WT<#ODA)]ETXY
M7IW'8>.Y0U%:5^=V^4A=M6'2[9J2\^:L  +_QC@=.>,$HB%7#LA&M%5?4#CI
MZ&W.C4+BK(X!R6"V-B&B+SHZJO4<NJ1"3Z78WKUA2M#?T42JSULHT>ZJ^+B'
M3?B;A-.$J@W='A2=/B/YRF1N=XX>,0"-Y/$8S3<\S$Q/<7WVY(=0Y[ETM^SO
M%NW"[=C[\XB:C.TFWO(4F#C.0^=#A-[EXE/ +WNTD*CUG^I _[U.95T@B0R1
M9,D7OGW%OS322M:[/V)6>G1+.FY27NN90,I7=(.O2THTC0;>+/U"*NARY,1%
M1VS/F>."HIT^VC6='IZV-_ 4E@J[V5W*VE?_]"T=^:3]ZP'R,4I@&F8"F77J
M_/NTD2H^B57"UI><,0QX_,PMGZ4HBWXUSN:&6\6P#E>WP!7+)2!9X/P^.J,#
M*X4^[%:A-\-X>W8%Q3YV1W@_3_\1P,!>0Z=39VXQ<JI,9P>5V$U/ _M&_Y/N
M=.M?(HW;OJ1SGIDO-S-S.Z&G?P0J" 8[J"U>WC8W>1"7E_H\53L/N-[UO]".
M;H[XM^TSOAUMIW#@K@IQ&'@)"-R@BH[Q-[[(,JN/&Q6?IO<W3KOZ"/!#2A;)
M"EYJ0N"/<$[4)N++HXT#.OSAMCLMO=(3,TCB1$/(Z:U%GHP>...4<^;NK23W
MG.X>OVAGK*??HS3GA.I3-]BN??U^WI0)YSL+6L[M <[5+J]6MKBC#W72\UYO
MV,G&/G!<_1ANF^W$$:FF[1J<:E:J+<>61T>BX7"&(:(##H5IW-;(<X/RD"]\
M(N9W*D'OA:#'O9V:;.:'(D:.XFYJ>54"O\%CR9>(C#A3].G1!=@%G&8R.NM]
MAG.&@*:%@=\&9?*=RCOKZ09Y^E4'IZ5]\JD3AA%2AI;ICE5:#%_B\/:9O=A\
M\9F_N[__T]L?>')@R75+_DF,\//_3F@B;^+@A5RWSKVUEU4S5TO<,Q/4[!?L
MYGMKK^JIE=A*I6LQ.HB;G"YGD5Q*L,XF_B>D)G2. 2(AEJ9XU,OZ7?JM.'LS
M/'_D9/83P8@'+;$?7P-?E'L2"?4OEZ%DWC)"0>V$AIF6RQ=T_'M8E8:PUY\7
MF@XCNC=6 OCPJ?2GZ[S'F:\Q$Z#W@Q/AXD1FC'D:)1H/['I.H[6X8/87-T<5
MOKY$A"B6MH/\!P&(RZ Z*%E "DI,P_4B&&$2N)[#<(T*XZ[U+="L;J72'2U;
M8:5;\M$!V&GG1ZJ143]?6V_[$F7.44KTH 4AN9C&OEP>S]GBZ$!C[XHZ^<"L
MV")>=*9)Y4>3I!LATW'+T0,/LNL/HQ))XO#^'-"XI=4HG#?$0^%KUA-=]_0]
M+]][G.5\2=V<NM:C+/$BKZ[PWP4 A "<G6'@3,@LBI!-^8IXC)S-L*J9(-M^
MUGHE/0FU&O&6,89WO2@43=90NA%QN<<"F"*_\,U_AW4=Z04FRONV0V=?+OV9
MBGI(O$%PU&Y6%=*(;V@('DMX4H!\XR\26\09-_+V0?R^\\LPA;]6^&!::EBF
M2$" (5M7J_$"&><&[#8U1QS:(549YVO6AY<U,#K!VYXDN0WKK9(9F!2N<UZ*
MZ<ZL0VM<.>?5NT_/LUQ6E:??@U!92G#!O0*"U$O$F3);B%.>AY6%N\C37YHR
M*SG!67[XEP.*LNH.Q+FF]U=E;("9@< Y*&&!\A;A5H=#];U 6.!E<J-VQ1PV
MM."WN#R"[C#?R#R7JM*\"?O^P9D)H(I.1Y8HA(:&FH9@O<_:/(B\)NWVT8+?
M$'""UL*L^9>1D<< CC9Y&]D,O%1G,S1.Z:QN0;)E;136R??N_KV&7/^75T #
M0]@)D@>,E5*JIU1X=0D1.8A&"<PMR@Q.-CU1&EW]R-W\K>$WG7M*=EJC<9?/
MHJ!T)N4*S44NP23PT5V[X509/"I>L7C,"3](:9U]>C'QDZF"<8SIZ^C7-:V5
M?*^USC.!SMV!'^%0V\DD%:*19;P=;K<3R3&#:L<8%XL\;OG!FY0HJG/AFBY_
MSPLN&GP/ R= Q6E)GDJ,IO9[HZ@YF4@$<JDDM^8PEH8A$1&9KC'Z(%O]8DP5
MW?W!9XP?KM1-65G+EP7RG=<_:$HZQ_^\^EHINRHSUAWI"IK97.Y6P6PE1U(%
M,AS2?Z/T\V9EXAWJY\"9KA>%8%WGWJRKM 3M!.1XSGRF/Y*BQ"&6\MJ4*0D'
MQP"N$* -K@D/B:X7??-4T7%E>L@)5GHV+2WA#OYL?EF!?,?MJ\Q^OEJ4?+@N
M^3YM-<+)06.RPV2-"TTA4^;#!Z("GI\B%#.>C'J;_?QI.G#N[KW;%R-O3?T)
M7JZ:Z5H"=B^8U%?%@#@/Q!%W8#XM+6,5*TT/=)C>%;\S^N)E;;0$?'D,8-/G
MOZX(.DT6+PRQ]5&5T?%.T*Q0UGF6R%,&)K-D HC-B' D[A<49P82)LODW/TZ
MKE[%X+F'&A"6D2!L3F)"$U\MO;5^$N.G5GJ)GSCP7W;(1KQ.92,= V0#GAT#
M'@Y>/ 9<>WYD2F7Q/ 9([B8@_TS13&?8=^M0H8?*@G/M%A<F:R\OT$/PRF^D
M"O\ILO$K^GSON;3AFIQH8?$RJ784&UP0IFH_3G1?PHIVFI8(#0Z/JI-"Z;3C
M@S/6*#GJJ-I0[X4//I<V:0 QCU*,6/J(K%^/1+HC1=R?,\=]PBV^1U]^L@^I
M&;TS2^]+"-6>O?1S0-KK\<7ST2XNV@M[7"W^%!68//X#DILJ0-3%B$UB1B%\
M;K/PS\,)&-EOC2;]I_<C44G/JM8+EA&=0XD(W&W4'"?IREB;A-$2&!BB0]VZ
M,?X'[V&C'F3)EQH:/Y@27S)SF^7,G6L13-?24Y$%2(Z04%-<1K1Z%9M;RI%.
M4+P[8UH-;VJUO:%48@"*+>\VTP*"72VDYK =*@;JT_&Z,.\8$MQM="=*NW:U
M-3TCYXD"5A(K<^62Y/+'JIW,5I%U@@WEG:_/X]96XM6EHQVYH%03:1PUY]=.
MG^+/WM.I)C_D4FDK<?0OUNWVM9TBFI+,X8M@@<K LI!=/=,RCUJF\<"YI3N]
M(TS,N[)L4@8&Z#,)KO1>[KT*?P=K*!E(ET0U_\!BF#0NL7!@!#/\]. AL1PP
M5;LQZY-=:'O]D[OF%UO;N<_&'\,%+BU;#)^7!P!I;+:[C8LZE,-!O(SC-:?D
M'ER;$KE<F7TYK7L4(-V<BM-N>M]WZ_O>1>]??%P%80I'.JE#RQEDWCE"1O3M
M])]V(?&=&1?9W7W.!#PLM?W^2?.IMJ4T;_=\VH/OYFHU*J 9RA-]-1J:!<<T
M>_Q&<<&T/A&S((:+#7^S/VA5ERV+1MRJS%O^*IP'7+,DI-.<M8I\C9('Y_:
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ML+?O[#HAO*F.>*;2DRJA?R9'IG;X()04[EH\9U@B^%[AT\0](93ZS]*6V$N
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MIO4@M![5-T*Z2&,(6CV?%<=NCS\]B%OL7+QVXXFC@W%USYH30[[ XA+7S1)
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M;H<2,MG8Y994PKE469N<*[:GSDEN]S$GK.>D_9V!=B(Z?K3)SY%O#<L2SZL
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MAP,D R@I^3.Q'J;?@/)VEVYN3$F?YEBS&A.?O1T.?V36=HK<M[J&O(I<^H#
M62"XX,//MV"\Q!G"PV46K-V+BY:1-T"S$0 [MZ+(*P;97,)T">=K%&"EUFLT
M<EBU)DI(Q@/)?/E &I3DSB.&Y/("(Y?Q3(7-4$+@IU("U$D0N$+)SD_X&.^B
MR7^I]T(/ J)^^W\;3?68[+?KE3E]]]VX<Z!8H' >8XU:_0<.?=B82/KWCH7P
M#\D5ME6KECV@!B@60=*BCFOI,Q,S\,"[4^JYC,3(L\CZ#P8--"YMDK9?)RD)
M\;I>>2&Q?>J@!R^*<7F)(Z&U8N#*$+7[&W82*?YE"@JPVCX^6;=.":HKG?]X
M2AS@(%/A*(L2@7#;G:,G)%)*]+30ET,QYF6!Z#F!#)O),Q*W8V9F'[9^HKMD
MXN*&EKHL48KHN +V0LP&H).Q <NH4R',&(&"?#<14_<!3U??518,S\;DF+[:
MJ^Q171K$K*.C:(U !Z9HZ< =2CR7C+7P1.!!:-EL#(=HAQU\-4J%LWNXF^&^
MOO(5V\I5H:-.'CK2YS!L91]!D+9\F;"'8W"%WP@V&A3A\";3&!N/@U%QWXN0
M.)6G6R5SSLJCI26ILJ\C7YNFANU8T=VL9CXH,8"5D6C8T8YY^STN: NC6>2A
M86:U^?C+J!<[GZ!6C8+J8CO/E]ZX7^O#WLP!2G ZHNXRC5<? P@_)O\X0- 2
MM66#WL75^P4C10TC=20'E%JW; K:RNL)_^HSEI65V\Q_S P0%Z <")I]UQ\#
MMEOP;F0]2HE3\]3!ENW#Z#O5$V=B-=B-[T?X*/F<M5C+CGZRZR[UVJ^\:1%<
M1*%W&"%;?-Q8E,7]F0_^ZUCAR[]0U&UT89#AMW22P>6)MQ&7$P&/8-?PJ&A]
M0:*H(S$60WKI71#RY)?G5C% 8&_I3L]M'BU=)P]EN(LD9SWYQXE02D0Q=2I7
MB.SQ%]QQ;9%O;*?(N7I,O4QH]P_K:^>J]](IMW9EM?7OY$E$"X-'M?I +ZD2
MQ"-<&91H@&D9& 2;X/G\#?0(G"GS^3UJMS358\^>KGL@]K$_]?(6>C<ZMU9P
MNY$6[(;'8$;X8\#MJ?JL+-N*I3&7YO%4A:D&T]AQ.C8[>R/)?="#@._MXMIY
M0!I/X4!TW*01KZ%PJG*\.;$H6+.\>OO9 8)[P]WUXHV%KL+;]\]([7R1"?AA
M)<S\UX;(B"_N M>I=((Y88ZX5#T!$3+C3Y[7SHTY<F[%D=^7WJU8W3]X0,_)
M4K563&4S(MG#]"A59-^E;-#28O*S0.:H@I97CH.^J_.H0?@P-DK>^FG4)7)5
M1I!0;0,?I_VA)95U Y?1"Z(_!C@GLQ'M>R?OV&V-4:HL<WJ(Z<"&FZ,][$R]
M?7N$7<O#^Z^?,87I+^<CWW H4-D"2*YF^/0YZ)MNH!ZOAW%TU[5?=&XC=2WP
MWI+5H[SE%2!R<$BF%CKY O!LJ%?<\!A@1#1:?@&]^374=$X<>">'M>!1E=@7
M>^/OFUVO^]NY0D6H>HJ(D_N,UCH)BW_!\7"I-&RAR2FSSV:*7K<CZ N^6%DF
MW8U@6<)#IP7[P$=G$5R(;<<)Y$&J'?4"#;Q%-!=C6?'F VC]2#^E/PYV W<S
MOS><NCR1EG#HU]U-F4C#L-@3K[LVR-.3V"@9^F B@O".> Y-0P*S$M]=OR5_
M'_>^NS*SJ1JF?$9[G:[-62X],:5EJ@]\<KBY>YN2 Q>P"V%&$S[]123#/"!O
M]( -H1SZLA*!_2G]K8DQ!?H[_4_2CEAIIK!*J8C>3L,'V.*L>TQ<QUH%,4 U
M<7-MJ2=_X44N0D9:;^D>F'"<+F4ROYO[YX%UMD-C-Y@HC\)ZEV^E/FM(#W;W
M#Y7#5[[)V^B_*;G9TH"].K/^QK]W^8I$,8F+.@&MRTU$>NQ&+?+A$=V#")N1
M>B5(?U-=\[AL.NN;_M?8IRYGHJY<TEC\SW]Z3 $OY8+WGJ'8P-M*)V)J5=NC
M8>#XRZZ$)DHM6;O,T4WB#/$CAJ)B.;8:HNSM4[63E\/J="ED)?&[\V,]_@<L
MESUG"_#69'[7U11>3!<G"_C1) OXB)W!.HPZ"]T+0M&BU;;;!/C@XQ;)IO88
MD&P,GH>N7I%@Q$<3\H@@DI[;Y!1"J-7>,Q\%\5 ^^T4[G;H$,'2J3U!_)<@8
MS,_:(EG=T;>_C-^ELJV3;A"1&(Z)P_;$NT3>#IQ\W.2HO2C[0$GGF_<[$FO"
MG2WK.X9S? "U/D6$,=(WERBWVTTSJ]UEZ\C6AVAOA,EP'8>*H9G.COUD]LZ-
M^ #UPAX&_S3_AJN)H\62)%?\2P*9DD$^0Y(AF^(RNL"L'H(Z3<VX>9'$/]A)
M_DH5F=:6V/=.T'1U5I[S>7)"/URD4^DH*M0N**^>+SZ>8(4#=2?'S&80D#%_
M/OO:[6S]B$+]O "]?RUZ(%PJT2^F8-7B@_/^&ZC-5"<"=VOWZ,)NY#'@3Y?%
M,6 L;>)%??GF7]_H@U!LJ&VV]U.*)JN/CRQ<X-+#.SOK,W=YW.AQNE2V'M(#
MVIN!>H8X3VXAQV"O=_&XV3W[-K$RINRXL/JU3;+K=!&+7'\D0]A3RN[J7S,<
MS00DJD@7X-TZX.[=62E[Y%1]-LC0S-0R?<]28WLJ\U6.LZ9];O;FODSS>GC"
MFS SQ.5<AJ<O3 EK)[4-]EO-9 [-K*JM-Y[-KY[ !@3>/%KTL$=",P:,*\)I
M:>>%YU]%RE>PRQ O=0+!=(9HC7[Q'-4UAO"8@T(NC_M*/[GN*U8P,"?,++,@
MY)J<,<5'1SX&A!Q2V:));F0;_-T1\N4)2.1VL2M),RU_NB?@?"^GX491G.V*
MG_[^J5+(&3Y_AXQV)%$!@I7!K?<*3()$=P1[J6*\,;X?<R9%'0QGM+R#HHSO
M2#J;F_]XZ4-J>:,;O46S-0X2.W([]#&F;(A[LT%?"L\<4QC.0YAE3OQ8&VZR
M=_6--%-*O.8\4^>ZKB&8%;E4HB^+4XD]!G@A^,V6?&6O%G>X/RXQ8](T*['O
M:PA(VQQ)_**]U<1R69[^[SAN-T8]62 $<0L/B=ZQVC>=5'K86I>MOUU]7S)5
M2^)G.4M%)KEO2N\%_CKAY#S.\;>$&FZU$B44$MHY*^TF%V-*N!B$N^: T6:8
MZU,.JI942VS_?+:-D_93;_@\J [5 SXAO%"\7+=E"/+*%-:W,!?+=:W"F3"L
MMZ&F9QQY+YO!P-QR70BP-,Q\8 G]0(M10S&+>D0'D@JBTP*W#OV&6ZRB-#UD
MGMV6"WW66B+PZ,<W%EUS)J-Z>++UO[W -@PLA'"E1: ,6F**0@JUZF*28W-T
M)EMMT=(?KI9.0QT&GB;^-_+>*ZK)J'L?#(+21(ITA"!5J:(4$22@TD0$1'J)
M2@<!1:I 0I'>04!!B$@3*9%>)=*EB71(I(6F0B !"2^D\(_??\W%S,6LWS=S
M,VO-16Y8">][SMG[V<]S]MG[>*@-2F049Y'FZC>DKA@ZE*RDP.V.]9!E7L?&
M.>T?%O1#RSVOZ+_PUKPGJ%[T]G;_KYZHJA*.T&AH;U!$YRD@":O8!8E'\76H
MM6U2>;Y\S_3%6?@9IWY0L#2*3(7[X<M6)IVN76!0.=8A2?W;5;%;+M_.Q>[&
M%DIFU)"A*^Z!P=>_E>EF*_)_3+SEISJO?C6BUR?YR"OE0\1-1BI+)"DX^% ?
M:/3%0Y?U$W?#;K)']\"?+O[.96/(%7SU'EXL("[ZNOG>&8$3D/4(OZN28QP-
MHV. +0+M$6FPBW-AIH2R:FR^-^1>?0[ZIMZ.47;"HINE\[G[S/0,B62W<1A;
M\,  XDRG&'4"?= [6@; CK_/_1S.#:58/6B]?4EA?BQ7Z*V$^O?-M!ICV'O:
M^W- UDK"3$Y GXWCJ&DO0=04=^20+PWAR=STYI3<W/O 8WP=OX)F2+5=>)U=
M9?;^XTEY@40]JLV1<YZEY5Q5X$>'D2H!'7(W'E;]K^08:%YY3"CO:BM/;!3F
MTM[OD5.S;*IX%ITY<QP2//(-'C<<\_JO_0_& WEH+/3?G6NI$/Y.#@"Q4H#L
MWA7P[.2),Z^?6ORMO-4J_VJ4.YU!@2.E[_8%MS+C1["O4+RY2;RC$I!51CY-
M*2F/)6[99E?[+WACC>RR.Z4YT0[Z@B7>&^"%_BZ+:)SE0KL? 8JW-SD2ZN0Z
M <VF5O]K7OJ1_N\LE;EY%2D09D!))XMC=\%>5C#1F9T=%=V\/:)E80B#U:38
MF2")@D]%^N_YD>VR^^549N,3D)3.<MKQT?0)Z._J<^CE_R=[ )ETI!A=N/R-
MA0$R#_(>\$P+\J=M-U$4/S8/:1"QF)*?_E"/V0C9\_A%&E<E][[1FUZ/</3:
M5?ROMP"4Z0Z0. 3)/QA.5&W#9]>TKA@AN1"\DEO]WC4/E@9)G*\X,-/-/ONQ
M2I,\.&C=+HZQA#IY F)L6$IJ4\W0BO/]:!+@2S1*X+72:\HNEGX)8GKJ]O[O
M(7+]&A'52:G:U=0I94?'!)2FJOOVQU&0'/$ADJO['>]DUN"?%@"K<<CG_B)2
M8%DI?F=XQ1.(H_*(!Z=..0I9/_R]Y*960:3L\:P$[BZ-7:"9 %079D.;25V4
M[];8_!.,"? </['(.@;>:NK?'O7K=!9TR;^FE_D&X#(2EV7Z45#94!_%4@G3
M!J#_<MS75EWCGA/LN@3'4E0*!-6R.R?+LGR]Q?4,,AXUO]++Q(E66!<_8I)-
M3J81_&Q=N#JB5IK,HX%]"N9H2(N!-%3O;;4I-#X73A8<R9#@:^+C$LZ@% ];
MV#Q1N-5^->[>KMQ73F@5&&^*^L]6.DD\>&D ?N[ P_\FW,1;R7M7E,4YV>0C
MYK;4PDK<J%#=IC#PGIVFJ]<&5A3)W$G$'U&3]GB]R$^+P&I?IZQJT_&]>NWF
M9EYY@?1AHMV=^ 27UU>36UQ,6^?FA_9%KE(J_FGK4QU.7M*]2-[@XAYT=7?U
MB&I;+_37?K]09KJQ0$P61-;;\<8%VEB&*U5+\AQ6?PT+_6$]&[O@\BUYA/OH
M,>'[Q-Q8(UP=7F=/$^FTN.#UA0XFUIQ2/(XQ2]]:M>5#S$6-!@ET,^LT"%RP
M.X+T6@UK>!&MB)J4#QN4LA.0F[<0MG&]*E!PDGG[X-)CAENY,^5>#3I)'*DL
MW]YG/E2=N'\5S@AY@L+H$TN %-)#L@;>-Z53W-.V*:'RC[SP0DFG:>+#/6?O
M$IES5^E6N>DHAF;0I"6\E2)::-7D:P65]S8^K2\7QF_L'5#VA:28^W:TMI[3
M1Z$*!E7"G[E!D=W?[08WZ^-.0 3DUS9H-R0ZVG)&95321WJZ,>7&E*.GE:'R
M""$DDZG)=D 0JX*)?:)U M( ,1X8Z<+%E\Y!EHN@3?I?%1,&/0BRO8(UK>?>
M!JS].6:/M\ASR(_+Y[]&I\P5><@D2I]<J?#P!&2C)3*K? (Z_TO0-\$_]ZKU
MGYD?"YA:?GGN7Q*W])]6LH#FD*LFO?#&,1P\A,!JCM^,@UT*KL%BPQ^$&FD8
M>9%R,Q;*E?JXS8JY1N[S6.@9?CV%JANB7@QCJ_Q="*9\ZH @MX(NNY1[="HW
MM+86FC==+XI[8)4Q1[0P-=2*BM"*FNV\!.^Z'\99-HHUX?D#/N]OK#KBF[-E
MVCPMVI2B'Q2RRL0XT]E)B84L?X3R[73*!(>N* Y0=#5-BH#"/_(W,.:9_"M?
MZMI:'E\06N31S9'RXSFL.5A P;@K*$X$&FZ?)ZK@D;&*!T8GH'BTY1?!V]+'
M9]XM^;2T'IGLY$B<]CL!!6W*O"./G#&&*YR ZI9ZQCC"/"@?._C>!RL:N[\Z
MQG467?UZ;EB(-32FT(.5;J_*+/GR]6%OLV$Z;3":PK.'Q"60S-S!=6Y=&&0\
M.OOCM(I=1<Z X6<Y4_O%;U4]H:"[ X*R&@B=!N&11H!Q>3<5A3<_ 6&D[:8#
M(*]>?D>J-!7V?$_3R\'H3>*"PH8Y\O1C;&J_666OB6=E:(.G57C(?6'_VA4F
MP69IK[?;5XS?)Y:F;D$GJUUBA>_V/(R5F)*_Z,?<TMB2H)\7*#S\I215I[MN
M,YA"!=I)M\E:@#Y>W)3ROI&UJ +P867R?9I2?\J7.M]@*R%Q AISS0 ]?:PC
M%WPFXN9B(M4D (&I) *43UJBPS1Q]2HOMO31_E$FQKV3+V[XBG;+L.$-Y+NO
M9WTR#4^MX?E$S<I@/Z'-N]NEA#/"]-C%XHK%00[#\O$.,_8\!>^Y=$'UN9"O
M%SCJ=*46OJZILM P+D8WF#T2Y7X"BBM4IA0\/0%YY!0T[+(8E1A7.H0@-'.&
M/2_8=P=2#A,-%B&YNU>.7B920\-<:(&4CM($]X(D(O#1U.\(;_Q!Z5JJ/T5<
MUX ZNU9.;FS[\HS_D1^N\WJN>.JK"/@#;JN]82P$36/;7B1>(%<W=U6KZ..@
MR\L1 L8KS;?2>DG&*0SJ%;/VZ"N'06I P#?IZ+&_/"0EZGBG$*6\D^DWBK?C
M&G]=RUOGYBFYH*-JIX_:C/G,3]EZLOTEV,;K,NDD0.PEEY!KC"LT\VHG-N#=
M4N0ZS+'L @M T_<?]KP3NV]Y)T(D8U:3A\1TG]1^&Y::EKF_4)2K+GP"ZD4F
M(_ /JS5Z5E<1*8V*?,$O>H(4,N4(ND362P\>,(16.UDP"SDS>)BS9>QS^6E#
M*H^!V\0Q2ILFA"3D$'QWUAY?.IM@DL1UL*HZ>]EWC1+?S>3]!],<TL/_._&H
MDLK\EA0.M!,3.J8ZSX6YY,FB^#T"8X]['J0JO_K#6_O9,--]E94_3VQ(1Y?N
M1^9#;DD4C0QXD7;1W_=[!4TI'ZULK5=SR.YP-($I+M,1HC'87:-_7+T4 X);
MPO_GL;'(Z\B4$JO"CFE448P+A+):]4+P%4*]@1_PZ.[R^R3U+R;-N^E(UF88
M-7@#97T"HL%]\\'F=JUW.?DZX.%[>C/M .,4Z-H*O<IV=?1ML>&],&;)C.Q7
M[O>GT39=IRTB(.:TR9_M/@'].UR!$%+62$M<9)H)\ZCZ-=Y132Q0S@_U$+QZ
M)^ETAYARKL?INWU"(!U[YR>=N90$R'+%TOE'0$Q)V&5*J6^NPWA 9?SVHQGG
M!-$OGUO2M]-P(K:?ACG]>.9?WW +<04E@JC)OY!)-$"%<W9XXXN)>@34_Y%!
M+D0_P2QJ<P_R(\R:8HW;>]CSU%R^:Q"@8T$]N\!E-5R^2XE7(<=$F&$(-HTS
M^&WUX\^MA0P=K;6<(;%F'CYB,GNCK7H;EFCNE2".(3J*GQDTCR8H,;OH%P^!
M%UB*$;$ RB%5K5H-GF.,?Y+'3!T1=5A\:"YS=:"#:'H-\9(B]YY]!(F&TW08
MGG6Y+.ZC!_1<HQT\7D3EE$$UC1"-?FY^<Y:QK0VZ\-I\6LS53V_RLW#/7C'1
M]S\G;>?!'#3IAXAS9"% TV)F8K!@3H\FJYRD4H_GE1C[GQ\,^3/D[WQBJ16*
MCA4.<LL[9E^!D#GAO6J+RKF]8+ FU#E/&ET(W\8Q#<L=7K+_;*@@E7J12;RF
M]T4JG?DW<C$E;4H:YXM/X(OHE!__2E84?\^.R_E/&0GYYK]M#7C7'9A4&!?P
M"L80QIXC+&Y>W]#<.JT2<M%P1RQS+20#@RDI^F"VSN,6:"D=S-I0(8W]XK-*
M99DM"[L.!A\X!/5Q!+MM(]#L,G]X_XS;X/8UCY3_AO_*ASVY)^ZY]U51F8YB
M1(NWM.F$8W:Q^C1EQ.,)/ZVE/"I268V>TRHN]QSD#MPSOG V8YCA-\=#MYXX
M?0L!%E+=,Z]^FBU^@C>JX1CQ=L3X'V1Q/++_<%%H?!,_6KJ*L3UZ;(NU:_^&
MOF7#GVFI+/R\#P37H4'-!*()2N8V(:;AR]Y^"#M?-VL<%^-/"G6X3[K5X)5?
MB?FV*N+2-XKNR\XTS[%^(CO@)AY@0<F"+Y? &ZQZ=I-MP3$P)2!SOP_&/;7[
M83) -MSB3FX@[&FA6=YE:[E/!*7AXDP!'?LS/9<8#W1TP\))/K!I2TB=55="
M1P!/R4M$?(!1S.1?+W5#3D/_/]^=\SW8UN\DVGS6<6J\6AK-OAG7A6JP(G-G
M$?,)KD4!^)X^$<D9I)QV8;#_DZ9 RV^]KRRM7SV[=/WB[?5\!G+O>6WP>PC>
M"IF*$H!Q!A^NK,?1W$S0<Y&W:4IY>-#':;)FK<G&04K7\MDKYXAGS,@?$$#:
M)#7L,4&<J(D')X>%5MEOH=<)T[RAF,&S]4,7IVJ>I(4VRS=R/G3[S$/^!IN&
MB'1>)T.G-#56%-&"W490 ;)6XI9)2QYV:3OWA=Q.9CE:E"51PO1Z .A&]O7O
M-J@2*"")(+]!]2 .#Q 4#8<?C+_D85?^Y:7_Y89$) #&50$MIC#VV#F@;(*_
M=#K Z&/O[R>3[S.O7XSIU,MUDDL>:^6^XE":@"'=A,;">6F_RNQ4!QI)MX+3
ML#N-JZ/*OQ;%9DNF7.J\0M,T;31)KX2ZZ)_%,6?TOWRN#<Y3HMDJQ+= U"ZX
M>VO@9>3GUG2F]9:);6J?TH77]ABF,="F*QML'=ZEB?(UA'@YR%K@@U*KO/^B
M1  _[M;\[58[+Y+J8X&6%/YZO6_KE@\'[>OJWBE9X"#+Q3>0/5!Z6)^6RKBF
MOK>7KUN0VYFWQ38R8NS-/M"ZZ@XG4(B&YHCBPAV?;M0%R')RV[E&..F!ER#N
MM8\R3K8G]\F.MM:]GR:G^@2TJH:LSZVPEX+@9OY6^S&T8'F>T@;W!,<B&JCM
M^(&5I00I?&SDRIOMSE'A+QUG9UVQ,[)QA58Y:@JL!J:7-$#V/ LMLSBU[0""
M>3]8".*:1D<V(?QE]45NY?BIS'PCEV:_+S3@?18=<[[$2^$,W\8R7:0VV&AV
M_R+)_%^#(%K\V&6@3E A0 A^LA_U9%S9VS/\1O>H<O6-]=G!Q[Q?)]"#LIG+
M!T_\GD,GP^$";>5]QHQ=T.;.>D)^[\S^DL=+Q5Y6BJN!]RWE"0G!UUD?^H6S
M7Z2#AL^R@(B^0+ O34!08[UIJ\U<K7$"2O<B[E.9RPGEJT$#BE&"AXE:FHM&
MX4AK(!8[Q"Q5&]M%_9:34_=Q;SF11U0S;=][\'?A=:",'5!0B\/8</PD7VPS
MOO3YC/^,6<VI0RW#AH?2F%&P+<6#4@#W@,9 &QDC42OJ@!UL7Y<^WO?ICJEN
MB).Z0[?ZZNF(;^LV-AFMZ %&D CIWXW;>RZDQ[ 9<,/ *X@G.&&1#]_<N\OQ
MVU;O;8U#EY>']T?C"U=Z4V+NZ#[BT7\D>]SRHS0S_+Q)H:NB1 [AFM):IBF7
MR0PJV0232[U/PFY2DM50Q\*P-0\HWF9LWG7 J+XNOZ=0\:I=SX6GEOT] KJ@
M50JDG)L.!\<_1/[OO2(%!'>8^NQNF%KE"<C'6H?8SERXZ"NCF^OG>^O<9&0&
M#DI/6QP-F#KU!XI72Q V/HP,'G D.+:6!%L;%E7E7EOXV1,N^>4PQ]M*#FN9
M<=ZGJ^6S_8M$&N?S_;?;\74)G;2L!#S&D_0);*F5E$J/T W/P*9:NR-39GJV
M'POW,*F$R&81;#L4N#A 3H;SH;8F=4] X[G^=(3[Q:MI@,S]M/(%3W3#$H]<
MU=,/(3L*THW3JXG\Q0_&)%+'8RPL&.JY0/12'?4]X$8KW)=5;[_9'I&S0-KJ
MS5";+XORVU6*B@HUKGL_OE'ME7@#T8DCS\Z!)/!L<+NE!A-R_F'O+HGG $D1
MRT%E+P%2?&0$I =\>.!+45XT940C/F_&TR*V&J11.A+7J2S=J[3<Z@AX2MLW
M3&698(A"T7SO9CGC9P^+5#/U1R/4^P*AS59D'@B6/;I3P@O*"'&[+-_0B_^Y
M9^,IN/:Y=&K/\4[@*$_#BS,)7-)GDW=2;2)E&[7E22<@: R8%;*<WBF#7QJ0
M9\?F]J8)>FA)3CP->/YI<8[5IMY_:.-1R@97B< 5:]7;9Z.8KK]G_Q[*#ER:
MQ6TMA]\:MIOI< E1^;*YZQ3W< ('&_6/%L"\X6S:4T_(W8+^0&Y?(SW^#6]B
M[)&MAF&[;PKUP43>R@<D\;]ID-FK<'>+J)5?O\?SF3_'TM+^,UW^!A*0BTL(
M8RZCCMC"8U7&SQ:*3Q_DNXT7BPH4DZ[(O[B:6L0KM3>7NG=I%TJ#-'9E87=/
M**_F?2?_"4%YF1%UL$3NQ1H)49$-97&MR(%J$"R6NK#4K!I)NAAL.79_HEIL
M5C,4R[_FK=JMUWOE#NIR>QOZ]I%.RQW^JU<>"=RJ9]_\19U$X$U]T:&]S1G
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MA3X$P@DH;'5S(E4=S.C)EV>2KU#^R=/RI4>T2?S81;> O8S'%J<3+I[A\1L
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M[7*AS6'8#%@+"X T.(;$VQ'^K$3>,8C;P*_OBS3-6,9,S&>&*3Q2(3RAS/S
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M&)5P#"2-T,F5I:93OHXU9L3L01LO/GC7L[O$WS?R$JG;^=2+:JF:M@2^\G(
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M/;!0?)IV=P]0I*-6$Y?I:A1Y^GPO>&==H=U_U5U_FG/K61H[R;#K.B73[>2
MW(Y\'H;_S+F8?MJDPD%50.+;*[/=*=M$S?=N8U]CBY13K$&'0>;Q)EI,@SP)
M$>,_'RK[ /08-WZ@#CZLN^H%U18H*F@/BEM\[K U$?-+O<Y16D<^0WG];V2M
M))%^JGDY(80JM/0@\F+1QO59EP\MX>%EPJQX;(GX$PM4GUR<PV.:XC-K:TK_
MY@NH4(H[S7S7H,E4Y@X"?:.[1XZR@V!0N!O?MXY/%09-&;)]QAM2W&.J*=8'
M)B214.NA*'I*7M190'75K0ACG:BFHV;K@.DH3>6(,3+6\YA_2?TEOI)>AE#N
MTC@I?H;H,8C27%@.#33,6;O#1YBWM_4\92POK\ Y?VBNVG9/N/#5C^R_4N>[
M,;%'-0 #?F(-N]>33D]6_MAU)7LY(>B3PB-%$S=NAPL_W6\OXE3X,.SB_N=I
MS5=;!]GC0<S4!FDS4^N V2,=6OW?:\VDF_4C$G\GXL^77DM;Q&FOB?[Y_1T=
M25)'].CK<@"Y*ZAX,ERCN=@HP)WX]Z!PIE5C?TBLB(-MD16MG+)QZ,/X";NO
M!5M@P4JAFU [AZO(.#Y-6=?W<"/>,:1:[*%WF*?$%ZZV#29QN$+>P_?U8B+W
MT3G+"0AN<)'& 9G6_LA;WY=O?L#7ED<DLQ$+JNQ>R:-*4NI3 ?&'S*8\.8):
M=:QWZ\1$-TA/H_J^4OOS$YZ3(_$= YBX[UG5BZ:GV?U'SI2XAIQ*L++%];O$
MREYRU;]@>'G,FYA+94HFZ0,CQ 3*ZP(+(#'X"90SU/I.@7$12(=FEGHS#+15
M3:-ILGRZ[$5K&@-=\[+(^V0ORMMCB"=R863@2#2Y>A-7L[BY,'OK6Y.PK';>
M]\=O3;3K7#->M50H2+XL#FCB1FZR4YG^D-1#TXE.E-?.^-RDTPA\CG=KX+90
MRH65M=8/19=6TY9'G=AS18Q%:@WW2::*3) C/MC\)%;>"=Q<<67\?3@V;?L-
M821.V0723M);_X)^%+'X^V?DSN_7LXVS!%"X-<WBX%AX.FZ-G3>TT2EV\*E;
M-1LN;GIT1###]2].=*HNY9K1)PF6.D6-E/OHQB/(_G@:8E^?*G8,F?M8A=B4
M:B:C0&XOCUC_VW7V&#*KXPY2:^LG% ORX]O+=+IB%U*R5G!W(5K'D+<F)\DP
M9*X>$TI;ERB'RNFGP[K+A L=/#2'2F2> BK3!D%F$";P $"3=$+OFP4K\57I
M-KMZ?3.<.7IN0X]E.DMCGRW6HA(Q$.S7);>]/*=$U.^BO$*[C?-L%VG7\17!
M"*G94YCG/O>^C\T(E/(1"_[)*+J9Z:O=2'=YCBVJPEII+4X!B^( !U2^%,V
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M?YBMC6#7.7*:GQ]T:]/(W692E;K!<BD1U^U<_!(:?%$@FAW$WY@;QY#AG-!
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MT?M<\/39&Q$(" M&@X*"*KV:CX[+NG)O>1R0QK@G)M^_2KCZFKU"B&I,.@=
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M]'G+^W7;4+TBZ;WW*#Q3&,GD8;F 4D^0Z>=FH[.F^4 384EQ#7<,F0\ST8)
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M>T=$SET<!@M'1\/QPP;8X)A&TID07]3W%=ZZ](?[.E_WQ.7B39^@SHBDD,(
MT(+__41%?R '5"S$?%DI0AT1?U[S$X\ ,!:=O_7SSF=4!ZU>_\93478C^3Z9
MM:\,?@8P 9  S(\59;I2WC<?-J"EE-JAORRL=/MMKH+<C1\[: 4?A8SUA(MI
MQG%@#WJC?N?/OJH1)'ORT'%_S0KK3,'RK7;XPMA[+X?4Z(.PQ-RJ-P*>&SF.
MEV?6THTD\V;BY;^82*SE ([^OGKPE=[EV#CB-8H?%U^@%ZW:/'('+C%:C*[?
MR#.C/S.?Y-($@'D>W ;'%F <S<PMQR%,F*;&WZT^IEL.:2Z<]1RTRBY7C$<
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MUZ"^LOE5L>IY1:*)J%U2:<W$;0FWWHHOH:.:OV1HCEE)&2 O)D02K%ZX8*!
MX'H!JDT]OXCT(:N720)EL[>3H+.9HVY_*2):*:*+F[A\%^)'>G<"\/5+QIT_
M]P,JJABM%%_K9BIGFFSHHW&MGOI24))$6,R-6J3D71.^<%-E.(KB' F(EO7
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MR71\XF[1EK,Z8H?8?'O?1EW;E^ECN%T"N?8$X,KZ1UTI"H&3^04[-N"&R9P
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M!O\&*WZ=U-0IOBF@E'#HS21H^WU2+BQL<R7A(LJMBBTNA5OOH<12D,2A^N$
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M45F?$PI( M_AYX&+1<.-Z]TFLI4NUTJ2G1T_XD8B?=(='(3Q4Y6(#@$UNC(
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MA''?1ZW):Q%VN]$A\_@O<)XAP2PO_Y11-T;HF)P6;V" GY0]3H;C,V8N?*J
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MO4=TA.]FN'OWNI[69?6A_K"^ :B2##:L%9%+JB%D+8<L^.>S0^GA* G*?O(
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M4[D31:3/=:+?OT-E"<%'+J-[I=U4ES,Z2!OB@&.Q_RV4LJ)P$=%I+4S1ZHZ
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M\'XT.TRQ4#+-MM _XW%=D^%.CT>Q=6\8_CD721OZ81YO@HJ<4P>227< B_M
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M4:*K>2I?/:0<I#LINWZCP<)MH$AT]\J3E*VS"+>:AXSXE67P6R3.;#%QT+,
M=M0!YM34/W-?4,JWUY>A)O'!!6'6P>3\-G%_H TEB38Y**)-DVQ*4MWF!PG
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MW5G)O*XWO@@9)"_-7Z4@+FGQDR]/:$GJ+[/+=_+_NY+_8T(I3@(Y9.!D/Q[
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M;%)EP(Q-P2ND0;RPL\\NGVT=_HO NUV=WU>T1S7>_89\&AZ,L^\W-TDU M!
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M(PO047SS<%[]SS_.&M[IE51YXL0F MR^''>%]GD(6]/!;PV0BXEV"#TQ@+*
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M_/>FB[2(M?VJ\KB^\CS'8$7H)F+^,\6J]=9U<OCI.0.;FRFHFF ::E_)!Y:
MS+[8OL1FY-^P=S$'U,,@^)W\8(R>JA.NOH=3^ZAH"%.!84OV>(%Y.].3E&+1
M\^Q5$[<@;J=UXK>K$' 'HRA+R[K;W:/GBIO6';:>?[*G.=V[Z5K"VIX CL1
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M("?FY@SS %GU(4)*_\)TE1%89F?1?M[UCZ/,@9]S_J=3T (D.FM>!M6BS)#
M71B^)V,>._ZL_/*39S<WV"*&7LT(9:LC*MD)L"@84=]S:MD8*'A%,L37)1(2
MOA3,31KC?-&P#_VR15F[)V;>;)?*7A[(+[L.02!:9>E7^TGVY.>Q;=;]TT_<
M4.!RC-''?+NM7Y^F,H=UY6J'B<AJ\P,$[ ^8>J:JT[I['4EYZX8"!3Q3B9F&
M_6PDCK5ZIE]IKD[.Z7JIN5]P5V]5;N 7PGB4B;J(:'6[7&9_#Z@G;FA?.?"_
M'7CJ=9N0[45C=%8*;]S$!FQ]0K&*_C>74_;CGQ0#G!'7QP^+'^/CI%.,3=V(
ML71.[T.0# (W0 LJA^X4E^PYD1DPF.H)F!V"['+"#T'YIP=9[4EF;0??XNF"
MONVM[V3:K%<UZ(E%+N21NW^2N[7'&CM%JB0<.4I;4CXG:1QSVU]EY"8=^B1T
MQS1 \Q 4JL1X4M+:@>G7(&B,MAF.M?.7'#G)>"H"P:L I.WV!1Y_HK0X, D?
M>2.IBVSZG-''TF6<T2BT[[:C0!>E4)X>@H8,B)OTDS7&]%M("8;.*$!CZ+VZ
M:4=-[2UW[:]#)%=S3U<?=<36'?3.C?-9*Y[SE;HULM/3W*^@Z6H=9U*JP-=X
MCV^R=U7?T>3FL76066*+#2J6P5XMJ;RI>/$"' STY,DCX)TL3T_AY$P6E]3]
M6L<.Q(M/[BZ3V-Q<__J3]G%,-?"0HP*C "-4$Q!*9(3'^JD>^X*52K?4<U#%
MU+D_Y"$/\0J9QGGTK358&>0'M%5,#@M;_X7]=6I\]%:)6ZW)FG5U&%C5<!H8
M-RW7@\EPM&FGCJ9<ATIDT-FR2!6ES=/*'8%LKO6S/_3>VL].Z/A=I_GO>^.V
M F[1&H] ,D=[1 TBZ"J@;BOV,SD_HG=UL88+;!8LPA/K)Z+$O,4^M7BWWG3U
M81!F[%= !<69>GH8#H7WTR\1[Q"*<DU#>MWU# *X2*X6KZI_\&G7)=D%>.L]
MFPO28.C].G(HT8F@3LRZ"Y1A?PW>\FL0:;PFJ#:NGFS?7Y>44/!:R(;YM6KM
MB77+)LOMHT99ID!68'[ 4]*W-JM/M=EX;1GOJZ,Y/&OWT^SW]=Q)]Z>CUBK>
MC"2NZ 1Q+#<]P9>!6^;XQK5<\&[)3OG.%JF8)W]FI4*F3J9<T<0]),TU"&]Y
M)J XW'6N4J5(T#8;VGUW<4S'.,HA96/6?"':L(2'[^>UZ1!M]H4CN/3L1-5^
M(Z H'E2+!J+ ^A]OR"EG;"-Z\M^64D&'113E3C_]2[VUZNLO%?*Z[!S?^_OD
M$IJ%&?%OB7+4/N89DXF,U[J!R%^)<6I*4?*N*2I[_WI NZ#]MQ K"9K>FY<N
M\096 ZU KIOA()/+=TE*&9&[/=0[/GB7LH7,U:6YJ]+ZA+20VU?X>Q>G&G8O
MS\ 9] FBPT_E J[ALRWQ)TJ<4V=7)BS([^Q_1RS1_;X^U[>/U/R@\JQIGJ/>
M48(#M#]!9Q^CO,3 QW/.C%&UY_N<%9M\<'>B-S(G7X0<C-N97S!5O=]M\:2R
M2/.&?%_0M"5#6+GGHOMT:<G-W'5QF6AMLX[,IL*^.S^2DD4G-'VT4@AGFSY8
M+@4\33%G,L5%+N12N:5:Q*4R\ (=X!A==JE!]^KJH;!O48N-.;[E',B]S*MX
MEHJ]6^5P(E*;X<V#0+?)42/K0Q G(/1<V0%W" )W*KYB_O08,W/7X<6[2CTV
MZCGF#X ?0X"PDM'"D1U@%M]VFYHAR8]Y9UJ_9[,:J7[3N<=MTW3SYL?6IV6A
M>QAO-P!,1M.J&)D#$?<@0(/V36ZT22\OKVN"+-Q4XN_E[O B\'L7M4KM XAP
MPB(ZZOE9FR78OT:L3[L[%+O7NLD:<''DF;X]<2[#S9'^B,G6*\YOZY.WB\.%
M=?^J,[ T%-$:&9%NW=V*8*6:AQRG#Q'G*FBYTA^8^G.^G*DXOL>I>#YX^@WW
MZ (S6;V]66)8RPI'N]2I ZFWZ5>VJHG8&O;^.^6^<=I )&X[PN*X)0Y#Y=6D
M<VB26%M1W/\9&E@[O_ZN-F?%_?OJ8$>=@.[68\07JSR%(H<9YI^F]&>367=3
M,(\0K2HZY^: 4#)D^++8.Y@6(&ND=W_.6';N]S[I/'3]CN3G0Y##';@6HO5B
MTWGU;LATE"^EL[=N^U_2JNWY>M7XUDWI9+N$^XAHN08KRY\.K#4@GW>1+3!
M(2/R:,HMGQ-)+U;L2R3!=%(NVB&'9O>@,>NLY@F)UW9,N;5_%BP94M\( 9Q#
MQ,(U?*/IQZFO,S51_'X\QOFKQ3PW)]8\"I9"?.<Y0I['"5B:F_PN^^DAA$ +
MTXT9Q]QX'N6  LZ7-I\E9A;$EZ&B=@@>QXW3+WD61RTVQ#*+/(A+U;W>W3<B
M:L*Z&_R_+A##>I2IO)[S=='-JO1Q'?D*HCMAH0$:8A\H/J4X9]2H-K@%NV^A
M<Z6TRP[V+3W&H&7^P)I6W*QJ<S0[B.I.,I^UV-3[\<JN+$2<CHUR%Q!K_3CB
M0Y'(&0,8P'(\@I;C=0B*L83P-BOXTB=7A9\0PN@"\07[<<.NT2@3]VZH1IO]
MXX.[HTQ[>U0>S_DX##_44;])IG2V9KR1>$#8F<K455:8ZO]8)FWG[Z[,0;D#
M^[9+;6$$O*:6>2F\EY'B'1N)K%UG!,MJ*+$HKL?\^_9N:P9"ZT[,J,R'^?"O
M 92)'=IU2!\KE4_3=D(1ZK[69R.FNS3';9^7G?SG7[U*'/'4->0J'/4>"<@/
M4'.5EFF^SI@#1<M=M^L0+?@8AIUJ1>HF!Y(0;2AFURL'%O7(SA?I$Y:FAKPJ
M'SR^?HS5.K=U,O\YUW<_J5HCN#"B/1?Q G)P7D>,L<1T!LGZ[4T[_^ ZI!/2
M.A &X:=?"7@;R9!] S'\ [:9_I17;_S\7M<^J_ZWF'[36LWO8ILLYY:WU-4E
MU"T!.CL3Y5D>JW&TK;B%69)NP?=C;!O0P;5N%#;W$+25*@*FL/OF'8(,E-T.
M*CZ#4Z!NGNB\=D@EN(V-ZH0_IXLLG^.K'*X>2[6W?1+6=TF%)5VPNU\*.R^/
M\DM'Y0YP6M'G&"S0=),',]M:/@,^.37CGF-P0>3^H*(0W2'Z;*RLTT.IKX;G
M3#GK^E./U( C::F.=(G<=0@*=_A68B@0IKA#DQT&O:Y\XLJ6X8%]ZWBI6X@A
MJNU0^<C@7#;J-:(<3CT"S@M8RQA"P5/=G#\%+\UP-_AA"JVM#*_M7144Y&4"
M1'S^@S7+WR:Y;MT$8K\8E>ARLDU=((SXBK)D/YAF@%I35@NFQIB0S?@] /CB
M3IR8?]H\7LWYM.Q"[/?'G$4%56_"L^[_DKT9])3 UJ4]96G40J 7*VS;TSF^
M$&\9 "44A;4<)?XOU!O$/>%?<2U<>%!O1D7JA/WU>V$^SH/DS^"&9H& NPRR
M"XE$"W1@F)_0JFZ3N"H?3Z.8WJN#18/.U.K/\'H/]/;JN6ZZ$=OI;*FD*Q0S
MHEX'-,SRKRT7Q]:$157/WS&498R7>(SP\:>L0F^UC:'U.R#+(*HKK8A^##Y@
M0:$K EU]NDV^ 4"INM#F4J*T@I[;:9>[5>=-%F\^%_W1BH0C^Y71C73V7[@!
M=-^\8S;)K-/V2N.0VIJ2[/2]5./*ZOC"U-\Y+O=BWTBEW8NN".6T%QIP!5&]
M:25'%[&$FE5]QV6!2R6KB%,!4@61AL[N%^X)U,5U?RR?.S,:=*6CU/S:_H=/
M$SOJ%$'?K X=55JZCA#PK?-=W$$SLMB9V._MXWTVW25?IO(O(:7C(),*90!'
M$?POC WE.!#)R,-GB1FWC"[,X9=M4C9PD_T^?O+=SYD'+E'_Z%U]$/8X.^9S
M,JPZ]P>,^G&BS9/"U$I%!^E\'[NL#;T]<F$WVQJGI/CB; H>[W)J-.;<_[Z+
MB;B4*X#PA*+[R"W ;PP'(Y^R>XMQWLYQD1IQKT[G;P@?O9B:U=C89O[95,?N
MZ^UX)H[.K"4H$D$T@PG#?!7(BD#PJT+#A9G5%9>""%9(PZ^&A/,3=!:F9(0P
MP.!;R<2_O1,MJ-/-%V>N)_H7NU[\]W8K2;V;ZY/!&XWB57[='*6Y0I65ZQ!1
MJMXP"EL,J_B;ZT;2[)Q3FRA7>YAF81,Q?JK1_F3EZ6.S-UYNRT?*.3L:%40Q
MU7'#:G-_^!""72BV ?(_)RYKZE</" "O'Q$NE^A?6MA,,[SUZA1>/^%I6;AT
MFH-##TCEH IO'%R-B$:!F_2(V[!HAQ&JWK>9R7MB/J Z[O<SK-]3A(Q-KDLE
MP_IA5!ZISLS-()1;F1FNH&\]M,/:@98V(]1+^V;DJ2UJ7R)A\-!?TX1U1XYB
M0 T@UJV/$!&/@1I\M;K*RO<*:VLI=_^^J>9'$F9_U=45)S5-+CTEM-+?-BF3
M;.@<AI0 W[I'OX G>#%C@^$7D+WB?(P8^&Z%E:KI&46/Q$OS56J5]JE;$Z.,
MC/ 8(@S3<R(B<0L\^+\^HS6&4=M[!5&WCG,EDF^G@KM0!O^_6MB$%?<+0Q!@
MI(Z3M&"ZU$H#K"O;\L'$SO3 7*RV!W&UUCJ^X;2HC6V5@?3]CY!7[6<5?G$D
MB1S<!S1)ENT0$88.>8.O"WV2I4^2^3[340F2C@X^KV@<%T_2+Q-YFEQ_GYV/
M)$?E>X,KR$A$V&^>=BL\GOJ ^&0LI\QU@6NUV77Z+[,WJ%U!18S]P<Q)7QB5
MVZ8;G=-(5.X29VK.Z ]M:^@U=&5?NNHM6/>AFZ+SXO[\;&80U+'H?X[:HL8Q
M8J"5ZOT3>$,4N O /L]=+J^:IV"E5:X9G+D_TMNO<K*I?#].@3Z\*?X5=0F*
MS8"(-AD0Z\BE(TU<\VZ-/W<P45?LC9R1UM=YEI[;9.N85+ZAC$3-2T6<.795
M8AQ)@'VWI4]#B0_6P&'6HH0KT86N%WWM^..6'6IBJQORUQ+8+2BW3HB9"^2D
MS3* Y+$.MQ'1;3XCJ%F3"HVDR')9C\_Q^@H<PY@.-M4$1UR%_*/KWS@$W6-L
MH<"5VLI8>P/,=@53R=7_-_>53#5J.M,9<^;]BS.RNI8GFE<!".F6(3!&C&R#
M\GG%E[!&5_^[@+Y\[?2?OFC<0*EI1!RE&'GTDO8'9,O)!TH6&X%^>L\4STC!
MGJ/*N\I3EH]^CGHX-+SW+:?=ZETG5%M;?7*(9D#6([<M0SI;YR%(-K?T$#0Y
MA6#HRK?F!]/7(=&'H%ICZIDL<ASM,\I9^73 0R!P_@E$;W#W4:FIB$WC-.!X
MR]U-](*51&V*2L9-7<$%\9>^2 :VHZO(F@"-<O:?!C@*?M9WN,^\CL3RI_;'
MA8Q ?ZF\CN">5UH7@]BTGJ;FC-&"+'&;5/X]ND%BNS+EI.TA:$5CD+4-=@R*
M_02KWB.P$'.O ZTXB/@*OX9QE(5/B CAEHGA>_X]'IO:W1CT;2'G'D'[5C$
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MNC-171FCNVS*'KNI1=H=IH9D?_^^:-NE<Z.TSJZNK1%*T<N+A:BJS6 8[\Y
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M$.W,M& H-@_"5PY7M*+W'X*JU[=<!32R>T9>7%;X>5LXO#"_;+$L&\O1V)'
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MKRZU_WY,MUU4;>'WL4_W>9/N8V<5W2/]'RGU?[<Q/' ?@2Z(N#"4<1[#0'=
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M/G(,2A6*_0(_.PYUW9P>N4G+I4)4TJ=OYHRTOU2E#A7,]D5[;C#"N="FUH#
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MD=7Q-NO#L[8W%C<3-*_--RST;;',GIXQO@'[@#I^"')!3$K1V2DX(S><95B
M'X)T;&O3+.5@:\VX4D#QN8H>3T>=O&1M\FF]M"DID%7]PL0;QOEDD#:CJ4J4
MJ_]T! :=4H;[.M^A;5R51?BVW;$A!F%<"=^W6%YK[ONN9.)1V ^8"I]U AX<
MI"'0M2GBS*^C3E*.RF^\T) BLU@0,OVXYUA;^M^3SWH_OW6R>%'7>W->0ER%
M COJ0(ER\D2?(2-(B-;-4[ZPCFA$>2>HYF=S;64,6V'=SP2OMRJSO5CXIN@%
MO^XR?P$JM["?#7:OP\9T*D;['>N#?P.N7Q+QO'#S=1C1%'F:/@!C9?""31Z
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M/(B\^C_>?=E1(2GA$I$P#RPG1'1ZZ&QS"++V*&W H^/L8(<2O\6V!%?*U^7
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M/\XGEO*2ZYL?K>?1_W;0AGGI('B[^1QJ<$Z'%/1)*M5BLDDGP-.M(-_^6V6
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MOO-H4QBLAW#XJY*Y8M"_ .?XE18$@ EC BFHB%1)M"\C/,[@R:!QSSZ?WMD
MI=1DJ/9Z#'9_K##*?9(S1C>&;I5IEG"'\%"3]C!",],7;#/B,=L8[\_=V[+F
MGI&5X68;U5:\]UZ=&C"9TSQ27$ID\D<ORH=58T[YEXXC7@2A1CP5"^V=->Z\
M-^[.Y_AMNLS-LFR]8DWA95[<CD3"R1?;\0UZR[0YO-+6LH^M.I?V9D;EM[$[
M"ONJ&6FCE]^87JX\4B<@%A-?-[-3=":;Y4ASA M[[Y@FS".56VVM;Y/KG'K%
M/J;AH_)3.MA M"< =*<XGIEHHB.[P"EZ.0[)&Z^\"PH<VE!K62W1X\&TG4Q[
M^C^#&_ /)_7,_V,:'0L!T!/"/HGT(UM[0OF]D[YA(JKZ^[.+0UF9=N\@Y#2&
M'ONZ9P:>P?Q _^>,AX%$-X77?&$HE*)#/NOF"!G1*'Q X(I5UF0>PY0W!'26
M;$[@/^_VQ/.JOA9VZ,P6>>2Y?QJK#SSK?TY:4#GR3F%3<*1S7!V<X)-JA^$;
MMI$=8NZ^"#:2]>WA3>\G[V4&4F]6); JYR4^HW\1-^HDRU%[>P);HD"S.@8A
MOO%33I^\/=M)D.EXY?\-3\LO=,N1O?_QM9G$^%?(=8=KMVDF TG7/\$>J4\$
M0XY!M2=]GE!#Z4DFGI[S7+Q7.11X>'@[[PD8GRH4$@:=!@D< BJ6D85:@N)!
M33I*X2-C46"2T^T?FN\$Y]:'+'(M[M,[V%4:$[]PJ)GEGF]:^@ZAHF$H$1*"
MK.\_U#[M%ZNON,#%Z9$%*3EE/^U@^'E:_\Y5J5]?O\K\,?G]8Q?.B/H%2+U-
M )K%/5!"^'U,*Y:3U&]#8+#65I]FV;K@^'U:.IH_,5:GET_UZ5NN?:_>/*Z:
M8Y +EM>!M$UT)#DMLK_YY;@.$1YE&)6$;[%[)/?*7S9[>O\Q5JD9[*]'% "&
MYXJT&4/:8"CW&@DJL<NCGT<C_JGI#7SF)I>B(_'3]CUWW[5 @[0?:8];I"9Q
M*%T2ML2&UBJ*Z1IB<G-J$TWK#DTH?OC0NR5>M;3D:N?O--/NO_21\&34MN$(
MEA<[GP:PB3;X-+2+IDE =%V3/(-@8S^OM%>_HJ?\Z9NZB++RW8>_[ZH&,VU]
MRMQF#C: 7ME/)"DQ;Y:SIH^,MD,4QY8>W,TMMY&]Q<6 VMG3XD*6H+P CSZ+
M\.+:JE3\4T@\"II++H[*1WIS"\8/VXF("-LOU6'^6'?I:F]BR=HDIF-0MZ0T
M'A>I#UX8E-9O2EJK*?N=.)L@FW!QQ'0UW(@Q<T^ <@!<44'E:S5TYLN2Y:C,
MSI._>UL>;A:%EN4]?3V-)O2@D)"6/*Y"]'P=1'V,!R) T0]]5*/VSOQN76QE
M/SB5@0,]:YW)=1"/>DMK.0:Q[\'"X17P]G@5TUKNH9(UK8;9W22&E-GUY)+^
M#)DB@PW1(X5S6_!L*-YN&^3AIZO2#HX1+/<N*\LY!IDU/H4L9YB+$UO(/!RX
M*,GJHY.4W!YI= $;EUM1&_(]-4 \"_-Z;\:!ZVX-A_X?^;(X@WCIY22Y>$&C
MRRSR=5*@5]U;>F0=D@GQ(PD6@"_N/.!UQP\]0_@B D_)#'EJ-D;@A).XV>5(
M0V1E3S[B#6H&!4H^2]'Z1G)?*'EY *]L&EL9&Y@L%FU":%AT.!D*@Y3/<'Z_
M9?85,V-"?%M!_8?&"J<8A2NI-!EJ$(E9MW)?;!8'Z*=@LBZ^ALA$(E\G0"Q8
MEUTSJ&%H]VTQU 2491\6[:B!WR^(S)J\GWVKQDXK+3_GW(,(X]2#CSF2EO4,
M<47BW&[T^!GB&'XB?@E*4NB@<1'XP1XCOCANTI6V':F!')=OXSGO^(OJ35U^
MQ1D;,KS4P:QKM]/ /RCR[W^2/-NUN-U?W7K#9C<]_:\TP>TX!6EE$.BE *6;
M-H[>R:!":5U##.@UR!OXF!$(K7X":\<@KK4)L&23P*+B?4O%$NOV.8=VA6!G
MK4G+UZXRVUJ3,ZG?^4\'6^_!\&U'2W=(G@N7KV_5#OE]O'_SS'Z TG F[3$V
M%T92PE'2L)%@XDG:=B05_H.YC>M0=HX5H)IRV4 L&O[!_,%Z)Y_L22U>PE+X
M1VD"WPNW(+ERM7G^C_D9$I4G8&<>6YC('%1>7R;V8M8;L&FY,^O==TCT )Z(
MQ2Z6C'$16?>5V#NU7)@XDJ<SK[7ZM")TYPSCCEQ+0.@[NM[9#_/7)AJ,TQ 2
M[]+BS!BX.][+Q)P;4Y ^-Z]0"*+[<5(C5S!UH2OY*X41W]WQ<XM[ R(VL52I
M#7K8&;^G=A@%>[9JPB.R]AU"&-JH#=>_MX 3]_>\28A\C5D<U_!ZQ%!?U1 2
MUGW!DJ/X%/3VF"27)FD8>++/I/:%?JYP1T&2C"LRQ3_2>MQIO-0K.4S#2C#9
M7/2-@0Y<RYV_.WDW )'P#]U>(H4WL&LZ,@[JY'5JR#)[",VQ+G1DJ4IN.[?,
MU_41F*E41LD8$*:/BZ0D3WD'CT1OPLJ R20?40$&$6J+U!N'@%'=DH)!CV00
M/HN!L=\\^Q]<9?'.?<+A,XE4S4]\+'!X4@T'N%)J,7Z;&DT$'\'1!N Q)7[K
MOAIHS>IF>1'R/ICA"4K*9G")J5&+_8ETW8XC7FOHC/< _+$[._+]M8_IA\9V
M,:"C+S'G\KAZ$DD7K+MP)( UN&YI+T RGOU>1W-O7[GQY6G[S=&^FZI+R<U.
M;$=J&9+5\VC\3:YI*/$:%5ALU\,+E, E\DV5+D?Y,=?FL;Q \^X4ED6(4=79
MI9"DX"@787DF2W6X%&TF1WX<^T1EA@8.=^1_V^_RL-"69-R:L6)**3+]]C:D
ME5U]H#/R_G @';P0CE_AFKI*"T,!5*2%#*5=R>/ZGDA2J.U,G&I<FJB?QT3#
M&9$/O3 ;-4]AGSR2.A$^[-DN"-V)&X/\'E?T^@I24"Z;B@=Z1&$2(+C8MXEP
M/"S^[^KN?JSG[4_KK]]B9[Y"?62P9,M"F^84-I+)(IS"@YD_&]D^Q(NCZ(Q3
MS*$Q7B\VBJKJ2C%*+J%V/4N/(W0$E'AB&H,+.%B^>Z["2=+8KOQ\?UP7%%0=
M0#3$&&B^TQ&>9^\WD*XW L^E\,8%O=>@VX+^MTJ&%R_"2< P*:F)@)@@"F*/
M0<.L<"^ L:*7NU$G>4=.DV/0+;^[= =>)]F@/C^*0!@-AEJEM39 :2'P\7CT
M>1S>BNOP,CF7S/3G&'3$B+;2H*/LHEN???5.[<AEJ99[Y/6Y:N*1X4]]2UOU
MW Y=VKVC;V2&=2M=S*8//FL#IO#H)J^PF'O/KM?4^PP"KXPK[E]]R^_!IG:M
M2+-D[=HH_?.NQ"%N)+3>R_;2C\<V3VZXJ,C$^>F]-$\HZ&OIE0)'_4L4UV2$
M(646#K&/$V,:JG35@KZ88[@<9W4[GZ!^^ T]WBEGBW,>2/9>F)KU:7Q4QKP'
M-I*NJ(BXDQ3 \$*ZF8O: /7B8D3UXSCV[93T[H6N+FJ5>,F*0K+YOJ8:7B@.
M;ZPS\!%7=?6?350-OC<T<)<>'SOO7$XJH+$5"[[/NT367.W@]"#*Q?V^V?#+
MX=;3((X'- 'R!MF"-I?+#'7&\/VA\9'2/FUD'&3-OFD.J2H.#,B_GVX<%:EN
MWW+5!0;B2=@_<2<&;VKN?BX?\M[X,<CMV_,Q@%S[.[)N:JPM?W\\KCQVX>OK
M?1Z[QDA(1:GZ=Z@O2@DU@*9KUO-(UYWLQ#)-^Z>3;[Z>F1E\.E)LPJ>U$];_
MHN>7V2J@=KDHD%3BW6/0>[\N,(GN(6  ^T=>^.)%2#@!O3 4B9(G/1*+#5+L
MF'@V-V/R\DOJ5\NXPN3;LU=?!7<$3@[B\'^/03\K:=%6@+NAE=&D_:!["[F<
M_M8+0Z^_ZJLL%-]_@>#Z(]C/V:3PLAV!8,-KZURZ1Y\"J]>@&YV<AU+X8VEL
M/$)1BUAJ!MK5+GW<=1R\*3I7[/)&?V2K;&W"6/\-1^1RVJ14J)/][ZB58Y W
MG'0N(YJF[KE-5D?U,JW0)N]EDR&[]T;'LU;O)7\?]7Q8N<(MF7ANY7;21Z-4
M^9_0,GD*7Z0!]5W)$]IYBFT$I^NB?8^D<%WZI-%I'5.8M'F<N'Y[^&^G)>5Y
M,0 YP#\_;Q!=\1*3B2CIJ8]H'J0#[U?"LKI[ ^KJI\\+W9F;]$-A<:_A\[TG
M>>W06;LYE4Y<I- M]+#SCU)>U35I!]YC4/Y9M.DXZ21W64JZ$U1*4<-K=W%>
M-B\(1Y1J;'3>?FM8]$7C>6V>V0/6_20+YO7<S27-;]V;N_CF0,,H67Q-U'#B
M-:V+R4?6:2@<GUTK61QI$YC\CZ[L%RC.SPA&\8\A;)/.XKIO,B\.;58N#+&Q
M[Z5VY(!BR3(6U8\E/0SY+E8D*?O\KA+CUU*MET!'-&%H['2$_BMX^";A&,3F
M/4'EBJ($^'HUC L'%!787I=/<:5/,T[7B/<YV&EQ5GQ OXHCG2GY-OV3XM+H
M1(O9<6/)IV5)-5] R]E2=S$]0R091+N2>1NX\C%FZ9N57'@3XJO9Y<*'\40K
M4Z5A:D#F#4@PSP366M\0XRXI\,-7A8\4NG;AQ3?I:<_&QNC3O.>DKLHF= _?
MY76C)TS2V(7( ("T\>&[S:FY^CJ^E?<)S<K[ER,Y!5.]CT'2DDM;?*5T?\M-
M"R(P*&"^'6C?<_&  'I,!O-XOFPVB8&<R=P/G&WG-?+HIX71;>]T=%WA4MBI
MNZQ(*%BP2BY!MYI"$1N)_*3T.6-\>:/NITV5OID_MCX*=M/B3SFPC='$)269
MNFWX>(.T<:RXA\!=$ C0#L%L(%\!SLX.P20S7U_I=@X%A]F>>T:W4P9@(+I>
MN>:'_Q?;F +BHT8(OB&]K\^Z/KW)#/Z2YYP"7&SL!_.\*T6P<<F[1Y^/#'&W
M%N^SZQ#]4$03P"&<(R4+AAX5#'-]"H1NWB3;HCK!E9.;H_.XR%>Y'=EZ7D_M
MLJDVJ&[D?0^A@N]OA$OJ.1[UM2>WLER$V5*J:D<!' ^-1K=>04C5U=7!3OO'
MWGV3Y<9BH[3'J:96_L^%K^5-21UYO!]9G7N9Y:$EN?\>TGJ'2.<B.\%A<^>I
M!1KH1'2E7^S#\;\(I<V_?W_71O@[SMP;%;]@N>BV]/U/"J]J[AOAG _80F@H
MEJ\*$W<,8D6>)=PQGJZ9DQLMV68[/Y2FB-E^+S]QGO[,P1UXS#&HVH_"ZS>/
M:QLZ*4H.YFWF77>4:B)P12@9YY7!9^T&&=++=*LGK!3=LL\S'3!HWVL5G\Q'
MMPI!- %C,<(W=D)/[9L=.)",-SUL7Y4O__1@."P,&U$,OS"WRP8Z+/AOU "?
M7-"F"&[0KA^#VG/)=/;HM3O6?X<V!X]!<CA\ :WS,A 63<_D<7F?U# YO/5O
M5;KA?7[QT-_*$T!0M-3 4!5"3YI<T&RP\Q4UVE;8ZM+<9WJ"";MM1\ARUSS#
M9[XB]#2&.+0H+:-9$(AL0^TJ+!NB#ZTJFX<WY8/?]V5^JC6^ ;[!$T.)!%:M
MGS:451N'9%S )J)$*LDWYMAWGU0'A:EQ0M;&W_^3L,8P$^:4E_%LGE=7A70V
M=ZMH?DB$H@0P0-=<\#I^+4<5__71J#GYSE>S(O?U9Z>N#!BX+S#WJW)E?BA6
MWLYU8]Z,=_8/LRP?KI(POS_65_(NOFKTN_W"M=MG7&6/O)@U,? 4,/X.;@;6
MBN5HYO?$GJ+P%+<7DK8[)W;<#Y[-Z/9I]+-&]*<^O4M)Z1=Q&U'?!77V@)3G
MN?H32;*<\>.XK5CW9]Z=3A4_]G4^T3?PB#\ D\2*,-/;TT(TMMMX,:('*3L0
MG]_= (W":,8**ZT&:&S8V7CUV><E@]R]%Y\$!QSJ'DV>]*<S!@,!'K\=J0\C
M7_-/&=I<ZA@N3?N0(>Q7&6%YX$-'[94S'8;Y\#V+XSL*(J@0#:E9-%7_+P@Q
MR@V\1,*WTE\FXFH. Z.*%5<:+<#*1N!S\\_>6C"WH_%'L*D[M'"<,'J>$9AM
M^<D-Y>2BF0W;F^F5;E_+X*T2'0];.'COG7X?+.O*_)8/#@8,I!&PFJ&CL[8(
M*@50%$OC)V_1TQ,PG?"PW(J:XJ7$$-M8-]'<"&^-G1U#!O5_RMP9&PL3_)<=
M\E_QOEP&W3)@"H8DDS;PQ&/0XE K1A2I-H*Y<ZN) $GS*VCWD7ILZKBH%O)3
M1?:43[<FY1?% ;"!:[01'&<3-'!)Y31\S5$O\I95CJ>YX!N5K$NM+YTCW-KZ
M@[EZ*H2\8[[>4MS7H[&&DQ]YX*I@[52G-K2@_JVLV@XOP2.SE_WB@B._UBH^
M9'Z,N62EB59J+]ZR+_QIM\U&52- HRG0>2R7!^0"P?']Z;3\M8N7!\?'-GG/
M/8IS>1.]!X[^HP.P[F,0Z>SV5G4>TGH4NY"CB>-T1_$0F,(]#G3]1Z3LS!6!
M6(!#YR?P+JA)X&&9[! A]Z%59HJ H7,YM?%3XSC$TZ1R^*P!>C4FSPI\,/+-
M". P:P%-)^>8Q2L)Z-=*<YS@+8C,N*S1G:@GREY_+:66RG;EHP/^FB"MF]"M
M3R#\.'<<#X63\&'*_*?G*Y\_M0Q<Z7K9(I+^O9"*;CT0="TYC^O/"O8BP/!*
M1^VZR:+KT1?[^[^Z>X(KH\W!E!>:09?)DL@7/]!NT*G=-DF=4961W3L)7>R7
M'UUNZ6<J0(A^:NNI[_O[<$4.M:-6^XKR%9C[,>3S'P7#36?($+?:M6=%G?Z^
MWVR%,_F\B_B,W,7K_HP$5$#:>]B^&HN8@;:P\YFZ*(P*A0^WV&3U]UIM0V(4
MJK?[RHO8NPSH&0//WP 7?S*Q0;[J/\T$QJ+93?O0/^TV+'#%2JBJ8U"K-HIO
MEG*9&J=_YH-_ E/,1B>/@\?DQ;I6'H];MCSKVG8!SF$]LC&4B]1_D&9"FU>!
M6:/+;D-S8U"M^3]Q'I(B8][+AWR;M<Q4P=^]+?>SC$*MG(*+TK<,P!,.: 4H
MWNJ3YS%HYI&=TL5'FVNZUVPDD"L<UGLNF/57!U8C>[/*03ZWFR)F;M6$EYZM
M3S<R=0H7\C'];FH18FS.%ZR#6<;='I>E5@,S^\G"PU%X5T4CR*=CHOE&]K-X
M,5,64:^"OV%>WLZ@8Q#?@QTW^J,)BU8#I[J0WK746X7>RE)5H>;%18+"#RW_
M_KWR12$N_5_]5C1WN=JY9NX0'Y#ZEZ8@(D@MPN_2RD4-WG]JN'^UR7.'C@3E
MV'PP+9C.J_T[6Y%7UA?J1K]^_5SA2I:B?T[ K%."YH6!#L9[]+(IP,4^!T/I
MH?/5.+&7AO.Y4[O7ZU8LYZ3&!6#X4G*@[*5]2*  )"I(<>HDQST]2CQ'S<$^
MSF6BZ(W19*=F/$-_X=;[B7J+[1;?("]Z.KUZG 2MQ!-8#$-?3?[^U)RM3>$W
MI['Q!3!V=K;Y^W38?AP8-;C2B\AS3TZ+>^_B$K\<<1:4)F4N9ZJC0WUR#(J\
MB.H#[XD1$#1FX'X[ B#4+73K-<@YBB0!MJ633PFD9C?9G<;X!"!<_?R4FM3;
MB-.EF0N/,OA,)/VN)27'47HZ]@6HAA0!TKM/2%>2^8)*3);6> U!ZQW"__8M
M9)$#.H@54FXJPM601;$^*8.<BF6B":*&:!=):?@,2P+C:A12U4.3,92V/N<F
M6QTR7EI1;G=MRE2[[DQ#*<O*-S$:2ST!0^-5"9\[3Q+Z FO8;M-VLAP=3Y1K
MMY ?O":9;'_^\4&F!?,JCB+@2H.E[]*:-!!40<6C:LQO11I;)8"2_0''($=1
M;5JL -7V!]V_DK+O_E4.\QCT3^9/]$_S3O"16>#_EGLP0%>:Q4=27S?=!B)M
M1C7U_@_F'6NR4R\X'#O_N6$E'U.G-9$C]P/AXGZ:WR[SR<KR$<MW2"BVY#K-
M!SU?F5NY4O*9M'J%FE^E=_D(4NEU.K783+@WY@CG-[6<^L/\M QSGBKHJ8W/
MD>'_JLA9K2]"-@%"8),29AT_3;G^0\FI:NR)JV^")^[LRY+?=?('Q=*E:Z?B
MN@X9&,_=I]^[WNQ&K=14E) GWB!A?0O3[N>V-32QU\T'U IB.*ZN._MV-RNN
MO:+P_*NQXS2*<QPI>@RJ!+=MV4H\^DM;%&DR\O784&KBGKF4KJ<JG2)Z1R&_
MAY\2HB5I$QH<4$OA8>I:AT7#^:IEG8AN&K'";U^J*+57@%N,<>]0P<A[P%5+
M:=^A+! 9_]B%R.@]*+^]1[-(4WK7BKFYGG;(IZB%N"<'A9U!K!9!Q6(T5B4R
MQ /'C'5MS!4G?1G:?(7K"(RJ9HR/D+VI)DR<8I:(W4Z_31N(?2L><Y3:!2T[
MV,Q?.@;Q>SAJ$!+;XZ%W)O:CLQ;__I[S#?B$;MKDO6>?0^*GV\D(1\^7H2N%
M8BFPC_ZP&S_T;216J@,0+NSF+L[E7VO5+IC:E^QRYY7U@MZ^U#RJA$NYX<JT
M-X,6MAYUPX=IPFL3DT=/"/8S?9+SF2OA8?F@D:279<P,/!MP.$!H"RA"\C2#
M8Q S>J,9B)QY-M9KN9N >I7SQ6?36IZBM3 #0R1E&"6$=OH8-!GD=PPRJ,",
M0G^JT&YL+&A3@^=I7@;@2^A6^-:V'#6A]&/-I01.OQL!WY;DKH%)9*4'Z%91
MN=I4HOE8"D]D;*=N:._?E>GA2)JN49 UV1]YOIG43Y9'7L4_3OFT+ULN&O_A
M7+\9)%MZ]NOURRX\PMV-ULL'%!ZGI<]A'SQRU$B,B^Q[50V3+I'6P_G)H5]W
MNT5B=C1Z5ZZ*=JSGIQ2ND@!D$\?\AA(YS52P\P4OK5_!>Y]DU<:X/-"1-+=U
M# =G*Z%-X%68+MQIVE N8Q.,H-<AE#P#>>>N\--X&5$_)GM%*2\>-N>:*D)_
MR6( =4\610\ OPA-;)UVGOI!WX1@M2:Q!Z@R=[6.T5H]3+4VJVC*JU3>&]U8
M^LMN](7_/Q(3M4W[KF[W"S4$95^M$@Z%L;O%"^]==6(%?T)9H5L]F_EQGEB.
M)DY"&,QR;<%N(UZ7<->5V\,C7KSD#^_]4T'. GO;%-YM8!X(KD0;_&HXXY'9
M(@QD1$TNM*WDTI2*SK0Q%=+9F>:,$1/^E8!M-Y!L)R-O(I@WGQ%<_AI;_$D!
MGBUH5@!*6%3<E:&Q>")>UD!%O'\>@SXT99TZ=PSZ'*42"^Y-;SYI,],"1-0F
M(;(^NBV[&GMU$2KI8.==;2SIX3Z1$KW\IN7W[4_Q,O942ID(VT\$A:=V(?W3
M M=4I35AKICORISVA&S.V,4NLJ*LX!]:TX <V(!EPP!<^L)ZX!@D@GX"FVHD
MH@@2&:]12J0)3BX;;/SCA#&[7[,]Y3H*%=>5/F3T61JVIGH_-9WG@U]UF^Y*
M6Y20[H?_*%W$COJ>DZFOJ0_I2+[)T2>IPQ-Q5?$\ T\K4[!&<0O4 QZ7?@P"
M-8/\9Q:+&THF$A\L=MHQ7*:V<D\KZX6I?]XF/@^TQD[.PT[4&R(#\5_$H$U8
M3B?L _BJ ?@,NE6%)D^A)YD3?#KAPA (J5F"S[*F7+#A?GW$RL)*UF&__2^F
MB/,7>Y(WST;)7G\U.8?&6R1.QQ*UJ?F V'V':),4)$6[HA??R04&69O$;F84
M.M?7/DH4=@VY*R*5 GR\I7+2KLXS4WBYYC/B(.S^>ITX 5\8S[1_L?WH>^RW
MT+[U:>$SGN]7NKD3S&U$;&1<K/MSWZK./[T<1A-O)9]#_T!T8DE@UV-0SUVZ
M%8!]&V'BT3/'($Y]:[S\O5Q?7+AR1%%!L>3-^,..GC!RN?UYI^V+&,3)VJ)[
MW_TZ!OWTNT%[;KVLTBHVD_L32F/3/@:Q/"[RD7TED(-1#O&]T$&OG/A%0*NR
MSX#^MW7H0IEJVB+6$?L?JVX/HEN%L<NC^[ED,95CT%Y"'];N_ZO*-B-*\J2[
M-'HYDZ)V\O[2-BVU!+7P7Q7%GD;C;V /58<BP/O=EB='(6:110"1JBAO2"4&
MX2$?XE!#S#&\\HZ=OROJG>7_\&!UCS TU@S@ECKX=EK=.OS(I[%TE+A*X@PD
M&Z,&)15)0>];*DFA9Q-OCUSE5@]TGGOT(;7%/1_'(@]"+(<,@OR!15"T+&^F
MQFMDVUWY[*!W?URJKK67M^K#P\8?A\_E%V*HNIC?QR :JRO9\0^TLC:^&@<X
MB9 WMEQ?<['XGQ3%XN3?W04>PX\$A1C+?W>K,9J\7!#A>SFNW'[D5_FM<LSK
M#'9T-6%]8D'0]%-T6+?TQ;Z*BF5N$ZFP, -!ST-5:H5+8B<@X;X]QAD^E<WM
M:):L,(Y;%>(Q=/$^!D6EW0K:.+I$+<!Z("*@%;AV,DZ0-&,1O6\5C:W4>)V,
MFD(_-60IDO1C.>":NVX\)M'_$+8+D!J&%=*])?!T&+$[=2DQ=H'L^&ZAQ!C.
MNR%TH]$IZ-;"<OJ([#J]6.)<^!]>K>5G25RX8]!T!A%+<B++N.LRE1.4VZVP
M81T^0XQU(WFACZUK[[U48RT(!EWE>)#;UJP.4*@15%_NGO+)F430!>@A!&L,
M448RD@P)B]VP490RZ=%,Q\3TC43-+_8B0GT!(&L%)V?]8/74!,5VZ,+L,:C<
ME<I;HDVCV1^#".L@(G1J8VDU#.T.C[!""U 8/8-<\W&P9][)ZZK= BV!KJKU
MBOP5I:SB2.KE\VAW]*$V. 9+/+^!/3+4? GE;!;V9Y\_!KW>HG#B)XTC#7^4
M2)I)5P>7&P5D-M;85_(.F"W3TKI1(P#3\X8*H#?O3*+W0CU %$W &:2.0;W7
M20 S>A +IIY[18O?..SYK[[^0W]X!_@^X$(Z&&\9:*=DM_I-*$<N*K5U-V7Z
M3STEK?CH*V:9O#A53XV#SG].)4U:[@J95A,4-MJNV5>NZ?:K_XIJZ5I,'M2X
M]+?'"'WOE>2W#Z3L:Q4$^4C,^[$7)=?YZVL:0CJ2!CEBZR7$G06DED5!M)?8
M^=I*N]J.8U#$TW/4([>#N&YJ1!T=^IX'M8N:X?5W"_HX\75-[:KO (3W1\J5
M5]MV+(94S\,2X#E#*5? U9%;&.:P9J%;FHV!,DX+#LJFMTC>RC<&7%XH)MW9
MXM/=%A<PF)H)@X_#(S3$X&PD3S-\9ZQ@S?"65&54#JNY_X2FO&2_@5@:I80V
MA]Y)G8)N*B[ J7(5F/44;!IV9HAF&2A/#4<J AX^<9>.:GG;Z"F6%R7GS[7
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MHB91I_&H$#SNSLB+&0P7_)?]=U_W@@CM!+=04,0<:^\#$ZE"X>WIYG?43(C
M!HX1Z[K-0#E'<";69F$B+S"6#*0_V;'3VWXLIY4F\[P.L6AT9-T,/.G00=<0
M21;;.<1&L<Q=1&]&+_8'R<W^=?P[,6)75+6QI6;&*J?GF7DOK$/MRE_G!Q_/
MXT*[KUX#_ 6! B2)N*8#9))82VK5G^.M2I9-;Y.XM72[+A5Q6_RY](SQ,D=
M08#$R]JKY"4C$$J:<M(?U(ZTM #;2OY <<%+T,*=\*,&X[Q_1V&!_5.^&C7W
MM02DS1\;/U_.<>WBNCV"]2[\$ P5.@8AT"0Y= =XVF[I&E2PF<=C6C+E*"*7
ML[E$L$1S@%-IO,8IP5F+.$E7>;I#+V;I09=/]RRN'+:)D]^LQ+.;DAX6#7H%
M8$3^JE1[9JMM,1QD<,5UC<AZWY.^O\289L;ZEF.QN>)#L"K29&&6JW,./-:D
MN.AY;E]"WKHV?>3O],,&G;PWUTWC+HN8"9#4"7PT5C A8V$H\2,!MQE&$'@1
M%=LXT^[GYU/@(>A&.52=G5&,'JV!]U]J\>J^@,YC YQI9!P[GPU8!"RA=L+6
MKWLHQFK7K29!/*C1JG&,\L&8O=VC4$;-J?[%T$$Q,9;X@/JFB8ZL0%&+7!@*
MT>__G'+'M]!#"!3TX6BKQ2JY9>&N0O@U<86$39OL/PT @U8G=>-SV]#BS2+^
M80NP!&GW%VCNF<RSJDFRT6EAG1><0^D[I8M+#45N)QD;O7+AIZ,LV0#.AO5&
M!\\I-S=0WT%D;#L+YG)5MEZ^BN]*T_A1I,<XWMQUQ;J4OH?9*>L %HG%7Q^*
M=H2.;^O[D1]3KF1TB[9-WQ0(?^UWX*?Z]?OK:Y-"SU\G&<='[+RW8*6_8*"
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ME?HREXX^@L:"^.G^;&Q/D;2A>I1LJK@I;@_S4VUSCY!(VHH473_^5>Z8?1L
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ME;/^&X6[B2 J!G2??8[9BY(2?/#YAWS66Z>;,PT2JJ[ _7%KKZ3S+7L-^2>
M>K])*C.\2]K0+'3E'YIW<R%^5>>WVJ"\#]/I]TO,[DQ[9CP#?RJ3AI32?\_7
M0W6A;:*V UM&G>EI0C#>>:XWS81>)7! -/J:F;"#@S@-][BRB%NG(8,T>X5
MO2A5QCJ^--LSEO3+9<[[</>7(_I>[6:.4*#-ANGSYYJ7JOXE]6J7EE<E 5W
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M6QQ-ZHRHT>K+E/05&];9A9YWF2;EFX&#;1'V#3FW&!_R<7&;)FS",1,G@*8
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MW"A?!%%&)QKK[WW4!ZHKBR_"#2\,>E'[IAS-:^/S,J1;XJRT? UD+.0UP[\
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M#:RXFZ[R\F:[G-8_;V&_LTHI:X/V@XZ6/PX>WN^BO'L?+AJ7_IXFE,P  &8
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MJWR'\?2C)/F;YH3077-$H%$&?X%9NC_Z\> MS!L+V:B4AN.SM#6ZU C'F9\
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MI3.#\T\E6CV-M@[VED?C#T%B4"F<>M+AM-/D(87CQJ3:6_[S(KO5GME7*_0
M=>)<4^1QVF_>. & EZ(1#<8(7$[_"> ,4A;HU3!5A/K4:B>QEK1-^,;WD"E&
M^&%QY:6++"SGPJDI*&_47UV;: 1!R1=^;,H)>.5P6B4C&X2S1\TK]"]]IJU
M^[E"J#PJ9J"/*M>:BUG+9MV]YA)4X0\=4/1B=GYXI<KBVE.C9B117FBG#R]&
MR)HV]#DM36)<QER$E=!AU5;5L?0O:E#W:1MJN9I6\7%_X;WTBD+H-A,LF/RD
M-8] $TR1;]!$YG[S5MQ4RD?!F&@VI5;'%'?7OP*QPNG9F!]'/XO'*X@Q>B>
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MKPSR"?[:(W,Z'%BEO+6E>NGKRNW)LI3I\7'=7'"I1_J N$==6YV'4CECQBT
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MG?UE\AHVOL-N-J20^QWP$3=110OM%(<T9"&I@0717Z+;4XF6ZEEK*<Y6:-C
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M5E2:LZY6N=\J'83#?.)A6F'P%>"=B#T(E?_G >@/#VB7Y5V^8$ 5PN#..WD
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MUCT[?56\7JGB^A?Q>^^"<AC!_S8P*L3T0ZB'QECE)?,&,PR"CS\ [3R6U3H
MU=Q",C3J\@76:C&GD;#A)$@3%(N.WS^23E-=E2RI) PFRRBVI?4;,\>3818]
M7VV*=T[AYAP_3+WNXI2>W/BWNZ&3%5<L[1==!M?[*=6#.7:^W1+[]++I:ZEV
MD^X:Q^EX!=I']\PINR"W9^]RXCKGFW3I(O+$T%3%EPCIM?W4A/.?2_S"6D8-
MU$1F>,\IUUUW3YAZHV=W]_IC-MF&?5;E/@P_ *7K=1R JN=8R>6#X6,H^;K
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MG8<^AY"O:20C8>2]9".0;Y-$KOGKD%E-\45&7F2U2\&^LNG)>X8>;M#6,39
MB@9'S!Z ZDL[4W%I*X0X+/28DP]3-F74(N-^6C>.T#23?PY\SGZJV8@>BIY7
M9M[%X#]!=N!-J%U"(7*U!CI>"8)3:';A6<3AYQ"O>3$@%>_QG@5/*0\+&O7=
M11M1L.S9J@(SG6D24DM03,%?3\+P$WF4*<DB&H$#T&6OEQAR\@%HZP;S35F^
MP!($B_I/G$ND6W<<(1?3_(SD0S/$+.K(C/J]%WA;'^O+K[261.RK^T'2?]#W
MH+A4)B]?A3B@TJ/*]ET@)MRH7S1_,A79!3D +9W6 5./4TR8::Z3NVZ79+TH
M\L3^: 0_7+\-R*:86%F(F8S*F7Q^W:7J#C^<H-?GL!AZT0:D@.J9Q.OV0 $5
M$Y(:):Y/!3_,PAAV4[,EC[JK=?I]-<'Y>,U$O^YLL-;)/IHEO?Z$^Q++.SR8
M%];S3@.]!72.D6TIFEBWSJMYU^GRSLB[N^8?'AE14J;2O4ISF TT$9H XBM"
MG)%EQ._C>,.>%>[<>0W^_-\QD4U:YL$+R%?2.R>;9FN$[TF+R0=IY@OTES/5
MD5U>= @[4$"[1>&@]IJW0<FI:W7TC^>0/XF-YS3P^9-5S"$63T8Z6AYW9/%D
MV4__/T">95U'^WWI5PWU^:2AI>S9OL<RQ.DZYA-94\8>NI=U>TV;A024(%T+
M17U++D')H.+IVJ?:G@[VM%HP45H5/#ML6'/VVOL4E%+U@\LG0. ZJAC5L3BY
MH[3$V23,*TS2@N_GV?#%E$L2,A*/)>R/&4L+VF[L2#&Y*/_>%2>3Y>T!)Z)*
M7^N8D8Q+K\B'H$P7]5V'RH4OBR^+4CS LQ8)9T'HR1R0"GNOZQGR7K2!=CF
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M!)^+.L84A7MU "C:C55;L4\EN*R18[/7$*5W,HU;"#\"#B]<ZN4-]IPQ\N
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MU73GXMNE22/>>D?XRF)X0ZVSDD'&O#M+-9S#.((8^P4=?HQLB"_F!;@A+";
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M@3E"3II3/@ ]Q]*TO-+#&_-,J$A<W?N?9JU(W!%]-QB<LO^7" 64&U!Q" Y
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MYV^DT<,5M,@*I&:;+AQSC5')/#-//SM*YPTDE#\,+M^]$J*V[Z+"=3H6K/$
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M8#TXG8RPD-(IDH_!],M"U<)!Y_-O:7..[X>3/WT1^;O "LT?C+(#D \:)WD
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MV90'=6PV5XO_R=V@9/LZO$\WE(=,.S%;ND2P+6^J"K5C=K-VVE&[6)"C13^
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M8=:SM@Z]Z"]ASQ8KLH1BJTE@[M.#/^]Y@+3]D[L&=IQU8,GS>*.=R9%%@^Y
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MMB/Q-Z-,X A*0YF<RB>M&4$/3>M(!E8A%</^0A]V01F:W@UDRWR5SY8223%
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MHQ#LRE\J\P)JB.2^>FEHUX 2DJN]W#JM4*:,2A>@9E0'WN^X/HSU;KZ+N#"
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MM;JXX>%Y6+/XN9)[(KHO>TS%,R[*IIE49!\!5M_15%+._!IT*;&S@WX,X"Y
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M6.'35Z-@^-LHW5:GIO)-&P?K7LV&G^GS/ZF;KU<E[^I8?C\>H6J-N7)T3!#
M\.X9VFM]=12$5@L]0_)Z44N#=1XXY%4[2V)#"N=LINR13JF7!J2#,)\Y&D$^
M*8'RY>@:!FX:HN0(6 ET#X9'5V4Q5_(W?!QK9?I+^8G*<E-CSM<Q%3F,JD)Z
M;MV[:G'F4+8UI6V&+OB50V?C)JX2N#O-IW:[+\&Z,)P>:(%1U19+;V^!NE)7
MS81=MJKJ*]*]EV3XE<O>5KZX(K(XL;;;K2,V8(Y/CO\S=PG<V-P\M,?Z($Y3
M^9>)7//'CR7+&;(@\!V'H_C$P?B4$$";%(+/[-J%;$!X=;DJ@-OCOXWJX]B.
M3AA[+CZR"^WFJ9"Y_ TLR_G::OJ(EAZ")G&W::7Z$NM-@Z$M1:35\&^#SN(5
M,J:;-J'JMD(7[CW[6LYW<5I80.Y:!GSXD@+SWV? 1<HMQ@(8X!Z5GX"%IU(O
M?1Y7UE@-W"KW&^"S:-+J?_W7?\3.A"VP^FOH]S>0S 3V\*6 -H9IM+>=%P><
MR9' X)L-GN+HAR_T^#HMW']S]$7.?;/\4I?]Z$KQ]>L^RE7?.!-*P-]*&V$?
M;B@P_^:FLYU?Y):@7J#]LZ?'3(!$:T(Y-IX%9ASXU8XIKU3EO@U!&-@<]WEW
M_NJ]T"=.*8:!F@=!!@Q\V<:TWZ?*40RH?L#?=X%*;3 NJEE%H%T[^7PGR\^\
MET%ZKR:FDZ8\94TC$KKN65P3DYB\;W0\R9N22X3B_7.)=Q9WP^D"[B$W'45'
MG&H"KH0I;S3FV0?WGPW0WW;$&H $@*,YJ&A:IFX(B:.K%0PT$HL[@O/C-,%U
M.49C4L-/WG_.XA54G_Y*FBFH6\A[Y"K#S-JXS$Z;?Q>J+PN(E:-N, CQEKJ7
M%XFY,[LB=<F->AY3Z&#MH>5C!S?S01S/&.I;_OIQ>5:Q,/SG<AT+YB*.J>4\
M!8T>0"NTDI([H)'SJL.U#H8#9?)I</9YAQ/U[KRWWSZN<P&C/)Z=".SU@4\B
M&8OPXW\2X_>\MJS^1<;/+F&GF0V)@]M<^$3/SG:A^Q/O-T)V.5HS.9_U,K=<
M;*3H7C%)O1IJQ_7:^0)V1I%ABQPZ>^8B7)1ZC?8*VJ*SR,5L05+]Z/?\DJ7K
M>]O^H&?.1LAOTI$.7^P34B[LVO=2>:WP^\EH,?2WIKI($E]G<&;DWL46\Y"G
M&4U%A>-67!RVT])?I',MR8*&H*7CX>OP$GX+)G@JAFC!#9RIP=3<+X7U<(?7
MGW+/T_=-A);MV/77C G*L6)70*C2R,M"WE\OL(NYBR5O%C$^%!<(7;*B"D#)
M-T<8E(7I,S&COM2MZ;*U4_+=H96QK<6D\Z$I<#O7\V&A JXN%B"+6NT$-.QH
MG#7.0T\7X+Y!3*HO< ^N6'-U@!CDWWAQU[NF<&(?LK$D<SHL5R#L=)720<B[
M4)@$S D"G$%0CT\@T>HHKVR&QXE-1],'1I"39HCWF;??V\CVR#5,&SO@9(-D
MA1ZRH[N'#$#_F@2@"*LO#L4\64C$U43'[_AQ@P)Q7?IB/_S$FB68M[+E_M3Q
MK).^7/?R?!C1,^\1.B@EV]ASZUA8/3%^B9O*W[\(#RO3ET"=!V!E:P<JH5^N
M$\UF3#3*$W^;G0[W36O5?^R<%^H$ N_)_\]/DY"81W 1JB,03M$#[+IQ$G\^
MU)B+.])J/ 0S!=7<AXM?!FE89-2E*)T![HF]X3R);Q?XD\Y8TPGZ..Z3US8+
M19_Z+)\<27NUM5NK(FVZKFEG62B?6^(NI,8[W(%\)9@QF^'4?*\WX^:SBHMH
MH5Y<;3Z5'TM^<=0(<*+WQ9Z2QAC?5L!N82!Z9WIG15[,\>+/YYN\%PY!UA;7
MV9?Y/J5@2CXRL#&:SE9$847 J_6S2JB60+FXR=("CUV\]=:2WROW#+D,P\1"
M^U)SI8^9DS9W%4-[5<P8 >Y3'\5H \>I"UV$AAYH-9:YM\KED6&GC-Y:VSO>
M'"?)&@H7(7P#DLYRZ./;GC??,KQ"<V)8,3DY-$^ U@A[O,LW"XS@L>WP4Q6-
MNHY7'18"#<F_[ *_!\1PIJ"W&B[X.QH+?V<#;W$#3[@!)2R-#\F(%JPY6/IY
M^+ >/]-?.<H)*HK6U"I/=1QKN4@Q W0L?[1 !6/UQCX/[$9[:KS2[O/Q3.VI
M-A%5$DQ<UKDHJVHTIWDP8\ /LOHE1K%&=QU- (%2C -_FP#>Q)$NV_TH5<V+
M4(V9S^K&S4W5%#VR*J]LMG 6S&<ER&R0Y23BX->[4-V<1:-.'7@XY@1*B-@T
M"J7>L;U7_KKLLVR#<6^^/*WF57.^#SP<=S1::,J(D!G#H" (;@:Q8=?E*0,^
M3G3;WI6Q0,K<:L#]PI:9IV:A!\6V%L!I0O[:R">N8,@00W;_W60$DB^ 0"F5
MDY:IT0P7=/=9HY\A&?S\7EXR/=?QP[[-/D8J[GH*^+94K' IZ%Y6PW?$- XQ
M.)79>0BJ]6HOOX;/*W_:Y%\D'AM2!'^U0#9="V/O-F0SNN^V#)E[:/3MA/X;
MAAG^28Z</VJ=2\"TZU9H<H.N$.F;7:U\07E^D645F@[*.N(:X_7W;W*>N7G,
M\I_@F@=5[C@AM"S#9Z]CO( RNK 1<7RWDRY,N?YLP M9/+M.5C..V KI[Q\_
M'1&D?$JMXC(R8:,08ZYA 69PZTK,5K\K18'*-=(JFE,SZI>3M3SJ%U(2QF.*
MN?3N4W* OKU;K&@:DU-S#$L,)!E3@VT;3 S>IPK S('(MP S?!2EK&NV2 DO
MG5D/N+U.$+/6V,N[YIOZSXOKSD^W[#AJ5H4U::*6EUE0 @R,[LE8J)WH-#5]
MSDZ0T.FA"P5Y:L1GA?'<J"KAL[W9*7?[=LFUQ2T7L+ R]WP-@X)<)!:0PQ@+
MD4CO%E4 #+!4:"M),KR(3R+;0Q0YMG7_ZRU4LQU%Z->\<IZ0;UBPZE"W3_XI
M7RR@8,3@W=W!JJD$+Q8&/^!T3\N,,'/Q+G(;3UA4FC61&W+WE.7HX?_2QLO#
MK^YZ$,78.P&+X/9R,!D-Z. Q$9+BKV:G _TGOB*B'!*]O65JZOD$^F96;NQ0
MGOF')[RVJF0 %PI'<41_:X702M%<'A#./43D2*W"LNF<(O7](:@*?IWUON*Y
M&Y>JC:3HF[SZ3N<!2V)SUP+1,AF03^]YN\BJ#YD+S.SP4O_^J3:]I[0HVCDJ
M>WRC+RRB+_2&.O?]!"TSS*TC$L9%"B"84_F-R(>@N$%\!(;+DPK#)]<8*8^3
MIY]_SW>6C;G5V]+R^:&P45H[L^+RB<GO'XUVS+?@%+4I^E<8L^]NU/MM38G'
M*T&:$HX;4M=O+WPO*9.9&\P4E38L#+56)3 ]!(\SF'I??CVX;8ERA?YM7HTH
MD%@_[5=2CJNI2;=L_/[6F3*9"IO^YT3T^FGLJC,91HNC7PK<)"<0!;-(SOC]
MF#]0\-J$-/G7<V?3EIH:.X06 EL-;DBT8%OYJW6V[[=(Y>C$7BV#%E"_HH?S
MJU:WKU#DT&-""S5>;1*\^PY#%7ZFY8X=N^9U(;M5M(;&ANJ6^A@A:Y),;T-B
MN8CPT[\<-$V&_!I,H\_@B+=WD^MDVO(Y6GFYN> >2LO]I7;K 2DQVJBR?N_G
MI^O"L?//OYU/ORC ".()N ?0:>W%0]"VV.+FQ1H5'P)W3D#A1M/[QO?K5A/^
M)GZ:7T)>(3XEB?=<@<JDR^MD66G2'@]=!CMR850.BK<^4[SHG7#(GCD$Q42L
M/03%U"RH;7!PS*E^V:AT<*_G^OR@L39&H^3RW7GVDI-O"GBB8*.1_$PD VPX
MRH=B3^\R8[PY\2 DT+E[7GM8SNZ+;&WVEREXMXZ)QRY2U<7 1#IVRES65<(
M#:9JC\ 6WT(^01+V:#KMK>QCD@L62ER39JK/[0P_GW_4K7'G:G, J.M%1063
MXF:[)<WY* ]1OAN&6RR"$"TN&,:3'G+D'P..]6NK&WD7UV5Y*:>\^")3C:RW
M2N/;9ZZ,-?[^4R]D 9 %MV,2X)QT]<"9NT#RHEE(1X95,"A*9 ^INM%S5HYB
MKU(I&3AD4_?BZ<FG;-@UK3@0M8#A>47HWM8+M$*4$'Y0C*I4)YH92Q4@OWI^
M0:TPL\[*3J3+(.:$=?:Y>VQBX>=$G#ZB61@,^!E]88$%Q?>>*I2)9YF(V4'I
M';.>U"IXY_&"K'":23K.(*+XG\H2]F*W)R .R5J:TE&Y$,-,+)1SZ'EX#;1S
M[AKY%;#JBO&KL#7S<B\(O-K181??59MWN>I+AC]EH$J>,P"<3LK2"BVDUS$P
M3Q7%MP2+7JCRS,(/2JZ)1D?5NNTYW#"L'MUVJ6ZX&\1T__S-DL5SR^).9.P0
M@Z23JNGLE101JCEP@(*2K/ G<FG-'P'_<:3^(<@L,5W5I=9==ZTH]*+%3Y%"
MSM =G3"+(.PE6AK&+1E0^$4U(H([('$+7'L:Q&=F HED;$G@,S+;PYHX:6:3
M0*W+K.PGR+=--DPT*94&(/11E97Q(<CI\QUR_HCO(2@6SG'\+(/4CF][C ]7
M=647Y1'6N;.[%$WYU(6G/I4)EYYC,@:T\8RU.&JY%:?EHBZ".[G%4&<_DQ2&
M4FRG'3P.#-_LGY86ODXQJU8.8'WS]!"DSD-]C"L\JNM ,Z+?]M&II@10_SX0
MNZ0:Z[.XP&63+&L_;V-2;+U.=MDWKKM?G7\I"$[IJB/PZ\9]/$]3#'1NHXL1
M,\-\<=&B!N\2F8U&W@Z_J<>\?I[&&L&>F/_YE?#%38<COMQ(=:(E'8(\L),A
M2]4H*UJ.+\W4EK@LQ&OVWG']Z><_*=-?NW)4KDXQZRA6\&2]ZI6:;D^GW]N3
MIV$QBR6XFJ17"YPH'N(?P-_!S*SFH"*W8-[]EZRGECYE9CV/ Q6^/^*,O2L5
M1T\J></]4QUOM65#N4(]1:NC2ZZ+%D=HY@:8$/=C:CAR!M"]-UI>&G?2\@CX
MC*WNG_\LNKI-7^U\)??B=0F];.VH!-$/MUBQP$S7H)K2"E#G*Z@7B2=QA'(M
M"+NM;9]/D7N U8_"=0QJ6\SDN.='O(/U!RE\V!KBX.R[4$5KF6YGI'@X0M:-
M]<]I0\3?\:-6(10G,$&<(;^>J-V-R0--4*'O85%>Y>.[=X=WRLKG75NJ71)=
M\C0,GWWL4I!-85OCPAB^8G#U[^94A85$!,,<=H>@R!@4$X$;,(#ASU&LR W#
M%=]SR3Z0@X5:5FIN_K9G3R!V;?H_JA_=88M%.";]B\ ^N:^!I!W6*AD8W66K
M6V=[0X6<6^0P-YV1>*SA/XYY!9<^8TQ]_Z.(Z#N\;2$L7_1/,J"X4D3BNT<\
M@7/!&Y$P\9X35CFF3<FW$"'_[%*S#$8,3Y\]LS<Y\ZD[5$36ZH_[D2!<IB\<
M@IC1FD O>6^XQ07/X.#A#C^$**"ZMP\8[[2%IFVN>.8I3)^O!OO;)>U1\ PA
M/9Y/"L![Q>L+;52+(;SXUS-M0VX6^%SUE%&H8IHM.-46T!VLR7CT!ZI:':T)
MMIB#X?6C(,7:K$3',TN?1&T*:@LQ-G.*X"_Y.,*$NY'%UEW!^TPQJ>IM!_Z'
MH&X,T7(74%##=BH-<F(Z"H$@5+N?W7A54V42PKM?Z7/_WXF+WW5+_ M>L[':
M?Z*''Z5X=^EL]90+J,< C.+A:$988$$<8*+_-.L][M%SW#=IJJYJF&Z7]LN^
M_NL0%"ST#+0J132WI8D==5VCN[,'M^T6563L 10)FX02=]6Z__M2MP"MML]<
M:Z[PR?&G%AHWNU0#E)ST?](8VP26DQ^)JQ.B\LN3K8GE^1UP<>II!BW)Q_^Q
MTQ&IY5*C?$]2H%L33)M1G;K&YTHN.]> Q$//=S'X],3V3\:&4 !RWSA0KQ#M
MY]F(/4FVPH^;*G-NC?RAA$3=T1TJGV&K*'H:FQ)9=<^0YYG1G[\&(._Y$T3#
MQ$4H: URTK?PMR^6V[VNR5Y)"HP2_%2FU.)[\=[J."[/*PG^:7?[(@6">IJY
MA-O"N >5!3Y_G$&85M&"U<Q-=NOPDM6GJ(,^7N&1+E9_+T-K1\_3TQC.MFIW
M="-.XE'60M>L !>AJT=$UF!/V4-3O%1T81]-?<1><PU=43<1Q5$V%EV+0L!4
M/A\R&"A8/"I8'H'7Z$(?8!7MZ[**9_M6X6(YBWUZVS/'9JQ[=CXFF*9M#=:4
M<%%>_E>E)T"=I$]CCNEK PP(/D?7)-9W+IS:H$L@S3MO:>J8*>Z$2*3832N7
MDR,2NNO4RL1W.E)\$D3I+TO^5>W)ON^?,4&NMIXWK+:;E3&2/O>UZ4+G6<D(
M<5&ZFZX5Y2Q],O\3N%=G(0Y3K94:0C@$<5Q,4W)'JLQ8NC]Q/3WP_JT+T^^D
MCA./[K'?*"V50972U(]8A5 L;O$=0U:;QV1S+;QHX2#>7KT^OLM3OORY:JA6
M)_X?SG!WM]N7;\N+?'%GCMQ,6EJ' G*#6]HD9G)PXX3^>=2#.@>EKNR]?#(R
M+_.S7,;T0&&2NVSNTF-+V7)14.C/>[=V[#SHW8PW11V"B/<PD_F$Z&X,_SH,
MTLJU[A,8]>MKAQ[L[@CRQ.9 W2^=3A\OX;]%%U(*WKGTC"H6>BHMY7$Q;!-S
M9!L9(@T;Z@3HR,?HFB)%9SC^_E&Y.:?#5&.B:UEE^&C'CKUQ&6M+CSLZ=;M&
M_H>6< A")@L&^IC1WM!5IC9:-4@3\5X)O&O!#@G3B3U9CU(S8XL$PY;"U'^5
M*>1877P\;V/T1X3"'XAQ)!9O%1![.UL51CQ]G]MV&L4IY>A\<9PGL#%KW38N
M9%_K' K5W)-@>/8J*A@0(6&/9@)5K&-X-))!B/UY?G.A0/WMVD"-Y@\:/^MK
MD\U__]0V%8F0=;2+?CAYNU#<:>*/\Q'BT.DS,*(Y@R(Y<@!CVML&%)E.O6_[
M0M'W&SZ-Q!71\TM<?:OM#,UW"5F_!GA?M%6K]B20OLM3^5_2V4^[%'!SS*.$
MN D"R5\I]GF28[>?=9V2U6KO",H%+++HG-[PH:.ZH-_T[D/0)]PV"PE&CJBC
M?<1XS-CE*MMX,-N8/C>Y'IQ44-)S;2:C7EB+>!5OK:1(C!<]\]UJ?Z)'4K2*
M5!Q1BP-[7"]_W^SL\^ \B%>F*?;=,Z:E"\X.1U]> 4 65ZG\V@PW>%L^1U4B
M,@1WS(//UQ!R/;GO^\K6IQ.K]-<*SWJ*&D]*7D:FJ1KK\N4O#$YN$J ]C.W)
MHJ+K0+D,(*E*A'6L)R%$1%E^Q,8I-C1VX'.?&E>GO'SXJ#?\CM4KE ]0C"0:
MX2%Q:&5']]V/[?AXK980ZV4>W79CL6LI[>9Z3]V8?PO1.=2)GKW=,&8-6$+=
MO+UM<=CN^/3M+B53YP]5718!_B9=-PM>GTTYF.B'$PT67OP"X@F0!)B;RK,S
MV1#N*[3TXOXS=GY[:PL^4L[?@44F<SUY:FL(K0R#Q#&4<3V]&(\)AW.U"'B_
M=W]'-#N1[G6^M6446E<EFZ96Z/&!5SVEH>-G[@P(28_".2>'\J '8-4+4?I"
MWWEJ8YP1 [;67Y3.%/@&#$1!@IP)LIYK<6[,&T>#R?0OT%I@KD@O\FM:KF9^
M-)H_0X%Z#>GM]6']G?\4?[U6X<H9GXZ_J<WO*A?/B\789U.O C)+^<#9U:U8
M?']R9!XW<*?,PU9#6VU0XG-O=$6ML5/&5=U.KNY,%NN$1>/^-.,-']I51E0\
MAIYKE03"2% R.\DQL=!-*+L^WB]$@MUJ1%G%)7N]V.'J=T1$TASS%]2GBANA
MQNP^/_XU7O<T79QZ!7"GZ '%1D R/M&\HRER(DY55;IN[,E*92Y>Z[Z;K/7J
M]8>1Z:^TSAG+Z(K2;(Z8Q[-#T.)+"+.^)E6+5JRY'4*0#]5D -%Z,CYGTZ]Y
M3*.Y5"D@:U=YRMG&-9'G]<=*=C;98\',\*$B?J:_1X>O-VC)*&^*,0#MS-,&
MK)YH0OD I6V%@Z<N)M G%77J,?&G."LUG#[R:I]P4FN_2^4@^I!_TG"M[("\
M&0"%=G!@>6:!X..5GY!&U\=8MBRN'C/@CV<S/^]L(7#KQR1(4 ]Q<)\1OC(/
M0=,<9"=:"\X-'MT4O7V6]/T[?=.^)GM^Q) 8&1E1+Q2+T US257>WL]Y=$MX
MAUMI20W)9$)#,CS='I#OP7#C'LVI=^;I_=#DYO(8VFAZE>CZ8;K?]6G)KV-E
M#[,LVQY\.6IO>>=K 2;44P7@9"6@G+1@1QSL@81/NU)E+T4E%]>EEZP/-<GU
MU9LX!CZ.N&AY1M1&X(<$]<,]KQRO(DP[3%\)/04YM:?G@Z_?OK>X?>W6#XU$
M 9G:UC$-TT1]N[Z 0A7QEU\^\'=UF2!+&WYUY2'VT SR]/C_)!"L.QZE6AB;
MO?V*OK2;-IJ="&TWS>6S:S&L3R/W&X[NJ#JI<16]-6$R?NUZNO"D4(5.\IH_
M0QWY'BT'O1-S"N9:FNNS)-0CYC+<8G*$AX^GUD.&;9!ET\8K:2;S6BZ\-X;>
ML)Z\=W?G9QUVRX&AMN/0PTV&I03NJ4'"^_"W-@,E&[:9D9K]"#N$K_OCO*"R
M,\9+B?R"KOZG[UV630-A5\!D-"T5YVG.P75G*;D#Q[&)YB7!PU151*>_TSL0
M'/V 9\:#BW5)OS22?CJSEBK+:OU, ;$Q!*B#A@7XM]42=&:)SNY,F#NYBO^)
M[;1+YO:HYQ%S5_V#X]KPW@C-3\_2G4B7>0:+E68Q5[R[!+G*6 H-W&*^(PSP
M7O*CO:/#K.NRRNV,S@W5?)@U\1.O5[QMUU_&*]!2YV(\F=FO?N'^O<&=YT>9
MNU7&'GX!7$$0-\E)(W2Y-<^4*R0A<_?5)"WVS9!'@M/XNJ2KIGS7?:@W'VT.
MH.?I4X>@.M5,BD2@52==?I1Z7CNV-P8J5VW\MLD.KO(N^=OLMZ&^E."G2G_I
MKL @X]D6M-*R/1.-Z!%?,4RUG3WM=4U&DV2B6 9RY!S3^Y=J:LO,LM%,5SD5
MP%OU5-Z Q4RJ(F[J67_W03HNO8QJT'"II2A*W$;A5]G+N9M.WW![DQ/K8X_7
MFO2S\-N2O9>'D.,CYB-2<>/3_,+6;R.O&L;I"5P^5E,"PO8, HJ]6ZXDV-(Z
M$=<-CQ -(.^4XF=L:B@T+:V[C1ECA;_?98!^7GOU.$6-N6&'Y<H*[A$C$'=@
MIN3_=6E-,K0+ T*=!LJ)"W?,P;)#U@L>!]'14*<,)>-W4AJ9X8] H6^\7&3S
M"E_:+1!M8!$+_'0% V)BJVB@C@W)B^R,6$#0OXSL0 =P><JZ. V[@E<+E>2=
M'O_7OMB9CPK,[1B71"%KXNK6$+&TDRY5F7-S],\NQQIY_W[]^1KU=@W_U-)>
M64]FF=)C(M;'6-M%L)FXQ0^M+*3Z+MB4X>_.>1"1_I;@8$5QOO6/S7I&U;R]
M\%"^#^M;JV=",K(G=2;6CO*>?8>@XU5$6"):DOY5"RU!VH_>8_A^?YF'6H[>
MK6$[G3"Q*J0/_]?DVLKV'FZ/OZ5T=FW&7Y!)$]T04?EM(8I.[PKP21E\=T0Z
M'5DAGS'*)+!=5O:U]=G'CU6>M_U+3T-3%NJ.#HP+\ S>'T#E=\:38[G#4<Y$
MM(.73;6Y'-1/ GPG;N,V3G4][43216Z*\8>\ECQS,6(^^0*M%(-<2-8Z!(GB
M/,JU=COIHFKM<IL>Y\1$*E2D+IJ**6G-R'I_6FQ6+.$<]@QBXSIJ4)*4HYBL
M3><U4RY0[Q#WH[>*<*-^W&R;&?^%O?>,:NK[UD:#J$B--.E$J4H515!:0*2)
MB(@(2(E(!R$BTB0D%.D=!*0W 9$2Z54B742D2@DM-.F0 (9 "C?\S[EWO.=_
MQCCC_CZ\8]QQQ_MA?<E(]EY9<\YG/L]:>\]9GUH_G"Z:X4P-P8(H^;,URA<_
MY]E10_ 'F"#LTP&.FF>2;9/JQ\FV9TR\2S:*OV=A7+9^>$G0+V(N7059*P2=
M:O)Q^Z7(])?SE/3"A:B19$=AAQD3\KDZ% C.F&W';M14+#( 210V;$0I4'R_
M[)&&W>.,X;W3+3QHCQ'4(_ _M.7;@O]H19N%0IMB''N^^E,8<DM(=X=(-,@-
MM4N"8MB ]M_;!RVE;W#,Y;QO!Z\TZ_[4$))K])8.19^2Z]C37,Q 1H%M]:'H
MS86BHK90#Y;L)01C:P.OUL]O$47F3^@KQ&R22J\]N8+UOA$2<XEN3V=!9YOV
M7RU_H^2-L-$0 B1@497NOIBR_)C\=-EDQ?NL(^\&O.Q*J[F*S/J9 ZO"*,J'
M4UZZNLB20OW9A5/-Y8O4&E$QP)22Y!9B;SS&1I97RE?P#F>=\X\4:9:6[@KR
M[4CG/G-7*.SE"4 S]PSE@J\MQK$=S$)B&P%.'PQ<ZJLH3M*:QC<Y.B3]>?H@
MRZ_Z^W:#N)/R:W6D"W4MTN,Y*3\0]>);-+A?AXNY6P,?K0FHCE]V46@+?>^Q
M9Q8\WSV=/YFKPY:^!*5SWDWZO/%]7N+8]!\J@6.!?YUZ8=+ 7^:[@%,;JY:$
M;ES8U!LDF^LX8JK^K?5!JH6K0M*=CTD^L>GWDFJ=SM"FF"@WN94M4)6 Y?Q?
MQ#FU-N$3P(P;G#R!$?^W2A.J,*[3/G5!E*XYVB$8!)O;N=H+9E'Q+YYT'9ZN
M>']<E,4V;R%2\C-J*ND/^@D3ZX<;O6(<I"Y ZT2W(?NI7$!@\GAS4C"QKM\:
MCN&QT*OI+[??3,>*Z^@9GO%/W^4)X33>"T_Y<K/J]4-$_N 4(\7 $+-+CN+E
MHB1T0^X-T?W(K6K8ZOU(^0$Z>W ""!L_O/;)E8OM*Z7*G_N*C&PQ0\5*6#MK
M3T15L?IWJZ[SMA!)Q#_>Z"(_^9>2#J>F@%P2AR?>"[L,8E)QPQ8?=A5J:[@Z
M>Y6M\X;,O(NP8=]6^%DU(Q342?JI@\M8$".P$M\@VG7@TNLYDH3^ DN"8N=3
MVSXNQ=3'SN-* >D!(](IY:N_<DPI..G&4*#0YQC$(VH:E%Z0/4] M%LS#I-H
M\BTN'!BP=# KH.F.OM771]R-FB+."P5Z3GQ%*$$$4#8@M"M>BS VSP^VDW2=
MA:B'^;F7I^E#ZB#.N/[#K=5:Y9P__&QYG[_ST.V>J:>GI)P^TK5K34:A,,6"
M2L.@;QET'>MOW*S75<+:1E442\E?]8[T+V>O1"FHK+2BWN^UO)([\"&Q&U+H
MR3C:!?&8%7*!FJH&'LCZ02Q:;U0DP<"3UJIRJG+'2O]<2J&#ED'WEQT(<R#8
MC7H;-O)'-=;<N!/ &9(S-DGY?4UN5P8LP6+@LMCMG4>1SQT![%_N1UG0WOYU
M![FJ@QG/I8:;)#FL3MJ_HXV&X/C9Q9LW:U/T)WWA0,6DGI1ZP0!'O7F[9'MG
M3* B4U#\ACN5U;23BPH(4[A."GW*YX8(F##L!,"FHEFRSCZ[EOHLH&.V?/WS
MM)Z0:")0Z7TL8W6"+B!YI J,H7)F%OAEDCPYAV1<2-+!]I0L6-W=[.;B8K5P
MJ?<T^X7-E)1GDSI]$N''#SYN$=8<9GCYL#I/\WA\,2%<IVWH5IE7R^C?VZ)U
M3:%'YC;I#+JQ6S]T;Y$\8??($6#GW0NDASBN3A 3216G75<PO;$-=49 B^;T
M2F:[^>-2&[3?1'3&R]S53WXW\RUQWQ1OJ@7P"V^'ABD9ML>_FV,GF!8\1Q,<
M'P8/OHWQJRZ@'+]0M4^H#9^-A=7\_^M$BN-_&8B3T?]2 .#_C/\S_K>/STHY
M:<6N3]G7GPU\5,2;2E:;R0B;OT@T=-0Y9^;/:OHICX5*],]A#=]EKV"1X;7;
M/"M\5N455QJDE# ??K^6_%SP'YO@_V_'*DQK 4A/:+O@UFI>8+;Y:KK*=^08
M+9FB+7SN_?UR&N&8J*9")UZN<*F>[(5MI6G]VK-?PL8Y@J\;&M<!>$B2S_[9
MW?[O(9F. P63!)8X@U2L\LU<75W,.F0K7C2QIO5LY[C4SV <!5Y)%A<$2IJ;
MFZ_7OW(^AK&BT>B>*DVF^VRWES3JC#C_\XUQDXRK_]K8_*<#>#+V[Y&-A<;D
MUAY^DYTB4QEGZ-<E"Q!PYF'^4NV+0ZZX=PD";F[C>C_L6!O%9@[S@'X%;738
MU=-*VZ(XF>*,!R#6QSW.ED*W\+D!KHR.31FZ9YW:=OHAGD['OQ(7!60F+(=D
M\\8.-B?'+?PSG9\ZB<4V ?DC[E?G=+$Q YR-K,UQ/DN.';N!<[P-N/#NKW!9
MEK5#'V=;SJZJ?HFZGXE]$KT11M.B0IY)<KW6*5TNJ#KDUD(^Z>8(_/JFFNKH
M5JLHT@\U=>C)P[K+Q,9==-'B_?[RU0W-<S&)8[@0=<%$G./BPU"L_T)))/PJ
M(5TT[0&V.V9B5.=,6*H&V[)V8(+BG8Z8!)H[(DP91WQX.7);JP#QQ09<!$M)
M6RA#,6[,"<0IYTKXC?RYLVWOR>V5R*E0G="2@.0+&W_)[Y\;WJ8,'YP7@-,3
M"A<5TLHTD23%VH8QM[^1.R]WA .G+33:<';!ODDZ&HQLK\)?W>91,7U/Z54$
M5W&@L.^GX;VE)= 8=%]Y79;IBP?W[8FW_60YY"S+,TT>_EX-RE%7FROXY))1
MF9:_WJ#44^?'DFMCSZ>OVMT5S2&G'2*ULW/W<U"?2*#DDK0MA4&9R+[VMM"9
M"\6Q99?-G>_JZCK=>$-5O"%8-^(0&+*I#G(WS2&9$Y+S88($YT5(E)J8GOVH
MBISMK8/A;_E%"?>:6/-$F'^]*A0!/-2C%4-)H)P'"9(*(0L"K@98G2UDT3.8
M[C@4HY=SU+4WI3URYND%S+M>^9%0'H^F,Z_4'&:XMI"!X$NW=J,AU;=ZNY#H
M,HWZH4N+_69N\!^N?-'^-L46\C^V\#7IHE?'^Y/4W#H3[IP)O .:[,4?8WVV
MHTL)R9W'D+!*DFR9K_?M'5CIJOZ'U;J4GS;C]YZ@?]S=N=OJSF?^Q>-P%J9)
MY)^A=#T^ 708NQ$%B[/;;KJ*58][6$7*74O;6EAN?=3]NMK-1-DTY[P?_O0
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M08/B00. -_*FG:]/ .UZ)X 75[UHB\'=?)K7;\_4/PO1Z@5MID[V$G:0X2<
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ME@9BMNXPJ3DM3Q*;'(CQ5'"H+B%QFBZ=SZ:+H%PAN3=AA>:OIFVYELY,S_:
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M.X,C<Q*@O8*,N'@TW3LO,MB2*#:OO*5H9'GDO]^ >#_0X,UR<^(\ZL-@M($
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MRUI?6P8CY$(T)=,J'K;N50]R/(LT9!GF/@](,*P?00C](7/2)*LV\1$_'#<
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M;3P>V<[$_!KTMV!X_6G5]JS^C:['_?;L(7195!!P'F)BYRN/(-U;; CRGM(
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MFY(U:J;UAOCA4@O;/QV]WZO>B6$"G%VZKXIM>(/FP=@5/T^-R18Y;DSA 6K
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MVHE"-X$\\%GIJ4VYP(9_GE8F84/)NF*T1B#%UW9B<@4%GWS:T7$QL, ZB7V
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M0Q;W6JJH$QW@RA9R]\T 2]XZ*$'@4&3 *)R8<=AC[D!X%\C?S?(RE2^YIJ'
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MPK=T2&.>!]PI87C"I;G)B<ZT;QA1;EW<OUBA[WT _8FBL4DB'>X/.(E$K@K
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M=MSP4%?'S@J1AX=UD9*$!\Q*-LLH$3(BQT/W0DI$N)BHZ.1$>2<HRIBD@#/
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MU3.EXD/O ,#&=_@@=3#)7(+9RG5#GW@YH: BFY.4EEC"J.JPS3:]U/@ANI(
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MA^M>^KT7207?!LF.BDD]]A/?P_V$AKY+(XM2T)5=%V.&M_U3&<8;1A'_$M"
M5>X!V##+B]CZ+H!2T5^S,RAYW'B!>0&>4):<DJ53Q8_T]SKRPC\N&_ WI4S-
M&=_'XYLYIQVF W*DOL#'8990]E/BXX#D<9CG-KM9277NA1(V;&0/#R9+G=B
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M<7]HV>&0KX.K_.R.1U)C&5SH&_("DF/ P/\RV?D()+2NU2A%<]EE!5'#T?H
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MI]>9#I%ABTQ56E#.S91(2NDVHP,NEFDS)<XPR6;R.57?>D[9>LQNZ!,M'^G
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M#Y):AK[%.(QQXE)V0'5CAR:I8]E>" )2G"1G>/T)FMNB^><5:KY5=8O82/=
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MW<K=*;7S"5F'A]Q*+\4!U15**+OOE]S#DO1!40[(T^T+2Z'PR,Y:DMHX\?,
M$YLXKAU1/W*S?M;>E]D_S9QM>%6;,2K^^QJG2\[)\*(3 #L+:  QVL(4[<UA
MQ_@K0"":T^E+(PF=Y.^? Q%H3KW:D'UF"2E$6;^5=Y?E!X[T<]%<Y;\V;7GW
MKN7>F/H?]?O_;I\OOM=9PWZ=799OG^KL'W6?+R ;=E4<WW0<MJL=8E9U!Q6&
MB.B^Q-&11.&VJ"O*>59C57>NR!ZK3,Q%,X D>UNQ Q'[D3\$B-JJJEXBC+N
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M';K?;WK&C\28V+:=.9[H'H<SRR'42_S #N43CN?IF3\S"@90TW,@O!MTPP/
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M-F+$$:<.[9(YJJAI"Z%/?)@U4)5<H1OFE&!G=,$<'7;A[I=3HAUWO9Q\&AY
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MK-1-DNWSEG<MX>%@9DI5Y(FNG+^2VR(IG\\GQ/(<)]M/C#AP/"-TW#B.[23
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M!- 23BECY)K"R7THL&YPPF1.]H.;7V6]CG#"%!WUA!-_2Z9O[7/>?&S^E1>
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M:Z0^H9H.AUZ$D^6UWFJ0U9T3LIMC_,(0J-DEGH)'/ %'8QFWHHT4T[7O97N
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MYQJSUS^4K#+K-.P4.R$]1(AE^*YG69Z;>('8X :=2&H^+#A@Q" K3A&0V0_
M$7%!+L,.A0.#T6\M+-4:6Q,KU@K?RZ#XOB+W"Y@,#MHO@27AG-BI\[\_44W^
M=O='0=*]^R\G9VYT@K$1LRK0-/5Q&-I>XEJ^L&]B!IAN#]_>S/J#PT<E0P#5
M/0P ]_$YQ@FX)Q2R Z:R#IQH02,.&WW3PPF 8T(A1^3\$DLX W-.")(ZZ9N8
M6V,]UX0@-4>>"=%WX,&&C_]NWJ[_J-+Z.OUG#4O!'GA5LUKJ/&!M[VUTZ%<D
M*()C],[')!:2"E,YHU0J3M6>($HJ.C&TWFHQB@EB^I&*J<?D+F.?";4^6$71
M[?-+5;ZVALE9M();!-B*C-BE_[22Q+&(:;M6"KI33<#2+'E[R"CO@89=DZ8X
M)7;;440_3!P/I/>A*I1% '6*[B%3D%:]3@B0?'HK$'E%H@*WJ(N?BZQA>D&B
M6^'(ZYJ%\I[>B9A+]6=2D"QOCLX*F5Z%8TR8/Q\5T \32C'2-70JG*%4KKQV
M9,WURFJGB3HJIYUY5.X0_3NN>,,)>E__REI-]!/NN[PXMK6WQ<OV;/B)1Q(#
MQY%C6$$4^&&",WJ\0DY5"'#-$KU#Y0H]'P"CG$&&G;4@AHH=OKK8!!/\'19\
M7&2+QW&-4 \5=#O)./ !+<,!12<V"/2J1[@,4T[/=*DUX(=\;U4VG>F55&_,
MLPCHL#&^@F;%<!Q"!7;1F*![_FA70S),R'LPT0XH@K  =*3/4RAUJD\LN]K!
M/D]:_VP7>%KN>#^>ZOP))Z3=O]-\E0R'1IB$&65D['F9Y1';<B!'^1@@W9E\
MI'I&FU(T:6^6+6('L@IB87)Y-@6= 54^:'&.+D5'ZBB858_/.6)/C\K9YU5(
MZ&!:0)MP&]H&=GQJ;%L9=EV36MQ6)B^AJX7VS[Y<!GD^" WCE8S8KA%VER1^
MH>!JBZ*/@KF@X,Y'LV>?7[ESR+X$[;JNM\]MYA*KKDT:DGY@11"$&N.X.>MK
M3*S$"%/7-C+'=:/8)0XV8=5ANC'6K4HZ4.@M)YOQ03T7VBTQ'?2N]@"FS!0D
MEO8F0/;(N$([0M!^BQDI[Z#+")3KE^XV(HSO^\I=4L5^9=U'P(!EFABV%[V[
M[&-5,?0. SD_YP6Y;<BS6'^_^67TZ82]CZ#,$(5?%J3<UILNA'ZJ)PZ8H=\8
M;H@CIZP?H#@?)!L$"@!8L6.@.+G'+00![TFDZK$Q[/4GBFI;E4LA/)=%6YM;
MI/<5^;0MZ'>Q<SO>%O=5_DKEZ'Y#[U-,^IC1D\:A9QE^8+I&D&+'"./8-\R4
M$#-++#<-G=\+\DA?2A\$4_J6(B4D/U$K/V>HB4?66OU3([;3J.ZJRQ..+*IY
MD3ESO;_0PS7C"*,_=B[YO&"%:C[]&T<<O>PP!V3(+=ZY:5VUWD;(C<1EF"&&
M&N)U_7<9:K'KROL9YRF"1HLAV@=#;@O4(8GN+\%T0-[BFLR72VQ<91-@&9"J
MF#:9(KD8R'HYE*KX<91DJ6Q1N!7V2_&2LR/P(7\FZ:>2'XG4\/NTP8^BH:F)
M)31?B'_Y<G_;MZHX!B@KJV.[:[IE(X@E\_:H(F[ M#>$$>@WAHLBJU. 6BEC
M<VK=U6Q, >+ZIJ7(XQ+3;'DR[@W=6/)0[D  6[1,K:%91&$=6R:)G9<]573"
MA*]+E^9@F27*]A\U)3H1REI3DQ<1HN7&V$XMO-XL6P'RC@;:BCS_WB;^[0MW
M(</^>+5LE(0&CD-L.*YCIC8)+)(ZO[_PX4G?&EPUFEWC"DF#2.@I@3()'E<H
M)H]YP<>@QI@^E9!W/@I0_C/!CF7$D6\;7I@X'B%9A.VD^TP^%NG_YH]D1Y[<
M)T+:7*#_==^'YFC-A79\]8".X(#(7A^1_SV3(>%;>.GHD$J2?HP DH9-7&\4
MI 1N<H8=FRM4Y2RV=8/K)PJ6=<$EQ5E'_,R)C2B(Z#^)F_F)F4:A:4(R$,8
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M)F!I%A<."CFPPV^*-6*'GB*"8>)T.-JN4 OW"G7T:VB^+T"BH@-N"M*J!YL
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M1.0[-9'3MLH9.(E G*=BFD QB^3<91T.K-ZFPP+MT+A"')&KMF?!#A>%XPK
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M!PE358E^M/:ZU>=#9)U5G \^!$]N>ZC2ZZJBE[>\XK8H&ULOVAU^Z%W-4G,
MAA@T\1[P@W1.RX\*$F$B]%!A-B#@J-9-E&)0 M\465+Y>X,+KI:^-T5./WMO
M\KD%'LPNJ#@?/LW<P(AL3 SB9YBDA(21V+A$,7"K>"XQ@XXW-7?4)2U@M#G@
M(N'!'.<?P'NIA"LRGLM=2%EOA%2,1I4>RW%@ZWLK9PD?]%3.OR4S%A7G!3MT
M;PL.XV[7]^4Z:?)7#H2>S:?I>=B,C<A,7",(<!12%> [B= Y*PY2L_#?/+$C
MB659\2Y+@/9* *X)^":5\P(F\@S\SKZ]+5"K ?9(H ,65^B+!@9!QK"J9I3D
M7%8U# ..;870/CW'56BE%0>[0B@[GO0*>G/E3B7\/W\C-4.HS7JSSH;F9-1V
M"J/8\+ ?^A8VB>,(C:'0@9QF9=L!8VG+%-I*;4>&]D#06WHASL)4MX+6(FV-
MU6YW[J=W9[U&(A-LO'3KD"'4WE<^L 13E;4'F8(AVVB>-2)LWM@8PN:Z2)DS
MFL?G!XQ2XGI&[+F1@8,@#NR8V-@&W4:G@&G6D#O0;=KN#JY$TT\(PUPW-+!M
M$L,B%LY(Z+HQRW04=[ K8QC<W[X.P\3."U5L@.G_'=0KQ.%R1GP\,$*)]0FA
M4%G#_PE0*S?_GR?Z?!" P#N2QBAY9 M])2\L:,\:LV9E]3P]9BD+4R,F)#3"
M+$Z=Q'<RVX0%U@6 ZHZIMRB@/0ZHA\2"Z4="_!0T&!5S"6@(+F<0W+8#4*S*
M9A,!N:XM!F#"F8T%>5=Z2$]&JHJD/)I_.NCYU!APN); J9%:+G9,*Z/_\X C
M>R; :;>?.N"[62%X#UE^'L@, T6- U5L@9H'.XYT4S^Z61\'V$IG  G0J&XB
MT!2PM><#"1 ^,"U(Y"W9Z/=U6K[(Q;[[;VH6V!THJ;CW$8738KB<.)C8#<6\
MQ6B5B'@/D;0@WGVTW,K1[B%2SF/=@T])!+UN-KBN[[*N^.>N^LI*DN_IEC[A
MKA)Y_\>Z^VM]%@/#MH$3US2PE;@8!VEJ>IY87SYI'"#?K51KO1U\!7VCY1DM
M$#;3S3R8T'-LT%VVJ\=#=Q7B,.G=?,=0CE3OF7K_$*144XJ?@"B;;K[*!=UT
M\1<6A5O"F\F@G-3"Z\7HEM!]%+);M!#<&F+.Z^NDV>+-YNT>Y^G?ZGV6X2%_
M7M ^$EE+=\;"48RGPP4Q9-!K_?^B0[ZJN#4EQ*%Y^THU<X#*5Y0OBFL/H)1+
M&69" %8SU2#D]HTWT'LP04])_OO'HLF;MRX7:N]1^48/F>V9U>:$J8'M@!BA
MZV78=)(@\81&@LP!TBS]+>A='E[/U]="%Y/Y669-R[I*%L!D7)9Z86$6)6U"
MB.D2K1#3'PY"/+OP*L(K2MY.:(6?E_-,=M/+F2'(AY2S8NNDK31^'F[*PLH$
MH\B-C1C[B6^;"0XC4+;,/$C= MP!1/3=9Y@?4H!=8KY(M4R B7 /-N+ K]">
M);R-Z&P7%[!;4IQ<1:Y) 8"KNB?%&7#JH@2\*=F!NK[9E#5Y*'\I7G)66,B'
MV8F:X^,KZ'9;<L"(0^;SLO-G7@OVRY?[VWZ7:G$;?((9\Y:W&C[ !%F4!=U\
M0I4]NB<IE6_4/;SLNMVZ)TD[:]D]_;1DZ<_QQ->3BM2V*R\VC3!V3,/'KF^'
MCAW8)J@B=P"&YCPA!J(=J-E-M"T+:$G/ %_$CMN%U,+$\I"#?E2UJK!B9YP:
M564Z Q#6K<T9)_&L(&?B43GY^TH:G!<DW8W=O$Z2[?.6]T'\0+(\R<_*[PB+
M0)@^%<?(SV+7\DS3 HVWG >I^S@] $1I"Q$FG'"F!;YM1(Z/C=@C)/ 2WPP]
M!]!E23'O%K=:6H.%8NI.[=<$TWX[V(<YR3_U&=/!5Z@-Q8E5I!P% *ZJ*\49
M<*HZ 6\N'3/?]PW?E'7SJ:S.,]=[C:RO-WSG^?CCX2QXMDK],\_OY$;7<$\C
MEGH980,GGF4DD6DE5F"9V+'D)M&O2(5F?=_6HL2\%J6;EX+P ?,KE%#$6-'*
M"WU-=@S]FILNIAG?_5;"E.U@15%_%V^Z761(K32F_@*,53[)?DT:+C3L_@+;
M=)9Y>U%DY$ZT7;'K7?$-,\R/R@SV-09G]X. 7M?3T#$<B_Z"1*X=I*&$J2L&
M?1USE]_GRX*U$GTI:[Q!989P71/HW"U!CHKI=X4,6ES%S](,.6]R'A"G[-F7
M2K5U0GM\U*EA&/V*]*8@T%45'8P1IYH)^+9LDTXJ>6R=N^Q37N BR?'FOOM:
MKN.ZJ7 B^MF++*71"ME!9]_X'C[:(8!^VZ&@M,^D.,7*6DP*@%RYNZ0X$\X;
M2P+>A4>6_E%]+-)/U=_PYB[[^._F[?J/*JW_6A5->EO<O%;I/ZJ[;5.GQ>-U
MD?Y:O-9-VL5/!>-.LNMKOE;]@^#*($6*/N&\0A2[+6%"T;5<[0(VNSER]*BX
M*5\)JPQA[Z'F";-+&$$,]087/'V=%9-2 DC=3-2)J&/_?*1K#<[#](]>IBL,
MAZM@GU1P31KH:J&WI6SI!^86KP57=Q^_DV3;Y*_DAFK5Q[)ZN_Z>UZ*Z;/!E
M[4DP'4RT _IG<>TR3.V\ZEA,*$POG--(31$*49$D3U(C):;#*ZXF@Y,$]05L
M^L&5.SP-CC8\C9=GB6=$+C:-E(29Y=NQ%9LP'[!2]#0+-P7":YCICB/<'G]Y
M76^75. JWA[!:\W%F"[OAI5L #4Q=);ES;.+55EE)&\F<YK6ZPPUR>%+]X8:
M1N['Z XUR5AE_:&FH2P>L7134N.Y:O)X0^C2"2LS>R1W6<_$Y@77O^#O^?/V
M^:PRP$D,G-F^D9DX2"P[RB*Q%./%F&C6RQT45L#98<($N^Q=/'C/!.DQ1$"V
M3ROA59D)T[=GXXIZB%VA VJL"+%_K>OZ+W3XK<5FZ4E0^MBM:$J46K8O&2,E
MQRK B"D@@$N-GY+CP\1H*LD%%WK$N_I4OC2_6YZFOSJQ$3JF;]A.1!(O3A(O
M!$T+'X6D^01HZZ>ITN< YZZC0"8!8P5+2(?I:QC5\K& ,8I4!P#.X%S&ZS]&
M[JBK?_0%>*5G5XWV*:\3O&&.U(]%RIO G%Z\K=C CF\:61A8H16XCNT+-;.:
M J);2+OBQA9NZR;^R(;'"C?(F>30M)BJHALHH3(D@VHZYVB2JN<<772U6LXY
MLOIUG+//+O"<Q?.7P/CT$LC")3Q:<EW7V^?V1M@O+SOKE)Z$@8&MR#1LUTMQ
M&,4X"4%I[OI0U>XN[]6,<B_:&]T_*2>:GIT".-0NSO_5G6N]N& /_Y.R5\5.
M-:U<5NE@TX/H^LXVK0P?=+SIA2@1A-S%.F^+;]OGY^J-X58WQ4.\^516UR^;
M>/./"I9F 5A2LP:^?GRL>*YBZR'GELE$P!]=/[/YYG77H:(-_#,2</5VK$9X
M>B@@]@E@LD!$5 ]_81I6+VL5YT](<$PN%@N LUZ$%D[\4=Q6XG69GHXL]_H3
M1;Q-GJ1 GLNBO706Z7U%/FV+E*2[_F*WQ7V5O])/[GZ#$ZX[OY3-/TC#VA,Q
M S1- R\TTL3RZ&V2)$;D9YZ1D32SL9V1T':$(P/J\-)] 66(MK72-465"6#"
MD6WC SP]Z84:.QE'&/VQZ[-'Y9#Y,5G+2(8XJ]UI,4=%V5"+M4$O%'E(DT-U
M.RD0;+C,_@ ORGQK&)*(8<E<W2V>G6^+;0U%U6AQ/;1 O"U0AR[:XXLHPO2J
MW? 6:9?9%4A#RHOLCF2;RM5W"=C 4CDOI]M:J@.W8K-+Y3PZ;H&I?GF)H_*6
MW@)8FHX, J2YRW;O<VINB]XBW='))M?[L<M")H$16J%OV$&0!8%'4C<2RH#2
MC*?FHW0'>/D9RB<:L67RW9()US+@E"K=&R]PTKZ/[82=O/N=/%7FUZTR1V+*
MG.XA76"_6'M2W!9'2[Z/?02<S>]C/^7.ZO>PK[#36S^W)T]SC>#7.]WU\_#H
MM%\!W,*4A[;17#_@$AI!0"^]V.;-<J+8B@/'2;$ME>>P1DN^0QW@7,,Y$58
MLQDT]]H3ITT^?6&NB=ZBG(456^E-$S::G:"B==YU^L]MW? > 0_E5\(0S3=D
MW^.:U?0^E#>X?KJORM><ROW/;[_6)+TM!J96[VMP3U(:(I(9$2:1D5FI9[-Y
MG7X20812!Y*ZO>\'E%F'R6J'-+>)-ZP3 /TM^SFA:*-MW3J%RWTG/+Q'6+#,
M2.N&BJF62V\3T(F_QY9MQ1[=?M=]^GN&+MKARZ*F/_W:[M6?T*%M88?VFY;"
M;9U<5:0SM:"XJN;5R>13_:T5EMPI<,,&)<4E6_V5](*RAYZX0\W"N')/HM#
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M[?-9+^^VXM7&!@Y3TTC3S#4)(6YL":57J$-)LR1WL-!S6T>9'"$"</RH8;^
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M#H<;M#83XOB#WI--%(5MOQ7SUNE[VOQF_][L4E&EWS2W_,QVY ]91H] ,$2
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MZB!3RW-_,G]E?_WR4_<)^\$S?'_YZ2]02P,$%     @ S#NM7!F 62YG>
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MWPLJLG2HY)!M$2 Y<RZJ8'GSSX=J[M$V$XQ+8(2&@&(H"#=8"JHS &3'T+W
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M[2O[&H*=7H25@*6C + 86QL%0.Q3[:]TY=[^O$K>0V3O?'41'<B'PFL?MY-
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M_:F;-B0Z<0IQ)*458";;G'VJ_96NW)L;>FZ<X[/YIM%EXSRWZR:1 !HY![S
M.M# 81"Y\^##*"VM!5L>W#P)S^Q*G-Z5[&;VS-K%.JY9G_3UKO:<A 9@+/$
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M,C+[B;&GJ9IX.R&/^K=!E5<74^]D_Q?^3Q]?7'R/ DVW9WWX\/K>P#X2DL5
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MSSE+/TCH9443-S.BW0"+ F.,!Y9Q@K!D"(8AG>=N'M\/"L\BP9Y)AF6A()G
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M<(I3^6Z[!Q,"RKKHJWA)F4$X4)3[IIRG:.H'LF>Q+3.*&@J'U7:'OM9N$8%
M$L0 (=2BY/9QFOMRZD/HZP>W9[$A,KIZI@Y4MC9[4A7W8OX@"ONZ>/OW=;6Z
M/EN]G?FFD\MY^.#GKNWMXK1GB90 QB*CC$R7@0^YMO80&OHA[;EN;8RFC;)
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MWY[P6YZ'NR-ZGWV::RY5D=T?:6GMZG -HJ_' 2440>\\=CZW:W,LS249L8'
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M,I['?0"#(Z4APCX6-MD1\W$QM_=\/"K<P@280#% T@F+G;<D>Z.;W90\CSL
M!N-FH,B?0ZW<@Z,ZW]+YQ7DZQKBJOA];%??D<[/7OQW&R4DKW;1Q0/F@ #7&
M0.Q-4&&,VR GJ72#5 .%6)P"6@9KI>.*VA&8>X:5;GOU/J#2;:^H)PR@EO7J
MKY_U_)O?59+# @-*6@T0H8ENK[SNM541G_H &_&W>UP\&G!Z)!REML6Q,BQ!
M\1TU,M&GTEPPX(CWAI'@$>]E&OJH?LH"I".4M:WN 9*;6.&_Z9^I,VD'X1X!
M+3T'/D ,25 <NE[-3)Y0^:-!)U;Z$)4M<LBON"V97?!7+&V_*P:\@MX398G
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MQR3V4'L_Y%*T :24M+F4?34=6S5E ?%ASO8FNCV?;V[%N?G(NVWV=(JAK>"
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M5NQ![5Z>E')Q.-G=R*)96J6*4T<3()F57FC"5/:V#<^QW<O3.A[0[N5)@1<
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M#<#*T/YM3RJN)!2>H@G3)DRC0 5$@ R!(B\\HRYW ///_FU] 3AE_[8GT5#
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MMI@JAR7)W<MG#SF%X"P_"+K@=J1&"@47WLV*<0P8(2!PPDOEC5.*ZQ. "Q\
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M#5;C;C@,D&D!@.B81\U$B7,ISK?SN>\XHYHZX0EE  F4,\VLI3YWNN0 \HH
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MQG.75AY,9.$5'.-:]7%56@!F!\MW4\"W_%/\XFKY?OZIN?'H3_5B>7N3IZ7
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MP_TW<2#>E\7JON/^><JF'X*[E3F-4^0FD^X?H=.]*X,M.W ='PE18D.I+"?
M-8#(=? !-+>432F*%.8.H2QSRTV=(9E:S2/!<62@"WF,?[UNLM.I200%3T0
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MV\7JUE(Q+_X4KO-^6][?/^U;S1?%C9Q]*JN+[S,Y^ZN"X.SHK_F<J;4Q5@+
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M;T0=-S\^#(SW67)M%<3SE]LM>2M"<.SZI<']4"BYR1>CEY9;37FK)C"0E"T
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M$<K2TFUVV>G&VN_P=9U3_S6AOP%02P,$%     @ S#NM7&4NL:4!"   BC0
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MV66G$W=^Q^\"'8?O(/T%4$L#!!0    ( ,P[K5R3PK9W  4  -,>   ?
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MG!]9MN:C93O-1983#"DYR(B"H%]S)JA>=!F5$'(A(V )G.4QQ<(1PVYN3W>
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M4$L! A0#%     @ S#NM7#P!B!+T-P$ SSL- !$              ( !
M &%L=&\M,C R-C S,S$N:'1M4$L! A0#%     @ S#NM7.]/_X]-$0  8+4
M !$              ( !(S@! &%L=&\M,C R-C S,S$N>'-D4$L! A0#%
M  @ S#NM7#)ND(G0%   ..(  !4              ( !GTD! &%L=&\M,C R
M-C S,S%?8V%L+GAM;%!+ 0(4 Q0    ( ,P[K5Q$[XKQ5DH  ,CZ P 5
M          "  :)> 0!A;'1O+3(P,C8P,S,Q7V1E9BYX;6Q02P$"% ,4
M" #,.ZU<G)^C-:Z3"0 F60T %               @ $KJ0$ 86QT;RTR,#(V
M,#,S,5]G,2YJ<&=02P$"% ,4    " #,.ZU<(OC2\9/>  !+E0D %0
M        @ $+/0L 86QT;RTR,#(V,#,S,5]L86(N>&UL4$L! A0#%     @
MS#NM7!F 62YG>   P;X& !4              ( !T1L, &%L=&\M,C R-C S
M,S%?<')E+GAM;%!+ 0(4 Q0    ( ,P[K5R!/WAP_P<  "TT   ?
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9:'1M4$L%!@     +  L   ,  &*O#     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>alto-20260331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:alto="http://www.altoneuroscience.com/20260331"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="alto-20260331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <instant>2026-05-08</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-21</startDate>
            <endDate>2025-10-21</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-21</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:K2HealthventuresLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-17</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:K2HealthventuresLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-17</startDate>
            <endDate>2025-11-17</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-17</startDate>
            <endDate>2026-03-17</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-17</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:K2HealthventuresLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-18</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:K2HealthventuresLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-18</startDate>
            <endDate>2026-03-18</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alto:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alto:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alto:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alto:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-16</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-16</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-16</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alto:K2WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alto:NewK2WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-16</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-17</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-18</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alto:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alto:DebtInstrumentTrancheAxis">alto:DebtInstrumentTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:A2025InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-06</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:A2025InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alto:The2024EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alto:TwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">alto:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alto:K2CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alto:K2CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alto:K2WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alto:K2WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alto:AdditionalK2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:K2WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:K2WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alto:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alto:EmployeeStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alto:EmployeeStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alto:EmployeeStockOptionsAvailableForFutureGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alto:EmployeeStockOptionsAvailableForFutureGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto300Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto300Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto101Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto101Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto203Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto203Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto207Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alto:Alto207Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alto:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">alto:AmitEtkinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">alto:AmitEtkinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">alto:NicholasSmithMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001999480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">alto:NicholasSmithMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>alto:subsidiary</measure>
    </unit>
    <unit id="clinical-stageasset">
        <measure>alto:clinical-stageAsset</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tranche">
        <measure>alto:tranche</measure>
    </unit>
    <unit id="segment">
        <measure>alto:segment</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0001999480</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-30">false</dei:AmendmentFlag>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-612"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-613">Subsequent Events&lt;div&gt;&lt;span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%"&gt;PLACEHOLDER&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-41944</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Alto Neuroscience, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">83-4210124</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">650 Castro Street, Suite 450</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Mountain View</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94041</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">200-0412</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">ANRO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-23">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">35093940</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">263762000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">176484000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">5364000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">1234000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">269126000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">177718000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">2234000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">1872000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">4061000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">4261000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">338000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">338000</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">276259000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">184689000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">3369000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">1878000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">7610000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">8862000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">2136000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">585000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">13115000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">11325000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">13885000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">16172000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ConvertibleDebt contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">2335000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">2227000</us-gaap:ConvertibleDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">3555000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">3823000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">32890000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">33547000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-63" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-64" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-65"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-66"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-67" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-68" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-69" unitRef="shares">35053000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-70" unitRef="shares">35053000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-71" unitRef="shares">31924000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-72" unitRef="shares">31924000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-3" decimals="-3" id="f-73" unitRef="usd">3000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">3000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-75" unitRef="usd">471224000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">352751000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-77" unitRef="usd">-227871000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">-201634000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-79" unitRef="usd">13000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">22000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-81" unitRef="usd">243369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">151142000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-83" unitRef="usd">276259000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">184689000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-85" unitRef="usd">20294000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">9974000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-87" unitRef="usd">6844000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">5702000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-89" unitRef="usd">27138000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-90" unitRef="usd">15676000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-91" unitRef="usd">-27138000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">-15676000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-93" unitRef="usd">1561000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-5" decimals="-3" id="f-94" unitRef="usd">1827000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-95" unitRef="usd">545000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-5" decimals="-3" id="f-96" unitRef="usd">598000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-97" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-5" decimals="-3" id="f-98" unitRef="usd">-681000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-99" unitRef="usd">115000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-5" decimals="-3" id="f-100" unitRef="usd">41000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-101" unitRef="usd">901000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">507000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">-26237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">-15169000</us-gaap:NetIncomeLoss>
    <us-gaap:OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">7000</us-gaap:OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent>
    <us-gaap:OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent contextRef="c-5" decimals="-3" id="f-106" unitRef="usd">134000</us-gaap:OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-107" unitRef="usd">-16000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-108" unitRef="usd">-19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">115000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-111" unitRef="usd">-26246000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-112" unitRef="usd">-15054000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">-0.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-114"
      unitRef="usdPerShare">-0.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-115"
      unitRef="usdPerShare">-0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-116"
      unitRef="usdPerShare">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-117" unitRef="shares">32893000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-118" unitRef="shares">32893000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-119" unitRef="shares">27049000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-120" unitRef="shares">27049000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="4"
      id="f-121"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="-3" id="f-122" unitRef="shares">26987000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-123" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-124" unitRef="usd">289954000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-125" unitRef="usd">-138396000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-126" unitRef="usd">-101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-127" unitRef="usd">151460000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-12" decimals="-3" id="f-128" unitRef="shares">85000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-13" decimals="-3" id="f-129" unitRef="usd">198000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-130" unitRef="usd">198000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <alto:APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock contextRef="c-13" decimals="-3" id="f-131" unitRef="usd">524000</alto:APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock>
    <alto:APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock contextRef="c-5" decimals="-3" id="f-132" unitRef="usd">524000</alto:APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-133" unitRef="usd">1968000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-134" unitRef="usd">1968000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-135" unitRef="usd">115000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-136" unitRef="usd">115000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-137" unitRef="usd">-15169000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-138" unitRef="usd">-15169000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-16" decimals="-3" id="f-139" unitRef="shares">27072000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-140" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-141" unitRef="usd">292644000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-142" unitRef="usd">-153565000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-143" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-144" unitRef="usd">139096000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="4"
      id="f-145"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-20" decimals="-3" id="f-146" unitRef="shares">31924000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-147" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-148" unitRef="usd">352751000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-149" unitRef="usd">-201634000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-150" unitRef="usd">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-151" unitRef="usd">151142000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-24" decimals="-3" id="f-152" unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-25" decimals="-3" id="f-153" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-24" decimals="-3" id="f-155" unitRef="shares">18000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="c-25" decimals="-3" id="f-156" unitRef="usd">-190000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">-190000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <alto:IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock contextRef="c-24" decimals="-3" id="f-158" unitRef="shares">2900000</alto:IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock>
    <alto:StockAndPreFundedWarrantsIssuedDuringPeriodValue contextRef="c-25" decimals="-3" id="f-159" unitRef="usd">114892000</alto:StockAndPreFundedWarrantsIssuedDuringPeriodValue>
    <alto:StockAndPreFundedWarrantsIssuedDuringPeriodValue contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">114892000</alto:StockAndPreFundedWarrantsIssuedDuringPeriodValue>
    <alto:StockIssuedDuringPeriodShareConversionOfTermLoan contextRef="c-24" decimals="-3" id="f-161" unitRef="shares">207000</alto:StockIssuedDuringPeriodShareConversionOfTermLoan>
    <alto:StockIssuedDuringPeriodValueConversionOfTermLoan contextRef="c-25" decimals="-3" id="f-162" unitRef="usd">941000</alto:StockIssuedDuringPeriodValueConversionOfTermLoan>
    <alto:StockIssuedDuringPeriodValueConversionOfTermLoan contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">941000</alto:StockIssuedDuringPeriodValueConversionOfTermLoan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-25" decimals="-3" id="f-164" unitRef="usd">2824000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-165" unitRef="usd">2824000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-26" decimals="-3" id="f-166" unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-167" unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-168" unitRef="usd">-26237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">-26237000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-28" decimals="-3" id="f-170" unitRef="shares">35053000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-171" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-172" unitRef="usd">471224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-173" unitRef="usd">-227871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-174" unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-175" unitRef="usd">243369000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">-26237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-177" unitRef="usd">-15169000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">2824000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-179" unitRef="usd">1968000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-180" unitRef="usd">184000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-181" unitRef="usd">171000</us-gaap:Depreciation>
    <alto:InterestExpenseNoncash contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">206000</alto:InterestExpenseNoncash>
    <alto:InterestExpenseNoncash contextRef="c-5" decimals="-3" id="f-183" unitRef="usd">180000</alto:InterestExpenseNoncash>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">200000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-5" decimals="-3" id="f-185" unitRef="usd">190000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">-9000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-5" decimals="-3" id="f-187" unitRef="usd">-41000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <alto:GainLossInOtherOperatingActivitiesNet contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">116000</alto:GainLossInOtherOperatingActivitiesNet>
    <alto:GainLossInOtherOperatingActivitiesNet contextRef="c-5" decimals="-3" id="f-189" unitRef="usd">41000</alto:GainLossInOtherOperatingActivitiesNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-5" decimals="-3" id="f-191" unitRef="usd">-681000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">4130000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-193" unitRef="usd">1692000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">1490000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-5" decimals="-3" id="f-195" unitRef="usd">-266000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">-1753000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-5" decimals="-3" id="f-197" unitRef="usd">-2701000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">-27091000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-199" unitRef="usd">-16556000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">556000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-201" unitRef="usd">24000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">-556000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-203" unitRef="usd">-24000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <alto:ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">120000000</alto:ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement>
    <alto:ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement contextRef="c-5" decimals="-3" id="f-205" unitRef="usd">0</alto:ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement>
    <alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">4875000</alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement>
    <alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement contextRef="c-5" decimals="-3" id="f-207" unitRef="usd">0</alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">190000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" id="f-209" unitRef="usd" xsi:nil="true"/>
    <alto:PaymentsOnIssuanceCostFromRegistrationStatement contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">0</alto:PaymentsOnIssuanceCostFromRegistrationStatement>
    <alto:PaymentsOnIssuanceCostFromRegistrationStatement contextRef="c-5" decimals="-3" id="f-211" unitRef="usd">419000</alto:PaymentsOnIssuanceCostFromRegistrationStatement>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-5" decimals="-3" id="f-213" unitRef="usd">19688000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-5" decimals="-3" id="f-215" unitRef="usd">10213000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-5" decimals="-3" id="f-217" unitRef="usd">127000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">6000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-5" decimals="-3" id="f-219" unitRef="usd">198000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">114941000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-221" unitRef="usd">9127000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">-16000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-223" unitRef="usd">-22000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">87278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-225" unitRef="usd">-7475000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-226" unitRef="usd">176984000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-227" unitRef="usd">168729000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-228" unitRef="usd">264262000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-229" unitRef="usd">161254000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">941000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-5" decimals="-3" id="f-231" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">233000</alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid>
    <alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid contextRef="c-5" decimals="-3" id="f-233" unitRef="usd">0</alto:CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid>
    <alto:DeferredOfferingAndShareIssueCostsNotYetPaid contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">0</alto:DeferredOfferingAndShareIssueCostsNotYetPaid>
    <alto:DeferredOfferingAndShareIssueCostsNotYetPaid contextRef="c-5" decimals="-3" id="f-235" unitRef="usd">138000</alto:DeferredOfferingAndShareIssueCostsNotYetPaid>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-5" decimals="-3" id="f-237" unitRef="usd">524000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-238" unitRef="usd">342000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-5" decimals="-3" id="f-239" unitRef="usd">311000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-240">Description of the Business&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alto Neuroscience, Inc. (the &#x201c;Company&#x201d; or &#x201c;Alto&#x201d;) was incorporated in Delaware on March&#160;25, 2019. The Company maintains its headquarters in Mountain View, California. The Company has one wholly-owned subsidiary in Australia that was formed during 2020 to conduct clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alto is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through insights derived from the Company&#x2019;s scalable and proprietary Precision Psychiatry Platform, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. The Company&#x2019;s current pipeline consists of seven clinical-stage assets addressing high-need therapeutic areas, including major depressive disorder (&#x201c;MDD&#x201d;), bipolar depression (&#x201c;BPD&#x201d;), treatment resistant depression (&#x201c;TRD&#x201d;), schizophrenia, and Parkinson&#x2019;s disease.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred significant operating losses since inception and has relied primarily upon equity financings to fund its operations. At March&#160;31, 2026, the Company had an accumulated deficit of approximately $227.9 million. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the generation of sufficient revenues to support its cost structure. No assurance can be provided that the Company will ever be profitable, and unless or until it becomes profitable, the Company will need to continue to raise additional capital.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2024, the Company completed its initial public offering (&#x201c;IPO&#x201d;) of its common stock. The Company issued and sold 9,246,000 shares of common stock at a public offering price of $16.00 per share, which included 1,206,000 shares sold pursuant to the exercise of the underwriters&#x2019; option to purchase additional shares, and received net proceeds of $133.0 million after deducting underwriting discounts and commissions and other offering costs. Upon completion of the IPO, all outstanding shares of the Company&#x2019;s outstanding preferred stock converted into an aggregate of 13,664,261 shares of common stock. In addition, the IPO resulted in the net exercise and conversion of all outstanding Series A Preferred Stock Warrants for an aggregate of 72,631 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 21, 2025, the Company completed a private placement transaction in which it issued and sold (i) 3,832,263 shares of common stock and (ii) pre-funded warrants (in lieu of common stock) to purchase an aggregate of 4,622,251 shares of common stock. The Company received net proceeds of $49.7&#160;million (see Note 10 for additional information). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 17, 2025, K2 HealthVentures LLC elected to convert $4.0&#160;million of its outstanding loan balance into the Company&#x2019;s common stock. Pursuant to the terms of the Amended Loan Agreement, the conversion price was $4.83 per share, resulting in the issuance of 828,860 shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2026, the Company completed a private placement transaction in which it issued and sold (i) 2,900,000 shares of common stock and (ii) pre-funded warrants (in lieu of common stock) to purchase an aggregate of 3,100,000 shares of common stock. The Company received net proceeds of $114.9&#160;million (See Note 10 for additional information).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 18, 2026, K2 HealthVentures LLC elected to convert $1.0&#160;million of its outstanding loan balance into the Company&#x2019;s common stock. Pursuant to the terms of the Amended Loan Agreement, the conversion price was $4.83 per share, resulting in the issuance of 207,215 shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <alto:NumberOfWhollyOwnedSubsidiaries
      contextRef="c-3"
      decimals="INF"
      id="f-241"
      unitRef="subsidiary">1</alto:NumberOfWhollyOwnedSubsidiaries>
    <alto:NumberOfClinicalStageAssets
      contextRef="c-3"
      decimals="INF"
      id="f-242"
      unitRef="clinical-stageasset">7</alto:NumberOfClinicalStageAssets>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-243" unitRef="usd">-227900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-32"
      decimals="INF"
      id="f-244"
      unitRef="shares">9246000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-33"
      decimals="2"
      id="f-245"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-34"
      decimals="INF"
      id="f-246"
      unitRef="shares">1206000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-32" decimals="-5" id="f-247" unitRef="usd">133000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <alto:TemporaryEquitySharesConversionOfConvertibleSecurities
      contextRef="c-35"
      decimals="INF"
      id="f-248"
      unitRef="shares">13664261</alto:TemporaryEquitySharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-33"
      decimals="INF"
      id="f-249"
      unitRef="shares">72631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-36"
      decimals="INF"
      id="f-250"
      unitRef="shares">3832263</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-37"
      decimals="INF"
      id="f-251"
      unitRef="shares">4622251</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-36" decimals="-5" id="f-252" unitRef="usd">49700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <alto:SaleOfStockConversionOfOutstandingLoan contextRef="c-38" decimals="-5" id="f-253" unitRef="usd">4000000.0</alto:SaleOfStockConversionOfOutstandingLoan>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-38"
      decimals="2"
      id="f-254"
      unitRef="usdPerShare">4.83</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c-39"
      decimals="INF"
      id="f-255"
      unitRef="shares">828860</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-40"
      decimals="INF"
      id="f-256"
      unitRef="shares">2900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-41"
      decimals="INF"
      id="f-257"
      unitRef="shares">3100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-40" decimals="-5" id="f-258" unitRef="usd">114900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <alto:SaleOfStockConversionOfOutstandingLoan contextRef="c-42" decimals="-5" id="f-259" unitRef="usd">1000000.0</alto:SaleOfStockConversionOfOutstandingLoan>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-42"
      decimals="2"
      id="f-260"
      unitRef="usdPerShare">4.83</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c-43"
      decimals="INF"
      id="f-261"
      unitRef="shares">207215</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-262">Summary of Significant Accounting Policies and Basis of Presentation&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;), as determined by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;), and include the accounts of Alto and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim condensed consolidated financial statements are unaudited and have been prepared on the same basis as the audited annual financial st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;atements and, in management&#x2019;s opinion, include all adjustments consisting of only normal recurring adjustments necessary for the fair statement of the&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Company&#x2019;s financial position as of March&#160;31, 2026 and its results of operations and statements of equity for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended March&#160;31, 2026 and 2025 and cash flows for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March&#160;31, 2026 and 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f operations for the three months ended March&#160;31, 2026 are not necessarily indicative of the results to be expected for the full fiscal year or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and the related notes thereto for the year ended December&#160;31, 2025 included in the Company&#x2019;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 16, 2026 (the &#x201c;Annual Report&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ materially from those estimates. The most significant estimates and assumptions in the Company&#x2019;s condensed consolidated financial statements relate to the determination of the volatility of its common stock (as an input for calculating stock-based compensation and warrants), estimating accrued or prepaid research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies used in the preparation of these condensed consolidated financial statements for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended March&#160;31, 2026 are consistent with those discussed in Note 3 to the consolidated financial statements in the Annual Report. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU No. 2024-04, Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, which affects entities that settle convertible debt instruments for which the conversion privileges were changed to induce conversion. The standard is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company adopted the provisions of ASU 2024-04 prospectively beginning January 1, 2026. The adoption did not have an impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU No. 2024-03, Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which expands disclosures about specific expense categories presented on the face of the income statement. The standard is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. This standard clarifies current interim reporting requirements on Topic 270 and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. This standard will be effective for fiscal years beginning after December 15, 2027, with the option to apply it retrospectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early adoption is allowed. Currently, the Company is evaluating the impact the adoption of this standard will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-263">&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;), as determined by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;), and include the accounts of Alto and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim condensed consolidated financial statements are unaudited and have been prepared on the same basis as the audited annual financial st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;atements and, in management&#x2019;s opinion, include all adjustments consisting of only normal recurring adjustments necessary for the fair statement of the&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Company&#x2019;s financial position as of March&#160;31, 2026 and its results of operations and statements of equity for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended March&#160;31, 2026 and 2025 and cash flows for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March&#160;31, 2026 and 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f operations for the three months ended March&#160;31, 2026 are not necessarily indicative of the results to be expected for the full fiscal year or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and the related notes thereto for the year ended December&#160;31, 2025 included in the Company&#x2019;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 16, 2026 (the &#x201c;Annual Report&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-264">&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ materially from those estimates. The most significant estimates and assumptions in the Company&#x2019;s condensed consolidated financial statements relate to the determination of the volatility of its common stock (as an input for calculating stock-based compensation and warrants), estimating accrued or prepaid research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-265">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU No. 2024-04, Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, which affects entities that settle convertible debt instruments for which the conversion privileges were changed to induce conversion. The standard is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company adopted the provisions of ASU 2024-04 prospectively beginning January 1, 2026. The adoption did not have an impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU No. 2024-03, Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which expands disclosures about specific expense categories presented on the face of the income statement. The standard is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. This standard clarifies current interim reporting requirements on Topic 270 and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. This standard will be effective for fiscal years beginning after December 15, 2027, with the option to apply it retrospectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early adoption is allowed. Currently, the Company is evaluating the impact the adoption of this standard will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-266">Balance Sheet Components&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,894&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,470&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,043&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,364&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,234&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,125&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;453&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;453&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;574&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;574&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;246&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;246&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Less&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;: accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,706)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,234&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,872&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.2 million for both the three months ended March&#160;31, 2026, and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll, vacation and employee-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,001&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,870&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,124&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest, short term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accruals and current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,048&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;599&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability, short term &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,304&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,151&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,610&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,862&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-267">&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,894&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,470&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,043&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,364&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,234&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance contextRef="c-3" decimals="-3" id="f-268" unitRef="usd">1894000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c-4" decimals="-3" id="f-269" unitRef="usd">191000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-3" decimals="-3" id="f-270" unitRef="usd">3470000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-271" unitRef="usd">1043000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-272" unitRef="usd">5364000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-273" unitRef="usd">1234000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-274">&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,125&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;453&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;453&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;574&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;574&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;246&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;246&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Less&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;: accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,706)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,234&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,872&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-44" decimals="-3" id="f-275" unitRef="usd">2667000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-45" decimals="-3" id="f-276" unitRef="usd">2125000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-46" decimals="-3" id="f-277" unitRef="usd">453000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-47" decimals="-3" id="f-278" unitRef="usd">453000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-48" decimals="-3" id="f-279" unitRef="usd">574000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-49" decimals="-3" id="f-280" unitRef="usd">574000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-50" decimals="-3" id="f-281" unitRef="usd">246000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-51" decimals="-3" id="f-282" unitRef="usd">246000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-283" unitRef="usd">1706000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-284" unitRef="usd">1526000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-285" unitRef="usd">2234000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-286" unitRef="usd">1872000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-287" unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-5" id="f-288" unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-289">&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll, vacation and employee-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,001&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,870&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,124&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest, short term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accruals and current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,048&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;599&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability, short term &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,304&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,151&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,610&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,862&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-290" unitRef="usd">2001000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-291" unitRef="usd">4870000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <alto:AccruedResearchExpense contextRef="c-3" decimals="-3" id="f-292" unitRef="usd">3142000</alto:AccruedResearchExpense>
    <alto:AccruedResearchExpense contextRef="c-4" decimals="-3" id="f-293" unitRef="usd">2124000</alto:AccruedResearchExpense>
    <us-gaap:InterestPayableCurrent contextRef="c-3" decimals="-3" id="f-294" unitRef="usd">115000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-4" decimals="-3" id="f-295" unitRef="usd">118000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-296" unitRef="usd">1048000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-297" unitRef="usd">599000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-298" unitRef="usd">1304000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-299" unitRef="usd">1151000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-300" unitRef="usd">7610000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-301" unitRef="usd">8862000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-302">Debt&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;K2 HealthVentures LLC Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On December&#160;16, 2022, the Company entered into a Loan and Security Agreement (the &#x201c;Original Loan Agreement&#x201d;) with K2 HealthVentures LLC as a lender, the other lenders party thereto (collectively, the &#x201c;Lender&#x201d;), K2 HealthVentures LLC, as administrative agent for Lender (the &#x201c;Administrative Agent&#x201d;), and Ankura Trust Company, LLC, as collateral agent for the Lender. Pursuant to the terms of the Original Loan Agreement, the Lender agreed to make available to the Company term loans (each, collectively, the &#x201c;Term Loan&#x201d;) in an aggregate principal amount of up to $35.0 million. As of December &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;31, 2024, the Company had drawn a principal amount of $10.0 million. The Lender&#x2019;s commitment to make available additional Term Loans under the Original Loan Agreement expired without being drawn on January 1, 2025. The Original Loan Agreement had a Term Loan maturity date of December&#160;1, 2026 (the &#x201c;Original Term Loan Maturity Date&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 13, 2025, the Company entered into an amendment to the Original Loan Agreement (the &#x201c;Amendment&#x201d; and the Original Loan Agreement as amended thereby, the &#x201c;Amended Loan Agreement&#x201d;) to, among other things, extend the Original Term Loan Maturity Date and increase the maximum available amount of term loans. The Amended Loan Agreement provides for term loans in an aggregate principal amount of up to $75.0&#160;million, consisting of:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;a first tranche term loan of $20.0&#160;million;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;second tranche term loans of up to $30.0&#160;million in the aggregate available at the Company&#x2019;s request until December 15, 2025, subject to certain time-based, clinical milestones; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;third tranche term loans of up to $25.0&#160;million in the aggregate available at the Company&#x2019;s request subject to the Lender&#x2019;s approval. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company drew $20.0&#160;million upon entry into the Amendment (approximately $10.0&#160;million of which was used to refinance obligations under the Original Loan Agreement and pay fees and expenses incurred in connection with the Amendment). The second tranche term loan was available until December 15, 2025 based on certain milestones and expired without being drawn.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Loan Agreement has a Term Loan maturity date of January 1, 2029 (the &#x201c;Amended Term Loan Maturity Date&#x201d;). The Amended Loan Agreement provides for an interest only period until January 1, 2027, following which the Term Loan shall be repaid in equal monthly payments through the Amended Term Loan Maturity Date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan bears interest at (i) a variable per annum cash pay rate equal to the Prime Rate plus 1.45% (subject to a floor of 8.45% per annum) and (ii) a fixed per annum paid-in-kind rate equal to 1.0%. Interest is due and payable monthly in arrears. Upon final payment or prepayment of the Term Loan, the Company is required to pay a final payment equal to 5.95% of the amount borrowed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Loan Agreement was accounted for as a debt extinguishment, as the new loan was considered substantially different from the original loan. The Company recognized debt issuance costs and discount upon issuance of $2.0&#160;million within Term Loan, non-current on its condensed consolidated balance sheet and recorded a loss on debt extinguishment of $0.7&#160;million, which was recorded within loss on debt extinguishment in its condensed consolidated statement of operations and comprehensive loss for &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the three mont&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hs ended March&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fees&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Original Loan Agreement, the Company was obligated to pay a final fee equal to 6.25% of the aggregate amount of the term loans funded thereunder (the &#x201c;Original Exit Fee&#x201d;) upon the earliest of (i)&#160;the Original Term Loan Maturity Date, (ii)&#160;the acceleration of the Term Loan, and (iii)&#160;the prepayment of the Term Loan. The Company was also obligated to pay the Lender a one-time facility fee of $0.2&#160;million (&#x201c;Original Facility Fee&#x201d;) on the initial closing date. The Original Exit Fee of $0.6 million and Original Facility Fee of $0.2&#160;million were recorded as debt discount, and were being accreted using the effective interest method within interest expense in the condensed consolidated statements of operations and comprehensive loss. The Company&#x2019;s obligation to pay the Original Exit Fee remains outstanding, and the timing for payment thereof was unaffected by, and reaffirmed in connection with, the Amendment, and is recorded in the condensed consolidated balance sheet within Term loan, current as of March&#160;31, 2026 and December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was obligated to pay the Lender a one-&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;time facility fee of $0.3&#160;million upon entry into the Amendment. The Company is also obligated to pay a funding fee on each third tranche term loan in an amount equal to the sum of 0.5% multiplied by the amount of such third tranche term loan, if and when funded. Under the terms of the Amended Loan Agreement, the Company is obligated to pay a final fee equal to 5.95% of the aggregate amount of the Term Loan funded thereunder (the &#x201c;Amended Exit Fee&#x201d;) upon the earliest of (i)&#160;the Amended Term Loan Maturity Date, (ii) the acceleration of the Term Loan, and (iii) the prepayment of the Term Loan. As of March&#160;31, 2026, the amount owed under the Amended Exit Fee is equal to $1.2&#160;million. The Original Exit Fe&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e and the Amended Exit Fee have been fully accrued and recorded as debt discount as of the closing date of the Amendment and are being accreted using the effective interest method within interest expense in the consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has the option to prepay all, but not less than all, of the Term Loan prior to the Amended Term Loan Maturity Date, which would require that the Company pay the Lender a prepayment penalty fee based on a percentage of the outstanding principal balance and the funding date of the individual tranches thereunder. As to each such tranche under the Term Loan, such fee shall be equal to 3% if the payment occurs on or before 24 months after the funding date of such tranche, 2% if the prepayment occurs more than 24 months after, but on or before 36 months after the funding date of such tranche, or 1% if the prepayment occurs more than 36 months after the funding date of such tranche. No prepayment penalty fee is required if the applicable tranche is prepaid within six months prior to the Amended Term Loan Maturity Date or refinanced with the Lender. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Terms&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company must maintain, at all times, a cash runway of at least 5 months, provided that this covenant will be waived during any period in which the Company&#x2019;s market capitalization exceeds $700.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligations under the Amended Loan Agreement are secured by a first priority security interest in substantially all of its assets (with an exclusion for intellectual property). The Amended Loan Agreement contains customary represent&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ations and warranties, and also includes customary events of default, including payment default, breach of covenants, change of control, and material adverse effects. The Amended Loa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n Agreement restricts certain activities, such as disposing of the Company&#x2019;s business or certain assets, incurring additional debt or liens or making payments on other debt, making certain investments and declaring dividends, acquiring or merging with another entity, engaging in transactions with affiliates or encumbering intellectual property, among others. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of an event of default, a default interest rate of an additional 5% per annum may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and exercise all of its rights and remedies as set forth in the Amended Loan Agreement and u&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nder applicable law. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Original Loan Agreement, the Company issued to the Lender a warrant (the &#x201c;Original Warrant&#x201d;), which Original Warrant is exercisable for 35,773 shares of the Company&#x2019;s common stock and expires on December 15, 2032. In connection with the Amendment, the Original Warrant was amended and restated (the &#x201c;Amended and Restated Warrant&#x201d;) to reduce the exercise price from $10.49 to $3.71 per share (the &#x201c;Exercise Price&#x201d;). The incremental value associated with this modification was immaterial, and was included as part of the determination of the loss on debt extinguishment, with a corresponding increase in additional paid-in capital during&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; the three months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;March&#160;31, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Amendment, the Company issued an additional warrant (the &#x201c;New Warrant&#x201d;, together with the Amended and Restated Warrant, the &#x201c;Warrants&#x201d;) to purchase a number of shares of the Company&#x2019;s common stock calculated as follows: (a) (i) 0.025, multiplied by (ii) the aggregate principal amount of the term loans actually funded under the Amended Loan Agreement, divided by (b) the Exercise Price. The New Warrant expires on January 13, 2035 and allows for the purchase of 134,691 shares of the Company&#x2019;s common stock. If the Company draws down on additional tranches of the Term Loan, the number of shares available for purchase by the Lender under the New Warrant would increase. The Company determined the estimated fair value of the New Warrant at the date of issuance to be $0.5&#160;million, which was included as part of the determination of the loss on debt extinguishment, with a corresponding increase in additional paid-in capital. As of the date of the issuance, significant assumptions include an expected life of 10 years, a risk-free rate of 4.79% and an expected volatility of 89.47%. See Note 10 for additional information regarding the New Warrant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loan Conversion Feature&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Amended Loan Agreement, the Lender may, at its option, elect to convert up to $9.0&#160;million of the then outstanding Term Loan (the &#x201c;Conversion Amount&#x201d;) ($4.0&#160;million of which was reflected in the Original Loan Agreement and $5.0&#160;million of which is reflected in the Amended Loan Agreement) into shares of the Company&#x2019;s common stock (the &#x201c;Conversion Shares&#x201d;). The number of shares to be issued upon conversion is determined by dividing (a) the portion of the term loan amount converted, by (b) the Applicable Conversion Price. Applicable Conversion Price means (i) with respect to any conversion of up to $4.0&#160;million of the Conversion Amount, $10.49, and (ii) with respect to any conversion of the remaining $5.0&#160;million of the Conversion Amount, $4.83, in each case subject to certain adjustments set &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forth in the Amended Loan Agreement. The Company determined that the embedded conversion option is not required to be separated from the Term Loan. The embedded conversion option meets the derivative accounting scope exception since the embedded conversion option is indexed to the Company&#x2019;s own common stock and qualifies for classification within stockholders&#x2019; equity. On November 17, 2025 and March 18, 2026, the Lender elected to convert $4.0&#160;million and $1.0&#160;million, respectively, of its outstanding loan balance into the Company&#x2019;s common stock. Pursuant to the terms of the Amended Loan Agreement, the conversion price was $4.83 per share, resulting in the issuance of 828,860 and 207,215 shares, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Expense and future repayments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The C&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ompany recorded interest expense at a weighted average rate of 12.35% and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.94%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to the Loan Agreement for the three months ended March&#160;31, 2026, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; respectively. During the three months ended March&#160;31, 2026, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company recorded interest expense of $0.5 million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.6 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future principal debt payments and Exit Fee of the term loan funded as of March&#160;31, 2026 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026 (remainder of year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,858&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,467&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;675&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,815&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;235&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments and Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,050&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: unamortized debt discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,029)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Term loan, current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,136)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term loan,&#160;non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,885&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Wellcome Trust Limited Convertible Grant Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2024, the Company entered into a convertible loan agreement (the &#x201c;Convertible Grant Agreement&#x201d;) with The Wellcome Trust Limited (&#x201c;Wellcome&#x201d;). The Convertible Grant Agreement provides for an unsecured convertible loan (the &#x201c;Convertible Loan&#x201d;) from Wellcome of up to approximately $11.7&#160;million, payable to Alto in six tranches, of which up to $2.0&#160;million could be funded upon the execution of the Convertible Grant Agreement and the remainder of which will be funded upon the completion of certain milestones as set forth in the Convertible Grant Agreement. As of March&#160;31, 2026, the Company has drawn down the entirety of the $2.0&#160;million execution tranche and will continue to access the loan as needed as the ALTO-100 study in bipolar depression progresses. Interest accrues at an annual rate equal to the Sterling Overnight Index Rate plus 2%, subject to potential adjustment if such annual interest rate equals or exceeds 9% at any time. Proceeds from the Convertible Loan may be used by the Company solely to advance development of ALTO-100 in bipolar depression. The Convertible Grant Agreement also includes customary covenants, representations and warranties, including with respect to the conduct of the Company&#x2019;s Phase 2b clinical trial evaluating ALTO-100 in patients with bipolar depression and certain information and audit rights of Wellcome in connection therewith, as well as with respect to the Company&#x2019;s efforts to develop and exploit ALTO-100. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At any time after the second anniversary of the effective date of the Convertible Grant Agreement or in connection with an event of default, Wellcome has the right, at its election, to convert some or all of the Convertible Loan into shares of the Company&#x2019;s common stock at a price per share equal to a 20% discount to the thirty-day volume-weighted average price of Common Stock on the New York Stock Exchange at the date of such conversion. The Convertible Grant Agreement provides that in no event shall the aggregate number of shares of Common Stock issued pursuant to conversion of the Convertible Loan exceed 5,363,326, which is equal to 19.9% of the number of shares of Common Stock outstanding as of the date of the Convertible Grant Agreement. At any time after the fifth anniversary of the effective date of the Convertible Grant Agreement or in connection with an event of default, Wellcome may require repayment of the Convertible Loan in full, together with accrued interest, to the extent not converted as described above.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future principal debt payments of the Convertible Grant Agreement funded as of March&#160;31, 2026 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026 (remainder of year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term loan,&#160;non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the terms and features of the Convertible Grant Agreement and determined that the Company was eligible to elect the fair value option under ASC 825, Financial Instruments. The Convertible Grant Agreement contains various embedded features and the election of the fair value option allowed the Company to bypass analysis of potential embedded derivatives and further analysis of bifurcation of any recognized financial liabilities. Under the fair value option, the financial liability is initially measured at its fair value on the issue date and subsequently remeasured at estimated fair value on a recurring basis at each reporting date. Changes in the fair value of the Convertible Grant Agreement, which include accrued interest, if any, are recorded as a component &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of other, net or within other comprehensive income (loss) in the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; condensed consolidated statements of operations and comprehensive loss. The Company has not elected to present interest expense separately from changes in fair value and therefore will not present interest expense associated with the Convertible Grant Agreement. Any changes in fair value caused by instrument-specific credit risk are presented separately in other comprehensive income or loss. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial fair value of the Convertible Grant Agreement using a probability-weighted income approach. Draw downs under the Convertible Grant Agreement were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.8 million and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.3 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ended December&#160;31, 2025, and 2024, respectively. The Company remeasured the fair value of the Convertible Grant Agreement as of March&#160;31, 2026 to b&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e $2.3 million using&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a probability-weighted income approach. The Company calculated discounted cash flows of the Convertible Grant Agreement using a discount rate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.69%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and adjusted for the probability of various repayment scenarios. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the change in fair value of the Convertible Grant Agreement during the three months ended March&#160;31, 2026 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value balance as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,227&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issuance of new tranches&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in fair value reported in statements of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in fair value reported in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value balance as of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-52" decimals="-5" id="f-303" unitRef="usd">35000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-53" decimals="-5" id="f-304" unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-54" decimals="-5" id="f-305" unitRef="usd">75000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-55" decimals="-5" id="f-306" unitRef="usd">20000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-56" decimals="-5" id="f-307" unitRef="usd">30000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-57" decimals="-5" id="f-308" unitRef="usd">25000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-58" decimals="-5" id="f-309" unitRef="usd">20000000.0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="c-59" decimals="-5" id="f-310" unitRef="usd">10000000.0</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-60" decimals="4" id="f-311" unitRef="number">0.0145</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <alto:DebtInstrumentInterestRateFloor contextRef="c-60" decimals="4" id="f-312" unitRef="number">0.0845</alto:DebtInstrumentInterestRateFloor>
    <alto:DebtInstrumentFixedRatePaidInKind contextRef="c-60" decimals="3" id="f-313" unitRef="number">0.010</alto:DebtInstrumentFixedRatePaidInKind>
    <alto:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed contextRef="c-60" decimals="4" id="f-314" unitRef="number">0.0595</alto:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-61" decimals="-5" id="f-315" unitRef="usd">2000000.0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-62" decimals="-5" id="f-316" unitRef="usd">-700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <alto:DebtInstrumentExitFeePercentOfLoansFunded contextRef="c-52" decimals="4" id="f-317" unitRef="number">0.0625</alto:DebtInstrumentExitFeePercentOfLoansFunded>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-52" decimals="-5" id="f-318" unitRef="usd">200000</us-gaap:DebtInstrumentFeeAmount>
    <alto:DebtInstrumentExitFee contextRef="c-63" decimals="-5" id="f-319" unitRef="usd">600000</alto:DebtInstrumentExitFee>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-52" decimals="-5" id="f-320" unitRef="usd">200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-54" decimals="-5" id="f-321" unitRef="usd">300000</us-gaap:DebtInstrumentFeeAmount>
    <alto:DebtInstrumentFundingFeeMultiplier contextRef="c-57" decimals="3" id="f-322" unitRef="number">0.005</alto:DebtInstrumentFundingFeeMultiplier>
    <alto:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed contextRef="c-60" decimals="4" id="f-323" unitRef="number">0.0595</alto:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed>
    <alto:DebtInstrumentExitFee contextRef="c-64" decimals="-5" id="f-324" unitRef="usd">1200000</alto:DebtInstrumentExitFee>
    <alto:DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal contextRef="c-65" decimals="2" id="f-325" unitRef="number">0.03</alto:DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal>
    <alto:DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal contextRef="c-65" decimals="2" id="f-326" unitRef="number">0.02</alto:DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal>
    <alto:DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal contextRef="c-65" decimals="2" id="f-327" unitRef="number">0.01</alto:DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal>
    <alto:DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum contextRef="c-60" id="f-328">P5M</alto:DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum>
    <alto:DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount contextRef="c-54" decimals="-5" id="f-329" unitRef="usd">700000000.0</alto:DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount>
    <alto:DebtInstrumentInterestRateIncreaseInEventOfDefault contextRef="c-52" decimals="2" id="f-330" unitRef="number">0.05</alto:DebtInstrumentInterestRateIncreaseInEventOfDefault>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-66"
      decimals="INF"
      id="f-331"
      unitRef="shares">35773</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-67"
      decimals="2"
      id="f-332"
      unitRef="usdPerShare">10.49</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-54"
      decimals="2"
      id="f-333"
      unitRef="usdPerShare">3.71</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <alto:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier
      contextRef="c-54"
      decimals="INF"
      id="f-334"
      unitRef="number">0.025</alto:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-68"
      decimals="INF"
      id="f-335"
      unitRef="shares">134691</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-68" decimals="-5" id="f-336" unitRef="usd">500000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-69" id="f-337">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-70" decimals="4" id="f-338" unitRef="number">0.0479</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-71" decimals="4" id="f-339" unitRef="number">0.8947</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <alto:DebtInstrumentPortionConvertibleToEquityAtElectionOfLender contextRef="c-72" decimals="-5" id="f-340" unitRef="usd">9000000.0</alto:DebtInstrumentPortionConvertibleToEquityAtElectionOfLender>
    <alto:DebtInstrumentPortionConvertibleToEquityAtElectionOfLender contextRef="c-73" decimals="-5" id="f-341" unitRef="usd">4000000.0</alto:DebtInstrumentPortionConvertibleToEquityAtElectionOfLender>
    <alto:DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender contextRef="c-74" decimals="-5" id="f-342" unitRef="usd">5000000.0</alto:DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender>
    <alto:DebtInstrumentPortionConvertibleToEquityAtElectionOfLender contextRef="c-73" decimals="-5" id="f-343" unitRef="usd">4000000.0</alto:DebtInstrumentPortionConvertibleToEquityAtElectionOfLender>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-67"
      decimals="2"
      id="f-344"
      unitRef="usdPerShare">10.49</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <alto:DebtInstrumentPortionConvertibleToEquityAtElectionOfLender contextRef="c-74" decimals="-5" id="f-345" unitRef="usd">5000000.0</alto:DebtInstrumentPortionConvertibleToEquityAtElectionOfLender>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-65"
      decimals="INF"
      id="f-346"
      unitRef="usdPerShare">4.83</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <alto:SaleOfStockConversionOfOutstandingLoan contextRef="c-38" decimals="-5" id="f-347" unitRef="usd">4000000.0</alto:SaleOfStockConversionOfOutstandingLoan>
    <alto:SaleOfStockConversionOfOutstandingLoan contextRef="c-42" decimals="-5" id="f-348" unitRef="usd">1000000.0</alto:SaleOfStockConversionOfOutstandingLoan>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-75"
      decimals="2"
      id="f-349"
      unitRef="usdPerShare">4.83</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-76"
      decimals="2"
      id="f-350"
      unitRef="usdPerShare">4.83</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c-39"
      decimals="INF"
      id="f-351"
      unitRef="shares">828860</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c-43"
      decimals="INF"
      id="f-352"
      unitRef="shares">207215</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime contextRef="c-77" decimals="4" id="f-353" unitRef="number">0.1235</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime contextRef="c-78" decimals="4" id="f-354" unitRef="number">0.1294</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:InterestExpenseDebt contextRef="c-77" decimals="-5" id="f-355" unitRef="usd">500000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-78" decimals="-5" id="f-356" unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-357">&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future principal debt payments and Exit Fee of the term loan funded as of March&#160;31, 2026 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026 (remainder of year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,858&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,467&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;675&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,815&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;235&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments and Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,050&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: unamortized debt discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,029)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Term loan, current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,136)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term loan,&#160;non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,885&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future principal debt payments of the Convertible Grant Agreement funded as of March&#160;31, 2026 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026 (remainder of year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term loan,&#160;non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c-79" decimals="-3" id="f-358" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-79" decimals="-3" id="f-359" unitRef="usd">6858000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-79" decimals="-3" id="f-360" unitRef="usd">7467000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-79" decimals="-3" id="f-361" unitRef="usd">675000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-79" decimals="-3" id="f-362" unitRef="usd">15000000</us-gaap:DebtInstrumentCarryingAmount>
    <alto:DebtInstrumentExitFee contextRef="c-79" decimals="-3" id="f-363" unitRef="usd">1815000</alto:DebtInstrumentExitFee>
    <alto:DebtInstrumentDeferredInterest contextRef="c-79" decimals="-3" id="f-364" unitRef="usd">235000</alto:DebtInstrumentDeferredInterest>
    <alto:LongTermDebtPrincipalPaymentsAndExitFee contextRef="c-79" decimals="-3" id="f-365" unitRef="usd">17050000</alto:LongTermDebtPrincipalPaymentsAndExitFee>
    <alto:DebtInstrumentUnamortizedExitFee contextRef="c-79" decimals="-3" id="f-366" unitRef="usd">1029000</alto:DebtInstrumentUnamortizedExitFee>
    <us-gaap:LongTermDebtCurrent contextRef="c-79" decimals="-3" id="f-367" unitRef="usd">2136000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-79" decimals="-3" id="f-368" unitRef="usd">13885000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-80" decimals="-5" id="f-369" unitRef="usd">11700000</us-gaap:DebtInstrumentFaceAmount>
    <alto:DebtInstrumentNumberOfTranches
      contextRef="c-81"
      decimals="INF"
      id="f-370"
      unitRef="tranche">6</alto:DebtInstrumentNumberOfTranches>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-82" decimals="-5" id="f-371" unitRef="usd">2000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-83" decimals="-5" id="f-372" unitRef="usd">2000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-84" decimals="2" id="f-373" unitRef="number">0.02</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <alto:DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment contextRef="c-84" decimals="2" id="f-374" unitRef="number">0.09</alto:DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment>
    <alto:DebtInstrumentConvertibleDiscountOnSharesConverted contextRef="c-85" decimals="2" id="f-375" unitRef="number">0.20</alto:DebtInstrumentConvertibleDiscountOnSharesConverted>
    <alto:DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement contextRef="c-85" id="f-376">P30D</alto:DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement>
    <alto:DebtInstrumentConvertibleMaximumSharesIssuable
      contextRef="c-85"
      decimals="INF"
      id="f-377"
      unitRef="shares">5363326</alto:DebtInstrumentConvertibleMaximumSharesIssuable>
    <alto:DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum contextRef="c-85" decimals="3" id="f-378" unitRef="number">0.199</alto:DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c-86" decimals="-3" id="f-379" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-86" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-86" decimals="-3" id="f-381" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-86" decimals="-3" id="f-382" unitRef="usd">2000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c-86" decimals="-3" id="f-383" unitRef="usd">2000000</us-gaap:LongTermDebt>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-87" decimals="-5" id="f-384" unitRef="usd">800000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-88" decimals="-5" id="f-385" unitRef="usd">1300000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-89" decimals="-5" id="f-386" unitRef="usd">2300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c-90" decimals="4" id="f-387" unitRef="number">0.2069</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-388">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the change in fair value of the Convertible Grant Agreement during the three months ended March&#160;31, 2026 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value balance as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,227&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issuance of new tranches&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in fair value reported in statements of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in fair value reported in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value balance as of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-91" decimals="-3" id="f-389" unitRef="usd">2227000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-92" decimals="-3" id="f-390" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-92" decimals="-3" id="f-391" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-92" decimals="-3" id="f-392" unitRef="usd">115000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome contextRef="c-92" decimals="-3" id="f-393" unitRef="usd">-7000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-93" decimals="-3" id="f-394" unitRef="usd">2335000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-395">Fair Value&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments that are measured at fair value on a recurring basis consist of money market funds and the Convertible Grant Agreement. The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.757%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible Grant Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.757%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible Grant Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its money market funds, which are valued based on quoted market prices in an active market with no valuation adjustment, as Level 1 assets within the fair value hierarchy. The Company&#x2019;s Convertible Grant Agreement is classified as a Level 3 instrument under the fair value hierarchy as the fair values were determined based on significant inputs not observable in the market. See Note 4 for additional information on the Convertible Grant Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-396">The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands):&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.757%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible Grant Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.757%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible Grant Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-94" decimals="-3" id="f-397" unitRef="usd">263498000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-95" decimals="-3" id="f-398" unitRef="usd">263498000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-96" decimals="-3" id="f-399" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-97" decimals="-3" id="f-400" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-94" decimals="-3" id="f-401" unitRef="usd">500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-95" decimals="-3" id="f-402" unitRef="usd">500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-96" decimals="-3" id="f-403" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-97" decimals="-3" id="f-404" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-405" unitRef="usd">263998000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-98" decimals="-3" id="f-406" unitRef="usd">263998000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-99" decimals="-3" id="f-407" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-100" decimals="-3" id="f-408" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-3" decimals="-3" id="f-409" unitRef="usd">2335000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-98" decimals="-3" id="f-410" unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-99" decimals="-3" id="f-411" unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-100" decimals="-3" id="f-412" unitRef="usd">2335000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-3" decimals="-3" id="f-413" unitRef="usd">2335000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-98" decimals="-3" id="f-414" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-99" decimals="-3" id="f-415" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-100" decimals="-3" id="f-416" unitRef="usd">2335000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-101" decimals="-3" id="f-417" unitRef="usd">176430000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-102" decimals="-3" id="f-418" unitRef="usd">176430000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-103" decimals="-3" id="f-419" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-104" decimals="-3" id="f-420" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-101" decimals="-3" id="f-421" unitRef="usd">500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-102" decimals="-3" id="f-422" unitRef="usd">500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-103" decimals="-3" id="f-423" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-104" decimals="-3" id="f-424" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-425" unitRef="usd">176930000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-105" decimals="-3" id="f-426" unitRef="usd">176930000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-106" decimals="-3" id="f-427" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-107" decimals="-3" id="f-428" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-4" decimals="-3" id="f-429" unitRef="usd">2227000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-105" decimals="-3" id="f-430" unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-106" decimals="-3" id="f-431" unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-107" decimals="-3" id="f-432" unitRef="usd">2227000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-433" unitRef="usd">2227000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-105" decimals="-3" id="f-434" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-106" decimals="-3" id="f-435" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-107" decimals="-3" id="f-436" unitRef="usd">2227000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-437">&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Purchase and License Agreements&lt;/span&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company enters into asset purchase and license agreements with third parties. For a detailed description of the significant agreements with certain financial commitments to which the Company is a party, see Note 10 to the consolidated financial statements included in the Company&#x2019;s Annual Report. No payments were made during the three months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2026&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; pursuant to any of these significant agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-438">Stock-Based Plans&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2024 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2024, the Board adopted, and the Company&#x2019;s stockholders approved, the 2024 Equity Incentive Plan (the &#x201c;2024 Plan&#x201d;), which became effective on the execution of the underwriting agreement related to the IPO. Under the 2024 Plan, the Company may grant incentive stock options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to employees, including employees of any parent or subsidiary, and nonstatutory stock options, stock appreciation rights, restricted stock awards (&#x201c;RSAs&#x201d;), restricted stock units (&#x201c;RSUs&#x201d;), performance awards and other forms of stock awards to employees, directors, and consultants, including employees and consultants of the Company&#x2019;s affiliates. The 2024 Plan is a successor to the 2019 Equity Incentive Plan, which was adopted by the Board of Directors in March 2019 (as amended, the &#x201c;2019 Plan&#x201d;). &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following effectiveness of the 2024 Plan, no further issuance may be made under the 2019 Plan. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; total of 2,000,000 shares of common stock were approved to be initially reserved for issuance under the 2024 Plan. In addition, the number of shares of the Company&#x2019;s common stock reserved for issuance under the 2024 Plan automatically increases on January 1 of each calendar year, starting on January 1, 2025 and continuing through and including January 1, 2034, in an amount equal to 5% of the total number of shares of the Company&#x2019;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Board.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the total number of shares authorized to be issued under the 2024 Plan was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,945,504 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,349,328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of March&#160;31, 2026 and December&#160;31, 2025, there wer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e 527,407 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and 625,142 shares of common stock, respectively, reserved and available for issuance under the 2024 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2025 Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 6, 2025, the Board adopted the 2025 Inducement Plan (the &#x201c;Inducement Plan&#x201d;), pursuant to which it reserved&#160;500,000 shares of common stock for issuance to individuals who were not previously employees of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company, in accordance with New York Stock Exchange Listed Company Manual Rule 303A.08. Under the&#160;Inducement&#160;Plan, the Company has the ability to issue non-statutory stock options, stock appreciation rights, RSAs, RSUs, and performance awards. As of March&#160;31, 2026, stock options to purchase 150,000 shares of common stock had been granted under the Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2026, the Company had not opened the 2024 Employee Stock Purchase Plan for enrollment, and therefore there were no purchases or share issuances during this period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Repricing &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2025, the Board approved a stock option repricing, which was effective at the close of market on July 3, 2025 (&#x201c;Repricing Effective Date&#x201d;). The repricing generally applied to the outstanding stock options held by then current employees and consultants that had an exercise price greater than $2.35 per share. As of the Repricing Effective Date, the eligible stock options were immediately repriced such that the exercise price per share for such stock options was reduced to $2.35 (the closing price of the Company&#x2019;s common stock on the New York Stock Exchange on the Repricing Effective Date), subject to certain retention requirements. The retention period is 12 months following the Repricing Effective Date and can be accelerated under certain conditions. If an eligible stock option is exercised prior to the end of the relevant retention period, the participant will be required to pay a premium exercise price equal to the original exercise price per share of such stock option. There were no changes to the number of shares underlying the eligible stock options or to the vesting schedules or expiration dates of the eligible stock options. There were 4,225,763 shares underlying the repriced stock options, which had then-current exercise prices ranging from $2.44 to $16.00 per share. An incremental $1.4 million &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;of stock-based compensation expense will be recognized over the greater of the 12-month retention period or the remaining vesting period of the outstanding stock options. Stock options held by non-employee members of the Board were not eligible for the repricing. For the three months ended March&#160;31, 2026, the Company recognized $0.2 million of incremental stock-based compensation expense in connection with the stock option repricing. In addition, the Company has $0.8 million of unrecognized stock based compensation related to the stock option repricing which is expected to be recognized over a weighted-average period of 1.0 year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The options have a&#160;10-year&#160;contractual life and generally vest over a period of four years, with the first 25% of the award vesting after one year and then monthly thereafter, subject to continuous service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted during the three months ended March&#160;31, 2026 and 2025 for awards subject only to service-based vesting conditions wer&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e $12.90 and $3.09 per&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; share, respectively. Weighted-average grant date fair value assumptions were based on the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.819%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.745%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 10.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 10.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below summarizes activity related to stock options subject only to service-based vesting conditions (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price per share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted &#x2013;&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term (in&lt;br/&gt;years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding, December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,950&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,078&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,727&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and cancelled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding, March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,643&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,702&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,733&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,552&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="24" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Since the reporting period covered by the table above is before the expiration of the aforementioned retention period and any employees who exercised their repriced stock options during the reporting period, with certain exceptions, would have to pay the original exercise price, the weighted average exercise price and intrinsic value in the table above does not reflect the effect of repricing.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="24" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026, there was approximate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ly $34.0 million of unrecognized stock-based compensation expense related to these service-based unvested stock options, excluding the impact of the option repricing, which is expected to be recognized ov&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;er a weighted-average period of 2.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;arizes activity related to RSUs subject only to service-based vesting conditions (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-average&lt;br/&gt;grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding, December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding, March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2024, the Company issued 53,864 RSUs under the 2024 Plan; 50% of the shares of common stock underlying the RSUs vest after 18 months and the remainder vest after 24 months from the grant date. The RSUs are subject only to a service-based vesting condition. Such shares are not accounted for as outstanding until they vest.&#160;As of March&#160;31, 2026, there is no unrecognized stock-based compensation expense related to the RSUs. The fair value of the RSUs vested during the three months ended March&#160;31, 2026 was $0.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Option Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board granted options to purchase common stock to certain employees and consultants that vest upon the achievement of certain performance conditions (&#x201c;Performance Awards&#x201d;) such as the completion of a future financing event or upon the achievement of defined clinical milestones or outcomes. The Company did not issue Performance Awards during the three months ended March&#160;31, 2026 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2026, there are 435,381 Performance Awards vested and outstanding, and no Performance awards remain unvested&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Performance Awards have a contractual term of 10 years. There is no unrecognized stock-based compensation expense related to Performance Awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash&#160;stock-based compensation expense recognized in the accompanying condensed consolidated statements of operations and comprehensive loss for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended March&#160;31, 2026 and 2025 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.030%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.970%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,524&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;982&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;986&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,824&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,968&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-108"
      decimals="INF"
      id="f-439"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <alto:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock contextRef="c-109" decimals="2" id="f-440" unitRef="number">0.05</alto:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-110"
      decimals="INF"
      id="f-441"
      unitRef="shares">4945504</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-111"
      decimals="INF"
      id="f-442"
      unitRef="shares">3349328</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-110"
      decimals="INF"
      id="f-443"
      unitRef="shares">527407</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-111"
      decimals="INF"
      id="f-444"
      unitRef="shares">625142</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-112"
      decimals="INF"
      id="f-445"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-113"
      decimals="INF"
      id="f-446"
      unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-114"
      decimals="2"
      id="f-447"
      unitRef="usdPerShare">2.35</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-114"
      decimals="2"
      id="f-448"
      unitRef="usdPerShare">2.35</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-115" id="f-449">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-116"
      decimals="INF"
      id="f-450"
      unitRef="shares">4225763</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-1"
      decimals="2"
      id="f-451"
      unitRef="usdPerShare">2.44</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-1"
      decimals="2"
      id="f-452"
      unitRef="usdPerShare">16.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-116" decimals="-5" id="f-453" unitRef="usd">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-117" id="f-454">P12M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-5" id="f-455" unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="-5" id="f-456" unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-119" id="f-457">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-120" id="f-458">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-120" id="f-459">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-121" decimals="2" id="f-460" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-121" id="f-461">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-118"
      decimals="2"
      id="f-462"
      unitRef="usdPerShare">12.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-122"
      decimals="2"
      id="f-463"
      unitRef="usdPerShare">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-464">Weighted-average grant date fair value assumptions were based on the following: &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.819%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.745%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 10.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 10.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-123"
      decimals="2"
      id="f-465"
      unitRef="usdPerShare">16.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-124"
      decimals="2"
      id="f-466"
      unitRef="usdPerShare">4.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <alto:ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward
      contextRef="c-123"
      decimals="2"
      id="f-467"
      unitRef="usdPerShare">16.72</alto:ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward>
    <alto:ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward
      contextRef="c-124"
      decimals="2"
      id="f-468"
      unitRef="usdPerShare">4.08</alto:ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-118" id="f-469">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-122" id="f-470">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-118" decimals="3" id="f-471" unitRef="number">0.920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-122" decimals="3" id="f-472" unitRef="number">0.887</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-118" decimals="3" id="f-473" unitRef="number">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-122" decimals="3" id="f-474" unitRef="number">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-118" decimals="2" id="f-475" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-122" decimals="2" id="f-476" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-477">&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below summarizes activity related to stock options subject only to service-based vesting conditions (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price per share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted &#x2013;&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term (in&lt;br/&gt;years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding, December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,950&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,078&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,727&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and cancelled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding, March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,643&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,702&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,733&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,552&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="24" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Since the reporting period covered by the table above is before the expiration of the aforementioned retention period and any employees who exercised their repriced stock options during the reporting period, with certain exceptions, would have to pay the original exercise price, the weighted average exercise price and intrinsic value in the table above does not reflect the effect of repricing.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="24" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-125"
      decimals="INF"
      id="f-478"
      unitRef="shares">4950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-125"
      decimals="2"
      id="f-479"
      unitRef="usdPerShare">7.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-126" id="f-480">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-125" decimals="-3" id="f-481" unitRef="usd">52078000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-118"
      decimals="INF"
      id="f-482"
      unitRef="shares">1727</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-118"
      decimals="2"
      id="f-483"
      unitRef="usdPerShare">16.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-118"
      decimals="INF"
      id="f-484"
      unitRef="shares">4</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-118"
      decimals="2"
      id="f-485"
      unitRef="usdPerShare">1.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-118" decimals="-3" id="f-486" unitRef="usd">85000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-118"
      decimals="INF"
      id="f-487"
      unitRef="shares">30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-118"
      decimals="2"
      id="f-488"
      unitRef="usdPerShare">9.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-123"
      decimals="INF"
      id="f-489"
      unitRef="shares">6643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-123"
      decimals="2"
      id="f-490"
      unitRef="usdPerShare">9.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-118" id="f-491">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-123" decimals="-3" id="f-492" unitRef="usd">84702000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-123"
      decimals="INF"
      id="f-493"
      unitRef="shares">2733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-123"
      decimals="2"
      id="f-494"
      unitRef="usdPerShare">6.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-118" id="f-495">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-123" decimals="-3" id="f-496" unitRef="usd">42552000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-123" decimals="-5" id="f-497" unitRef="usd">34000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-118" id="f-498">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-499">&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;arizes activity related to RSUs subject only to service-based vesting conditions (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-average&lt;br/&gt;grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding, December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding, March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-127"
      decimals="-3"
      id="f-500"
      unitRef="shares">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-127"
      decimals="2"
      id="f-501"
      unitRef="usdPerShare">14.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-128"
      decimals="-3"
      id="f-502"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-128"
      decimals="2"
      id="f-503"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-128"
      decimals="-3"
      id="f-504"
      unitRef="shares">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-128"
      decimals="2"
      id="f-505"
      unitRef="usdPerShare">14.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-128"
      decimals="-3"
      id="f-506"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-128"
      decimals="2"
      id="f-507"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-129"
      decimals="-3"
      id="f-508"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-129"
      decimals="2"
      id="f-509"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c-130"
      decimals="INF"
      id="f-510"
      unitRef="shares">53864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-131" decimals="2" id="f-511" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-132" decimals="2" id="f-512" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-131" id="f-513">P18M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-132" id="f-514">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-129" decimals="-5" id="f-515" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-128" decimals="-5" id="f-516" unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-133"
      decimals="-3"
      id="f-517"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-134"
      decimals="-3"
      id="f-518"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c-133"
      decimals="INF"
      id="f-519"
      unitRef="shares">435381</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c-135"
      decimals="INF"
      id="f-520"
      unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-133" id="f-521">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-135" decimals="-5" id="f-522" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-523">&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash&#160;stock-based compensation expense recognized in the accompanying condensed consolidated statements of operations and comprehensive loss for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended March&#160;31, 2026 and 2025 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.030%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.970%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,524&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;982&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;986&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,824&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,968&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-136" decimals="-3" id="f-524" unitRef="usd">1524000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-137" decimals="-3" id="f-525" unitRef="usd">982000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-138" decimals="-3" id="f-526" unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-139" decimals="-3" id="f-527" unitRef="usd">986000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-528" unitRef="usd">2824000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-529" unitRef="usd">1968000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-530">Loss Per Share&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The Company&#x2019;s unvested restricted common stock is not included in the determination of loss per share until the award vests. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2025 and March 2026, the Company issued equity-classified Pre-Funded Warrants with a nominal exercise price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share (see Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). In accordance with ASC 260, Earnings Per Share (ASC 260), shares issuable for little to no cash consideration should be included in the number of outstanding shares used to calculate basic loss per share as long as all conditions necessary for exercise are met. The Pre-Funded Warrants are therefore included as outstanding shares as of their issuance date to calculate the weighted average number of shares outstanding to calculate basic loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;K2 Common Stock Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-140"
      decimals="INF"
      id="f-531"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-532">&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;K2 Common Stock Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-141"
      decimals="-3"
      id="f-533"
      unitRef="shares">170000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-142"
      decimals="-3"
      id="f-534"
      unitRef="shares">170000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-143"
      decimals="-3"
      id="f-535"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-144"
      decimals="-3"
      id="f-536"
      unitRef="shares">54000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-145"
      decimals="-3"
      id="f-537"
      unitRef="shares">7078000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-146"
      decimals="-3"
      id="f-538"
      unitRef="shares">5651000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-539" unitRef="shares">7248000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="-3" id="f-540" unitRef="shares">5875000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-541">Income Taxes&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, including its net operating losses. Based on its history of operating losses, the Company believes that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for its net deferred tax assets as of March&#160;31, 2026 and December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-542">Stockholders&#x2019; Equity&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;K2 Warrant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, in connection with the closing of the Original Loan Agreement, the Company issued a warrant to the Lender to purchase a number of shares of the Company&#x2019;s Series B convertible preferred stock, or at Lender&#x2019;s election, next round stock (&#x201c;K2 Warrant&#x201d;). The number of shares of convertible preferred stock issuable upon exercise of the warrant was equal to (a) (i) 0.0375, multiplied by (ii)&#160;the aggregate principal amount of term loans actually funded under the Original Loan Agreement, divided by (b)&#160;the warrant price then in effect. Following the conversion of all outstanding convertible preferred stock to common stock upon the completion of the IPO in February 2024, the K2 Warrant became a warrant to purchase up to an aggregate of 35,773 shares of the Company&#x2019;s common stock at an exercise price of $10.49 per share (referred to in Note 4 as the Original Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 13, 2025, in connection with the Amended Loan Agreement (see Note 4 for additional information), the K2 Warrant was amended and restated (referred to in Note 4 as the Amended and Restated Warrant) to reduce the exercise price from $10.49 per share to $3.71 per share (referred to in Note 4 as the Exercise Price). Further, in connection with the Amendment, the Company issued an additional warrant (referred to in Note 4 as the New Warrant and, together with the Amended and Restated Warrant, the Warrants) to purchase a number of shares of the Company&#x2019;s common stock calculated as follows: (a) (i) 0.025, multiplied by (ii) the aggregate principal amount of the term loans actually funded under the Amended Loan Agreement, divided by (b) the Exercise Price. The New Warrant expires on January 13, 2035. The New Warrant is classified as equity as it meets all the conditions under GAAP for equity classification, and is therefore not subject to ongoing remeasurement. The Company reassesses whether equity classification for the warrant is appropriate upon any changes to the warrants or capital structure, at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f March&#160;31, 2026 the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;New Warrant allowed for the purchase of 134,691 shares of the Company&#x2019;s common stock. If the Company draws down on additional tranches of the Term Loan, the number of shares available for purchase by the Lender under the New Warrant would increase.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is conditionally obligated to issue a fixed number of additional shares in connection with the New Warrant (&#x201c;Additional Warrants&#x201d;) in the potential amount of 168,363 shares upon the funding of additional amounts under the Term Loan with the same exercise price and contractual term. The contingent obligation to issue the Additional Warrants did not meet the derivative scope exception or equity classification criteria and were accounted for as a derivative liability. The &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;con&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tingently issuable Additional Warrants derivative liability had a de minimis value at the time of issuance and as of March&#160;31, 2026. The Additional Warrants derivative liability will be remeasured each reporting period until settled or extinguished&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with subsequent changes in fair value recorded through other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. The initial fair value of the Additional Warrants derivative liability was determined using a Black-Scholes option pricing model based on the same input assumptions above, with an additional assessment required for the probability that additional amounts under the Term Loan will be funded which would trigger the issuance of the Additional Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pre-Funded Warrants Issued in October 2025 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2025, the Company entered into a Securities Purchase Agreement (the &#x201c;2025 PIPE Purchase Agreement&#x201d;) with certain institutional and other accredited investors (the &#x201c;2025 PIPE Purchasers&#x201d;), pursuant to which the Company sold and issued to the 2025 PIPE Purchasers in a private placement transaction (the &#x201c;2025 Private Placement&#x201d;) (i) 3,832,263&#160;shares of the Company&#x2019;s common stock (the &#x201c;2025 PIPE Shares&#x201d;), and (ii) with respect to certain 2025 PIPE Purchasers, pre-funded warrants to purchase&#160;4,622,251&#160;shares of the Company&#x2019;s common stock (the &#x201c;2025 Pre-Funded Warrants&#x201d;) in lieu of shares of the Company&#x2019;s common stock. The purchase price per share of common stock was$5.9140&#160;per share (the &#x201c;2025 PIPE Purchase Price&#x201d;), and the purchase price for the 2025 Pre-Funded Warrants was $5.9139&#160;per 2025 Pre-Funded Warrant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Pre-Funded Warrants have a per share exercise price of $0.0001, subject to proportional adjustments in the event of stock splits or combinations or similar events. The 2025 Pre-Funded Warrants will not expire until exercised in full. The 2025 Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation; provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving&#160;61 days&#x2019; notice to the Company, but not to any percentage in excess of&#160;19.9%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the 2025 Pre-Funded Warrants meet the criteria for equity classification at issuance and were recorded as a component of stockholders&#x2019; equity within additional paid-in capital. The 2025 Pre-Funded Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#x2019;s common stock and (vi) meet the equity classification criteria. In addition, such 2025 Pre-Funded Warrants do not provide any guarantee of value or return.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pre-Funded Warrants Issued in March 2026 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2026, the Company entered into a Securities Purchase Agreement (the &#x201c;2026 PIPE Purchase Agreement&#x201d;) with certain institutional investors (the &#x201c;2026 PIPE Purchasers&#x201d;), pursuant to which the Company sold and issued to the 2026 PIPE Purchasers in a private placement transaction (the &#x201c;2026 Private Placement&#x201d;) (i) 2,900,000 shares of the Company&#x2019;s common stock (the &#x201c;2026 PIPE Shares&#x201d;), and (ii) with respect to certain 2026 PIPE Purchasers, pre-funded warrants to purchase 3,100,000 shares of the Company&#x2019;s common stock (the &#x201c;2026 Pre-Funded Warrants&#x201d;) in lieu of shares of the Company&#x2019;s common stock. The purchase price per share of common stock was $20.00 per share (the &#x201c;2026 PIPE Purchase Price&#x201d;), and the purchase price for the 2026 Pre-Funded Warrants was $19.9999 per 2026 Pre-Funded Warrant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2026 Pre-Funded Warrants have a per share exercise price of $0.0001, subject to proportional adjustments in the event of stock splits or combinations or similar events. The 2026 Pre-Funded Warrants will not expire until exercised in full. The 2026 Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation; provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving&#160;61 days&#x2019; notice to the Company, but not to any percentage in excess of&#160;19.9%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the 2026 Pre-Funded Warrants meet the criteria for equity classification at issuance and were recorded as a component of stockholders&#x2019; equity within additional paid-in capital. The 2026 Pre-Funded Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exercise, (v) are indexed to the Company&#x2019;s common stock and (vi) meet the equity classification criteria. In addition, such 2026 Pre-Funded Warrants do not provide any guarantee of value or return.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock and Authorized Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of both March&#160;31, 2026 and December&#160;31, 2025, the Company h&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ad 500,000,000 authorized shares of common stock with a par value of $0.0001 per share, of which 35,052,731 and 31,923,521 shares, respectively, were issued and outstanding. On February 6, 2024, the Company amended its certificate of incorporation such that the total number of shares of common stock authorized to be issued was increased to 500,000,000, and the total number of shares of new preferred stock authorized to be issued was 10,000,000 with a par value per share of $0.0001. As of March&#160;31, 2026, no shares of preferred stock were issued or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026 and December&#160;31, 2025, the Company had reserved common stock, on an&#160;as-if&#160;converted basis, for issuance as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.035%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.897%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;K2 Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 4.37pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,622&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options issued and outstanding from 2024, 2019 Equity Incentive Plan and Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares available for future grant from 2024 Equity Incentive Plan and Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reserved common stock in the table above does not include (i) the number of shares of the Company&#x2019;s common stock issuable upon conversion of the remaining amount of the Conversion Amount specified within the Amended Loan Agreement (see Note 4), (ii) the variable number of shares issuable pursuant to conversion of amounts funded under the Convertible Grant Agreement (see Note 4), and (iii) the variable number of shares issuable pursuant to terms of the asset purchase agreement, dated May 31, 2025, between the Company and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chase Therapeutics Corporation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <alto:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier contextRef="c-147" decimals="4" id="f-543" unitRef="number">0.0375</alto:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-66"
      decimals="INF"
      id="f-544"
      unitRef="shares">35773</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-66"
      decimals="2"
      id="f-545"
      unitRef="usdPerShare">10.49</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-66"
      decimals="2"
      id="f-546"
      unitRef="usdPerShare">10.49</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-148"
      decimals="2"
      id="f-547"
      unitRef="usdPerShare">3.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alto:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier
      contextRef="c-54"
      decimals="INF"
      id="f-548"
      unitRef="number">0.025</alto:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-68"
      decimals="INF"
      id="f-549"
      unitRef="shares">134691</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-149"
      decimals="INF"
      id="f-550"
      unitRef="shares">168363</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-150"
      decimals="INF"
      id="f-551"
      unitRef="shares">3832263</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-151"
      decimals="INF"
      id="f-552"
      unitRef="shares">4622251</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-151"
      decimals="3"
      id="f-553"
      unitRef="usdPerShare">5.9140</us-gaap:SaleOfStockPricePerShare>
    <alto:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights
      contextRef="c-152"
      decimals="4"
      id="f-554"
      unitRef="usdPerShare">5.9139</alto:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-152"
      decimals="4"
      id="f-555"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alto:ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation contextRef="c-153" id="f-556">P61D</alto:ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation>
    <alto:ClassOfWarrantsOrRightsWarrantExcessPercentage contextRef="c-153" decimals="3" id="f-557" unitRef="number">0.199</alto:ClassOfWarrantsOrRightsWarrantExcessPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-154"
      decimals="INF"
      id="f-558"
      unitRef="shares">2900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-155"
      decimals="INF"
      id="f-559"
      unitRef="shares">3100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-156"
      decimals="2"
      id="f-560"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <alto:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights
      contextRef="c-155"
      decimals="4"
      id="f-561"
      unitRef="usdPerShare">19.9999</alto:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-155"
      decimals="4"
      id="f-562"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alto:ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation contextRef="c-153" id="f-563">P61D</alto:ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation>
    <alto:ClassOfWarrantsOrRightsWarrantExcessPercentage contextRef="c-153" decimals="3" id="f-564" unitRef="number">0.199</alto:ClassOfWarrantsOrRightsWarrantExcessPercentage>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-565" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-566" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-567"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-568"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-569" unitRef="shares">35052731</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-570" unitRef="shares">35052731</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-571" unitRef="shares">31923521</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-572" unitRef="shares">31923521</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-157"
      decimals="INF"
      id="f-573"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-157"
      decimals="INF"
      id="f-574"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-157"
      decimals="4"
      id="f-575"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-576" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-577" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <alto:ScheduleOfStockReservedForIssuanceTableTextBlock contextRef="c-1" id="f-578">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026 and December&#160;31, 2025, the Company had reserved common stock, on an&#160;as-if&#160;converted basis, for issuance as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.035%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.897%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;K2 Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 4.37pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,622&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options issued and outstanding from 2024, 2019 Equity Incentive Plan and Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares available for future grant from 2024 Equity Incentive Plan and Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt;text-indent:-12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reserved common stock in the table above does not include (i) the number of shares of the Company&#x2019;s common stock issuable upon conversion of the remaining amount of the Conversion Amount specified within the Amended Loan Agreement (see Note 4), (ii) the variable number of shares issuable pursuant to conversion of amounts funded under the Convertible Grant Agreement (see Note 4), and (iii) the variable number of shares issuable pursuant to terms of the asset purchase agreement, dated May 31, 2025, between the Company and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chase Therapeutics Corporation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alto:ScheduleOfStockReservedForIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-158"
      decimals="INF"
      id="f-579"
      unitRef="shares">170000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-159"
      decimals="INF"
      id="f-580"
      unitRef="shares">170000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-155"
      decimals="-3"
      id="f-581"
      unitRef="shares">7722000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-160"
      decimals="-3"
      id="f-582"
      unitRef="shares">4622000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-161"
      decimals="INF"
      id="f-583"
      unitRef="shares">7078000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-162"
      decimals="INF"
      id="f-584"
      unitRef="shares">5385000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-163"
      decimals="INF"
      id="f-585"
      unitRef="shares">877000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-164"
      decimals="INF"
      id="f-586"
      unitRef="shares">975000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-3" decimals="INF" id="f-587" unitRef="shares">15847000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-4" decimals="INF" id="f-588" unitRef="shares">11152000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-589">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is subject to occasional lawsuits, investigations and claims arising out of the ordinary course of business.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other than as set forth below, the Company had no significant pending or threatened litigation as of March&#160;31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 21, 2025, a purported stockholder of the Company filed a lawsuit against the Company, certain executive officers, and certain current and former directors in the United States District Court for the Northern District of California (Case No. 3:25-cv-06105). The plaintiff filed an amended complaint on January 23, 2026 and a second amended complaint on April 6, 2026. The complaint is a putative class action alleging violations of the Securities Act of 1933, as amended, related to the Company&#x2019;s IPO in February 2024, and violations of the Exchange Act thereafter. The proposed classes consist of purchasers or acquirers of the Company&#x2019;s common stock pursuant or traceable to the Company&#x2019;s IPO as well as purchasers or acquirers of the Company&#x2019;s common stock between March 18, 2024 and October 22, 2024, both dates inclusive. The plaintiff seeks unspecified damages, as well as interest, fees, and costs. The complaint claims, among other things, that the Company&#x2019;s offering documents and subsequent public disclosures contained materially false and misleading statements and omitted material facts about the prospects of ALTO-100. The Company believes these allegations lack merit, and the Company filed a motion to dismiss on May 5, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, a consolidated stockholder derivative action, captioned In re Alto Neuroscience, Inc. Derivative Litigation, Lead Case No. 5:25-cv-07144-NW was filed on behalf of the Company against certain executive officers and certain current and former directors for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the federal securities laws. The claims arise out of the same factual allegations as the putative class action described above. The plaintiffs seek unspecified damages, as well as interest, fees, and costs. The &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated stockholder derivative action was stayed on January 14, 2026 pending resolution of the motion to dismiss in the securities class action. The Company believes that these claims lack merit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not recorded a liability related to these lawsuits because, at this time, the Company does not believe that an unfavorable outcome is either probable or estimable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company indemnifies its directors and officers who are, or were, serving at the Company&#x2019;s request in such capacities. The Company&#x2019;s maximum exposure under these arrangements is unknown at March&#160;31, 2026. The Company does not anticipate recognizing any significant losses relating to these arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-590">Segments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a single reportable segment entity, the Company&#x2019;s segment performance measure is consolidated net loss. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset information is not used by the Company&#x2019;s President and Chief Executive Officer, its chief operating decision maker (&#x201c;CODM&#x201d;) to allocate resources.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain significant segment expenses below loss from operations are presented in the Company&#x2019;s consolidated statements of operations and are therefore not presented below. Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company&#x2019;s condensed consolidated statements of operations, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.189%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel expenses excluding stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct external program expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ALTO-100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ALTO-300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ALTO-101&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ALTO-203&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ALTO-207&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a) Other research and development expenses primarily consists of license fees, facility charges, third party consultant costs, early research costs related to other product candidates, and other unallocated costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(b) General and administrative costs include professional fees, insurance, consultant fees and facility charges.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-591">Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company&#x2019;s condensed consolidated statements of operations, are presented below (in thousands):&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.189%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel expenses excluding stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct external program expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ALTO-100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ALTO-300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ALTO-101&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ALTO-203&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ALTO-207&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a) Other research and development expenses primarily consists of license fees, facility charges, third party consultant costs, early research costs related to other product candidates, and other unallocated costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(b) General and administrative costs include professional fees, insurance, consultant fees and facility charges.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:LaborAndRelatedExpense contextRef="c-165" decimals="-3" id="f-592" unitRef="usd">6249000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-166" decimals="-3" id="f-593" unitRef="usd">5783000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-165" decimals="-3" id="f-594" unitRef="usd">2824000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-166" decimals="-3" id="f-595" unitRef="usd">1968000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-167" decimals="-3" id="f-596" unitRef="usd">1764000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-168" decimals="-3" id="f-597" unitRef="usd">1124000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-169" decimals="-3" id="f-598" unitRef="usd">1507000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-170" decimals="-3" id="f-599" unitRef="usd">922000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-171" decimals="-3" id="f-600" unitRef="usd">5356000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-172" decimals="-3" id="f-601" unitRef="usd">969000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-173" decimals="-3" id="f-602" unitRef="usd">6000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-174" decimals="-3" id="f-603" unitRef="usd">737000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-175" decimals="-3" id="f-604" unitRef="usd">4143000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-176" decimals="-3" id="f-605" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-165" decimals="-3" id="f-606" unitRef="usd">1198000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-166" decimals="-3" id="f-607" unitRef="usd">1129000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c-165" decimals="-3" id="f-608" unitRef="usd">4091000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c-166" decimals="-3" id="f-609" unitRef="usd">3044000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-165" decimals="-3" id="f-610" unitRef="usd">27138000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-166" decimals="-3" id="f-611" unitRef="usd">15676000</us-gaap:NetIncomeLoss>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-614">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-615">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-616">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-177" id="f-617">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 13, 2026, Amit Etkin, M.D., Ph.D., our President, Chief Executive Officer, and Chair of the Board, terminated a Rule 10b5-1 trading plan effective March 17, 2026. No sales of common stock occurred under the plan prior to its termination. Prior to its termination, the plan had provided for the potential sale of up to 100,000 shares of our common stock at each of two specified price points (60,000 shares to be sold at $35.00 and 40,000 shares to be sold at $80.00). Transactions under Dr. Etkin&#x2019;s plan were based upon pre-established dates and stock price thresholds and would only occur upon the expiration of the applicable mandatory cooling-off period. Dr. Etkin&#x2019;s plan had a termination date of December&#160;31, 2026, or the date all shares subject to the plan had been sold.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrTerminationDate contextRef="c-177" id="f-618">March 13, 2026</ecd:TrdArrTerminationDate>
    <ecd:TrdArrIndName contextRef="c-177" id="f-619">Amit Etkin, M.D., Ph.D.</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-177" id="f-620">President, Chief Executive Officer, and Chair of the Board</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-177" id="f-621">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-178"
      decimals="INF"
      id="f-622"
      unitRef="shares">100000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-179" id="f-623">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 11, 2026, Nicholas Smith, our Chief Financial Officer and Chief Business Officer, terminated a Rule 10b5-1 trading plan effective March 13, 2026. No sales of common stock occurred under the plan prior to its termination. Prior to its termination, the plan had provided for the potential sale of up to 14,376 shares of our common stock at a price per share of $45.00. Transactions under Mr. Smith&#x2019;s plan were based upon pre-established dates and stock price thresholds and would only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Smith&#x2019;s plan had a termination date of December&#160;31, 2026, or the date all shares subject to the plan had been sold.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrTerminationDate contextRef="c-179" id="f-624">March 11, 2026</ecd:TrdArrTerminationDate>
    <ecd:TrdArrIndName contextRef="c-179" id="f-625">Nicholas Smith</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-179" id="f-626">Chief Financial Officer and Chief Business Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-179" id="f-627">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-180"
      decimals="INF"
      id="f-628"
      unitRef="shares">14376</ecd:TrdArrSecuritiesAggAvailAmt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>May 08, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alto Neuroscience, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-4210124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">650 Castro Street, Suite 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mountain View<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">200-0412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANRO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,093,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001999480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 263,762<span></span>
</td>
<td class="nump">$ 176,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,364<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">269,126<span></span>
</td>
<td class="nump">177,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,234<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use asset</a></td>
<td class="nump">4,061<span></span>
</td>
<td class="nump">4,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">276,259<span></span>
</td>
<td class="nump">184,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,369<span></span>
</td>
<td class="nump">1,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,610<span></span>
</td>
<td class="nump">8,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Term loan, current</a></td>
<td class="nump">2,136<span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,115<span></span>
</td>
<td class="nump">11,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan,&#160;non-current</a></td>
<td class="nump">13,885<span></span>
</td>
<td class="nump">16,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Grant Agreement</a></td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, long-term</a></td>
<td class="nump">3,555<span></span>
</td>
<td class="nump">3,823<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">32,890<span></span>
</td>
<td class="nump">33,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock (par value $0.0001), 500,000 shares authorized; 35,053 and 31,924 shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in&#160;capital</a></td>
<td class="nump">471,224<span></span>
</td>
<td class="nump">352,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(227,871)<span></span>
</td>
<td class="num">(201,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">243,369<span></span>
</td>
<td class="nump">151,142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 276,259<span></span>
</td>
<td class="nump">$ 184,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">35,052,731<span></span>
</td>
<td class="nump">31,923,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">35,052,731<span></span>
</td>
<td class="nump">31,923,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 20,294<span></span>
</td>
<td class="nump">$ 9,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,844<span></span>
</td>
<td class="nump">5,702<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">27,138<span></span>
</td>
<td class="nump">15,676<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(27,138)<span></span>
</td>
<td class="num">(15,676)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(545)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Other, net</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,237)<span></span>
</td>
<td class="num">(15,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent', window );">Change in fair value attributable to instrument specific credit risk</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (26,246)<span></span>
</td>
<td class="num">$ (15,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in dollars per share)</a></td>
<td class="num">$ (0.80)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in dollars per share)</a></td>
<td class="num">$ (0.80)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares outstanding, basic (in shares)</a></td>
<td class="nump">32,893,000<span></span>
</td>
<td class="nump">27,049,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares outstanding, diluted (in shares)</a></td>
<td class="nump">32,893,000<span></span>
</td>
<td class="nump">27,049,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustments, of unrealized gain (loss) from (increase) decrease in instrument-specific credit risk on contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (n)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 151,460<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 289,954<span></span>
</td>
<td class="num">$ (138,396)<span></span>
</td>
<td class="num">$ (101)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,987,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock', window );">Issuance of K2 warrants</a></td>
<td class="nump">524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,072,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">139,096<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">292,644<span></span>
</td>
<td class="num">(153,565)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">139,096<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">292,644<span></span>
</td>
<td class="num">(153,565)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 151,142<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">352,751<span></span>
</td>
<td class="num">(201,634)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">31,923,521<span></span>
</td>
<td class="nump">31,924,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">RSU Vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Restricted stock units vesting</a></td>
<td class="num">(190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock', window );">Issuance of common stock and pre-funded warrants in 2026 private placement, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue', window );">Issuance of common stock and pre-funded warrants in 2026 private placement, net of issuance costs</a></td>
<td class="nump">114,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_StockIssuedDuringPeriodShareConversionOfTermLoan', window );">Issuance of common stock for conversion of the K2 term loan, net of issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_StockIssuedDuringPeriodValueConversionOfTermLoan', window );">Issuance of common stock for conversion of the K2 term loan, net of issuance</a></td>
<td class="nump">941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">2,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2026</a></td>
<td class="nump">35,052,731<span></span>
</td>
<td class="nump">35,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2026</a></td>
<td class="nump">$ 243,369<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">471,224<span></span>
</td>
<td class="num">(227,871)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 243,369<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 471,224<span></span>
</td>
<td class="num">$ (227,871)<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>APIC Increase For Reclassification Of Warrants For Conversion Of Convertible Securities To Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock And Pre Funded Warrants In Private Placement Net Of Issuance Costs In Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock And Pre Funded Warrants Issued During Period Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_StockIssuedDuringPeriodShareConversionOfTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Share, Conversion Of Term Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_StockIssuedDuringPeriodShareConversionOfTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_StockIssuedDuringPeriodValueConversionOfTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Conversion Of Term Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_StockIssuedDuringPeriodValueConversionOfTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,237)<span></span>
</td>
<td class="num">$ (15,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">1,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_InterestExpenseNoncash', window );">Non-cash&#160;interest expense related to term loan</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash&#160;lease expense</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_GainLossInOtherOperatingActivitiesNet', window );">Change in other, net</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(4,130)<span></span>
</td>
<td class="num">(1,692)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,490<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued liabilities and other liabilities</a></td>
<td class="num">(1,753)<span></span>
</td>
<td class="num">(2,701)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(27,091)<span></span>
</td>
<td class="num">(16,556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(556)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(556)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement', window );">Proceeds from sale of common stock and pre-funded warrants in 2026 private placement</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement', window );">Payments from sale of common stock and pre-funded warrants in 2026 private placement</a></td>
<td class="num">(4,875)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of withholding taxes for stock-based compensation</a></td>
<td class="num">(190)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_PaymentsOnIssuanceCostFromRegistrationStatement', window );">Payments on issuance cost from registration statement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from issuance of term loan, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of former term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,213)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of loan financing cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">114,941<span></span>
</td>
<td class="nump">9,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">87,278<span></span>
</td>
<td class="num">(7,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">176,984<span></span>
</td>
<td class="nump">168,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">264,262<span></span>
</td>
<td class="nump">161,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of&#160;Non-cash&#160;Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Conversion of K2 term loan into shares of common stock</a></td>
<td class="nump">941<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid', window );">Costs from sale of common stock and pre-funded warrants in 2026 private placement not yet paid</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DeferredOfferingAndShareIssueCostsNotYetPaid', window );">Deferred offering and share issue costs not yet paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants in connection with term loan agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidAbstract', window );"><strong>Supplemental Disclosure of&#160;Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 342<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DeferredOfferingAndShareIssueCostsNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering And Share Issue Costs Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DeferredOfferingAndShareIssueCostsNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_GainLossInOtherOperatingActivitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) In Other Operating Activities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_GainLossInOtherOperatingActivitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_InterestExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Noncash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_InterestExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_PaymentsOnIssuanceCostFromRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments on Issuance Cost from Registration Statement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_PaymentsOnIssuanceCostFromRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Common Stock and Pre-Funded Warrants In Private Placement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of the Business</a></td>
<td class="text">Description of the Business<div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Alto Neuroscience, Inc. (the &#8220;Company&#8221; or &#8220;Alto&#8221;) was incorporated in Delaware on March&#160;25, 2019. The Company maintains its headquarters in Mountain View, California. The Company has one wholly-owned subsidiary in Australia that was formed during 2020 to conduct clinical trials.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Alto is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Through insights derived from the Company&#8217;s scalable and proprietary Precision Psychiatry Platform, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. The Company&#8217;s current pipeline consists of seven clinical-stage assets addressing high-need therapeutic areas, including major depressive disorder (&#8220;MDD&#8221;), bipolar depression (&#8220;BPD&#8221;), treatment resistant depression (&#8220;TRD&#8221;), schizophrenia, and Parkinson&#8217;s disease.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred significant operating losses since inception and has relied primarily upon equity financings to fund its operations. At March&#160;31, 2026, the Company had an accumulated deficit of approximately $227.9 million. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the generation of sufficient revenues to support its cost structure. No assurance can be provided that the Company will ever be profitable, and unless or until it becomes profitable, the Company will need to continue to raise additional capital.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company completed its initial public offering (&#8220;IPO&#8221;) of its common stock. The Company issued and sold 9,246,000 shares of common stock at a public offering price of $16.00 per share, which included 1,206,000 shares sold pursuant to the exercise of the underwriters&#8217; option to purchase additional shares, and received net proceeds of $133.0 million after deducting underwriting discounts and commissions and other offering costs. Upon completion of the IPO, all outstanding shares of the Company&#8217;s outstanding preferred stock converted into an aggregate of 13,664,261 shares of common stock. In addition, the IPO resulted in the net exercise and conversion of all outstanding Series A Preferred Stock Warrants for an aggregate of 72,631 shares of common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2025, the Company completed a private placement transaction in which it issued and sold (i) 3,832,263 shares of common stock and (ii) pre-funded warrants (in lieu of common stock) to purchase an aggregate of 4,622,251 shares of common stock. The Company received net proceeds of $49.7&#160;million (see Note 10 for additional information). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2025, K2 HealthVentures LLC elected to convert $4.0&#160;million of its outstanding loan balance into the Company&#8217;s common stock. Pursuant to the terms of the Amended Loan Agreement, the conversion price was $4.83 per share, resulting in the issuance of 828,860 shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2026, the Company completed a private placement transaction in which it issued and sold (i) 2,900,000 shares of common stock and (ii) pre-funded warrants (in lieu of common stock) to purchase an aggregate of 3,100,000 shares of common stock. The Company received net proceeds of $114.9&#160;million (See Note 10 for additional information).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2026, K2 HealthVentures LLC elected to convert $1.0&#160;million of its outstanding loan balance into the Company&#8217;s common stock. Pursuant to the terms of the Amended Loan Agreement, the conversion price was $4.83 per share, resulting in the issuance of 207,215 shares.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies and Basis of Presentation</a></td>
<td class="text">Summary of Significant Accounting Policies and Basis of Presentation<div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), as determined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;), and include the accounts of Alto and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated financial statements are unaudited and have been prepared on the same basis as the audited annual financial st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">atements and, in management&#8217;s opinion, include all adjustments consisting of only normal recurring adjustments necessary for the fair statement of the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Company&#8217;s financial position as of March&#160;31, 2026 and its results of operations and statements of equity for the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March&#160;31, 2026 and 2025 and cash flows for the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March&#160;31, 2026 and 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">f operations for the three months ended March&#160;31, 2026 are not necessarily indicative of the results to be expected for the full fiscal year or any other period.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and the related notes thereto for the year ended December&#160;31, 2025 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 16, 2026 (the &#8220;Annual Report&#8221;).</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ materially from those estimates. The most significant estimates and assumptions in the Company&#8217;s condensed consolidated financial statements relate to the determination of the volatility of its common stock (as an input for calculating stock-based compensation and warrants), estimating accrued or prepaid research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies used in the preparation of these condensed consolidated financial statements for the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March&#160;31, 2026 are consistent with those discussed in Note 3 to the consolidated financial statements in the Annual Report. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-04, Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, which affects entities that settle convertible debt instruments for which the conversion privileges were changed to induce conversion. The standard is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company adopted the provisions of ASU 2024-04 prospectively beginning January 1, 2026. The adoption did not have an impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03, Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which expands disclosures about specific expense categories presented on the face of the income statement. The standard is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. This standard clarifies current interim reporting requirements on Topic 270 and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. This standard will be effective for fiscal years beginning after December 15, 2027, with the option to apply it retrospectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Early adoption is allowed. Currently, the Company is evaluating the impact the adoption of this standard will have on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"><tr><td style="width:1.0%"></td><td style="width:63.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:120%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,894</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">191</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other prepaid expenses</span></div></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,470</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,043</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,364</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,234</span></td></tr></table></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"><tr><td style="width:1.0%"></td><td style="width:63.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,125</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">453</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">453</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer software and equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">574</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">574</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">246</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">246</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Less</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">: accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,706)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,526)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,234</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,872</span></td></tr></table></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$0.2 million for both the three months ended March&#160;31, 2026, and 2025.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"><tr><td style="width:1.0%"></td><td style="width:63.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll, vacation and employee-related expenses</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,001</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,870</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,142</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,124</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest, short term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">115</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">118</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other accruals and current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,048</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">599</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability, short term </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,304</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,151</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,610</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,862</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">K2 HealthVentures LLC Loan Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On December&#160;16, 2022, the Company entered into a Loan and Security Agreement (the &#8220;Original Loan Agreement&#8221;) with K2 HealthVentures LLC as a lender, the other lenders party thereto (collectively, the &#8220;Lender&#8221;), K2 HealthVentures LLC, as administrative agent for Lender (the &#8220;Administrative Agent&#8221;), and Ankura Trust Company, LLC, as collateral agent for the Lender. Pursuant to the terms of the Original Loan Agreement, the Lender agreed to make available to the Company term loans (each, collectively, the &#8220;Term Loan&#8221;) in an aggregate principal amount of up to $35.0 million. As of December </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">31, 2024, the Company had drawn a principal amount of $10.0 million. The Lender&#8217;s commitment to make available additional Term Loans under the Original Loan Agreement expired without being drawn on January 1, 2025. The Original Loan Agreement had a Term Loan maturity date of December&#160;1, 2026 (the &#8220;Original Term Loan Maturity Date&#8221;).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On January 13, 2025, the Company entered into an amendment to the Original Loan Agreement (the &#8220;Amendment&#8221; and the Original Loan Agreement as amended thereby, the &#8220;Amended Loan Agreement&#8221;) to, among other things, extend the Original Term Loan Maturity Date and increase the maximum available amount of term loans. The Amended Loan Agreement provides for term loans in an aggregate principal amount of up to $75.0&#160;million, consisting of:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a first tranche term loan of $20.0&#160;million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">second tranche term loans of up to $30.0&#160;million in the aggregate available at the Company&#8217;s request until December 15, 2025, subject to certain time-based, clinical milestones; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">third tranche term loans of up to $25.0&#160;million in the aggregate available at the Company&#8217;s request subject to the Lender&#8217;s approval. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company drew $20.0&#160;million upon entry into the Amendment (approximately $10.0&#160;million of which was used to refinance obligations under the Original Loan Agreement and pay fees and expenses incurred in connection with the Amendment). The second tranche term loan was available until December 15, 2025 based on certain milestones and expired without being drawn.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Loan Agreement has a Term Loan maturity date of January 1, 2029 (the &#8220;Amended Term Loan Maturity Date&#8221;). The Amended Loan Agreement provides for an interest only period until January 1, 2027, following which the Term Loan shall be repaid in equal monthly payments through the Amended Term Loan Maturity Date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan bears interest at (i) a variable per annum cash pay rate equal to the Prime Rate plus 1.45% (subject to a floor of 8.45% per annum) and (ii) a fixed per annum paid-in-kind rate equal to 1.0%. Interest is due and payable monthly in arrears. Upon final payment or prepayment of the Term Loan, the Company is required to pay a final payment equal to 5.95% of the amount borrowed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Loan Agreement was accounted for as a debt extinguishment, as the new loan was considered substantially different from the original loan. The Company recognized debt issuance costs and discount upon issuance of $2.0&#160;million within Term Loan, non-current on its condensed consolidated balance sheet and recorded a loss on debt extinguishment of $0.7&#160;million, which was recorded within loss on debt extinguishment in its condensed consolidated statement of operations and comprehensive loss for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the three mont</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">hs ended March&#160;31, 2025. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Original Loan Agreement, the Company was obligated to pay a final fee equal to 6.25% of the aggregate amount of the term loans funded thereunder (the &#8220;Original Exit Fee&#8221;) upon the earliest of (i)&#160;the Original Term Loan Maturity Date, (ii)&#160;the acceleration of the Term Loan, and (iii)&#160;the prepayment of the Term Loan. The Company was also obligated to pay the Lender a one-time facility fee of $0.2&#160;million (&#8220;Original Facility Fee&#8221;) on the initial closing date. The Original Exit Fee of $0.6 million and Original Facility Fee of $0.2&#160;million were recorded as debt discount, and were being accreted using the effective interest method within interest expense in the condensed consolidated statements of operations and comprehensive loss. The Company&#8217;s obligation to pay the Original Exit Fee remains outstanding, and the timing for payment thereof was unaffected by, and reaffirmed in connection with, the Amendment, and is recorded in the condensed consolidated balance sheet within Term loan, current as of March&#160;31, 2026 and December&#160;31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company was obligated to pay the Lender a one-</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">time facility fee of $0.3&#160;million upon entry into the Amendment. The Company is also obligated to pay a funding fee on each third tranche term loan in an amount equal to the sum of 0.5% multiplied by the amount of such third tranche term loan, if and when funded. Under the terms of the Amended Loan Agreement, the Company is obligated to pay a final fee equal to 5.95% of the aggregate amount of the Term Loan funded thereunder (the &#8220;Amended Exit Fee&#8221;) upon the earliest of (i)&#160;the Amended Term Loan Maturity Date, (ii) the acceleration of the Term Loan, and (iii) the prepayment of the Term Loan. As of March&#160;31, 2026, the amount owed under the Amended Exit Fee is equal to $1.2&#160;million. The Original Exit Fe</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e and the Amended Exit Fee have been fully accrued and recorded as debt discount as of the closing date of the Amendment and are being accreted using the effective interest method within interest expense in the consolidated statement of operations and comprehensive loss.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the option to prepay all, but not less than all, of the Term Loan prior to the Amended Term Loan Maturity Date, which would require that the Company pay the Lender a prepayment penalty fee based on a percentage of the outstanding principal balance and the funding date of the individual tranches thereunder. As to each such tranche under the Term Loan, such fee shall be equal to 3% if the payment occurs on or before 24 months after the funding date of such tranche, 2% if the prepayment occurs more than 24 months after, but on or before 36 months after the funding date of such tranche, or 1% if the prepayment occurs more than 36 months after the funding date of such tranche. No prepayment penalty fee is required if the applicable tranche is prepaid within six months prior to the Amended Term Loan Maturity Date or refinanced with the Lender. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Terms</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company must maintain, at all times, a cash runway of at least 5 months, provided that this covenant will be waived during any period in which the Company&#8217;s market capitalization exceeds $700.0&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Amended Loan Agreement are secured by a first priority security interest in substantially all of its assets (with an exclusion for intellectual property). The Amended Loan Agreement contains customary represent</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ations and warranties, and also includes customary events of default, including payment default, breach of covenants, change of control, and material adverse effects. The Amended Loa</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">n Agreement restricts certain activities, such as disposing of the Company&#8217;s business or certain assets, incurring additional debt or liens or making payments on other debt, making certain investments and declaring dividends, acquiring or merging with another entity, engaging in transactions with affiliates or encumbering intellectual property, among others. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of an event of default, a default interest rate of an additional 5% per annum may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and exercise all of its rights and remedies as set forth in the Amended Loan Agreement and u</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">nder applicable law. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Original Loan Agreement, the Company issued to the Lender a warrant (the &#8220;Original Warrant&#8221;), which Original Warrant is exercisable for 35,773 shares of the Company&#8217;s common stock and expires on December 15, 2032. In connection with the Amendment, the Original Warrant was amended and restated (the &#8220;Amended and Restated Warrant&#8221;) to reduce the exercise price from $10.49 to $3.71 per share (the &#8220;Exercise Price&#8221;). The incremental value associated with this modification was immaterial, and was included as part of the determination of the loss on debt extinguishment, with a corresponding increase in additional paid-in capital during</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> the three months ended </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Amendment, the Company issued an additional warrant (the &#8220;New Warrant&#8221;, together with the Amended and Restated Warrant, the &#8220;Warrants&#8221;) to purchase a number of shares of the Company&#8217;s common stock calculated as follows: (a) (i) 0.025, multiplied by (ii) the aggregate principal amount of the term loans actually funded under the Amended Loan Agreement, divided by (b) the Exercise Price. The New Warrant expires on January 13, 2035 and allows for the purchase of 134,691 shares of the Company&#8217;s common stock. If the Company draws down on additional tranches of the Term Loan, the number of shares available for purchase by the Lender under the New Warrant would increase. The Company determined the estimated fair value of the New Warrant at the date of issuance to be $0.5&#160;million, which was included as part of the determination of the loss on debt extinguishment, with a corresponding increase in additional paid-in capital. As of the date of the issuance, significant assumptions include an expected life of 10 years, a risk-free rate of 4.79% and an expected volatility of 89.47%. See Note 10 for additional information regarding the New Warrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loan Conversion Feature</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Amended Loan Agreement, the Lender may, at its option, elect to convert up to $9.0&#160;million of the then outstanding Term Loan (the &#8220;Conversion Amount&#8221;) ($4.0&#160;million of which was reflected in the Original Loan Agreement and $5.0&#160;million of which is reflected in the Amended Loan Agreement) into shares of the Company&#8217;s common stock (the &#8220;Conversion Shares&#8221;). The number of shares to be issued upon conversion is determined by dividing (a) the portion of the term loan amount converted, by (b) the Applicable Conversion Price. Applicable Conversion Price means (i) with respect to any conversion of up to $4.0&#160;million of the Conversion Amount, $10.49, and (ii) with respect to any conversion of the remaining $5.0&#160;million of the Conversion Amount, $4.83, in each case subject to certain adjustments set </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">forth in the Amended Loan Agreement. The Company determined that the embedded conversion option is not required to be separated from the Term Loan. The embedded conversion option meets the derivative accounting scope exception since the embedded conversion option is indexed to the Company&#8217;s own common stock and qualifies for classification within stockholders&#8217; equity. On November 17, 2025 and March 18, 2026, the Lender elected to convert $4.0&#160;million and $1.0&#160;million, respectively, of its outstanding loan balance into the Company&#8217;s common stock. Pursuant to the terms of the Amended Loan Agreement, the conversion price was $4.83 per share, resulting in the issuance of 828,860 and 207,215 shares, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense and future repayments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The C</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ompany recorded interest expense at a weighted average rate of 12.35% and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.94%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> related to the Loan Agreement for the three months ended March&#160;31, 2026, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> respectively. During the three months ended March&#160;31, 2026, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recorded interest expense of $0.5 million and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$0.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, respectively.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future principal debt payments and Exit Fee of the term loan funded as of March&#160;31, 2026 are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"><tr><td style="width:1.0%"></td><td style="width:79.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026 (remainder of year)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,858</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,467</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">675</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exit Fee</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,815</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred interest</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">235</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments and Exit Fee</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,050</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: unamortized debt discount</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,029)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Term loan, current portion</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,136)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Term loan,&#160;non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,885</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Wellcome Trust Limited Convertible Grant Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, the Company entered into a convertible loan agreement (the &#8220;Convertible Grant Agreement&#8221;) with The Wellcome Trust Limited (&#8220;Wellcome&#8221;). The Convertible Grant Agreement provides for an unsecured convertible loan (the &#8220;Convertible Loan&#8221;) from Wellcome of up to approximately $11.7&#160;million, payable to Alto in six tranches, of which up to $2.0&#160;million could be funded upon the execution of the Convertible Grant Agreement and the remainder of which will be funded upon the completion of certain milestones as set forth in the Convertible Grant Agreement. As of March&#160;31, 2026, the Company has drawn down the entirety of the $2.0&#160;million execution tranche and will continue to access the loan as needed as the ALTO-100 study in bipolar depression progresses. Interest accrues at an annual rate equal to the Sterling Overnight Index Rate plus 2%, subject to potential adjustment if such annual interest rate equals or exceeds 9% at any time. Proceeds from the Convertible Loan may be used by the Company solely to advance development of ALTO-100 in bipolar depression. The Convertible Grant Agreement also includes customary covenants, representations and warranties, including with respect to the conduct of the Company&#8217;s Phase 2b clinical trial evaluating ALTO-100 in patients with bipolar depression and certain information and audit rights of Wellcome in connection therewith, as well as with respect to the Company&#8217;s efforts to develop and exploit ALTO-100. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At any time after the second anniversary of the effective date of the Convertible Grant Agreement or in connection with an event of default, Wellcome has the right, at its election, to convert some or all of the Convertible Loan into shares of the Company&#8217;s common stock at a price per share equal to a 20% discount to the thirty-day volume-weighted average price of Common Stock on the New York Stock Exchange at the date of such conversion. The Convertible Grant Agreement provides that in no event shall the aggregate number of shares of Common Stock issued pursuant to conversion of the Convertible Loan exceed 5,363,326, which is equal to 19.9% of the number of shares of Common Stock outstanding as of the date of the Convertible Grant Agreement. At any time after the fifth anniversary of the effective date of the Convertible Grant Agreement or in connection with an event of default, Wellcome may require repayment of the Convertible Loan in full, together with accrued interest, to the extent not converted as described above.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future principal debt payments of the Convertible Grant Agreement funded as of March&#160;31, 2026 are as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"><tr><td style="width:1.0%"></td><td style="width:79.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026 (remainder of year)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Term loan,&#160;non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the terms and features of the Convertible Grant Agreement and determined that the Company was eligible to elect the fair value option under ASC 825, Financial Instruments. The Convertible Grant Agreement contains various embedded features and the election of the fair value option allowed the Company to bypass analysis of potential embedded derivatives and further analysis of bifurcation of any recognized financial liabilities. Under the fair value option, the financial liability is initially measured at its fair value on the issue date and subsequently remeasured at estimated fair value on a recurring basis at each reporting date. Changes in the fair value of the Convertible Grant Agreement, which include accrued interest, if any, are recorded as a component </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of other, net or within other comprehensive income (loss) in the</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> condensed consolidated statements of operations and comprehensive loss. The Company has not elected to present interest expense separately from changes in fair value and therefore will not present interest expense associated with the Convertible Grant Agreement. Any changes in fair value caused by instrument-specific credit risk are presented separately in other comprehensive income or loss. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial fair value of the Convertible Grant Agreement using a probability-weighted income approach. Draw downs under the Convertible Grant Agreement were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$0.8 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">during the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">years</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> ended December&#160;31, 2025, and 2024, respectively. The Company remeasured the fair value of the Convertible Grant Agreement as of March&#160;31, 2026 to b</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e $2.3 million using</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> a probability-weighted income approach. The Company calculated discounted cash flows of the Convertible Grant Agreement using a discount rate of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20.69%</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and adjusted for the probability of various repayment scenarios. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in fair value of the Convertible Grant Agreement during the three months ended March&#160;31, 2026 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value balance as of December 31, 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,227</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of new tranches</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value reported in statements of operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">115</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value reported in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value balance as of March 31, 2026</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,335&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments that are measured at fair value on a recurring basis consist of money market funds and the Convertible Grant Agreement. The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">263,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">263,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">263,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">263,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Convertible Grant Agreement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">176,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">176,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">176,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">176,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Convertible Grant Agreement</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its money market funds, which are valued based on quoted market prices in an active market with no valuation adjustment, as Level 1 assets within the fair value hierarchy. The Company&#8217;s Convertible Grant Agreement is classified as a Level 3 instrument under the fair value hierarchy as the fair values were determined based on significant inputs not observable in the market. See Note 4 for additional information on the Convertible Grant Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Purchase and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Asset Purchase and License Agreements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Asset Purchase and License Agreements</span><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into asset purchase and license agreements with third parties. For a detailed description of the significant agreements with certain financial commitments to which the Company is a party, see Note 10 to the consolidated financial statements included in the Company&#8217;s Annual Report. No payments were made during the three months ended </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> pursuant to any of these significant agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Plans</a></td>
<td class="text">Stock-Based Plans<div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Equity Incentive Plan</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the Board adopted, and the Company&#8217;s stockholders approved, the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), which became effective on the execution of the underwriting agreement related to the IPO. Under the 2024 Plan, the Company may grant incentive stock options</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to employees, including employees of any parent or subsidiary, and nonstatutory stock options, stock appreciation rights, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), performance awards and other forms of stock awards to employees, directors, and consultants, including employees and consultants of the Company&#8217;s affiliates. The 2024 Plan is a successor to the 2019 Equity Incentive Plan, which was adopted by the Board of Directors in March 2019 (as amended, the &#8220;2019 Plan&#8221;). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following effectiveness of the 2024 Plan, no further issuance may be made under the 2019 Plan. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> total of 2,000,000 shares of common stock were approved to be initially reserved for issuance under the 2024 Plan. In addition, the number of shares of the Company&#8217;s common stock reserved for issuance under the 2024 Plan automatically increases on January 1 of each calendar year, starting on January 1, 2025 and continuing through and including January 1, 2034, in an amount equal to 5% of the total number of shares of the Company&#8217;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Board.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the total number of shares authorized to be issued under the 2024 Plan was </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,945,504 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,349,328</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. As of March&#160;31, 2026 and December&#160;31, 2025, there wer</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e 527,407 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and 625,142 shares of common stock, respectively, reserved and available for issuance under the 2024 Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2025 Inducement Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2025, the Board adopted the 2025 Inducement Plan (the &#8220;Inducement Plan&#8221;), pursuant to which it reserved&#160;500,000 shares of common stock for issuance to individuals who were not previously employees of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company, in accordance with New York Stock Exchange Listed Company Manual Rule 303A.08. Under the&#160;Inducement&#160;Plan, the Company has the ability to issue non-statutory stock options, stock appreciation rights, RSAs, RSUs, and performance awards. As of March&#160;31, 2026, stock options to purchase 150,000 shares of common stock had been granted under the Inducement Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2026, the Company had not opened the 2024 Employee Stock Purchase Plan for enrollment, and therefore there were no purchases or share issuances during this period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Repricing </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In July 2025, the Board approved a stock option repricing, which was effective at the close of market on July 3, 2025 (&#8220;Repricing Effective Date&#8221;). The repricing generally applied to the outstanding stock options held by then current employees and consultants that had an exercise price greater than $2.35 per share. As of the Repricing Effective Date, the eligible stock options were immediately repriced such that the exercise price per share for such stock options was reduced to $2.35 (the closing price of the Company&#8217;s common stock on the New York Stock Exchange on the Repricing Effective Date), subject to certain retention requirements. The retention period is 12 months following the Repricing Effective Date and can be accelerated under certain conditions. If an eligible stock option is exercised prior to the end of the relevant retention period, the participant will be required to pay a premium exercise price equal to the original exercise price per share of such stock option. There were no changes to the number of shares underlying the eligible stock options or to the vesting schedules or expiration dates of the eligible stock options. There were 4,225,763 shares underlying the repriced stock options, which had then-current exercise prices ranging from $2.44 to $16.00 per share. An incremental $1.4 million </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">of stock-based compensation expense will be recognized over the greater of the 12-month retention period or the remaining vesting period of the outstanding stock options. Stock options held by non-employee members of the Board were not eligible for the repricing. For the three months ended March&#160;31, 2026, the Company recognized $0.2 million of incremental stock-based compensation expense in connection with the stock option repricing. In addition, the Company has $0.8 million of unrecognized stock based compensation related to the stock option repricing which is expected to be recognized over a weighted-average period of 1.0 year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The options have a&#160;10-year&#160;contractual life and generally vest over a period of four years, with the first 25% of the award vesting after one year and then monthly thereafter, subject to continuous service. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the three months ended March&#160;31, 2026 and 2025 for awards subject only to service-based vesting conditions wer</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e $12.90 and $3.09 per</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> share, respectively. Weighted-average grant date fair value assumptions were based on the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.090%"><tr><td style="width:1.0%"></td><td style="width:56.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.08</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of common stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.72</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 10.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 10.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">92.0%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88.7%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.2%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td></tr></table></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> below summarizes activity related to stock options subject only to service-based vesting conditions (in thousands, except per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>average<br/>exercise<br/>price per share</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted &#8211;<br/>average<br/>remaining<br/>contractual<br/>term (in<br/>years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>value </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,950</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,078</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,727</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">85</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and cancelled</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,643</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84,702</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,733</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42,552</span></td></tr><tr style="height:15pt"><td colspan="24" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Since the reporting period covered by the table above is before the expiration of the aforementioned retention period and any employees who exercised their repriced stock options during the reporting period, with certain exceptions, would have to pay the original exercise price, the weighted average exercise price and intrinsic value in the table above does not reflect the effect of repricing.</span></div></td></tr><tr style="height:15pt"><td colspan="24" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, there was approximate</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ly $34.0 million of unrecognized stock-based compensation expense related to these service-based unvested stock options, excluding the impact of the option repricing, which is expected to be recognized ov</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">er a weighted-average period of 2.9 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below summ</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">arizes activity related to RSUs subject only to service-based vesting conditions (in thousands, except per share amounts):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.787%"><tr><td style="width:1.0%"></td><td style="width:60.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.764%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-average<br/>grant date fair value per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.88</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.88</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and cancelled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, March 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, the Company issued 53,864 RSUs under the 2024 Plan; 50% of the shares of common stock underlying the RSUs vest after 18 months and the remainder vest after 24 months from the grant date. The RSUs are subject only to a service-based vesting condition. Such shares are not accounted for as outstanding until they vest.&#160;As of March&#160;31, 2026, there is no unrecognized stock-based compensation expense related to the RSUs. The fair value of the RSUs vested during the three months ended March&#160;31, 2026 was $0.5 million.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Option Awards</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Board granted options to purchase common stock to certain employees and consultants that vest upon the achievement of certain performance conditions (&#8220;Performance Awards&#8221;) such as the completion of a future financing event or upon the achievement of defined clinical milestones or outcomes. The Company did not issue Performance Awards during the three months ended March&#160;31, 2026 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2026, there are 435,381 Performance Awards vested and outstanding, and no Performance awards remain unvested</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Performance Awards have a contractual term of 10 years. There is no unrecognized stock-based compensation expense related to Performance Awards.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash&#160;stock-based compensation expense recognized in the accompanying condensed consolidated statements of operations and comprehensive loss for the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March&#160;31, 2026 and 2025 was as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.030%"><tr><td style="width:1.0%"></td><td style="width:61.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.952%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,524</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">982</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,300</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">986</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,824</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,968</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text">Loss Per Share<div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The Company&#8217;s unvested restricted common stock is not included in the determination of loss per share until the award vests. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025 and March 2026, the Company issued equity-classified Pre-Funded Warrants with a nominal exercise price of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.0001</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> per share (see Note </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). In accordance with ASC 260, Earnings Per Share (ASC 260), shares issuable for little to no cash consideration should be included in the number of outstanding shares used to calculate basic loss per share as long as all conditions necessary for exercise are met. The Pre-Funded Warrants are therefore included as outstanding shares as of their issuance date to calculate the weighted average number of shares outstanding to calculate basic loss per share.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.363%"><tr><td style="width:1.0%"></td><td style="width:58.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.649%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">K2 Common Stock Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, including its net operating losses. Based on its history of operating losses, the Company believes that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for its net deferred tax assets as of March&#160;31, 2026 and December&#160;31, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">K2 Warrant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, in connection with the closing of the Original Loan Agreement, the Company issued a warrant to the Lender to purchase a number of shares of the Company&#8217;s Series B convertible preferred stock, or at Lender&#8217;s election, next round stock (&#8220;K2 Warrant&#8221;). The number of shares of convertible preferred stock issuable upon exercise of the warrant was equal to (a) (i) 0.0375, multiplied by (ii)&#160;the aggregate principal amount of term loans actually funded under the Original Loan Agreement, divided by (b)&#160;the warrant price then in effect. Following the conversion of all outstanding convertible preferred stock to common stock upon the completion of the IPO in February 2024, the K2 Warrant became a warrant to purchase up to an aggregate of 35,773 shares of the Company&#8217;s common stock at an exercise price of $10.49 per share (referred to in Note 4 as the Original Warrant).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2025, in connection with the Amended Loan Agreement (see Note 4 for additional information), the K2 Warrant was amended and restated (referred to in Note 4 as the Amended and Restated Warrant) to reduce the exercise price from $10.49 per share to $3.71 per share (referred to in Note 4 as the Exercise Price). Further, in connection with the Amendment, the Company issued an additional warrant (referred to in Note 4 as the New Warrant and, together with the Amended and Restated Warrant, the Warrants) to purchase a number of shares of the Company&#8217;s common stock calculated as follows: (a) (i) 0.025, multiplied by (ii) the aggregate principal amount of the term loans actually funded under the Amended Loan Agreement, divided by (b) the Exercise Price. The New Warrant expires on January 13, 2035. The New Warrant is classified as equity as it meets all the conditions under GAAP for equity classification, and is therefore not subject to ongoing remeasurement. The Company reassesses whether equity classification for the warrant is appropriate upon any changes to the warrants or capital structure, at each balance sheet date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">f March&#160;31, 2026 the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">New Warrant allowed for the purchase of 134,691 shares of the Company&#8217;s common stock. If the Company draws down on additional tranches of the Term Loan, the number of shares available for purchase by the Lender under the New Warrant would increase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is conditionally obligated to issue a fixed number of additional shares in connection with the New Warrant (&#8220;Additional Warrants&#8221;) in the potential amount of 168,363 shares upon the funding of additional amounts under the Term Loan with the same exercise price and contractual term. The contingent obligation to issue the Additional Warrants did not meet the derivative scope exception or equity classification criteria and were accounted for as a derivative liability. The </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">con</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">tingently issuable Additional Warrants derivative liability had a de minimis value at the time of issuance and as of March&#160;31, 2026. The Additional Warrants derivative liability will be remeasured each reporting period until settled or extinguished</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> with subsequent changes in fair value recorded through other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. The initial fair value of the Additional Warrants derivative liability was determined using a Black-Scholes option pricing model based on the same input assumptions above, with an additional assessment required for the probability that additional amounts under the Term Loan will be funded which would trigger the issuance of the Additional Warrants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-Funded Warrants Issued in October 2025 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025, the Company entered into a Securities Purchase Agreement (the &#8220;2025 PIPE Purchase Agreement&#8221;) with certain institutional and other accredited investors (the &#8220;2025 PIPE Purchasers&#8221;), pursuant to which the Company sold and issued to the 2025 PIPE Purchasers in a private placement transaction (the &#8220;2025 Private Placement&#8221;) (i) 3,832,263&#160;shares of the Company&#8217;s common stock (the &#8220;2025 PIPE Shares&#8221;), and (ii) with respect to certain 2025 PIPE Purchasers, pre-funded warrants to purchase&#160;4,622,251&#160;shares of the Company&#8217;s common stock (the &#8220;2025 Pre-Funded Warrants&#8221;) in lieu of shares of the Company&#8217;s common stock. The purchase price per share of common stock was$5.9140&#160;per share (the &#8220;2025 PIPE Purchase Price&#8221;), and the purchase price for the 2025 Pre-Funded Warrants was $5.9139&#160;per 2025 Pre-Funded Warrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Pre-Funded Warrants have a per share exercise price of $0.0001, subject to proportional adjustments in the event of stock splits or combinations or similar events. The 2025 Pre-Funded Warrants will not expire until exercised in full. The 2025 Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation; provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving&#160;61 days&#8217; notice to the Company, but not to any percentage in excess of&#160;19.9%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the 2025 Pre-Funded Warrants meet the criteria for equity classification at issuance and were recorded as a component of stockholders&#8217; equity within additional paid-in capital. The 2025 Pre-Funded Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such 2025 Pre-Funded Warrants do not provide any guarantee of value or return.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-Funded Warrants Issued in March 2026 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2026, the Company entered into a Securities Purchase Agreement (the &#8220;2026 PIPE Purchase Agreement&#8221;) with certain institutional investors (the &#8220;2026 PIPE Purchasers&#8221;), pursuant to which the Company sold and issued to the 2026 PIPE Purchasers in a private placement transaction (the &#8220;2026 Private Placement&#8221;) (i) 2,900,000 shares of the Company&#8217;s common stock (the &#8220;2026 PIPE Shares&#8221;), and (ii) with respect to certain 2026 PIPE Purchasers, pre-funded warrants to purchase 3,100,000 shares of the Company&#8217;s common stock (the &#8220;2026 Pre-Funded Warrants&#8221;) in lieu of shares of the Company&#8217;s common stock. The purchase price per share of common stock was $20.00 per share (the &#8220;2026 PIPE Purchase Price&#8221;), and the purchase price for the 2026 Pre-Funded Warrants was $19.9999 per 2026 Pre-Funded Warrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2026 Pre-Funded Warrants have a per share exercise price of $0.0001, subject to proportional adjustments in the event of stock splits or combinations or similar events. The 2026 Pre-Funded Warrants will not expire until exercised in full. The 2026 Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation; provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving&#160;61 days&#8217; notice to the Company, but not to any percentage in excess of&#160;19.9%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the 2026 Pre-Funded Warrants meet the criteria for equity classification at issuance and were recorded as a component of stockholders&#8217; equity within additional paid-in capital. The 2026 Pre-Funded Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such 2026 Pre-Funded Warrants do not provide any guarantee of value or return.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock and Authorized Shares</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of both March&#160;31, 2026 and December&#160;31, 2025, the Company h</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ad 500,000,000 authorized shares of common stock with a par value of $0.0001 per share, of which 35,052,731 and 31,923,521 shares, respectively, were issued and outstanding. On February 6, 2024, the Company amended its certificate of incorporation such that the total number of shares of common stock authorized to be issued was increased to 500,000,000, and the total number of shares of new preferred stock authorized to be issued was 10,000,000 with a par value per share of $0.0001. As of March&#160;31, 2026, no shares of preferred stock were issued or outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, the Company had reserved common stock, on an&#160;as-if&#160;converted basis, for issuance as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.393%"><tr><td style="width:1.0%"></td><td style="width:60.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">K2 Warrants</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-Funded Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,722</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 4.37pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,622</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options issued and outstanding from 2024, 2019 Equity Incentive Plan and Inducement Plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future grant from 2024 Equity Incentive Plan and Inducement Plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reserved common stock in the table above does not include (i) the number of shares of the Company&#8217;s common stock issuable upon conversion of the remaining amount of the Conversion Amount specified within the Amended Loan Agreement (see Note 4), (ii) the variable number of shares issuable pursuant to conversion of amounts funded under the Convertible Grant Agreement (see Note 4), and (iii) the variable number of shares issuable pursuant to terms of the asset purchase agreement, dated May 31, 2025, between the Company and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chase Therapeutics Corporation.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to occasional lawsuits, investigations and claims arising out of the ordinary course of business.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Other than as set forth below, the Company had no significant pending or threatened litigation as of March&#160;31, 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On July 21, 2025, a purported stockholder of the Company filed a lawsuit against the Company, certain executive officers, and certain current and former directors in the United States District Court for the Northern District of California (Case No. 3:25-cv-06105). The plaintiff filed an amended complaint on January 23, 2026 and a second amended complaint on April 6, 2026. The complaint is a putative class action alleging violations of the Securities Act of 1933, as amended, related to the Company&#8217;s IPO in February 2024, and violations of the Exchange Act thereafter. The proposed classes consist of purchasers or acquirers of the Company&#8217;s common stock pursuant or traceable to the Company&#8217;s IPO as well as purchasers or acquirers of the Company&#8217;s common stock between March 18, 2024 and October 22, 2024, both dates inclusive. The plaintiff seeks unspecified damages, as well as interest, fees, and costs. The complaint claims, among other things, that the Company&#8217;s offering documents and subsequent public disclosures contained materially false and misleading statements and omitted material facts about the prospects of ALTO-100. The Company believes these allegations lack merit, and the Company filed a motion to dismiss on May 5, 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a consolidated stockholder derivative action, captioned In re Alto Neuroscience, Inc. Derivative Litigation, Lead Case No. 5:25-cv-07144-NW was filed on behalf of the Company against certain executive officers and certain current and former directors for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the federal securities laws. The claims arise out of the same factual allegations as the putative class action described above. The plaintiffs seek unspecified damages, as well as interest, fees, and costs. The </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">consolidated stockholder derivative action was stayed on January 14, 2026 pending resolution of the motion to dismiss in the securities class action. The Company believes that these claims lack merit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not recorded a liability related to these lawsuits because, at this time, the Company does not believe that an unfavorable outcome is either probable or estimable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is unknown at March&#160;31, 2026. The Company does not anticipate recognizing any significant losses relating to these arrangements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">Segments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a single reportable segment entity, the Company&#8217;s segment performance measure is consolidated net loss. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Asset information is not used by the Company&#8217;s President and Chief Executive Officer, its chief operating decision maker (&#8220;CODM&#8221;) to allocate resources.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Certain significant segment expenses below loss from operations are presented in the Company&#8217;s consolidated statements of operations and are therefore not presented below. Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company&#8217;s condensed consolidated statements of operations, are presented below (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"><tr><td style="width:1.0%"></td><td style="width:71.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expenses excluding stock-based compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct external program expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-100</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-300</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-101</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-203</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-207</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other research and development </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(a) Other research and development expenses primarily consists of license fees, facility charges, third party consultant costs, early research costs related to other product candidates, and other unallocated costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(b) General and administrative costs include professional fees, insurance, consultant fees and facility charges.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">PLACEHOLDER</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_IndividualAxis=alto_AmitEtkinMember', window );">Amit Etkin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2026, Amit Etkin, M.D., Ph.D., our President, Chief Executive Officer, and Chair of the Board, terminated a Rule 10b5-1 trading plan effective March 17, 2026. No sales of common stock occurred under the plan prior to its termination. Prior to its termination, the plan had provided for the potential sale of up to 100,000 shares of our common stock at each of two specified price points (60,000 shares to be sold at $35.00 and 40,000 shares to be sold at $80.00). Transactions under Dr. Etkin&#8217;s plan were based upon pre-established dates and stock price thresholds and would only occur upon the expiration of the applicable mandatory cooling-off period. Dr. Etkin&#8217;s plan had a termination date of December&#160;31, 2026, or the date all shares subject to the plan had been sold.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Amit Etkin, M.D., Ph.D.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President, Chief Executive Officer, and Chair of the Board<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">March 13, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_IndividualAxis=alto_NicholasSmithMember', window );">Nicholas Smith [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2026, Nicholas Smith, our Chief Financial Officer and Chief Business Officer, terminated a Rule 10b5-1 trading plan effective March 13, 2026. No sales of common stock occurred under the plan prior to its termination. Prior to its termination, the plan had provided for the potential sale of up to 14,376 shares of our common stock at a price per share of $45.00. Transactions under Mr. Smith&#8217;s plan were based upon pre-established dates and stock price thresholds and would only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Smith&#8217;s plan had a termination date of December&#160;31, 2026, or the date all shares subject to the plan had been sold.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Nicholas Smith<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer and Chief Business Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">March 11, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">14,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=alto_AmitEtkinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=alto_AmitEtkinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=alto_NicholasSmithMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=alto_NicholasSmithMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), as determined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;), and include the accounts of Alto and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated financial statements are unaudited and have been prepared on the same basis as the audited annual financial st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">atements and, in management&#8217;s opinion, include all adjustments consisting of only normal recurring adjustments necessary for the fair statement of the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Company&#8217;s financial position as of March&#160;31, 2026 and its results of operations and statements of equity for the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March&#160;31, 2026 and 2025 and cash flows for the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March&#160;31, 2026 and 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">f operations for the three months ended March&#160;31, 2026 are not necessarily indicative of the results to be expected for the full fiscal year or any other period.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and the related notes thereto for the year ended December&#160;31, 2025 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 16, 2026 (the &#8220;Annual Report&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ materially from those estimates. The most significant estimates and assumptions in the Company&#8217;s condensed consolidated financial statements relate to the determination of the volatility of its common stock (as an input for calculating stock-based compensation and warrants), estimating accrued or prepaid research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-04, Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, which affects entities that settle convertible debt instruments for which the conversion privileges were changed to induce conversion. The standard is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company adopted the provisions of ASU 2024-04 prospectively beginning January 1, 2026. The adoption did not have an impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03, Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which expands disclosures about specific expense categories presented on the face of the income statement. The standard is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. This standard clarifies current interim reporting requirements on Topic 270 and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. This standard will be effective for fiscal years beginning after December 15, 2027, with the option to apply it retrospectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Early adoption is allowed. Currently, the Company is evaluating the impact the adoption of this standard will have on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"><tr><td style="width:1.0%"></td><td style="width:63.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:120%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,894</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">191</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other prepaid expenses</span></div></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,470</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,043</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,364</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,234</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"><tr><td style="width:1.0%"></td><td style="width:63.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,125</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">453</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">453</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer software and equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">574</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">574</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">246</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">246</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Less</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">: accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,706)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,526)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,234</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,872</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"><tr><td style="width:1.0%"></td><td style="width:63.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll, vacation and employee-related expenses</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,001</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,870</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,142</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,124</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest, short term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">115</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">118</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other accruals and current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,048</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">599</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability, short term </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,304</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,151</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,610</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,862</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of future principal debt payments and exit fee</a></td>
<td class="text"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future principal debt payments and Exit Fee of the term loan funded as of March&#160;31, 2026 are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"><tr><td style="width:1.0%"></td><td style="width:79.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026 (remainder of year)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,858</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,467</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">675</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exit Fee</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,815</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred interest</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">235</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments and Exit Fee</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,050</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: unamortized debt discount</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,029)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Term loan, current portion</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,136)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Term loan,&#160;non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,885</span></td></tr></table></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future principal debt payments of the Convertible Grant Agreement funded as of March&#160;31, 2026 are as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"><tr><td style="width:1.0%"></td><td style="width:79.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026 (remainder of year)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Term loan,&#160;non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of change in the air value of the Convertible Grant Agreement</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in fair value of the Convertible Grant Agreement during the three months ended March&#160;31, 2026 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value balance as of December 31, 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,227</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of new tranches</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value reported in statements of operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">115</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value reported in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value balance as of March 31, 2026</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,335&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of classes of financial assets and liabilities measured at fair value on recurring basis</a></td>
<td class="text">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">263,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">263,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">263,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">263,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Convertible Grant Agreement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">176,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">176,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">176,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">176,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Convertible Grant Agreement</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of share-based payment award, stock options, valuation assumptions</a></td>
<td class="text">Weighted-average grant date fair value assumptions were based on the following: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.090%"><tr><td style="width:1.0%"></td><td style="width:56.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.08</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of common stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.72</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 10.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 10.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 10.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">92.0%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88.7%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.2%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of share-based compensation arrangements by share-based payment award</a></td>
<td class="text"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> below summarizes activity related to stock options subject only to service-based vesting conditions (in thousands, except per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>average<br/>exercise<br/>price per share</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted &#8211;<br/>average<br/>remaining<br/>contractual<br/>term (in<br/>years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>value </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,950</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,078</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,727</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">85</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and cancelled</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,643</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84,702</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,733</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42,552</span></td></tr><tr style="height:15pt"><td colspan="24" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Since the reporting period covered by the table above is before the expiration of the aforementioned retention period and any employees who exercised their repriced stock options during the reporting period, with certain exceptions, would have to pay the original exercise price, the weighted average exercise price and intrinsic value in the table above does not reflect the effect of repricing.</span></div></td></tr><tr style="height:15pt"><td colspan="24" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Share-based payment arrangement, restricted stock unit, activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below summ</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">arizes activity related to RSUs subject only to service-based vesting conditions (in thousands, except per share amounts):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.787%"><tr><td style="width:1.0%"></td><td style="width:60.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.764%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-average<br/>grant date fair value per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.88</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.88</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and cancelled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, March 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Share-based payment arrangement, cost by plan</a></td>
<td class="text"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash&#160;stock-based compensation expense recognized in the accompanying condensed consolidated statements of operations and comprehensive loss for the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March&#160;31, 2026 and 2025 was as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.030%"><tr><td style="width:1.0%"></td><td style="width:61.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.952%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,524</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">982</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,300</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">986</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,824</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,968</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.363%"><tr><td style="width:1.0%"></td><td style="width:58.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.649%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">K2 Common Stock Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ScheduleOfStockReservedForIssuanceTableTextBlock', window );">Schedule of stock reserved for issuance</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, the Company had reserved common stock, on an&#160;as-if&#160;converted basis, for issuance as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.393%"><tr><td style="width:1.0%"></td><td style="width:60.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">K2 Warrants</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-Funded Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,722</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 4.37pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,622</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options issued and outstanding from 2024, 2019 Equity Incentive Plan and Inducement Plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future grant from 2024 Equity Incentive Plan and Inducement Plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reserved common stock in the table above does not include (i) the number of shares of the Company&#8217;s common stock issuable upon conversion of the remaining amount of the Conversion Amount specified within the Amended Loan Agreement (see Note 4), (ii) the variable number of shares issuable pursuant to conversion of amounts funded under the Convertible Grant Agreement (see Note 4), and (iii) the variable number of shares issuable pursuant to terms of the asset purchase agreement, dated May 31, 2025, between the Company and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chase Therapeutics Corporation.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_ScheduleOfStockReservedForIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Stock Reserved for Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_ScheduleOfStockReservedForIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text">Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company&#8217;s condensed consolidated statements of operations, are presented below (in thousands):<div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.454%"><tr><td style="width:1.0%"></td><td style="width:71.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expenses excluding stock-based compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct external program expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-100</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-300</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-101</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-203</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ALTO-207</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other research and development </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(a) Other research and development expenses primarily consists of license fees, facility charges, third party consultant costs, early research costs related to other product candidates, and other unallocated costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(b) General and administrative costs include professional fees, insurance, consultant fees and facility charges.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 18, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 17, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 21, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>subsidiary </div>
<div>clinical-stageAsset </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_NumberOfWhollyOwnedSubsidiaries', window );">Number of wholly owned subsidiaries | subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_NumberOfClinicalStageAssets', window );">Number of clinical-stage assets | clinical-stageAsset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_TemporaryEquitySharesConversionOfConvertibleSecurities', window );">Preferred stock conversion, number of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,664,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,832,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">3,832,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 5.9140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,622,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alto_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,622,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alto_K2HealthventuresLLCMember', window );">K2 Healthventures LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_SaleOfStockConversionOfOutstandingLoan', window );">Sale of stock conversion of outstanding loan | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock issued during period (in shares)</a></td>
<td class="nump">207,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_NumberOfClinicalStageAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Clinical-Stage Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_NumberOfClinicalStageAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_NumberOfWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Wholly Owned Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_NumberOfWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_SaleOfStockConversionOfOutstandingLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Conversion Of Outstanding Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_SaleOfStockConversionOfOutstandingLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_TemporaryEquitySharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_TemporaryEquitySharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alto_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alto_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alto_K2HealthventuresLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alto_K2HealthventuresLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of prepaid expenses and other current assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 1,894<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">3,470<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 5,364<span></span>
</td>
<td class="nump">$ 1,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of property and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">$ (1,706)<span></span>
</td>
<td class="num">$ (1,526)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,234<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alto_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property equipment, gross</a></td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property equipment, gross</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alto_ComputerSoftwareAndEquipmentMember', window );">Computer software and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property equipment, gross</a></td>
<td class="nump">574<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property equipment, gross</a></td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alto_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alto_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alto_ComputerSoftwareAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alto_ComputerSoftwareAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of accrued expenses and other current liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll, vacation and employee-related expenses</a></td>
<td class="nump">$ 2,001<span></span>
</td>
<td class="nump">$ 4,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_AccruedResearchExpense', window );">Accrued research</a></td>
<td class="nump">3,142<span></span>
</td>
<td class="nump">2,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest, short term</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accruals and current liabilities</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, short term</a></td>
<td class="nump">1,304<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,610<span></span>
</td>
<td class="nump">$ 8,862<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_AccruedResearchExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_AccruedResearchExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 18, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 17, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 13, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Dec. 16, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate, basis spread (greater of)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alto_K2HealthventuresLLCMember', window );">K2 Healthventures LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_SaleOfStockConversionOfOutstandingLoan', window );">Sale of stock conversion of outstanding loan</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock issued during period (in shares) | shares</a></td>
<td class="nump">207,215<span></span>
</td>
<td class="nump">828,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alto_K2WarrantMember', window );">K2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier', window );">Number of shares called by warrants, multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alto_K2WarrantMember', window );">K2 Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants or rights outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alto_NewK2WarrantMember', window );">New Warrant | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principle amount (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentExitFeePercentOfLoansFunded', window );">Final fee, percent of loan funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">One-time facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal', window );">Prepayment fee, percent of outstanding principal, applicable on or before 24 months after initial funding date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal', window );">Prepayment fee, percent of outstanding principal, applicable on or before 36 months after initial funding date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal', window );">Prepayment fee, percent of outstanding principal, applicable 36 months after initial funding date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault', window );">Interest rate increase in event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.35%<span></span>
</td>
<td class="nump">12.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement | Secured Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender', window );">Amount of debt convertible to equity at election of lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender', window );">Amount of debt convertible to equity at election of lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement | Secured Debt | Fourth tranche, available through January 1, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principle amount (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement | Secured Debt | First tranche, funded on December 16, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentExitFee', window );">Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember', window );">Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentExitFee', window );">Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate, basis spread (greater of)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentInterestRateFloor', window );">Interest rate floor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentFixedRatePaidInKind', window );">Fixed rate, paid-in-kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed', window );">Final payment, percentage of amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt issuance costs and discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">One-time facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentExitFee', window );">Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum', window );">Minimum number of months of cash runway</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount', window );">Minimum market capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier', window );">Number of shares called by warrants, multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Secured Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender', window );">Amount of debt convertible to equity at election of lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Secured Debt | First tranche, funded on December 16, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Secured Debt | Second tranche, available between October 1, 2023 and March 1, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Secured Debt | Third tranche, available from October 1, 2023 and March 1, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentFundingFeeMultiplier', window );">Funding fee multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Multiplier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Amount Convertible To Equity At Election Of Lender</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentExitFeePercentOfLoansFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee, Percent Of Loans Funded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentExitFeePercentOfLoansFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentFixedRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fixed Rate, Paid-In-Kind</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentFixedRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentFundingFeeMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Funding Fee Multiplier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentFundingFeeMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentInterestRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate Floor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentInterestRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentInterestRateIncreaseInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate Increase In Event Of Default</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentInterestRateIncreaseInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Next Fiscal Year Covenant, Cash Runway Period, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Covenant, Minimum Market Capitalization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percentage Of Amount Borrowed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Portion Convertible To Equity At Election Of Lender</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty Fee, After 36 Months After Initial Funding Date, Percent Of Outstanding Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty Fee, On Or Before 24 Months After Initial Funding Date, Percent Of Outstanding Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty Fee, On Or Before 36 Months After Initial Funding Date, Percent Of Outstanding Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_SaleOfStockConversionOfOutstandingLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Conversion Of Outstanding Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_SaleOfStockConversionOfOutstandingLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alto_K2HealthventuresLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alto_K2HealthventuresLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alto_K2WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alto_K2WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alto_NewK2WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alto_NewK2WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alto_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alto_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentTrancheAxis=alto_DebtInstrumentTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentTrancheAxis=alto_DebtInstrumentTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentTrancheAxis=alto_DebtInstrumentTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentTrancheAxis=alto_DebtInstrumentTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentTrancheAxis=alto_DebtInstrumentTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentTrancheAxis=alto_DebtInstrumentTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentTrancheAxis=alto_DebtInstrumentTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentTrancheAxis=alto_DebtInstrumentTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of future principal debt payments and exit fee (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Term loan, current portion</a></td>
<td class="num">$ (2,136)<span></span>
</td>
<td class="num">$ (585)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan,&#160;non-current</a></td>
<td class="nump">13,885<span></span>
</td>
<td class="nump">$ 16,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember', window );">Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2026 (remainder of year)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2027</a></td>
<td class="nump">6,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2028</a></td>
<td class="nump">7,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2029</a></td>
<td class="nump">675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal payments</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentExitFee', window );">Exit Fee</a></td>
<td class="nump">1,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentDeferredInterest', window );">Deferred interest</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_LongTermDebtPrincipalPaymentsAndExitFee', window );">Total principal payments and Exit Fee</a></td>
<td class="nump">17,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentUnamortizedExitFee', window );">Less: unamortized debt discount</a></td>
<td class="num">(1,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Term loan, current portion</a></td>
<td class="num">(2,136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan,&#160;non-current</a></td>
<td class="nump">$ 13,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentDeferredInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Deferred Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentDeferredInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentUnamortizedExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Unamortized Exit Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentUnamortizedExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_LongTermDebtPrincipalPaymentsAndExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Principal Payments And Exit Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_LongTermDebtPrincipalPaymentsAndExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Convertible grant narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate, basis spread (greater of)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment', window );">Variable rate threshold for potential adjustment</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Grant Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,335<span></span>
</td>
<td class="nump">$ 2,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Loan at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Loan at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_GrantAgreementMember', window );">Grant Agreement | Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentConvertibleDiscountOnSharesConverted', window );">Discount on shares</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement', window );">Term of weighted average price for share conversion</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentConvertibleMaximumSharesIssuable', window );">Maximum shares issuable (in shares) | shares</a></td>
<td class="nump">5,363,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum', window );">Maximum percentage of outstanding stock</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Grant Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_GrantAgreementMember', window );">Grant Agreement | Convertible debt | First tranche, funded on December 16, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principle amount (up to)</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_GrantAgreementMember', window );">Grant Agreement | Convertible debt | First tranche, funded on December 16, 2022 | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Grant Agreement | Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Price, Term Of Weighted Average Price Measurement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentConvertibleDiscountOnSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Discount On Shares Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentConvertibleDiscountOnSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentConvertibleMaximumSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Maximum Shares Issuable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentConvertibleMaximumSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Percentage Of Outstanding Stock, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Interest Rate, Threshold For Potential Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alto_GrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alto_GrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_DebtInstrumentTrancheAxis=alto_DebtInstrumentTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_DebtInstrumentTrancheAxis=alto_DebtInstrumentTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Convertible grant maturity (Details) - Convertible debt<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2026 (remainder of year)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2029</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan,&#160;non-current</a></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Change in fair value of convertible grant agreement (Details) - Convertible debt<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 2,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of new tranches</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Principal payments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value reported in statements of operations</a></td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Changes in fair value reported in other comprehensive loss</a></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 2,335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 263,762<span></span>
</td>
<td class="nump">$ 176,484<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">263,998<span></span>
</td>
<td class="nump">176,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Grant Agreement</a></td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">263,498<span></span>
</td>
<td class="nump">176,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">263,998<span></span>
</td>
<td class="nump">176,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Grant Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">263,498<span></span>
</td>
<td class="nump">176,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Grant Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Grant Agreement</a></td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jul. 03, 2025</div></th>
<th class="th"><div>Feb. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance under ESPP plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Retention period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares underlying repriced options, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,225,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise prices, lower range (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise prices, upper range (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,824<span></span>
</td>
<td class="nump">$ 1,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of unrecognized share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.90<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of unrecognized share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding | Vested after 18 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage vested in year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">RSU unrecognized compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Value of the RSUs vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">RSU unrecognized compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Performance awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Performance awards vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Performance awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alto_The2024EquityIncentivePlanMember', window );">The 2024 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares approved, initially reserved for issuance under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">4,945,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,349,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock', window );">Annual increase, percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance under ESPP plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">527,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alto_The2024EquityIncentivePlanMember', window );">The 2024 Equity Incentive Plan | Restricted Stock Units | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">RSUs issued (in shares)</a></td>
<td class="nump">53,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alto_The2024EquityIncentivePlanMember', window );">The 2024 Equity Incentive Plan | Restricted Stock Units | Vested after 18 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage vested in year one</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alto_The2024EquityIncentivePlanMember', window );">The 2024 Equity Incentive Plan | Restricted Stock Units | Vested after 24 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage vested in year one</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alto_A2025InducementPlanMember', window );">2025 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares approved, initially reserved for issuance under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Annual Increase, Percentage of Outstanding Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alto_The2024EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alto_The2024EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alto_A2025InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alto_A2025InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Plans - Stock option weighted average assumptions (Details) - Stock Options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 16.72<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward', window );">Fair value of common stock (in dollars per share)</a></td>
<td class="nump">$ 16.72<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">88.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation By Share Based Payment Award, Fair Value Assumptions, Fair Value Of Award, Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Plans - Schedule of stock option activity (Details) - Stock options issued and outstanding - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">4,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and cancelled (in shares)</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">6,643<span></span>
</td>
<td class="nump">4,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at period end (in shares)</a></td>
<td class="nump">2,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Weighted-&#8232;average&#8232;exercise&#8232;price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">16.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and cancelled (in dollars per share)</a></td>
<td class="nump">9.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">9.73<span></span>
</td>
<td class="nump">$ 7.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at period end (in dollars per share)</a></td>
<td class="nump">$ 6.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract', window );"><strong>Weighted &#8211;&#8232;average&#8232;remaining&#8232;contractual&#8232;term (in&#8232;years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate&#8232;intrinsic&#8232;value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 84,702<span></span>
</td>
<td class="nump">$ 52,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 42,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share Based Payment Award, Options, Weighted Average Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Plans - Schedule of activity related to RSUs (Details) - Restricted Stock Units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited and cancelled (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward', window );"><strong>Weighted-average&#8232;grant date fair value per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">14.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited and cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Rollforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Plans - Schedule of stock-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,824<span></span>
</td>
<td class="nump">$ 1,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,524<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loss Per Share - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alto_TwoThousandTwentyFivePreFundedWarrantsMember', window );">Two Thousand Twenty Five Pre Funded Warrants | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alto_TwoThousandTwentyFivePreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alto_TwoThousandTwentyFivePreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=alto_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=alto_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">7,248<span></span>
</td>
<td class="nump">5,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alto_K2CommonStockWarrantsMember', window );">K2 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">7,078<span></span>
</td>
<td class="nump">5,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alto_K2CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alto_K2CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 17, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 21, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2026 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 17, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 13, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,052,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,923,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,052,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,923,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,622,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">3,832,263<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">3,832,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 5.9140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alto_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">4,622,251<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.9999<span></span>
</td>
<td class="nump">$ 5.9139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation', window );">Increase or decrease the beneficial ownership limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage', window );">Warrant in excess percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier', window );">Number of shares called by warrants, multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alto_K2WarrantMember', window );">K2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier', window );">Number of shares called by warrants, multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | K2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants or rights outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.71<span></span>
</td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | New Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Additional Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Multiplier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Purchase Price Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Rights, Notice Period For Beneficial Ownership Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alto_ClassOfWarrantsOrRightsWarrantExcessPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrent in excess percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alto_ClassOfWarrantsOrRightsWarrantExcessPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alto_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alto_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alto_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alto_K2WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alto_K2WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alto_NewK2WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alto_NewK2WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alto_AdditionalK2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alto_AdditionalK2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of stock reserved for issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance under ESPP plan (in shares)</a></td>
<td class="nump">15,847,000<span></span>
</td>
<td class="nump">11,152,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alto_K2WarrantMember', window );">K2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance under ESPP plan (in shares)</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alto_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance under ESPP plan (in shares)</a></td>
<td class="nump">7,722,000<span></span>
</td>
<td class="nump">4,622,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alto_EmployeeStockOptionsIssuedAndOutstandingMember', window );">Stock options issued and outstanding from 2024, 2019 Equity Incentive Plan and Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance under ESPP plan (in shares)</a></td>
<td class="nump">7,078,000<span></span>
</td>
<td class="nump">5,385,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alto_EmployeeStockOptionsAvailableForFutureGrantMember', window );">Shares available for future grant from 2024 Equity Incentive Plan and Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance under ESPP plan (in shares)</a></td>
<td class="nump">877,000<span></span>
</td>
<td class="nump">975,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alto_K2WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alto_K2WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alto_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alto_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alto_EmployeeStockOptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alto_EmployeeStockOptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alto_EmployeeStockOptionsAvailableForFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alto_EmployeeStockOptionsAvailableForFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,824<span></span>
</td>
<td class="nump">$ 1,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Direct external program expenses:</a></td>
<td class="nump">20,294<span></span>
</td>
<td class="nump">9,974<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,237)<span></span>
</td>
<td class="num">(15,169)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=alto_ReportableSegmentMember', window );">Reportable segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Personnel expenses excluding stock-based compensation</a></td>
<td class="nump">6,249<span></span>
</td>
<td class="nump">5,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">1,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,091<span></span>
</td>
<td class="nump">3,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">27,138<span></span>
</td>
<td class="nump">15,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=alto_ReportableSegmentMember', window );">Reportable segment | ALTO-100</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Direct external program expenses:</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=alto_ReportableSegmentMember', window );">Reportable segment | ALTO-300</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Direct external program expenses:</a></td>
<td class="nump">1,507<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=alto_ReportableSegmentMember', window );">Reportable segment | ALTO-101</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Direct external program expenses:</a></td>
<td class="nump">5,356<span></span>
</td>
<td class="nump">969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=alto_ReportableSegmentMember', window );">Reportable segment | ALTO-203</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Direct external program expenses:</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=alto_ReportableSegmentMember', window );">Reportable segment | ALTO-207</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Direct external program expenses:</a></td>
<td class="nump">$ 4,143<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=alto_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=alto_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alto_Alto100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alto_Alto100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alto_Alto300Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alto_Alto300Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alto_Alto101Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alto_Alto101Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alto_Alto203Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alto_Alto203Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alto_Alto207Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alto_Alto207Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>180</ContextCount>
  <ElementCount>286</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentation</Role>
      <ShortName>Summary of Significant Accounting Policies and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Asset Purchase and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/AssetPurchaseandLicenseAgreements</Role>
      <ShortName>Asset Purchase and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Stock-Based Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/StockBasedPlans</Role>
      <ShortName>Stock-Based Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentationPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altoneuroscience.com/role/BalanceSheetComponents</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altoneuroscience.com/role/Debt</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altoneuroscience.com/role/FairValue</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Stock-Based Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/StockBasedPlansTables</Role>
      <ShortName>Stock-Based Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altoneuroscience.com/role/StockBasedPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altoneuroscience.com/role/LossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altoneuroscience.com/role/StockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.altoneuroscience.com/role/Segments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Description of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails</Role>
      <ShortName>Description of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altoneuroscience.com/role/DescriptionoftheBusiness</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Balance Sheet Components - Schedule of prepaid expenses and other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of prepaid expenses and other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Balance Sheet Components - Schedule of property and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of property and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Balance Sheet Components - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/BalanceSheetComponentsNarrativeDetails</Role>
      <ShortName>Balance Sheet Components - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Balance Sheet Components - Schedule of accrued expenses and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of accrued expenses and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Debt - Schedule of future principal debt payments and exit fee (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails</Role>
      <ShortName>Debt - Schedule of future principal debt payments and exit fee (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Debt - Convertible grant narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails</Role>
      <ShortName>Debt - Convertible grant narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Debt - Convertible grant maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails</Role>
      <ShortName>Debt - Convertible grant maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Debt - Change in fair value of convertible grant agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails</Role>
      <ShortName>Debt - Change in fair value of convertible grant agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/FairValueDetails</Role>
      <ShortName>Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.altoneuroscience.com/role/FairValueTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Stock-Based Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails</Role>
      <ShortName>Stock-Based Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Stock-Based Plans - Stock option weighted average assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails</Role>
      <ShortName>Stock-Based Plans - Stock option weighted average assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Stock-Based Plans - Schedule of stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails</Role>
      <ShortName>Stock-Based Plans - Schedule of stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Stock-Based Plans - Schedule of activity related to RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails</Role>
      <ShortName>Stock-Based Plans - Schedule of activity related to RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Stock-Based Plans - Schedule of stock-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails</Role>
      <ShortName>Stock-Based Plans - Schedule of stock-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Loss Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails</Role>
      <ShortName>Loss Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Stockholders??? Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders??? Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Stockholders??? Equity - Schedule of stock reserved for issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails</Role>
      <ShortName>Stockholders??? Equity - Schedule of stock reserved for issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Segments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/SegmentsNarrativeDetails</Role>
      <ShortName>Segments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="alto-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Segments - Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segments - Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="alto-20260331.htm">alto-20260331.htm</File>
    <File>alto-20260331.xsd</File>
    <File>alto-20260331_cal.xml</File>
    <File>alto-20260331_def.xml</File>
    <File>alto-20260331_lab.xml</File>
    <File>alto-20260331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>alto-20260331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="510">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>128
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "alto-20260331.htm": {
   "nsprefix": "alto",
   "nsuri": "http://www.altoneuroscience.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "alto-20260331.htm"
     ]
    },
    "schema": {
     "local": [
      "alto-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "alto-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "alto-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "alto-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "alto-20260331_pre.xml"
     ]
    }
   },
   "keyStandard": 239,
   "keyCustom": 47,
   "axisStandard": 21,
   "axisCustom": 1,
   "memberStandard": 28,
   "memberCustom": 29,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://fasb.org/us-gaap/2025": 2
   },
   "contextCount": 180,
   "entityCount": 1,
   "segmentCount": 63,
   "elementCount": 544,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 510,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 15
   },
   "report": {
    "R1": {
     "role": "http://www.altoneuroscience.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
     "longName": "9952154 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "longName": "9952156 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.altoneuroscience.com/role/DescriptionoftheBusiness",
     "longName": "9952157 - Disclosure - Description of the Business",
     "shortName": "Description of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentation",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation",
     "shortName": "Summary of Significant Accounting Policies and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.altoneuroscience.com/role/BalanceSheetComponents",
     "longName": "9952159 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.altoneuroscience.com/role/Debt",
     "longName": "9952160 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.altoneuroscience.com/role/FairValue",
     "longName": "9952161 - Disclosure - Fair Value",
     "shortName": "Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.altoneuroscience.com/role/AssetPurchaseandLicenseAgreements",
     "longName": "9952162 - Disclosure - Asset Purchase and License Agreements",
     "shortName": "Asset Purchase and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.altoneuroscience.com/role/StockBasedPlans",
     "longName": "9952163 - Disclosure - Stock-Based Plans",
     "shortName": "Stock-Based Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.altoneuroscience.com/role/LossPerShare",
     "longName": "9952164 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.altoneuroscience.com/role/IncomeTaxes",
     "longName": "9952165 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.altoneuroscience.com/role/StockholdersEquity",
     "longName": "9952166 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.altoneuroscience.com/role/CommitmentsandContingencies",
     "longName": "9952167 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.altoneuroscience.com/role/Segments",
     "longName": "9952168 - Disclosure - Segments",
     "shortName": "Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.altoneuroscience.com/role/SubsequentEvents",
     "longName": "9952169 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentationPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies)",
     "shortName": "Summary of Significant Accounting Policies and Basis of Presentation (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.altoneuroscience.com/role/BalanceSheetComponentsTables",
     "longName": "9955512 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.altoneuroscience.com/role/DebtTables",
     "longName": "9955513 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.altoneuroscience.com/role/FairValueTables",
     "longName": "9955514 - Disclosure - Fair Value (Tables)",
     "shortName": "Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.altoneuroscience.com/role/StockBasedPlansTables",
     "longName": "9955515 - Disclosure - Stock-Based Plans (Tables)",
     "shortName": "Stock-Based Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.altoneuroscience.com/role/LossPerShareTables",
     "longName": "9955516 - Disclosure - Loss Per Share (Tables)",
     "shortName": "Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.altoneuroscience.com/role/StockholdersEquityTables",
     "longName": "9955517 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alto:ScheduleOfStockReservedForIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alto:ScheduleOfStockReservedForIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.altoneuroscience.com/role/SegmentsTables",
     "longName": "9955518 - Disclosure - Segments (Tables)",
     "shortName": "Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails",
     "longName": "9955519 - Disclosure - Description of the Business (Details)",
     "shortName": "Description of the Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "alto:NumberOfWhollyOwnedSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "alto:NumberOfWhollyOwnedSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails",
     "longName": "9955520 - Disclosure - Balance Sheet Components - Schedule of prepaid expenses and other current assets (Details)",
     "shortName": "Balance Sheet Components - Schedule of prepaid expenses and other current assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails",
     "longName": "9955521 - Disclosure - Balance Sheet Components - Schedule of property and equipment, net (Details)",
     "shortName": "Balance Sheet Components - Schedule of property and equipment, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.altoneuroscience.com/role/BalanceSheetComponentsNarrativeDetails",
     "longName": "9955522 - Disclosure - Balance Sheet Components - Narrative (Details)",
     "shortName": "Balance Sheet Components - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails",
     "longName": "9955523 - Disclosure - Balance Sheet Components - Schedule of accrued expenses and other current liabilities (Details)",
     "shortName": "Balance Sheet Components - Schedule of accrued expenses and other current liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
     "longName": "9955524 - Disclosure - Debt - Narrative (Details)",
     "shortName": "Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-84",
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-69",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails",
     "longName": "9955525 - Disclosure - Debt - Schedule of future principal debt payments and exit fee (Details)",
     "shortName": "Debt - Schedule of future principal debt payments and exit fee (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-79",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
     "longName": "9955526 - Disclosure - Debt - Convertible grant narrative (Details)",
     "shortName": "Debt - Convertible grant narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-84",
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-84",
      "name": "alto:DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails",
     "longName": "9955527 - Disclosure - Debt - Convertible grant maturity (Details)",
     "shortName": "Debt - Convertible grant maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails",
     "longName": "9955528 - Disclosure - Debt - Change in fair value of convertible grant agreement (Details)",
     "shortName": "Debt - Change in fair value of convertible grant agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-91",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.altoneuroscience.com/role/FairValueDetails",
     "longName": "9955529 - Disclosure - Fair Value (Details)",
     "shortName": "Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
     "longName": "9955530 - Disclosure - Stock-Based Plans - Narrative (Details)",
     "shortName": "Stock-Based Plans - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alto:ScheduleOfStockReservedForIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails",
     "longName": "9955531 - Disclosure - Stock-Based Plans - Stock option weighted average assumptions (Details)",
     "shortName": "Stock-Based Plans - Stock option weighted average assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-123",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-123",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails",
     "longName": "9955532 - Disclosure - Stock-Based Plans - Schedule of stock option activity (Details)",
     "shortName": "Stock-Based Plans - Schedule of stock option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-125",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-118",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails",
     "longName": "9955533 - Disclosure - Stock-Based Plans - Schedule of activity related to RSUs (Details)",
     "shortName": "Stock-Based Plans - Schedule of activity related to RSUs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails",
     "longName": "9955534 - Disclosure - Stock-Based Plans - Schedule of stock-based compensation expense (Details)",
     "shortName": "Stock-Based Plans - Schedule of stock-based compensation expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-136",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails",
     "longName": "9955535 - Disclosure - Loss Per Share - Narrative (Details)",
     "shortName": "Loss Per Share - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "longName": "9955536 - Disclosure - Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9955537 - Disclosure - Stockholders\u2019 Equity - Narrative (Details)",
     "shortName": "Stockholders\u2019 Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-157",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails",
     "longName": "9955538 - Disclosure - Stockholders\u2019 Equity - Schedule of stock reserved for issuance (Details)",
     "shortName": "Stockholders\u2019 Equity - Schedule of stock reserved for issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alto:ScheduleOfStockReservedForIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-158",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alto:ScheduleOfStockReservedForIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.altoneuroscience.com/role/SegmentsNarrativeDetails",
     "longName": "9955539 - Disclosure - Segments - Narrative (Details)",
     "shortName": "Segments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails",
     "longName": "9955540 - Disclosure - Segments - Schedule of Segment Reporting Information, by Segment (Details)",
     "shortName": "Segments - Schedule of Segment Reporting Information, by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-165",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alto-20260331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "alto_A2025InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "A2025InducementPlanMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Inducement Plan",
        "label": "2025 Inducement Plan [Member]",
        "documentation": "2025 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "alto_APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "APICIncreaseForReclassificationOfWarrantsForConversionOfConvertibleSecuritiesToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of K2 warrants",
        "label": "APIC Increase For Reclassification Of Warrants For Conversion Of Convertible Securities To Common Stock",
        "documentation": "APIC Increase For Reclassification Of Warrants For Conversion Of Convertible Securities To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r689"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails",
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "alto_AccruedResearchExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "AccruedResearchExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research",
        "label": "Accrued Research Expense",
        "documentation": "Accrued Research Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r115",
      "r499"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r59",
      "r123",
      "r496",
      "r530",
      "r531",
      "r921"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r15",
      "r416",
      "r419",
      "r473",
      "r526",
      "r527",
      "r801",
      "r802",
      "r803",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "alto_AdditionalK2WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "AdditionalK2WarrantsMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Warrants",
        "label": "Additional K2 Warrants [Member]",
        "documentation": "Additional K2 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional\u00a0paid-in\u00a0capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r689",
      "r980"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r859",
      "r860",
      "r861",
      "r862",
      "r922",
      "r984"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units vesting",
        "label": "APIC, Share-Based Payment Arrangement, Recognition and Exercise",
        "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of warrants in connection with term loan agreement",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r29",
      "r78"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r726",
      "r736",
      "r768"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r729",
      "r739",
      "r771"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r730",
      "r740",
      "r764",
      "r772",
      "r776",
      "r784"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r376",
      "r377"
     ]
    },
    "alto_Alto100Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "Alto100Member",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ALTO-100",
        "label": "Alto-100 [Member]",
        "documentation": "Alto-100"
       }
      }
     },
     "auth_ref": []
    },
    "alto_Alto101Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "Alto101Member",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ALTO-101",
        "label": "Alto-101 [Member]",
        "documentation": "Alto-101"
       }
      }
     },
     "auth_ref": []
    },
    "alto_Alto203Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "Alto203Member",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ALTO-203",
        "label": "Alto-203 [Member]",
        "documentation": "Alto-203"
       }
      }
     },
     "auth_ref": []
    },
    "alto_Alto207Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "Alto207Member",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ALTO-207",
        "label": "Alto-207 [Member]",
        "documentation": "Alto-207"
       }
      }
     },
     "auth_ref": []
    },
    "alto_Alto300Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "Alto300Member",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ALTO-300",
        "label": "Alto-300 [Member]",
        "documentation": "Alto-300"
       }
      }
     },
     "auth_ref": []
    },
    "alto_AmendedLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "AmendedLoanAgreementMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Loan Agreement",
        "label": "Amended Loan Agreement [Member]",
        "documentation": "Amended Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "alto_AmitEtkinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "AmitEtkinMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amit Etkin [Member]",
        "documentation": "Amit Etkin"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r96",
      "r117",
      "r144",
      "r147",
      "r148",
      "r182",
      "r194",
      "r212",
      "r216",
      "r223",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r405",
      "r408",
      "r453",
      "r487",
      "r488",
      "r494",
      "r578",
      "r648",
      "r649",
      "r661",
      "r689",
      "r695",
      "r696",
      "r707",
      "r880",
      "r881",
      "r936"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r125",
      "r144",
      "r147",
      "r148",
      "r223",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r405",
      "r408",
      "r453",
      "r689",
      "r880",
      "r881",
      "r936"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/FairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431",
      "r681"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of K2 term loan into shares of common stock",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.altoneuroscience.com/role/FairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r113",
      "r630"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r66",
      "r141"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r66"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r120",
      "r121",
      "r122",
      "r144",
      "r148",
      "r172",
      "r173",
      "r175",
      "r177",
      "r184",
      "r185",
      "r223",
      "r258",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r300",
      "r301",
      "r303",
      "r304",
      "r306",
      "r307",
      "r310",
      "r311",
      "r314",
      "r317",
      "r324",
      "r453",
      "r537",
      "r538",
      "r539",
      "r540",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r566",
      "r586",
      "r604",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r795",
      "r854",
      "r856",
      "r863"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r184",
      "r303",
      "r310",
      "r311",
      "r312",
      "r314",
      "r317",
      "r322",
      "r324",
      "r414",
      "r537",
      "r538",
      "r539",
      "r540",
      "r662",
      "r795",
      "r852",
      "r854"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r150",
      "r325"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares called by warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "alto_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsMultiplier",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares called by warrants, multiplier",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Multiplier",
        "documentation": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Multiplier"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants or rights outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "alto_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchase price (in dollars per share)",
        "label": "Class Of Warrant Or Right, Purchase Price Of Warrants Or Rights",
        "documentation": "Class Of Warrant Or Right, Purchase Price Of Warrants Or Rights"
       }
      }
     },
     "auth_ref": []
    },
    "alto_ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ClassOfWarrantsOrRightsNoticePeriodForBeneficialOwnershipLimitation",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase or decrease the beneficial ownership limitation",
        "label": "Class Of Warrants Or Rights, Notice Period For Beneficial Ownership Limitation",
        "documentation": "Class Of Warrants Or Rights, Notice Period For Beneficial Ownership Limitation"
       }
      }
     },
     "auth_ref": []
    },
    "alto_ClassOfWarrantsOrRightsWarrantExcessPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ClassOfWarrantsOrRightsWarrantExcessPercentage",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant in excess percentage",
        "label": "Class Of Warrants Or Rights, Warrant Excess Percentage",
        "documentation": "Warrent in excess percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/AssetPurchaseandLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Purchase and License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r402",
      "r403"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 11)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r90",
      "r495",
      "r565"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r250",
      "r251",
      "r624",
      "r872",
      "r877"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved for issuance under ESPP plan (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "alto_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentageOfOutstandingStock",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual increase, percentage of outstanding shares",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Annual Increase, Percentage of Outstanding Stock",
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Annual Increase, Percentage of Outstanding Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r699",
      "r700",
      "r702",
      "r703",
      "r704",
      "r705",
      "r859",
      "r860",
      "r862",
      "r922",
      "r979",
      "r984"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r566"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53",
      "r566",
      "r584",
      "r984",
      "r985"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock (par value $0.0001), 500,000 shares authorized; 35,053 and 31,924 shares issued and outstanding as of March\u00a031, 2026 and December\u00a031, 2025, respectively",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r566"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "alto_ComputerSoftwareAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ComputerSoftwareAndEquipmentMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software and equipment",
        "label": "Computer Software And Equipment [Member]",
        "documentation": "Computer Software And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Grant Agreement",
        "label": "Convertible Debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r89",
      "r947"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/FairValueDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Grant Agreement",
        "label": "Convertible Debt, Fair Value Disclosures",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails",
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails",
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r268",
      "r269",
      "r279",
      "r280",
      "r281",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ]
    },
    "alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments from sale of common stock and pre-funded warrants in 2026 private placement",
        "label": "Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement",
        "documentation": "Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "alto_CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "CostsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacementNotYetPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs from sale of common stock and pre-funded warrants in 2026 private placement not yet paid",
        "label": "Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement Not Yet Paid",
        "documentation": "Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r144",
      "r146",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r256",
      "r257",
      "r267",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r283",
      "r290",
      "r291",
      "r293",
      "r414",
      "r466"
     ]
    },
    "alto_DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentAdditionalAmountConvertibleToEquityAtElectionOfLender",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of debt convertible to equity at election of lender",
        "label": "Debt Instrument, Additional Amount Convertible To Equity At Election Of Lender",
        "documentation": "Debt Instrument, Additional Amount Convertible To Equity At Election Of Lender"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails",
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r44",
      "r45",
      "r88",
      "r89",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r688",
      "r852",
      "r853",
      "r855",
      "r858",
      "r873",
      "r874",
      "r875",
      "r934",
      "r935",
      "r946"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, basis spread (greater of)",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails": {
       "parentTag": "alto_LongTermDebtPrincipalPaymentsAndExitFee",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total principal payments",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r89",
      "r294"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r270"
     ]
    },
    "alto_DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentConvertibleConversionPriceTermOfWeightedAveragePriceMeasurement",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of weighted average price for share conversion",
        "label": "Debt Instrument, Convertible, Conversion Price, Term Of Weighted Average Price Measurement",
        "documentation": "Debt Instrument, Convertible, Conversion Price, Term Of Weighted Average Price Measurement"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentConvertibleDiscountOnSharesConverted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentConvertibleDiscountOnSharesConverted",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount on shares",
        "label": "Debt Instrument, Convertible, Discount On Shares Converted",
        "documentation": "Debt Instrument, Convertible, Discount On Shares Converted"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentConvertibleMaximumSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentConvertibleMaximumSharesIssuable",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum shares issuable (in shares)",
        "label": "Debt Instrument, Convertible, Maximum Shares Issuable",
        "documentation": "Debt Instrument, Convertible, Maximum Shares Issuable"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentConvertiblePercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of outstanding stock",
        "label": "Debt Instrument, Convertible, Percentage Of Outstanding Stock, Maximum",
        "documentation": "Debt Instrument, Convertible, Percentage Of Outstanding Stock, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentDeferredInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentDeferredInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails": {
       "parentTag": "alto_LongTermDebtPrincipalPaymentsAndExitFee",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred interest",
        "label": "Debt Instrument, Deferred Interest",
        "documentation": "Debt Instrument, Deferred Interest"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentExitFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentExitFee",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails": {
       "parentTag": "alto_LongTermDebtPrincipalPaymentsAndExitFee",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exit Fee",
        "label": "Debt Instrument, Exit Fee",
        "documentation": "Debt Instrument, Exit Fee"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentExitFeePercentOfLoansFunded": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentExitFeePercentOfLoansFunded",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final fee, percent of loan funded",
        "label": "Debt Instrument, Exit Fee, Percent Of Loans Funded",
        "documentation": "Debt Instrument, Exit Fee, Percent Of Loans Funded"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r466",
      "r467",
      "r657",
      "r658",
      "r688"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time facility fee",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "alto_DebtInstrumentFixedRatePaidInKind": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentFixedRatePaidInKind",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed rate, paid-in-kind",
        "label": "Debt Instrument, Fixed Rate, Paid-In-Kind",
        "documentation": "Debt Instrument, Fixed Rate, Paid-In-Kind"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentFundingFeeMultiplier": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentFundingFeeMultiplier",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funding fee multiplier",
        "label": "Debt Instrument, Funding Fee Multiplier",
        "documentation": "Debt Instrument, Funding Fee Multiplier"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentInterestRateFloor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentInterestRateFloor",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate floor",
        "label": "Debt Instrument, Interest Rate Floor",
        "documentation": "Debt Instrument, Interest Rate Floor"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentInterestRateIncreaseInEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentInterestRateIncreaseInEventOfDefault",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate increase in event of default",
        "label": "Debt Instrument, Interest Rate Increase In Event Of Default",
        "documentation": "Debt Instrument, Interest Rate Increase In Event Of Default"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails",
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r414",
      "r490",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r688",
      "r852",
      "r853",
      "r855",
      "r858",
      "r934",
      "r935"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input",
        "label": "Debt Instrument, Measurement Input",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails",
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r688",
      "r852",
      "r853",
      "r855",
      "r858",
      "r873",
      "r874",
      "r875",
      "r934",
      "r935",
      "r946"
     ]
    },
    "alto_DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentNextFiscalYearCovenantCashRunwayPeriodMinimum",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum number of months of cash runway",
        "label": "Debt Instrument, Next Fiscal Year Covenant, Cash Runway Period, Minimum",
        "documentation": "Debt Instrument, Next Fiscal Year Covenant, Cash Runway Period, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentNextFiscalYearCovenantMarketCapitalizationMinimumAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum market capitalization",
        "label": "Debt Instrument, Next Fiscal Year Covenant, Market Capitalization, Minimum Amount",
        "documentation": "Debt Instrument Covenant, Minimum Market Capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentNumberOfTranches",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Debt Instrument, Number Of Tranches",
        "documentation": "Debt Instrument, Number Of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentageOfAmountBorrowed",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final payment, percentage of amount borrowed",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percentage Of Amount Borrowed",
        "documentation": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percentage Of Amount Borrowed"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentPortionConvertibleToEquityAtElectionOfLender": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentPortionConvertibleToEquityAtElectionOfLender",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of debt convertible to equity at election of lender",
        "label": "Debt Instrument, Portion Convertible To Equity At Election Of Lender",
        "documentation": "Debt Instrument, Portion Convertible To Equity At Election Of Lender"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentPrepaymentPenaltyFeeAfter36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment fee, percent of outstanding principal, applicable 36 months after initial funding date",
        "label": "Debt Instrument, Prepayment Penalty Fee, After 36 Months After Initial Funding Date, Percent Of Outstanding Principal",
        "documentation": "Debt Instrument, Prepayment Penalty Fee, After 36 Months After Initial Funding Date, Percent Of Outstanding Principal"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentPrepaymentPenaltyFeeOnOrBefore24MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment fee, percent of outstanding principal, applicable on or before 24 months after initial funding date",
        "label": "Debt Instrument, Prepayment Penalty Fee, On Or Before 24 Months After Initial Funding Date, Percent Of Outstanding Principal",
        "documentation": "Debt Instrument, Prepayment Penalty Fee, On Or Before 24 Months After Initial Funding Date, Percent Of Outstanding Principal"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentPrepaymentPenaltyFeeOnOrBefore36MonthsAfterInitialFundingDatePercentOfOutstandingPrincipal",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment fee, percent of outstanding principal, applicable on or before 36 months after initial funding date",
        "label": "Debt Instrument, Prepayment Penalty Fee, On Or Before 36 Months After Initial Funding Date, Percent Of Outstanding Principal",
        "documentation": "Debt Instrument, Prepayment Penalty Fee, On Or Before 36 Months After Initial Funding Date, Percent Of Outstanding Principal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails",
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r34",
      "r37",
      "r41",
      "r76",
      "r77",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r414",
      "r490",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r688",
      "r852",
      "r853",
      "r855",
      "r858",
      "r934",
      "r935"
     ]
    },
    "alto_DebtInstrumentTrancheAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentTrancheAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Tranche [Axis]",
        "label": "Debt Instrument, Tranche [Axis]",
        "documentation": "Debt Instrument, Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentTrancheDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentTrancheDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Tranche [Domain]",
        "label": "Debt Instrument, Tranche [Domain]",
        "documentation": "Debt Instrument, Tranche [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentTrancheFourMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fourth tranche, available through January 1, 2025",
        "label": "Debt Instrument, Tranche Four [Member]",
        "documentation": "Debt Instrument, Tranche Four"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentTrancheOneMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First tranche, funded on December 16, 2022",
        "label": "Debt Instrument, Tranche One [Member]",
        "documentation": "Debt Instrument, Tranche One"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentTrancheThreeMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third tranche, available from October 1, 2023 and March 1, 2024",
        "label": "Debt Instrument, Tranche Three [Member]",
        "documentation": "Debt Instrument, Tranche Three"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentTrancheTwoMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second tranche, available between October 1, 2023 and March 1, 2024",
        "label": "Debt Instrument, Tranche Two [Member]",
        "documentation": "Debt Instrument, Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs and discount",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r295",
      "r465",
      "r466",
      "r467",
      "r657",
      "r658",
      "r688"
     ]
    },
    "alto_DebtInstrumentUnamortizedExitFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentUnamortizedExitFee",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: unamortized debt discount",
        "label": "Debt Instrument, Unamortized Exit Fee",
        "documentation": "Debt Instrument, Unamortized Exit Fee"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DebtInstrumentVariableInterestRateThresholdForPotentialAdjustment",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable rate threshold for potential adjustment",
        "label": "Debt Instrument, Variable Interest Rate, Threshold For Potential Adjustment",
        "documentation": "Debt Instrument, Variable Interest Rate, Threshold For Potential Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "alto_DeferredOfferingAndShareIssueCostsNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "DeferredOfferingAndShareIssueCostsNotYetPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering and share issue costs not yet paid",
        "label": "Deferred Offering And Share Issue Costs Not Yet Paid",
        "documentation": "Deferred Offering And Share Issue Costs Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredRevenueArrangementTypeAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Revenue Arrangement Type [Axis]",
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "documentation": "Information by type of deferred revenue arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredRevenueArrangementTypeDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Revenue [Domain]",
        "label": "Deferred Revenue [Domain]",
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r26",
      "r135",
      "r633",
      "r634",
      "r636",
      "r638"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r342",
      "r371",
      "r372",
      "r374",
      "r671"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of share-based compensation arrangements by share-based payment award",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r134",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r170",
      "r172",
      "r175",
      "r176",
      "r177",
      "r181",
      "r299",
      "r375",
      "r396",
      "r401",
      "r427",
      "r428",
      "r486",
      "r503",
      "r640"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r134",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r172",
      "r175",
      "r176",
      "r177",
      "r181",
      "r299",
      "r375",
      "r396",
      "r401",
      "r427",
      "r428",
      "r486",
      "r503",
      "r640"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r178",
      "r179",
      "r180"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll, vacation and employee-related expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU unrecognized compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period for recognition of unrecognized share based compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options issued and outstanding",
        "verboseLabel": "Stock Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ]
    },
    "alto_EmployeeStockOptionsAvailableForFutureGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "EmployeeStockOptionsAvailableForFutureGrantMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grant from 2024 Equity Incentive Plan and Inducement Plan",
        "label": "Employee Stock Options Available For Future Grant [Member]",
        "documentation": "Employee Stock Options Available For Future Grant"
       }
      }
     },
     "auth_ref": []
    },
    "alto_EmployeeStockOptionsIssuedAndOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "EmployeeStockOptionsIssuedAndOutstandingMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options issued and outstanding from 2024, 2019 Equity Incentive Plan and Inducement Plan",
        "label": "Employee Stock Options Issued And Outstanding [Member]",
        "documentation": "Employee Stock Options Issued And Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r103",
      "r104",
      "r105",
      "r130",
      "r131",
      "r132",
      "r153",
      "r154",
      "r155",
      "r157",
      "r164",
      "r166",
      "r168",
      "r183",
      "r224",
      "r225",
      "r238",
      "r298",
      "r326",
      "r375",
      "r387",
      "r388",
      "r393",
      "r394",
      "r395",
      "r397",
      "r400",
      "r401",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r468",
      "r469",
      "r473",
      "r502",
      "r526",
      "r527",
      "r528",
      "r543",
      "r604"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r726",
      "r736",
      "r768"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r723",
      "r733",
      "r765"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ExtinguishmentOfDebtAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of debt, amount",
        "label": "Extinguishment of Debt, Amount",
        "documentation": "Gross amount of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other, net",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431",
      "r445",
      "r681"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431",
      "r445",
      "r681"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r429",
      "r431",
      "r432",
      "r433",
      "r434",
      "r443",
      "r445",
      "r447",
      "r452",
      "r476",
      "r477",
      "r478",
      "r628",
      "r657",
      "r658",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r681",
      "r683",
      "r687"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails",
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r446"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r439",
      "r441",
      "r442",
      "r443",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r483",
      "r681",
      "r684"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r328",
      "r333",
      "r334",
      "r431",
      "r445",
      "r452",
      "r476",
      "r628",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r681",
      "r687"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r328",
      "r333",
      "r334",
      "r336",
      "r431",
      "r432",
      "r445",
      "r452",
      "r477",
      "r628",
      "r657",
      "r658",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r681",
      "r687"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r431",
      "r432",
      "r433",
      "r434",
      "r445",
      "r452",
      "r478",
      "r628",
      "r657",
      "r658",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r681",
      "r683",
      "r687"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of change in the air value of the Convertible Grant Agreement",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails",
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r446"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r446"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in fair value reported in statements of operations",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r446"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value reported in other comprehensive loss",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r446"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of new tranches",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r444",
      "r446"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal payments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r446"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtChangeinfairvalueofconvertiblegrantagreementDetails",
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan at fair value",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r446"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r429",
      "r431",
      "r432",
      "r433",
      "r434",
      "r443",
      "r445",
      "r447",
      "r452",
      "r476",
      "r477",
      "r478",
      "r628",
      "r657",
      "r658",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r681",
      "r683",
      "r687"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/FairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r730",
      "r740",
      "r772"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r730",
      "r740",
      "r772"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r730",
      "r740",
      "r772"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r730",
      "r740",
      "r772"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r730",
      "r740",
      "r772"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment and furniture",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "alto_GainLossInOtherOperatingActivitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "GainLossInOtherOperatingActivitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in other, net",
        "label": "Gain (Loss) In Other Operating Activities, Net",
        "documentation": "Gain (Loss) In Other Operating Activities, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on debt extinguishment",
        "negatedLabel": "Loss on extinguishment of debt",
        "negatedTerseLabel": "Loss on debt extinguishment",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r30",
      "r31"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r588"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "alto_GrantAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "GrantAgreementMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Agreement",
        "label": "Grant Agreement [Member]",
        "documentation": "Grant Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r246",
      "r247",
      "r410",
      "r411",
      "r412",
      "r413",
      "r436",
      "r440",
      "r446",
      "r454",
      "r455",
      "r456",
      "r523",
      "r525",
      "r589",
      "r627",
      "r628",
      "r675",
      "r676",
      "r679",
      "r680",
      "r682",
      "r687",
      "r919",
      "r920",
      "r950"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r410",
      "r411",
      "r412",
      "r413",
      "r436",
      "r440",
      "r446",
      "r454",
      "r455",
      "r456",
      "r523",
      "r525",
      "r589",
      "r627",
      "r628",
      "r675",
      "r676",
      "r679",
      "r680",
      "r682",
      "r687",
      "r919",
      "r920",
      "r950"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r149",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r492",
      "r533",
      "r542",
      "r674"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r730",
      "r740",
      "r764",
      "r772",
      "r776",
      "r784"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r788"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r788"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r788"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r287",
      "r297",
      "r659",
      "r660",
      "r982"
     ]
    },
    "alto_InterestExpenseNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "InterestExpenseNoncash",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash\u00a0interest expense related to term loan",
        "label": "Interest Expense, Noncash",
        "documentation": "Interest Expense, Noncash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r635",
      "r639",
      "r806"
     ]
    },
    "us-gaap_InterestPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosure of\u00a0Cash Flow Information",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r139",
      "r140"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest, short term",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r197",
      "r216",
      "r648",
      "r805"
     ]
    },
    "alto_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementNetOfIssuanceCostsInCommonStock",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants in 2026 private placement, net of issuance costs (in shares)",
        "label": "Issuance Of Common Stock And Pre Funded Warrants In Private Placement Net Of Issuance Costs In Common Stock",
        "documentation": "Issuance Of Common Stock And Pre Funded Warrants In Private Placement Net Of Issuance Costs In Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "alto_K2CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "K2CommonStockWarrantsMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "K2 Common Stock Warrants",
        "label": "K2 Common Stock Warrants [Member]",
        "documentation": "K2 Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "alto_K2HealthventuresLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "K2HealthventuresLLCMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "K2 Healthventures LLC",
        "label": "K2 Healthventures LLC [Member]",
        "documentation": "K2 Healthventures LLC"
       }
      }
     },
     "auth_ref": []
    },
    "alto_K2WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "K2WarrantMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "K2 Warrants",
        "label": "K2 Warrant [Member]",
        "documentation": "K2 Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel expenses excluding stock-based compensation",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r637",
      "r804"
     ]
    },
    "alto_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r472"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r44",
      "r45",
      "r46",
      "r48",
      "r49",
      "r50",
      "r51",
      "r144",
      "r147",
      "r148",
      "r223",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r406",
      "r408",
      "r409",
      "r453",
      "r564",
      "r642",
      "r661",
      "r707",
      "r880",
      "r936",
      "r937"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities:",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r91",
      "r498",
      "r689",
      "r695",
      "r696",
      "r852",
      "r857",
      "r870",
      "r933"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r112",
      "r144",
      "r147",
      "r148",
      "r223",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r406",
      "r408",
      "r409",
      "r453",
      "r689",
      "r880",
      "r936",
      "r937"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principle amount (up to)",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r47"
     ]
    },
    "alto_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan and Security Agreement",
        "label": "Loan And Security Agreement [Member]",
        "documentation": "Loan And Security Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Term loan,\u00a0non-current",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r89",
      "r145",
      "r152",
      "r280",
      "r296",
      "r490",
      "r657",
      "r658",
      "r688",
      "r947"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, current",
        "negatedLabel": "Less: Term loan, current portion",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails",
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r145",
      "r152",
      "r285",
      "r490"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails",
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r145",
      "r152",
      "r285",
      "r490"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails",
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r145",
      "r152",
      "r285",
      "r490"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantmaturityDetails",
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026 (remainder of year)",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r858"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Term loan,\u00a0non-current",
        "terseLabel": "Term loan,\u00a0non-current",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "alto_LongTermDebtPrincipalPaymentsAndExitFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "LongTermDebtPrincipalPaymentsAndExitFee",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtScheduleoffutureprincipaldebtpaymentsandexitfeeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total principal payments and Exit Fee",
        "label": "Long-Term Debt, Principal Payments And Exit Fee",
        "documentation": "Long-Term Debt, Principal Payments And Exit Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average interest rate",
        "label": "Long-Term Debt, Weighted Average Interest Rate, over Time",
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r873",
      "r874",
      "r875"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r28",
      "r873",
      "r874",
      "r875"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r252",
      "r253",
      "r254",
      "r255",
      "r337",
      "r366",
      "r367",
      "r368",
      "r378",
      "r434",
      "r481",
      "r522",
      "r524",
      "r532",
      "r556",
      "r557",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625",
      "r626",
      "r653",
      "r662",
      "r670",
      "r675",
      "r677",
      "r678",
      "r683",
      "r684",
      "r685",
      "r686",
      "r691",
      "r882",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r677",
      "r678",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r683",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r432",
      "r433",
      "r434",
      "r675",
      "r677",
      "r678",
      "r683"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r675",
      "r677",
      "r678",
      "r683"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r252",
      "r253",
      "r254",
      "r255",
      "r337",
      "r366",
      "r367",
      "r368",
      "r378",
      "r434",
      "r481",
      "r522",
      "r524",
      "r532",
      "r556",
      "r557",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625",
      "r626",
      "r653",
      "r662",
      "r670",
      "r675",
      "r677",
      "r678",
      "r683",
      "r684",
      "r685",
      "r691",
      "r882",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r885"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Financing Activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Investing Activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Operating Activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r68",
      "r92",
      "r105",
      "r110",
      "r126",
      "r128",
      "r132",
      "r144",
      "r147",
      "r148",
      "r151",
      "r156",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r174",
      "r223",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r299",
      "r302",
      "r305",
      "r308",
      "r375",
      "r396",
      "r401",
      "r428",
      "r453",
      "r501",
      "r585",
      "r602",
      "r603",
      "r635",
      "r637",
      "r639",
      "r706",
      "r880"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted and Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "alto_NewK2WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "NewK2WarrantMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Warrant",
        "label": "New K2 Warrant [Member]",
        "documentation": "New K2 Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "alto_NicholasSmithMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "NicholasSmithMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nicholas Smith [Member]",
        "documentation": "Nicholas Smith"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r730",
      "r740",
      "r764",
      "r772"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "alto_NumberOfClinicalStageAssets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "NumberOfClinicalStageAssets",
     "presentation": [
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of clinical-stage assets",
        "label": "Number Of Clinical-Stage Assets",
        "documentation": "Number Of Clinical-Stage Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r652",
      "r865"
     ]
    },
    "alto_NumberOfWhollyOwnedSubsidiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "NumberOfWhollyOwnedSubsidiaries",
     "presentation": [
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of wholly owned subsidiaries",
        "label": "Number of Wholly Owned Subsidiaries",
        "documentation": "Number of Wholly Owned Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value attributable to instrument specific credit risk",
        "label": "OCI, Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), after Adjustments and Tax, Parent",
        "documentation": "Amount, after tax and adjustments, of unrealized gain (loss) from (increase) decrease in instrument-specific credit risk on contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r404",
      "r407"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r635",
      "r639",
      "r643",
      "r864",
      "r866",
      "r867",
      "r868",
      "r869"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability, short term",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability, long-term",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash\u00a0lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/DescriptionoftheBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of the Business",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r106",
      "r107",
      "r108",
      "r534",
      "r535"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofaccruedexpensesandothercurrentliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accruals and current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r116",
      "r493",
      "r649",
      "r695",
      "r696",
      "r707"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r8",
      "r85"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r12",
      "r127",
      "r129",
      "r133",
      "r164",
      "r458",
      "r459",
      "r464",
      "r485",
      "r502",
      "r801",
      "r802"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss)",
        "terseLabel": "Other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r8",
      "r85",
      "r127",
      "r129",
      "r164"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r983"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and development",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r728",
      "r738",
      "r770"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r731",
      "r741",
      "r773"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r731",
      "r741",
      "r773"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of loan financing cost",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "alto_PaymentsOnIssuanceCostFromRegistrationStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "PaymentsOnIssuanceCostFromRegistrationStatement",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments on issuance cost from registration statement",
        "label": "Payments on Issuance Cost from Registration Statement",
        "documentation": "Payments on Issuance Cost from Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of withholding taxes for stock-based compensation",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Capital expenditures",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "alto_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r310"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r566"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r310"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r566",
      "r584",
      "r984",
      "r985"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails",
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r226",
      "r227",
      "r631"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofprepaidexpensesandothercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r654",
      "r871"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of debt",
        "label": "Proceeds from Issuance of Secured Debt",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of term loan, net",
        "label": "Proceeds from Long-Term Lines of Credit",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "alto_ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ProceedsFromSaleOfCommonStockAndPreFundedWarrantsInPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of common stock and pre-funded warrants in 2026 private placement",
        "label": "Proceeds From Sale Of Common Stock and Pre-Funded Warrants In Private Placement",
        "documentation": "Proceeds From Sale Of Common Stock and Pre-Funded Warrants In Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r482",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r629",
      "r634",
      "r637",
      "r639",
      "r663",
      "r664",
      "r690",
      "r691",
      "r692",
      "r694",
      "r697",
      "r796",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r878",
      "r879",
      "r949",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r482",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r629",
      "r634",
      "r637",
      "r639",
      "r663",
      "r664",
      "r690",
      "r691",
      "r692",
      "r694",
      "r697",
      "r796",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r878",
      "r879",
      "r949",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r472"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r114",
      "r500"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails",
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r472",
      "r491",
      "r500",
      "r689"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of property and equipment, net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r472"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r252",
      "r253",
      "r254",
      "r255",
      "r327",
      "r337",
      "r366",
      "r367",
      "r368",
      "r374",
      "r378",
      "r434",
      "r479",
      "r480",
      "r481",
      "r522",
      "r524",
      "r532",
      "r556",
      "r557",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625",
      "r626",
      "r653",
      "r662",
      "r670",
      "r675",
      "r677",
      "r678",
      "r683",
      "r684",
      "r685",
      "r686",
      "r691",
      "r700",
      "r876",
      "r882",
      "r926",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtConvertiblegrantnarrativeDetails",
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r252",
      "r253",
      "r254",
      "r255",
      "r327",
      "r337",
      "r366",
      "r367",
      "r368",
      "r374",
      "r378",
      "r434",
      "r479",
      "r480",
      "r481",
      "r522",
      "r524",
      "r532",
      "r556",
      "r557",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625",
      "r626",
      "r653",
      "r662",
      "r670",
      "r675",
      "r677",
      "r678",
      "r683",
      "r684",
      "r685",
      "r686",
      "r691",
      "r700",
      "r876",
      "r882",
      "r926",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r723",
      "r733",
      "r765"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of former term loan",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r540"
     ]
    },
    "alto_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "terseLabel": "Direct external program expenses:",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r627",
      "r635",
      "r636",
      "r648",
      "r944"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r724",
      "r734",
      "r766"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r725",
      "r735",
      "r767"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r732",
      "r742",
      "r774"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/FairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r850",
      "r945",
      "r948"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r799",
      "r850"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r78",
      "r497",
      "r529",
      "r531",
      "r541",
      "r567",
      "r689"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r153",
      "r154",
      "r155",
      "r157",
      "r164",
      "r166",
      "r168",
      "r224",
      "r225",
      "r238",
      "r298",
      "r375",
      "r387",
      "r388",
      "r393",
      "r394",
      "r395",
      "r397",
      "r400",
      "r401",
      "r415",
      "r417",
      "r418",
      "r420",
      "r426",
      "r468",
      "r469",
      "r526",
      "r528",
      "r543",
      "r984"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "alto_SaleOfStockConversionOfOutstandingLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "SaleOfStockConversionOfOutstandingLoan",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock conversion of outstanding loan",
        "label": "Sale Of Stock, Conversion Of Outstanding Loan",
        "documentation": "Sale Of Stock, Conversion Of Outstanding Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accrued liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, cost by plan",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of classes of financial assets and liabilities measured at fair value on recurring basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of future principal debt payments and exit fee",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of prepaid expenses and other current assets",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponentsScheduleofpropertyandequipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r472"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r374"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, restricted stock unit, activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of share-based payment award, stock options, valuation assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r76",
      "r77",
      "r78",
      "r120",
      "r121",
      "r122",
      "r184",
      "r310",
      "r311",
      "r312",
      "r314",
      "r317",
      "r322",
      "r324",
      "r414",
      "r537",
      "r538",
      "r539",
      "r540",
      "r662",
      "r795",
      "r852",
      "r854"
     ]
    },
    "alto_ScheduleOfStockReservedForIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ScheduleOfStockReservedForIssuanceTableTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock reserved for issuance",
        "label": "Schedule of Stock Reserved for Issuance [Table Text Block]",
        "documentation": "Schedule of Stock Reserved for Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable",
     "presentation": [
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary of LLC or LP [Table]",
        "label": "Subsidiary of LLC or LP [Table]",
        "documentation": "Disclosure of information about subsidiary of limited liability company (LLC) or limited partnership (LP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "alto_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement",
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96",
      "r182",
      "r191",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r221",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r248",
      "r249",
      "r398",
      "r399",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r645",
      "r648",
      "r649",
      "r655",
      "r693",
      "r949",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/Segments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r182",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r206",
      "r208",
      "r209",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r644",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retention period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited and cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited and cancelled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355"
     ]
    },
    "alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollforwardRollForward",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average\u2028grant date fair value per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Rollforward [Roll Forward]",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Rollforward"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of the RSUs vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares approved, initially reserved for issuance under plan (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate\u2028intrinsic\u2028value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at period end (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at period end (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited and cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited and cancelled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance awards issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualTermAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted \u2013\u2028average\u2028remaining\u2028contractual\u2028term (in\u2028years)",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Options, Weighted Average Contractual Term [Abstract]",
        "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Options, Weighted Average Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "alto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-\u2028average\u2028exercise\u2028price per share",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted Average Exercise Price [Roll Forward]",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofactivityrelatedtoRSUsDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested after 18 months",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested after 24 months",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ]
    },
    "alto_ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "ShareBasedCompensationByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common stock (in dollars per share)",
        "label": "Share Based Compensation By Share Based Payment Award, Fair Value Assumptions, Fair Value Of Award",
        "documentation": "Share Based Compensation By Share Based Payment Award, Fair Value Assumptions, Fair Value Of Award, Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise prices, lower range (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares underlying repriced options, (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise prices, upper range (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage vested in year one",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansStockoptionweightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance awards outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance awards vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies and Basis of Presentation",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/SegmentsScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96",
      "r109",
      "r182",
      "r191",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r221",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r248",
      "r249",
      "r398",
      "r399",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r645",
      "r648",
      "r649",
      "r655",
      "r693",
      "r949",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r120",
      "r121",
      "r122",
      "r144",
      "r148",
      "r172",
      "r173",
      "r175",
      "r177",
      "r184",
      "r185",
      "r223",
      "r258",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r300",
      "r301",
      "r303",
      "r304",
      "r306",
      "r307",
      "r310",
      "r311",
      "r314",
      "r317",
      "r324",
      "r453",
      "r537",
      "r538",
      "r539",
      "r540",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r566",
      "r586",
      "r604",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r795",
      "r854",
      "r856",
      "r863"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53",
      "r56",
      "r57",
      "r103",
      "r104",
      "r105",
      "r130",
      "r131",
      "r132",
      "r153",
      "r154",
      "r155",
      "r157",
      "r164",
      "r166",
      "r168",
      "r183",
      "r224",
      "r225",
      "r238",
      "r298",
      "r326",
      "r375",
      "r387",
      "r388",
      "r393",
      "r394",
      "r395",
      "r397",
      "r400",
      "r401",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r468",
      "r469",
      "r473",
      "r502",
      "r526",
      "r527",
      "r528",
      "r543",
      "r604"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r183",
      "r300",
      "r301",
      "r303",
      "r306",
      "r469",
      "r482",
      "r536",
      "r544",
      "r555",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r566",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r587",
      "r588",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r637",
      "r639",
      "r701",
      "r981"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r183",
      "r222",
      "r300",
      "r301",
      "r303",
      "r306",
      "r469",
      "r482",
      "r536",
      "r544",
      "r555",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r566",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r587",
      "r588",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r637",
      "r639",
      "r701",
      "r981"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r727",
      "r737",
      "r769"
     ]
    },
    "alto_StockAndPreFundedWarrantsIssuedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "StockAndPreFundedWarrantsIssuedDuringPeriodValue",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants in 2026 private placement, net of issuance costs",
        "label": "Stock And Pre Funded Warrants Issued During Period Value",
        "documentation": "Stock And Pre Funded Warrants Issued During Period Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ]
    },
    "alto_StockIssuedDuringPeriodShareConversionOfTermLoan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "StockIssuedDuringPeriodShareConversionOfTermLoan",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for conversion of the K2 term loan, net of issuance (in shares)",
        "label": "Stock Issued During Period, Share, Conversion Of Term Loan",
        "documentation": "Stock Issued During Period, Share, Conversion Of Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during period (in shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU Vesting (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r78"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.altoneuroscience.com/role/StockBasedPlansScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of common stock options (in shares)",
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r53",
      "r78",
      "r351"
     ]
    },
    "alto_StockIssuedDuringPeriodValueConversionOfTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "StockIssuedDuringPeriodValueConversionOfTermLoan",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for conversion of the K2 term loan, net of issuance",
        "label": "Stock Issued During Period, Value, Conversion Of Term Loan",
        "documentation": "Stock Issued During Period, Value, Conversion Of Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of common stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53",
      "r56",
      "r57",
      "r78"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "terseLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r56",
      "r57",
      "r69",
      "r568",
      "r584",
      "r605",
      "r606",
      "r689",
      "r707",
      "r852",
      "r856",
      "r857",
      "r870",
      "r933",
      "r984"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r309",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r326",
      "r414",
      "r425",
      "r607",
      "r608",
      "r619"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r475"
     ]
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems",
     "presentation": [
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary of Limited Liability Company or Limited Partnership [Line Items]",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails",
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityNarrativeDetails",
      "http://www.altoneuroscience.com/role/StockholdersEquityScheduleofstockreservedforissuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.altoneuroscience.com/role/BalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosure of\u00a0Non-cash\u00a0Activities",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "alto_TemporaryEquitySharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "TemporaryEquitySharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.altoneuroscience.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock conversion, number of common stock (in shares)",
        "label": "Temporary Equity, Shares, Conversion Of Convertible Securities",
        "documentation": "Temporary Equity, Shares, Conversion Of Convertible Securities"
       }
      }
     },
     "auth_ref": []
    },
    "alto_The2024EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "The2024EquityIncentivePlanMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The 2024 Equity Incentive Plan",
        "label": "The 2024 Equity Incentive Plan [Member]",
        "documentation": "The 2024 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.altoneuroscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "alto_TwoThousandTwentyFivePreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.altoneuroscience.com/20260331",
     "localname": "TwoThousandTwentyFivePreFundedWarrantsMember",
     "presentation": [
      "http://www.altoneuroscience.com/role/LossPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Thousand Twenty Five Pre Funded Warrants",
        "label": "Two Thousand Twenty Five Pre Funded Warrants [Member]",
        "documentation": "Two Thousand Twenty Five Pre Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.altoneuroscience.com/role/SummaryofSignificantAccountingPoliciesandBasisofPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r186",
      "r187",
      "r188",
      "r189",
      "r487",
      "r489",
      "r641"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.altoneuroscience.com/role/StockBasedPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, expected life",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.altoneuroscience.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of warrants",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924",
      "r928"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r177"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.altoneuroscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r177"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(n)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2G",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
